<SEC-DOCUMENT>0001140361-21-027950.txt : 20210811
<SEC-HEADER>0001140361-21-027950.hdr.sgml : 20210811
<ACCEPTANCE-DATETIME>20210811170603
ACCESSION NUMBER:		0001140361-21-027950
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		73
CONFORMED PERIOD OF REPORT:	20210630
FILED AS OF DATE:		20210811
DATE AS OF CHANGE:		20210811

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ADMA BIOLOGICS, INC.
		CENTRAL INDEX KEY:			0001368514
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				562590442
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36728
		FILM NUMBER:		211164451

	BUSINESS ADDRESS:	
		STREET 1:		C/O ADMA BIOLOGICS, INC.
		STREET 2:		465 STATE ROUTE 17
		CITY:			RAMSEY
		STATE:			NJ
		ZIP:			07446
		BUSINESS PHONE:		(201) 478-5552

	MAIL ADDRESS:	
		STREET 1:		C/O ADMA BIOLOGICS, INC.
		STREET 2:		465 STATE ROUTE 17
		CITY:			RAMSEY
		STATE:			NJ
		ZIP:			07446

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	R&R ACQUISITION VI, INC
		DATE OF NAME CHANGE:	20060707
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>brhc10027771_10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:adma="http://admabiologics.com/20210630" xmlns="http://www.w3.org/1999/xhtml">
<head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using EDGARfilings PROfile 8.0.0.0
         Copyright 1995 - 2021 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="background-color: #ffffff; color: #000000;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_16424b7faa9c4ba5bb45066a3d70235f" contextRef="c20210101to20210630" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" id="Fact_839f2a878e96425d9b939d239048597d" contextRef="c20210101to20210630" format="ixt:datemonthday">12-31</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" id="Fact_eb8baaf1209d4130afd8ba98681be698" contextRef="c20210101to20210630">2021</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" id="Fact_ea22fb2f847741208d9b9ce9ad800fdd" contextRef="c20210101to20210630">Q2</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_ef7dde1ce93a40ba84fb284a01d64bbb" contextRef="c20210101to20210630">0001368514</ix:nonNumeric><ix:nonNumeric name="dei:NoTradingSymbolFlag" id="Fact_273b8602e1574290ac4ea428a0ea6a9d" contextRef="c20210101to20210630_StatementClassOfStockAxis_PreferredSharePurchaseRightMember" format="ixt:booleantrue">true</ix:nonNumeric><ix:nonNumeric name="adma:ProductCycleFromProcurementOfRawMaterialsToFinishedProduct" id="Fact_53babb8f6d26472fabf16dec51a6b0a4" contextRef="c20210101to20210630_RangeAxis_MinimumMember">P7M</ix:nonNumeric><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact_06457f177efa4ffeb98a18387724a0a7" contextRef="c20210101to20210630_RangeAxis_MinimumMember">P3Y</ix:nonNumeric><ix:nonFraction name="adma:PercentageOfPlasmaPurchasePriceEqualToCost" id="Fact_5246f96bd6684b0493a757c543cd5bb9" contextRef="c20210101to20210630_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember" unitRef="U007" decimals="2">0.05</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:href="adma-20210630.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20210101to20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_StatementClassOfStockAxis_PreferredSharePurchaseRightMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adma:PreferredSharePurchaseRightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_StatementClassOfStockAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20200401to20200630_ProductOrServiceAxis_LicenseAndServiceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_ProductOrServiceAxis_LicenseAndServiceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200401to20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210401to20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200101to20200630_ProductOrServiceAxis_LicenseAndServiceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210401to20210630_ProductOrServiceAxis_ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200101to20200630_ProductOrServiceAxis_ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_ProductOrServiceAxis_ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210401to20210630_ProductOrServiceAxis_LicenseAndServiceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200401to20200630_ProductOrServiceAxis_ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200101to20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20200101to20200331_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210401to20210630_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200101to20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200401to20200630_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200101to20200331_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200101to20200331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210331_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210331_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210401to20210630_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210401to20210630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200401to20200630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200401to20200630_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200331_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20200331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210331_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20200630_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210630_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20200630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20200630_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210630_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20200331_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210331_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_ConsolidatedEntitiesAxis_JefferiesLLCMember_TypeOfArrangementAxis_SaleAgreement2020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">adma:JefferiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:SaleAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210731to20210731_ConsolidatedEntitiesAxis_JefferiesLLCMember_SubsequentEventTypeAxis_SubsequentEventMember_TypeOfArrangementAxis_SaleAgreement2020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:SaleAgreement2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">adma:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-31</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210811_ConsolidatedEntitiesAxis_JefferiesLLCMember_SubsequentEventTypeAxis_SubsequentEventMember_TypeOfArrangementAxis_SaleAgreement2021Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">adma:JefferiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:SaleAgreement2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210528to20210528_ConsolidatedEntitiesAxis_JefferiesLLCMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_SaleAgreement2021Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">adma:JefferiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:SaleAgreement2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-28</xbrli:startDate><xbrli:endDate>2021-05-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_SixCustomersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:SixCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200101to20201231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_ThreeCustomersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:ThreeCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_TypeOfArrangementAxis_BiotestLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:BiotestLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200101to20200630_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_ThreeCustomersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:ThreeCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_FiveCustomersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:FiveCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200101to20200630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200101to20200630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200101to20200630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20201231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">adma:TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerContractsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">adma:RightToIntermediatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210630_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">adma:TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210630_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerContractsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210630_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">adma:RightToIntermediatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210630_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210630_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210630_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_PropertyPlantAndEquipmentByTypeAxis_LandMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210630_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210630_PropertyPlantAndEquipmentByTypeAxis_AssetUnderConstructionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_PropertyPlantAndEquipmentByTypeAxis_AssetUnderConstructionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210630_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210630_PropertyPlantAndEquipmentByTypeAxis_LandMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_PropertyPlantAndEquipmentByTypeAxis_BuildingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210630_DebtInstrumentAxis_PerceptiveCreditAgreementMember_LongtermDebtTypeAxis_SeniorNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:PerceptiveCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_DebtInstrumentAxis_PerceptiveCreditAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:PerceptiveCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210630_DebtInstrumentAxis_PerceptiveCreditAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:PerceptiveCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_DebtInstrumentAxis_PerceptiveCreditAgreementMember_VariableRateAxis_LondonInterbankOfferedRateLIBORMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:PerceptiveCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210630_DebtInstrumentAxis_PerceptiveCreditFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:PerceptiveCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210630_DebtInstrumentAxis_PerceptiveCreditAgreementMember_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:PerceptiveCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211001to20211231_DebtInstrumentAxis_PerceptiveCreditAgreementMember_StatementScenarioAxis_ScenarioForecastMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:PerceptiveCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190401to20190630_DebtInstrumentAxis_PerceptiveCreditAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:PerceptiveCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200805to20200805_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_JefferiesLLCMember_TypeOfArrangementAxis_SaleAgreement2020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:SaleAgreement2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adma:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-05</xbrli:startDate><xbrli:endDate>2020-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210203to20210203_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_JefferiesLLCMember_TypeOfArrangementAxis_SaleAgreement2020AmendedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:SaleAgreement2020AmendedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adma:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-03</xbrli:startDate><xbrli:endDate>2021-02-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210528to20210528_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_JefferiesLLCMember_TypeOfArrangementAxis_SaleAgreement2021Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adma:JefferiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:SaleAgreement2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-28</xbrli:startDate><xbrli:endDate>2021-05-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200211to20200211_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_OverAllotmentOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-11</xbrli:startDate><xbrli:endDate>2020-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200221to20200221_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_OverAllotmentOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-21</xbrli:startDate><xbrli:endDate>2020-02-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210528to20210528_RelatedPartyTransactionsByRelatedPartyAxis_JefferiesLLCMember_StatementEquityComponentsAxis_CommonStockMember_TypeOfArrangementAxis_SaleAgreement2021Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:SaleAgreement2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adma:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-28</xbrli:startDate><xbrli:endDate>2021-05-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_RelatedPartyTransactionsByRelatedPartyAxis_JefferiesLLCMember_StatementEquityComponentsAxis_CommonStockMember_TypeOfArrangementAxis_SaleAgreement2020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:SaleAgreement2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adma:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_RelatedPartyTransactionsByRelatedPartyAxis_JefferiesLLCMember_TypeOfArrangementAxis_SaleAgreement2020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:SaleAgreement2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adma:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200101to20200630_SubsidiarySaleOfStockAxis_OverAllotmentOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200221to20200221_SubsidiarySaleOfStockAxis_OverAllotmentOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-21</xbrli:startDate><xbrli:endDate>2020-02-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200211to20200211_SubsidiarySaleOfStockAxis_OverAllotmentOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-11</xbrli:startDate><xbrli:endDate>2020-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200101to20200630_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200101to20200630_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200101to20200630_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20201231_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210630_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210630_PlanNameAxis_EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_PlanNameAxis_EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_AwardTypeAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200101to20200630_AwardTypeAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200101to20200630_AwardTypeAxis_RestrictedStockUnitsRSUMember_TitleOfIndividualAxis_DirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_AwardTypeAxis_RestrictedStockUnitsRSUMember_TitleOfIndividualAxis_EmployeesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:EmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210630_AwardTypeAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_AwardTypeAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210630_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20200101to20200630_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200401to20200630_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200101to20200630_IncomeStatementLocationAxis_CostOfSalesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210401to20210630_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210401to20210630_IncomeStatementLocationAxis_OperatingExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200401to20200630_IncomeStatementLocationAxis_CostOfSalesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_IncomeStatementLocationAxis_CostOfSalesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200101to20200630_IncomeStatementLocationAxis_OperatingExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210401to20210630_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_IncomeStatementLocationAxis_OperatingExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200101to20200630_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200401to20200630_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210401to20210630_IncomeStatementLocationAxis_CostOfSalesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200401to20200630_IncomeStatementLocationAxis_OperatingExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_RelatedPartyTransactionsByRelatedPartyAxis_ArethLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adma:ArethLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200401to20200630_RelatedPartyTransactionsByRelatedPartyAxis_ArethLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adma:ArethLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_RelatedPartyTransactionsByRelatedPartyAxis_GenesisBPSMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adma:GenesisBPSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210630_TitleOfIndividualAxis_ChiefScientificOfficerAndChiefMedicalOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:ChiefScientificOfficerAndChiefMedicalOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_TitleOfIndividualAxis_ChiefScientificOfficerAndChiefMedicalOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:ChiefScientificOfficerAndChiefMedicalOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_LineOfCreditFacilityAxis_PerceptiveCreditHoldingsIILPMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adma:PerceptiveCreditHoldingsIILPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200211to20200211_TitleOfIndividualAxis_ExecutiveVicePresidentAndChiefFinancialOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:ExecutiveVicePresidentAndChiefFinancialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-11</xbrli:startDate><xbrli:endDate>2020-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200211to20200211_OwnershipAxis_IndirectOwnershipMember_TitleOfIndividualAxis_PresidentAndChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">adma:IndirectOwnershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:PresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-11</xbrli:startDate><xbrli:endDate>2020-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200211to20200211_TitleOfIndividualAxis_DirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-11</xbrli:startDate><xbrli:endDate>2020-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200211to20200211_TitleOfIndividualAxis_ChiefScientificOfficerAndChiefMedicalOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:ChiefScientificOfficerAndChiefMedicalOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-11</xbrli:startDate><xbrli:endDate>2020-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200211to20200211_OwnershipAxis_IndirectOwnershipMember_TitleOfIndividualAxis_ViceChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">adma:IndirectOwnershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:ViceChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-11</xbrli:startDate><xbrli:endDate>2020-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200211to20200211_OwnershipAxis_DirectOwnershipMember_TitleOfIndividualAxis_PresidentAndChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">adma:DirectOwnershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:PresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-11</xbrli:startDate><xbrli:endDate>2020-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200211to20200211_OwnershipAxis_DirectOwnershipMember_TitleOfIndividualAxis_ViceChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:ViceChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">adma:DirectOwnershipMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-11</xbrli:startDate><xbrli:endDate>2020-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200211to20200211_LineOfCreditFacilityAxis_PerceptiveCreditHoldingsIILPMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adma:PerceptiveCreditHoldingsIILPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-11</xbrli:startDate><xbrli:endDate>2020-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_RangeAxis_MaximumMember_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:PlasmaPurchaseAgreementOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_TypeOfArrangementAxis_PlasmaPurchaseAgreementTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:PlasmaPurchaseAgreementTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:PlasmaPurchaseAgreementOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200101to20200630_StatementGeographicalAxis_US"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200401to20200630_StatementGeographicalAxis_US"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210401to20210630_StatementGeographicalAxis_US"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200101to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200101to20200630_StatementGeographicalAxis_NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_StatementGeographicalAxis_NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_StatementBusinessSegmentsAxis_CorporateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200401to20200630_StatementGeographicalAxis_NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_StatementGeographicalAxis_US"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200401to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210401to20210630_StatementGeographicalAxis_NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210401to20210630_StatementBusinessSegmentsAxis_CorporateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200401to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200101to20200630_StatementBusinessSegmentsAxis_CorporateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200401to20200630_StatementBusinessSegmentsAxis_CorporateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210401to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210401to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200101to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20200630_StatementBusinessSegmentsAxis_CorporateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210630_StatementBusinessSegmentsAxis_CorporateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210611to20210611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-11</xbrli:startDate><xbrli:endDate>2021-06-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210611to20210611_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-11</xbrli:startDate><xbrli:endDate>2021-06-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210611to20210611_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-11</xbrli:startDate><xbrli:endDate>2021-06-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210726to20210726_SubsequentEventTypeAxis_SubsequentEventMember_TypeOfArrangementAxis_SaleAgreement2020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:SaleAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-26</xbrli:startDate><xbrli:endDate>2021-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U001"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U002"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U003"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U004"><xbrli:measure>adma:Facility</xbrli:measure></xbrli:unit><xbrli:unit id="U005"><xbrli:measure>adma:Product</xbrli:measure></xbrli:unit><xbrli:unit id="U006"><xbrli:measure>adma:Customer</xbrli:measure></xbrli:unit><xbrli:unit id="U007"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U008"><xbrli:measure>adma:Term</xbrli:measure></xbrli:unit><xbrli:unit id="U009"><xbrli:measure>adma:Center</xbrli:measure></xbrli:unit><xbrli:unit id="U010"><xbrli:measure>adma:Lease</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" />
    <div>
      <div style="text-align: center; font-weight: bold;"><span style="font-size: 14pt;">UNITED STATES</span></div>

      <div style="text-align: center; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

      <div style="text-align: center; font-size: 12pt; font-weight: bold;">WASHINGTON, D.C. 20549</div>

      <div style="text-align: center; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_033967c9224a464b8818a92ef4f84a4c" contextRef="c20210101to20210630">10-Q</ix:nonNumeric></div>

      <div>(Mark One)</div>

      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt; vertical-align: top;"><ix:nonNumeric name="dei:DocumentQuarterlyReport" id="Fact_28c9642f73b84cfcb0abd89387439186" contextRef="c20210101to20210630" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric><br />
            </td>

    <td style="width: auto; vertical-align: top;">
              <div>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</div>
            </td>

  </tr>


</table>
      <div style="margin-left: 36pt;">For the quarterly period ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_c92e4fb6011347e081b1b8f2f7e152b7" contextRef="c20210101to20210630" format="ixt:datemonthdayyearen">June 30, 2021</ix:nonNumeric><span style="text-decoration: underline;"></span></div>

      <div style="text-align: center;">OR</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt; vertical-align: top;"><ix:nonNumeric name="dei:DocumentTransitionReport" id="Fact_82be25f2344e4cecb6fb902ef07b03c7" contextRef="c20210101to20210630" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </td>

    <td style="width: auto; vertical-align: top;">
              <div>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</div>
            </td>

  </tr>


</table>
      <div style="margin-left: 36pt;">For the transition period from ________ to ________</div>

      <div style="text-align: center;">Commission file number <ix:nonNumeric name="dei:EntityFileNumber" id="Fact_a7733ef3c9f94a9eb4e5090d28e21308" contextRef="c20210101to20210630">001-36728</ix:nonNumeric></div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 24pt; font-weight: bold;"><span style="text-decoration: underline;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_4e3b8851bf5a4c1db6ab22389e3dacf0" contextRef="c20210101to20210630">ADMA BIOLOGICS, INC.</ix:nonNumeric><br />
        </span></div>

      <div style="text-align: center; color: rgb(0, 0, 0);">(Exact Name of Registrant as Specified in Its Charter)</div>

      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0);"><span style="text-decoration: underline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_2c65d664fa1d41158edc92593db858b6" contextRef="c20210101to20210630" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br />
                </span></div>
            </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 49%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0);"><span style="text-decoration: underline;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_2d94e7af1ef2412ca4c53c36e330d2ba" contextRef="c20210101to20210630">56-2590442</ix:nonNumeric><br />
                </span></div>
            </td>

  </tr>

  <tr>

    <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0);">(State or Other Jurisdiction of Incorporation or Organization)</div>
            </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0);">(I.R.S. Employer Identification No.)</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0);"><span style="text-decoration: underline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_3b835463acaa486594d507a02c794254" contextRef="c20210101to20210630">465 State Route 17</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_6c478f3fc81b4b89a9164eaf2c2a3258" contextRef="c20210101to20210630">Ramsey</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_afd523726cef40e39c573246e1749b4a" contextRef="c20210101to20210630" format="ixt-sec:stateprovnameen">New Jersey</ix:nonNumeric></span></div>
            </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0);"><span style="text-decoration: underline;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_f93f7ff9c83b4d96880e0e3f2fbb4463" contextRef="c20210101to20210630">07446</ix:nonNumeric><br />
                </span></div>
            </td>

  </tr>

  <tr>

    <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0);">(Address of Principal Executive Offices)</div>
            </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0);">(Zip Code)</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="text-align: center; color: rgb(0, 0, 0);"><span style="text-decoration: underline;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_a49f4345d22646d6a9b5463f34355e41" contextRef="c20210101to20210630">201</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_328de645c50c4759acbcf986cf4be9e7" contextRef="c20210101to20210630">478-5552</ix:nonNumeric></span></div>

      <div style="text-align: center; color: rgb(0, 0, 0);">(Registrant&#8217;s Telephone Number, Including Area Code)</div>

      <div style="text-align: center; color: rgb(0, 0, 0);"> <br />
      </div>

      <div style="text-align: center; color: rgb(0, 0, 0);">(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)</div>

      <div style="text-align: center; color: rgb(0, 0, 0);"> <br />
      </div>

      <div style="text-align: center; color: rgb(0, 0, 0);">Securities registered pursuant to Section 12(b) of the Act:</div>

      <div style="text-align: center; color: rgb(0, 0, 0);"> <br />
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 35%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center; color: rgb(0, 0, 0);">Title of each class</div>
            </td>

    <td style="width: 30%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center; color: rgb(0, 0, 0);">Trading Symbol(s)</div>
            </td>

    <td style="width: 35%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center; color: rgb(0, 0, 0);">Name of each exchange on which registered</div>
            </td>

  </tr>

  <tr>

    <td style="width: 35%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; color: rgb(0, 0, 0);"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_255e93c0795b443b8555a4b4253f53a9" contextRef="c20210101to20210630_StatementClassOfStockAxis_CommonStockMember">Common Stock</ix:nonNumeric></div>
            </td>

    <td style="width: 30%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; color: rgb(0, 0, 0);"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_db81a98acb5c42dab261aeb63c5d84a4" contextRef="c20210101to20210630_StatementClassOfStockAxis_CommonStockMember">ADMA</ix:nonNumeric></div>
            </td>

    <td style="width: 35%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; color: rgb(0, 0, 0);"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_77ebb6fc7cec469fb7876b0d25642940" contextRef="c20210101to20210630_StatementClassOfStockAxis_CommonStockMember" format="ixt-sec:exchnameen">Nasdaq Global Market</ix:nonNumeric></div>
            </td>

  </tr>

  <tr>

    <td style="width: 35%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; color: rgb(0, 0, 0);"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_3fb4218939f542f0b71a21aa93994cbf" contextRef="c20210101to20210630_StatementClassOfStockAxis_PreferredSharePurchaseRightMember">Preferred Share Purchase Right</ix:nonNumeric></div>
            </td>

    <td style="width: 30%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; color: rgb(0, 0, 0);"><span style="-sec-ix-hidden:Fact_273b8602e1574290ac4ea428a0ea6a9d">-</span><br />
              </div>
            </td>

    <td style="width: 35%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; color: rgb(0, 0, 0);"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_4ef94fc09dc54db9890867f97eb33f17" contextRef="c20210101to20210630_StatementClassOfStockAxis_PreferredSharePurchaseRightMember" format="ixt-sec:exchnameen">Nasdaq Global Market</ix:nonNumeric></div>
            </td>

  </tr>


</table>
      <div style="text-align: justify; text-indent: 36pt;"> <br />
      </div>

      <div style="text-align: justify; text-indent: 36pt;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for
        such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160; &#160; <ix:nonNumeric name="dei:EntityCurrentReportingStatus" id="Fact_c2eb97aba99a4893a4e4613d16713d43" contextRef="c20210101to20210630">Yes</ix:nonNumeric>
        &#9746;&#160; &#160; No &#9744;</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br />
      </div>

      <div style="text-align: justify; text-indent: 36pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter)
        during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160; &#160; <ix:nonNumeric name="dei:EntityInteractiveDataCurrent" id="Fact_bf74f7d1cc724e39a9f6851adf25e2ec" contextRef="c20210101to20210630">Yes</ix:nonNumeric> &#9746;&#160; &#160; No &#9744;</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br />
      </div>

      <div style="text-align: justify; text-indent: 36pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the
        definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br />
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 15%; vertical-align: top;" colspan="1">&#160;</td>

    <td style="width: 50%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Large accelerated filer&#160; &#160; &#9744;</div>
            </td>

    <td style="width: 35%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Accelerated filer&#160; &#160; &#9744;</div>
            </td>

  </tr>

  <tr>

    <td style="width: 15%; vertical-align: top;" colspan="1">&#160;</td>

    <td style="width: 50%; vertical-align: top;">
              <div><span style="color: rgb(0, 0, 0);"><ix:nonNumeric name="dei:EntityFilerCategory" id="Fact_679ceb9e5c6848738efae54d6110b8c3" contextRef="c20210101to20210630" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric>&#160; &#160; </span>&#9746;</div>
            </td>

    <td style="width: 35%; vertical-align: top;">
              <div><span style="color: rgb(0, 0, 0);">Smaller reporting company&#160; &#160; <ix:nonNumeric name="dei:EntitySmallBusiness" id="Fact_1f02ca5c210e408cb232a16fc5b1e12f" contextRef="c20210101to20210630" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric></span></div>
            </td>

  </tr>

  <tr>

    <td style="width: 15%; vertical-align: top;" colspan="1">&#160;</td>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 35%; vertical-align: top;">
              <div><span style="color: rgb(0, 0, 0);">Emerging growth company&#160; &#160; </span><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_f7b4a4a5e7c54dbba9b3e16d18380d16" contextRef="c20210101to20210630" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></div>
            </td>

  </tr>


</table>
      <div style="text-align: justify; text-indent: 36pt;"> <br />
      </div>

      <div style="text-align: justify; text-indent: 36pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
        provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br />
      </div>

      <div style="text-align: justify; text-indent: 36pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160; &#160; Yes <ix:nonNumeric name="dei:EntityShellCompany" id="Fact_bb41edf2dd4b4d8484c4ce87a072dc58" contextRef="c20210101to20210630" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160; &#160; No &#9746;</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br />
      </div>

      <div style="text-align: justify; text-indent: 36pt;">As of August 6, 2021, there were <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" id="Fact_616a2568cd2442b09691d90e8acecee9" contextRef="c20210806" unitRef="U001" decimals="INF" scale="0" format="ixt:numdotdecimal">132,769,471</ix:nonFraction> shares of the issuer&#8217;s common stock
        outstanding.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br />
      </div>

      <div style="text-align: justify; text-indent: 36pt;">
        <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /></div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      </div>

      <!--PROfilePageNumberReset%LCR%1%%%--> </div>

  </div>

</div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <div style="text-align: center; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

      <div style="text-align: center; font-weight: bold;"> <br />
      </div>

      <div style="text-align: center; font-weight: bold;"><a id="INDEX"><!--Anchor--></a>INDEX</div>

      <div style="text-align: center; font-weight: bold;"> <br />
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="vertical-align: top;" colspan="3">
              <div><a href="#PARTI">PART I FINANCIAL INFORMATION</a></div>
            </td>

    <td style="width: 5%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top;" colspan="3">&#160;</td>

    <td style="width: 5%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Item 1.</div>
            </td>

    <td style="width: 85%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="#FinancialStatements.">Financial Statements</a></div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: right;">1<br />
            </td>

  </tr>

  <tr>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 8%; vertical-align: top;">&#160;</td>

    <td style="width: 85%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 85%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="#BALANCESHEETS">Condensed Consolidated Balance Sheets as of June 30, 2021 (Unaudited) and December 31, 2020</a></div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">1</div>
            </td>

  </tr>

  <tr>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 8%; vertical-align: top;">&#160;</td>

    <td style="width: 85%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top; text-align: right;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 85%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="#STATEMENTSOFOPERATIONS">Condensed Consolidated Statements of Operations (Unaudited) for the Three and Six Months Ended June 30, 2021 and 2020</a></div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">2</div>
            </td>

  </tr>

  <tr>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 8%; vertical-align: top;">&#160;</td>

    <td style="width: 85%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top; text-align: right;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 85%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="#STATEMENTSOFCHANGESIN">Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity (Unaudited) for the Three and Six Months Ended June 30, 2021 and 2020</a></div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">3</div>
            </td>

  </tr>

  <tr>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 8%; vertical-align: top;">&#160;</td>

    <td style="width: 85%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top; text-align: right;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 85%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="#CASHFLOWS">Condensed Consolidated Statements of Cash Flows (Unaudited) for the Six Months Ended June 30, 2021 and 2020</a></div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">4</div>
            </td>

  </tr>

  <tr>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 8%; vertical-align: top;">&#160;</td>

    <td style="width: 85%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top; text-align: right;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 85%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="#FINANCIALSTATEMENTS">Notes to (Unaudited) Condensed Consolidated Financial Statements</a></div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">5</div>
            </td>

  </tr>

  <tr>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 8%; vertical-align: top;">&#160;</td>

    <td style="width: 85%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top; text-align: right;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Item 2.</div>
            </td>

    <td style="width: 85%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="#ManagementsDiscussionandA">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</a></div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">23</div>
            </td>

  </tr>

  <tr>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 8%; vertical-align: top;">&#160;</td>

    <td style="width: 85%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top; text-align: right;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Item 3.</div>
            </td>

    <td style="width: 85%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="#QuantitativeandQualitativ">Quantitative and Qualitative Disclosures About Market Risk.</a></div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">37</div>
            </td>

  </tr>

  <tr>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 8%; vertical-align: top;">&#160;</td>

    <td style="width: 85%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top; text-align: right;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Item 4.</div>
            </td>

    <td style="width: 85%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="#ControlsandProcedures.">Controls and Procedures.</a></div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">37</div>
            </td>

  </tr>

  <tr>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 8%; vertical-align: top;">&#160;</td>

    <td style="width: 85%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top; text-align: right;">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255);" colspan="3">
              <div><a href="#PARTII">PART II OTHER INFORMATION</a></div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">38</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: top;" colspan="3">&#160;</td>

    <td style="width: 5%; vertical-align: top; text-align: right;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Item 1.</div>
            </td>

    <td style="width: 85%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="#Item1.">Legal Proceedings.</a></div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">38</div>
            </td>

  </tr>

  <tr>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 8%; vertical-align: top;">&#160;</td>

    <td style="width: 85%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top; text-align: right;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Item 1A.</div>
            </td>

    <td style="width: 85%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="#Item1A.">Risk Factors.</a></div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">38</div>
            </td>

  </tr>

  <tr>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 8%; vertical-align: top;">&#160;</td>

    <td style="width: 85%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top; text-align: right;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Item 2.</div>
            </td>

    <td style="width: 85%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="#Item2.">Unregistered Sales of Equity Securities and Use of Proceeds.</a></div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">68</div>
            </td>

  </tr>

  <tr>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 8%; vertical-align: top;">&#160;</td>

    <td style="width: 85%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top; text-align: right;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Item 3.</div>
            </td>

    <td style="width: 85%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="#Item3.">Defaults Upon Senior Securities.</a></div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">68</div>
            </td>

  </tr>

  <tr>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 8%; vertical-align: top;">&#160;</td>

    <td style="width: 85%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top; text-align: right;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Item 4.</div>
            </td>

    <td style="width: 85%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="#Item4.">Mine Safety Disclosures.</a></div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">68</div>
            </td>

  </tr>

  <tr>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 8%; vertical-align: top;">&#160;</td>

    <td style="width: 85%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top; text-align: right;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Item 5.</div>
            </td>

    <td style="width: 85%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="#Item5.">Other Information.</a></div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">68</div>
            </td>

  </tr>

  <tr>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 8%; vertical-align: top;">&#160;</td>

    <td style="width: 85%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top; text-align: right;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Item 6.</div>
            </td>

    <td style="width: 85%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="#Item6.">Exhibits.</a></div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">68</div>
            </td>

  </tr>

  <tr>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 8%; vertical-align: top;">&#160;</td>

    <td style="width: 85%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top; text-align: right;">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255);" colspan="3">
              <div><a href="#SIGNATURES">SIGNATURES</a></div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">69<br />
              </div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="text-indent: 36pt; color: rgb(0, 0, 0);">This Quarterly Report on Form 10-Q includes our trademarks, trade names and service marks, such as &#8220;ASCENIV<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#8482;</sup>,&#8221;
        &#8220;Nabi-HB<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>&#8221; and &#8220;BIVIGAM<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>,&#8221; which are protected under applicable intellectual property
        laws and are the property of ADMA Biologics, Inc., or its subsidiaries. Solely for convenience, trademarks, trade names and service marks referred to in this report may appear without the <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#8482;</sup> or <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">SM</sup> symbols, but such references are not
        intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks, trade names and service marks. We do not intend our use or display of
        other parties&#8217; trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties.</div>

      <div style="color: rgb(0, 0, 0);">&#160;</div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">i</span></div>

        <div style="page-break-after: always;" class="DSPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index<br />
                  </a></td>

  </tr>


</table>
        </div>

      </div>

      <div>
        <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Special Note Regarding Forward-Looking Statements</div>

        <div><br />
        </div>

        <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Some of the information in this Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of
          Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended.&#160;These statements include, among others, statements about:&#160;</div>

        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">our ability to continue as a going concern;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">our ability to manufacture BIVIGAM and ASCENIV on a commercial scale and commercialize these products as a result of their approval by the U.S. Food and Drug
                  Administration (the &#8220;FDA&#8221;) in 2019;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">our plans to develop, manufacture, market, launch and expand our commercial infrastructure and commercialize our current and future products and the success of such
                  efforts;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the safety, efficacy and expected timing of and our ability to obtain and maintain regulatory approvals for our current products and product candidates, and the
                  labeling or nature of any such approvals;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the achievement of or expected timing, progress and results of clinical development, clinical trials and potential regulatory approvals for our product candidates;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">our dependence upon our third-party customers and vendors and their compliance with applicable regulatory requirements;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">our belief that we have addressed the delays experienced with final drug product Good Manufacturing Practices (&#8220;GMP&#8221;) release testing by our third-party vendors by
                  adding additional release testing laboratories to our FDA-approved consortium listed in our drug approval documents;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">our ability to obtain adequate quantities of FDA-approved plasma with proper specifications;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">our plans to increase our supplies of source plasma, which include plasma collection center expansion and reliance on third-party supply agreements as well as any
                  extensions to such agreements;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the potential indications for our products and product candidates;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">potential investigational new product applications;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the acceptability of any of our products, including BIVIGAM, ASCENIV and Nabi-HB, for any purpose, including FDA-approved indications, by physicians, patients or
                  payers;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">our plans to evaluate the clinical and regulatory paths to grow the ASCENIV franchise through expanded FDA-approved uses;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Federal, state and local regulatory and business review processes and timing by such governmental and regulatory agencies of our business and regulatory
                  submissions;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">concurrence by the FDA with our conclusions concerning our products and product candidates;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the comparability of results of our hyperimmune and immune globulin products to other comparably run hyperimmune and immune globulin clinical trials;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the potential for ASCENIV and BIVIGAM to provide meaningful clinical improvement for patients living with Primary Immune Deficiency Disease, Primary Humoral
                  Immunodeficiency Disease (&#8220;PIDD&#8221; or &#8220;PI&#8221;)&#160;&#160; or other immune deficiencies or any other condition for which the products may be prescribed or evaluated;</div>
              </td>

  </tr>


</table>
        <div> <br />
        </div>

        <div> </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">ii</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index<br />
                    </a></td>

  </tr>


</table>
          </div>

        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">our ability to market and promote Nabi-HB in a highly competitive environment with increasing competition from other antiviral therapies and to generate meaningful
                  revenues from this product;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">our intellectual property position and the defense thereof, including our expectations regarding the scope of patent protection with respect to ASCENIV or other
                  future pipeline product candidates;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">our manufacturing capabilities, third-party contractor capabilities and vertical integration strategy;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">our plans related to the expansion of our manufacturing capacity, yield improvements, supply-chain robustness, in-house fill-finish capabilities, distribution and
                  other collaborative agreements and the success of such endeavors;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">our estimates regarding revenues, expenses, capital requirements, timing to profitability and the need for and availability of additional financing;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">possible or likely reimbursement levels for our currently marketed products;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">estimates regarding market size, projected growth and sales of our existing products as well as our expectations of market acceptance of ASCENIV and BIVIGAM;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">effects of the coronavirus COVID-19 pandemic on our business, financial condition, liquidity and results of operations, and our ability to continue operations in
                  the same manner as previously conducted prior to the macroeconomic effects of the COVID-19 pandemic;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">future domestic and global economic conditions or performance; and</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">expectations for future capital requirements.</div>
              </td>

  </tr>


</table>
        <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

        <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">These statements may be found under the &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition
          and Results of Operations&#8221; sections of this Quarterly Report on Form 10-Q.&#160;Forward-looking statements&#160; may be identified by the use of terms such as &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221;
          &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; or &#8220;should&#8221; or the negative thereof or other variations thereof or comparable terminology.&#160;Our actual results could differ materially from those contained in the forward-looking statements due to the factors
          described in the sections entitled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020 and in this Quarterly
          Report on Form 10-Q for the quarter ended June 30, 2021. Any forward-looking statement included or incorporated by reference in this Quarterly Report on Form 10-Q reflects our current views with respect to future events and is subject to these
          and other risks, uncertainties and assumptions related to our operations, industry and future growth. These forward-looking statements speak only as of the dates such statements are made and we undertake no obligation to publicly update any
          forward-looking statements or to publicly announce revisions to any of the forward-looking statements, unless otherwise required by the federal securities laws.</div>

        <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">iii</span></div>

          <div style="page-break-after: always;" class="DSPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index<br />
                    </a></td>

  </tr>


</table>
          </div>

        </div>

        <!--PROfilePageNumberReset%Num%1%%%--> </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <div>
        <div style="text-align: center; font-weight: bold;"><a id="PARTI"><!--Anchor--></a><!--Anchor-->PART I</div>

        <div style="text-align: center; font-weight: bold;">FINANCIAL INFORMATION</div>

        <a id="FinancialStatements."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 45pt; vertical-align: top;"><span style="font-weight: bold;">Item 1<!--Anchor-->.</span></td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Financial Statements.</div>
              </td>

  </tr>


</table>
        <div style="text-align: center; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

        <div style="text-align: center; font-weight: bold;"><!--Anchor-->CONDENSED CONSOLIDATED <a id="BALANCESHEETS"><!--Anchor--></a>BALANCE SHEETS</div>

        <div style="text-align: center; font-weight: bold;"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;"> June 30,</div>
                <div style="text-align: center; font-weight: bold;">2021<br />
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">December 31,</div>
                <div style="text-align: center; font-weight: bold;">2020<br />
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">
                <div style="text-align: center;">(Unaudited)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">ASSETS</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Current assets:</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Cash and cash equivalents</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_2433aaa0f77c4c2088cd8707941d7e68" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">42,408,958</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_9cbd99f142bc49918de54d35b82c9d7f" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">55,921,152</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Accounts receivable, net</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" id="Fact_a65a3741507a430fb1245c9c1f8d85e2" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">23,544,594</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" id="Fact_86347a9c044b48f19dc559a37403ea87" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">13,237,290</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Inventories</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:InventoryNet" id="Fact_9142fbb79b634d9da8f751e35db17e72" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">99,699,743</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:InventoryNet" id="Fact_c733c840f9854e208bc854b08f2bbeeb" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">81,535,599</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Prepaid expenses and other current assets</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" id="Fact_a5421b8588ca4ecfadbf6cbaacc9c7b6" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">5,701,863</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" id="Fact_9177520ab36c49ea97cd19a1c968df92" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">3,046,466</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Total current assets</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AssetsCurrent" id="Fact_f0a49f8ce9bd4d899b3db3c19e04efdd" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">171,355,158</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AssetsCurrent" id="Fact_f45b3271b441455cb2105680565b129e" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">153,740,507</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Property and equipment, net</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_d8c833d9f27b421dbaa3e2b268ca0bab" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">46,486,980</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_c7aaf9819ea84e03bf8722ce95af85af" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">41,593,090</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Intangible assets, net</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" id="Fact_f17de370315f4091b0f89c2e84d973d1" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">2,086,445</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" id="Fact_0514a0e23bdc4d0ea5e717bdf3754926" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">2,444,121</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Goodwill</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:Goodwill" id="Fact_769d5f0c97eb4064bdb43ac410530a21" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">3,529,509</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:Goodwill" id="Fact_146dfcca9c3e49fa9b8a31f975e6acc2" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">3,529,509</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Right to use assets</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" id="Fact_bbc32b4cc98043e9a94ba4f7220fb722" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">6,829,040</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" id="Fact_6dd902973f4846a4bb1c1594e27f8f57" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">4,259,191</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Deposits and other assets</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="adma:DepositsAndOtherNoncurrentAssets" id="Fact_fdb7387d5b0a4d048c2f6366a42a0e3e" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">2,526,660</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="adma:DepositsAndOtherNoncurrentAssets" id="Fact_a50743018b6247889bc69ddeeb66ade6" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">2,106,976</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">TOTAL ASSETS</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:Assets" id="Fact_c2f9187a8f1347b180e4de1c4e0650a0" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">232,813,792</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:Assets" id="Fact_7667a4f3673d4a5c8f4ea222c3c2efa1" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">207,673,394</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Current liabilities:</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Accounts payable</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AccountsPayableCurrent" id="Fact_7dde0dfcef624d98a7c818296df97379" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">6,167,465</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AccountsPayableCurrent" id="Fact_79f8959f51c440058a2b2ae73dcbf97b" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">11,073,708</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Accrued expenses and other current liabilities</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" id="Fact_dd0f579f43084bb2aa500ce0cc36df30" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">11,490,239</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" id="Fact_0e9ccf6016784da8a8b04f3a1af923c3" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">8,365,143</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Current portion of deferred revenue</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" id="Fact_717f5016a22d44e788a7623ed89d02dc" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">142,834</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" id="Fact_f9a0da175433427abcd2517ac58e7ac3" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">142,834</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Current portion of lease obligations</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" id="Fact_e15d10dae4084e71835cb788dda3105c" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">385,858</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" id="Fact_133ea3e3d3ae4a4c84dea5f17daf07ff" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">365,682</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Total current liabilities</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:LiabilitiesCurrent" id="Fact_e040cd8f2ecf4ad193d82978ff855ac5" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">18,186,396</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:LiabilitiesCurrent" id="Fact_df082a6c52ae4c43b80203fb015af4c8" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">19,947,367</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Senior notes payable, net of discount</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:SeniorLongTermNotes" id="Fact_5dbbafa983e447648edea5d160779986" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">93,877,017</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:SeniorLongTermNotes" id="Fact_a253f9727f7042bdb255854fc1f4cc07" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">92,968,866</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Deferred revenue, net of current portion</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DeferredRevenueNoncurrent" id="Fact_c6a34d215f70489cb00ad0517bb21b35" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">2,047,281</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DeferredRevenueNoncurrent" id="Fact_c686e6297dea4e4d93efce7816cca250" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">2,118,698</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Lease obligations, net of current portion</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" id="Fact_67604891dc8248dba7f483ed9d867778" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">7,073,415</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" id="Fact_c7f10b40133643d19d8ee5f69eb7ddd7" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">4,334,151</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Other non-current liabilities</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" id="Fact_1425725201a64a6b81c6061265b988a6" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">36,151</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" id="Fact_019efd73590a4e5fb4700d5a202f9ba9" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">54,886</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">TOTAL LIABILITIES</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:Liabilities" id="Fact_4b09c740ef954edab33c4b39d9ffc56e" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">121,220,260</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:Liabilities" id="Fact_95d12ad8d1e64b189d1268bbd917203d" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">119,423,968</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">COMMITMENTS AND CONTINGENCIES</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" id="Fact_9109aae765d343688bd225ff5a0745fd" contextRef="c20210630" unitRef="U002" xsi:nil="true" format="ixt:nocontent"></ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" id="Fact_cd2a31ec8a274e85bda554fc0b8b2bc8" contextRef="c20201231" unitRef="U002" xsi:nil="true" format="ixt:nocontent"></ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">STOCKHOLDERS&#8217; EQUITY</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Preferred Stock, $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact_4b322bc4ff9047ada11d276fba00f032" contextRef="c20201231" unitRef="U003" decimals="4" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact_6fc4cd5d6f0b44aba187135f7f5f2546" contextRef="c20210630" unitRef="U003" decimals="4" scale="0" format="ixt:numdotdecimal">0.0001</ix:nonFraction></ix:nonFraction></span> par value, <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" id="Fact_c51731a3209d45bc9c438cd58e2594ec" contextRef="c20201231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" id="Fact_6460774f302542369b031f1439c51371" contextRef="c20210630" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></ix:nonFraction></span> shares authorized, <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" id="Fact_7357d7c8b24b4172b404e8fb73377a70" contextRef="c20201231" unitRef="U001" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" id="Fact_6a23abbcd48d427490a73e11ae49d3bd" contextRef="c20210630" unitRef="U001" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" id="Fact_985ef26e70de4d438886de20409f6e62" contextRef="c20201231" unitRef="U001" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" id="Fact_65817be99e324befbc84fa32051df194" contextRef="c20210630" unitRef="U001" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span>
                  shares issued and outstanding</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:PreferredStockValue" id="Fact_32421b2e655449bc95407ba53997b2dd" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:PreferredStockValue" id="Fact_1b0624f0760d4befb7bf3f49d8cdc325" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Common Stock - voting, $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_772895fcdb8948edaa197e1a3cbda00b" contextRef="c20201231" unitRef="U003" decimals="4" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_0b9116e5ffd647cd91be96bc28d8ec95" contextRef="c20210630" unitRef="U003" decimals="4" scale="0" format="ixt:numdotdecimal">0.0001</ix:nonFraction></ix:nonFraction></span> par value, <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_e17fd8ff3db44d0db345255c9de5d29c" contextRef="c20210630" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">300,000,000</ix:nonFraction></span> and <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_a33bbef49e4c4c0c9b8a70c07e1a3c1f" contextRef="c20201231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">150,000,000</ix:nonFraction></span>
                  shares authorized, <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_be2280b446274185893dcebcbf2be1f3" contextRef="c20210630" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_a47a04445e0a40c0ac5864df134f7b0a" contextRef="c20210630" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">131,872,026</ix:nonFraction></ix:nonFraction></span> and <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_6acdb1cf62784deea606e18a567d8916" contextRef="c20201231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_4889dba395554041a519d29516e511d1" contextRef="c20201231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">104,902,888</ix:nonFraction></ix:nonFraction></span> shares issued and outstanding</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:CommonStockValue" id="Fact_58134c88742643e59d1016963f21fc5a" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">13,187</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:CommonStockValue" id="Fact_a9deedc4c75a4eca9914e129648a18c2" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">10,490</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Additional paid-in capital</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" id="Fact_c293fe47874d4c80ae1b7165eead05cc" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">489,330,692</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" id="Fact_393b6c347b684f7c93234fece20c7a2e" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">428,704,039</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Accumulated deficit</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" id="Fact_670ee4f1c7ce4252ae8b84b63c0b3e46" contextRef="c20210630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">377,750,347</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" id="Fact_4f86c6a8492a4d20b20ca60fb4d5913a" contextRef="c20201231" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">340,465,103</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">TOTAL STOCKHOLDERS&#8217; EQUITY</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_1a6712ef74b145788070fef039c2ef2d" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">111,593,532</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_3acf9855c6604de4b9fef2d7902b6e9c" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">88,249,426</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" id="Fact_b55ab3549e7148a98c2fb93694e5d4ad" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">232,813,792</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" id="Fact_cceb9a747e2849a3a60625fde7c5ccf2" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">207,673,394</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
        <div style="text-align: justify;"><br />
        </div>

        <div style="text-align: center;">The accompanying notes are an integral part of these condensed consolidated financial statements.</div>

        <div><br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">1</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index<br />
                    </a></td>

  </tr>


</table>
          </div>

        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <div>
        <div style="text-align: center; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

        <div style="text-align: center; font-weight: bold;"><!--Anchor-->CONDENSED CONSOLIDATED <a id="STATEMENTSOFOPERATIONS"><!--Anchor--></a>STATEMENTS OF OPERATIONS</div>

        <div style="text-align: center; font-weight: bold;">(Unaudited)</div>

        <div style="text-align: center; font-weight: bold;"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-weight: bold;">Three Months Ended June 30,</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-weight: bold;">Six Months Ended June 30,</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-weight: bold;">2021<br />
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-weight: bold;">2020<br />
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-weight: bold;">2021<br />
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-weight: bold;">2020<br />
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">REVENUES:</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Product revenue</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_c6b6bce5012d4eb49231fb67e6fe8add" contextRef="c20210401to20210630_ProductOrServiceAxis_ProductMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">17,794,881</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_8b8a95af880c4848a5335ff17ee4cd83" contextRef="c20200401to20200630_ProductOrServiceAxis_ProductMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">7,751,885</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_6ebf9c66719342d1b1c57fc4895ddbbf" contextRef="c20210101to20210630_ProductOrServiceAxis_ProductMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">33,807,791</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_d6a310fe1fb64e42b233075d83db32fd" contextRef="c20200101to20200630_ProductOrServiceAxis_ProductMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">17,915,921</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">License revenue</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_638d48f759d843b986cc623c094eade2" contextRef="c20210401to20210630_ProductOrServiceAxis_LicenseAndServiceMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">35,709</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_67ca54a911714c0a9189ca6cb5a32515" contextRef="c20200401to20200630_ProductOrServiceAxis_LicenseAndServiceMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">35,709</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_448a203311114732b7548e69af691b06" contextRef="c20210101to20210630_ProductOrServiceAxis_LicenseAndServiceMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">71,417</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_77bb68ea3ea1472895b5bbcc786d04a8" contextRef="c20200101to20200630_ProductOrServiceAxis_LicenseAndServiceMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">71,417</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt; font-weight: bold;">Total revenues</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_8c80cfc03fa74e58958a9587696524f5" contextRef="c20210401to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">17,830,590</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_d65c68a297bb40a6abc800115fd3e089" contextRef="c20200401to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">7,787,594</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_db1c99d55665420f861dc5da714d74f6" contextRef="c20210101to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">33,879,208</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_5276c028bca94dea939e43baf7116995" contextRef="c20200101to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">17,987,338</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">OPERATING EXPENSES:</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Cost of product revenue (exclusive of amortization expense shown below)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="adma:CostOfProductRevenueExcludingAmortizationExpense" id="Fact_2a32a17bf1c04120a3956c557c29a5e1" contextRef="c20210401to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">18,832,624</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="adma:CostOfProductRevenueExcludingAmortizationExpense" id="Fact_8185b8bd22884c3797aaa65583bc5c0d" contextRef="c20200401to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">13,495,629</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="adma:CostOfProductRevenueExcludingAmortizationExpense" id="Fact_6a7985388ce14d67b72b256e7c011084" contextRef="c20210101to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">36,602,746</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="adma:CostOfProductRevenueExcludingAmortizationExpense" id="Fact_fab689db4ac34073a3eccd5aa0fdb6a4" contextRef="c20200101to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">30,324,855</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Research and development</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_76fd52e789af4a42ada5afe548ae34ca" contextRef="c20210401to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,158,866</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_538c4a8ac16743929e2629256f082196" contextRef="c20200401to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,656,420</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_767d365ccb6e4f8a941c3e2bf80e5305" contextRef="c20210101to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">2,146,515</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_3978299636d3471ba982778fb79b6d7f" contextRef="c20200101to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">3,185,158</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Plasma center operating expenses</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" id="Fact_2508b08896b84f05ad8886a40f7a89c2" contextRef="c20210401to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">2,803,326</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" id="Fact_52fbac27372245c1845f8f60f81b05dc" contextRef="c20200401to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">877,902</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" id="Fact_f95713b8e2534090b79a2181f9f873de" contextRef="c20210101to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">5,045,669</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" id="Fact_67e7731d006e4d6194d461677b19b7a7" contextRef="c20200101to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,378,546</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Amortization of intangible assets</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" id="Fact_68d14fb4cdbc4d52bef5ca7b73bae20b" contextRef="c20210401to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">178,838</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" id="Fact_f5817a3d25a9452f8064504e0a6ad533" contextRef="c20200401to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">178,838</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" id="Fact_e047b89e58ce483392bb4e610b6699ab" contextRef="c20210101to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">357,676</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" id="Fact_86f686ac3c8944008b56a6e12dec6117" contextRef="c20200101to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">357,676</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Selling, general and administrative</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" id="Fact_d15b4b179ab441fe9251ccd2c2a696fb" contextRef="c20210401to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">10,438,168</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" id="Fact_bb8adde31d404947b7945ee85af00d37" contextRef="c20200401to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">8,702,630</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" id="Fact_d1a168e6e11f401184561b77d9ad0a24" contextRef="c20210101to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">20,472,083</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" id="Fact_0ae9a0b15ed14b248b6ad733e1240f4a" contextRef="c20200101to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">16,634,714</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt; font-weight: bold;">Total operating expenses</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_f58f61080187486cb5d586586e7c4a2a" contextRef="c20210401to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">33,411,822</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_2bb5a41ed61441d79b84be8f5aa9af0e" contextRef="c20200401to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">24,911,419</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_829a82c7dd954db2b1c95648aa88c175" contextRef="c20210101to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">64,624,689</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_b791a46855dc487d86f347326cd93297" contextRef="c20200101to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">51,880,949</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">LOSS FROM OPERATIONS</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_9905cc735ec943c78fde9b7157776e2f" contextRef="c20210401to20210630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">15,581,232</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_7ccce697ae9746d696a1b2909639981d" contextRef="c20200401to20200630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">17,123,825</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_3d55c702be5d4b7289ed0dfcd1bbd61c" contextRef="c20210101to20210630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">30,745,481</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_e3db1982360a453da28f6cb67140efc7" contextRef="c20200101to20200630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">33,893,611</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">OTHER INCOME (EXPENSE):</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Interest income</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" id="Fact_e55d7714fff74a22a9e1abdc4c73dd92" contextRef="c20210401to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">5,926</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" id="Fact_3665c88c4a624fd0b89c4ea358fc88d7" contextRef="c20200401to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">19,411</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" id="Fact_3983f011cf9c44c2b31e921ee99a3c71" contextRef="c20210101to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">27,985</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" id="Fact_5d0ca20aa1ca4d6f8b95e4d9dde57be9" contextRef="c20200101to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">267,479</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Interest expense</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:InterestExpense" id="Fact_a71ce3062d4b4766935dbad0677878b9" contextRef="c20210401to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">3,246,680</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:InterestExpense" id="Fact_49f9029bdfea42409552df53f24b26c9" contextRef="c20200401to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">3,067,306</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:InterestExpense" id="Fact_ae318561cdb542efba63f477ea144d24" contextRef="c20210101to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">6,442,430</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:InterestExpense" id="Fact_de970281193a47b3a8597ec3af3e3f43" contextRef="c20200101to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">5,784,397</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Other expense</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:OtherNonoperatingExpense" id="Fact_3c85d6b811a84eeebac14ccc274b24ce" contextRef="c20210401to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">83,317</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:OtherNonoperatingExpense" id="Fact_d87fb0a9fd664540a55938448c6dc318" contextRef="c20200401to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">6,371</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:OtherNonoperatingExpense" id="Fact_897e5502eb4941bb9bb5bc25680f05e7" contextRef="c20210101to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">125,318</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:OtherNonoperatingExpense" id="Fact_4b207b7d0347476683916641fb38cd62" contextRef="c20200101to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">12,792</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt; font-weight: bold;">Other expense, net</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_b922c5a89fdd43df81e81fd831e92aee" contextRef="c20210401to20210630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">3,324,071</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_e13d75cb9d9247dba7d6ebc9bbd1d554" contextRef="c20200401to20200630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">3,054,266</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_c24f7f1c9c08401ca83a2922629bf451" contextRef="c20210101to20210630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">6,539,763</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_15362ef7299a48d5b7e06be643481db3" contextRef="c20200101to20200630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">5,529,710</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">NET LOSS</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_68a96a78aa6d416585ca6b454281fac2" contextRef="c20210401to20210630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">18,905,303</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_80d68c6beb7f4bd0a0041e1773a29226" contextRef="c20200401to20200630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">20,178,091</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_a6c25bda09c94616b5d74178043a2d99" contextRef="c20210101to20210630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">37,285,244</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_368890b0c61546a488d23fc526638660" contextRef="c20200101to20200630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">39,423,321</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">BASIC AND DILUTED LOSS PER COMMON SHARE</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_1767fd2ea00b4462b2287acdd39f05a3" contextRef="c20210401to20210630" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_02e2b4857360489c945db42e05ffd436" contextRef="c20210401to20210630" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:numdotdecimal">0.15</ix:nonFraction></ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_a486c19f3fdf440aaff7ba2317905801" contextRef="c20200401to20200630" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_7761f59e984a497ba9d69362f54febdf" contextRef="c20200401to20200630" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:numdotdecimal">0.23</ix:nonFraction></ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_74ac9617cd87418ba63abfdfdf6233ce" contextRef="c20210101to20210630" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_10b9fb718a51441fa6a1439efe4ed952" contextRef="c20210101to20210630" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:numdotdecimal">0.31</ix:nonFraction></ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_ba3f9da89374448dbee1b2cfe53a211d" contextRef="c20200101to20200630" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_00022220cc2441389dbb2915aa6793c4" contextRef="c20200101to20200630" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:numdotdecimal">0.49</ix:nonFraction></ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Basic and Diluted</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_96e3128f83b7487380c8b5b70089ff97" contextRef="c20210401to20210630" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_c276c4c49cca42a7b83987aaf34ef168" contextRef="c20210401to20210630" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">127,416,126</ix:nonFraction></ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_c4eb368859cd47a9958f1d90fe5371a6" contextRef="c20200401to20200630" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_997d6212b374457ebe5c352b4ae66f9a" contextRef="c20200401to20200630" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">86,347,467</ix:nonFraction></ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_9b47bdc675484b8dac471b4fa61d9e21" contextRef="c20210101to20210630" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_5c0c0d319b0346c2ad6b398b656c4519" contextRef="c20210101to20210630" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">121,571,501</ix:nonFraction></ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_d26d1cb38b874fa999335c65fd03d99b" contextRef="c20200101to20200630" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_be62392da41f437abc039947c0b7eb74" contextRef="c20200101to20200630" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">80,064,641</ix:nonFraction></ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: center;">The accompanying notes are an integral part of these condensed consolidated financial statements.</div>

        <div style="text-align: center;"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">2</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index<br />
                    </a></td>

  </tr>


</table>
          </div>

        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <div>
        <div style="text-align: center; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

        <div style="text-align: center; font-weight: bold;">CONDENSED CONSOLIDATED <a id="STATEMENTSOFCHANGESIN"><!--Anchor--></a>STATEMENTS OF CHANGES IN</div>

        <div style="text-align: center; font-weight: bold;"><!--Anchor-->STOCKHOLDERS&#8217; EQUITY</div>

        <div style="text-align: center; font-weight: bold;">(Unaudited)</div>

        <div><br />
        </div>

        <div style="text-align: center; font-weight: bold;">For the Three and Six Months Ended June 30, 2021</div>

        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="6">
                <div style="text-align: center; font-weight: bold;"> Common Stock</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">
                <div style="text-align: center; font-weight: bold;"> Additional</div>
                <div style="text-align: center; font-weight: bold;"> Paid-in</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">
                <div style="text-align: center; font-weight: bold;"> Accumulated</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">
                <div style="text-align: center; font-weight: bold;">Total</div>
                <div style="text-align: center; font-weight: bold;">Stockholders&#8217;</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                <div style="text-align: center; font-weight: bold;"> Shares</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                <div style="text-align: center; font-weight: bold;"> Amount</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                <div style="text-align: center; font-weight: bold;"> Capital</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                <div style="text-align: center; font-weight: bold;"> Deficit</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                <div style="text-align: center; font-weight: bold;">Equity</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Balance at December 31, <span style="text-indent: 0pt;">2020</span></div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_d9bb0eac3ebb4b438bf5b4a5f361df8f" contextRef="c20201231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">104,902,888</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_a416aadadf354cd1a73ce97bfc0a6f99" contextRef="c20201231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">10,490</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_2d81533587df46d7927c7c09c5ab56c2" contextRef="c20201231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">428,704,039</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_31c5976c53964850a0a9a217ef48dd3d" contextRef="c20201231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">340,465,103</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_3b63271b81644b3ca62cc53dca107351" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">88,249,426</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Stock-based compensation</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div>-</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_17e33565766842c6bedcd987230ca868" contextRef="c20210101to20210331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_43764f7d695b490882c0f1f46ce6173d" contextRef="c20210101to20210331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">781,397</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_6ed615c81846454f9853e8777ae40da1" contextRef="c20210101to20210331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_4a68e1ea3a574b7a9cdde3ba16e13931" contextRef="c20210101to20210331" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">781,397</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Vesting of Restricted Stock Units, net of shares withheld for taxes and retired</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares" id="Fact_7d65e85c9377477ea19162a214a34d60" contextRef="c20210101to20210331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">61,385</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" id="Fact_f1393b46fc2846d994eb32052518cd62" contextRef="c20210101to20210331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">6</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" id="Fact_c540f22d1ae34c53aa80d9959d74dd70" contextRef="c20210101to20210331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">59,317</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" id="Fact_e18b5f8c8db2487485a6965e0f4efbad" contextRef="c20210101to20210331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" id="Fact_22796e2d74e04038bf14989404237ac7" contextRef="c20210101to20210331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">59,311</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Issuance of common stock, net of offering expenses</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_fd4ec9d5d5804992a6b24579d1e47fa5" contextRef="c20210101to20210331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">18,080,708</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_60628656272d4120bbbb68dd625c873a" contextRef="c20210101to20210331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,808</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_3744968e8ea84782b579ce927fc5b296" contextRef="c20210101to20210331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">41,910,707</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_22a616d6162e423ea9de10dc025543b0" contextRef="c20210101to20210331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_dd70fabfa4124ea08591b315695f73f8" contextRef="c20210101to20210331" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">41,912,515</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Net loss</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>-</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_bdb5aab902734720af630acea4eaed7f" contextRef="c20210101to20210331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_223a6581262f404aa77d5c9642c5da73" contextRef="c20210101to20210331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_b60a607c72f3446f93ca39f04d80db0e" contextRef="c20210101to20210331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">18,379,941</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_90820523ce2148689e9f144e4f634cab" contextRef="c20210101to20210331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">18,379,941</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Balance at March 31, <span style="text-indent: 0pt;">2021</span></div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_847da51dd20c4b85922257084a19d0b6" contextRef="c20210331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">123,044,981</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_aec245a25df645cba1bf26b341923cd8" contextRef="c20210331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">12,304</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_b9f5179391c44efdac9eec358175fd56" contextRef="c20210331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">471,336,826</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_4225c99cae7b428d99ef3ced0ad03892" contextRef="c20210331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">358,845,044</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_c5935e1d84324fc8834083db0335567c" contextRef="c20210331" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">112,504,086</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Stock-based compensation</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>-</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_7f8bd3c091a84861b0b5c6a5f33a4311" contextRef="c20210401to20210630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_f46421f936c044fb93d56d5b70b4c43b" contextRef="c20210401to20210630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">805,189</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_eda8e36eeddc44adb5ab109a861a6e86" contextRef="c20210401to20210630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_21914908bd2d4036a4aa4f5a2804d071" contextRef="c20210401to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">805,189</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Issuance of common stock, net of offering expenses</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_748aedb12326479a8d9fdd991add8f90" contextRef="c20210401to20210630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">8,827,045</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_a311ab818c7f47e3bf13e9022be29184" contextRef="c20210401to20210630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">883</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_cc5497e825fc4eaa836eeb14726f3db2" contextRef="c20210401to20210630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">17,188,677</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_9b37d6321fcb48bcb9ad6f502e2ab32f" contextRef="c20210401to20210630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_2dc6488fa7b4499399a89a3928fb53aa" contextRef="c20210401to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">17,189,560</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Net loss</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>-</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_747d7c814aea453bb5dce71090b09422" contextRef="c20210401to20210630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_561c9623e978431bb8fc5f7f64bc45aa" contextRef="c20210401to20210630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_b9779245840e40bf8166ccf6d93169f2" contextRef="c20210401to20210630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">18,905,303</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_835408b616034d9faa76f9df5b43151d" contextRef="c20210401to20210630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">18,905,303</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 4px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Balance at June 30, <span style="text-indent: 0pt;">2021</span></div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_3315d84d6afd4fda99947163488f5872" contextRef="c20210630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">131,872,026</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_f10b5fac998d4e33bd27c1c3e494347e" contextRef="c20210630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">13,187</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_e357f33876e94c35a9221bb458c4aa7f" contextRef="c20210630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">489,330,692</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_15179b67f8df4031899f0b4543d4867c" contextRef="c20210630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">377,750,347</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">
                <div style="color: rgb(0, 0, 0);">)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_de3b06ca2b0e4c0d9be8a02c29fb68dd" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">111,593,532</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: center; font-weight: bold;">For the Three and Six Months Ended June 30, 2020</div>

        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="6">
                <div style="text-align: center; font-weight: bold;"> Common Stock</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">
                <div style="text-align: center; font-weight: bold;"> Additional</div>
                <div style="text-align: center; font-weight: bold;"> Paid-in</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">
                <div style="text-align: center; font-weight: bold;"> Accumulated</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">
                <div style="text-align: center; font-weight: bold;">Total</div>
                <div style="text-align: center; font-weight: bold;">Stockholders&#8217;</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                <div style="text-align: center; font-weight: bold;"> Shares</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                <div style="text-align: center; font-weight: bold;"> Amount</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                <div style="text-align: center; font-weight: bold;"> Capital</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                <div style="text-align: center; font-weight: bold;"> Deficit</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                <div style="text-align: center; font-weight: bold;">Equity</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Balance at December 31, <span style="text-indent: 0pt;">2019</span></div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_e3af723878b24acf8d021cd279f9b6c3" contextRef="c20191231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">59,318,355</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_d26666681ce04244a40a267d760c23dd" contextRef="c20191231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">5,932</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_df1f6f2f177046ff9b8aa1e09cbba7e2" contextRef="c20191231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">290,903,772</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_58a9cf00c013468f9a1d263e058c4a0a" contextRef="c20191231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">264,716,555</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_5881244e5fc4452cb44683e94e1cfe0a" contextRef="c20191231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">26,193,149</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Stock-based compensation</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div>-</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_a0ffbe2cf56b498884f12792290356d7" contextRef="c20200101to20200331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_dcf771f123cf4f5e87c0eb4dd0f0c56c" contextRef="c20200101to20200331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">676,548</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_d0b4768edbfe4ffdbb56616e9701cc30" contextRef="c20200101to20200331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_5d5ac49545fd4fa898b3cb5f31c0c623" contextRef="c20200101to20200331" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">676,548</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Issuance of common stock, net of offering expenses</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_ada50275eda24bfb94e747a548220fdf" contextRef="c20200101to20200331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">27,025,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_559c7123223145dda85c5bf8a5ddc05e" contextRef="c20200101to20200331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">2,703</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_75980879834e4eacb1498bf6445393cd" contextRef="c20200101to20200331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">88,701,336</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_4b5f381ebbee41a2bbd901a1fa1ed789" contextRef="c20200101to20200331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_c0c1f109bdcb42e5a7019aff7a7bd8da" contextRef="c20200101to20200331" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">88,704,039</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Exercise of stock options</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_2d24d454ca15479eb0b5dc26fa6a0ef1" contextRef="c20200101to20200331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">1,958</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_7ee7f9f7dcc04c41ad8ba65b848acc13" contextRef="c20200101to20200331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_f43acf3260c345cda98068846c5d85dc" contextRef="c20200101to20200331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">7,177</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_c8be8287c06d41c3aae0bd855a7a993b" contextRef="c20200101to20200331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_0da0e3b660b441ebac8de6b209478ec3" contextRef="c20200101to20200331" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">7,177</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 2px; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Net loss</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>-</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_ed05126635fe445baf1a05e06f893314" contextRef="c20200101to20200331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_83a6894d51aa43599197d6f50eb13745" contextRef="c20200101to20200331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_c310bbb136464734a0ab7bd10fbbb1cd" contextRef="c20200101to20200331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">19,245,230</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_a0fb27d99e6449ef9d1c54766adf5484" contextRef="c20200101to20200331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">19,245,230</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Balance at March 31, <span style="text-indent: 0pt;">2020</span></div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_f1bd0ca111954cab850c2557cf0bfdda" contextRef="c20200331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">86,345,313</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_355e50adcdc74fc3956641f095cbc781" contextRef="c20200331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">8,635</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_eac31b33353f4162a66b494f67bacaac" contextRef="c20200331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">380,288,833</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_aa870c133a754af2adaed679adff1350" contextRef="c20200331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">283,961,785</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_1a2bd3a2b89e491e989cf408beb63542" contextRef="c20200331" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">96,335,683</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Stock-based compensation</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>-</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_f271dccbb78b4cd6bb8e7c2621787fcf" contextRef="c20200401to20200630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_52083d1b4e6f438bb9063656ee4d015c" contextRef="c20200401to20200630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">715,608</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_a964ffa25c9447ff9923e847dc22a1c7" contextRef="c20200401to20200630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_6065b0c5d0904ad7b42761ae3c5c8dca" contextRef="c20200401to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">715,608</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Exercise of stock options</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_5f5e340dc1aa462ebae9aaf7b25ea3d7" contextRef="c20200401to20200630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">4,668</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_db6d541c60bd42969d3de03622f25b9a" contextRef="c20200401to20200630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_1fa37fb7d6314366bba755b0f92a5ddb" contextRef="c20200401to20200630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">6,255</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_a4a8496a5f6a455480e7b139af04fda2" contextRef="c20200401to20200630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_75f1f9a4a4ca4064abffe062bb3a1cb9" contextRef="c20200401to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">6,255</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 2px; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Net loss</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>-</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_be478214ac9d4e638d8686d690010837" contextRef="c20200401to20200630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_187697f3f9274e038e26f859a8abdfc2" contextRef="c20200401to20200630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_23137b069bad49d496494f37e43889b4" contextRef="c20200401to20200630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">20,178,091</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_36da3705617f483d985618c936fe9438" contextRef="c20200401to20200630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">20,178,091</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 4px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Balance at June 30, <span style="text-indent: 0pt;">2020</span></div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_bb5bad4b835247aea9472bb73090d4ab" contextRef="c20200630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">86,349,981</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_03be9aa3ae29435096e5d69ef2a7d78d" contextRef="c20200630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">8,635</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_26202f5d634d4717a2becb5d57f8aa79" contextRef="c20200630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">381,010,696</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_001f6983a47045c3becedc4948db400d" contextRef="c20200630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">304,139,876</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_773acc9bd45a493a81c90eea013a9f4c" contextRef="c20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">76,879,455</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: center;">The accompanying notes are an integral part of these condensed consolidated financial statements.</div>

        <div style="text-align: center;"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">3</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index<br />
                    </a></td>

  </tr>


</table>
          </div>

        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <div>
        <div style="text-align: center; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

        <div style="text-align: center; font-weight: bold;">CONDENSED CONSOLIDATED STATEMENTS OF<!--Anchor--> <a id="CASHFLOWS"><!--Anchor--></a>CASH FLOWS</div>

        <div style="text-align: center; font-weight: bold;">(Unaudited)</div>

        <div style="text-align: center; font-weight: bold;"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="6">
                <div style="text-align: center; font-weight: bold;">Six Months Ended June 30,</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                <div style="text-align: center; font-weight: bold;"> 2021<br />
                </div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                <div style="text-align: center; font-weight: bold;">2020<br />
                </div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">CASH FLOWS FROM OPERATING ACTIVITIES:</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Net loss</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_63479501b6734fa9b4bafb7d53a92ae4" contextRef="c20210101to20210630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">37,285,244</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_554cda1cba654604bbccaaebde7db98c" contextRef="c20200101to20200630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">39,423,321</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Adjustments to reconcile net loss to net cash used in operating activities:</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Depreciation and amortization</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_83080cccdd6c41ebbae85287f51e38d5" contextRef="c20210101to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">2,555,622</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_ca7370b0b19e46f99b974659c5ad04e6" contextRef="c20200101to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,674,490</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Loss on disposal of fixed assets</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets" id="Fact_515262ae94b843ba8af2bd8952c28fa5" contextRef="c20210101to20210630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">78,135</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets" id="Fact_68fa0d6ea69d4931b29a903cca06f2d5" contextRef="c20200101to20200630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">3,518</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Stock-based compensation</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_8d5c2bb295224d419c3420694af40e45" contextRef="c20210101to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,586,586</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_670daf81ec0e4ae59184cfe715be7bcc" contextRef="c20200101to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,392,156</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Amortization of debt discount</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" id="Fact_fd92d9f44d34479786a5d68a3983d2af" contextRef="c20210101to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">908,151</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" id="Fact_f13bdc7f5a914f4084b4953436f3654d" contextRef="c20200101to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">874,732</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Amortization of license revenue</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="adma:AmortizationOfLicenseRevenue" id="Fact_3e57e53903a545c1ac13b4b75ab07fce" contextRef="c20210101to20210630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">71,417</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="adma:AmortizationOfLicenseRevenue" id="Fact_89a9d124aac042ee93e9b2e64f0875e0" contextRef="c20200101to20200630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">71,417</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Changes in operating assets and liabilities:</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Accounts receivable</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" id="Fact_1dd109c39b304e7c91c47847eb964c36" contextRef="c20210101to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">10,307,304</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" id="Fact_9b8f4c75f5734cdc85490f66d98fe227" contextRef="c20200101to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">3,044,246</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Inventories</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" id="Fact_264d1acc9c834f019a733c35d2177df8" contextRef="c20210101to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">18,164,144</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" id="Fact_a9b6140c5d234afdb8706bbbf1d75f35" contextRef="c20200101to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">2,936,614</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Prepaid expenses and other current assets</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" id="Fact_f5acef387bce4b40a96171dd2a65c78a" contextRef="c20210101to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">2,655,397</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" id="Fact_c77b61709a1d49c7b5267b2f15dde1bc" contextRef="c20200101to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">2,159,834</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Deposits and other assets</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="adma:IncreaseDecreaseInDepositsAndOtherAssets" id="Fact_b1d73d329b954767897f8f303d9ffebf" contextRef="c20210101to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">144,657</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="adma:IncreaseDecreaseInDepositsAndOtherAssets" id="Fact_bf9008a7b96d42e0a6fa92a97ab7c4a8" contextRef="c20200101to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">283,195</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Accounts payable</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" id="Fact_3f886d78219940d3ae9eb541eb90c632" contextRef="c20210101to20210630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">4,906,244</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" id="Fact_5bbf598ffc494351b32f0efe70ce5fee" contextRef="c20200101to20200630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">2,264,932</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Accrued expenses</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" id="Fact_40dbe8521d1446c6936e91f772fa3bf3" contextRef="c20210101to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">2,980,534</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" id="Fact_fd95dbec2e6c4bf48dfad93fd19f3ed9" contextRef="c20200101to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">399,295</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Other current and non-current liabilities</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" id="Fact_f25bbf8593734543b01b1dfd3ea1038e" contextRef="c20210101to20210630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">65,984</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" id="Fact_973d5a4d2ef14b7abe9ed0af9a9d952f" contextRef="c20200101to20200630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">92,067</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Net cash used in operating activities</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Fact_6cfe9408e8844ab9b40d95553100bcca" contextRef="c20210101to20210630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">65,491,363</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Fact_a0dea6324de24915a75e5abd788855e6" contextRef="c20200101to20200630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">45,931,435</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">CASH FLOWS FROM INVESTING ACTIVITIES:</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Purchase of property and equipment</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" id="Fact_b1f5fe8caf7047798637405d4650fbb9" contextRef="c20210101to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">7,046,735</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" id="Fact_4e1c44f0ac144022bf9d800076d23a3a" contextRef="c20200101to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">6,243,284</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Proceeds from the sale of property and equipment</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" id="Fact_6797a2378adb4390a83c89996c6db0aa" contextRef="c20210101to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" id="Fact_319349c6d12d469ea5b228d443c43f4e" contextRef="c20200101to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">2,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Net cash used in investing activities</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" id="Fact_8b1af39671aa45ceb09f7ef327d9e32a" contextRef="c20210101to20210630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">7,046,735</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" id="Fact_d8843976a13c448cafd94324f9287089" contextRef="c20200101to20200630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">6,241,284</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">CASH FLOWS FROM FINANCING ACTIVITIES:</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Proceeds from issuance of common stock, net of offering expenses</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_336dc76cd6de47ed99aa178e48304f19" contextRef="c20210101to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">59,102,075</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_06d204f867994332ab5b936e4c9ddb74" contextRef="c20200101to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">88,704,039</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Proceeds from the exercise of stock options</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" id="Fact_e1a434839c5c4e438182727f622e3fb7" contextRef="c20210101to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" id="Fact_946f591d558d46f9bea90b6cd5f7f278" contextRef="c20200101to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">13,432</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Taxes paid on vested Restricted Stock Units</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="adma:TaxesPaidOnVestedRestrictedStockUnits" id="Fact_d32a8fddbec241f5ab3ae2c5cfadb6a4" contextRef="c20210101to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">59,311</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="adma:TaxesPaidOnVestedRestrictedStockUnits" id="Fact_f2f6799b325341b3a9d32f52e87bc068" contextRef="c20200101to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Proceeds from issuance of note payable</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" id="Fact_daafaa6a38a548018b49111022183f8d" contextRef="c20210101to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" id="Fact_e7be14b72a6c429caeb899de0f038105" contextRef="c20200101to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">12,500,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Payments on finance lease obligations</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" id="Fact_32e891ca8de644d3b4189b5bb7913221" contextRef="c20210101to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">16,860</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" id="Fact_ae409d8f4bc74c5ebf7a79249c40adb1" contextRef="c20200101to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">15,765</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Net cash provided by financing activities</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" id="Fact_69272294317744fcbfbcc384392b85ee" contextRef="c20210101to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">59,025,904</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" id="Fact_d0382ac483a34ed6abd49cbd4df0a0eb" contextRef="c20200101to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">101,201,706</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Net (decrease) increase in cash and cash equivalents</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" id="Fact_45c3b87b315a4c698252bde2791e3307" contextRef="c20210101to20210630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">13,512,194</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" id="Fact_79454785ed50456da17cfe72739aa946" contextRef="c20200101to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">49,028,987</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Cash and cash equivalents - beginning of period</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_b2be9221ca3942a0b45e4f329506aeb1" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">55,921,152</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_2bd75314b7494603aa085ca7d4edf16b" contextRef="c20191231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">26,752,135</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Cash and cash equivalents - end of period</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_ab8dcca17d114290a2011513bb272e45" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">42,408,958</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_2c2c2920b7a9492c8d90f7f638ebc74e" contextRef="c20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">75,781,122</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: center;">The accompanying notes are an integral part of these condensed consolidated financial statements.</div>

        <div><br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">4</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index<br />
                    </a></td>

  </tr>


</table>
          </div>

        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
      <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">
        <a id="FINANCIALSTATEMENTS"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100.00%;">
                <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>
                <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>
              </td>

  </tr>


</table>
        <div><br /></div>

      </div>

      <div>
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

        <div><ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Text_88329a42a4ee4d0fa66d0bad3c26ba8f" contextRef="c20210101to20210630" escape="true" continuedAt="Text_57ea12eb992c47c8bd7d5aea1b1783341">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_57ea12eb992c47c8bd7d5aea1b1783341" continuedAt="Text_57ea12eb992c47c8bd7d5aea1b1783342">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">ORGANIZATION AND BUSINESS</span></div>
                </td>

  </tr>


</table>
</ix:continuation>
          <ix:continuation id="Text_57ea12eb992c47c8bd7d5aea1b1783342" continuedAt="Text_57ea12eb992c47c8bd7d5aea1b1783343">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_57ea12eb992c47c8bd7d5aea1b1783343" continuedAt="Text_57ea12eb992c47c8bd7d5aea1b1783344">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_57ea12eb992c47c8bd7d5aea1b1783344" continuedAt="Text_57ea12eb992c47c8bd7d5aea1b1783345">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_57ea12eb992c47c8bd7d5aea1b1783345" continuedAt="Text_57ea12eb992c47c8bd7d5aea1b1783346">
<div style="display:none;"><br /></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">ADMA Biologics, Inc. (&#8220;ADMA&#8221; or the &#8220;Company&#8221;) is an end-to-end commercial
            biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The
            Company&#8217;s targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons.</div>
</ix:continuation>
          <ix:continuation id="Text_57ea12eb992c47c8bd7d5aea1b1783346" continuedAt="Text_57ea12eb992c47c8bd7d5aea1b1783347">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_57ea12eb992c47c8bd7d5aea1b1783347" continuedAt="Text_57ea12eb992c47c8bd7d5aea1b1783348">
<div style="display:none;"><br /></div>
<div style="text-indent: 33.75pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_57ea12eb992c47c8bd7d5aea1b1783348" continuedAt="Text_57ea12eb992c47c8bd7d5aea1b1783349">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_57ea12eb992c47c8bd7d5aea1b1783349" continuedAt="Text_57ea12eb992c47c8bd7d5aea1b17833410">
<div style="display:none;"><br /></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">ADMA operates through its wholly-owned subsidiaries ADMA BioManufacturing, LLC (&#8220;ADMA
            BioManufacturing&#8221;) and ADMA BioCenters Georgia Inc. (&#8220;ADMA BioCenters&#8221;). ADMA BioManufacturing was formed in January 2017 to facilitate the acquisition of the Biotest Therapy Business Unit (&#8220;BTBU&#8221;) from BPC Plasma, Inc. (formerly Biotest
            Pharmaceuticals Corporation) (&#8220;BPC&#8221; and, together with Biotest AG, &#8220;Biotest&#8221;) on June 6, 2017. The acquisition included certain assets (the &#8220;Biotest Assets&#8221;) of BTBU, which included the FDA-licensed BIVIGAM and Nabi-HB immunoglobulin products,
            and an FDA-licensed plasma fractionation manufacturing facility located in Boca Raton, FL (the &#8220;Boca Facility&#8221;) (the &#8220;Biotest Transaction&#8221;). BTBU had previously been the Company&#8217;s third-party contract manufacturer. ADMA BioCenters is the
            Company&#8217;s source plasma collection business with <ix:nonFraction name="adma:NumberOfPlasmaCollectionFacilitiesUnderDevelopment" id="Fact_031fdfc61f444092b07221fedfa54d04" contextRef="c20210101to20210630" unitRef="U004" decimals="INF" scale="0" format="ixt-sec:numwordsen">eight</ix:nonFraction> plasma collection facilities in various stages of approval and development
            located throughout the U.S., <ix:nonFraction name="adma:NumberOfFDALicensedPlasmaCollectionFacilities" id="Fact_5b60fa18617a487692f8cc703f2d5d9a" contextRef="c20210101to20210630" unitRef="U004" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> of which hold an approved license with the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) while a
            third facility has a Biologics License Application (&#8220;BLA&#8221;) pending FDA approval.</div>
</ix:continuation>
          <ix:continuation id="Text_57ea12eb992c47c8bd7d5aea1b17833410" continuedAt="Text_57ea12eb992c47c8bd7d5aea1b17833411">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_57ea12eb992c47c8bd7d5aea1b17833411" continuedAt="Text_57ea12eb992c47c8bd7d5aea1b17833412">
<div style="display:none;"><br /></div>
<div style="text-indent: 33.75pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_57ea12eb992c47c8bd7d5aea1b17833412" continuedAt="Text_57ea12eb992c47c8bd7d5aea1b17833413">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_57ea12eb992c47c8bd7d5aea1b17833413" continuedAt="Text_57ea12eb992c47c8bd7d5aea1b17833414">
<div style="display:none;"><br /></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The Company has <ix:nonFraction name="adma:NumberOfFDAApprovedProduct" id="Fact_53446129f2e5474f80608ef59aff3c5e" contextRef="c20210101to20210630" unitRef="U005" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction> FDA-approved products, all of which are currently marketed and commercially available: (i) BIVIGAM (Immune Globulin Intravenous, Human), an Intravenous Immune Globulin (&#8220;IVIG&#8221;)
            product indicated for the treatment of Primary Humoral Immunodeficiency (&#8220;PI&#8221;), also known as Primary Immunodeficiency Disease (&#8220;PIDD&#8221;), and for which the Company received FDA approval on May 9, 2019 and commenced commercial sales in August
            2019; (ii) ASCENIV (Immune Globulin Intravenous, Human &#8211; slra 10% Liquid), an IVIG product indicated for the treatment of PI, for which the Company received FDA approval on April 1, 2019 and commenced first commercial sales in October 2019; and
            (iii) Nabi-HB (Hepatitis B Immune Globulin, Human), which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen (&#8220;HBsAg&#8221;) and other listed exposures to Hepatitis B. In addition to its commercially
            available immunoglobulin products, the Company provides contract manufacturing and laboratory services for certain clients and generates revenues from the sale of intermediate by-products that result from the immunoglobulin production process.
            The Company seeks to develop a pipeline of plasma-derived therapeutics, and its products and product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients with or at risk for certain
            infectious diseases.</div>
</ix:continuation>
          <ix:continuation id="Text_57ea12eb992c47c8bd7d5aea1b17833414" continuedAt="Text_57ea12eb992c47c8bd7d5aea1b17833415">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_57ea12eb992c47c8bd7d5aea1b17833415" continuedAt="Text_57ea12eb992c47c8bd7d5aea1b17833416">
<div style="display:none;"><br /></div>
<div style="text-indent: 33.75pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_57ea12eb992c47c8bd7d5aea1b17833416" continuedAt="Text_57ea12eb992c47c8bd7d5aea1b17833417">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_57ea12eb992c47c8bd7d5aea1b17833417" continuedAt="Text_57ea12eb992c47c8bd7d5aea1b17833418">
<div style="display:none;"><br /></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">As of June 30, 2021, the Company had working capital of $<ix:nonFraction name="adma:WorkingCapital" id="Fact_8194587f8e614d498f3b7f84de810705" contextRef="c20210630" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">153.2</ix:nonFraction> million, including $<ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" id="Fact_683cefc756784e1583e970c2928e0af1" contextRef="c20210630" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">42.4</ix:nonFraction>
            million of cash and cash equivalents. Based upon the Company&#8217;s current projected revenue and expenditures, including capital expenditures and continued implementation of the Company&#8217;s commercialization and expansion activities, the Company&#8217;s
            management currently believes that its cash, cash equivalents, projected revenue and accounts receivable will be sufficient to fund ADMA&#8217;s operations, as currently conducted, into the fourth quarter of 2021. In order to have sufficient cash to
            fund its operations thereafter, the Company anticipates it will need to raise additional capital before the end of the fourth quarter of 2021. These estimates may change based upon several factors, including the success of the Company&#8217;s
            commercial sales of its products, manufacturing ramp-up activities, the acceptability of ADMA&#8217;s immune globulin products by physicians, patients or payers and the various financing options that may be available to the Company. In addition, the
            Company&#8217;s end-to-end production cycle from procurement of raw materials to commercial release of finished product can take between <span style="-sec-ix-hidden:Fact_53babb8f6d26472fabf16dec51a6b0a4">seven</span>
            and <ix:nonNumeric name="adma:ProductCycleFromProcurementOfRawMaterialsToFinishedProduct" id="Fact_a74ad2c25ec64e86b81e16715fdc49b2" contextRef="c20210101to20210630_RangeAxis_MaximumMember" format="ixt-sec:durmonth">12</ix:nonNumeric> months or potentially longer, requiring substantial investments in raw material plasma and other manufacturing materials. The
            Company currently has no firm commitments for additional financing, and there can be no assurance that the Company will be able to secure additional financing on terms that are acceptable to the Company, or at all. Furthermore, if the Company&#8217;s
            assumptions underlying its estimated expenses and revenues are incorrect, it may have to raise additional capital sooner than currently anticipated.</div>
</ix:continuation>
          <ix:continuation id="Text_57ea12eb992c47c8bd7d5aea1b17833418" continuedAt="Text_57ea12eb992c47c8bd7d5aea1b17833419">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <div>
            <div>
              <ix:continuation id="Text_57ea12eb992c47c8bd7d5aea1b17833419" continuedAt="Text_57ea12eb992c47c8bd7d5aea1b17833420">
<div><br />
              </div>
</ix:continuation>
            </div>

            <ix:continuation id="Text_57ea12eb992c47c8bd7d5aea1b17833420" continuedAt="Text_57ea12eb992c47c8bd7d5aea1b17833421">
<div><br /></div>
</ix:continuation>
          </div>

          <ix:continuation id="Text_57ea12eb992c47c8bd7d5aea1b17833421" continuedAt="Text_57ea12eb992c47c8bd7d5aea1b17833422">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
            <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">5</span></div>

            <div style="page-break-after:always;" class="DSPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

            <div style="width: 100%;" class="DSPFPageHeader">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 100%; font-size: 8pt; font-style: italic;">
                      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>
                      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>
                    </td>

  </tr>


</table>
            </div>

          </div>

          <ix:continuation id="Text_57ea12eb992c47c8bd7d5aea1b17833422" continuedAt="Text_57ea12eb992c47c8bd7d5aea1b17833423">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Due to numerous risks and uncertainties associated with FDA review, inspections and approvals related to the
            Company&#8217;s products or the labeled indications of such products, ongoing compliance requirements and capacity expansion efforts at the Company&#8217;s Boca Facility and future commercialization of the Company&#8217;s products, including the Company&#8217;s
            ability to obtain adequate quantities of FDA-approved plasma with proper specifications on acceptable terms for use in the Company&#8217;s manufacturing process, as well as the additional uncertainties surrounding the COVID-19 pandemic (see Note 10),
            the Company is unable to estimate with certainty the amounts of increased capital outlays and operating expenditures required to fund its commercial and development activities. The Company&#8217;s current estimates may be subject to change as
            circumstances regarding its business requirements evolve. Failure to secure any necessary financing in a timely manner and on commercially reasonable terms could have a material adverse effect on the Company&#8217;s business plan and financial
            performance and it could be forced to delay or discontinue its commercialization, product development or clinical activities or delay or discontinue the approval efforts for any of the Company&#8217;s products or product candidates. The Company has
            reported cumulative losses since inception in June 2004 through June 30, 2021 of $<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" id="Fact_d1886db912c74841aa633cd5372f7284" contextRef="c20210630" unitRef="U002" decimals="-5" sign="-" scale="6" format="ixt:numdotdecimal">377.8</ix:nonFraction> million. As such, these factors raise
            substantial doubt about the Company&#8217;s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments related to the recoverability and classification of asset carrying amounts and the
            classification of liabilities that might be necessary from the outcome of this uncertainty.</div>
</ix:continuation>
          <ix:continuation id="Text_57ea12eb992c47c8bd7d5aea1b17833423" continuedAt="Text_57ea12eb992c47c8bd7d5aea1b17833424">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_57ea12eb992c47c8bd7d5aea1b17833424" continuedAt="Text_57ea12eb992c47c8bd7d5aea1b17833425">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_57ea12eb992c47c8bd7d5aea1b17833425" continuedAt="Text_57ea12eb992c47c8bd7d5aea1b17833426">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_57ea12eb992c47c8bd7d5aea1b17833426" continuedAt="Text_57ea12eb992c47c8bd7d5aea1b17833427">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The Company may decide to raise capital through public or private equity offerings or debt financings, or
            obtain a bank credit facility or enter into corporate collaboration and licensing arrangements. The sale of additional equity or debt securities, if convertible, could result in dilution to the Company&#8217;s existing stockholders and, in such
            event, the market value of its common stock may decline. The incurrence of additional indebtedness would result in increased fixed obligations and could also result in covenants that would restrict the Company&#8217;s operations or other financing
            alternatives. In addition, the Company is exploring additional contract manufacturing arrangements and other business development opportunities, which may provide additional liquidity to the Company.</div>
</ix:continuation>
          <ix:continuation id="Text_57ea12eb992c47c8bd7d5aea1b17833427" continuedAt="Text_57ea12eb992c47c8bd7d5aea1b17833428">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_57ea12eb992c47c8bd7d5aea1b17833428" continuedAt="Text_57ea12eb992c47c8bd7d5aea1b17833429">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_57ea12eb992c47c8bd7d5aea1b17833429" continuedAt="Text_57ea12eb992c47c8bd7d5aea1b17833430">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_57ea12eb992c47c8bd7d5aea1b17833430" continuedAt="Text_57ea12eb992c47c8bd7d5aea1b17833431">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">During the six months ended June 30, 2021, the Company raised $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" id="Fact_7fa614f8e0e54f74a221311d32613a6d" contextRef="c20210101to20210630_ConsolidatedEntitiesAxis_JefferiesLLCMember_TypeOfArrangementAxis_SaleAgreement2020Member" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">59.1</ix:nonFraction> million from the open market sale agreement dated August 5, 2020, as amended, (the &#8220;2020 Sale Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;), pursuant to which the
            Company could offer and sell, from time to time, at its option, through or to Jefferies, shares of the Company&#8217;s common stock (see Note 8). In July of 2021, the Company raised an additional $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" id="Fact_904e693f7e3f4c1983c50b867b469a54" contextRef="c20210731to20210731_ConsolidatedEntitiesAxis_JefferiesLLCMember_SubsequentEventTypeAxis_SubsequentEventMember_TypeOfArrangementAxis_SaleAgreement2020Member" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction> million under the 2020 Sale Agreement, and the Company has reached the maximum amount of funds that can be raised under the 2020 Sale Agreement.</div>
</ix:continuation>
          <ix:continuation id="Text_57ea12eb992c47c8bd7d5aea1b17833431" continuedAt="Text_57ea12eb992c47c8bd7d5aea1b17833432">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_57ea12eb992c47c8bd7d5aea1b17833432" continuedAt="Text_57ea12eb992c47c8bd7d5aea1b17833433">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_57ea12eb992c47c8bd7d5aea1b17833433" continuedAt="Text_57ea12eb992c47c8bd7d5aea1b17833434">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_57ea12eb992c47c8bd7d5aea1b17833434" continuedAt="Text_57ea12eb992c47c8bd7d5aea1b17833435">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">On May 28, 2021, the Company entered into a new Open Market Sale AgreementSM (the &#8220;2021 Sale Agreement&#8221;) with
            Jefferies, pursuant to which the Company may offer and sell, from time to time, at its option, through or to Jefferies, up to an aggregate of $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_2b5f8c6009ab40e6aec57a77b9348a52" contextRef="c20210528to20210528_ConsolidatedEntitiesAxis_JefferiesLLCMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_SaleAgreement2021Member" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">50,000,000</ix:nonFraction>
            of shares of the Company&#8217;s common stock. As of August 11, 2021, there have been <ix:nonFraction name="us-gaap:CommonUnitIssuanceValue" id="Fact_54f8eb44153d4d7ab3546705cb597f69" contextRef="c20210811_ConsolidatedEntitiesAxis_JefferiesLLCMember_SubsequentEventTypeAxis_SubsequentEventMember_TypeOfArrangementAxis_SaleAgreement2021Member" unitRef="U002" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction> sales of common stock under the 2021 Sale
            Agreement.</div>
</ix:continuation>
          <ix:continuation id="Text_57ea12eb992c47c8bd7d5aea1b17833435" continuedAt="Text_57ea12eb992c47c8bd7d5aea1b17833436">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_57ea12eb992c47c8bd7d5aea1b17833436" continuedAt="Text_57ea12eb992c47c8bd7d5aea1b17833437">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_57ea12eb992c47c8bd7d5aea1b17833437" continuedAt="Text_57ea12eb992c47c8bd7d5aea1b17833438">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_57ea12eb992c47c8bd7d5aea1b17833438">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">There can be no assurance that the Company&#8217;s approved products will be commercially viable, or that research
            and development, plant capacity expansion, plasma center build-outs or other capital improvements will be successfully completed or that any product developed in the future will be approved. The Company is subject to risks common to companies
            in the biotechnology and pharmaceutical manufacturing industries including, but not limited to, dependence on collaborative arrangements, development by the Company or its competitors of new technological innovations, dependence on key
            personnel, protection of proprietary technology, and compliance with FDA and other governmental regulations and approval requirements.</div>
</ix:continuation>
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

          <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

        <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

  </div>
<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

        <div><ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Text_de030162bc8b448998134934872398f9" contextRef="c20210101to20210630" escape="true" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c34161">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c34161" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c34162">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></div>
                </td>

  </tr>


</table>
</ix:continuation>
          <ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c34162" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c34163">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c34163" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c34164">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation><ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Text_1b842d491338428ea527247b3dcb683e" contextRef="c20210101to20210630" escape="true" continuedAt="Text_a06944d40ca045bbb6c3706472b138bf1"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c34164" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c34165">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:nonNumeric>
          <ix:continuation id="Text_a06944d40ca045bbb6c3706472b138bf1" continuedAt="Text_a06944d40ca045bbb6c3706472b138bf2"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c34165" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c34166">
<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Basis of presentation</span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_a06944d40ca045bbb6c3706472b138bf2" continuedAt="Text_a06944d40ca045bbb6c3706472b138bf3"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c34166" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c34167">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_a06944d40ca045bbb6c3706472b138bf3" continuedAt="Text_a06944d40ca045bbb6c3706472b138bf4"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c34167" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c34168">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_a06944d40ca045bbb6c3706472b138bf4" continuedAt="Text_a06944d40ca045bbb6c3706472b138bf5"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c34168" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c34169">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_a06944d40ca045bbb6c3706472b138bf5" continuedAt="Text_a06944d40ca045bbb6c3706472b138bf6"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c34169" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341610">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with
            accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards
            Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (the &#8220;FASB&#8221;).</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_a06944d40ca045bbb6c3706472b138bf6" continuedAt="Text_a06944d40ca045bbb6c3706472b138bf7"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341610" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341611">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_a06944d40ca045bbb6c3706472b138bf7" continuedAt="Text_a06944d40ca045bbb6c3706472b138bf8"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341611" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341612">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_a06944d40ca045bbb6c3706472b138bf8" continuedAt="Text_a06944d40ca045bbb6c3706472b138bf9"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341612" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341613">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
            <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">6</span></div>

            <div style="page-break-after:always;" class="DSPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

            <div style="width: 100%;" class="DSPFPageHeader">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 100%; font-size: 8pt; font-style: italic;">
                      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>
                      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>
                    </td>

  </tr>


</table>
            </div>

          </div>

          <ix:continuation id="Text_a06944d40ca045bbb6c3706472b138bf9" continuedAt="Text_a06944d40ca045bbb6c3706472b138bf10"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341613" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341614">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the
            annual audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2020 included in the Company&#8217;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on March
            25, 2021.&#160; The accompanying consolidated balance sheet as of December 31, 2020 was derived from the audited financial statements as of and for the year ended December 31, 2020. These condensed consolidated interim financial statements have been
            prepared in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X, and therefore omit or condense certain footnotes and other information normally included in complete consolidated financial statements prepared in
            accordance with U.S. GAAP. All intercompany balances and transactions have been eliminated in consolidation.&#160; In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all normal and recurring
            adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company&#8217;s financial position as of June 30, 2021 and its results of operations, changes
            in equity and cash flows for the three and six months ended June 30, 2021.</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_a06944d40ca045bbb6c3706472b138bf10" continuedAt="Text_a06944d40ca045bbb6c3706472b138bf11"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341614" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341615">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_a06944d40ca045bbb6c3706472b138bf11" continuedAt="Text_a06944d40ca045bbb6c3706472b138bf12"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341615" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341616">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_a06944d40ca045bbb6c3706472b138bf12" continuedAt="Text_a06944d40ca045bbb6c3706472b138bf13"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341616" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341617">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_a06944d40ca045bbb6c3706472b138bf13"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341617" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341618">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">During the three and six months ended June 30, 2021 and 2020, comprehensive loss was equal to the net loss
            amounts presented for the respective periods in the accompanying condensed consolidated statements of operations.&#160;&#160; Operating results for interim periods are not necessarily indicative of the results that may be expected for the full fiscal
            year.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341618" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341619">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341619" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341620">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation><ix:nonNumeric name="us-gaap:UseOfEstimates" id="Text_8dc991838e454edf8db537076279b401" contextRef="c20210101to20210630" escape="true" continuedAt="Text_86e932dfd5ac4b7581f81d6dd8f9e24f1"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341620" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341621">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:nonNumeric>
          <ix:continuation id="Text_86e932dfd5ac4b7581f81d6dd8f9e24f1" continuedAt="Text_86e932dfd5ac4b7581f81d6dd8f9e24f2"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341621" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341622">
<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Use of estimates</span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_86e932dfd5ac4b7581f81d6dd8f9e24f2" continuedAt="Text_86e932dfd5ac4b7581f81d6dd8f9e24f3"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341622" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341623">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_86e932dfd5ac4b7581f81d6dd8f9e24f3" continuedAt="Text_86e932dfd5ac4b7581f81d6dd8f9e24f4"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341623" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341624">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_86e932dfd5ac4b7581f81d6dd8f9e24f4" continuedAt="Text_86e932dfd5ac4b7581f81d6dd8f9e24f5"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341624" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341625">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_86e932dfd5ac4b7581f81d6dd8f9e24f5"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341625" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341626">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The preparation of financial statements requires management to make estimates and assumptions that affect the
            reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ
            from those estimates. Significant estimates include the realizable value of accounts receivable, valuation of inventory, assumptions used in projecting future liquidity and capital requirements, assumptions used in the fair value of awards
            granted under the Company&#8217;s equity incentive plans and warrants issued in connection with the issuance of notes payable and the valuation allowance for the Company&#8217;s deferred tax assets.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341626" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341627">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341627" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341628">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation><ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Text_960edfd623ae41ecbb40cabb46d04a99" contextRef="c20210101to20210630" escape="true" continuedAt="Text_7f52102ed1a243f79a473e2dcc71c5f71"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341628" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341629">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:nonNumeric>
          <ix:continuation id="Text_7f52102ed1a243f79a473e2dcc71c5f71" continuedAt="Text_7f52102ed1a243f79a473e2dcc71c5f72"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341629" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341630">
<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Fair value of financial instruments</span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_7f52102ed1a243f79a473e2dcc71c5f72" continuedAt="Text_7f52102ed1a243f79a473e2dcc71c5f73"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341630" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341631">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_7f52102ed1a243f79a473e2dcc71c5f73" continuedAt="Text_7f52102ed1a243f79a473e2dcc71c5f74"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341631" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341632">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_7f52102ed1a243f79a473e2dcc71c5f74" continuedAt="Text_7f52102ed1a243f79a473e2dcc71c5f75"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341632" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341633">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_7f52102ed1a243f79a473e2dcc71c5f75"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341633" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341634">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The carrying amounts of certain of the Company&#8217;s financial instruments, including cash and cash equivalents,
            accounts receivable and accounts payable, are shown at cost which approximates fair value due to the short-term nature of these instruments.&#160; The debt outstanding under the Company&#8217;s senior secured term loan (see Note 7) approximates fair value
            due to the variable interest rate on this debt.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341634" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341635">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341635" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341636">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation><ix:nonNumeric name="us-gaap:ReceivablesPolicyTextBlock" id="Text_1d7ad30ef88342e895d372c263a22966" contextRef="c20210101to20210630" escape="true" continuedAt="Text_276b4517208b4e669e17a229c4d5b6f61"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341636" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341637">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:nonNumeric>
          <ix:continuation id="Text_276b4517208b4e669e17a229c4d5b6f61" continuedAt="Text_276b4517208b4e669e17a229c4d5b6f62"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341637" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341638">
<div style="font-style: italic;"><span style="text-decoration: underline;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Accounts receivable<br />
              </span></span> <span style="text-decoration: underline;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
              </span></span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_276b4517208b4e669e17a229c4d5b6f62" continuedAt="Text_276b4517208b4e669e17a229c4d5b6f63"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341638" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341639">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_276b4517208b4e669e17a229c4d5b6f63"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341639" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341640">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Accounts receivable is reported at realizable value, net of allowances for contractual credits and doubtful
            accounts in the amount of $<ix:nonFraction name="adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" id="Fact_f9aeec2ee42b4158ae576a190462cc87" contextRef="c20210630" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction> million and $<ix:nonFraction name="adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" id="Fact_84ebdf5555a34034a92a8e0b907d7a7b" contextRef="c20201231" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction> million at June 30, 2021 and December 31, 2020, respectively, which are recognized in the period the related revenue is recorded. <span style="color: rgb(33, 37, 41);">The Company
              extends credit to its customers based upon an evaluation of each customer&#8217;s financial condition and credit history. Evaluations of the financial condition and associated credit risk of customers are performed on an ongoing basis.</span> Based
            on these evaluations, the Company has concluded that its credit risk is minimal. At June 30, 2021, <ix:nonFraction name="adma:NumberOfCustomers" id="Fact_765cd720dbb84638856e02caa4ffe34a" contextRef="c20210101to20210630_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_SixCustomersMember" unitRef="U006" decimals="INF" scale="0" format="ixt-sec:numwordsen">six</ix:nonFraction> customers accounted for an
            aggregate of <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_edc6bca224f9451fa65d0b352bcb7705" contextRef="c20210101to20210630_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_SixCustomersMember" unitRef="U007" decimals="2" scale="-2" format="ixt:numdotdecimal">94</ix:nonFraction>% of the Company&#8217;s total accounts receivable, and at December 31, 2020, <ix:nonFraction name="adma:NumberOfCustomers" id="Fact_b817f141c32e420796bf77d976d87774" contextRef="c20200101to20201231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_ThreeCustomersMember" unitRef="U006" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction> customers accounted for approximately <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_de0c4115bbb6401695d47ca7588242d3" contextRef="c20200101to20201231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_ThreeCustomersMember" unitRef="U007" decimals="2" scale="-2" format="ixt:numdotdecimal">92</ix:nonFraction>% of the
            Company&#8217;s total accounts receivable.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341640" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341641">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341641" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341642">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation><ix:nonNumeric name="us-gaap:InventoryPolicyTextBlock" id="Text_a6c7a7396fa04bec80b800afedb33d14" contextRef="c20210101to20210630" escape="true" continuedAt="Text_75a298ebdc484865912f8dca9bfcf22b1"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341642" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341643">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:nonNumeric>
          <ix:continuation id="Text_75a298ebdc484865912f8dca9bfcf22b1" continuedAt="Text_75a298ebdc484865912f8dca9bfcf22b2"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341643" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341644">
<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Inventories</span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_75a298ebdc484865912f8dca9bfcf22b2" continuedAt="Text_75a298ebdc484865912f8dca9bfcf22b3"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341644" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341645">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_75a298ebdc484865912f8dca9bfcf22b3" continuedAt="Text_75a298ebdc484865912f8dca9bfcf22b4"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341645" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341646">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_75a298ebdc484865912f8dca9bfcf22b4" continuedAt="Text_75a298ebdc484865912f8dca9bfcf22b5"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341646" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341647">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_75a298ebdc484865912f8dca9bfcf22b5" continuedAt="Text_75a298ebdc484865912f8dca9bfcf22b6"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341647" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341648">
<div style="display:none;"><br /></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Raw materials inventory consists of various materials purchased from suppliers,
            including normal source plasma, used in the production of the Company&#8217;s products. Work-in-process and finished goods inventories (see Note 3) reflect the cost of raw materials as well as costs for direct and indirect labor, primarily salaries,
            wages and benefits for applicable employees, as well as an allocation of overhead costs related to the Boca Facility including utilities, property taxes, general repairs and maintenance, consumable supplies and depreciation. The allocation of
            Boca Facility overhead to inventory is generally based upon the estimated square footage of the Boca Facility that is used in the production of the Company&#8217;s products relative to the total square footage of the facility.</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_75a298ebdc484865912f8dca9bfcf22b6" continuedAt="Text_75a298ebdc484865912f8dca9bfcf22b7"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341648" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341649">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_75a298ebdc484865912f8dca9bfcf22b7" continuedAt="Text_75a298ebdc484865912f8dca9bfcf22b8"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341649" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341650">
<div style="display:none;"><br /></div>
<div style="text-indent: 33.75pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_75a298ebdc484865912f8dca9bfcf22b8" continuedAt="Text_75a298ebdc484865912f8dca9bfcf22b9"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341650" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341651">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_75a298ebdc484865912f8dca9bfcf22b9"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341651" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341652">
<div style="display:none;"><br /></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Inventories, including plasma intended for resale and plasma intended for internal
            use in the Company&#8217;s manufacturing, commercialization or research and development activities, are carried at the lower of cost or net realizable value determined by the first-in, first-out method. Net realizable value is generally determined
            based upon the consideration the Company expects to receive when the inventory is sold, less costs to deliver the inventory to the recipient. The estimates for net realizable value of inventory are based on contractual terms or upon historical
            experience and certain other assumptions, and the Company believes that such assumptions are reasonable. Inventory is periodically reviewed to ensure that its carrying value does not exceed its net realizable value, and adjustments are recorded
            to write down such inventory, with a corresponding charge to cost of product revenue, when the carrying value or historical cost exceeds its estimated net realizable value. In addition, costs associated with the production of conformance or
            engineering lots that would not qualify as immediately available for commercial sale are charged to cost of product revenue and not capitalized into inventory.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341652" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341653">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341653" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341654">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341654" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341655">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
            <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">7</span></div>

            <div style="page-break-after:always;" class="DSPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

            <div style="width: 100%;" class="DSPFPageHeader">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 100%; font-size: 8pt; font-style: italic;">
                      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>
                      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>
                    </td>

  </tr>


</table>
            </div>

          </div>
<ix:nonNumeric name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="Text_0213f3d0f66b495f8215943a938312e6" contextRef="c20210101to20210630" escape="true" continuedAt="Text_cb745f1f2e7c4dd5bbdf9e774df12fc71"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341655" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341656">
<div>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:nonNumeric>
          <ix:continuation id="Text_cb745f1f2e7c4dd5bbdf9e774df12fc71" continuedAt="Text_cb745f1f2e7c4dd5bbdf9e774df12fc72"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341656" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341657">
<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Goodwill</span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_cb745f1f2e7c4dd5bbdf9e774df12fc72" continuedAt="Text_cb745f1f2e7c4dd5bbdf9e774df12fc73"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341657" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341658">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_cb745f1f2e7c4dd5bbdf9e774df12fc73" continuedAt="Text_cb745f1f2e7c4dd5bbdf9e774df12fc74"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341658" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341659">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_cb745f1f2e7c4dd5bbdf9e774df12fc74" continuedAt="Text_cb745f1f2e7c4dd5bbdf9e774df12fc75"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341659" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341660">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_cb745f1f2e7c4dd5bbdf9e774df12fc75" continuedAt="Text_cb745f1f2e7c4dd5bbdf9e774df12fc76"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341660" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341661">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company.&#160;
            Goodwill at June 30, 2021 and December 31, 2020 was $<ix:nonFraction name="us-gaap:Goodwill" id="Fact_b434950da0d244eaad6af314e31a9db9" contextRef="c20201231" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:Goodwill" id="Fact_7f97a79b2f634754a8c1448c59e2341a" contextRef="c20210630" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">3.5</ix:nonFraction></ix:nonFraction> million.&#160; All of the Company&#8217;s goodwill is attributable to its ADMA
            BioManufacturing business segment and is related to the 2017 Biotest Transaction.</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_cb745f1f2e7c4dd5bbdf9e774df12fc76" continuedAt="Text_cb745f1f2e7c4dd5bbdf9e774df12fc77"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341661" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341662">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_cb745f1f2e7c4dd5bbdf9e774df12fc77" continuedAt="Text_cb745f1f2e7c4dd5bbdf9e774df12fc78"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341662" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341663">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_cb745f1f2e7c4dd5bbdf9e774df12fc78" continuedAt="Text_cb745f1f2e7c4dd5bbdf9e774df12fc79"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341663" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341664">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_cb745f1f2e7c4dd5bbdf9e774df12fc79"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341664" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341665">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Goodwill is not amortized but is assessed for impairment on an annual basis or more frequently if impairment
            indicators exist. The Company has the option to perform a qualitative assessment of goodwill to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill and
            other intangible assets. If the Company concludes that this is the case, then it must perform a goodwill impairment test by comparing the fair value of the reporting unit to its carrying value. An impairment charge is recorded to the extent the
            reporting unit&#8217;s carrying value exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. The Company performs its annual goodwill impairment test as of October 1 of each year.&#160; The Company&#8217;s annual
            goodwill impairment test as of October 1, 2020 did not result in a goodwill impairment charge, and the Company did <ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" id="Fact_e31e614ea2a64555ae55c0a1b239e03a" contextRef="c20200401to20200630" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" id="Fact_dfda9694a19f4e86a27c7afab7dc7e6c" contextRef="c20210401to20210630" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" id="Fact_348a1fcf4d2041fabe9cce687927ae5a" contextRef="c20200101to20200630" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" id="Fact_22300304dbf44f7ba1de021402ff3e09" contextRef="c20210101to20210630" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>t record
            any impairment charges related to goodwill for the three and six months ended June 30, 2021 and 2020.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341665" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341666">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341666" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341667">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation><ix:nonNumeric name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" id="Text_545ada14f0fa4349907835c9c9451111" contextRef="c20210101to20210630" escape="true" continuedAt="Text_deac957e0dcc40e7bc1d5bdcc33d92e21"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341667" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341668">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:nonNumeric>
          <ix:continuation id="Text_deac957e0dcc40e7bc1d5bdcc33d92e21" continuedAt="Text_deac957e0dcc40e7bc1d5bdcc33d92e22"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341668" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341669">
<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Impairment of long-lived assets</span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_deac957e0dcc40e7bc1d5bdcc33d92e22" continuedAt="Text_deac957e0dcc40e7bc1d5bdcc33d92e23"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341669" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341670">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_deac957e0dcc40e7bc1d5bdcc33d92e23" continuedAt="Text_deac957e0dcc40e7bc1d5bdcc33d92e24"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341670" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341671">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_deac957e0dcc40e7bc1d5bdcc33d92e24" continuedAt="Text_deac957e0dcc40e7bc1d5bdcc33d92e25"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341671" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341672">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_deac957e0dcc40e7bc1d5bdcc33d92e25"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341672" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341673">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The Company assesses the recoverability of its long-lived assets, which include property and equipment and
            finite-lived intangible assets, whenever significant events or changes in circumstances indicate impairment may have occurred. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to
            its carrying amount to determine whether the asset&#8217;s carrying value is recoverable. Any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a charge to operating results. For
            the three and six months ended June 30, 2021 and 2020, the Company determined that there was <ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" id="Fact_b88a7b3f103d48d7b059500d9c92ccc3" contextRef="c20200101to20200630" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" id="Fact_96ed18fd4f4b42e0af74efd7954eaa00" contextRef="c20210101to20210630" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" id="Fact_5c5ca898bfdc4ff0bb699939d6742007" contextRef="c20200401to20200630" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" id="Fact_2d3b3bcd432d4fbab2c7e374d2e45ecf" contextRef="c20210401to20210630" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment of its long-lived
            assets.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341673" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341674">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341674" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341675">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation><ix:nonNumeric name="us-gaap:RevenueRecognitionPolicyTextBlock" id="Text_3fb205bcaf1f40118c3c5793f85cc5d1" contextRef="c20210101to20210630" escape="true" continuedAt="Text_4e4a789fd12d4dce90b3bc027136790a1"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341675" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341676">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:nonNumeric>
          <ix:continuation id="Text_4e4a789fd12d4dce90b3bc027136790a1" continuedAt="Text_4e4a789fd12d4dce90b3bc027136790a2"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341676" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341677">
<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Revenue recognition</span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_4e4a789fd12d4dce90b3bc027136790a2" continuedAt="Text_4e4a789fd12d4dce90b3bc027136790a3"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341677" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341678">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_4e4a789fd12d4dce90b3bc027136790a3" continuedAt="Text_4e4a789fd12d4dce90b3bc027136790a4"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341678" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341679">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_4e4a789fd12d4dce90b3bc027136790a4" continuedAt="Text_4e4a789fd12d4dce90b3bc027136790a5"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341679" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341680">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_4e4a789fd12d4dce90b3bc027136790a5" continuedAt="Text_4e4a789fd12d4dce90b3bc027136790a6"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341680" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341681">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Revenues for the three and six months ended June 30, 2021 and 2020 are comprised of (i) revenues from the
            sale of the Company&#8217;s immunoglobulin products, BIVIGAM, ASCENIV and Nabi-HB, (ii) product revenues from the sale of human plasma collected through the Company&#8217;s Plasma Collection Centers business segment, (iii) contract manufacturing and
            laboratory services revenue, (iv) revenues from the sale of intermediate by-products; and (v) license and other revenues primarily attributable to the out-licensing of ASCENIV to Biotest in 2012 to market and sell this product in Europe and
            selected countries in North Africa and the Middle East. Biotest has provided the Company with certain services and financial payments in accordance with the related Biotest license agreement and is obligated to pay the Company certain amounts
            in the future if certain milestones are achieved. Deferred revenue is amortized into income over the term of the Biotest license, representing a period of approximately <ix:nonNumeric name="adma:DeferredRevenueRemainingAmortizationPeriod" id="Fact_857680b06654436294bb045b3513be50" contextRef="c20210101to20210630_TypeOfArrangementAxis_BiotestLicenseAgreementMember" format="ixt-sec:duryear">22</ix:nonNumeric> years.</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_4e4a789fd12d4dce90b3bc027136790a6" continuedAt="Text_4e4a789fd12d4dce90b3bc027136790a7"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341681" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341682">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_4e4a789fd12d4dce90b3bc027136790a7" continuedAt="Text_4e4a789fd12d4dce90b3bc027136790a8"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341682" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341683">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_4e4a789fd12d4dce90b3bc027136790a8" continuedAt="Text_4e4a789fd12d4dce90b3bc027136790a9"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341683" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341684">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_4e4a789fd12d4dce90b3bc027136790a9" continuedAt="Text_4e4a789fd12d4dce90b3bc027136790a10"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341684" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341685">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Product revenue is recognized when the customer is deemed to have control over the product. Control is
            determined based on when the product is shipped or delivered and title passes to the customer. Revenue is recorded in an amount that reflects the consideration the Company expects to receive in exchange. Revenue from the sale of the Company&#8217;s
            immunoglobulin products is recognized when the product reaches the customer&#8217;s destination, and is recorded net of estimated rebates, price protection arrangements and customer incentives, including prompt pay discounts, wholesaler chargebacks
            and other wholesaler fees. These estimates are based on historical experience and certain other assumptions, and the Company believes that such estimates are reasonable. For revenues associated with contract manufacturing and the sale of
            intermediates, control transfers to the customer and the performance obligation is satisfied when the customer takes possession of the product from the Boca Facility or from a third-party warehouse that is utilized by the Company.</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_4e4a789fd12d4dce90b3bc027136790a10" continuedAt="Text_4e4a789fd12d4dce90b3bc027136790a11"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341685" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341686">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_4e4a789fd12d4dce90b3bc027136790a11" continuedAt="Text_4e4a789fd12d4dce90b3bc027136790a12"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341686" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341687">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_4e4a789fd12d4dce90b3bc027136790a12" continuedAt="Text_4e4a789fd12d4dce90b3bc027136790a13"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341687" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341688">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
            <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">8</span></div>

            <div style="page-break-after:always;" class="DSPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

            <div style="width: 100%;" class="DSPFPageHeader">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 100%; font-size: 8pt; font-style: italic;">
                      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>
                      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>
                    </td>

  </tr>


</table>
            </div>

          </div>

          <ix:continuation id="Text_4e4a789fd12d4dce90b3bc027136790a13" continuedAt="Text_4e4a789fd12d4dce90b3bc027136790a14"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341688" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341689">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Product revenues from the sale of human plasma collected at the Company&#8217;s plasma collection centers are
            recognized at the time control of the product has been transferred to the customer, which generally occurs at the time of shipment. Product revenues are recognized at the time of delivery if the Company retains control of the product during
            shipment.</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_4e4a789fd12d4dce90b3bc027136790a14" continuedAt="Text_4e4a789fd12d4dce90b3bc027136790a15"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341689" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341690">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_4e4a789fd12d4dce90b3bc027136790a15" continuedAt="Text_4e4a789fd12d4dce90b3bc027136790a16"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341690" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341691">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_4e4a789fd12d4dce90b3bc027136790a16" continuedAt="Text_4e4a789fd12d4dce90b3bc027136790a17"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341691" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341692">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_4e4a789fd12d4dce90b3bc027136790a17"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341692" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341693">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">For the six months ended June 30, 2021, <ix:nonFraction name="adma:NumberOfCustomers" id="Fact_6c016d3e373a407eaa468742a38c5e1a" contextRef="c20210101to20210630_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_FiveCustomersMember" unitRef="U006" decimals="INF" scale="0" format="ixt-sec:numwordsen">five</ix:nonFraction> customers represented an aggregate of <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_a402f527b8204294ac484dab5b668fce" contextRef="c20210101to20210630_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_FiveCustomersMember" unitRef="U007" decimals="2" scale="-2" format="ixt:numdotdecimal">85</ix:nonFraction>% of the Company&#8217;s
            consolidated revenues. For the six months ended June 30, 2020, <ix:nonFraction name="adma:NumberOfCustomers" id="Fact_3643058089f94682a7543f7e2fa227ad" contextRef="c20200101to20200630_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_ThreeCustomersMember" unitRef="U006" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction> customers represented an aggregate of <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_23eb3ddb24b747e7a24a0fae2e7a662c" contextRef="c20200101to20200630_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_ThreeCustomersMember" unitRef="U007" decimals="2" scale="-2" format="ixt:numdotdecimal">81</ix:nonFraction>% of the Company&#8217;s consolidated revenues.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341693" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341694">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341694" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341695">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation><ix:nonNumeric name="us-gaap:CostOfSalesPolicyTextBlock" id="Text_6ca79cd1448e48568dbd38122f71c2fe" contextRef="c20210101to20210630" escape="true" continuedAt="Text_b908c16fc7fe46e88e6101f71606c6ab1"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341695" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341696">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">
          </span></div>
</ix:continuation></ix:nonNumeric>
          <ix:continuation id="Text_b908c16fc7fe46e88e6101f71606c6ab1" continuedAt="Text_b908c16fc7fe46e88e6101f71606c6ab2"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341696" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341697">
<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Cost of product revenue</span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_b908c16fc7fe46e88e6101f71606c6ab2" continuedAt="Text_b908c16fc7fe46e88e6101f71606c6ab3"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341697" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341698">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_b908c16fc7fe46e88e6101f71606c6ab3" continuedAt="Text_b908c16fc7fe46e88e6101f71606c6ab4"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341698" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c341699">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_b908c16fc7fe46e88e6101f71606c6ab4" continuedAt="Text_b908c16fc7fe46e88e6101f71606c6ab5"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c341699" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416100">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_b908c16fc7fe46e88e6101f71606c6ab5"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416100" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416101">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue includes costs associated with the manufacture of the Company&#8217;s FDA approved
            products, intermediates and the sale of human source plasma, as well as expenses related to conformance batch production, process development and scientific and technical operations when these operations are attributable to marketed products.
            When the activities of these operations are attributable to new products in development, the expenses are classified as research and development expenses.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416101" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416102">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416102" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416103">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation><ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" id="Text_be7a6a17aee344fd8c382498d5806f8b" contextRef="c20210101to20210630" escape="true" continuedAt="Text_69da5394aba84a0a83ee4847497187f71"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416103" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416104">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:nonNumeric>
          <ix:continuation id="Text_69da5394aba84a0a83ee4847497187f71" continuedAt="Text_69da5394aba84a0a83ee4847497187f72"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416104" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416105">
<div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Loss per common share</span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_69da5394aba84a0a83ee4847497187f72" continuedAt="Text_69da5394aba84a0a83ee4847497187f73"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416105" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416106">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_69da5394aba84a0a83ee4847497187f73" continuedAt="Text_69da5394aba84a0a83ee4847497187f74"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416106" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416107">
<div style="color: rgb(0, 0, 0); font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_69da5394aba84a0a83ee4847497187f74" continuedAt="Text_69da5394aba84a0a83ee4847497187f75"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416107" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416108">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_69da5394aba84a0a83ee4847497187f75" continuedAt="Text_69da5394aba84a0a83ee4847497187f76"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416108" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416109">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Basic loss per common share is computed by dividing net loss attributable to common
              stockholders by the weighted average number of shares of common stock outstanding during the period.&#160; Diluted loss per common share is calculated by dividing net loss attributable to common stockholders, as adjusted for the effect of dilutive
              securities, if any, by the weighted average number of shares of common stock and dilutive common stock outstanding during the period. Potentially dilutive common stock includes the shares of common stock issuable upon the exercise of
              outstanding stock options and warrants, using the treasury stock method. Potentially dilutive common stock is excluded from the diluted loss per common share computation to the extent that it would be anti-dilutive. As a result, no
              potentially dilutive securities are included in the computation of any of the accompanying diluted loss per share amounts in the accompanying condensed consolidated financial statements as the Company reported a net loss for all periods
              presented. </span><ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Text_757dcc9acfdb4a958e5767203abe6501" contextRef="c20210101to20210630" escape="true" continuedAt="Text_bc53339ff78d4759813fb1574ab76b301"><span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">For the six months ended June 30, 2021 and 2020, the following securities were excluded
              from the calculation of diluted loss per common share because of their anti-dilutive effects:</span></span></ix:nonNumeric></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_bc53339ff78d4759813fb1574ab76b301" continuedAt="Text_bc53339ff78d4759813fb1574ab76b302"><ix:continuation id="Text_69da5394aba84a0a83ee4847497187f76" continuedAt="Text_69da5394aba84a0a83ee4847497187f77"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416109" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416110">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation></ix:continuation>
          <ix:continuation id="Text_bc53339ff78d4759813fb1574ab76b302" continuedAt="Text_bc53339ff78d4759813fb1574ab76b303"><ix:continuation id="Text_69da5394aba84a0a83ee4847497187f77" continuedAt="Text_69da5394aba84a0a83ee4847497187f78"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416110" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416111">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation></ix:continuation>
          <ix:continuation id="Text_bc53339ff78d4759813fb1574ab76b303" continuedAt="Text_bc53339ff78d4759813fb1574ab76b304"><ix:continuation id="Text_69da5394aba84a0a83ee4847497187f78" continuedAt="Text_69da5394aba84a0a83ee4847497187f79"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416111" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416112">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation></ix:continuation>
          <ix:continuation id="Text_bc53339ff78d4759813fb1574ab76b304" continuedAt="Text_bc53339ff78d4759813fb1574ab76b305"><ix:continuation id="Text_69da5394aba84a0a83ee4847497187f79" continuedAt="Text_69da5394aba84a0a83ee4847497187f710"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416112" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416113">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="6">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">For the Six Months Ended June 30,</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2021<br />
                    </span> </div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2020<br />
                    </span> </div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Stock options</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_b0ec6bf02b9047e1a6f5aa1e08fe7cc2" contextRef="c20210101to20210630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">7,783,029</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_2a90e1ec001d476b82a56367acf2351e" contextRef="c20200101to20200630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">6,801,779</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Restricted stock units</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_ec18de2ae8a34627b01b6dbdd0e7979f" contextRef="c20210101to20210630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">686,133</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_7a9b7f19451047629e553fa815cbbb51" contextRef="c20200101to20200630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">326,000</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Warrants</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_621ea809f9864d42a1ee1d82dcb8797d" contextRef="c20210101to20210630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">4,528,160</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_770481d06bd54b60a45601bc9c2e513a" contextRef="c20200101to20200630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">2,138,160</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_7fe5fe5656f1444389acb0cb53dcb606" contextRef="c20210101to20210630" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">12,997,322</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_40e4366bc5774e05902dc05e2a065031" contextRef="c20200101to20200630" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">9,265,939</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation></ix:continuation>
          <ix:continuation id="Text_bc53339ff78d4759813fb1574ab76b305"><ix:continuation id="Text_69da5394aba84a0a83ee4847497187f710"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416113" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416114">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation></ix:continuation>
          <ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416114" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416115">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span></div>
</ix:continuation><ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Text_1186b39f37a3449d98632bcb312117f8" contextRef="c20210101to20210630" escape="true" continuedAt="Text_c8f5e20958144ac8aefa04dc931a94801"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416115" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416116">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">
          </span></div>
</ix:continuation></ix:nonNumeric>
          <ix:continuation id="Text_c8f5e20958144ac8aefa04dc931a94801" continuedAt="Text_c8f5e20958144ac8aefa04dc931a94802"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416116" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416117">
<div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Stock-based compensation</span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c8f5e20958144ac8aefa04dc931a94802" continuedAt="Text_c8f5e20958144ac8aefa04dc931a94803"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416117" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416118">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c8f5e20958144ac8aefa04dc931a94803" continuedAt="Text_c8f5e20958144ac8aefa04dc931a94804"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416118" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416119">
<div style="color: rgb(0, 0, 0); font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c8f5e20958144ac8aefa04dc931a94804" continuedAt="Text_c8f5e20958144ac8aefa04dc931a94805"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416119" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416120">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c8f5e20958144ac8aefa04dc931a94805"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416120" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416121">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The Company follows recognized accounting guidance which requires all equity-based payments, including grants
            of stock options, to be recognized in the statement of operations as compensation expense based on their fair values at the date of grant. Compensation expense related to awards to employees and directors with service-based vesting conditions
            is recognized on a straight-line basis over the associated vesting period of the award based on the grant date fair value of the award. Stock options granted under the Company&#8217;s equity incentive plans generally have a <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact_7ddccfe384494a22b332c087d24df9f7" contextRef="c20210101to20210630" format="ixt-sec:durwordsen">four-year</ix:nonNumeric> vesting period and a term of <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="Fact_f10cd9d6deb6466294dac26bbf9e6e8b" contextRef="c20210101to20210630" format="ixt-sec:duryear">10</ix:nonNumeric>
            years. Pursuant to ASU No. 2016-09, <span style="font-style: italic;">Improvements to Employee Share-Based Payment Accounting (Topic 718)</span>, the Company has elected not to establish a forfeiture rate, as stock-based compensation expense
            related to forfeitures of unvested stock options is fully reversed at the time of forfeiture.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416121" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416122">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416122" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416123">
<div> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation><ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" id="Text_4e76a2f0cb524e40a7bd3220a1b1553c" contextRef="c20210101to20210630" escape="true" continuedAt="Text_f8c6dce37ea24db598115373b4b0b3dd1"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416123" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416124">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:nonNumeric>
          <ix:continuation id="Text_f8c6dce37ea24db598115373b4b0b3dd1" continuedAt="Text_f8c6dce37ea24db598115373b4b0b3dd2"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416124" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416125">
<div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Income Taxes</span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_f8c6dce37ea24db598115373b4b0b3dd2" continuedAt="Text_f8c6dce37ea24db598115373b4b0b3dd3"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416125" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416126">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_f8c6dce37ea24db598115373b4b0b3dd3" continuedAt="Text_f8c6dce37ea24db598115373b4b0b3dd4"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416126" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416127">
<div style="color: rgb(0, 0, 0); font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_f8c6dce37ea24db598115373b4b0b3dd4" continuedAt="Text_f8c6dce37ea24db598115373b4b0b3dd5"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416127" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416128">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_f8c6dce37ea24db598115373b4b0b3dd5" continuedAt="Text_f8c6dce37ea24db598115373b4b0b3dd6"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416128" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416129">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events
            that have been included in the consolidated financial statements or its tax returns. Under this method, deferred tax assets and liabilities are recognized for the temporary differences between the tax bases of assets and liabilities and their
            respective financial reporting amounts at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. The Company records a valuation allowance on its deferred tax assets if it is more likely than not
            that the Company will not generate sufficient taxable income to utilize its deferred tax assets. The Company is subject to income tax examinations by major taxing authorities for all tax years since 2016 and for previous periods as it relates
            to the Company&#8217;s net operating loss carryforwards.</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_f8c6dce37ea24db598115373b4b0b3dd6" continuedAt="Text_f8c6dce37ea24db598115373b4b0b3dd7"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416129" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416130">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_f8c6dce37ea24db598115373b4b0b3dd7" continuedAt="Text_f8c6dce37ea24db598115373b4b0b3dd8"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416130" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416131">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_f8c6dce37ea24db598115373b4b0b3dd8" continuedAt="Text_f8c6dce37ea24db598115373b4b0b3dd9"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416131" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416132">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
            <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">9</span></div>

            <div style="page-break-after:always;" class="DSPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

            <div style="width: 100%;" class="DSPFPageHeader">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 100%; font-size: 8pt; font-style: italic;">
                      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>
                      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>
                    </td>

  </tr>


</table>
            </div>

          </div>

          <ix:continuation id="Text_f8c6dce37ea24db598115373b4b0b3dd9"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416132" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416133">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">In accordance with U.S. GAAP, the Company is required to determine whether a tax position of the Company is
            more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit to be recognized is
            measured as the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. Derecognition of a tax benefit previously recognized could result in the Company recording a tax liability that would reduce
            net assets. Based on its analysis, the Company has determined that it has not incurred any liability for unrecognized tax benefits as of June 30, 2021 and December 31, 2020, and during the three and six months ended June 30, 2021 and 2020, the
            Company recognized <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" id="Fact_9336d6533c59498c84a77fc670792924" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" id="Fact_264d67f0fcb9482d8b477f062519733e" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> adjustments for uncertain tax positions.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416133" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416134">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416134" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416135">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Text_5d994092f5414d759c1e66c8cee1a148" contextRef="c20210101to20210630" escape="true" continuedAt="Text_6fbd2f99287a4b1b98d1d36ff4e9a9031"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416135" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416136">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:nonNumeric>
          <ix:continuation id="Text_6fbd2f99287a4b1b98d1d36ff4e9a9031" continuedAt="Text_6fbd2f99287a4b1b98d1d36ff4e9a9032"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416136" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416137">
<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Recent Accounting Pronouncements</span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_6fbd2f99287a4b1b98d1d36ff4e9a9032" continuedAt="Text_6fbd2f99287a4b1b98d1d36ff4e9a9033"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416137" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416138">
<div><span style="text-decoration: underline;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_6fbd2f99287a4b1b98d1d36ff4e9a9033" continuedAt="Text_6fbd2f99287a4b1b98d1d36ff4e9a9034"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416138" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416139">
<div style="font-style: italic;"><span style="text-decoration: underline;"> </span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_6fbd2f99287a4b1b98d1d36ff4e9a9034" continuedAt="Text_6fbd2f99287a4b1b98d1d36ff4e9a9035"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416139" continuedAt="Text_e8d3cab35b0f47d6a2b6685bd91c3416140">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_6fbd2f99287a4b1b98d1d36ff4e9a9035"><ix:continuation id="Text_e8d3cab35b0f47d6a2b6685bd91c3416140">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">In June 2016, the FASB issued ASU No. 2016-13, <span style="font-style: italic;">Financial Instruments &#8211;
              Credit Losses (Topic 326)</span> (&#8220;ASU 2016-13&#8221;), which requires financial assets to be presented at the net amount expected to be collected, with an allowance for credit losses to be deducted from the amortized cost basis of the financial
            asset such that the net carrying value of the asset is presented as the amount expected to be collected. Under ASU 2016-13, the entity&#8217;s statement of operations is required to reflect the measurement of credit losses for newly recognized
            financial assets, as well as expected increases or decreases in expected credit losses that have taken place during the period. For public business entities, ASU 2016-13 is effective for fiscal years beginning after December 15, 2019.&#160; The
            Company adopted ASU 2016-13 on January 1, 2020, and the adoption of this update did not have a significant impact on the Company&#8217;s consolidated financial statements.</div>
</ix:continuation></ix:continuation>
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

          <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

        <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

  </div>
<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

        <div><ix:nonNumeric name="us-gaap:InventoryDisclosureTextBlock" id="Text_b0ac280d826c42309d29f504917785df" contextRef="c20210101to20210630" escape="true" continuedAt="Text_88abcc0541cf4f6ea1cf177be164e4951">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_88abcc0541cf4f6ea1cf177be164e4951" continuedAt="Text_88abcc0541cf4f6ea1cf177be164e4952">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">3.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">INVENTORIES</span></div>
                </td>

  </tr>


</table>
</ix:continuation>
          <ix:continuation id="Text_88abcc0541cf4f6ea1cf177be164e4952" continuedAt="Text_88abcc0541cf4f6ea1cf177be164e4953">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_88abcc0541cf4f6ea1cf177be164e4953" continuedAt="Text_88abcc0541cf4f6ea1cf177be164e4954">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation><ix:nonNumeric name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="Text_bf83d86f9e0a4222991cdbebd88801ef" contextRef="c20210101to20210630" escape="true" continuedAt="Text_6330e1ef5e294b5386aa96b4557cc98d1"><ix:continuation id="Text_88abcc0541cf4f6ea1cf177be164e4954" continuedAt="Text_88abcc0541cf4f6ea1cf177be164e4955">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:nonNumeric>
          <ix:continuation id="Text_6330e1ef5e294b5386aa96b4557cc98d1" continuedAt="Text_6330e1ef5e294b5386aa96b4557cc98d2"><ix:continuation id="Text_88abcc0541cf4f6ea1cf177be164e4955" continuedAt="Text_88abcc0541cf4f6ea1cf177be164e4956">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The following table provides the components of inventories:</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_6330e1ef5e294b5386aa96b4557cc98d2" continuedAt="Text_6330e1ef5e294b5386aa96b4557cc98d3"><ix:continuation id="Text_88abcc0541cf4f6ea1cf177be164e4956" continuedAt="Text_88abcc0541cf4f6ea1cf177be164e4957">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_6330e1ef5e294b5386aa96b4557cc98d3" continuedAt="Text_6330e1ef5e294b5386aa96b4557cc98d4"><ix:continuation id="Text_88abcc0541cf4f6ea1cf177be164e4957" continuedAt="Text_88abcc0541cf4f6ea1cf177be164e4958">
<div style="margin-left: 13.5pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_6330e1ef5e294b5386aa96b4557cc98d4" continuedAt="Text_6330e1ef5e294b5386aa96b4557cc98d5"><ix:continuation id="Text_88abcc0541cf4f6ea1cf177be164e4958" continuedAt="Text_88abcc0541cf4f6ea1cf177be164e4959">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_6330e1ef5e294b5386aa96b4557cc98d5" continuedAt="Text_6330e1ef5e294b5386aa96b4557cc98d6"><ix:continuation id="Text_88abcc0541cf4f6ea1cf177be164e4959" continuedAt="Text_88abcc0541cf4f6ea1cf177be164e49510">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">June 30,</span></div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2021<br />
                    </span> </div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">December 31,</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2020<br />
                    </span> </div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Raw materials</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:InventoryRawMaterials" id="Fact_527fb3c30e30438ba359a2e8c79a1475" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">33,058,221</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:InventoryRawMaterials" id="Fact_c91f1d76395840c0aeebf90392124dc9" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">32,044,393</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Work-in-process</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" id="Fact_49addd6918df4b1e863be6f5dde00376" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">49,163,125</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" id="Fact_d877f0887a244d41b83e05fbbabbddcd" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">30,293,288</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Finished goods</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" id="Fact_3b8a7bf4100a4172987bd7851d7d4a45" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">17,478,397</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" id="Fact_b237f9c9645a40c49ea0cb93d7710d48" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">19,197,918</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Total inventories</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:InventoryNet" id="Fact_57c803b6a4bb4e8ba71f2165eec17864" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">99,699,743</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:InventoryNet" id="Fact_372d280e8bd34d0b8512003fa601b468" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">81,535,599</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_6330e1ef5e294b5386aa96b4557cc98d6"><ix:continuation id="Text_88abcc0541cf4f6ea1cf177be164e49510" continuedAt="Text_88abcc0541cf4f6ea1cf177be164e49511">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_88abcc0541cf4f6ea1cf177be164e49511" continuedAt="Text_88abcc0541cf4f6ea1cf177be164e49512">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span></div>
</ix:continuation>
          <ix:continuation id="Text_88abcc0541cf4f6ea1cf177be164e49512" continuedAt="Text_88abcc0541cf4f6ea1cf177be164e49513">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_88abcc0541cf4f6ea1cf177be164e49513" continuedAt="Text_88abcc0541cf4f6ea1cf177be164e49514">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Raw materials includes plasma and other materials expected to be used in the production of BIVIGAM, ASCENIV
            and Nabi-HB, as there are alternative uses for these materials that provide a probable future benefit or will be consumed in the production of goods expected to be available for sale. All other activities and materials associated with the
            production of inventories used in research and development activities are expensed as incurred.</div>
</ix:continuation>
          <ix:continuation id="Text_88abcc0541cf4f6ea1cf177be164e49514" continuedAt="Text_88abcc0541cf4f6ea1cf177be164e49515">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_88abcc0541cf4f6ea1cf177be164e49515" continuedAt="Text_88abcc0541cf4f6ea1cf177be164e49516">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_88abcc0541cf4f6ea1cf177be164e49516" continuedAt="Text_88abcc0541cf4f6ea1cf177be164e49517">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_88abcc0541cf4f6ea1cf177be164e49517">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Work-in-process inventory primarily consists of bulk drug substance and unlabeled filled vials of the
            Company&#8217;s immunoglobulin products. Finished goods inventory is comprised of immunoglobulin product inventory and related intermediates that are available for commercial sale, as well as plasma collected at the Company&#8217;s plasma collection
            centers which is expected to be sold to third-party customers.</div>
</ix:continuation>
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

          <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
            <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">10</span></div>

            <div style="page-break-after:always;" class="DSPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

            <div style="width: 100%;" class="DSPFPageHeader">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 100%; font-size: 8pt; font-style: italic;">
                      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>
                      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>
                    </td>

  </tr>


</table>
            </div>

          </div>

        </div>

        <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

  </div>
<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

        <div><ix:nonNumeric name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="Text_f46b388b3a2a480ca88f823b8eb2cec7" contextRef="c20210101to20210630" escape="true" continuedAt="Text_00a5012b628649d98f5094893f11e0401">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_00a5012b628649d98f5094893f11e0401" continuedAt="Text_00a5012b628649d98f5094893f11e0402">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">4.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">INTANGIBLE ASSETS</span></div>
                </td>

  </tr>


</table>
</ix:continuation>
          <ix:continuation id="Text_00a5012b628649d98f5094893f11e0402" continuedAt="Text_00a5012b628649d98f5094893f11e0403">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_00a5012b628649d98f5094893f11e0403" continuedAt="Text_00a5012b628649d98f5094893f11e0404">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation><ix:nonNumeric name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="Text_198a34bb24c64972a597f9e24fef66c1" contextRef="c20210101to20210630" escape="true" continuedAt="Text_93c3e861cbe94ff68bdf46de42c681291"><ix:continuation id="Text_00a5012b628649d98f5094893f11e0404" continuedAt="Text_00a5012b628649d98f5094893f11e0405">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:nonNumeric>
          <ix:continuation id="Text_93c3e861cbe94ff68bdf46de42c681291" continuedAt="Text_93c3e861cbe94ff68bdf46de42c681292"><ix:continuation id="Text_00a5012b628649d98f5094893f11e0405" continuedAt="Text_00a5012b628649d98f5094893f11e0406">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Intangible assets at June 30, 2021 and December 31, 2020 consist of the following:</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_93c3e861cbe94ff68bdf46de42c681292" continuedAt="Text_93c3e861cbe94ff68bdf46de42c681293"><ix:continuation id="Text_00a5012b628649d98f5094893f11e0406" continuedAt="Text_00a5012b628649d98f5094893f11e0407">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_93c3e861cbe94ff68bdf46de42c681293" continuedAt="Text_93c3e861cbe94ff68bdf46de42c681294"><ix:continuation id="Text_00a5012b628649d98f5094893f11e0407" continuedAt="Text_00a5012b628649d98f5094893f11e0408">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_93c3e861cbe94ff68bdf46de42c681294" continuedAt="Text_93c3e861cbe94ff68bdf46de42c681295"><ix:continuation id="Text_00a5012b628649d98f5094893f11e0408" continuedAt="Text_00a5012b628649d98f5094893f11e0409">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_93c3e861cbe94ff68bdf46de42c681295" continuedAt="Text_93c3e861cbe94ff68bdf46de42c681296"><ix:continuation id="Text_00a5012b628649d98f5094893f11e0409" continuedAt="Text_00a5012b628649d98f5094893f11e04010">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="10">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">June 30, 2021</span></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="10">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">December 31, 2020</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> Cost</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">
                    <div style="color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Accumulated</div>
                    <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> Amortization</span></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Net</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Cost</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">
                    <div style="color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Accumulated</div>
                    <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> Amortization</span></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Net</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Trademark and other intangible rights related to Nabi-HB</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" id="Fact_b74a0adb91f14351a69efe85b7e9b490" contextRef="c20210630_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">4,100,046</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" id="Fact_f04c3df0a90d4d2da160ecb87eca7b72" contextRef="c20210630_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">2,391,693</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" id="Fact_c45bd005ea3a4821bffc1f02b555fdb4" contextRef="c20210630_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,708,353</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" id="Fact_05ec63b4278e4094a58ff967b9ce000e" contextRef="c20201231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">4,100,046</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" id="Fact_3da2219f23704774a076f9d1d0de7a2f" contextRef="c20201231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">2,098,833</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" id="Fact_222f3d5a7ca64bcbaa739ce2e2bc3214" contextRef="c20201231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">2,001,213</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 28%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Rights to intermediates</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" id="Fact_9f936fcb17f94a1e94fd804c9eb3d970" contextRef="c20210630_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">907,421</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" id="Fact_d8ca3b23ad2b4770a6e405cda9bdaa69" contextRef="c20210630_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">529,329</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" id="Fact_6e69768fd81141c2b77ffd4c111a4be3" contextRef="c20210630_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">378,092</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" id="Fact_f08ccb63aac04056983b5606be749f78" contextRef="c20201231_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">907,421</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" id="Fact_9818fee6ac224c78a2cb73df8f524a69" contextRef="c20201231_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">464,513</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" id="Fact_e6dc8e27792043cc8f15faaa9ffcc955" contextRef="c20201231_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">442,908</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Customer contract</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" id="Fact_e9baa7920fc7409b9dd3e88df8fe62da" contextRef="c20210630_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerContractsMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,076,557</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" id="Fact_d82744dc45ab4156bbc6d6fda450d25d" contextRef="c20210630_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerContractsMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,076,557</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" id="Fact_3dfa6bad96f94faba0a3c8f0714215b5" contextRef="c20210630_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerContractsMember" unitRef="U002" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" id="Fact_e7550bdc6f73474cbf0c1d255987c9aa" contextRef="c20201231_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerContractsMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,076,557</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" id="Fact_f81925b8a5114ac792c0180d9360e2ce" contextRef="c20201231_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerContractsMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,076,557</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" id="Fact_9e8c4929136c421094a1829b18fa2f9d" contextRef="c20201231_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerContractsMember" unitRef="U002" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 28%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" id="Fact_ad182d01a2714b15b2d466dd4b3af2e7" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">6,084,024</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" id="Fact_2b7ff99af9dc465d911a5b351025c0ee" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">3,997,579</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" id="Fact_e8bc8743842c4af0934be2b2c577dc21" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">2,086,445</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" id="Fact_e7b354c296cf43ca848a8fad4d297f4c" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">6,084,024</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" id="Fact_df23fa5c8baa45dbbf157c82d571d810" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">3,639,903</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" id="Fact_ec316a666c42447da6f184f02ec1d192" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">2,444,121</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_93c3e861cbe94ff68bdf46de42c681296"><ix:continuation id="Text_00a5012b628649d98f5094893f11e04010" continuedAt="Text_00a5012b628649d98f5094893f11e04011">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_00a5012b628649d98f5094893f11e04011" continuedAt="Text_00a5012b628649d98f5094893f11e04012">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span></div>
</ix:continuation>
          <ix:continuation id="Text_00a5012b628649d98f5094893f11e04012" continuedAt="Text_00a5012b628649d98f5094893f11e04013">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_00a5012b628649d98f5094893f11e04013" continuedAt="Text_00a5012b628649d98f5094893f11e04014">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">All of the Company&#8217;s intangible assets were acquired in the Biotest Transaction. Amortization
              expense related to these intangible assets was $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" id="Fact_126ef81d669f4b68a75963df73aac867" contextRef="c20210401to20210630" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" id="Fact_094ae4a5baeb47f1bab1494afc054b89" contextRef="c20200401to20200630" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></ix:nonFraction> million for the three months ended June 30, 2021 and 2020, and $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" id="Fact_2d31f285567d43e5885f5c63c793961f" contextRef="c20200101to20200630" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" id="Fact_18c87486451e45cba6cb8bdaaa56dafa" contextRef="c20210101to20210630" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></ix:nonFraction> million for the six months ended June 30, 2021 and 2020. </span><ix:nonNumeric name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="Text_fb3841ea63e849d5b88c7023ee6513dd" contextRef="c20210101to20210630" escape="true" continuedAt="Text_71948331d9aa473dbb6d08d1d7854e561"><span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Estimated aggregate future aggregate amortization expense is expected to be as follows:</span></span></ix:nonNumeric></div>
</ix:continuation>
          <ix:continuation id="Text_71948331d9aa473dbb6d08d1d7854e561" continuedAt="Text_71948331d9aa473dbb6d08d1d7854e562"><ix:continuation id="Text_00a5012b628649d98f5094893f11e04014" continuedAt="Text_00a5012b628649d98f5094893f11e04015">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_71948331d9aa473dbb6d08d1d7854e562" continuedAt="Text_71948331d9aa473dbb6d08d1d7854e563"><ix:continuation id="Text_00a5012b628649d98f5094893f11e04015" continuedAt="Text_00a5012b628649d98f5094893f11e04016">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_71948331d9aa473dbb6d08d1d7854e563" continuedAt="Text_71948331d9aa473dbb6d08d1d7854e564"><ix:continuation id="Text_00a5012b628649d98f5094893f11e04016" continuedAt="Text_00a5012b628649d98f5094893f11e04017">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_71948331d9aa473dbb6d08d1d7854e564"><ix:continuation id="Text_00a5012b628649d98f5094893f11e04017">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">2021</span><br />
                    </span> </div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" id="Fact_5cd6d93ee2044a628addb65369d7fbfa" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">357,676</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">2022</span><br />
                    </span> </div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" id="Fact_1c9b4833806b4a96a67f46d9cd97cff9" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">715,352</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">2023</span><br />
                    </span> </div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" id="Fact_1f34843077c64ef685398928a3bcd416" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">715,352</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">2024</span><br />
                    </span> </div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" id="Fact_646e20b3cf9e4e31bf1c6458a0933022" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">298,065</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

          <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

        <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

  </div>
<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

        <div><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Text_c58c1d3b3a2e40808b659d66e69f3c99" contextRef="c20210101to20210630" escape="true" continuedAt="Text_ae72bd5ba7c649b2ad29cf4a2dabb91a1">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_ae72bd5ba7c649b2ad29cf4a2dabb91a1" continuedAt="Text_ae72bd5ba7c649b2ad29cf4a2dabb91a2">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">5.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">PROPERTY AND EQUIPMENT</span></div>
                </td>

  </tr>


</table>
</ix:continuation>
          <ix:continuation id="Text_ae72bd5ba7c649b2ad29cf4a2dabb91a2" continuedAt="Text_ae72bd5ba7c649b2ad29cf4a2dabb91a3">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_ae72bd5ba7c649b2ad29cf4a2dabb91a3" continuedAt="Text_ae72bd5ba7c649b2ad29cf4a2dabb91a4">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation><ix:continuation id="Text_ae72bd5ba7c649b2ad29cf4a2dabb91a4" continuedAt="Text_ae72bd5ba7c649b2ad29cf4a2dabb91a5"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Text_593a680e06f44efe9f78af2c2597bdb7" contextRef="c20210101to20210630" escape="true" continuedAt="Text_8ac8637dead5419caa07bf36e84ef3e31">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_ae72bd5ba7c649b2ad29cf4a2dabb91a5" continuedAt="Text_ae72bd5ba7c649b2ad29cf4a2dabb91a6"><ix:continuation id="Text_8ac8637dead5419caa07bf36e84ef3e31" continuedAt="Text_8ac8637dead5419caa07bf36e84ef3e32">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Property and equipment and related accumulated depreciation are summarized as follows:</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_ae72bd5ba7c649b2ad29cf4a2dabb91a6" continuedAt="Text_ae72bd5ba7c649b2ad29cf4a2dabb91a7"><ix:continuation id="Text_8ac8637dead5419caa07bf36e84ef3e32" continuedAt="Text_8ac8637dead5419caa07bf36e84ef3e33">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_ae72bd5ba7c649b2ad29cf4a2dabb91a7" continuedAt="Text_ae72bd5ba7c649b2ad29cf4a2dabb91a8"><ix:continuation id="Text_8ac8637dead5419caa07bf36e84ef3e33" continuedAt="Text_8ac8637dead5419caa07bf36e84ef3e34">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_ae72bd5ba7c649b2ad29cf4a2dabb91a8" continuedAt="Text_ae72bd5ba7c649b2ad29cf4a2dabb91a9"><ix:continuation id="Text_8ac8637dead5419caa07bf36e84ef3e34" continuedAt="Text_8ac8637dead5419caa07bf36e84ef3e35">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_ae72bd5ba7c649b2ad29cf4a2dabb91a9" continuedAt="Text_ae72bd5ba7c649b2ad29cf4a2dabb91a10"><ix:continuation id="Text_8ac8637dead5419caa07bf36e84ef3e35" continuedAt="Text_8ac8637dead5419caa07bf36e84ef3e36">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">June 30, 2021</span></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">December 31, 2020</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Manufacturing and laboratory equipment</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_2c175418a7654108a35345494fed389b" contextRef="c20210630_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">15,082,205</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_8cba11ac5dca42ebbee1f55fbe870d6d" contextRef="c20201231_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">14,468,874</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Office equipment and computer software</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_ce36a24b8da847389b97fd90b9107ccd" contextRef="c20210630_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">3,649,504</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_7ca07f41969344bd80d925df529cbd5d" contextRef="c20201231_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">3,253,528</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Furniture and fixtures</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_27112b2cb5ff4b2da9776b7697d1a5ad" contextRef="c20210630_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">2,516,729</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_34b55090808d4bf394ae2cb8f50c2966" contextRef="c20201231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">2,039,398</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Construction in process</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_29ceb6fa9d39489db0cf1098bdaad041" contextRef="c20210630_PropertyPlantAndEquipmentByTypeAxis_AssetUnderConstructionMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">5,966,844</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_97c9612ab90e4868aea08a592737f1bf" contextRef="c20201231_PropertyPlantAndEquipmentByTypeAxis_AssetUnderConstructionMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">3,336,557</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Leasehold improvements</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_abf87fa5832444288db4b83e78b9e240" contextRef="c20210630_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">7,192,820</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_90acb1fabb98443a8822d116a7aab696" contextRef="c20201231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">5,272,490</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Land</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_c7fd96371e8348b38ee74fc91f97cd5d" contextRef="c20210630_PropertyPlantAndEquipmentByTypeAxis_LandMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">4,339,441</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_2b574a0687864c23be2876fb4fba62a5" contextRef="c20201231_PropertyPlantAndEquipmentByTypeAxis_LandMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">4,339,441</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Buildings and building improvements</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_88a5d5b0a39b422b96872750efcab8de" contextRef="c20210630_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">18,694,960</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_4b9ea9c832d34abe929900ca57b624eb" contextRef="c20201231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">17,746,744</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 76%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_886726622550403ca500ad1258afaac1" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">57,442,503</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_9f5497c16d8c4e68aa79c6656e6a6730" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">50,457,032</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Less: Accumulated depreciation</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" id="Fact_3dafb370d28944dfb131b254fabc764c" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">10,955,523</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" id="Fact_ea9b4bd62db146a788e9e6a03c72c668" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">8,863,942</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Total property and equipment, net</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_e69006edba5847bfb29ccdc0d305b696" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">46,486,980</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_44a51fb982e84ac5ac15122a73ebacb8" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">41,593,090</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_ae72bd5ba7c649b2ad29cf4a2dabb91a10" continuedAt="Text_ae72bd5ba7c649b2ad29cf4a2dabb91a11"><ix:continuation id="Text_8ac8637dead5419caa07bf36e84ef3e36">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_ae72bd5ba7c649b2ad29cf4a2dabb91a11" continuedAt="Text_ae72bd5ba7c649b2ad29cf4a2dabb91a12">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span></div>
</ix:continuation>
          <ix:continuation id="Text_ae72bd5ba7c649b2ad29cf4a2dabb91a12" continuedAt="Text_ae72bd5ba7c649b2ad29cf4a2dabb91a13">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_ae72bd5ba7c649b2ad29cf4a2dabb91a13" continuedAt="Text_ae72bd5ba7c649b2ad29cf4a2dabb91a14">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Fixed assets are stated at cost less accumulated depreciation. Depreciation is calculated using the
            straight-line method over the asset&#8217;s estimated useful life.&#160; Land is not depreciated. The buildings were assigned a useful life of <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact_2eda57c5d24c4eb7acbd922f12b25dbc" contextRef="c20210101to20210630_PropertyPlantAndEquipmentByTypeAxis_BuildingMember" format="ixt-sec:duryear">30</ix:nonNumeric>
            years. Property and equipment other than land and buildings have useful lives ranging from <span style="-sec-ix-hidden:Fact_06457f177efa4ffeb98a18387724a0a7">three</span> to <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact_cc1f606ddd494dffa9ad6acccd5a597d" contextRef="c20210101to20210630_RangeAxis_MaximumMember" format="ixt-sec:duryear">10</ix:nonNumeric> years.&#160; Leasehold improvements are amortized over the lesser of the lease term or their estimated useful lives.</div>
</ix:continuation>
          <ix:continuation id="Text_ae72bd5ba7c649b2ad29cf4a2dabb91a14" continuedAt="Text_ae72bd5ba7c649b2ad29cf4a2dabb91a15">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_ae72bd5ba7c649b2ad29cf4a2dabb91a15" continuedAt="Text_ae72bd5ba7c649b2ad29cf4a2dabb91a16">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_ae72bd5ba7c649b2ad29cf4a2dabb91a16" continuedAt="Text_ae72bd5ba7c649b2ad29cf4a2dabb91a17">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_ae72bd5ba7c649b2ad29cf4a2dabb91a17">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The Company recorded depreciation expense on property and equipment for
              the three and six months ended June 30, 2021 of $<ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" id="Fact_f716318d759641b1acde06129bb9ac20" contextRef="c20210401to20210630" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" id="Fact_782f2e7922a049bdad707d58e720385e" contextRef="c20210101to20210630" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">2.2</ix:nonFraction> million, respectively. Depreciation expense for the three and six months ended June 30, 2020 was $</span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" id="Fact_9fd2b8dee66f4085bbf00d395bced584" contextRef="c20200401to20200630" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction><span style="color: rgb(0, 0, 0);"> million and $</span><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" id="Fact_e15d4f50beb74ea6a2f9fbec788cab35" contextRef="c20200101to20200630" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction><span style="color: rgb(0, 0, 0);"> million, respectively. </span></span></div>
</ix:continuation>
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

          <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
            <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">11</span></div>

            <div style="page-break-after:always;" class="DSPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

            <div style="width: 100%;" class="DSPFPageHeader">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 100%; font-size: 8pt; font-style: italic;">
                      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>
                      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>
                    </td>

  </tr>


</table>
            </div>

          </div>

        </div>

        <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

  </div>
<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

        <div><ix:nonNumeric name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Text_ba86dceeeabc4c1dba19c743f8d13860" contextRef="c20210101to20210630" escape="true" continuedAt="Text_20417a5f71f648819d8a3b4055908fea1">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_20417a5f71f648819d8a3b4055908fea1" continuedAt="Text_20417a5f71f648819d8a3b4055908fea2">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">6.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></div>
                </td>

  </tr>


</table>
</ix:continuation>
          <ix:continuation id="Text_20417a5f71f648819d8a3b4055908fea2" continuedAt="Text_20417a5f71f648819d8a3b4055908fea3">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_20417a5f71f648819d8a3b4055908fea3" continuedAt="Text_20417a5f71f648819d8a3b4055908fea4">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation><ix:continuation id="Text_20417a5f71f648819d8a3b4055908fea4" continuedAt="Text_20417a5f71f648819d8a3b4055908fea5"><ix:nonNumeric name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="Text_d77cd9f2ea5a4f698f33265e16548c2e" contextRef="c20210101to20210630" escape="true" continuedAt="Text_6029290cc085490f95fe8c70b636acd61">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_20417a5f71f648819d8a3b4055908fea5" continuedAt="Text_20417a5f71f648819d8a3b4055908fea6"><ix:continuation id="Text_6029290cc085490f95fe8c70b636acd61" continuedAt="Text_6029290cc085490f95fe8c70b636acd62">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued expenses and other current liabilities at June 30, 2021 and December 31, 2020 are as follows:</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_20417a5f71f648819d8a3b4055908fea6" continuedAt="Text_20417a5f71f648819d8a3b4055908fea7"><ix:continuation id="Text_6029290cc085490f95fe8c70b636acd62" continuedAt="Text_6029290cc085490f95fe8c70b636acd63">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_20417a5f71f648819d8a3b4055908fea7" continuedAt="Text_20417a5f71f648819d8a3b4055908fea8"><ix:continuation id="Text_6029290cc085490f95fe8c70b636acd63" continuedAt="Text_6029290cc085490f95fe8c70b636acd64">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_20417a5f71f648819d8a3b4055908fea8" continuedAt="Text_20417a5f71f648819d8a3b4055908fea9"><ix:continuation id="Text_6029290cc085490f95fe8c70b636acd64" continuedAt="Text_6029290cc085490f95fe8c70b636acd65">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_20417a5f71f648819d8a3b4055908fea9"><ix:continuation id="Text_6029290cc085490f95fe8c70b636acd65">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">June 30, 2021</span></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">December 31, 2020</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued rebates</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:AccruedRebatesCurrent" id="Fact_41c719c528e3459b8888bf240ee1370b" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">3,721,888</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:AccruedRebatesCurrent" id="Fact_92b4f4d3a4154dc793ed280e77a11237" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">2,604,245</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued distribution fees</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" id="Fact_4e8dfa15482644c58393790fe4d1d054" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,928,901</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" id="Fact_5762360155e34e158cb27077438c22e8" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">828,120</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued payroll</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" id="Fact_c224df12c2be46269ccfd33516d7e0e3" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">691,483</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" id="Fact_da196edb37ff435ab593c23547539135" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">734,972</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued testing</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount" id="Fact_f48292f4d7244ed8b6d47d74be964607" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,673,120</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount" id="Fact_8529173c98994f1abb50fb3eb52717d0" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">779,660</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued incentives</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" id="Fact_9d669b64b2344ea1a4e63074c6b5a396" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,539,491</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" id="Fact_e4e50ddd301a417892b184780cf5cbc4" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">3,210,884</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued severance</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits" id="Fact_96c1df4e7d034e639c610076ae10d654" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">789,534</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits" id="Fact_a65570df1969408ab1cf0cf9b9602316" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Other</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" id="Fact_63d31af9e52b401b88c919f89b33e1e9" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,145,822</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" id="Fact_8ca45eeb425540e88e381605a7215d38" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">207,262</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Total accrued expenses and other current liabilities</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" id="Fact_631d7514e524465abb18a1af67f3c8d2" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">11,490,239</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" id="Fact_840dc4a07dab4a4c9bb1c89eec064a01" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">8,365,143</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

          <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

        <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

  </div>
<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

        <div><ix:nonNumeric name="us-gaap:LongTermDebtTextBlock" id="Text_8d67bee99c5242b6b262160cf53a6e8e" contextRef="c20210101to20210630" escape="true" continuedAt="Text_dff85e01ae454717a78fd0e8467cbbde1">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_dff85e01ae454717a78fd0e8467cbbde1" continuedAt="Text_dff85e01ae454717a78fd0e8467cbbde2">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="font-weight: bold;">7.</span></td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">DEBT</span></div>
                </td>

  </tr>


</table>
</ix:continuation>
          <ix:continuation id="Text_dff85e01ae454717a78fd0e8467cbbde2" continuedAt="Text_dff85e01ae454717a78fd0e8467cbbde3">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_dff85e01ae454717a78fd0e8467cbbde3" continuedAt="Text_dff85e01ae454717a78fd0e8467cbbde4">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation><ix:nonNumeric name="us-gaap:ScheduleOfDebtTableTextBlock" id="Text_fb30672c877d44ed80eab25761383540" contextRef="c20210101to20210630" escape="true" continuedAt="Text_729365f771cd47a0ab644f9298c4b4041"><ix:continuation id="Text_dff85e01ae454717a78fd0e8467cbbde4" continuedAt="Text_dff85e01ae454717a78fd0e8467cbbde5">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:nonNumeric>
          <ix:continuation id="Text_729365f771cd47a0ab644f9298c4b4041" continuedAt="Text_729365f771cd47a0ab644f9298c4b4042"><ix:continuation id="Text_dff85e01ae454717a78fd0e8467cbbde5" continuedAt="Text_dff85e01ae454717a78fd0e8467cbbde6">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">A summary of outstanding senior notes payable is as follows:</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_729365f771cd47a0ab644f9298c4b4042" continuedAt="Text_729365f771cd47a0ab644f9298c4b4043"><ix:continuation id="Text_dff85e01ae454717a78fd0e8467cbbde6" continuedAt="Text_dff85e01ae454717a78fd0e8467cbbde7">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_729365f771cd47a0ab644f9298c4b4043" continuedAt="Text_729365f771cd47a0ab644f9298c4b4044"><ix:continuation id="Text_dff85e01ae454717a78fd0e8467cbbde7" continuedAt="Text_dff85e01ae454717a78fd0e8467cbbde8">
<div style="margin-left: 13.5pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_729365f771cd47a0ab644f9298c4b4044" continuedAt="Text_729365f771cd47a0ab644f9298c4b4045"><ix:continuation id="Text_dff85e01ae454717a78fd0e8467cbbde8" continuedAt="Text_dff85e01ae454717a78fd0e8467cbbde9">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_729365f771cd47a0ab644f9298c4b4045" continuedAt="Text_729365f771cd47a0ab644f9298c4b4046"><ix:continuation id="Text_dff85e01ae454717a78fd0e8467cbbde9" continuedAt="Text_dff85e01ae454717a78fd0e8467cbbde10">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">June 30, 2021</span></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">December 31, 2020</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Notes payable</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:SeniorNotesPayableBeforeDebtDiscount" id="Fact_426c94243fae42a8aecdc9e76c6b85ee" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">100,000,000</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:SeniorNotesPayableBeforeDebtDiscount" id="Fact_ac74dcba15724b1f8d31cb1d092ad7ff" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">100,000,000</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Less:</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Debt discount</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" id="Fact_a0d8dbbcdd1b41eaaff2142b0edd0dec" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">6,122,983</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" id="Fact_cf0b794cdbd644d69b39a85037a9a545" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">7,031,134</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Senior notes payable</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:SeniorLongTermNotes" id="Fact_196eed8e93bd42ae8e604d0fe5983056" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">93,877,017</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:SeniorLongTermNotes" id="Fact_d0c973068df44ba28d11289e6042d38b" contextRef="c20201231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">92,968,866</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_729365f771cd47a0ab644f9298c4b4046"><ix:continuation id="Text_dff85e01ae454717a78fd0e8467cbbde10" continuedAt="Text_dff85e01ae454717a78fd0e8467cbbde11">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_dff85e01ae454717a78fd0e8467cbbde11" continuedAt="Text_dff85e01ae454717a78fd0e8467cbbde12">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span></div>
</ix:continuation>
          <ix:continuation id="Text_dff85e01ae454717a78fd0e8467cbbde12" continuedAt="Text_dff85e01ae454717a78fd0e8467cbbde13">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_dff85e01ae454717a78fd0e8467cbbde13" continuedAt="Text_dff85e01ae454717a78fd0e8467cbbde14">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Under the Credit Agreement and Guaranty, as amended from time to time, (the &#8220;Perceptive Credit Agreement&#8221;)
            with Perceptive Credit Holdings II, LP, as the lender and administrative agent (&#8220;Perceptive&#8221;), the Company has a principal balance outstanding to Perceptive in the form of senior secured notes payable to Perceptive aggregating to $<ix:nonFraction name="adma:SeniorNotesPayableBeforeDebtDiscount" id="Fact_a23b41f8c71149a4846efc0a28fbec3d" contextRef="c20210630" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">100.0</ix:nonFraction> million with a maturity date of <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" id="Fact_997dbbe710f34278ae764df98710adc4" contextRef="c20210101to20210630_DebtInstrumentAxis_PerceptiveCreditAgreementMember" format="ixt:datemonthdayyearen">March 1, 2024</ix:nonNumeric>
            (the &#8220;Maturity Date&#8221;), subject to acceleration pursuant to the Perceptive Credit Agreement, including upon an Event of Default (as defined in the Perceptive Credit Agreement). On the Maturity Date, the Company will pay Perceptive the entire
            outstanding principal amount and any accrued and unpaid interest thereon. Prior to the Maturity Date, there are no scheduled principal payments due under the Perceptive Credit Agreement.</div>
</ix:continuation>
          <ix:continuation id="Text_dff85e01ae454717a78fd0e8467cbbde14" continuedAt="Text_dff85e01ae454717a78fd0e8467cbbde15">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_dff85e01ae454717a78fd0e8467cbbde15" continuedAt="Text_dff85e01ae454717a78fd0e8467cbbde16">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_dff85e01ae454717a78fd0e8467cbbde16" continuedAt="Text_dff85e01ae454717a78fd0e8467cbbde17">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_dff85e01ae454717a78fd0e8467cbbde17" continuedAt="Text_dff85e01ae454717a78fd0e8467cbbde18">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Borrowings under the Perceptive Credit Agreement bear interest at a rate per annum equal to <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_71a6c33b844b4f26b4410e9e5ee20a8d" contextRef="c20210630_DebtInstrumentAxis_PerceptiveCreditAgreementMember" unitRef="U007" decimals="3" scale="-2" format="ixt:numdotdecimal">7.5</ix:nonFraction>% plus the greater of (i) <ix:nonNumeric name="adma:DebtInstrumentTermOfVariableRate" id="Fact_70198b365427459c80621e18d8e6f833" contextRef="c20210101to20210630_DebtInstrumentAxis_PerceptiveCreditAgreementMember_VariableRateAxis_LondonInterbankOfferedRateLIBORMember" format="ixt-sec:durwordsen">one-month</ix:nonNumeric>
            LIBOR and (ii) <ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" id="Fact_415e8037cec142609c8ca4d26ee55a15" contextRef="c20210101to20210630_DebtInstrumentAxis_PerceptiveCreditAgreementMember" unitRef="U007" decimals="3" scale="-2" format="ixt:numdotdecimal">3.5</ix:nonFraction>%; provided, however, that upon, and during the continuance of, an Event of Default, the interest rate will
            automatically increase by an additional <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" id="Fact_2535d04d809b4f8dbe59fb4300b3c382" contextRef="c20210101to20210630_DebtInstrumentAxis_PerceptiveCreditAgreementMember" unitRef="U007" decimals="4" scale="-4" format="ixt:numdotdecimal">400</ix:nonFraction> basis points. Accrued interest is payable to Perceptive on the last day of each month
            during the term of the Perceptive Credit Facility. The rate of interest in effect as of June 30, 2021 was <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" id="Fact_d5ae3613281c49479cf1fb971850b1fa" contextRef="c20210630_DebtInstrumentAxis_PerceptiveCreditAgreementMember" unitRef="U007" decimals="3" scale="-2" format="ixt:numdotdecimal">11.0</ix:nonFraction>%, and the Company
            paid interest to Perceptive during the six months ended June 30, 2021 and 2020 in the amount of $<ix:nonFraction name="adma:RepaymentsOfDebtInterest" id="Fact_527de7a16f914970bc63b8b09f7a7e8f" contextRef="c20210101to20210630" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">5.5</ix:nonFraction> million and $<ix:nonFraction name="adma:RepaymentsOfDebtInterest" id="Fact_d8c4a4c19e3e4b7baf69b6e92c551cef" contextRef="c20200101to20200630" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">4.4</ix:nonFraction> million, respectively.</div>
</ix:continuation>
          <ix:continuation id="Text_dff85e01ae454717a78fd0e8467cbbde18" continuedAt="Text_dff85e01ae454717a78fd0e8467cbbde19">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_dff85e01ae454717a78fd0e8467cbbde19" continuedAt="Text_dff85e01ae454717a78fd0e8467cbbde20">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_dff85e01ae454717a78fd0e8467cbbde20" continuedAt="Text_dff85e01ae454717a78fd0e8467cbbde21">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_dff85e01ae454717a78fd0e8467cbbde21" continuedAt="Text_dff85e01ae454717a78fd0e8467cbbde22">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">All of the Company&#8217;s obligations under the Perceptive Credit Agreement are secured by a first-priority lien
            and security interest in substantially all of the Company&#8217;s tangible and intangible assets, including intellectual property and all of the equity interests in the Company&#8217;s subsidiaries. The Perceptive Credit Agreement contains certain
            representations and warranties, affirmative covenants, negative covenants and conditions that are customarily required for similar financings. The negative covenants restrict or limit the ability of the Company and its subsidiaries to, among
            other things and subject to certain exceptions contained in the Perceptive Credit Agreement, incur new indebtedness; create liens on assets; engage in certain fundamental corporate changes, such as mergers or acquisitions, or changes to the
            Company&#8217;s or its subsidiaries&#8217; business activities; make certain Investments or Restricted Payments (each as defined in the Perceptive Credit Agreement); change its fiscal year; pay dividends; repay other certain indebtedness; engage in certain
            affiliate transactions; or enter into, amend or terminate any other agreements that have the impact of restricting the Company&#8217;s ability to make loan repayments under the Perceptive Credit Agreement. In addition, the Company must (i) at all
            times prior to the Maturity Date maintain a minimum cash balance of $<ix:nonFraction name="us-gaap:Cash" id="Fact_d19f99d6554c40f5b8f68c652ad6323a" contextRef="c20210630_DebtInstrumentAxis_PerceptiveCreditAgreementMember_RangeAxis_MinimumMember" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction> million; and (ii) as of the last day of each fiscal quarter
            commencing with the fiscal quarter ended June 30, 2019, report revenues for the trailing 12-month period that exceed the amounts set forth in the Perceptive Credit Agreement, which range from $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_c0c5e4c7214941ef947393646fe1969a" contextRef="c20190401to20190630_DebtInstrumentAxis_PerceptiveCreditAgreementMember" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">7.0</ix:nonFraction> million for the fiscal quarter ended June 30, 2019 to $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_b2afe6436376469abcd97a1fcf0b289f" contextRef="c20211001to20211231_DebtInstrumentAxis_PerceptiveCreditAgreementMember_StatementScenarioAxis_ScenarioForecastMember" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">55.0</ix:nonFraction>
            million for the fiscal quarter ending December 31, 2021. At June 30, 2021, the Company was in compliance with all of the covenants contained in the Perceptive Credit Agreement.</div>
</ix:continuation>
          <ix:continuation id="Text_dff85e01ae454717a78fd0e8467cbbde22" continuedAt="Text_dff85e01ae454717a78fd0e8467cbbde23">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_dff85e01ae454717a78fd0e8467cbbde23" continuedAt="Text_dff85e01ae454717a78fd0e8467cbbde24">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_dff85e01ae454717a78fd0e8467cbbde24" continuedAt="Text_dff85e01ae454717a78fd0e8467cbbde25">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
            <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">12</span></div>

            <div style="page-break-after:always;" class="DSPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

            <div style="width: 100%;" class="DSPFPageHeader">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 100%; font-size: 8pt; font-style: italic;">
                      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>
                      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>
                    </td>

  </tr>


</table>
            </div>

          </div>

          <ix:continuation id="Text_dff85e01ae454717a78fd0e8467cbbde25">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">As a result of the fees paid to Perceptive and the value of the warrants issued to Perceptive under the terms
            of the Perceptive Credit Agreement, the Company recognized an aggregate discount on the senior secured notes in the amount of $<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" id="Fact_34f2d5303d594b4abaec127ecc9bb4c5" contextRef="c20210630_DebtInstrumentAxis_PerceptiveCreditAgreementMember_LongtermDebtTypeAxis_SeniorNotesMember" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">7.1</ix:nonFraction>
            million.&#160; The Company records debt discount as a reduction to the face amount of the debt, and the debt discount is amortized as interest expense over the life of the debt using the interest method. Based on the fair value of the Perceptive
            Warrants and the aggregate amount of fees and expenses associated with obtaining the Perceptive Credit Facility, the effective interest rate on senior secured notes payable to Perceptive as of June 30, 2021 was approximately <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" id="Fact_fa9f8fb29b884d6ebbf5a8426109f80c" contextRef="c20210630_DebtInstrumentAxis_PerceptiveCreditFacilityMember" unitRef="U007" decimals="3" scale="-2" format="ixt:numdotdecimal">13.7</ix:nonFraction>%.</div>
</ix:continuation>
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

          <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

        <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

  </div>
<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

        <div><ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Text_5ecaf0c606624acda2de24059b4958ef" contextRef="c20210101to20210630" escape="true" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c1">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c1" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c2">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">8.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">STOCKHOLDERS&#8217; EQUITY</span></div>
                </td>

  </tr>


</table>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c2" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c3">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c3" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c4">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c4" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c5">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c5" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c6">
<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Preferred Stock</span></div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c6" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c7">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c7" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c8">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c8" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c9">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c9" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c10">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The Company is currently authorized to issue up to <ix:nonFraction name="us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance" id="Fact_c5aa594bdfcb46bfa703964d238bb7f8" contextRef="c20201231" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance" id="Fact_1ad471244f8c4ba5926dc35ad53497fe" contextRef="c20210630" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction></ix:nonFraction> million shares of preferred stock, $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact_e36989c2f28b42ffac930f2acc7e1d4f" contextRef="c20201231" unitRef="U003" decimals="4" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact_9bcd923836844f3abcc769beaeabdff5" contextRef="c20210630" unitRef="U003" decimals="4" scale="0" format="ixt:numdotdecimal">0.0001</ix:nonFraction></ix:nonFraction>, par
            value per share.&#160; There were <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" id="Fact_97e658641dcb4b7f9dca22d60dfaf5e4" contextRef="c20210630" unitRef="U001" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" id="Fact_19bfc313615040bb85ce5867d4ac3efd" contextRef="c20201231" unitRef="U001" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> shares of preferred stock outstanding at June 30, 2021 and December 31, 2020.</div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c10" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c11">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c11" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c12">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c12" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c13">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c13" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c14">
<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Common Stock</span></div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c14" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c15">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c15" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c16">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c16" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c17">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c17" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c18">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">As of June 30, 2021 and December 31, 2020, the Company was authorized to issue <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_fbe414bac83745e6ad1110a42acecff8" contextRef="c20210630" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">300,000,000</ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_2dadc6e251d24d74bc9986e1a1f7fac7" contextRef="c20201231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">150,000,000</ix:nonFraction> shares,
            respectively, of its common stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_6ef668dd62dc4ef480ed001d88561df6" contextRef="c20201231" unitRef="U003" decimals="4" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_04a74998a0984a49a5af7a4bfad67177" contextRef="c20210630" unitRef="U003" decimals="4" scale="0" format="ixt:numdotdecimal">0.0001</ix:nonFraction></ix:nonFraction> par value per share, and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_38e8a93c07b5453d8a170b3d478b634c" contextRef="c20210630" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">131,872,026</ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_892dbb4ab68b46b6abdaf0ff14f819b7" contextRef="c20201231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">104,902,888</ix:nonFraction> shares of common stock were
            outstanding as of June 30, 2021 and December 31, 2020, respectively. On May 27, 2021, the Company&#8217;s stockholders approved an amendment to the Company&#8217;s certificate of incorporation which increased the number of shares of common stock that the
            Company is authorized to issue from <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_7e235e82dd864a4d98893080a0d7837c" contextRef="c20201231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">150,000,000</ix:nonFraction> to <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_e687281a5dd24d3d9545d7aff01b2a02" contextRef="c20210630" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">300,000,000</ix:nonFraction>. After giving effect to the <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_609e8f2aaaa44cc1ba336f385f70492b" contextRef="c20210630" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">17,073,357</ix:nonFraction> shares reserved for
            outstanding warrants and awards issued or reserved for future issuance under the Company&#8217;s equity incentive plans, as of June 30, 2021 there were <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" id="Fact_a76d8c0cb3984d619cb711388866cde1" contextRef="c20210630" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">151,054,617</ix:nonFraction>
            shares of common stock available for issuance.</div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c18" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c19">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c19" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c20">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c20" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c21">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c21" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c22">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">On August 5, 2020, the Company entered into the 2020 Sale Agreement with Jefferies (see Note 1), pursuant to
            which the Company could offer and sell, from time to time, at its option, through or to Jefferies, up to an aggregate of $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_0624939f9c364750afc0261249f6abc5" contextRef="c20200805to20200805_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_JefferiesLLCMember_TypeOfArrangementAxis_SaleAgreement2020Member" unitRef="U002" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonFraction> million
            of shares of the Company&#8217;s common stock. On November 5, 2020 and February 3, 2021, the Company and Jefferies amended the 2020 Sale Agreement to provide for increases in the aggregate offering amount under the Sale Agreement such that the
            Company could sell shares having an aggregate offering price of up to $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_ca0e1654006c4321a19940c35947789d" contextRef="c20210203to20210203_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_JefferiesLLCMember_TypeOfArrangementAxis_SaleAgreement2020AmendedMember" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">105.4</ix:nonFraction> million under the 2020 Sale Agreement, as amended.
            During the six months ended June 30, 2021, the Company issued and sold <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_df5f1367f1544c4781aec18b980fbf9c" contextRef="c20210101to20210630_RelatedPartyTransactionsByRelatedPartyAxis_JefferiesLLCMember_StatementEquityComponentsAxis_CommonStockMember_TypeOfArrangementAxis_SaleAgreement2020Member" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">26,907,753</ix:nonFraction> shares of common stock under the 2020 Sale
            Agreement and received net proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_4ac97b4d67644fd6a1c840d883712cb5" contextRef="c20210101to20210630_RelatedPartyTransactionsByRelatedPartyAxis_JefferiesLLCMember_TypeOfArrangementAxis_SaleAgreement2020Member" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">59.1</ix:nonFraction> million (see Note 14).</div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c22" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c23">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c23" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c24">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c24" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c25">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c25" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c26">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">On May 28, 2021, the Company entered into the 2021 Sale Agreement with Jefferies, pursuant to which the
            Company may offer and sell, from time to time, at its option, through or to Jefferies, up to an aggregate of $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_b679a94569664fd58e5a715fd5b6d4fd" contextRef="c20210528to20210528_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_JefferiesLLCMember_TypeOfArrangementAxis_SaleAgreement2021Member" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">50,000,000</ix:nonFraction> of shares of
            the Company&#8217;s common stock. As of the date of this report, there have been <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_c031d491bd0c4ae58175758b8a8a4f63" contextRef="c20210528to20210528_RelatedPartyTransactionsByRelatedPartyAxis_JefferiesLLCMember_StatementEquityComponentsAxis_CommonStockMember_TypeOfArrangementAxis_SaleAgreement2021Member" unitRef="U001" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> sales of common stock under this agreement.</div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c26" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c27">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c27" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c28">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c28" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c29">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c29" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c30">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">On February 11, 2020, the Company completed an underwritten public offering of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_3e2137fe01974a86aae52632190fc8ea" contextRef="c20200211to20200211_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_OverAllotmentOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">23,500,000</ix:nonFraction> shares of its common stock for gross proceeds of $<ix:nonFraction name="adma:GrossProceedsFromIssuanceOfCommonStock" id="Fact_c6d0703b6702455c8deeb5b76de102f9" contextRef="c20200211to20200211_SubsidiarySaleOfStockAxis_OverAllotmentOptionMember" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">82.3</ix:nonFraction> million. On February 21, 2020, the Company sold an additional <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_ae569f4bd5f04ccc9fde7d1768d8949a" contextRef="c20200221to20200221_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_OverAllotmentOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">3,525,000</ix:nonFraction> shares pursuant to
            the underwriters&#8217; exercise of their option to purchase additional shares of the Company&#8217;s common stock for additional gross proceeds of $<ix:nonFraction name="adma:GrossProceedsFromIssuanceOfCommonStock" id="Fact_e9c6139b17ae468fb494b59f32b45208" contextRef="c20200221to20200221_SubsidiarySaleOfStockAxis_OverAllotmentOptionMember" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">12.3</ix:nonFraction>
            million. The Company received net proceeds, after underwriting discounts and other expenses associated with the offering, of approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_b3efc90e12fc4d219a2ce4c739007e15" contextRef="c20200101to20200630_SubsidiarySaleOfStockAxis_OverAllotmentOptionMember" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">88.7</ix:nonFraction>
            million.</div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c30" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c31">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c31" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c32">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c32" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c33">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c33" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c34">
<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Warrants</span></div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c34" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c35">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c35" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c36">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c36" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c37">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c37" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c38">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">At June 30, 2021 and December 31, 2020, the Company had outstanding warrants to purchase an aggregate of <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_94055a98035b4bb7815626bb0cfb6b28" contextRef="c20201231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_4ab5c5b6c61e49949e55285d6d03cd5a" contextRef="c20210630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">4,528,160</ix:nonFraction></ix:nonFraction> shares of common stock, with a weighted average exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_7fd9294b987d41aebddb5af01ff37603" contextRef="c20201231" unitRef="U003" decimals="2" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_17bd2f089463449db84d64eca81952e5" contextRef="c20210630" unitRef="U003" decimals="2" scale="0" format="ixt:numdotdecimal">2.82</ix:nonFraction></ix:nonFraction> per share and expiration dates ranging between June 2022 and December 2030.</div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c38" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c39">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c39" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c40">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c40" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c41">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
            <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">13</span></div>

            <div style="page-break-after:always;" class="DSPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

            <div style="width: 100%;" class="DSPFPageHeader">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 100%; font-size: 8pt; font-style: italic;">
                      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>
                      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>
                    </td>

  </tr>


</table>
            </div>

          </div>

          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c41" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c42">
<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Equity Incentive Plans</span></div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c42" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c43">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c43" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c44">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c44" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c45">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c45" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c46">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The fair value of stock options granted under the Company&#8217;s 2007 Employee Stock Option Plan
              (the &#8220;2007 Plan&#8221;) and the ADMA Biologics, Inc. 2014 Omnibus Incentive Compensation Plan, as amended and restated (the &#8220;2014 Plan&#8221;), was determined on the date of grant using the Black-Scholes option valuation model. The Black-Scholes model
              was developed for use in estimating the fair value of publicly traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of certain subjective assumptions including
              the expected stock price volatility. The stock options granted to employees and directors have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the
              fair value estimate. </span><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Text_91b9573094e44c8f81d6558493652ebe" contextRef="c20210101to20210630" escape="true" continuedAt="Text_107b2e5e15bd40df98f0735a0da62e7e1"><span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The following assumptions were used to determine the fair value of options granted during the six months ended June 30, 2021 and
              2020:</span></span></ix:nonNumeric></div>
</ix:continuation>
          <ix:continuation id="Text_107b2e5e15bd40df98f0735a0da62e7e1" continuedAt="Text_107b2e5e15bd40df98f0735a0da62e7e2"><ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c46" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c47">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_107b2e5e15bd40df98f0735a0da62e7e2" continuedAt="Text_107b2e5e15bd40df98f0735a0da62e7e3"><ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c47" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c48">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_107b2e5e15bd40df98f0735a0da62e7e3" continuedAt="Text_107b2e5e15bd40df98f0735a0da62e7e4"><ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c48" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c49">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_107b2e5e15bd40df98f0735a0da62e7e4" continuedAt="Text_107b2e5e15bd40df98f0735a0da62e7e5"><ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c49" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c50">
<table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 76%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Six Months Ended June 30,</div>
                </td>

  </tr>

  <tr>

    <td style="width: 76%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td style="width: 11%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2021<br />
                    </span> </div>
                </td>

    <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td style="width: 11%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2020<br />
                    </span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 76%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Expected term</div>
                </td>

    <td style="width: 11%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_5edf98fab3ad43ab82420efb6e1f88a3" contextRef="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember" format="ixt-sec:duryear">5.5</ix:nonNumeric> - <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_9e70bc64a9b14ef393eb3cb4673cbc40" contextRef="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember" format="ixt-sec:duryear">6.3</ix:nonNumeric> years</div>
                </td>

    <td style="width: 2%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td style="width: 11%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_82911ce5e15f4821b44e3caf8324b3bc" contextRef="c20200101to20200630_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember" format="ixt-sec:duryear">5.5</ix:nonNumeric> - <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_8b7d7a0570ab4f47b408a03ecc8bc56c" contextRef="c20200101to20200630_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember" format="ixt-sec:duryear">6.3</ix:nonNumeric> years</div>
                </td>

  </tr>

  <tr>

    <td style="width: 76%; vertical-align: bottom; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Volatility</div>
                </td>

    <td style="width: 11%; vertical-align: bottom; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_ad066e76b55c4b67a4eb36af8aadb867" contextRef="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U007" decimals="2" scale="-2" format="ixt:numdotdecimal">69</ix:nonFraction>%<br />
                    </span> </div>
                </td>

    <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td style="width: 11%; vertical-align: bottom; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_6fb81de8910d4f539abbb569f6255b7d" contextRef="c20200101to20200630_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember" unitRef="U007" decimals="2" scale="-2" format="ixt:numdotdecimal">62</ix:nonFraction>-<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_7a16b951e74846119f293c15500da749" contextRef="c20200101to20200630_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember" unitRef="U007" decimals="2" scale="-2" format="ixt:numdotdecimal">67</ix:nonFraction>%</div>
                </td>

  </tr>

  <tr>

    <td style="width: 76%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Dividend yield</div>
                </td>

    <td style="width: 11%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_fd89e78d74314c60b53e29b568086538" contextRef="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U007" decimals="1" scale="0" format="ixt:numdotdecimal">0.0</ix:nonFraction><br />
                    </span> </div>
                </td>

    <td style="width: 2%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td style="width: 11%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_b374b1b991414d1088806c8b9310de71" contextRef="c20200101to20200630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U007" decimals="1" scale="0" format="ixt:numdotdecimal">0.0</ix:nonFraction><br />
                    </span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 76%; vertical-align: bottom; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Risk-free interest rate</div>
                </td>

    <td style="width: 11%; vertical-align: bottom; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_ef870433a43140ebbc855ce35f51a777" contextRef="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember" unitRef="U007" decimals="4" scale="-2" format="ixt:numdotdecimal">0.80</ix:nonFraction>-<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_47ec553d5f724fbdb139d0cc2cc65cdf" contextRef="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember" unitRef="U007" decimals="4" scale="-2" format="ixt:numdotdecimal">1.14</ix:nonFraction>%</div>
                </td>

    <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td style="width: 11%; vertical-align: bottom; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_ede93fe1e9614961b990935fb83abb6b" contextRef="c20200101to20200630_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember" unitRef="U007" decimals="4" scale="-2" format="ixt:numdotdecimal">0.38</ix:nonFraction>-<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_a278f9a847e0442faf3737a6b734083d" contextRef="c20200101to20200630_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember" unitRef="U007" decimals="4" scale="-2" format="ixt:numdotdecimal">1.68</ix:nonFraction>%</div>
                </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_107b2e5e15bd40df98f0735a0da62e7e5"><ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c50" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c51">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c51" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c52">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span></div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c52" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c53">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c53" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c54">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">During the six months ended June 30, 2021 and 2020, the Company granted options to purchase an aggregate of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_9a863e3b6df846ccb70b653113a30c5b" contextRef="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">1,658,050</ix:nonFraction> and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_34e621b3a0fd4079a653ba92d67a1236" contextRef="c20200101to20200630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">1,232,500</ix:nonFraction> shares of
            common stock, respectively, to its directors, employees and certain third-party service providers.&#160; The weighted average remaining contractual life of stock options outstanding and expected to vest at June 30, 2021 is <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Fact_56a3149d760a408698cc2f034d26596f" contextRef="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="Fact_4ddbd46632bb40558d9b037ddbea7242" contextRef="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear">6.5</ix:nonNumeric></ix:nonNumeric> years. The weighted average remaining contractual life of stock options exercisable at June 30, 2021 is <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Fact_85c3b4b12b8545aa8048145d06a68fd0" contextRef="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear">5.2</ix:nonNumeric> years.</div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c54" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c55">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c55" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c56">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Text_619c0196e81947b1af4e026299b00e41" contextRef="c20210101to20210630" escape="true" continuedAt="Text_7f53aee7c27d46b19d9c1bc1ff54bc7f1"><ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c56" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c57">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:nonNumeric>
          <ix:continuation id="Text_7f53aee7c27d46b19d9c1bc1ff54bc7f1" continuedAt="Text_7f53aee7c27d46b19d9c1bc1ff54bc7f2"><ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c57" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c58">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">A summary of the Company&#8217;s option activity under the 2007 Plan and 2014 Plan and related information is as
            follows:</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_7f53aee7c27d46b19d9c1bc1ff54bc7f2" continuedAt="Text_7f53aee7c27d46b19d9c1bc1ff54bc7f3"><ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c58" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c59">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_7f53aee7c27d46b19d9c1bc1ff54bc7f3" continuedAt="Text_7f53aee7c27d46b19d9c1bc1ff54bc7f4"><ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c59" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c60">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_7f53aee7c27d46b19d9c1bc1ff54bc7f4" continuedAt="Text_7f53aee7c27d46b19d9c1bc1ff54bc7f5"><ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c60" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c61">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_7f53aee7c27d46b19d9c1bc1ff54bc7f5" continuedAt="Text_7f53aee7c27d46b19d9c1bc1ff54bc7f6"><ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c61" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c62">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Shares</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Weighted </div>
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Average </div>
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Exercise Price</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Options outstanding, vested and expected to vest at <span style="text-indent: 0pt;">December 31, 2020</span></div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" id="Fact_ea8f15b425764c1bb03bc6a367fa5b4e" contextRef="c20201231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">6,922,931</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" id="Fact_b13b66e0829c4bb0b7cf3bdcf4fcbc76" contextRef="c20201231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:numdotdecimal">4.40</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Forfeited</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" id="Fact_bd7c4eadc2124e45bbc1207e1d8e2ba0" contextRef="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">404,782</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div>)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" id="Fact_d58cf233c30340a6a898ea61e63bd45f" contextRef="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:numdotdecimal">2.96</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Expired</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" id="Fact_e66c935a897e4138b3469bc93318fb4c" contextRef="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">393,170</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" id="Fact_7d5a8e9cedb44f5ea692c0c5bb625d62" contextRef="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:numdotdecimal">5.03</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Granted</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" id="Fact_ab385a0e551e46f58d6483b01d16b73a" contextRef="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">1,658,050</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" id="Fact_b5d0ac4aaea24b33b2572704ab3a0dc9" contextRef="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:numdotdecimal">2.26</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Exercised</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" id="Fact_6cd0d2b1621a4365a91bf3bd957b4139" contextRef="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="INF" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" id="Fact_cf1448c48af64fc0af18979954090f55" contextRef="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Options outstanding, vested and expected to vest at <span style="text-indent: 0pt;">June 30, 2021</span></div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" id="Fact_889f0f5da755432ea3a68571727c3373" contextRef="c20210630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">7,783,029</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" id="Fact_b9a866771bc04c69a8cf81f13048dcd4" contextRef="c20210630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:numdotdecimal">3.98</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 76%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Options exercisable</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" id="Fact_e7a0611b1645413fa8560e6ec3495e3f" contextRef="c20210630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">5,011,506</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" id="Fact_d742804623e64614b4bbf7a422304d21" contextRef="c20210630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:numdotdecimal">4.70</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_7f53aee7c27d46b19d9c1bc1ff54bc7f6"><ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c62" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c63">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c63" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c64">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span></div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c64" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c65">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c65" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c66">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">As of June 30, 2021, the Company had $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" id="Fact_1a21ba963e8b49448a47c789cd3a755d" contextRef="c20210630_PlanNameAxis_EquityIncentivePlanMember" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">4.2</ix:nonFraction> million of unrecognized compensation expense related to options granted under the Company&#8217;s equity incentive plans, which is expected to be recognized over a
            weighted-average period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Fact_db6ada0c0ca04a6c9df4ab4ff22cd30f" contextRef="c20210101to20210630_PlanNameAxis_EquityIncentivePlanMember" format="ixt-sec:duryear">2.6</ix:nonNumeric> years.</div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c66" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c67">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c67" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c68">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c68" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c69">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c69" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c70">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">During the six months ended June 30, 2021 and 2020, the Company granted Restricted Stock Units
              (&#8220;RSUs&#8221;) representing an aggregate of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" id="Fact_52106f1da4e743719003af625beae328" contextRef="c20210101to20210630_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">542,244</ix:nonFraction> and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" id="Fact_db6c614af7f6450c9436ad2f0eea2cdb" contextRef="c20200101to20200630_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">341,000</ix:nonFraction> shares, respectively, to certain management employees of the Company and to members of its Board of Directors.&#160; The RSUs vest annually over a period of <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact_b71ea04f229f41969fe4c9b644c3292f" contextRef="c20210101to20210630_AwardTypeAxis_RestrictedStockUnitsRSUMember_TitleOfIndividualAxis_EmployeesMember" format="ixt-sec:durwordsen">four years</ix:nonNumeric> for employees and semi-annually over a period of <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact_9bb71f6432c045b49d53acf3c82f1e61" contextRef="c20200101to20200630_AwardTypeAxis_RestrictedStockUnitsRSUMember_TitleOfIndividualAxis_DirectorMember" format="ixt-sec:durwordsen">one year</ix:nonNumeric>
              for directors. During the six months ended June 30, 2021, <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" id="Fact_04a3b07706fe432582ddb53265fcfc82" contextRef="c20210101to20210630_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">87,750</ix:nonFraction> shares vested in connection with grants of RSUs. With respect to
              these vested RSUs, <ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" id="Fact_46a45c70c9f94cbab27714bc53a46f1f" contextRef="c20210630_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">26,365</ix:nonFraction> shares valued at approximately $<ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" id="Fact_249dad5be0ef43cfbf11f69e0c1daf16" contextRef="c20210630_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">59,000</ix:nonFraction> were withheld by the Company to cover employees&#8217; tax liabilities.&#160; On March 25, 2021, these shares were retired by the Company and were no longer outstanding as of
              June 30, 2021. </span><ix:nonNumeric name="us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" id="Text_9064e357ffdc4f8c83da8e349b856923" contextRef="c20210101to20210630" escape="true" continuedAt="Text_17e2677c44c444a3a8fc1a77cab016ec1"><span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">A summary of the Company&#8217;s unvested RSU activity and related information is as follows:</span></span></ix:nonNumeric></div>
</ix:continuation>
          <ix:continuation id="Text_17e2677c44c444a3a8fc1a77cab016ec1" continuedAt="Text_17e2677c44c444a3a8fc1a77cab016ec2"><ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c70" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c71">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
            <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">14</span></div>

            <div style="page-break-after:always;" class="DSPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

            <div style="width: 100%;" class="DSPFPageHeader">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 100%; font-size: 8pt; font-style: italic;">
                      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>
                      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>
                    </td>

  </tr>


</table>
            </div>

          </div>

          <ix:continuation id="Text_17e2677c44c444a3a8fc1a77cab016ec2" continuedAt="Text_17e2677c44c444a3a8fc1a77cab016ec3"><ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c71" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c72">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Shares</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Weighted </div>
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Average Grant </div>
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Date Fair Value</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Balance at <span style="text-indent: 0pt;">December 31, 2020</span></div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" id="Fact_9f291a1ddb1645be91d4c6c39295d9e4" contextRef="c20201231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">326,000</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="Fact_59e9040d6bfe4fdeb429f3bcdea8b1f7" contextRef="c20201231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="2" scale="0" format="ixt:numdotdecimal">2.81</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Granted</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" id="Fact_285a9b6a5ee54fbca06e460e6a8547e8" contextRef="c20210101to20210630_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">542,244</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="Fact_ec2a54b9e83f47f7a1b7b2e842dd6ff1" contextRef="c20210101to20210630_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="2" scale="0" format="ixt:numdotdecimal">2.29</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Vested</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" id="Fact_2278cf3e6210456e91e8f373baa263e7" contextRef="c20210101to20210630_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">87,750</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" id="Fact_01d47564bb49418793ef24b7fc7fc677" contextRef="c20210101to20210630_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="2" scale="0" format="ixt:numdotdecimal">2.81</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Forfeited</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" id="Fact_0bdf5d82f6ec4e44a8043d7999652c89" contextRef="c20210101to20210630_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">94,361</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                  <div>)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" id="Fact_394462b201c64639864ebe0264f32f79" contextRef="c20210101to20210630_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="2" scale="0" format="ixt:numdotdecimal">2.53</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Balance at <span style="text-indent: 0pt;">June 30, 2021</span></div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" id="Fact_d1555e70654f4816bcd2f5ab41e38fbe" contextRef="c20210630_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">686,133</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="Fact_650c2683a07a4150b6bfe43c3ddb7360" contextRef="c20210630_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="2" scale="0" format="ixt:numdotdecimal">2.44</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_17e2677c44c444a3a8fc1a77cab016ec3"><ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c72" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c73">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c73" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c74">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span></div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c74" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c75">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c75" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c76">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">As of June 30, 2021, the Company had $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" id="Fact_60932583165846a4a1dcb7b0e18d9dc6" contextRef="c20210630_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlanMember" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction> million of unrecognized compensation expense related to unvested RSUs granted under the Company&#8217;s equity incentive plans, which is expected to be recognized over a
            weighted-average period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Fact_d9adf9839e1349b2820ba9d8c3f649f7" contextRef="c20210101to20210630_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlanMember" format="ixt-sec:duryear">3.3</ix:nonNumeric> years.</div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c76" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c77">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c77" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c78">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation><ix:nonNumeric name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="Text_0cfebe5db0554c4a8d6b82f250a91866" contextRef="c20210101to20210630" escape="true" continuedAt="Text_c3887428b60e42da9a4a0f4519b2e81c1"><ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c78" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c79">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:nonNumeric>
          <ix:continuation id="Text_c3887428b60e42da9a4a0f4519b2e81c1" continuedAt="Text_c3887428b60e42da9a4a0f4519b2e81c2"><ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c79" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c80">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Total stock-based compensation expense for all awards granted under the Company&#8217;s equity incentive plans for
            the three months and six months June 30, 2021 and 2020 is as follows:</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c3887428b60e42da9a4a0f4519b2e81c2" continuedAt="Text_c3887428b60e42da9a4a0f4519b2e81c3"><ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c80" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c81">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c3887428b60e42da9a4a0f4519b2e81c3" continuedAt="Text_c3887428b60e42da9a4a0f4519b2e81c4"><ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c81" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c82">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c3887428b60e42da9a4a0f4519b2e81c4" continuedAt="Text_c3887428b60e42da9a4a0f4519b2e81c5"><ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c82" continuedAt="Text_b5b7516f352e45bf82ea6a77ad813c4c83">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c3887428b60e42da9a4a0f4519b2e81c5"><ix:continuation id="Text_b5b7516f352e45bf82ea6a77ad813c4c83">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Three Months Ended June 30,</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Six Months Ended June 30,</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; font-weight: bold;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2021<br />
                    </span> </div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2020<br />
                    </span> </div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2021<br />
                    </span> </div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2020<br />
                    </span> </div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Research and development</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_4eda738beddb43309201bb54037ea840" contextRef="c20210401to20210630_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">42,479</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_068bde74ca224e78bb8c8b06165001ac" contextRef="c20200401to20200630_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">105,029</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_8052c309b0c54548807b8917fe7aa9e2" contextRef="c20210101to20210630_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">147,706</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_1800b76e29ce4394a1537c2b88d68ca2" contextRef="c20200101to20200630_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">198,603</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Plasma center operating expenses</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_8c9c0d9e22814f22bc4b9481df49ebea" contextRef="c20210401to20210630_IncomeStatementLocationAxis_OperatingExpenseMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">13,637</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_89ca7c80b1f244a5aacd30dfaac7645c" contextRef="c20200401to20200630_IncomeStatementLocationAxis_OperatingExpenseMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">8,510</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_1f338f5df25a4e98be337f8f2240f5e6" contextRef="c20210101to20210630_IncomeStatementLocationAxis_OperatingExpenseMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">24,455</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_23b5d12a1548435581fc2948d2fd0fdd" contextRef="c20200101to20200630_IncomeStatementLocationAxis_OperatingExpenseMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">15,754</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Selling, general and administrative</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_d577bc8150264676b5285009e23c514f" contextRef="c20210401to20210630_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">665,836</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_8de38773fea74aac9a7782e57641746c" contextRef="c20200401to20200630_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">539,256</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_ff4281f5bb6b47419b7f2a3093453f92" contextRef="c20210101to20210630_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,254,327</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_79f40c9ecf0844158915f5b875cc5516" contextRef="c20200101to20200630_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,063,145</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_ce5e93afa4d04b8d9855a0357f68826c" contextRef="c20210401to20210630_IncomeStatementLocationAxis_CostOfSalesMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">83,237</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_d31bcf3745014e309a50b6b7b9b29d8b" contextRef="c20200401to20200630_IncomeStatementLocationAxis_CostOfSalesMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">62,813</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_527aa9f6c9e3476b81b8e2e790edb21c" contextRef="c20210101to20210630_IncomeStatementLocationAxis_CostOfSalesMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">160,098</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_44d4a848daf943f0b6e5603d85cef6e2" contextRef="c20200101to20200630_IncomeStatementLocationAxis_CostOfSalesMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">114,654</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Total stock-based compensation expense</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_f06354f639ec4a8fab7466422660f0ed" contextRef="c20210401to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">805,189</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_902844a26e7e4564a1da2a0b3f356af8" contextRef="c20200401to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">715,608</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_fd29e4724bb14396bc57cbd17699b6f8" contextRef="c20210101to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,586,586</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_31f2f180abc84b0b9177a182dbb7fd5b" contextRef="c20200101to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,392,156</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

          <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

        <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div><ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Text_5a916556c61144a7b4a413e35522597b" contextRef="c20210101to20210630" escape="true" continuedAt="Text_38f4234733924508998340d2d30caa651">
<div>  <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric>
      <ix:continuation id="Text_38f4234733924508998340d2d30caa651" continuedAt="Text_38f4234733924508998340d2d30caa652">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">9.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">RELATED PARTY TRANSACTIONS</div>
            </td>

  </tr>


</table>
</ix:continuation>
      <ix:continuation id="Text_38f4234733924508998340d2d30caa652" continuedAt="Text_38f4234733924508998340d2d30caa653">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
      <ix:continuation id="Text_38f4234733924508998340d2d30caa653" continuedAt="Text_38f4234733924508998340d2d30caa654">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
        </span> </div>
</ix:continuation>
      <ix:continuation id="Text_38f4234733924508998340d2d30caa654" continuedAt="Text_38f4234733924508998340d2d30caa655">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
      <ix:continuation id="Text_38f4234733924508998340d2d30caa655" continuedAt="Text_38f4234733924508998340d2d30caa656">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company leases an office building and equipment from Areth, LLC (&#8220;Areth&#8221;)
        pursuant to an agreement for services effective as of January 1, 2016, as amended from time to time. Rent expense for the six months ended June 30, 2021 and 2020 amounted to $<ix:nonFraction name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" id="Fact_a9f446d85fae4468aad8e2d50fc874df" contextRef="c20200401to20200630_RelatedPartyTransactionsByRelatedPartyAxis_ArethLLCMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" id="Fact_a6195e61567642eb81ff62f2ac428fb4" contextRef="c20210101to20210630_RelatedPartyTransactionsByRelatedPartyAxis_ArethLLCMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">60,000</ix:nonFraction></ix:nonFraction>. Areth is a company controlled by Dr. Jerrold B. Grossman, the Vice Chairman of the Company&#8217;s Board of Directors, and Adam S. Grossman, the Company&#8217;s President and Chief Executive
        Officer. The Company also reimburses Areth for office and building related (common area) expenses, equipment and certain other operational expenses, which were not material to the consolidated financial statements for the six months ended June 30,
        2021 and 2020. In addition, during the six months ended June 30, 2021, the Company purchased certain specialized medical equipment and services related to the Company&#8217;s plasma collection centers, as well as personal protective equipment, from
        GenesisBPS and its affiliates (&#8220;Genesis&#8221;), in the amount of $<ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" id="Fact_930ecdcad9a045e8acb8af5082cd322f" contextRef="c20210101to20210630_RelatedPartyTransactionsByRelatedPartyAxis_GenesisBPSMember" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction> million. This amount was immaterial to the consolidated financial
        statements for the three and six months ended June 30, 2020. Dr. Grossman and Adam Grossman each own shares of Genesis.</div>
</ix:continuation>
      <ix:continuation id="Text_38f4234733924508998340d2d30caa656" continuedAt="Text_38f4234733924508998340d2d30caa657">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
      <ix:continuation id="Text_38f4234733924508998340d2d30caa657" continuedAt="Text_38f4234733924508998340d2d30caa658">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
        </span> </div>
</ix:continuation>
      <ix:continuation id="Text_38f4234733924508998340d2d30caa658" continuedAt="Text_38f4234733924508998340d2d30caa659">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
      <ix:continuation id="Text_38f4234733924508998340d2d30caa659" continuedAt="Text_38f4234733924508998340d2d30caa6510">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">See Note 7 for a discussion of the Company&#8217;s credit facility and related
        transactions with Perceptive, a holder of more than <ix:nonFraction name="adma:MinimumPercentageOfCommonStockHeldByLender" id="Fact_076b3e912eeb4dfe923cba4c36e297ba" contextRef="c20210101to20210630_LineOfCreditFacilityAxis_PerceptiveCreditHoldingsIILPMember" unitRef="U007" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction>% of the Company&#8217;s common stock.</div>
</ix:continuation>
      <ix:continuation id="Text_38f4234733924508998340d2d30caa6510" continuedAt="Text_38f4234733924508998340d2d30caa6511">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
      <ix:continuation id="Text_38f4234733924508998340d2d30caa6511" continuedAt="Text_38f4234733924508998340d2d30caa6512">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
        </span> </div>
</ix:continuation>
      <ix:continuation id="Text_38f4234733924508998340d2d30caa6512" continuedAt="Text_38f4234733924508998340d2d30caa6513">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
      <ix:continuation id="Text_38f4234733924508998340d2d30caa6513" continuedAt="Text_38f4234733924508998340d2d30caa6514">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">During the three and six months ended June 30, 2021, in connection with the
        resignation of Dr. James Mond, the Company&#8217;s former Chief Scientific and Medical Officer, the Company recognized an expense and corresponding liability in the amount of $<ix:nonFraction name="adma:EstimatedPaymentForSeparationAndTransitionAgreement" id="Fact_1c591dbf551e47ebb5b2b2a98f5fe6b0" contextRef="c20210630_TitleOfIndividualAxis_ChiefScientificOfficerAndChiefMedicalOfficerMember" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction> million for estimated payments to be made under a separation and transition agreement with Dr. Mond. Such payments are to be made in scheduled installments over a period of <ix:nonNumeric name="adma:PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement" id="Fact_3c123bf3cf6a47889223bad5d1a551f7" contextRef="c20210101to20210630_TitleOfIndividualAxis_ChiefScientificOfficerAndChiefMedicalOfficerMember" format="ixt-sec:durmonth">10</ix:nonNumeric> months.</div>
</ix:continuation>
      <ix:continuation id="Text_38f4234733924508998340d2d30caa6514" continuedAt="Text_38f4234733924508998340d2d30caa6515">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
      <ix:continuation id="Text_38f4234733924508998340d2d30caa6515" continuedAt="Text_38f4234733924508998340d2d30caa6516">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
        </span> </div>
</ix:continuation>
      <ix:continuation id="Text_38f4234733924508998340d2d30caa6516" continuedAt="Text_38f4234733924508998340d2d30caa6517">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
      <ix:continuation id="Text_38f4234733924508998340d2d30caa6517">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In connection with the February 2020 public offering of the Company&#8217;s common stock
        (see Note 8) on February 11, 2020: (i) Perceptive Advisors, a principal stockholder of ADMA, purchased <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_6c5c3081b5ab4e5583b80dd3026f5058" contextRef="c20200211to20200211_LineOfCreditFacilityAxis_PerceptiveCreditHoldingsIILPMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">4,563,700</ix:nonFraction> shares of common stock
        through one of its affiliates, (ii) Dr. Grossman purchased <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_7301eca8f8b4426d9797a04af09d874a" contextRef="c20200211to20200211_OwnershipAxis_DirectOwnershipMember_TitleOfIndividualAxis_ViceChairmanMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">22,857</ix:nonFraction> shares of common stock directly and <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_de3a3eb50f9348dbaa217f788d07533a" contextRef="c20200211to20200211_OwnershipAxis_IndirectOwnershipMember_TitleOfIndividualAxis_ViceChairmanMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">22,857</ix:nonFraction> shares indirectly through an entity he controls, (iii) Lawrence P. Guiheen, a director of the Company, purchased <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_685ef449357a45e392ddeea0af0734a2" contextRef="c20200211to20200211_TitleOfIndividualAxis_DirectorMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">20,000</ix:nonFraction> shares of&#160; common stock, (iv) Mr. Grossman purchased <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_fa4447f60ca849d784bcb626adef07e7" contextRef="c20200211to20200211_OwnershipAxis_DirectOwnershipMember_TitleOfIndividualAxis_PresidentAndChiefExecutiveOfficerMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">28,571</ix:nonFraction> shares of common stock directly and <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_0242745a2a7e41c89c2580a8cb1e895f" contextRef="c20200211to20200211_OwnershipAxis_IndirectOwnershipMember_TitleOfIndividualAxis_PresidentAndChiefExecutiveOfficerMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">57,143</ix:nonFraction> shares indirectly through an
        entity he controls, (v) Brian Lenz, the Company&#8217;s Executive Vice President and Chief Financial Officer, purchased <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_b65e7014a7ed4fb89df91f010f237325" contextRef="c20200211to20200211_TitleOfIndividualAxis_ExecutiveVicePresidentAndChiefFinancialOfficerMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">7,142</ix:nonFraction> shares of common
        stock, and (vi) Dr. Mond purchased <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_5f8c1f6dd3b54f349397811cee30fdc1" contextRef="c20200211to20200211_TitleOfIndividualAxis_ChiefScientificOfficerAndChiefMedicalOfficerMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">4,285</ix:nonFraction> shares of common stock, all at the public offering price of $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" id="Fact_2520ee9bdc27461c823af005133a484b" contextRef="c20200211" unitRef="U003" decimals="2" scale="0" format="ixt:numdotdecimal">3.50</ix:nonFraction> per share.</div>
</ix:continuation>
       </div>


  </div>
<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

        <div>
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

          <div style="text-indent: 36pt;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
            <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">15</span></div>

            <div style="page-break-after:always;" class="DSPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

            <div style="width: 100%;" class="DSPFPageHeader">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 100%; font-size: 8pt; font-style: italic;">
                      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>
                      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>
                    </td>

  </tr>


</table>
            </div>

          </div>

        </div>

        <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

        <div><ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Text_4473a060a68a403d939a6af745d8e9bf" contextRef="c20210101to20210630" escape="true" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de91">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de91" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de92">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">10.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">COMMITMENTS AND CONTINGENCIES</span></div>
                </td>

  </tr>


</table>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de92" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de93">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de93" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de94">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de94" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de95">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de95" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de96">
<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">General Legal Matters</span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de96" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de97">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de97" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de98">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de98" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de99">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de99" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de910">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">From time to time the Company is or may become subject to certain legal proceedings and claims arising in
            connection with the normal course of its business. Management does not expect that the outcome of any such claims or actions will have a material effect on the Company&#8217;s liquidity, results of operations or financial condition.</div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de910" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de911">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de911" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de912">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de912" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de913">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de913" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de914">
<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">COVID-19 Pandemic</span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de914" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de915">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de915" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de916">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de916" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de917">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de917" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de918">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The Company continues to monitor the ongoing developments related to the COVID-19 pandemic, including the
            emergence of the Delta variant and other resistant strains of the coronavirus, and its impacts to the Company&#8217;s commercial and manufacturing operations and plasma collection facilities, including collections of source plasma, procurement of raw
            materials and packaging materials, a portion of which are sourced internationally, and the testing of finished drug product that is required prior to its availability for commercial sale.&#160; A substantial portion of such testing has historically
            been performed by contract laboratories outside the United States.</div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de918" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de919">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de919" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de920">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de920" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de921">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de921" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de922">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The Company had experienced some delays with final drug product release testing by third-party vendors. In
            response to these delays, the Company added additional release testing laboratories to its FDA-approved consortium listed in its drug approval documents which the Company believes has adequately addressed this issue. In addition, due to a
            combination of previous state and local &#8220;shelter-in-place&#8221; orders, as well as government stimulus packages, persisting social distancing measures and varying roll-outs of vaccinations by state, the Company has experienced lower than normal
            donor collections at its FDA approved plasma collection centers. The Company was also subject to delays in shipments of source plasma from its contracted third-party suppliers, as well as delays in deliveries for personal protective equipment,
            reagents and other non-plasma raw materials and supplies used in the manufacture and distribution of its products. The Company is also subject to supply chain delays as a result of certain of its suppliers diverting significant resources
            towards the rapid development and distribution of COVID-19 vaccines and, as a result, the Company may elect to carry more raw materials inventory than it has in the past. The COVID-19 pandemic has also impacted, to a certain degree, the
            Company&#8217;s customer engagement initiatives, whereby ADMA&#8217;s sales and medical affairs field personnel have faced difficulties communicating directly with physicians and other healthcare professionals, as well as the cancellation or postponement
            of a number of key scientific and medical meetings, further limiting the Company&#8217;s ability to communicate with potential customers.&#160; The Company has implemented a comprehensive suite of virtual engagement initiatives, however, clinician
            engagement has been reduced due to rapidly evolving COVID-19 priorities at U.S. medical centers.</div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de922" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de923">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de923" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de924">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de924" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de925">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de925" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de926">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The pandemic could also impact the Company&#8217;s ability to interact with the FDA or other regulatory authorities
            and may result in delays in the conduct of inspections or review of pending applications or submissions.&#160; During the second quarter of 2021, the Company was notified by the FDA that its submission for the approval of its in-house fill-finish
            process utilizing a recently installed aseptic filling machine will require a site inspection, either in person or virtually, of the Boca Facility. Although the inspection was completed in July of 2021, the FDA&#8217;s review of the Company&#8217;s
            regulatory filing with respect to its in-house fill-finish process and new aseptic filling machine remains ongoing. Although the Company anticipates receiving regulatory approval of this submission in the second half of 2021, no assurances can
            be provided as to the timing for completion of this FDA review or any other regulatory submissions or applications that may be impacted by restrictions related to COVID-19.</div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de926" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de927">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de927" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de928">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de928" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de929">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de929" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de930">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Notwithstanding the foregoing, the COVID-19 pandemic to date has not had a material impact on the Company&#8217;s
            financial condition or results of operations, and the Company does not believe that its production operations at the Boca Facility, the Company&#8217;s contract fill/finishers or its plasma collection facilities have been significantly impacted by
            the COVID-19 pandemic. As a result, the Company does not anticipate and has not experienced any material impairments with respect to any of its long-lived assets, including the Company&#8217;s property and equipment, goodwill or intangible assets.</div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de930" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de931">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de931" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de932">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de932" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de933">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
            <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">16</span></div>

            <div style="page-break-after:always;" class="DSPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

            <div style="width: 100%;" class="DSPFPageHeader">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 100%; font-size: 8pt; font-style: italic;">
                      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>
                      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>
                    </td>

  </tr>


</table>
            </div>

          </div>

          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de933" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de934">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Although the COVID-19 pandemic has not, to date, materially adversely impacted the Company&#8217;s capital and
            financial resources, because the Company is unable to determine the ultimate severity or duration of the pandemic or its long-term effects on, among other things, the global, national or local economies, the capital and credit markets or the
            Company&#8217;s workforce, customers or our suppliers, at this time the Company is unable to predict whether COVID-19 will have a material adverse impact on the Company&#8217;s business, financial condition, liquidity and results of operations.</div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de934" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de935">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de935" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de936">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de936" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de937">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de937" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de938">
<div style="font-style: italic;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Vendor Commitments</span><br />
            </span> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de938" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de939">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de939" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de940">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Pursuant to the terms of a plasma purchase agreement with BPC dated as of November 17, 2011 (the &#8220;2011 Plasma
            Purchase Agreement&#8221;), the Company agreed to purchase from BPC an annual minimum volume of source plasma containing antibodies to RSV to be used in the manufacture of ASCENIV. The Company must purchase a to-be-determined and agreed upon annual
            minimum volume from BPC, but may also collect high-titer RSV plasma from up to <ix:nonFraction name="adma:NumberOfPlasmaCollectionFacilities" id="Fact_b33ebe7530f64ca79944eab87543e97f" contextRef="c20210101to20210630_RangeAxis_MaximumMember_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember" unitRef="U004" decimals="INF" scale="0" format="ixt-sec:numwordsen">five</ix:nonFraction> wholly-owned ADMA plasma collection facilities.&#160;
            During 2015, the Company and BPC amended the 2011 Plasma Purchase Agreement to allow the Company the ability to collect its raw material RSV high-titer plasma from other third-party collection organizations, thus allowing the Company to expand
            its reach for raw material supply as it executes its commercialization plans for ASCENIV. Unless terminated earlier, the 2011 Plasma Purchase Agreement expires in June 2027, after which it may be renewed for <ix:nonFraction name="adma:NumberOfRenewalTerms" id="Fact_cd0f2988af684e7f8be59f723f6d5173" contextRef="c20210101to20210630_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember" unitRef="U008" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> additional <ix:nonNumeric name="adma:PlasmaPurchaseAgreementRenewalPeriod" id="Fact_bd444cd37f7d4ec2864a55bfe0fc8b53" contextRef="c20210101to20210630_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember" format="ixt-sec:durwordsen">five-year</ix:nonNumeric> periods if
            agreed to by the parties. As part of the closing of the Biotest Transaction, the parties amended the 2011 Plasma Purchase Agreement to extend the initial term through the <ix:nonNumeric name="adma:PlasmaPurchaseAgreementTerm" id="Fact_154a6679de8742529d07e173a0eb9df1" contextRef="c20210101to20210630_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember" format="ixt-sec:durwordsen">ten-year</ix:nonNumeric> anniversary of the closing date of the Biotest Transaction. On December 10, 2018, BPC assigned its rights and obligations under the 2011 Plasma Purchase Agreement
            to Grifols Worldwide Operations Limited (&#8220;Grifols&#8221;) as its successor-in-interest, effective January 1, 2019. On January 1, 2019, Grifols and the Company entered into an additional amendment to the 2011 Plasma Purchase Agreement for the purchase
            of source plasma containing antibodies to RSV from Grifols. Pursuant to this amendment, until January 1, 2022, the Company may purchase RSV plasma from Grifols from the <ix:nonFraction name="adma:NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity" id="Fact_09607613950449249b7874965f3117e6" contextRef="c20210101to20210630_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember" unitRef="U009" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> plasma collection centers that were transferred to BPC on January 1, 2019 at a price equal to cost plus <span style="-sec-ix-hidden:Fact_5246f96bd6684b0493a757c543cd5bb9">five percent</span> (<ix:nonFraction name="adma:PercentageOfPlasmaPurchasePriceEqualToCost" id="Fact_49e49dd196b747b0b14c4d6ff565c0e5" contextRef="c20210101to20210630_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember" unitRef="U007" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>%) (without any additional increase due to
            inflation).</div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de940" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de941">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de941" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de942">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de942" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de943">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de943" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de944">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">On June 6, 2017, the Company and BPC entered into a Plasma Supply Agreement pursuant to which BPC supplies,
            on an exclusive basis subject to certain exceptions, to ADMA BioManufacturing an annual minimum volume of hyperimmune plasma that contain antibodies to the Hepatitis B virus for the manufacture of Nabi-HB. The Plasma Supply Agreement has a <ix:nonNumeric name="adma:PlasmaSupplyAgreementTerm" id="Fact_16e928c73936497e9671b24c15058dcb" contextRef="c20210101to20210630" format="ixt-sec:duryear">10</ix:nonNumeric>-year term. On July 19, 2018, the Company and BPC entered into an amendment to the Plasma Supply Agreement to provide, among other things, that in
            the event BPC elects not to supply in excess of ADMA BioManufacturing&#8217;s specified amount of Hepatitis B plasma and ADMA BioManufacturing is unable to secure Hepatitis B plasma from a third party at a price that is within a low double- digit
            percentage of the price that ADMA BioManufacturing pays to BPC, then BPC shall reimburse ADMA BioManufacturing for the difference in price ADMA BioManufacturing incurs. On December 10, 2018, BPC assigned its rights and obligations under the
            Plasma Supply Agreement to Grifols, effective January 1, 2019.</div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de944" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de945">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de945" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de946">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de946" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de947">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de947" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de948">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">On June 6, 2017, the Company and BPC entered into a Plasma Purchase Agreement (the &#8220;2017 Plasma Purchase
            Agreement&#8221;), pursuant to which ADMA BioManufacturing purchases normal source plasma (&#8220;NSP&#8221;) from BPC at agreed upon annual quantities and prices. The 2017 Plasma Purchase Agreement has an initial term of <ix:nonNumeric name="adma:PlasmaPurchaseAgreementTerm" id="Fact_c862859f2f82402abb7ffbc9f7baf6b2" contextRef="c20210101to20210630_TypeOfArrangementAxis_PlasmaPurchaseAgreementTwoMember" format="ixt-sec:durwordsen">five years</ix:nonNumeric> after which the 2017 Plasma Purchase Agreement may be renewed for additional <ix:nonFraction name="adma:NumberOfRenewalTerms" id="Fact_39c91351233f47078d751e840bede949" contextRef="c20210101to20210630_TypeOfArrangementAxis_PlasmaPurchaseAgreementTwoMember" unitRef="U008" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> terms of <ix:nonNumeric name="adma:PlasmaPurchaseAgreementRenewalPeriod" id="Fact_61c43110ee71417197d470c73cbc2f61" contextRef="c20210101to20210630_TypeOfArrangementAxis_PlasmaPurchaseAgreementTwoMember" format="ixt-sec:durwordsen">two years</ix:nonNumeric> each upon the mutual written consent
            of the parties. On July 19, 2018, the Company and BPC entered into an amendment to the 2017 Plasma Purchase Agreement to, among other things, provide agreed upon amounts of normal source plasma to be supplied by BPC to ADMA BioManufacturing in
            calendar year 2019 at a specified price per liter, provided that ADMA BioManufacturing delivers a valid purchase order to BPC. Additionally, pursuant to the amendment to the 2017 Plasma Purchase Agreement, BPC agreed that, for calendar years
            2020 and 2021, it shall supply no less than a high double-digit percentage of ADMA BioManufacturing&#8217;s requested NSP amounts, provided that such requested NSP amounts are within an agreed range, at a price per liter to be mutually determined.
            Furthermore, pursuant to the amendment to the 2017 Plasma Purchase Agreement, in the event BPC fails to supply ADMA BioManufacturing with at least a high double-digit percentage of ADMA BioManufacturing&#8217;s requested NSP amounts, BPC shall
            promptly reimburse ADMA BioManufacturing the difference in price ADMA BioManufacturing incurs due to BPC&#8217;s election not to supply NSP to ADMA BioManufacturing in such amounts as requested. On December 10, 2018, BPC assigned its rights and
            obligations under the Plasma Purchase Agreement to Grifols, effective January 1, 2019. </div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de948" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de949">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de949" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de950">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de950" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de951">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
            <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">17</span></div>

            <div style="page-break-after:always;" class="DSPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

            <div style="width: 100%;" class="DSPFPageHeader">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 100%; font-size: 8pt; font-style: italic;">
                      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>
                      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>
                    </td>

  </tr>


</table>
            </div>

          </div>

          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de951" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de952">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Effective as of May 12, 2021, the Company and Grifols amended the foregoing 2017 Plasma Purchase Agreement
            whereby, among other things, the term of the agreement was extended through December 31, 2022, while certain historical provisions were deleted. In order to maintain a reliable supply of raw material plasma thereafter, the Company is in
            late-stage discussion with multiple third-party suppliers of NSP to supplement the 2017 Plasma Purchase Agreement, and the Company has also increased the number of planned plasma collection center buildouts and is continuing to increase its
            plasma collection capabilities at its ADMA BioCenters plasma collection centers business segment.</div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de952" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de953">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de953" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de954">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de954" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de955">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de955" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de956">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The Company purchases substantially all of its raw material plasma from Grifols. For the six months ended
            June 30, 2021, plasma purchases from Grifols totaled $<ix:nonFraction name="adma:PlasmaPurchased" id="Fact_e13a7f9200884c7798b1b56f08e18a1b" contextRef="c20210101to20210630" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">17.5</ix:nonFraction> million, or approximately <ix:nonFraction name="adma:PercentageOfInventoryPurchases" id="Fact_f9457417f6294b45bab493bbd898f6eb" contextRef="c20210101to20210630" unitRef="U007" decimals="2" scale="-2" format="ixt:numdotdecimal">67</ix:nonFraction>% of the Company&#8217;s total inventory purchases. For the six months ended June 30, 2020, plasma purchases from Grifols totaled approximately $<ix:nonFraction name="adma:PlasmaPurchased" id="Fact_2ce551695d83498999ab429a7903556b" contextRef="c20200101to20200630" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">3.7</ix:nonFraction> million, representing approximately <ix:nonFraction name="adma:PercentageOfInventoryPurchases" id="Fact_bf5d072f454542b29774e6d6f63f0f3c" contextRef="c20200101to20200630" unitRef="U007" decimals="2" scale="-2" format="ixt:numdotdecimal">42</ix:nonFraction>%
            of the Company&#8217;s total inventory purchases.</div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de956" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de957">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de957" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de958">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de958" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de959">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de959" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de960">
<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Post-marketing commitments</span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de960" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de961">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de961" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de962">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de962" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de963">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de963" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de964">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">In connection with the approval of the BLA for BIVIGAM, on December 19, 2012 Biotest committed to perform two
            additional post-marketing studies, a pediatric study to evaluate the efficacy and safety of BIVIGAM in children and adolescents, and a post-authorization safety study to further assess the potential risk of hypotension and hepatic and renal
            impairment in BIVIGAM-treated patients with primary humoral immunodeficiency. These studies are still pending completion. ADMA has assumed the remaining obligations, and the costs of the studies will be expensed as incurred as research and
            development expenses. The Company currently expects both studies to be completed by June of 2023.</div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de964" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de965">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de965" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de966">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de966" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de967">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de967" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de968">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">In connection with the FDA&#8217;s approval of ASCENIV on April 1, 2019, the Company is required to perform a
            pediatric study to evaluate the safety and efficacy of ASCENIV in children and adolescents. This study is required to be completed by June of 2023.</div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de968" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de969">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de969" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de970">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de970" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de971">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de971" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de972">
<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Employment contracts</span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de972" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de973">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de973" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de974">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de974" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de975">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de975" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de976">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The Company has entered into employment agreements with its executive management team consisting of its
            President and Chief Executive Officer, its Executive Vice President and Chief Financial Officer and its former Executive Vice President, Chief Medical Officer and Chief Scientific Officer (see Note 9).</div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de976" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de977">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de977" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de978">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de978" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de979">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de979" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de980">
<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Other commitments</span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de980" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de981">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de981" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de982">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de982" continuedAt="Text_27fc61f1b8854e85b45f8d4561c14de983">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_27fc61f1b8854e85b45f8d4561c14de983">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">In the normal course of business, the Company enters into contracts that contain a variety of
            indemnifications with its employees, licensors, suppliers and service providers. Further, the Company indemnifies its directors and officers who are, or were, serving at the Company&#8217;s request in such capacities. The Company&#8217;s maximum exposure
            under these arrangements is unknown as of June 30, 2021. The Company does not anticipate recognizing any significant losses relating to these arrangements.</div>
</ix:continuation>
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

          <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

        <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

  </div>
<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

        <div><ix:nonNumeric name="us-gaap:SegmentReportingDisclosureTextBlock" id="Text_8d577c5a49fb4883907c94d4289126da" contextRef="c20210101to20210630" escape="true" continuedAt="Text_bfa6dcfadb274e4d9dd0d88324c149111">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_bfa6dcfadb274e4d9dd0d88324c149111" continuedAt="Text_bfa6dcfadb274e4d9dd0d88324c149112">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">11.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">SEGMENTS</span></div>
                </td>

  </tr>


</table>
</ix:continuation>
          <ix:continuation id="Text_bfa6dcfadb274e4d9dd0d88324c149112" continuedAt="Text_bfa6dcfadb274e4d9dd0d88324c149113">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_bfa6dcfadb274e4d9dd0d88324c149113" continuedAt="Text_bfa6dcfadb274e4d9dd0d88324c149114">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_bfa6dcfadb274e4d9dd0d88324c149114" continuedAt="Text_bfa6dcfadb274e4d9dd0d88324c149115">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_bfa6dcfadb274e4d9dd0d88324c149115" continuedAt="Text_bfa6dcfadb274e4d9dd0d88324c149116">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The Company is engaged in the manufacture, marketing and development of specialty
              plasma-derived biologics.&#160; The Company&#8217;s ADMA BioManufacturing segment reflects the Company&#8217;s immunoglobulin manufacturing, commercial and development operations in Boca Raton, FL, acquired on June 6, 2017 (see Note 1).&#160; The Plasma Collection
              Centers segment as of June 30, 2021 consists of <ix:nonFraction name="adma:NumberOfPlasmaCollectionFacilitiesUnderDevelopment" id="Fact_5b21556d4509456ba68c97b32273b4cc" contextRef="c20200401to20200630" unitRef="U004" decimals="INF" scale="0" format="ixt-sec:numwordsen">eight</ix:nonFraction><span style="color: rgb(0, 0, 0);"> plasma collection facilities in various
                stages of approval and development located throughout the U.S., <ix:nonFraction name="adma:NumberOfFDALicensedPlasmaCollectionFacilities" id="Fact_33fbe50105da48769d80171e0051861a" contextRef="c20200401to20200630" unitRef="U004" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> of which hold an approved license with the FDA while a third
                facility has a BLA pending FDA approval</span>. The Corporate segment includes general and administrative overhead expenses. The Company defines its segments as those business units whose operating results are regularly reviewed by the
              chief operating decision maker (&#8220;CODM&#8221;) to analyze performance and allocate resources. The Company&#8217;s CODM is its President and Chief Executive Officer.&#160; </span><ix:nonNumeric name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="Text_60d8002bb1ba4c9dae45985bc0826d46" contextRef="c20210101to20210630" escape="true" continuedAt="Text_172b11ef2fc24967ba5f379fdca36a0c1"><span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Summarized financial information concerning reportable segments is shown in the following tables:</span></span></ix:nonNumeric></div>
</ix:continuation>
          <ix:continuation id="Text_bfa6dcfadb274e4d9dd0d88324c149116" continuedAt="Text_bfa6dcfadb274e4d9dd0d88324c149117"><ix:continuation id="Text_172b11ef2fc24967ba5f379fdca36a0c1" continuedAt="Text_172b11ef2fc24967ba5f379fdca36a0c2">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_bfa6dcfadb274e4d9dd0d88324c149117" continuedAt="Text_bfa6dcfadb274e4d9dd0d88324c149118"><ix:continuation id="Text_172b11ef2fc24967ba5f379fdca36a0c2" continuedAt="Text_172b11ef2fc24967ba5f379fdca36a0c3">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_bfa6dcfadb274e4d9dd0d88324c149118" continuedAt="Text_bfa6dcfadb274e4d9dd0d88324c149119"><ix:continuation id="Text_172b11ef2fc24967ba5f379fdca36a0c3" continuedAt="Text_172b11ef2fc24967ba5f379fdca36a0c4">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
            <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">18</span></div>

            <div style="page-break-after:always;" class="DSPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

            <div style="width: 100%;" class="DSPFPageHeader">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 100%; font-size: 8pt; font-style: italic;">
                      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>
                      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>
                    </td>

  </tr>


</table>
            </div>

          </div>

          <ix:continuation id="Text_bfa6dcfadb274e4d9dd0d88324c149119" continuedAt="Text_bfa6dcfadb274e4d9dd0d88324c1491110"><ix:continuation id="Text_172b11ef2fc24967ba5f379fdca36a0c4" continuedAt="Text_172b11ef2fc24967ba5f379fdca36a0c5">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="16">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Three Months Ended June 30, 2021</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">ADMA </div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">BioManufacturing</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Plasma Collection </div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Centers</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Corporate</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Consolidated</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Revenues</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_ae1c75b0729e4cbfb0a427c5be32a760" contextRef="c20210401to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">16,347,880</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_95b70e099c4e423d85e40aa146a5bec4" contextRef="c20210401to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,447,001</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_06762faffeaf4e3ea01d3b53a6a8ed2c" contextRef="c20210401to20210630_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">35,709</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_2dd128bf08e84ba5abf16d064978cf4f" contextRef="c20210401to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">17,830,590</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:CostOfProductRevenueExcludingAmortizationExpense" id="Fact_8de7963e2ac44672b43e8b9fc2156ea6" contextRef="c20210401to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">17,382,292</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:CostOfProductRevenueExcludingAmortizationExpense" id="Fact_a53f1721e88a42209e8ec339dd36c7b0" contextRef="c20210401to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,450,332</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:CostOfProductRevenueExcludingAmortizationExpense" id="Fact_1f47b0219955494aa209928542cb938f" contextRef="c20210401to20210630_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:CostOfProductRevenueExcludingAmortizationExpense" id="Fact_ca655c81584547f5aa550e879116b76c" contextRef="c20210401to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">18,832,624</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Loss from operations</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_379bae2ec882470e9ad94f8a0aed251d" contextRef="c20210401to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">8,337,405</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_aaedc1affee34a2c976877e84fc0b40e" contextRef="c20210401to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">2,794,219</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_df288b615af344aa91265912c29e3735" contextRef="c20210401to20210630_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">4,449,608</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_3aafa734f2fd4824bac227b1e9891e85" contextRef="c20210401to20210630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">15,581,232</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Interest and other expense, net</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_d64818b968b444079ff1d1e4b4697635" contextRef="c20210401to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">78,793</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_c210a840dbd84dff8bfdab767dca7f46" contextRef="c20210401to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">366</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_04049f47d71a411181325b41df32532f" contextRef="c20210401to20210630_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">3,244,912</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_c0fde8a54f92458a99da16ca0196b102" contextRef="c20210401to20210630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">3,324,071</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Net loss</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_2bd65dbd2e684d5886e999cd8a038829" contextRef="c20210401to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">8,416,198</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_e997cbcf60bb41ecad269fdffc78a4e4" contextRef="c20210401to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">2,794,585</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_4bc5f9089edc48c281e4002739100f3f" contextRef="c20210401to20210630_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">7,694,520</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_5574c96dac93447590c434a50a70fe35" contextRef="c20210401to20210630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">18,905,303</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Depreciation and amortization expense</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_0cc343456a8f4422b5aab8961275070f" contextRef="c20210401to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,055,537</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_1fe0211261664fbca018ab5ed05ff062" contextRef="c20210401to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">268,927</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_8f90ba44e0814c8b9adeac0fd1cdb262" contextRef="c20210401to20210630_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,530</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_4597ba4a88ab43c8a6925e697cfafb2a" contextRef="c20210401to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,325,994</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Total assets</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:Assets" id="Fact_3d1dab999b794b89be0b2864ae3c8ff8" contextRef="c20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">169,799,509</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:Assets" id="Fact_b94eab1d4ead4861b4cb7896f3aedd5e" contextRef="c20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">20,593,411</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:Assets" id="Fact_3cfc6da68b704c18bd0a33b4376a7850" contextRef="c20210630_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">42,420,872</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:Assets" id="Fact_e6586a6c74534f2280c04e02109eaae9" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">232,813,792</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_bfa6dcfadb274e4d9dd0d88324c1491110" continuedAt="Text_bfa6dcfadb274e4d9dd0d88324c1491111"><ix:continuation id="Text_172b11ef2fc24967ba5f379fdca36a0c5" continuedAt="Text_172b11ef2fc24967ba5f379fdca36a0c6">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_bfa6dcfadb274e4d9dd0d88324c1491111" continuedAt="Text_bfa6dcfadb274e4d9dd0d88324c1491112"><ix:continuation id="Text_172b11ef2fc24967ba5f379fdca36a0c6" continuedAt="Text_172b11ef2fc24967ba5f379fdca36a0c7">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_bfa6dcfadb274e4d9dd0d88324c1491112" continuedAt="Text_bfa6dcfadb274e4d9dd0d88324c1491113"><ix:continuation id="Text_172b11ef2fc24967ba5f379fdca36a0c7" continuedAt="Text_172b11ef2fc24967ba5f379fdca36a0c8">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_bfa6dcfadb274e4d9dd0d88324c1491113" continuedAt="Text_bfa6dcfadb274e4d9dd0d88324c1491114"><ix:continuation id="Text_172b11ef2fc24967ba5f379fdca36a0c8" continuedAt="Text_172b11ef2fc24967ba5f379fdca36a0c9">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="16">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Three Months Ended June 30, 2020</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">ADMA </div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">BioManufacturing</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Plasma Collection </div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Centers</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Corporate</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Consolidated</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Revenues</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_d1e869cfcddb49e68d4f3b9d72de0c60" contextRef="c20200401to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">6,502,865</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_919188437b8e4eab9c859ccd18a76bd1" contextRef="c20200401to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,249,020</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_3d4fe5cb9580473abb529b3a4af8a48b" contextRef="c20200401to20200630_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">35,709</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_d3da14b3ed27439fa431ac9be573413c" contextRef="c20200401to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">7,787,594</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:CostOfProductRevenueExcludingAmortizationExpense" id="Fact_6bd825dc85474598a355acba8adb7212" contextRef="c20200401to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">12,237,141</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:CostOfProductRevenueExcludingAmortizationExpense" id="Fact_d6b8d3a23c3847058ac39ec8c93e07ad" contextRef="c20200401to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,258,488</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:CostOfProductRevenueExcludingAmortizationExpense" id="Fact_815230690e6a4dedae0c563300efbd30" contextRef="c20200401to20200630_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:CostOfProductRevenueExcludingAmortizationExpense" id="Fact_0cb7543aed154282a6e07a4098862233" contextRef="c20200401to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">13,495,629</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Loss from operations</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_012aaf74b020413eb79be5d9ab6ebde6" contextRef="c20200401to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">12,852,835</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_066b344e579949b290e89e0897363f1a" contextRef="c20200401to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">919,309</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_af3c4ab624d947548dfb9cf0b75b29a0" contextRef="c20200401to20200630_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">3,351,681</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_db34f3b87a5243c7850c1ebdea0d6bd0" contextRef="c20200401to20200630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">17,123,825</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Interest and other expense, net</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_73c610a4bde24815b96f93771c7755a4" contextRef="c20200401to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">235,442</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_5ddaaa2a14fe489eae438033eee641c6" contextRef="c20200401to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">33</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_08f8eaa3080847cba11b20ab9754e39e" contextRef="c20200401to20200630_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">2,818,791</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_89e5b67257db4e48b62558a8d09186a2" contextRef="c20200401to20200630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">3,054,266</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Net loss</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_8dc56ff8b0f74e1eb31638271140e992" contextRef="c20200401to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">13,088,277</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_c7edeeb3eccd409da562712fa1b17670" contextRef="c20200401to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">919,342</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_ed12451a4741446eb999f331e1e3a705" contextRef="c20200401to20200630_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">6,170,472</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_fa1a1de237ec4ff2a15df70ff5080748" contextRef="c20200401to20200630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">20,178,091</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Depreciation and amortization expense</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_26e3c6fa23db4307830401c0d2cd2ff5" contextRef="c20200401to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">772,241</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_10df16f25d7e4f7e972d23cd2008a179" contextRef="c20200401to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">111,106</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_322aaf735c43488597a0f2a07efd5312" contextRef="c20200401to20200630_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">2,305</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_33ea992828464d0fa2ab135c75a337e4" contextRef="c20200401to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">885,652</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Total assets</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:Assets" id="Fact_33aff3ac442c46d39e1a88624d8e583a" contextRef="c20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">109,105,418</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:Assets" id="Fact_1e74fd07d19549d1b3bc474bf24610d8" contextRef="c20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">7,542,486</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:Assets" id="Fact_a6ae6d38638c410cbedeb2930f3ea0b9" contextRef="c20200630_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">74,893,664</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:Assets" id="Fact_97a5c8458ede46b6814e9cbe56104cc2" contextRef="c20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">191,541,568</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_bfa6dcfadb274e4d9dd0d88324c1491114" continuedAt="Text_bfa6dcfadb274e4d9dd0d88324c1491115"><ix:continuation id="Text_172b11ef2fc24967ba5f379fdca36a0c9" continuedAt="Text_172b11ef2fc24967ba5f379fdca36a0c10">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_bfa6dcfadb274e4d9dd0d88324c1491115" continuedAt="Text_bfa6dcfadb274e4d9dd0d88324c1491116"><ix:continuation id="Text_172b11ef2fc24967ba5f379fdca36a0c10" continuedAt="Text_172b11ef2fc24967ba5f379fdca36a0c11">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_bfa6dcfadb274e4d9dd0d88324c1491116" continuedAt="Text_bfa6dcfadb274e4d9dd0d88324c1491117"><ix:continuation id="Text_172b11ef2fc24967ba5f379fdca36a0c11" continuedAt="Text_172b11ef2fc24967ba5f379fdca36a0c12">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
            <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">19</span></div>

            <div style="page-break-after:always;" class="DSPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

            <div style="width: 100%;" class="DSPFPageHeader">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 100%; font-size: 8pt; font-style: italic;">
                      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>
                      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>
                    </td>

  </tr>


</table>
            </div>

          </div>

          <ix:continuation id="Text_bfa6dcfadb274e4d9dd0d88324c1491117" continuedAt="Text_bfa6dcfadb274e4d9dd0d88324c1491118"><ix:continuation id="Text_172b11ef2fc24967ba5f379fdca36a0c12" continuedAt="Text_172b11ef2fc24967ba5f379fdca36a0c13">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="16">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Six Months Ended June 30, 2021</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">ADMA </div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">BioManufacturing</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Plasma Collection </div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Centers</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Corporate</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Consolidated</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Revenues</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_3ab5f431d03b4f78bc9734f9897f9f67" contextRef="c20210101to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">29,768,923</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_b30ffe3d585e4044b4b7163d73a929d6" contextRef="c20210101to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">4,038,868</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_6a27e923eaff4dec8944a7aa940cf91a" contextRef="c20210101to20210630_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">71,417</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_72443bf3928047929fd2a257d544cc95" contextRef="c20210101to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">33,879,208</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:CostOfProductRevenueExcludingAmortizationExpense" id="Fact_1521869f85a1481f960992d9a0e00c71" contextRef="c20210101to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">32,832,049</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:CostOfProductRevenueExcludingAmortizationExpense" id="Fact_9504c3ab7e184ffe95e03db32facda55" contextRef="c20210101to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">3,770,697</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:CostOfProductRevenueExcludingAmortizationExpense" id="Fact_6d83529879bd46d1abedb8aeb301839a" contextRef="c20210101to20210630_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:CostOfProductRevenueExcludingAmortizationExpense" id="Fact_e59c3b150072466590cc1dae1bed13e4" contextRef="c20210101to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">36,602,746</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Loss from operations</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_374190270ce846a4b1fc4542b03b6e88" contextRef="c20210101to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">17,843,093</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_f681a186b05342d991e34d3128f712ad" contextRef="c20210101to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">4,765,060</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_5ac0246d4fdd417db97375fcaf86dd11" contextRef="c20210101to20210630_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">8,137,328</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_bd04bd6906714c24afcddbd1b74cc3a2" contextRef="c20210101to20210630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">30,745,481</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Interest and other expense, net</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_375bed906a0741788807c00c52acdc8a" contextRef="c20210101to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">100,307</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_4efbe8afa0484b88a0668e67418f8a1f" contextRef="c20210101to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">750</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_cd5089278e2147828470899dfba34d17" contextRef="c20210101to20210630_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">6,438,706</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_2c08d8a61f88442c8a0e85a1cee81d63" contextRef="c20210101to20210630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">6,539,763</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Net loss</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_0fc8899947b24c0194e9b89ae980b43e" contextRef="c20210101to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">17,943,400</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_e9eae77e48c049a6b8959280cfd4c300" contextRef="c20210101to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">4,765,810</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_e3b19c997d0e4d9bacbe3243d47ce532" contextRef="c20210101to20210630_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">14,576,034</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_52ec4bcdb7f544d7bfa8b4e3a77491b9" contextRef="c20210101to20210630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">37,285,244</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Capital expenditures</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" id="Fact_69b65294fa574c90b7d74090351578c7" contextRef="c20210101to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">2,725,432</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" id="Fact_2c0282d5eb0e46f68feb3b7a07577acf" contextRef="c20210101to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">4,321,303</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" id="Fact_00c72cfa1be4474087363482a932f869" contextRef="c20210101to20210630_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" id="Fact_696a0fe939c54fd3a622c9b41550059c" contextRef="c20210101to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">7,046,735</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Depreciation and amortization expense</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_896faca845534b52ab99a7118e15c4fd" contextRef="c20210101to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">2,065,307</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_8ae5d23a3a524c83abab20ecbee93836" contextRef="c20210101to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">486,918</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_766c62fd9b264ccd977ecf4844522155" contextRef="c20210101to20210630_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">3,397</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_c4ab21db3ff84910a4176349fa65c7a4" contextRef="c20210101to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">2,555,622</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_bfa6dcfadb274e4d9dd0d88324c1491118" continuedAt="Text_bfa6dcfadb274e4d9dd0d88324c1491119"><ix:continuation id="Text_172b11ef2fc24967ba5f379fdca36a0c13" continuedAt="Text_172b11ef2fc24967ba5f379fdca36a0c14">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_bfa6dcfadb274e4d9dd0d88324c1491119" continuedAt="Text_bfa6dcfadb274e4d9dd0d88324c1491120"><ix:continuation id="Text_172b11ef2fc24967ba5f379fdca36a0c14" continuedAt="Text_172b11ef2fc24967ba5f379fdca36a0c15">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_bfa6dcfadb274e4d9dd0d88324c1491120" continuedAt="Text_bfa6dcfadb274e4d9dd0d88324c1491121"><ix:continuation id="Text_172b11ef2fc24967ba5f379fdca36a0c15" continuedAt="Text_172b11ef2fc24967ba5f379fdca36a0c16">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_bfa6dcfadb274e4d9dd0d88324c1491121" continuedAt="Text_bfa6dcfadb274e4d9dd0d88324c1491122"><ix:continuation id="Text_172b11ef2fc24967ba5f379fdca36a0c16" continuedAt="Text_172b11ef2fc24967ba5f379fdca36a0c17">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="16">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Six Months Ended June 30, 2020</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">ADMA </div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">BioManufacturing</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Plasma Collection </div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Centers</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Corporate</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Consolidated</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Revenues</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_e57197a3dcbd412fbdc1da9760c3dc3d" contextRef="c20200101to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">14,246,139</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_c51449ee90044d2facd637a7236782b9" contextRef="c20200101to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">3,669,782</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_629aa179aee149a6966d1e752a620817" contextRef="c20200101to20200630_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">71,417</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_ee44bec8b61e481b8b3914f623fcdd6b" contextRef="c20200101to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">17,987,338</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:CostOfProductRevenueExcludingAmortizationExpense" id="Fact_a11aefe6c5794446909e5fac319983fc" contextRef="c20200101to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">26,689,094</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:CostOfProductRevenueExcludingAmortizationExpense" id="Fact_c1bd7b7212434c488051c4969c276635" contextRef="c20200101to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">3,635,761</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:CostOfProductRevenueExcludingAmortizationExpense" id="Fact_d49337d2aba0426ca7dfce7efa7a1628" contextRef="c20200101to20200630_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:CostOfProductRevenueExcludingAmortizationExpense" id="Fact_2f487d658251437a854b0f2c68b0d29a" contextRef="c20200101to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">30,324,855</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Loss from operations</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_9e43e18a60b840208ca6fa9acc420446" contextRef="c20200101to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">25,328,980</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_b497c4d62cdb43fbbbd59007acdc0321" contextRef="c20200101to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">1,376,464</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_6b928b5a2adc4f5fb5797fab368a4a1a" contextRef="c20200101to20200630_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">7,188,167</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_0d29e9b50ded430bb671128fe99b5aa4" contextRef="c20200101to20200630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">33,893,611</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Interest and other expense, net</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_a752336d52c14ef69ddc237159c8c765" contextRef="c20200101to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">474,314</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_5a36b52d2f294d818245eb531de47414" contextRef="c20200101to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">33</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_076b884726fa4ccab5c2ada606024aaa" contextRef="c20200101to20200630_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">5,055,363</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_b7bb527c783a4c049106f91c751257ba" contextRef="c20200101to20200630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">5,529,710</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Net loss</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_baf135c6f83240f19cc86c8520ca7d23" contextRef="c20200101to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">25,803,294</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_7b5e57735097442f90e91bbd7a27cca5" contextRef="c20200101to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">1,376,497</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_bd889d441c96474ab4a35f732be98f9b" contextRef="c20200101to20200630_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">12,243,530</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_f4ed534b73634c48a9110ac6c5c0f9b6" contextRef="c20200101to20200630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">39,423,321</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Capital expenditures</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" id="Fact_7986b159db8c46588ea249ec61b1cd37" contextRef="c20200101to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">5,064,494</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" id="Fact_39247938dfc148a1888052cb95a37498" contextRef="c20200101to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,178,790</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" id="Fact_ec6cac1af74d458f864c529a503aef33" contextRef="c20200101to20200630_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" id="Fact_449830af87464ac8a543cf1f9e7732e9" contextRef="c20200101to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">6,243,284</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Depreciation and amortization expense</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_f51a4d5117514dc28f99aa645c521339" contextRef="c20200101to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,447,214</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_0b56dbb3cc6044cc8ee576ce2f766f76" contextRef="c20200101to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">222,395</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_784b25dae90b4d92b5e812c66599f825" contextRef="c20200101to20200630_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">4,881</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_bf0602743bd34654ae529575e7582c05" contextRef="c20200101to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,674,490</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_bfa6dcfadb274e4d9dd0d88324c1491122" continuedAt="Text_bfa6dcfadb274e4d9dd0d88324c1491123"><ix:continuation id="Text_172b11ef2fc24967ba5f379fdca36a0c17">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_bfa6dcfadb274e4d9dd0d88324c1491123" continuedAt="Text_bfa6dcfadb274e4d9dd0d88324c1491124">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span></div>
</ix:continuation><ix:continuation id="Text_bfa6dcfadb274e4d9dd0d88324c1491124" continuedAt="Text_bfa6dcfadb274e4d9dd0d88324c1491125"><ix:nonNumeric name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="Text_cb3457db51a845d5ad4ccf3d19e66190" contextRef="c20210101to20210630" escape="true" continuedAt="Text_e813a49b01f044b4ba25291dfa93a52d1">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_bfa6dcfadb274e4d9dd0d88324c1491125" continuedAt="Text_bfa6dcfadb274e4d9dd0d88324c1491126"><ix:continuation id="Text_e813a49b01f044b4ba25291dfa93a52d1" continuedAt="Text_e813a49b01f044b4ba25291dfa93a52d2">
<div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Net revenues according to geographic area, based on the location of where the product is shipped, is as follows:</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_bfa6dcfadb274e4d9dd0d88324c1491126" continuedAt="Text_bfa6dcfadb274e4d9dd0d88324c1491127"><ix:continuation id="Text_e813a49b01f044b4ba25291dfa93a52d2" continuedAt="Text_e813a49b01f044b4ba25291dfa93a52d3">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_bfa6dcfadb274e4d9dd0d88324c1491127" continuedAt="Text_bfa6dcfadb274e4d9dd0d88324c1491128"><ix:continuation id="Text_e813a49b01f044b4ba25291dfa93a52d3" continuedAt="Text_e813a49b01f044b4ba25291dfa93a52d4">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_bfa6dcfadb274e4d9dd0d88324c1491128" continuedAt="Text_bfa6dcfadb274e4d9dd0d88324c1491129"><ix:continuation id="Text_e813a49b01f044b4ba25291dfa93a52d4" continuedAt="Text_e813a49b01f044b4ba25291dfa93a52d5">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_bfa6dcfadb274e4d9dd0d88324c1491129"><ix:continuation id="Text_e813a49b01f044b4ba25291dfa93a52d5">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="6">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Three Months Ended June 30,</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="6">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Six Months Ended June 30,</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; font-weight: bold;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2021<br />
                    </span> </div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2020<br />
                    </span> </div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2021<br />
                    </span> </div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2020<br />
                    </span> </div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">United States</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_3be7c03acc98435db1922b60348cf52f" contextRef="c20210401to20210630_StatementGeographicalAxis_US" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">15,424,839</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_655c63533d814f2dbe2d6fe1563aead1" contextRef="c20200401to20200630_StatementGeographicalAxis_US" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">6,797,170</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_91155d91098d4509b25ab5126c8ea6d4" contextRef="c20210101to20210630_StatementGeographicalAxis_US" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">29,102,848</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_5e72e2fc55cb432da3023ec4422fc3c3" contextRef="c20200101to20200630_StatementGeographicalAxis_US" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">15,453,443</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">International</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_934c36b3b9be445ba641a3e697d1e312" contextRef="c20210401to20210630_StatementGeographicalAxis_NonUsMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">2,405,751</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_0c71ba040dc54f4ba5c485595fd44e72" contextRef="c20200401to20200630_StatementGeographicalAxis_NonUsMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">990,424</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_bde3589b805a4f6b8377e9743eda474e" contextRef="c20210101to20210630_StatementGeographicalAxis_NonUsMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">4,776,360</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_ef6fd07674c1435392453ab99b844b8f" contextRef="c20200101to20200630_StatementGeographicalAxis_NonUsMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">2,533,895</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Total revenues</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_b206710de84f43feb4e52545a510fe99" contextRef="c20210401to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">17,830,590</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_e86732b3d7a04748acea12c95f6087ba" contextRef="c20200401to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">7,787,594</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_3ac0675c69844d78babc6cce46372846" contextRef="c20210101to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">33,879,208</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_cc3862e422004e83b3a0e34cc3dd8040" contextRef="c20200101to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">17,987,338</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

          <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
            <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">20</span></div>

            <div style="page-break-after:always;" class="DSPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

            <div style="width: 100%;" class="DSPFPageHeader">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 100%; font-size: 8pt; font-style: italic;">
                      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>
                      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>
                    </td>

  </tr>


</table>
            </div>

          </div>

        </div>

        <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

  </div>
<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

        <div><ix:nonNumeric name="us-gaap:LesseeOperatingLeasesTextBlock" id="Text_1ecd1dbe03aa49dc9cdb7a437126c258" contextRef="c20210101to20210630" escape="true" continuedAt="Text_ec2ca7e794b6452cb8981b6442eaa2fc1">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_ec2ca7e794b6452cb8981b6442eaa2fc1" continuedAt="Text_ec2ca7e794b6452cb8981b6442eaa2fc2">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">12.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">LEASE OBLIGATIONS</span></div>
                </td>

  </tr>


</table>
</ix:continuation>
          <ix:continuation id="Text_ec2ca7e794b6452cb8981b6442eaa2fc2" continuedAt="Text_ec2ca7e794b6452cb8981b6442eaa2fc3">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_ec2ca7e794b6452cb8981b6442eaa2fc3" continuedAt="Text_ec2ca7e794b6452cb8981b6442eaa2fc4">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_ec2ca7e794b6452cb8981b6442eaa2fc4" continuedAt="Text_ec2ca7e794b6452cb8981b6442eaa2fc5">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_ec2ca7e794b6452cb8981b6442eaa2fc5" continuedAt="Text_ec2ca7e794b6452cb8981b6442eaa2fc6">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The Company leases certain properties and equipment for its ADMA BioCenters subsidiary and certain equipment
            for its ADMA BioManufacturing subsidiary, which leases provide the right to use the underlying assets and require lease payments through the respective lease terms which expire at various dates through 2032. The Company&#8217;s lease agreements do
            not contain any material residual value guarantees or material restrictive covenants.</div>
</ix:continuation>
          <ix:continuation id="Text_ec2ca7e794b6452cb8981b6442eaa2fc6" continuedAt="Text_ec2ca7e794b6452cb8981b6442eaa2fc7">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_ec2ca7e794b6452cb8981b6442eaa2fc7" continuedAt="Text_ec2ca7e794b6452cb8981b6442eaa2fc8">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_ec2ca7e794b6452cb8981b6442eaa2fc8" continuedAt="Text_ec2ca7e794b6452cb8981b6442eaa2fc9">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_ec2ca7e794b6452cb8981b6442eaa2fc9" continuedAt="Text_ec2ca7e794b6452cb8981b6442eaa2fc10">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The Company determines if an arrangement is an operating lease at inception. Leases with an initial term of
            12 months or less are not recorded on the balance sheet. All other leases are recorded on the balance sheet with assets representing the right to use the underlying asset for the lease term and lease liabilities representing the obligation to
            make lease payments arising from the lease. Right-to-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term and include options to extend or terminate the
            lease when they are reasonably certain to be exercised. The present value of the lease payments is determined using the Company&#8217;s incremental borrowing rate of <ix:nonFraction name="adma:OperatingLeaseIncrementalBorrowingRatePercent" id="Fact_55f7c5cf48ad42f4b337ce7a4d017e14" contextRef="c20210401to20210630" unitRef="U007" decimals="2" scale="-2" format="ixt:numdotdecimal">13</ix:nonFraction>%. The Company&#8217;s lease expense is recognized on a straight-line basis over the lease term and is reflected in Plasma center operating expenses and Selling, general and administrative expenses. Aggregate lease
            expense for the Company&#8217;s leases for the three months ended June 30, 2021 and 2020 was approximately $<ix:nonFraction name="us-gaap:OperatingLeaseExpense" id="Fact_79a67d3de81f41eba8d0cabf7a711f31" contextRef="c20210401to20210630" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:OperatingLeaseExpense" id="Fact_2950ddff1a244f5a935ea7b3fba4d3b5" contextRef="c20200401to20200630" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction> million, respectively. Aggregate lease expense for the six months ended June 30, 2021 and 2020 was approximately $<ix:nonFraction name="us-gaap:OperatingLeaseExpense" id="Fact_5e1ff401ac144b29b2225e07025e7977" contextRef="c20210101to20210630" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:OperatingLeaseExpense" id="Fact_9d1d11ce4ecf4240b7f78c8e5600da83" contextRef="c20200101to20200630" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction> million,
            respectively. Cash paid for the Company&#8217;s leases for the three months ended June 30, 2021 and 2020 was approximately $<ix:nonFraction name="us-gaap:OperatingLeasePayments" id="Fact_5fcf9a4488304ff9adc75ef83548bcec" contextRef="c20210401to20210630" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction> million and
            $<ix:nonFraction name="us-gaap:OperatingLeasePayments" id="Fact_8f6d66f8a87c4cbf9deff8322abbd383" contextRef="c20200401to20200630" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction> million, respectively. Cash paid for the Company&#8217;s leases for the six months ended June 30, 2021 and 2020 was approximately $<ix:nonFraction name="us-gaap:OperatingLeasePayments" id="Fact_b3749ff97e2746ee94b36869f1c8f445" contextRef="c20210101to20210630" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:OperatingLeasePayments" id="Fact_80cc06cc7a6c4501962cdaf1c7a109d3" contextRef="c20200101to20200630" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction> million,
            respectively.</div>
</ix:continuation>
          <ix:continuation id="Text_ec2ca7e794b6452cb8981b6442eaa2fc10" continuedAt="Text_ec2ca7e794b6452cb8981b6442eaa2fc11">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_ec2ca7e794b6452cb8981b6442eaa2fc11" continuedAt="Text_ec2ca7e794b6452cb8981b6442eaa2fc12">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_ec2ca7e794b6452cb8981b6442eaa2fc12" continuedAt="Text_ec2ca7e794b6452cb8981b6442eaa2fc13">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_ec2ca7e794b6452cb8981b6442eaa2fc13" continuedAt="Text_ec2ca7e794b6452cb8981b6442eaa2fc14">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">During the six months ended June 30, 2021, the Company recognized additional right to use
              assets and corresponding lease liabilities of $<ix:nonFraction name="adma:LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease" id="Fact_7ddb5248b3974999814e3cb7041345cd" contextRef="c20210630" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal"><ix:nonFraction name="adma:LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease" id="Fact_f33de3af181348d0a55e1d293d68e667" contextRef="c20210630" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">2.8</ix:nonFraction></ix:nonFraction> million in connection with <ix:nonFraction name="adma:NumberOfNewPropertyLeases" id="Fact_d8f980828b604e928ffea165a0541d60" contextRef="c20210401to20210630" unitRef="U010" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction> new property leases where the Company intends to open additional plasma collection facilities. Including a finance lease the Company entered into in June 2018, the
              Company has aggregate lease liabilities of $<ix:nonFraction name="us-gaap:OperatingLeaseLiability" id="Fact_28418e11f07a4d819a967a6f2df610b0" contextRef="c20210630" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">7.5</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:OperatingLeaseLiability" id="Fact_c6374a3f65244a51bd16c6fe2907ed62" contextRef="c20201231" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">4.7</ix:nonFraction> million as of June 30, 2021 and December 31, 2020, respectively, which are comprised primarily of the leases for the Company&#8217;s plasma collection centers and an
              administrative office lease related to the Company&#8217;s ADMA BioCenters subsidiary.&#160; The Company&#8217;s operating leases have a weighted average remaining term of <ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Fact_07f24cbb2eba4271a2b57ab63c059442" contextRef="c20210630" format="ixt-sec:duryear">9.3</ix:nonNumeric> years. </span><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Text_94a9bedf8b6049e3ba04fbd1b3835c75" contextRef="c20210101to20210630" escape="true" continuedAt="Text_2660143901e949458b8346e9b77b206b1"><span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Scheduled payments under the Company&#8217;s lease obligations are as follows:</span></span></ix:nonNumeric></div>
</ix:continuation>
          <ix:continuation id="Text_2660143901e949458b8346e9b77b206b1" continuedAt="Text_2660143901e949458b8346e9b77b206b2"><ix:continuation id="Text_ec2ca7e794b6452cb8981b6442eaa2fc14" continuedAt="Text_ec2ca7e794b6452cb8981b6442eaa2fc15">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_2660143901e949458b8346e9b77b206b2" continuedAt="Text_2660143901e949458b8346e9b77b206b3"><ix:continuation id="Text_ec2ca7e794b6452cb8981b6442eaa2fc15" continuedAt="Text_ec2ca7e794b6452cb8981b6442eaa2fc16">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_2660143901e949458b8346e9b77b206b3" continuedAt="Text_2660143901e949458b8346e9b77b206b4"><ix:continuation id="Text_ec2ca7e794b6452cb8981b6442eaa2fc16" continuedAt="Text_ec2ca7e794b6452cb8981b6442eaa2fc17">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_2660143901e949458b8346e9b77b206b4" continuedAt="Text_2660143901e949458b8346e9b77b206b5"><ix:continuation id="Text_ec2ca7e794b6452cb8981b6442eaa2fc17" continuedAt="Text_ec2ca7e794b6452cb8981b6442eaa2fc18">
<table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 48%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Remainder of <span style="text-indent: 0pt;">2021</span></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" id="Fact_66f213eca6d44cb88c0b1718466616cf" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">595,836</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 48%; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Year ended December 31, <span style="text-indent: 0pt;">2022</span></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" id="Fact_7c8b32caf496451fba6675db1dbd1fda" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,512,443</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 48%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">2023</span></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" id="Fact_904cea01c7094440b74d69d4c87502c8" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,526,406</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 48%; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">2024</span></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" id="Fact_13b215c1860f47b88f7ad7eb2f84541d" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,399,474</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 48%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">2025</span></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" id="Fact_2819ea5750b84ff7a2279b1aab503e97" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,405,411</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 48%; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">2026</span></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" id="Fact_02e8c9ec86b94978b3a81e393d521819" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,137,321</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 48%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Thereafter</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" id="Fact_86f24fd93c434a2fa625e61fee723e49" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">5,486,813</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 48%; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Total payments</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" id="Fact_e6a8d527af1f413c8d87428916b1d905" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">13,063,704</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 48%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Less: imputed interest</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" id="Fact_e0286a846fb24f23b3ce53d86f82a2be" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">5,604,431</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 48%; padding-bottom: 2px; white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Current portion</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" id="Fact_2d8a1e09b09a480abb1ca603f79b06eb" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">385,858</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 48%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Balance at <span style="text-indent: 0pt;">June 30, 2021</span></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" id="Fact_8b9a3b111481466d9c27264ae42c9a63" contextRef="c20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">7,073,415</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_2660143901e949458b8346e9b77b206b5"><ix:continuation id="Text_ec2ca7e794b6452cb8981b6442eaa2fc18" continuedAt="Text_ec2ca7e794b6452cb8981b6442eaa2fc19">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_ec2ca7e794b6452cb8981b6442eaa2fc19" continuedAt="Text_ec2ca7e794b6452cb8981b6442eaa2fc20">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span></div>
</ix:continuation>
          <ix:continuation id="Text_ec2ca7e794b6452cb8981b6442eaa2fc20" continuedAt="Text_ec2ca7e794b6452cb8981b6442eaa2fc21">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_ec2ca7e794b6452cb8981b6442eaa2fc21">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">On June 11, 2021, t<span style="color: rgb(0, 0, 0);">he Company entered into an additional property lease
              that the Company intends to use to store certain inventory for its ADMA BioManufacturing business segment. The Company has not taken possession of this leased property and its lease commencement date has not been determined. </span>With the
            exception of a security deposit and six months&#8217; rent totaling $<ix:nonFraction name="us-gaap:SecurityDeposit" id="Fact_f0734cb11db541cea2f2c4c4037abaa4" contextRef="c20210611" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction> million, <ix:nonFraction name="us-gaap:PaymentsForRent" id="Fact_2b378f1f903c4993921b1cba57f103c3" contextRef="c20210611to20210611" unitRef="U002" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction> payments have been made under this lease. The initial term of the lease is for <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Fact_c8279d913ea8459c8eb764d7f7d2ea77" contextRef="c20210611" format="ixt-sec:durmonth">90</ix:nonNumeric> months with monthly rental payments varying between approximately $<ix:nonFraction name="adma:OperatingLeasesRentExpense" id="Fact_0254b898c7cc480c9992720c7844b774" contextRef="c20210611to20210611_RangeAxis_MinimumMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">14,000</ix:nonFraction> and $<ix:nonFraction name="adma:OperatingLeasesRentExpense" id="Fact_512a993ac40442848d38e304afab3c0f" contextRef="c20210611to20210611_RangeAxis_MaximumMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">24,000</ix:nonFraction>, including common area maintenance charges.</div>
</ix:continuation>
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

          <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
            <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">21</span></div>

            <div style="page-break-after:always;" class="DSPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

            <div style="width: 100%;" class="DSPFPageHeader">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>

  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;" rowspan="1">
                      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>
                      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>
                    </td>

  </tr>


</table>
            </div>

          </div>

        </div>

        <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

  </div>
<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

        <div><ix:nonNumeric name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" id="Text_673ec408ded04a738b2e6188e9f26692" contextRef="c20210101to20210630" escape="true" continuedAt="Text_116334ca7a104faa9199a3578b7ed0331">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_116334ca7a104faa9199a3578b7ed0331" continuedAt="Text_116334ca7a104faa9199a3578b7ed0332">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">13.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</span></div>
                </td>

  </tr>


</table>
</ix:continuation>
          <ix:continuation id="Text_116334ca7a104faa9199a3578b7ed0332" continuedAt="Text_116334ca7a104faa9199a3578b7ed0333">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_116334ca7a104faa9199a3578b7ed0333" continuedAt="Text_116334ca7a104faa9199a3578b7ed0334">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation><ix:nonNumeric name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="Text_35fb1c620ab44388bdc46b9d5e9dccc2" contextRef="c20210101to20210630" escape="true" continuedAt="Text_f1bc5bdc23fd4a918ce386845c29eca71"><ix:continuation id="Text_116334ca7a104faa9199a3578b7ed0334" continuedAt="Text_116334ca7a104faa9199a3578b7ed0335">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:nonNumeric>
          <ix:continuation id="Text_f1bc5bdc23fd4a918ce386845c29eca71" continuedAt="Text_f1bc5bdc23fd4a918ce386845c29eca72"><ix:continuation id="Text_116334ca7a104faa9199a3578b7ed0335" continuedAt="Text_116334ca7a104faa9199a3578b7ed0336">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Supplemental cash flow information for the six months ended June 30, 2021 and 2020 is as follows:</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_f1bc5bdc23fd4a918ce386845c29eca72" continuedAt="Text_f1bc5bdc23fd4a918ce386845c29eca73"><ix:continuation id="Text_116334ca7a104faa9199a3578b7ed0336" continuedAt="Text_116334ca7a104faa9199a3578b7ed0337">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_f1bc5bdc23fd4a918ce386845c29eca73" continuedAt="Text_f1bc5bdc23fd4a918ce386845c29eca74"><ix:continuation id="Text_116334ca7a104faa9199a3578b7ed0337" continuedAt="Text_116334ca7a104faa9199a3578b7ed0338">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_f1bc5bdc23fd4a918ce386845c29eca74" continuedAt="Text_f1bc5bdc23fd4a918ce386845c29eca75"><ix:continuation id="Text_116334ca7a104faa9199a3578b7ed0338" continuedAt="Text_116334ca7a104faa9199a3578b7ed0339">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_f1bc5bdc23fd4a918ce386845c29eca75"><ix:continuation id="Text_116334ca7a104faa9199a3578b7ed0339">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; font-weight: bold;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2021<br />
                    </span> </div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2020<br />
                    </span> </div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">SUPPLEMENTAL CASH FLOW INFORMATION:</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Cash paid for interest</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:InterestPaidNet" id="Fact_b9753325c53b44fdb9ba648f102d2d5a" contextRef="c20210101to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">5,534,279</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:InterestPaidNet" id="Fact_26c4ccfe76504ce68892f30a85ee6a80" contextRef="c20200101to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">4,192,165</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Non-cash Financing and Investing Activities:</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Equipment acquired reflected in accounts payable and accrued liabilities</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" id="Fact_69359f1938dd4e358eba137ab827292d" contextRef="c20210101to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,005,546</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" id="Fact_10c7c926bd5149fb8b311b6fef8fa8a7" contextRef="c20200101to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,228,000</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Right-to-use assets in exchange for lease obligations</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" id="Fact_193554f3777e425caef57031b10aef16" contextRef="c20210101to20210630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">2,844,875</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" id="Fact_7e89ae4268604b5bb6750e178340f566" contextRef="c20200101to20200630" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,723,594</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

          <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

        <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
   <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

    <div>
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

      <div><ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" id="Text_b1e5371a9f6b4e368821fb3a9ed0e8a0" contextRef="c20210101to20210630" escape="true" continuedAt="Text_06ce4f813f3340d9bd99bfa5e622b6271">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric>
        <ix:continuation id="Text_06ce4f813f3340d9bd99bfa5e622b6271" continuedAt="Text_06ce4f813f3340d9bd99bfa5e622b6272">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">14.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">SUBSEQUENT EVENTS</span></div>
              </td>

  </tr>


</table>
</ix:continuation>
        <ix:continuation id="Text_06ce4f813f3340d9bd99bfa5e622b6272" continuedAt="Text_06ce4f813f3340d9bd99bfa5e622b6273">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_06ce4f813f3340d9bd99bfa5e622b6273" continuedAt="Text_06ce4f813f3340d9bd99bfa5e622b6274">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
          </span> </div>
</ix:continuation>
        <ix:continuation id="Text_06ce4f813f3340d9bd99bfa5e622b6274" continuedAt="Text_06ce4f813f3340d9bd99bfa5e622b6275">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_06ce4f813f3340d9bd99bfa5e622b6275">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">On July 26, 2021, the Company sold an additional <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_4bbf2096b4f142e99188b23c01ba5eab" contextRef="c20210726to20210726_SubsequentEventTypeAxis_SubsequentEventMember_TypeOfArrangementAxis_SaleAgreement2020Member" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">897,445</ix:nonFraction> shares of its common stock under the 2020 Sale Agreement and received net proceeds of approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_d456b238d9a04e3ca364d7da466e37aa" contextRef="c20210726to20210726_SubsequentEventTypeAxis_SubsequentEventMember_TypeOfArrangementAxis_SaleAgreement2020Member" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction> million, which represents the remaining amount that could be raised under the 2020 Sale Agreement as of June 30, 2021. In accordance with terms of the 2020 Sale
          Agreement, the 2020 Sale Agreement automatically terminated upon the foregoing sale of common stock.</div>
</ix:continuation>
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
        <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

        <div><br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">22</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
          </div>

        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <a id="ManagementsDiscussionandA"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 45pt; vertical-align: top; font-weight: bold;">Item 2.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</div>
            </td>

  </tr>


</table>
      <div style="text-indent: 36pt; font-style: italic;"> <br />
      </div>

      <div style="text-indent: 36pt; font-style: italic;">The following discussion of our financial condition and results of operations, which refers to our historical results, should be read in conjunction with the other sections of this Quarterly Report
        on Form 10-Q, including &#8220;Risk Factors&#8221; and our unaudited consolidated financial statements and the notes thereto appearing elsewhere herein, and in conjunction with the Management&#8217;s Discussion and Analysis of Financial Condition and Results of
        Operations set forth in our Annual Report on Form 10-K for the year ended December 31, 2020, filed on March 25, 2021 (the &#8220;2020 10-K&#8221;). The various sections of this discussion contain a number of forward-looking statements, all of which are based
        on our current expectations and could be affected by the uncertainties and risk factors described throughout or referenced within this Quarterly Report on Form 10-Q. See &#8220;Special Note Regarding Forward-Looking Statements.&#8221;&#160; Our actual results may
        differ materially from our current expectations.</div>

      <div><br />
      </div>

      <div style="text-align: center; font-weight: bold;"><span style="text-decoration: underline;">OVERVIEW</span></div>

      <div style="text-align: center; font-weight: bold;"><span style="text-decoration: underline;"> <br />
        </span></div>

      <div style="font-weight: bold;">Our Business</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">ADMA Biologics, Inc. (the &#8220;Company,&#8221; &#8220;ADMA,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the
        treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Our targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who
        may be immune-suppressed for medical reasons.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">We currently have three products with U.S. Food and Drug Administration (the &#8220;FDA&#8221;) approval, all of which are currently marketed and commercially available: (i) BIVIGAM (Immune Globulin Intravenous, Human), an
        Intravenous Immune Globulin (&#8220;IVIG&#8221;) product indicated for the treatment of Primary Humoral Immunodeficiency (&#8220;PI&#8221;), also known as Primary Immunodeficiency Disease (&#8220;PIDD&#8221;), and for which we received FDA approval on May 9, 2019 and commenced
        commercial sales in August 2019; (ii) ASCENIV (Immune Globulin Intravenous, Human &#8211; slra 10% Liquid), an IVIG product indicated for the treatment of PI, for which we received FDA approval on April 1, 2019 and commenced first commercial sales in
        October 2019; and (iii) Nabi-HB (Hepatitis B Immune Globulin, Human), which is indicated for the treatment of acute exposure to blood containing HBsAg and other listed exposures to Hepatitis B. We seek to develop a pipeline of plasma-derived
        therapeutics, including a product based on our most recently approved patent application under U.S. Patent No. 10,259,865 related to methods of treatment and prevention of <span style="font-style: italic;">S. pneumonia</span> infection for an
        immunoglobulin manufactured to contain standardized antibodies to numerous serotypes of <span style="font-style: italic;">S. pneumoniae</span>. Our products and product candidates are intended to be used by physician specialists focused on caring
        for immune-compromised patients with or at risk for certain infectious diseases.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">We manufacture these products at our FDA-licensed, plasma fractionation and purification facility located in Boca Raton, Florida with a peak annual processing capability of up to 600,000 liters (the &#8220;Boca Facility&#8221;).
        Based on current production yields, our ongoing supply chain enhancements and capacity expansion initiatives, we believe this facility has the potential to produce quantities of our immune globulin (&#8220;IG&#8221;) products of more than $250 million in
        annual revenue beginning in 2024 and potentially in excess of $300 million of annual revenue thereafter, as well as achieving profitability during the first quarter of 2024, as we ramp-up production over the next three to five years. We anticipate
        exiting 2021 approaching an annualized revenue run rate of approximately $100 million or more.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">Through our ADMA BioCenters subsidiary, we currently operate FDA-licensed source plasma collection facilities in the U.S. This business unit, which we refer to as our Plasma Collection Centers business segment,
        provides us with a portion of our blood plasma for the manufacture of our products and product candidates, and also allows us to sell certain quantities of source plasma to customers for further manufacturing. As a part of our planned supply chain
        robustness initiative, we have opened four new plasma collection centers during the past 18 months, and we now have eight plasma collection centers in various stages of approval and development, including five that are fully operational and
        collecting plasma. With respect to our fully operational plasma collection centers, two plasma collection centers currently hold FDA licenses, while a third collection center has a Biologics License Application (&#8220;BLA&#8221;) under review pending FDA
        approval. In addition, one of our FDA-approved plasma collection centers also has approvals from the Korean Ministry of Food and Drug Safety (&#8220;MFDS&#8221;), as well as FDA approval to operate a Hepatitis B immunization program. After giving effect to the
        progress we made in 2020 and thus far in 2021 with our plasma collection network expansion, we believe we remain on track to achieve our goal of having 10 or more plasma collection centers operating in the U.S. by 2024. A typical plasma collection
        center, such as those operated by ADMA BioCenters, can collect approximately 30,000 to 50,000 liters of source plasma annually, which may be sold for different prices depending upon the type of plasma, quantity of purchase and market conditions at
        the time of sale. Plasma collected from ADMA BioCenters&#8217; facilities that is not used to manufacture our products or product candidates is sold to third-party customers in the U.S. and in other locations outside the U.S. where we are approved under
        supply agreements or in the open &#8220;spot&#8221; market.</div>

      <div style="text-indent: 36pt;"> <br />
      </div>

      <div> </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">23</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div style="text-indent: 36pt;">We sell plasma-derived intermediate fractions to certain customers, which are generated as part of our FDA-approved manufacturing process for IG and IVIG products. In January 2020, we announced our entry into a
        five-year manufacturing and supply agreement to produce and sell these intermediate by-products, which are used as the starting raw material to produce other plasma-derived biologics. In addition, from time to time we provide contract manufacturing
        and testing services for certain third-party clients. We also provide laboratory contracting services to certain customers and anticipate providing contract filling, labeling and packing services upon FDA approval and implementation of our in-house
        fill-finish capabilities.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">On June 6, 2017, we completed the acquisition of certain assets (the &#8220;Biotest Assets&#8221;) of the Therapy Business Unit (&#8220;BTBU&#8221;) of Biotest Pharmaceuticals Corporation (&#8220;BPC&#8221; and, together with Biotest AG, &#8220;Biotest&#8221;),
        which included two FDA-licensed products, Nabi-HB and BIVIGAM, and an FDA-licensed plasma fractionation facility located in Boca Raton, FL (the &#8220;Boca Facility&#8221;) (the &#8220;Biotest Transaction&#8221;).</div>

      <div><br />
      </div>

      <div style="font-weight: bold;">Recent Developments</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">On July 20, 2021, we announced that the FDA completed a Pre-Approval Inspection of the Boca Facility related to our application for approval of our Vanrx SA25 aseptic fill-finish machine and our related internal
        fill-finish processes, the drug product component of our manufacturing process. The inspection concluded successfully with no Form 483 observations. The FDA review of our regulatory filing related to approval of the new fill-finish machine remains
        ongoing, with anticipated regulatory approval in the second half of 2021.&#160; The anticipated approval would provide us with internal fill-finish production capabilities for our commercial products, which is expected to result in greater patient
        supply consistency and, coupled with the approval of our expanded plasma pool production scale process that we received earlier this year as discussed below, significantly improved operational efficiencies and gross margins.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">Effective as of May 12, 2021, we entered into a Second Amendment to our Plasma Purchase Agreement&#160; with Grifols Worldwide Operations Limited (&#8220;Grifols&#8221;) whereby, among other provisions, we extended the term of our
        supply agreement for the purchase of normal source plasma (&#8220;NSP&#8221;) through December 31, 2022, while certain historical provisions were deleted. In order to maintain a reliable supply of raw material plasma thereafter, we are in late-stage
        discussions with multiple third-party plasma suppliers to provide us with a long-term supply of NSP, which will be supplemented by our accelerated plasma center expansion activities, whereby we expect to have more than 10 plasma collection centers
        in operation by 2024.&#160; We expect these initiatives will ensure the raw material plasma supply necessary to meet our anticipated peak annual plasma processing capability of up to 600,000 liters.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">On April 28, 2021, we announced that the FDA granted approval for our expanded IVIG plasma pool production scale process, allowing for a 4,400-liter plasma pool for the manufacture of our commercial product BIVIGAM. We
        expect this increased IVIG plasma pool scale, which will allow us to produce BIVIGAM at an expanded capacity, will utilize the same equipment, release testing assays and labor force, and to have a favorable impact on our gross margins and operating
        results, potentially beginning late in the fourth quarter of 2021.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">On April 26, 2021, we announced the opening of our fourth plasma collection facility in the U.S. Pursuant to updated FDA guidance to obtain approval for plasma collection centers, sponsors are now required to collect
        plasma donations for three months prior to submitting a BLA filing. Accordingly, we filed a BLA for this plasma collection facility during the third quarter of 2021. Prior to receiving FDA approval, ADMA is permitted to collect plasma donations at
        this site and upon receipt of FDA approval we can utilize the plasma collected for further use in our IVIG manufacturing operations or for third party sale.</div>

      <div><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">24</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div style="font-weight: bold;">Our Products</div>

      <div><br />
      </div>

      <div style="font-style: italic; font-weight: bold;">BIVIGAM</div>

      <div style="font-style: italic; font-weight: bold;"> <br />
      </div>

      <div style="text-indent: 36pt;"><span style="color: rgb(0, 0, 0);">BIVIGAM is a plasma-derived IVIG that contains a broad range of antibodies similar to those found in normal human plasma. These antibodies are directed against bacteria and viruses,
          and help to protect PI patients against serious infections. BIVIGAM is a purified, sterile, ready-to-use preparation of concentrated human Immunoglobulin G antibodies indicated for the treatment of PI, a group of genetic disorders. This includes,
          but is not limited to, the humoral immune defect in common variable immunodeficiency, X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome and severe combined immunodeficiency. These PIs are a group of genetic
          disorders.</span>&#160;<span style="color: rgb(0, 0, 0);">Based on recent estimates, these disorders are no longer considered to be very rare, with as many as one in every 1,200 people in the United States having some form of PI.</span></div>

      <div><br />
      </div>

      <div style="text-indent: 36pt; color: rgb(0, 0, 0);">On May 9, 2019, the FDA approved the Prior Approval Supplement (the &#8220;PAS&#8221;) for the use of our IVIG manufacturing process, thereby enabling us to re-launch and commercialize this product in the
        United States. We resumed production of BIVIGAM during the fourth quarter of 2017 and commercial production is ongoing, using our FDA-approved IVIG manufacturing process under U.S. Department of Health and Human Services (&#8220;HHS&#8221;) License No. 2019.
        The commercial re-launch and first commercial sales for this product commenced in August of 2019.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">On April 28, 2021, we announced that the FDA has granted approval for our expanded plasma pool production scale process, allowing for a 4,400-liter plasma pool for the manufacture of our BIVIGAM IVIG product. We expect
        this increased IVIG plasma pool scale, which will allow us to produce BIVIGAM at an expanded capacity, will utilize the same equipment, release testing assays and labor force, and to have a favorable impact on our gross margins and operating
        results, potentially beginning late in the fourth quarter of 2021.</div>

      <div><br />
      </div>

      <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">ASCENIV</div>

      <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;"> <br />
      </div>

      <div style="text-indent: 36pt; color: rgb(0, 0, 0);">ASCENIV is a plasma-derived IVIG that contains naturally occurring polyclonal antibodies, which are proteins that are used by the body&#8217;s immune system to neutralize microbes, such as bacteria and
        viruses, and prevent against infection and disease. We manufacture ASCENIV under HHS License No. 2019 using a process known as fractionation. The Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) has issued a permanent, product-specific-J-code for
        ASCENIV.&#160; Under the Healthcare Common Procedure Coding System (&#8220;HCPCS&#8221;), the J-code (J1554) became effective April 1, 2021. As part of our proprietary manufacturing process for ASCENIV, we leverage our unique, patented plasma donor screening
        methodology and tailored plasma pooling design, which blends normal source plasma and plasma from donors tested to have high levels of neutralizing antibody titers to respiratory syncytial virus (&#8220;RSV&#8221;) using our proprietary microneutralization
        testing assay. We are able to identify the high titer or &#8220;hyperimmune&#8221; plasma that meets our internal and required specifications for ASCENIV with our patented testing methods and assay. This type of high titer plasma is typically found in less
        than 10% of the total donor collection samples we test.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt; color: rgb(0, 0, 0);">ASCENIV is approved for the treatment of Primary Immune Deficiency Disorder (&#8220;PIDD&#8221;), a class of inherited genetic disorders that causes a deficient or absent immune system in adults and
        adolescents (12 to 17 years of age). Our pivotal Phase 3 clinical trial in 59 PIDD patients met the primary endpoint of no Serious Bacterial Infections reported during 12 months of treatment. Secondary efficacy endpoints further demonstrated the
        benefits of ASCENIV in the low incidence of infection, therapeutic antibiotic use, days missed from work/school/daycare and unscheduled medical visits and hospitalizations. We believe this clinical data together with the FDA approval for the
        treatment of PIDD better positions ADMA to further evaluate ASCENIV in immune-compromised patients infected with or at-risk for RSV infection or potentially other respiratory viral pathogens. Due to the COVID-19 pandemic, our plans have been
        delayed.&#160; In the future however, we plan to work with the FDA and the immunology and infectious disease community to design an appropriate clinical trial to evaluate the use of ASCENIV in this patient population. Commercial sales of ASCENIV
        commenced in October of 2019.</div>

      <div><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">25</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div style="font-style: italic; font-weight: bold;">Nabi-HB</div>

      <div style="font-style: italic; font-weight: bold;"> <br />
      </div>

      <div style="text-indent: 36pt;">Nabi-HB is a hyperimmune globulin that is rich in antibodies to the Hepatitis B virus. Nabi-HB is a purified human polyclonal antibody product collected from plasma donors who have been previously vaccinated with a
        Hepatitis B vaccine. Nabi-HB is indicated for the treatment of acute exposure to blood containing HBsAg, prenatal exposure of infants born to HBsAg-positive mothers, sexual exposure to HBsAg-positive persons and household exposure to persons with
        acute Hepatitis B virus infection in specific, listed settings. Hepatitis B is a potentially life-threatening liver infection caused by the Hepatitis B virus. It is a major global health problem. It can cause chronic infection and puts people at
        high risk of death from cirrhosis and liver cancer. Nabi-HB has a well-documented record of long-term safety and effectiveness since its initial market introduction. The FDA approved Nabi-HB on March 24, 1999.&#160; Production of Nabi-HB at the Boca
        Facility has continued under our leadership since the third quarter of 2017. In early 2018, we received authorization from the FDA for the release of our first commercial batch of Nabi-HB for commercial distribution in the U.S. and we continue to
        manufacture Nabi-HB under HHS License No. 2019.</div>

      <div><br />
      </div>

      <div style="text-align: center; font-weight: bold;"><span style="text-decoration: underline;">IMPACT OF THE COVID-19 CRISIS</span></div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">We continue to closely monitor ongoing developments in connection with the COVID-19 global pandemic, including the emergence of the Delta variant and other resistant strains of the novel coronavirus, and its impacts to
        our commercial and manufacturing operations and plasma collection facilities, including but not limited to potential disruptions to our supply chain operations, including collections of source plasma, procurement of raw materials and packaging
        materials, a portion of which are sourced internationally, and testing of finished drug product that is required prior to its availability for commercial sale.&#160; Such testing has historically been performed by contract laboratories outside the
        United States. In addition, travel and other restrictions that have been implemented in the United States have impacted our commercial engagement efforts with respect to some of our products, including BIVIGAM and ASCENIV, as trade shows, industry
        and medical conferences and other events we had been planning to utilize and exhibit and attend with our staff to increase awareness of our products by physicians and payers remain subject to reduction in scope, rescheduling or outright
        cancellation due to the pandemic.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">We had experienced some delays with our third-party vendors and testing laboratories which perform final drug product GMP release testing. In response to these delays, we added additional release testing laboratories
        to our FDA approved consortium listed in our drug approval documents which we believe has adequately addressed this issue. In July 2020, we began receiving FDA lot releases with testing data from our new testing laboratory vendor. In addition, due
        to a combination of previous state and local &#8220;shelter-in-place&#8221; orders, as well as government stimulus packages, persisting social distancing measures and varying roll-outs of vaccinations by state, we have been experiencing lower than normal donor
        collections at our FDA-approved plasma collection centers. We were also subject to delays in shipments of source plasma from our contracted third-party suppliers, as well as delays in deliveries for personal protective equipment, reagents and other
        non-plasma raw materials and supplies used in the manufacture and distribution of our products. We are also subject to supply chain delays as a result of certain of our suppliers diverting significant resources towards the rapid development and
        distribution of COVID-19 vaccines and, as a result, we may elect to carry more raw materials inventory than we have in the past. In addition, we have also experienced challenges with respect to our customer engagement initiatives, as our sales and
        medical affairs field forces face difficulties communicating directly with physicians and other healthcare professionals and the cancellation or postponement of a number of key scientific and medical conferences, further limiting our ability to
        communicate with potential customers.&#160; We have implemented a comprehensive suite of virtual engagement initiatives, though clinician engagement remains lower due to continuing COVID-19-related priorities at U.S. medical centers.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">The pandemic could further impact our ability to interact with the FDA or other regulatory authorities and may result in delays in the conduct of inspections or review of pending applications or submissions.&#160; During
        the second quarter of 2021, we were notified by the FDA that our submission for the approval of our in-house fill-finish process utilizing our Vanrx SA25 Workcell aseptic filling machine will require a site inspection, either in person or
        virtually. Although the inspection was completed in July of 2021, the FDA&#8217;s review of our regulatory filing with respect to our in-house fill-finish process and new aseptic filling machine remains ongoing. Although we anticipate receiving
        regulatory approval of this submission in the second half of 2021, no assurances can be provided as to the timing for completion of this FDA review or any other regulatory submissions or applications that may be impacted by restrictions related to
        COVID-19.</div>

      <div><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">26</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div style="text-indent: 36pt;">As of the date of this report, we do not believe that the operations and immunoglobulin and plasma products production at our Boca Facility, our contract fill/finishers or our plasma collection facilities have been
        significantly impacted by the COVID-19 pandemic. As a result, as of the date of this report, we have not experienced, and currently do not anticipate, any material impairments with respect to any of our long-lived assets, including our property and
        equipment, goodwill or intangible assets.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">Although the COVID-19 pandemic has not, to date, materially adversely impacted our capital and financial resources, due to the economic uncertainty that has resulted from the pandemic, and the potential impact of such
        to our stakeholders, we are unable to predict with certainty any potential impacts to our business. Although we believe the effects of the COVID-19 pandemic on our business and our operations will be temporary, at the present time we are unable to
        determine the ultimate duration of the pandemic or its long-term effects on, among other things, the global, national or local economies, the capital and credit markets, our workforce, our customers or our suppliers.&#160; As a result, we are unable to
        predict whether the COVID-19 crisis will have a material adverse impact on our business, financial condition, liquidity and results of operations.</div>

      <div><br />
      </div>

      <div style="text-align: center; font-weight: bold;"><span style="text-decoration: underline;">RESULTS OF OPERATIONS</span></div>

      <div><br />
      </div>

      <div style="font-weight: bold;">Critical Accounting Policies and Estimates</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt; color: rgb(0, 0, 0);">This Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations is based on our consolidated financial statements, which have been prepared in accordance with Accounting
        Principles Generally Accepted in the United States of America (&#8220;U.S. GAAP&#8221;). The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues
        and expenses. On an ongoing basis, we evaluate these estimates and assumptions, including those described below. We base our estimates on our historical experience and on various other assumptions that we believe to be reasonable under the
        circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results and experiences may differ materially from these
        estimates. Significant estimates include the realizable value of accounts receivable, valuation of inventory, assumptions used in projecting future liquidity and capital requirements, assumptions used in the fair value of awards granted under our
        equity incentive plans and warrants issued in connection with the issuance of notes payable and the valuation allowance for our deferred tax assets.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">Some of the estimates and assumptions we have to make under U.S. GAAP require difficult, subjective and/or complex judgments about matters that are inherently uncertain and, as a result, actual results could differ
        from those estimates. Due to the estimation processes involved, the following summary of accounting policies and their application are considered to be critical to understanding our business operations, financial condition and results of
        operations. For a detailed discussion on the application of these and our other accounting policies, see Note 2 to the Consolidated Financial Statements included elsewhere in this Quarterly Report on Form 10-Q.</div>

      <div><br />
      </div>

      <div style="font-style: italic; font-weight: bold;">Revenue Recognition</div>

      <div style="font-style: italic; font-weight: bold;"> <br />
      </div>

      <div style="text-indent: 36pt;">Revenues for the six months ended June 30, 2021 and 2020 are comprised of (i) revenues from the sale of our FDA-approved immunoglobulin products, (ii) product revenues from the sale of human plasma collected from our
        Plasma Collection Centers business segment, (iii) product revenues from the sale of intermediate fractions, (iv) contract manufacturing and testing revenue from certain clients, and (v) license revenues attributable to the out-licensing of ASCENIV
        in December 2012 to Biotest AG (&#8220;Biotest&#8221;) to market and sell this product in Europe and selected countries in North Africa and the Middle East. Biotest has provided us with certain services and financial payments in accordance with the related
        Biotest license agreement and is obligated to pay us certain amounts in the future if certain milestones are achieved. Deferred revenue is amortized into income over the term of the Biotest license, representing a period of approximately 22 years.</div>

      <div><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">27</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div style="text-indent: 36pt;">Product revenue is recognized when the customer is deemed to have control over the product. Control is determined based on when the product is shipped or delivered and title passes to the customer. Revenue is recorded
        in an amount that reflects the consideration we expect to receive in exchange. Revenue from the sale of immunoglobulin products is generally recognized when the product reaches the customer&#8217;s destination, and is recorded net of distributor fees,
        estimated rebates, price protection arrangements and customer incentives, including prompt pay discounts, wholesaler chargebacks and other wholesaler fees. These estimates are based on historical experience and certain other assumptions, and we
        believe that such estimates are reasonable. For revenues associated with sales of our intermediates or contract manufacturing, control transfers to the customer and the performance obligation is satisfied when the customer takes possession of the
        product from the Boca Facility or a third-party warehouse that is utilized by the Company.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">Product revenues from the sale of human plasma collected at our plasma collection centers are recognized at the time control of the product has been transferred to the customer, which generally occurs at the time of
        shipment. Product revenues are recognized at the time of delivery if we retain control of the product during shipment. Payments received from customers where the foregoing revenue recognition criteria have not been satisfied are recorded as
        deferred revenue, which is reflected as a liability in our consolidated balance sheets.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">For the six months ended June 30, 2021, five customers, BioCARE, Inc. (&#8220;BioCare&#8221;), Biolife Plasma Services, L.P. (&#8220;Biolife&#8221;), Reliance Life Sciences Pvt Limited (&#8220;Reliance&#8221;), Priority Healthcare Distribution, Inc.
        (&#8220;Curascript&#8221;) and AmerisourceBergen Drug Corporation (&#8220;AmerisourceBergen&#8221;) represented an aggregate of 85% of our consolidated revenues. <span style="color: rgb(0, 0, 0);">For the six months ended June 30, 2020, BioCare, Biolife and Reliance
          represented an aggregate of 81% of our consolidated revenues.&#160; </span></div>

      <div><br />
      </div>

      <div style="font-style: italic; font-weight: bold;">Accounts Receivable</div>

      <div style="font-style: italic; font-weight: bold;"> <br />
      </div>

      <div style="text-indent: 36pt;">Accounts receivable are reported at realizable value, net of allowances for contractual credits and doubtful accounts, which are recognized in the period the related revenue is recorded. We extend credit to our
        customers based upon an evaluation of each customer&#8217;s financial condition and credit history. Evaluations of the financial condition and associated credit risk of customers are performed on an ongoing basis. Based on these evaluations, we have
        concluded that our credit risk is minimal.</div>

      <div style="text-indent: 36pt;"> <br />
      </div>

      <div style="font-style: italic; font-weight: bold;">Cost of Product Revenue</div>

      <div style="font-style: italic; font-weight: bold;"> <br />
      </div>

      <div style="text-indent: 36pt;">Cost of product revenue includes costs associated with the manufacture of the Company&#8217;s FDA approved products, intermediates and the sale of human source plasma, as well as expenses related to conformance batch
        production, process development and scientific and technical operations when these operations are attributable to marketed products. When the activities of these operations are attributable to new products in development, their expenses are
        classified as research and development expenses.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">As a manufacturer of biological products, we are subject to the risks inherent in biological production, which could include normal course losses and failures inherent in the manufacturing process. As our biologics
        production levels increase there may be normal course inventory losses as we ensure product quality and compliance with current Good Manufacturing Practices (&#8220;cGMP&#8221;), FDA, state and local regulations, or due to testing results not meeting
        specifications. Such losses are charged to cost of product revenue in the period they are incurred.</div>

      <div><br />
      </div>

      <div style="font-style: italic; font-weight: bold;">Stock-Based Compensation</div>

      <div style="font-style: italic; font-weight: bold;"> <br />
      </div>

      <div style="text-indent: 36pt;">All equity-based payments, including grants of stock options and restricted stock units (&#8220;RSUs&#8221;) are recognized at their estimated fair value at the grant date, and compensation expense is recognized on a straight-line
        basis over the grantee&#8217;s requisite vesting period. During the six months ended June 30, 2021, we granted RSUs to certain members of our management and employees representing an aggregate 542,244 shares of common stock, and during the six months
        ended June 30, 2020, we granted RSUs to members of our Board of Directors and certain members of our management and employees representing an aggregate of 341,000 shares of common stock. For the purpose of valuing stock options granted to our
        employees, directors and officers, we use the Black-Scholes option pricing model. We granted options to purchase an aggregate of 1,658,050 and 1,232,500 shares of common stock to management, employees and directors during the six months ended June
        30, 2021 and 2020, respectively. To determine the risk-free interest rate, we utilized the U.S. Treasury yield curve in effect at the time of the grant with a term consistent with the expected term of our awards. The expected term of the options
        granted is in accordance with SEC Staff Accounting Bulletins 107 and 110, and is based on the average between vesting terms and contractual terms. The expected dividend yield reflects our current and expected future policy for dividends on our
        common stock. The expected stock price volatility for our stock options was calculated by examining the historical volatility of our common stock since our common stock became publicly traded in the fourth quarter of 2013. We will continue to
        analyze the expected stock price volatility and expected term assumptions and will adjust our Black-Scholes option pricing assumptions as appropriate. In accordance with ASU No. 2016-09, <span style="font-style: italic;">Improvements to Employee
          Share-Based Payment Accounting (Topic 718)</span>, we have elected not to establish a forfeiture rate, as stock-based compensation expense related to forfeitures of unvested stock options is fully reversed at the time of forfeiture.</div>

      <div><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">28</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div style="font-style: italic; font-weight: bold;">Research and Development Expenses</div>

      <div style="font-style: italic; font-weight: bold;"> <br />
      </div>

      <div style="text-indent: 36pt;">Our research and development (&#8220;R&amp;D&#8221;) costs consist of clinical research organization costs, costs related to clinical trials, testing and evaluation of new or alternative products or processes, studies for
        potentially extending a product&#8217;s approved and labeled expiration dating and other potential label expansions, post-marketing commitment studies for BIVIGAM and ASCENIV and wages, benefits and stock-based compensation for employees directly related
        to research and development activities. All research and development costs are expensed as incurred.</div>

      <div><br />
      </div>

      <div style="font-style: italic; font-weight: bold;">Inventories</div>

      <div style="font-style: italic; font-weight: bold;"> <br />
      </div>

      <div style="text-indent: 36pt;">Raw materials inventory consists of various materials purchased from suppliers, including normal source plasma, that are used in the production of our products.&#160; Work-in-process and finished goods inventories reflect
        the cost of raw materials as well as costs for direct and indirect labor, primarily salaries, wages and benefits for applicable employees, as well as an allocation of overhead costs related to the Boca Facility including utilities, property taxes,
        general repairs and maintenance, consumable supplies and depreciation. The allocation of Boca Facility overhead to inventory is generally based upon the estimated square footage of the Boca Facility that is used in the production of our products
        relative to the total square footage of the facility.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">Inventories, including plasma intended for resale and plasma intended for internal use in the Company&#8217;s manufacturing, commercialization or research and development activities, are carried at the lower of cost or net
        realizable value determined by the first-in, first-out method.&#160; Net realizable value is generally determined based upon the consideration we expect to receive when the inventory is sold, less costs to deliver the inventory to the recipient. The
        estimates for net realizable value of inventory are based on contractual terms or upon historical experience and certain other assumptions which we believe are reasonable. Inventory is periodically reviewed to ensure that its carrying value does
        not exceed its net realizable value, and adjustments are recorded to write down such inventory, with a corresponding charge to cost of product revenue, when the carrying value or historical cost exceeds its estimated net realizable value.</div>

      <div><br />
      </div>

      <div style="font-style: italic; font-weight: bold;">Impairment of Long-Lived Assets</div>

      <div style="font-style: italic; font-weight: bold;"> <br />
      </div>

      <div style="text-indent: 36pt;">We assess the recoverability of our long-lived assets, which include property and equipment and finite-lived intangible assets, whenever significant events or changes in circumstances indicate impairment may have
        occurred. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to its carrying amount to determine whether the asset&#8217;s carrying value is recoverable. Any resulting impairment is recorded
        as a reduction in the carrying value of the related asset in excess of fair value and a charge to operating results. For the six months ended June 30, 2021 and 2020, we determined that there was no impairment of our long-lived assets.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">Goodwill is not amortized, but is assessed for impairment on an annual basis or more frequently if impairment indicators exist. We have the option to perform a qualitative assessment of goodwill to determine whether it
        is more likely than not that the fair value of the reporting unit associated with the goodwill is less than its carrying amount, including goodwill and other intangible assets. If we conclude that this is the case, then we must perform a goodwill
        impairment test by comparing the fair value of the reporting unit to its carrying value.&#160; An impairment charge is recorded to the extent the reporting unit&#8217;s carrying value exceeds its fair value, with the impairment loss recognized not to exceed
        the total amount of goodwill allocated to that reporting unit.&#160; We did not recognize any impairment charges related to goodwill for the six months ended June 30, 2021 and 2020.</div>

      <div><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">29</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div style="font-style: italic; font-weight: bold;">Recent Accounting Pronouncements</div>

      <div style="font-style: italic; font-weight: bold;"> <br />
      </div>

      <div style="text-indent: 36pt;">In June 2016, the FASB issued ASU No. 2016-13, <span style="font-style: italic;">Financial Instruments &#8211; Credit Losses (Topic 326)</span> (&#8220;ASU 2016-13&#8221;), which requires financial assets to be presented at the net
        amount expected to be collected, with an allowance for credit losses to be deducted from the amortized cost basis of the financial asset such that the net carrying value of the asset is presented as the amount expected to be collected. Under ASU
        2016-13, the entity&#8217;s statement of operations is required to reflect the measurement of credit losses for newly recognized financial assets, as well as expected increases or decreases in expected credit losses that have taken place during the
        period. For public business entities, ASU 2016-13 is effective for fiscal years beginning after December 15, 2019.&#160; We adopted ASU 2016-13 on January 1, 2020, and the adoption of this update did not have a significant impact on our consolidated
        financial statements.</div>

      <div><br />
      </div>

      <div style="text-align: justify; font-weight: bold;">Three Months Ended June 30, 2021 Compared to Three Months Ended June 30, 2020</div>

      <div style="text-align: justify; font-weight: bold;"> <br />
      </div>

      <div style="text-align: justify; text-indent: 36pt;">The following table presents a summary of the changes in our results of operations for the three months ended June 30, 2021, our second fiscal quarter, compared to the three months ended June 30,
        2020:</div>

      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1"><br />
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="10">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Three Months Ended June 30,</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> 2021</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2020</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Increase</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> (Decrease)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Revenues</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">17,830,590</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">7,787,594</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">10,042,996</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Cost of product revenue (exclusive of amortization expense shown below)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">18,832,624</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">13,495,629</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">5,336,995</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Gross loss</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(1,002,034</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(5,708,035</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">4,706,001</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Research and development expenses</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">1,158,866</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">1,656,420</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(497,554</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Plasma center operating expenses</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">2,803,326</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">877,902</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">1,925,424</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Amortization of intangibles</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">178,838</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">178,838</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Selling, general and administrative expenses</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">10,438,168</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">8,702,630</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">1,735,538</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Loss from operations</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(15,581,232</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(17,123,825</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">1,542,593</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Interest expense</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(3,246,680</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(3,067,306</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(179,374</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Other (expense) income, net</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(77,391</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">13,040</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(90,431</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Net loss</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(18,905,303</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(20,178,091</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">1,272,788</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="font-style: italic; font-weight: bold;">Revenues</div>

      <div style="font-style: italic; font-weight: bold;"> <br />
      </div>

      <div style="text-indent: 36pt;">We recorded total revenues of $17.8 million during the three months ended June 30, 2021, as compared to $7.8 million during the three months ended June 30, 2020, an increase of $10.0 million, or approximately 130%. The
        increase is due to increased sales of our immunoglobulin products generated by our Boca Facility manufacturing operations in 2021.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">Our revenues for the second quarter of 2021 as compared to the same period of a year ago were favorably impacted by the continued commercial scale-up, expanding customer base at both our ADMA BioManufacturing and ADMA
        BioCenters plasma collection center business segments and physician/payer acceptance of BIVIGAM and ASCENIV following these products&#8217; FDA approvals on May 9, 2019 and April 1, 2019, respectively, while we continued to benefit from the manufacturing
        and supply agreement we entered into in January 2020 to produce and sell intermediate fractions to a certain customer. In addition, revenues in the second quarter of 2020 were negatively impacted by COVID-19-related delays with some of our
        third-party vendors and testing laboratories which perform final drug product GMP release testing. In response to these delays, we added additional release testing laboratories to our FDA approved consortium listed in our drug approval documents
        which we believe has adequately addressed this issue.</div>

      <div style="text-indent: 36pt;"> <br />
      </div>

      <div style="font-style: italic; font-weight: bold;">Cost of Product Revenue</div>

      <div style="font-style: italic; font-weight: bold;"> <br />
      </div>

      <div style="text-indent: 36pt;">Cost of product revenue was $18.8 million for the three months ended June 30, 2021, as compared to $13.5 million for the three months ended June 30, 2020. This increase reflects higher product revenue costs in 2021 of
        $7.6 million corresponding to the increase in immunoglobulin revenues, partially offset by the absence of conformance batch production expenses in 2020 of $3.2 million.</div>

      <div><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">30</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div style="font-style: italic; font-weight: bold;">Research and Development Expenses</div>

      <div style="font-style: italic; font-weight: bold;"> <br />
      </div>

      <div style="text-indent: 36pt;">R&amp;D expenses totaled $1.2 million for the three months ended June 30, 2021, as compared to $1.7 million for the three months ended June 30, 2020. The decrease is primarily due to reduced compensation costs
        associated with R&amp;D activities during the quarter of $0.3 million, and the absence of <span style="color: rgb(0, 0, 0);">$0.2 million of non-recurring costs incurred in 2020 associated with our participation in a third-party clinical research
          project.</span>&#160;<span style="color: rgb(0, 0, 0);">&#160;</span></div>

      <div><br />
      </div>

      <div style="font-style: italic; font-weight: bold;">Plasma Center Operating Expenses</div>

      <div style="font-style: italic; font-weight: bold;"> <br />
      </div>

      <div style="text-indent: 36pt;">Plasma center operating expenses were $2.8 million for the three months ended June 30, 2021, as compared to $0.9 million for the three months ended June 30, 2020. Plasma center operating expenses consist of certain
        general and administrative plasma center costs, including rent, maintenance, utilities, compensation and benefits for center and administrative staff, advertising and promotion expenses and computer software fees related to donor collections. The
        increase in plasma center operating expenses is mainly attributable to increased staffing and travel expenses related to our plasma center expansion activities. We had four plasma collection centers in operation during the second quarter of 2021,
        as compared to one plasma collection center in operation during the second quarter of 2020. We also had four other plasma collection centers in various stages of construction or development during the second quarter of 2021.</div>

      <div><br />
      </div>

      <div style="font-style: italic; font-weight: bold;">Amortization of Intangibles</div>

      <div style="font-style: italic; font-weight: bold;"> <br />
      </div>

      <div style="text-indent: 36pt;">Amortization expense pertains to the amortization of intangible assets acquired in the Biotest Transaction and was $0.2 million for the three months ended June 30, 2021 and 2020.</div>

      <div><br />
      </div>

      <div style="font-style: italic; font-weight: bold;">Selling, General and Administrative Expenses</div>

      <div style="font-style: italic; font-weight: bold;"> <br />
      </div>

      <div style="text-indent: 36pt;">Selling, general and administrative (&#8220;SG&amp;A&#8221;) expenses were $10.4 million for the three months ended June 30, 2021, an increase of $1.7 million from the three months ended June 30, 2020. The increase was primarily
        due to higher employee compensation and related expenses of $1.2 million related to staffing increases, largely in support of our commercialization efforts for BIVIGAM and ASCENIV and increased insurance expense of $0.3 million. In addition, in
        connection with the resignation of our former Chief Medical Officer in the second quarter of 2021, we recognized an expense and corresponding liability in the amount of $0.8 million for estimated payments we expect to make under a separation and
        transition agreement. These increases were partially offset by lower third-party market intelligence and consulting fees associated with our ASCENIV commercialization efforts.</div>

      <div><br />
      </div>

      <div style="font-style: italic; font-weight: bold;">Loss from Operations</div>

      <div style="font-style: italic; font-weight: bold;"> <br />
      </div>

      <div style="text-indent: 36pt;">Our operating loss was $15.6 million for the second quarter of 2021, as compared to $17.1 million for the second quarter of 2020. The $1.5 million decrease in operating loss was mainly due to the significant narrowing
        of our gross loss of $4.7 million and the reduction in R&amp;D expenses, partially offset by the increases in SG&amp;A and plasma center operating expenses.</div>

      <div><br />
      </div>

      <div style="font-style: italic; font-weight: bold;">Interest Expense</div>

      <div style="font-style: italic; font-weight: bold;"> <br />
      </div>

      <div style="text-indent: 36pt;">Interest expense increased by approximately $0.2 million for the three months ended June 30, 2021 as compared to the same period of a year ago. The increase reflects the refinancing of $15 million of subordinated debt
        in December 2020 whereby the interest rate increased from 6% to 11% per annum, as the maturity date on this indebtedness was extended from June 2022 to March 2024 (see &#8220;Liquidity and Capital Resources&#8221;).</div>

      <div><br />
      </div>

      <div style="font-style: italic; font-weight: bold;">Net Loss</div>

      <div style="font-style: italic; font-weight: bold;"> <br />
      </div>

      <div style="text-indent: 36pt;">Our net loss was $18.9 million for the three months ended June 30, 2021, as compared to $20.2 million for the three months ended June 30, 2020.&#160; The $1.3 million decrease in net loss was primarily due to the decreased
        operating loss for the quarter of $1.5 million, partially offset by the increase in interest expense.</div>

      <div><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">31</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div style="text-align: justify; font-weight: bold;">Six Months Ended June 30, 2021 Compared to Six Months Ended June 30, 2020</div>

      <div style="text-align: justify; font-weight: bold;"> <br />
      </div>

      <div style="text-align: justify; text-indent: 36pt;">The following table presents a summary of the changes in our results of operations for the six months ended June 30, 2021, compared to the six months ended June 30, 2020:</div>

      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1"><br />
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="10">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Six Months Ended June 30,</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> 2021</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2020</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Increase </div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(Decrease)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Revenues</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">33,879,208</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">17,987,338</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">15,891,870</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Cost of product revenue (exclusive of amortization expense shown below)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">36,602,746</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">30,324,855</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">6,277,891</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Gross loss</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(2,723,538</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(12,337,517</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">9,613,979</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Research and development expenses</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">2,146,515</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">3,185,158</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(1,038,643</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Plasma center operating expenses</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">5,045,669</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">1,378,546</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">3,667,123</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Amortization of intangibles</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">357,676</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">357,676</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Selling, general and administrative expenses</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">20,472,083</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">16,634,714</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">3,837,369</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Loss from operations</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(30,745,481</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(33,893,611</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">3,148,130</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Interest expense</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(6,442,430</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(5,784,397</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(658,033</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Other (expense) income, net</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(97,333</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">254,687</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(352,020</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Net loss</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(37,285,244</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(39,423,321</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">2,138,077</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="font-style: italic; font-weight: bold;">Revenues</div>

      <div style="font-style: italic; font-weight: bold;"> <br />
      </div>

      <div style="text-indent: 36pt;">We recorded total revenues of $33.9 million during the six months ended June 30, 2021, as compared to $18.0 million during the six months ended June 30, 2020, an increase of $15.9 million, or approximately 88%. The
        increase is due to increased sales of our immunoglobulin products generated by our Boca Facility manufacturing operations in 2021, largely driven by the expansion of our customer base at both of our business segments that took place subsequent to
        June 30, 2020.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">Our revenues for the first six months of 2021 as compared to the same period of a year ago were favorably impacted by the continued commercial scale-up and increasing physician/payer acceptance of BIVIGAM and ASCENIV
        following these products&#8217; FDA approvals on May 9, 2019 and April 1, 2019, respectively, while we also continued to benefit from the manufacturing and supply agreement we entered into in January 2020 to produce and sell intermediate fractions to a
        certain customer. Revenues in the first six months of 2021 were also favorably impacted by the approvals we received from the FDA to implement a Hepatitis B immunization program at one of our FDA-approved plasma collection centers and from MFDS for
        the sale of source plasma into South Korea.</div>

      <div style="text-indent: 36pt;"> <br />
      </div>

      <div style="font-style: italic; font-weight: bold;">Cost of Product Revenue</div>

      <div style="font-style: italic; font-weight: bold;"> <br />
      </div>

      <div style="text-indent: 36pt;">Cost of product revenue was $36.6 million for the six months ended June 30, 2021, as compared to $30.3 million for the six months ended June 30, 2020. This increase reflects higher product revenue costs in 2021 of
        $13.6 million corresponding to the increase in immunoglobulin revenues, partially offset by the absence of conformance batch production expenses in 2020 of $7.3 million. The lack of such expenses in 2021, combined with the increase in revenues,
        resulted in a reduction of our gross loss in the amount of $9.6 million, or 78%, in the first half of 2021 as compared to the first half of 2020.</div>

      <div><br />
      </div>

      <div style="font-style: italic; font-weight: bold;">Research and Development Expenses</div>

      <div style="font-style: italic; font-weight: bold;"> <br />
      </div>

      <div style="text-indent: 36pt;">R&amp;D expenses totaled $2.1 million for the six months ended June 30, 2021, as compared to $3.2 million for the six months ended June 30, 2020. R&amp;D expenses in 2020 included non-recurring charges of $0.4 million
        related to <span style="color: rgb(0, 0, 0);">a study we conducted to potentially extend ASCENIV&#8217;s approved and labeled expiration dating, and $0.2 million related to our participation in a third-party clinical research project. We also
          experienced a reduction in R&amp;D related compensation expenses due to the resignation of our former Chief Medical Officer on June 8, 2021.</span></div>

      <div><br />
      </div>

      <div style="font-style: italic; font-weight: bold;">Plasma Center Operating Expenses</div>

      <div style="font-style: italic; font-weight: bold;"> <br />
      </div>

      <div style="text-indent: 36pt;">Plasma center operating expenses were $5.0 million for the six months ended June 30, 2021, as compared to $1.4 million for the six months ended June 30, 2020. The increase in plasma center operating expenses is mainly
        attributable to increased staffing and related expenses, including travel expenses, of $2.3 million, as well as increases in rent expense of $0.4 million, depreciation expense of $0.3 million, donor fees of $0.2 million, advertising expenses of
        $0.1 million and utilities of $0.1 million, all related to our plasma center expansion activities.</div>

      <div><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">32</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div style="font-style: italic; font-weight: bold;">Amortization of Intangibles</div>

      <div style="font-style: italic; font-weight: bold;"> <br />
      </div>

      <div style="text-indent: 36pt;">Amortization expense pertains to the amortization of intangible assets acquired in the Biotest Transaction and was $0.4 million for the six months ended June 30, 2021 and 2020.</div>

      <div><br />
      </div>

      <div style="font-style: italic; font-weight: bold;">Selling, General and Administrative Expenses</div>

      <div style="font-style: italic; font-weight: bold;"> <br />
      </div>

      <div style="text-indent: 36pt;">SG&amp;A expenses were $20.5 million for the six months ended June 30, 2021, an increase of $3.8 million from the six months ended June 30, 2020. The increase was primarily due to higher employee compensation and
        related expenses of $2.2 million related to staffing increases, largely in support of our commercialization efforts for BIVIGAM and ASCENIV, recognition of the $0.8 million related to the separation and transition agreement with our former Chief
        Medical Officer and $0.7 million of increased insurance expense.</div>

      <div><br />
      </div>

      <div style="font-style: italic; font-weight: bold;">Loss from Operations</div>

      <div style="font-style: italic; font-weight: bold;"> <br />
      </div>

      <div style="text-indent: 36pt;">Our operating loss was $30.7 million for the first six months of 2021, as compared to $33.9 million for the first six months of 2020. The $3.1 million decrease in operating loss was mainly due to the increase in
        revenues and corresponding reduction in gross loss and decrease in R&amp;D expenses, partially offset by the increases in SG&amp;A and plasma center operating expenses.</div>

      <div><br />
      </div>

      <div style="font-style: italic; font-weight: bold;">Interest Expense</div>

      <div style="font-style: italic; font-weight: bold;"> <br />
      </div>

      <div style="text-indent: 36pt;">Interest expense was $6.4 million for the six months ended June 30, 2021, as compared to $5.8 million for the six months ended June 30, 2020. The increase reflects the additional interest expense associated with the
        Perceptive Tranche III Loan which we drew down on March 20, 2020, as well as the higher interest on the $15 million note formerly due to Biotest that we refinanced in December 2020 (see &#8220;Liquidity and Capital Resources&#8221;).</div>

      <div><br />
      </div>

      <div style="font-style: italic; font-weight: bold;">Net Loss</div>

      <div style="font-style: italic; font-weight: bold;"> <br />
      </div>

      <div style="text-indent: 36pt;">Our net loss was $37.3 million for the six months ended June 30, 2021, as compared to $39.4 million for the six months ended June 30, 2020.&#160; The decrease in net loss of $2.1 million was primarily due to the decreased
        operating loss for the quarter of $3.1 million, the increase in interest expense of $0.7 million, and the decrease in interest income of $0.2 million due to the reduction of interest rates that took place during the first quarter of 2020.</div>

      <div><br />
      </div>

      <div style="text-align: center; font-weight: bold;"><span style="text-decoration: underline;">LIQUIDITY AND CAPITAL RESOURCES</span></div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">As of June 30, 2021, we had working capital of $153.2 million, including cash and cash equivalents of $42.4 million, and stockholders&#8217; equity of $111.6 million, as compared to working capital of $133.8 million,
        including cash and cash equivalents of $55.9 million, and stockholders&#8217; equity of $88.2 million as of December 31, 2020. We have incurred an accumulated deficit of $377.8 million since inception, had negative cash flows from operations of $65.5
        million and $45.9 million for the six months ended June 30, 2021 and 2020, respectively, and negative cash flows from operations of $102.0 million and $76.2 million for the years ended December 31, 2020 and 2019, respectively. We have funded our
        operations over the past few years primarily from the sale of our equity and debt securities.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">We expect to continue to spend substantial amounts on procurement of raw material plasma and other raw materials necessary to scale up our manufacturing operations, commercial product launches, capacity expansion at
        the Boca Facility, building additional plasma collection facilities, product development, quality assurance, regulatory affairs and conducting clinical trials for our product candidates and purchasing clinical trial materials, some of which may be
        required by the FDA. In addition, our end-to-end production cycle from procurement of raw materials to commercial release of finished product can take between seven and 12 months or potentially longer, requiring substantial investments in raw
        material plasma and other manufacturing materials. We expect that we will not be able to generate a sufficient amount of product revenue to achieve profitability until the beginning of 2024 and, as a result, we expect that we will need to continue
        to finance our operations through additional equity or debt financings or through corporate collaboration and licensing arrangements. Based upon our projected revenues and projected expenditures, including capital expenditures and continued
        implementation of our commercialization and expansion activities, we currently believe that our cash, cash equivalents, projected revenue and accounts receivable will be sufficient to fund our operations, as currently conducted, into the fourth
        quarter of 2021. In order to have sufficient cash to fund our operations thereafter, we will need to raise additional capital before the end of the fourth quarter of 2021. These estimates and timeframes may change based upon several factors,
        including the success of our commercial manufacturing ramp-up activities, the acceptability and reimbursement of BIVIGAM and ASCENIV by physicians, patients or payers, and the various financing options that may be available to us. We currently have
        no firm commitments for additional financing, and there can be no assurances that we will be able to secure additional financing on terms that are acceptable to us, or at all. Furthermore, if our assumptions underlying our estimated expenses and
        revenues are incorrect, we may have to raise additional capital sooner than currently anticipated.</div>

      <div><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">33</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div style="text-indent: 36pt;">On May 28, 2021, we entered into an Open Market Sale Agreement<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">SM</sup> (the &#8220;2021 Sale Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;), pursuant
        to which we may offer and sell, from time to time, at our option, through or to Jefferies, up to an aggregate of $50,000,000 of shares of our common stock. We intend to use the net proceeds from any offering under the 2021 Sale Agreement for
        general corporate purposes, including procurement of raw materials, source plasma, supply chain initiatives and production expenditures, funding expansion of plasma centers, working capital, capital expenditures, expansion and resources for
        commercialization activities, and other potential research and development and business opportunities. We may decide to utilize the 2021 Sale Agreement from time to time in order to supplement our cash resources and fund our operations beyond the
        fourth quarter of 2021. As of the date of this report, there have been no sales of common stock under the 2021 Sale Agreement.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">Our long-term liquidity depends upon our ability to raise additional capital, fund capacity expansion and commercial programs and generate sufficient revenues from our products, several of which have only recently
        achieved commercial status, to cover our operating expenses and meet our obligations on a timely basis. The COVID-19 pandemic has negatively affected the global economy and created significant volatility and disruption to the financial markets.
        Failure to secure any necessary financing in a timely manner and on commercially reasonable terms could have a material adverse effect on our business plan and financial performance and we could be forced to delay or discontinue our capacity
        expansion, commercialization, product development or clinical trial activities, delay or discontinue the approval efforts for any of our product candidates, or potentially cease operations. In addition, we could also be forced to reduce or forgo
        sales and marketing efforts and forgo attractive business opportunities.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">Due to numerous risks and uncertainties associated with the COVID-19 pandemic, FDA reviews, inspections and approvals related to our products and processes, patient/payer acceptance of our products, ongoing compliance
        and maintenance requirements and capacity expansion efforts at the Boca Facility, we are unable to estimate with certainty the amounts of increased capital outlays and operating expenditures required to fund our commercialization and other
        development activities. Our current estimates may be subject to change as circumstances regarding our business requirements evolve and are also subject to the effect of potential new government orders, policies and procedures that we must comply
        with which are outside of our control.&#160; As such, these factors raise substantial doubt about our ability to continue as a going concern.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">We may decide to raise capital through public or private equity offerings or debt financings, obtain a bank credit facility or enter into corporate collaboration and licensing arrangements. The sale of additional
        equity or debt securities, if convertible, could result in dilution to our stockholders and, in such event, the market value of our common stock may decline. The incurrence of additional indebtedness would result in increased fixed obligations and
        could also result in covenants that would restrict our operations or other financing alternatives. In addition, we are exploring additional contract manufacturing arrangements and other business development opportunities, which may provide
        additional liquidity to us. We are also considering alternative business opportunities to maximize stockholder value including, for example, the acquisition or sale of specific assets or businesses, collaboration and/or license agreements or
        co-development agreements.</div>

      <div><br />
      </div>

      <div style="text-indent: 31.5pt;">On August 5, 2020, we entered into an Open Market Sale Agreement (the &#8220;2020 Sale Agreement&#8221;) with Jefferies, pursuant to which we could offer and sell, from time to time, at our option, through or to Jefferies, up to
        an aggregate of $50 million of shares of our common stock. On November 5, 2020 and February 3, 2021, we and Jefferies entered into amendments to the 2020 Sale Agreement (as amended, the &#8220;Amended 2020 Sale Agreement&#8221;) to provide for an increase in
        the aggregate offering amount under the Amended 2020 Sale Agreement, such that, as of February 3, 2021, we could sell shares having a gross aggregate offering price of up to $105.4 million.</div>

      <div><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">34</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div style="text-indent: 36pt;">For the year ended December 31, 2020, we sold 18,537,907 shares of our common stock under the Amended 2020 Sale Agreement and received net proceeds in the amount of $42.5 million.&#160; During the six months ended June 30,
        2021, we sold an additional 26,907,753 shares of our common stock and received net proceeds of $59.1 million, and during July of 2021 we sold an additional 897,445 shares of our common stock under the Amended 2020 Sale Agreement and received net
        proceeds of approximately $1.5 million. As of the date of this report, we cannot raise any additional funds under the Amended 2020 Sale Agreement. The<span style="color: rgb(0, 0, 0);"> net proceeds from this offering were or are being used for
          general corporate purposes, which may include (i) the procurement of raw materials for the manufacturing of BIVIGAM and ASCENIV; (ii) supporting the ongoing commercial sales of our IVIG products; (iii) expanding the manufacturing capacity of our
          Boca Facility, including supply chain functions, and enhancing the robustness of our supply chain oversight; (iv) expanding our plasma collection facility network; and (v) research and development and business development opportunities. </span></div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">On February 11, 2019 (the &#8220;Perceptive Closing Date&#8221;), we and all of our subsidiaries entered into a Credit Agreement and Guaranty (the &#8220;Perceptive Credit Agreement&#8221;) with Perceptive Credit Holdings II, LP, as the
        lender and administrative agent (&#8220;Perceptive&#8221;). The Perceptive Credit Agreement, as amended, provides for a senior secured term loan facility in a principal amount of $100.0 million (the &#8220;Perceptive Credit Facility&#8221;), comprised of (i) a term loan
        made on the Perceptive Closing Date in the principal amount of $45.0 million, as evidenced by the Company&#8217;s issuance of a promissory note (the &#8220;Perceptive Tranche I Note&#8221;) in favor of Perceptive on the Perceptive Closing Date (the &#8220;Perceptive
        Tranche I Loan&#8221;), (ii) a term loan in the principal amount of $27.5 million (the &#8220;Perceptive Tranche II Loan&#8221;) evidenced by the Company&#8217;s issuance of a promissory note (the &#8220;Perceptive Tranche II Note&#8221;) in favor of Perceptive on May 3, 2019, (iii)
        a term loan in the principal amount of $12.5 million evidenced by the Company&#8217;s issuance of a promissory note (the &#8220;Perceptive Tranche III Note&#8221;) in favor of Perceptive on March 20, 2020 (the &#8220;Perceptive Tranche III Loan&#8221;); and (iv) a term loan in
        the principal amount of $15 million evidenced by our issuance of a promissory note in favor of Perceptive on December 8, 2020 (the &#8220;Perceptive Tranche IV Loan&#8221;, and together with the Perceptive Tranche I Loan, the Perceptive Tranche II Loan and the
        Perceptive Tranche III Loan, the &#8220;Perceptive Loans&#8221;). The Perceptive Tranche III Loan is the result of an amendment to the Perceptive Credit Agreement that the Company and Perceptive entered into on May 3, 2019 (the &#8220;First Perceptive Amendment&#8221;),
        and the Perceptive Tranche III Loan became available to the Company upon the approval of BIVIGAM on May 9, 2019. The Perceptive Tranche IV Loan is the result of an amendment to the Perceptive Credit Facility entered into on December 8, 2020 (the
        &#8220;Second Perceptive Amendment&#8221;), which also extended the maturity date of the Perceptive Credit Facility to March 1, 2024 (the &#8220;Maturity Date&#8221;), subject to acceleration pursuant to the Perceptive Credit Agreement, including upon an Event of Default
        (as defined in the Perceptive Credit Agreement).</div>

      <div><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>

      <div style="text-indent: 36pt;">The proceeds from the Perceptive Tranche IV Loan were used to retire the $15.0 million subordinated note we had payable to Biotest, which had a maturity date of June 17, 2022.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">Borrowings under the Perceptive Credit Agreement bear interest at a rate per annum equal to 7.5% plus the greater of (i) one-month LIBOR and (ii) 3.5%; provided, however, that upon, and during the continuance of, an
        Event of Default, the interest rate will automatically increase by an additional 400 basis points. Accrued interest of approximately $0.9 million per month is payable to Perceptive on the last day of each month during the term of the Perceptive
        Credit Facility.&#160; The rate of interest in effect as of the Perceptive Closing Date and at June 30, 2021 was 11.0%.</div>

      <div><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>

      <div style="text-indent: 36pt;">On the Maturity Date, we are required to pay Perceptive the entire outstanding principal amount underlying the Perceptive Loans and any accrued and unpaid interest thereon. There are no scheduled principal payments on
        the Perceptive Loans prior to the Maturity Date. We may prepay outstanding principal on the Perceptive Loans at any time and from time to time upon three business days&#8217; prior written notice, subject to the payment to Perceptive of (A) any accrued
        but unpaid interest on the prepaid principal amount plus (B) a redemption premium amount equal to (i) 5.0% of the prepaid principal amount, if prepaid on or prior to December 31, 2021, (ii) 2.0% of the prepaid principal amount, if prepaid after
        December 31, 2021 and on or prior to December 31, 2022, (iii) 4.0% of the prepaid principal amount, if prepaid after December 31, 2022 and on or prior to December 31, 2023, and (iv) 5.0% of the prepaid principal amount, if prepaid any time
        thereafter and prior to the Maturity Date.</div>

      <div><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">35</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div style="text-indent: 36pt;">All of our obligations under the Perceptive Credit Agreement are secured by a first-priority lien and security interest in substantially all of our tangible and intangible assets, including intellectual property and
        all of the equity interests in our subsidiaries. The Perceptive Credit Agreement contains certain representations and warranties, affirmative covenants, negative covenants and conditions that are customarily required for similar financings. The
        negative covenants restrict or limit our ability and that of our subsidiaries to, among other things and subject to certain exceptions contained in the Perceptive Credit Agreement, incur new indebtedness; create liens on assets; engage in certain
        fundamental corporate changes, such as mergers or acquisitions, or changes to our or our subsidiaries&#8217; business activities; make certain Investments or Restricted Payments (each as defined in the Perceptive Credit Agreement); change our fiscal
        year; pay dividends; repay other certain indebtedness; engage in certain affiliate transactions; or enter into, amend or terminate any other agreements that have the impact of restricting our ability to make loan repayments under the Perceptive
        Credit Agreement. In addition, we must (i) at all times prior to the Maturity Date maintain a minimum cash balance of $3.0 million; and (ii) as of the last day of each fiscal quarter commencing with the fiscal quarter ended June 30, 2019, report
        revenues for the trailing 12-month period that exceed the amounts set forth in the Perceptive Credit Agreement, which range from $37.3 million for the fiscal quarter ended June 30, 2021 to $55.0 million for the fiscal quarter ending December 31,
        2021. At June 30, 2021, we were in compliance with all of the covenants contained in the Perceptive Credit Agreement.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">In February 2020, we completed an underwritten public offering of 27,025,000 shares of our common stock and received net proceeds, after underwriting discounts and other expenses associated with the offering, of
        approximately $88.7 million. The proceeds from this offering were used (i) for the procurement of raw materials for the manufacturing of BIVIGAM and ASCENIV; (ii) to support the ongoing commercial sales of BIVIGAM and ASCENIV; (iii) to expand the
        manufacturing capacity of our Boca Facility and enhance our supply chain capabilities; (iv) to expand our plasma collection facility network; (v) for research and development and business development opportunities; and (vi) for general corporate
        purposes and other capital expenditures.</div>

      <div><br />
      </div>

      <div style="font-weight: bold;">Cash Flows</div>

      <div style="font-weight: bold;"> <br />
      </div>

      <div style="text-indent: 36pt;">The following table sets forth a summary of our cash flows for the periods indicated:&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="6">
              <div style="text-align: center; font-weight: bold;">Six Months Ended June 30,</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; font-weight: bold;"> 2021</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; font-weight: bold;">2020</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Net cash used in operating activities</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(65,491,363</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(45,931,435</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Net cash used in investing activities</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div>(7,046,735</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div>(6,241,284</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Net cash provided by financing activities</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>59,025,904</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>101,201,706</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Net change in cash and cash equivalents</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div>(13,512,194</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div>49,028,987</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Cash and cash equivalents - beginning of period</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
              <div>55,921,152</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
              <div>26,752,135</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Cash and cash equivalents - end of period</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>42,408,958</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>75,781,122</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="font-style: italic; font-weight: bold;">Net Cash Used in Operating Activities</div>

      <div style="font-style: italic; font-weight: bold;"> <br />
      </div>

      <div style="text-indent: 36pt;">Cash used in operations for the six months ended June 30, 2021 was $65.5 million, an increase of $19.6 million from the same period of a year ago, mainly due to an increases in inventory and accounts receivable. The
        following table illustrates the primary components of our cash flows from operations:</div>

      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="6">
              <div style="text-align: center; font-weight: bold;">Six Months Ended June 30,</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; font-weight: bold;"> 2021</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; font-weight: bold;">2020</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Net loss</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(37,285,244</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(39,423,321</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Non-cash expenses, gains and losses</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div>5,057,077</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div>3,873,479</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Changes in accounts receivable</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(10,307,304</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(3,044,246</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Changes in inventories</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div>(18,164,144</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div>(2,936,614</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Changes in prepaid expenses and other current assets</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(2,655,397</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(2,159,834</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Changes in accounts payable and accrued expenses</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div>(1,925,710</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div>(1,865,637</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Other</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
              <div>(210,641</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
              <div>(375,262</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Cash used in operations</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div>(65,491,363</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div>(45,931,435</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">36</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div style="font-style: italic; font-weight: bold;">Net Cash Used in Investing Activities</div>

      <div style="font-style: italic; font-weight: bold;"> <br />
      </div>

      <div style="text-indent: 36pt;">Net cash used in investing activities for the six months ending June 30, 2021 was $7.0 million, which primarily consisted of $4.3 million for the construction and buildout of new plasma centers and related equipment
        and capital expenditures at the Boca Facility of $2.7 million, which includes equipment purchases and implementation of our in-house fill/finish capabilities. Cash used in investing activities of $6.2 million for the six months ended June 30, 2020
        was mainly attributable to capital expenditures at the Boca Facility. Although we have no specific material commitments for capital expenditures as of June 30, 2021, we expect our total capital expenditures will be between $6.0 million and $12.0
        million for the remainder of fiscal 2021.</div>

      <div><br />
      </div>

      <div style="font-style: italic; font-weight: bold;">Net Cash Provided by Financing Activities</div>

      <div style="font-style: italic; font-weight: bold;"> <br />
      </div>

      <div style="text-indent: 36pt;">Cash provided by financing activities was $59.0 million for the six months ended June 30, 2021 and primarily consisted of proceeds received from the Amended Sale Agreement.&#160; Cash provided by financing activities of
        $101.2 million for the same period of a year ago was comprised of $88.7 million of net proceeds received from our underwritten public offering in February 2020 and $12.5 million of proceeds from the Perceptive Tranche III Loan received in March
        2020.</div>

      <div><br />
      </div>

      <div style="color: rgb(0, 0, 0); font-weight: bold;">Effect of Inflation</div>

      <div style="color: rgb(0, 0, 0); font-weight: bold;"> <br />
      </div>

      <div style="text-indent: 36pt; color: rgb(0, 0, 0);">Inflation or changing prices did not have a significant impact on our net revenues, operating expenses or net loss for the six months ended June 30, 2021 or in 2020 or 2019.</div>

      <div><br />
      </div>

      <div style="font-weight: bold;">Off-Balance Sheet Arrangements</div>

      <div style="font-weight: bold;"> <br />
      </div>

      <div style="text-indent: 36pt; color: rgb(0, 0, 0);">None.</div>

      <div style="text-indent: -72pt; margin-left: 72pt;"><br />
      </div>

      <a id="QuantitativeandQualitativ"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 45pt; vertical-align: top; font-weight: bold;">Item 3.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Quantitative and Qualitative Disclosures About Market Risk.</div>
            </td>

  </tr>


</table>
      <div style="text-indent: 36pt;"> <br />
      </div>

      <div style="text-indent: 36pt;">Not applicable.</div>

      <div><br />
      </div>

      <a id="ControlsandProcedures."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 45pt; vertical-align: top;"><span style="font-weight: bold;">Item 4.</span></td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Controls and Procedures.</div>
            </td>

  </tr>


</table>
      <div style="font-weight: bold;"> <br />
      </div>

      <div style="font-weight: bold;">Evaluation of Disclosure Controls and Procedures</div>

      <div style="text-indent: 36pt;"><br />
      </div>

      <div style="text-indent: 36pt;">We designed our disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;), to provide reasonable assurance
        that information required to be disclosed by us in reports we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission&#8217;s (the &#8220;SEC&#8221;)
        rules and forms, and (ii) accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosures.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt; color: rgb(0, 0, 0);">Under the supervision of and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of our disclosure
        controls and procedures as of June 30, 2021. Based on this evaluation, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures as of June 30, 2021 were functioning effectively to
        provide reasonable assurance that the information required to be disclosed by us in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and (ii)
        accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding disclosures.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;"><span style="color: rgb(0, 0, 0);">A control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control system are met, and no evaluation of controls can
          provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.</span>&#160;<span style="color: rgb(0, 0, 0);">&#160;</span>We do not expect that our disclosure controls and procedures or our internal
        control over financial reporting are able to prevent with certainty all errors and all fraud.</div>

      <div><br />
      </div>

      <div style="font-weight: bold;">Changes in Internal Control Over Financial Reporting</div>

      <div style="font-weight: bold;"> <br />
      </div>

      <div style="text-indent: 36pt;">There have been no changes in our internal control over financial reporting during the quarter ended June 30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over
        financial reporting.</div>

      <div style="text-indent: 36pt;"> <br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">37</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div style="text-align: center; font-weight: bold;"><a id="PARTII"><!--Anchor--></a>PART II</div>

      <div style="text-align: center; font-weight: bold;">OTHER INFORMATION</div>

      <div style="text-align: center; font-weight: bold;"> <br />
      </div>

      <a id="Item1."><!--Anchor--></a>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 45pt; vertical-align: top; font-weight: bold;">Item 1.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Legal Proceedings.</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="text-indent: 36pt;">We may become subject to certain legal proceedings and claims arising in connection with the normal course of our business. In the opinion of management, there are currently no material pending legal proceedings that
        would have a material adverse effect on our consolidated financial position, results of operations or cash flows.</div>

      <div><br />
      </div>

      <a id="Item1A."><!--Anchor--></a>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 45pt; vertical-align: top; font-weight: bold;">Item 1A.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Risk Factors</div>
            </td>

  </tr>


</table>
      <div><span style="font-weight: bold;"> </span><br />
      </div>

      <div style="font-weight: bold;">Summary of Risk Factors</div>

      <div><br />
      </div>

      <div style="font-style: italic;">Below is a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized
        in this risk factor summary, and other risks that we face, can be found below under the heading &#8220;Risk Factors&#8221; and should be carefully considered, together with other information in this Form 10-K and our other filings with the SEC, before making
        an investment decision regarding our common stock.</div>

      <div style="font-style: italic;"> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>To date, we have generated limited product revenues, have a history of losses and will need to raise additional capital to operate our business, which may not be available on favorable terms, if at all.</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>Our auditor&#8217;s report contains a going concern statement.</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>We are currently not profitable and may never become profitable.</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>The COVID-19 pandemic and efforts to reduce its spread has significantly affected worldwide economic conditions, and could have a material adverse impact on our business, liquidity, financial condition and results of operations, as well
                as a change to the overall market size and potential for our products.</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>We contract with third parties for the filling, packaging, testing and labeling of the drug substance we manufacture. This reliance on third parties carries the risk that the services upon which we rely may not be performed in a timely
                manner or according to our specifications, which could delay the availability of our finished drug product and could adversely affect our commercialization efforts and our revenues.</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>The estimates of market opportunity and forecasts of market and revenue growth included in our filings may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business could fail to grow
                at similar rates, if at all.</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>Both of our business segments and our facilities are subject to periodic inspections by the FDA, which, depending on the outcome of such inspection, could result in certain FDA actions, including the issuance of observations, notices,
                citations or warning letters.</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>Business interruptions could adversely affect our business.</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>If we are unsuccessful in obtaining regulatory approval for any of our product candidates or if any of our product candidates do not provide positive results, we may be required to delay or abandon development of such product, which
                would have a material adverse impact on our business.</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>If the results of our clinical trials do not support our product candidate claims, completing the development of such product candidate may be significantly delayed or we may be forced to abandon development of such product candidate
                altogether.</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>If we do not obtain and maintain the necessary U.S. or international regulatory approvals to commercialize a product candidate, we will not be able to sell that product candidate, which would make it difficult for us to recover the costs
                of researching and developing such product candidate.</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>Although we have received approval from the FDA to market ASCENIV as a treatment for PIDD, our ability to market or seek approval for ASCENIV for alternative indications could be limited and FDA could require clinical trials beyond what
                we may deem to be reasonable. Unless additional clinical trials are successfully conducted and the FDA approves a BLA or other required submission for review, we may not be authorized to market ASCENIV for any other indication.</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">38</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>With the approval to market ASCENIV, BIVIGAM and Nabi-HB, there can be no assurance that we will be successful in developing and expanding commercial operations or balancing our research and development activities with our
                commercialization activities.</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>We depend on third-party researchers, developers and vendors to develop, manufacture, supply materials or test products and product candidates, and such parties are outside of our control.</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>We may be unable to successfully expand our manufacturing processes to fulfill demand for our products or increase our production capabilities through the addition of new equipment, including if we do not obtain requisite approval from
                the FDA.</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>Our products, and any additional products for which we may obtain marketing approval in the future, could be subject to post-marketing restrictions or withdrawal from the market and we could be subject to substantial penalties if we fail
                to comply with regulatory requirements or if we experience unanticipated problems with our products following approval.</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>Historically, a few customers have accounted for a significant amount of our total revenue and accounts receivable and the loss of any of these customers could have a material adverse effect on our business, results of operations and
                financial condition.</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>Issues with product quality and compliance could have a material adverse effect upon our business, subject us to regulatory actions and cause a loss of customer confidence in us or our products.</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>If physicians, payers and patients do not accept and use our current products or our future product candidates, our ability to generate revenue from these products will be materially impaired.</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>Our long-term success may depend on our ability to supplement our existing product portfolio through new product development or the in-license or acquisition of other new products, product candidates and label expansion of existing
                products, and if our business development efforts are not successful, our ability to achieve profitability may be adversely impacted.</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>Our ADMA BioCenters operations collect information from donors in the U.S. that subjects us to consumer and health privacy laws, which could create enforcement and litigation exposure if we fail to meet their requirements.</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>The Perceptive Credit Facility is subject to acceleration in specified circumstances, which may result in Perceptive taking possession and disposing of any collateral.</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>If we are unable to protect our patents, trade secrets or other proprietary rights, if our patents are challenged or if our provisional patent applications do not get approved, our competitiveness and business prospects may be materially
                damaged.</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>Cyberattacks and other security breaches could compromise our proprietary and confidential information, which could harm our business and reputation.</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>Our ability to continue to produce safe and effective products depends on the safety of our plasma supply, testing by third parties and the timing of receiving the testing results, and manufacturing processes against transmittable
                diseases.</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>We could become supply-constrained and our financial performance would suffer if we cannot obtain adequate quantities of FDA-approved source plasma with proper specifications or other necessary raw materials.</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>We require additional funding and may be unable to raise capital in the future, which would force us to delay, curtail or eliminate one or more of our research and development programs or potentially modify our ongoing operations,
                commercialization efforts and expansion plans, as well as impact the overall business plan for the organization.</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>The market price of our common stock may be volatile and may fluctuate in a way that is disproportionate to our operating performance.</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">39</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div style="font-weight: bold;">Risk Factors</div>

      <div style="font-weight: bold;"> <br />
      </div>

      <div style="font-style: italic;">Described below are various risks and uncertainties that may affect our business. These risks and uncertainties are not the only ones we face. You should recognize that other significant risks and uncertainties may
        arise in the future, which we cannot foresee at this time. Also, the risks that we now foresee might affect us to a greater or different degree than expected. Certain risks and uncertainties, including ones that we currently deem immaterial or that
        are similar to those faced by other companies in our industry or business in general, may also affect our business. If any of the risks described below actually occur, our business, financial condition or results of operations could be materially
        and adversely affected. You should carefully consider the following risk factors and the section entitled &#8220;Special Note Regarding Forward-Looking Statements&#8221; before you decide to invest in our securities.</div>

      <div> <br />
      </div>

      <div style="font-weight: bold;">Risks Relating to our Business</div>

      <div style="font-weight: bold;"> <br />
      </div>

      <div style="font-style: italic; font-weight: bold;">To date, we have generated limited product revenues, have a history of losses and will need to raise additional capital to operate our business, which may not be available on favorable terms, if at
        all.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">Our long-term liquidity depends upon our ability to grow our commercial programs, expand our commercial operations at the Boca Facility, improve our supply-chain capabilities, improve production yields, provide more
        control and visibility for timing of commercial product releases, raise additional capital, fund and successfully implement our research and development and commercial programs, establish and build out a commercial sales force, medical affairs
        organization and commercial infrastructure and meet our ongoing obligations. In addition, our end-to-end production cycle from procurement of raw materials to commercial release of finished product can take between seven and 12 months or
        potentially longer, requiring substantial investments in raw material plasma and other manufacturing materials.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">We currently anticipate, based upon our projected revenue and expenditures, that our current cash, cash equivalents and accounts receivable will be sufficient to fund our operations into the fourth quarter of 2021.
        This time frame may change based upon how quickly we are able to execute on our commercialization efforts and operational initiatives. However, if the assumptions underlying our estimated revenues and expenses prove to be incorrect, we may have to
        raise additional capital sooner than we currently expect. We anticipate that we will not be able to generate a sufficient amount of product revenue to achieve profitability until the beginning of 2024 and, as a result, we anticipate that we will
        need to continue to finance our operations through additional equity or debt financings or corporate collaboration and licensing arrangements. If we are unable to raise additional capital as needed, we will have to delay, curtail or eliminate our
        commercialization efforts as well as product development activities. Even if we are able to raise additional capital, such financings may only be available on unattractive terms, resulting in significant dilution of stockholders&#8217; interests and, in
        such event, the value and potential future market price of our common stock may decline. In addition, if we raise additional funds through license arrangements or through the disposition of any of our assets, it may be necessary to relinquish
        potentially valuable rights to our product candidates or assets or grant licenses on terms that are not favorable to us.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">In addition, the auditor&#8217;s report on our financial statements for the year ended December 31, 2020 includes a going concern paragraph. To date, our products have not generated significant revenue. As a result, we have
        suffered recurring losses and require significant additional cash resources to execute our business plan. These losses are expected to continue for an extended period of time. These factors raise substantial doubt about our ability to continue as a
        going concern beyond one year from the date of filing this Quarterly Report on Form 10-Q. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of
        liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of asset amounts or the classification of liabilities that might be necessary should we be
        unable to continue as a going concern within one year after the date the financial statements are issued.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">We recognize that we will need to raise additional capital in order to continue to execute our business plan in the future. Historically, the major source of our cash has been from proceeds from various public and
        private offerings of our common stock. The actual amount of cash that we will need is subject to many factors. There can be no assurances that additional financing will be available when needed or that management will be able to obtain financing on
        terms acceptable to us or that we will become profitable and generate positive operating cash flow. If we are unable to raise sufficient additional funds, we will have to scale back our operations.</div>

      <div><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">40</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div style="font-style: italic; font-weight: bold;">We are currently not profitable and may never become profitable.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">We have a history of losses and expect to incur substantial losses and negative operating cash flows into fiscal 2023, and we may never achieve or maintain profitability. For the six months ended June 30, 2021 and
        2020, we incurred net losses of $37.3 million and $39.4 million, respectively, and for the years ended December 31, 2020 and 2019, we incurred net losses of $75.7 million and $48.3 million, respectively.&#160; From our inception in 2004 through June 30,
        2021, we have incurred an accumulated deficit of $377.8 million. We expect that we will not be able to generate a sufficient amount of product revenue to achieve profitability until the beginning of 2024 and, as a result, we expect that we will
        need to continue to finance our operations through additional equity or debt financings or corporate collaboration and licensing agreements.&#160; We also expect to continue to incur significant operating and capital expenditures and anticipate that our
        operating expenses will increase substantially in the foreseeable future as we:</div>

      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>expand commercialization and marketing efforts;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>implement additional internal systems, controls and infrastructure;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>hire additional personnel;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>expand and build out our plasma center network; and</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>expand production capacity at the Boca Facility.</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <div style="text-indent: 36pt;">As a result, we will need to generate significant revenues in order to achieve and maintain profitability. We may not be able to generate these revenues or achieve profitability in the future. These factors raise
        substantial doubt about our ability to continue as a going concern. Our failure to achieve or maintain profitability could negatively impact the value of our securities.</div>

      <div><br />
      </div>

      <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">The COVID-19 pandemic and efforts to reduce its spread has significantly affected worldwide economic conditions, and could have a material adverse impact on our business,
        liquidity, financial condition and results of operations</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">The COVID-19 pandemic, including the Delta variant and other resistant strains of the coronavirus, has the potential to adversely impact several aspects of each of our business segments, our commercial manufacturing
        operations and plasma collection facilities, including but not limited to potential disruptions to our supply-chain operations, including procurement of raw materials and packaging materials, a portion of which are sourced internationally, and the
        testing of finished drug product that is required prior to its availability for commercial sale.&#160; Such testing has historically been performed by contract laboratories outside the United States. While we do not believe that the COVID-19 pandemic
        has significantly affected operations and immunoglobulin production at our Boca Facility or our ADMA BioCenters plasma collection operations at this time, we may experience adverse effects in the future, particularly in light of the recent increase
        in COVID-19 cases in the State of Florida. For example, our employees becoming ill, the imposition of additional mandatory remote working environments and federal, state and local responses to the pandemic could materially affect the efficiency and
        pace of our operations and manufacturing at our Boca Facility. Employee or donor illness, if not properly managed, could also impact the quality of our products and product candidates. In addition, travel and other restrictions that have been
        implemented in the United States could impact our commercial efforts with respect to any of our products, including BIVIGAM and ASCENIV, as trade shows, industry and medical conferences and other events we had been planning to utilize and exhibit
        and attend with our staff to increase awareness of our products by physicians and payers are subject to limitations, rescheduling or outright cancellation in response to the pandemic. Also, due to a combination of previous state and local
        &#8220;shelter-in-place&#8221; orders, as well as government stimulus packages, persisting social distancing measures and varying roll-outs of vaccinations by state, we have experienced, and may experience in the future, lower than expected donor collections
        at our FDA-licensed plasma collection centers. We were also subject to delays in shipments of source plasma from our contracted third-party suppliers, as well as delays in deliveries for personal protective equipment, reagents and other non-plasma
        raw materials and supplies used in the manufacture and distribution of our products. We have also experienced supply chain delays as a result of significant resources being diverted towards the rapid development and distribution of COVID-19
        vaccines, which could result in our need to carry more inventory that we have in the past, which would put an additional strain on our cash resources.</div>

      <div><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">41</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div style="text-indent: 36pt;">In the future we may continue to experience pandemic-related challenges with respect to obtaining and manufacturing a sufficient amount of supplies, raw materials, and finished product to meet our need for commercial
        and clinical product supply.&#160; If we or any of our suppliers or manufacturers are adversely impacted by the pandemic or the restrictions resulting from the outbreak, if they or we cannot obtain the necessary supplies, or if third parties need to
        prioritize other products or customers over us, including under the Defense Production Act, we may experience future delays or disruptions in our supply chain, which could have a material and adverse impact on our business. Moreover, we, our
        suppliers, and any third-party manufacturers may also need to implement measures and changes, or deviate from typical requirements, because of the pandemic that may otherwise adversely impact our supply chains or the quality of the resulting
        products or supplies.&#160; Depending on the change, we may need to obtain FDA pre-approval or otherwise provide the FDA with a notification of the change.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">To the extent that we or our partners are conducting clinical trials, the pandemic could cause delays or disruptions in these or future development programs.&#160; By example, the pandemic may result in slower enrollment,
        the need to suspend enrollment into studies, patient withdrawals, postponement of planned clinical or preclinical studies, redirection of site resources from studies, study modification, suspension, or termination, the introduction of remote study
        procedures and modified informed consent procedures, study site changes, direct delivery of investigational products to patient homes requiring state licensing, study deviations or noncompliance, and changes or delays in site monitoring.&#160; The
        foregoing may require that we consult with relevant review and ethics committees, IRBs, and the FDA.&#160; The foregoing may also impact the integrity of our study data.&#160; The effects of the COVID-19 pandemic may also increase the need for clinical trial
        patient monitoring and regulatory reporting of adverse effects.&#160; The pandemic could further impact our ability to interact with the FDA or other regulatory authorities and may result in delays in the conduct of inspections or review of pending
        applications or submissions.&#160; During the second quarter of 2021, we were notified by the FDA that our submission for the approval of our in-house fill-finish process utilizing our Vanrx SA25 Workcell aseptic filling machine will require a site
        inspection, either in person or virtually. Although the inspection was completed in July of 2021, the FDA&#8217;s review of our regulatory filing with respect to our in-house fill-finish process and new aseptic filling machine remains ongoing. Although
        we anticipate receiving regulatory approval of this submission in the second half of 2021, no assurances can be provided as to the timing for completion of this FDA review or any other regulatory submissions or applications that may be impacted by
        restrictions related to COVID-19 or other circumstances unknown to us presently or that are out of our direct control. Due to the potential impact of the COVID-19 outbreak on clinical trials, drug development, and manufacturing, the FDA issued a
        number of guidances specifically concerning COVID-19, including guidances with respect to blood and blood components.&#160; The FDA&#8217;s guidance is continually evolving.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">Since the onset of the COVID-19 pandemic, there has been a noticeable decline in certain medical prescriptions attributed to lower incident rates for illnesses, fewer RSV, influenza and other respiratory viral
        pathogen-infected patients, hospital admissions and a reduction in doctor visits. In addition, physical and social distancing guidelines issued by public health authorities and the resulting global changes in human behavior have resulted in an
        observed reduction in infection transmission rates and spread of bacterial and viral infections, resulting in lower rates of infection across all patient populations, which, if continued, could potentially negatively impact the use of our IVIG
        products by patients.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">The COVID-19 pandemic may also result in changes in laws and regulations.&#160; By example, in March 2020, the U.S. Congress passed the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, which includes
        various provisions regarding FDA drug shortage reporting requirements, as well as provisions regarding supply chain security, such as risk management plan requirements, and the promotion of supply chain redundancy and domestic manufacturing.&#160; This
        and any future changes in law may require that we change our internal processes and procedures to ensure continued compliance.</div>

      <div><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">42</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div style="text-indent: 36pt;">The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, operations, or financial condition, or on
        healthcare systems or the global economy as a whole. Although the COVID-19 pandemic has not adversely affected our capital and financial resources to date, the pandemic&#8217;s effects could have a material impact on our ability to access the capital
        markets as needed and on our operations and business, including those of the third parties on which we rely. Because we are unable to determine the ultimate severity or duration of the pandemic or its effects on, among other things, the global,
        national or local economies, the capital and credit markets, our workforce, our customers or our suppliers, at this time we are unable to predict whether COVID-19 will have a material adverse impact on our business, financial condition, liquidity
        and results of operations.</div>

      <div><br />
      </div>

      <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">We contract with third parties for the filling, packaging, testing and labeling of the drug substance we manufacture. This reliance on third parties carries the risk that the
        services upon which we rely may not be performed in a timely manner or according to our specifications, which could delay the availability of our finished drug product and could adversely affect our commercialization efforts and our revenues.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt; color: rgb(0, 0, 0);">Third-party fill/finish providers may not perform as agreed or in accordance with FDA requirements. Any significant problem that our fill/finish providers experience could delay or interrupt our
        supply of finished drug product until the service provider cures the problem or until we locate, negotiate for, validate and receive FDA approval for an alternative provider (when necessary), if one is available. Failure to obtain the needed
        fill/finish services could have a material and adverse effect on our business, financial condition and results from operations.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt; color: rgb(0, 0, 0);">Although we have built our own fill/finish suite within the Boca Facility, we also intend to continue to utilize third parties to supplement our fill/finish process for final drug substance. In
        addition, our recently completed fill/finish suite has yet to be validated and approved by the FDA. Our anticipated reliance on a limited number of third-party manufacturers exposes us to the following risks:</div>

      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>we may be unable to identify contract fill/finishers on acceptable terms or at all because the number of potential service providers is limited and the FDA must inspect and qualify any contract manufacturers for current cGMP compliance
                as part of our marketing application;</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>a new fill/finisher would have to be educated in, or develop substantially equivalent processes for, the production of our products and product candidates;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>the COVID-19 pandemic could adversely affect our contracted fill/finishers&#8217; operations, supply chain or workforce;</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>our contracted fill/finishers&#8217; resources and level of expertise with plasma-derived biologics may be limited, and therefore they may require a significant amount of support from us in order to implement and maintain the infrastructure
                and processes required to deliver our finished drug product;</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>our third-party fill/finishers might be unable to timely provide finished drug product in sufficient quantity&#160; to meet our commercial needs;</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>contract manufacturers may not be able to execute our inspection procedures and required tests appropriately;</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>contract manufacturers are subject to ongoing periodic unannounced inspection by the FDA and corresponding state agencies to ensure strict compliance with cGMP and other government regulations, and we do not have control over third-party
                providers&#8217; compliance with these regulations;</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>our third-party fill/finishers could breach or terminate their agreements with us; and</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>our contract fill/finishers may have unacceptable or inconsistent drug product quality success rates and yields, and we have no direct control over our contract fill/finishers&#8217; ability to maintain adequate quality control, quality
                assurance and qualified personnel.</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">43</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div><span style="color: rgb(0, 0, 0);">Each of these risks could delay or prevent the completion of our finished drug product and the release of finished drug product by the FDA, which could result in higher costs or adversely impact the
          commercialization of our products. These risks could also result in the delay in obtaining clinical supply, which would delay our development programs. In addition, our contract fill/finishers and our other third-party vendors may source their
          materials and supplies globally, and are therefore subject to supply disruptions in the event of </span>fire, weather related events such as hurricanes, wind and rain, other acts of God or force majeure events or global health occurrences and
        emergencies, including the COVID-19 pandemic.</div>

      <div><br />
      </div>

      <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">The estimates of market opportunity and forecasts of market and revenue growth included in our filings may prove to be inaccurate, and even if the markets in which we compete
        achieve the forecasted growth, our business could fail to grow at similar rates, if at all.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt; color: rgb(0, 0, 0);">Market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates that may not prove to be accurate, including as a result of
        changing circumstances during the ongoing COVID-19 pandemic. In particular, the size and growth of the overall U.S. IVIG and source plasma markets are subject to significant variables that can be difficult to measure, estimate or quantify. Our
        business depends on, among other things, successful commercialization of our existing products, market acceptance of such products and ensuring that our products are safe and effective. Further, there can be no assurance that we will be able to
        generate the revenue that we believe our products and plasma facilities are capable of generating. As a result, we may not be able to accurately forecast or predict revenue. For these reasons, the estimates and forecasts in our filings relating to
        revenue generation and growth may prove to be inaccurate. Even if the markets in which we compete meet our size estimates and forecasted growth, our business could fail to grow at similar rates, if at all.</div>

      <div><br />
      </div>

      <div style="font-style: italic; font-weight: bold;">Both of our business segments and our facilities, as well as our suppliers and contractors, are subject to periodic inspections by the FDA, which, depending on the outcome of such inspection, could
        result in certain FDA actions, including the issuance of observations, notices, citations or warning letters.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;"><span style="color: rgb(0, 0, 0);">We and our suppliers and contractors may be unable to comply with our specifications, cGMP requirements and with other FDA, state, and foreign regulatory requirements for commercial
          and clinical supply. </span>The FDA is authorized to perform inspections of our and our suppliers&#8217; facilities, including the Boca Facility. The FDA also must inspect and approve our and our third-parties&#8217; facilities before they may be used for
        commercial production. At the end of such an inspection, the FDA could issue a Form 483 Notice of Inspectional Observations, which could cause us to modify certain activities identified during the inspection and may not approve the use of the
        facility. Following such inspections, the FDA may issue an untitled letter as an initial correspondence that cites violations that do not meet the threshold of regulatory significance of a warning letter. FDA guidelines also provide for the
        issuance of warning letters for violations of &#8220;regulatory significance&#8221; for which the failure to adequately and promptly achieve correction may be expected to result in an enforcement action. FDA also may issue warning letters and untitled letters
        in connection with events or circumstances unrelated to an FDA inspection.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">We may not be able to timely resolve concerns raised by the FDA as a result of an inspection or without expending significant resources. We are unable to control the timing of FDA inspections, responses, meeting
        requests, teleconference requests, requests for clarifications and similar regulatory communications, as well as whether or not the FDA will change its requirements, guidance or expectations. If the FDA determines that we have not remediated the
        issues identified in a warning letter or any other inspection issues and deficiencies, any failure of ours to address or provide requested documentation of corrections for these issues could disrupt our business operations and the timing of our
        commercialization efforts and could have a material adverse effect on our financial condition and operating results.</div>

      <div><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">44</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div>
        <div style="font-style: italic; font-weight: bold;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the
          success of our business.</div>

      </div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and
        wastes. Our commercial manufacturing and any research and development activities involve the use of biological and hazardous materials and produce hazardous waste products. We generally contract with third parties for the disposal of these
        materials and wastes. We cannot eliminate the risk of contamination or injury from these materials, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage
        resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized internally
        and by our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental
        contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain
        materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our
        future compliance. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our commercial manufacturing,
        research and development, or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties, or other sanctions.</div>

      <div><br />
      </div>

      <div><span style="font-weight: bold; font-style: italic;">Business interruptions could adversely affect our business</span><span style="font-weight: bold;">.</span></div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">Our operations, including our headquarters located in Ramsey, NJ, the Boca Facility and our plasma collection facilities, are vulnerable to interruption by fire, weather related events such as hurricanes, wind and
        rain, other acts of God or force majeure events, electric power loss, telecommunications failure, equipment failure and breakdown, human error, employee issues, global health occurrences such as the COVID-19 pandemic, and emergencies, product
        liability claims and events beyond our control. While we maintain several insurance policies with reputable carriers that provide partial coverage for a variety of these risks, including replacing or rebuilding a part of our facilities, these
        policies are subject to the insurance carriers&#8217; final determination of compensation to us and we may not have adequate coverage if we need to rebuild or replace our inventory, infrastructure, business income or our entire facility.&#160; In addition,
        our disaster recovery plans for our facilities may not be adequate and we do not have an alternative manufacturing facility or contractual arrangements with other manufacturers in the event of a casualty to or destruction of any of our facilities.
        If we are required to rebuild or relocate any of our facilities, a substantial investment in improvements and equipment would be necessary. We carry only a limited amount of business interruption insurance, which may not sufficiently compensate us
        for losses that may occur. As a result, any significant business interruption could adversely affect our business and results of operations.</div>

      <div><br />
      </div>

      <div style="font-style: italic; font-weight: bold;">If we are unsuccessful in obtaining regulatory approval for any of our product candidates or if any of our product candidates do not provide positive results, we may be required to delay or abandon
        development of such product, which would have a material adverse impact on our business.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">Product candidates require extensive clinical data analysis and regulatory review and may require additional testing. Clinical trials and data analysis can be very expensive, time-consuming and difficult to design and
        implement. The conduct of preclinical studies and clinical trials is subject to numerous risks and results of the studies and trials are highly uncertain.<span style="font-weight: bold; font-style: italic;">&#160;</span>Human clinical trials are very
        expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. The clinical trial process is also time-consuming. Furthermore, delays or setbacks can occur at any stage of the process, and we
        could encounter problems that cause us to abandon our product development programs and related INDs or BLAs, or to repeat clinical trials. The evolving COVID-19 pandemic may directly or indirectly affect the pace of enrollment in clinical trials as
        patients may be restricted in traveling to and accessing healthcare facilities and physicians&#8217; offices. Additionally, such healthcare facilities and offices have their limited resources directed towards treating patients with COVID-19 symptoms. The
        commencement and completion of clinical trials for any current or future development product candidate may be delayed by several factors, including:</div>

      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>unforeseen safety issues;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>determination of dosing issues;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>lack of effectiveness during clinical trials;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">45</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>slower than expected rates of patient recruitment;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>inability to monitor patients adequately during or after treatment</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>inability or unwillingness of medical investigators to follow our clinical protocols; and</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>temporary suspension resulting from the COVID-19 pandemic.</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="text-indent: 36pt;">We cannot be certain as to what type and how many clinical trials the FDA, or equivalent foreign regulatory agencies, will require us to conduct before we may successfully gain approval to market any of our product
        candidates that still require FDA approval. Prior to approving a new drug or biologic, the FDA generally requires that the effectiveness of the product candidate (which is not typically fully investigated until Phase 3) be demonstrated in two
        adequate and well-controlled clinical trials. However, if the FDA or an equivalent foreign regulatory authority determines that our Phase 3 clinical trial results do not demonstrate a statistically significant, clinically meaningful benefit with an
        acceptable safety profile, or if a relevant regulator requires us to conduct additional Phase 3 clinical trials in order to gain approval, we will incur significant additional development costs and commercialization of these products would be
        prevented or delayed and our business would be adversely affected.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">In addition, the FDA or an independent institutional review board may not permit us to commence a clinical trial, may require amendments to our clinical trial protocols, or may suspend our clinical trials at any time
        if it appears that we are exposing participants to unacceptable health risks or if the FDA or IRB finds deficiencies in our IND submissions or the conduct of these trials. Therefore, we cannot provide any assurance or predict with certainty the
        schedule for future clinical trials. In the event we do not ultimately receive regulatory approval for our product candidates, we may be required to terminate development of such product candidates. If we fail to obtain regulatory approval to
        market and sell our product candidates, or if approval is delayed, we will be unable to generate revenue from the sale of these products, our potential for generating positive cash flow will be diminished and the capital necessary to fund our
        operations will increase.</div>

      <div> <br />
      </div>

      <div style="font-style: italic; font-weight: bold;">If the results of our clinical trials do not support our product candidate claims, completing the development of such product candidate may be significantly delayed or we may be forced to abandon
        development of such product candidate altogether.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">We cannot be certain that the clinical trial results of our product candidates will support our product candidates&#8217; claims. Success in preclinical testing and early clinical trials does not ensure that later clinical
        trials will be successful, and we cannot be sure that the results of later clinical trials will replicate the results of prior clinical trials and preclinical testing.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">The clinical trial process may fail to demonstrate that our product candidates are safe for humans and effective for indicated uses. This failure would cause us to abandon a product candidate and may delay development
        of other product candidates. Any delay in, or termination of, our clinical trials will delay our ability to commercialize our product candidates and generate product revenues.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">Other issues that may impact our clinical trials and that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, include:</div>

      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>We may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites and our CROs;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>Regulators may require us to perform additional or unanticipated clinical trials to obtain approval or we may be subject to additional post-marketing testing, surveillance, or REMS requirements to maintain regulatory approval;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>Our third-party contractors may fail to comply with regulatory requirements or the clinical trial protocol, or meet their contractual obligations to us in a timely manner, or at all, or we may be required to engage in additional clinical
                trial site monitoring;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">46</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>The cost of clinical trials of our product candidates may be greater than we anticipate or we may have insufficient funds for a clinical trial or to pay the substantial user fees required by FDA upon the filing of a marketing
                application;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>The supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>We may not be able to achieve sufficient study enrollment, subjects may drop out or be withdrawn from out studies, we may have delays in adding new investigators or clinical trial sites, or we may experience a withdrawal of clinical
                trial sites;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>There may be flaws in our clinical trial design that are not discoverable until the clinical trial has progressed;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>The FDA or comparable foreign regulatory authorities may disagree with our intended indications or study design, including endpoints, or our interpretation of data from preclinical studies and clinical trials, may find that a product
                candidate&#8217;s benefits do not outweigh its safety risks, or may require that we conduct additional development or study work;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>The FDA or comparable foreign regulatory authorities may fail to approve or subsequently find fault with the manufacturing processes or our contract manufacturer&#8217;s manufacturing facility for clinical and future commercial supplies;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>We may need to make changes to our product candidates that require additional testing or that cause our product candidates to perform differently than expected;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>Global trade policies that may impact our or our manufacturers&#8217; ability to obtain raw materials and/or finished product for commercialization;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>FDA or comparable regulatory authorities may take longer than we anticipate to make decisions on our products or product candidates; and</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>We may not be able to demonstrate that a product or product candidate provides an advantage over current standards of care or current or future competitive therapies in development.</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="text-indent: 36pt;">In addition, our clinical trials involve a relatively small patient population. Because of the small sample size, the results of these clinical trials may not be indicative of future results. In addition, certain
        portions of our clinical trials and product testing for our product candidates may be performed outside of the U.S., and therefore, may not be performed in accordance with standards normally required by the FDA and other regulatory agencies.</div>

      <div> <br />
      </div>

      <div style="font-style: italic; font-weight: bold;">If we do not obtain and maintain the necessary U.S. or international regulatory approvals to commercialize a product candidate, we will not be able to sell that product candidate, which would make
        it difficult for us to recover the costs of researching and developing such product candidate.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">If we are not be able to generate revenue from our products and product candidates, our sources of revenue may continue to be from a product mix consisting only of plasma collection and sales revenues, revenues
        generated from sales of our FDA-approved commercial products, revenues generated from ongoing contract manufacturing for third parties and revenues generated from the sales of manufacturing intermediates. We cannot assure you that we will receive
        the approvals necessary to commercialize any product candidate we may acquire or develop in the future. In order to obtain FDA approval of any product candidate requiring FDA approval, our clinical development must demonstrate that the product
        candidate is safe for humans and effective for its intended use, and we must successfully complete an FDA BLA review. Obtaining FDA approval of a product candidate generally requires significant research and testing, referred to as preclinical
        studies, as well as human tests, referred to as clinical trials. Satisfaction of the FDA&#8217;s regulatory requirements typically takes many years, depends upon the type, complexity and novelty of the product candidate and requires substantial resources
        for research, development and testing. We cannot predict whether our research and clinical approaches will result in products that the FDA considers safe for humans and effective for indicated uses. The FDA has substantial discretion in the product
        approval process and may require us to conduct additional preclinical and clinical testing or to perform post-marketing studies or may require additional CMC or other data and information, and the development and provision of this data and
        information may be time-consuming and expensive. The approval process may also be delayed by changes in government regulation, future legislation, diversion of resources for FDA review during the ongoing COVID-19 pandemic or administrative action
        or changes in FDA policy that occur prior to or during our regulatory review. Delays in obtaining regulatory approvals may:</div>

      <div> <br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">47</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>delay commercialization of, and our ability to derive revenues from, our product candidate;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>impose costly procedures on us; and</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>diminish any competitive advantages that we may otherwise enjoy.</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="text-indent: 36pt;">Even if we comply with all FDA requests, the FDA may ultimately reject our product candidate&#8217;s BLA. In addition, the FDA could determine that we must test additional subjects and/or require that we conduct further
        studies with more subjects. We may never obtain regulatory approval for any future potential product candidate or label expansion activity. Failure to obtain FDA approval of any of our product candidates will severely undermine our business by
        leaving us without the ability to generate additional accretive revenues. There is no guarantee that we will ever be able to develop or acquire other product candidates. In foreign jurisdictions, we must receive approval from the appropriate
        regulatory authorities before we can commercialize any products or product candidates outside the U.S. Foreign regulatory approval processes generally include all of the risks and uncertainties associated with the FDA review, inspection and
        approval procedures described above. We cannot assure you that we will receive the approvals necessary to commercialize any product candidate for sale outside the U.S.</div>

      <div> <br />
      </div>

      <div style="font-style: italic; font-weight: bold;">Although we have received approval from the FDA to market ASCENIV as a treatment for PIDD, our ability to market or seek approval for ASCENIV for alternative indications could be limited, unless
        additional clinical trials are conducted successfully and the FDA approves a BLA or other required submission for review.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">The FDA and other governmental authorities strictly regulate and monitor marketing, labeling, advertising and promotion of prescription drugs. These regulations include standards and restrictions for direct-to-consumer
        advertising, industry-sponsored scientific and educational activities, promotional activities involving the Internet and off-label promotion. The FDA generally does not allow drugs to be promoted for &#8220;off-label&#8221; uses&#8201;&#8212;&#8201;that is, uses that are not
        described in the product&#8217;s labeling and that differ from those that were approved by the FDA. The FDA limits approved uses to those studied by a company in its clinical trials. In addition to the FDA approval required for new formulations, any new
        indication for an approved product also requires FDA approval. Although we have received approval from the FDA to market ASCENIV as a treatment for PIDD, we cannot be sure whether we will be able to obtain FDA approval for any desired future
        indications for ASCENIV.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">While physicians in the U.S. may choose, and are generally permitted, to prescribe drugs for uses that are not described in the product&#8217;s labeling, and for uses that differ from those tested in clinical studies and
        approved by the regulatory authorities, our ability to promote our products is narrowly limited to those indications that are specifically approved by the FDA. &#8220;Off-label&#8221; uses are common across medical specialties and may constitute an appropriate
        treatment for some patients in varied circumstances. Regulatory authorities in the U.S. generally do not regulate the behavior of physicians in their choice of treatments. Regulatory authorities do, however, restrict communications by
        pharmaceutical companies on the subject of off-label use. If the FDA determines that our promotional activities fail to comply with the FDA&#8217;s regulations or guidelines, we may be subject to warnings from, or enforcement action by, these
        authorities. In addition, our failure to follow FDA rules and guidelines related to promotion and advertising may cause the FDA to issue warning letters or untitled letters, bring an enforcement action against us, suspend or withdraw an approved
        product from the market, require a recall or institute fines or civil fines, or could result in disgorgement of money, operating restrictions, injunctions or criminal prosecution, among other consequences, any of which could harm our reputation and
        our business.</div>

      <div><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">48</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div>
        <div style="font-style: italic; font-weight: bold;">With the approval of ASCENIV, there can be no assurance that we will be successful in developing and expanding commercial operations or balancing our research and development activities with our
          commercialization activities.</div>

      </div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">Since receiving FDA approval for ASCENIV, we have been commercializing this product while also continuing our research and development activities. There can be no assurance that we will be able to successfully manage
        the balance of our research and development operations with our commercialization activities. Potential investors and stockholders should be aware of the problems, delays, expenses and difficulties frequently encountered by companies balancing
        development of product candidates, which can include problems such as unanticipated issues relating to clinical trials and receipt of approvals from the FDA and foreign regulatory bodies, with commercialization efforts, which can include problems
        related to managing manufacturing and supply, including supply chain constraints directly or indirectly caused by the ongoing COVID-19 pandemic and government responses thereto, reimbursement, marketing challenges, development of a comprehensive
        compliance program, and other related and additional costs. For example, the raw material plasma we collect and procure to manufacture ASCENIV using our patented proprietary microneutralization assay is comprised of plasma collected from donors
        which contains high titer antibodies to RSV.&#160; This high titer plasma <span style="color: rgb(0, 0, 0);">which meets our internal specifications for the manufacture of ASCENIV that we are able to identify with our patented testing assay </span>amounts





        to less than 10% of the total donor collection samples we test. Our product candidates will require significant additional research and clinical trials, and we will need to overcome significant regulatory burdens prior to commercialization in the
        U.S. and other countries. In addition, we may be required to spend significant funds on building out our commercial operations. There can be no assurance that after the expenditure of substantial funds and efforts, we will successfully develop and
        commercialize any of our product candidates, generate any significant revenues or ever achieve and maintain a substantial level of sales of our products.</div>

      <div> <br />
      </div>

      <div style="font-style: italic; font-weight: bold;">We depend on third-party researchers, developers and vendors to develop, manufacture or test products and product candidates, as well as for other pre-and-post approval services, and such parties
        are, to some extent, outside of our control.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">We depend on independent investigators and collaborators, such as universities and medical institutions, contract laboratories, clinical research organizations, contract manufacturers, contract fill/finishers and
        consultants to conduct our preclinical activities, clinical trials, CMC testing and other activities under agreements with us. These collaborators are not our employees and we cannot control the amount or timing of resources that they devote to our
        programs or the impact that the ongoing COVID-19 pandemic will have on such third parties. These investigators may not assign as great a priority to our programs or pursue them as diligently as we would if we were undertaking such programs
        ourselves. If outside collaborators fail to devote sufficient time and resources to our product-development programs, or if their performance is substandard, our trials may be repeated, extended, delayed, or terminated, the approval of our FDA
        application(s), if any, and our introduction of new products, if any, will be delayed. We or they may also be subject to regulatory enforcement actions and we may not be able to meet commercial demand. These collaborators may also have
        relationships with other commercial entities, some of whom may compete with us. If our collaborators assist our competitors at our expense, our competitive position would be harmed. Additionally, any change in the regulatory compliance status of
        any of our vendors may impede our ability to receive approval for our product candidates.</div>

      <div><br />
      </div>

      <div style="font-style: italic; font-weight: bold;">We may be unable to successfully expand our manufacturing processes to fulfill demand for our products or increase our production capabilities through the addition of new equipment, including if we
        do not obtain requisite approval from the FDA. </div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">We currently anticipate expanding the manufacturing capacity of our Boca Facility by approximately 50% or more. We also anticipate expanding our production capabilities through the addition of our fill-finish machine
        at our Boca Facility. Following the expansion of any of our manufacturing processes or the addition of new equipment, such as our fill-finish machine, we will need to validate the expanded facility and equipment and have it inspected by the FDA.
        Given the significant delays that may result during the validation process, including due to any diverted FDA attention during the COVID-19 pandemic, we may experience a significant supply shortage of our products or our production capabilities may
        be limited until completion of and validation of our facility expansion and new manufacturing equipment.</div>

      <div><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">49</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div>
        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Our products, and any additional products for which we may obtain marketing approval in the future, could be subject to post-marketing restrictions or
          withdrawal from the market and we could be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products following approval.</div>

      </div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">Our products, and any additional products for which we may obtain marketing approval in the future, could be subject to post-marketing restrictions, new FDA guidance, or other regulatory actions, such as withdrawal
        from the market. Such products, as well as the manufacturing processes, post-marketing studies and measures, labeling, advertising and promotional activities for such products, among other things, are subject to ongoing regulatory compliance
        requirements, and oversight, review, and inspection by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, adherence
        with labeling and promotional requirements and restrictions, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding safeguarding the drug supply
        chain as well as the distribution of samples to physicians and recordkeeping. For example, the FDA&#8217;s approval of our PAS to allow for the commercial relaunch of BIVIGAM requires us to conduct specified post-marketing studies related to our
        manufacturing controls and processes, and submit specified post-marketing reports to the FDA. If, during the post-marketing period (after marketing approval) previously unknown adverse events, discovery that the product is less effective than
        previously thought, or other potential concerns regarding our products or their manufacturing processes emerge, or we are observed in any way to fail to comply with the numerous regulatory requirements to which we are subject, those circumstances
        may yield various results, including:</div>

      <div style="text-align: justify;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>restrictions on such products or manufacturing processes;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>restrictions on the labeling or marketing of a product;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>restrictions on product distribution or use;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>clinical holds or termination of clinical trials;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>requirements to conduct further post-marketing studies or clinical trials, implement risk mitigation strategies, or to issue corrective information;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>warning letters or untitled letters;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>withdrawal of the products from the market;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>refusal to approve pending applications or supplements to approved applications that we submit;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>recall of products;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>restrictions on coverage by third-party payers;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>fines, restitution or disgorgement of profits or revenues;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>suspension or withdrawal of marketing approvals;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>refusal to permit the import or export of products;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>FDA debarment, suspension and debarment from government contracts, and refusal of orders under existing government contracts, exclusion from healthcare programs, consent decrees, or corporate integrity agreements;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>product seizure or detention; or</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>injunctions or the imposition of civil or criminal penalties.</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">50</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div style="font-style: italic; font-weight: bold;">Historically, a few customers have accounted for a significant amount of our total revenue and accounts receivable and the loss of any of these customers could have a material adverse effect on our
        business, results of operations and financial condition.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">For the six months ended June 30, 2021, five customers, BioCare, Biolife, Reliance, Curascript and AmerisourceBergen, represented an aggregate of 85% of our consolidated revenues. For the year ended December 31, 2020,
        three customers, BioCare, Reliance and Biolife, represented an aggregate of 82% of our consolidated revenues.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">As of June 30, 2021, six customers, Curascript, BioCare, 1<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">ST</sup> America Infusion Services, LLC, Reliance, Biolife and AmerisourceBergen,
        represented a total of 94% of our consolidated accounts receivable. As of December 31, 2020, three customers, BioCare, Reliance and Curascript, represented a total of 92% of our consolidated accounts receivable.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">The loss of any key customers or a material change in the revenue generated by any of these customers could have a material adverse effect on our business, results of operations and financial condition. Moreover, we
        anticipate deriving increased revenue from some of these customers over the next few years. Factors that could influence our relationships with our customers include, among other things:</div>

      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>our ability to sell our products at competitive prices;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>our ability to maintain features and quality standards for our products sufficient to meet the expectations of our customers;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>our ability to produce and deliver a sufficient quantity of our products in a timely manner to meet our customers&#8217; requirements; and</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>the impact of the ongoing COVID-19 pandemic and government responses thereto on our customers and their businesses, operations and financial condition.</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div>Additionally, an adverse change in the financial condition of any of our key customers could negatively affect revenue derived from such customer, which in turn could have a material adverse effect on our business and results of operations.</div>

      <div> <br />
      </div>

      <div style="font-style: italic; font-weight: bold;">Issues with product quality and compliance could have a material adverse effect upon our business, subject us to regulatory actions and cause a loss of customer confidence in us or our products.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">Our success depends upon the quality of our products. Quality management plays an essential role in meeting customer requirements, preventing defects, improving our products and services and assuring the safety and
        efficacy of our products. Our future success depends on our ability to maintain and continuously improve our quality management program. A quality or safety issue may result in failure to obtain product approval, adverse inspection reports, warning
        letters, product recalls or seizures, monetary sanctions, injunctions to halt manufacture and distribution of products, civil or criminal sanctions, costly litigation, refusal of a government to grant approvals and licenses, restrictions on
        operations or withdrawal of existing approvals and licenses. An inability to address a quality or safety issue by us or by a third-party vendor in an effective and timely manner may also cause negative publicity or a loss of customer confidence in
        us or our current or future products, which may result in the loss of sales and difficulty in successfully commercializing our current products and launching new products.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">In addition, as a manufacturer of biological products, we are subject to the risks inherent in biological production, which could include normal course losses and failures inherent in the manufacturing process. As our
        biologics production levels increase, there may be normal course inventory losses or write-downs as we ensure product quality and compliance with cGMP, FDA, state and local regulations, or due to testing results not meeting specifications. As a
        result, our operating results are subject to potentially significant variability from one reporting period to the next should such normal course losses occur in any given period.</div>

      <div><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">51</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div style="font-style: italic; font-weight: bold;">If physicians, payers and patients do not accept and use our current products or our future product candidates, our ability to generate revenue from these products will be materially impaired.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">Even if the FDA approves a product made by us, physicians, payers and patients may not accept and use it. Acceptance and use of our products depends on a number of factors including, but not limited to:</div>

      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>perceptions by members of the healthcare community, including physicians, about the safety and effectiveness of our products;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>cost-effectiveness of our products relative to competing products;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>availability of reimbursement for our products from government or other healthcare payers; and</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>the effectiveness of marketing and distribution efforts by us and our licensees and distributors, if any.</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <div>The failure of our current or future products to find market acceptance would harm our business and could require us to seek additional financing or make such financing difficult to obtain on favorable terms, if at all.</div>

      <div> <br />
      </div>

      <div style="font-style: italic; font-weight: bold;">Our long-term success may depend on our ability to supplement our existing product portfolio through new product development or the in-license or acquisition of other new products, product
        candidates and label expansion of existing products, and if our business development efforts are not successful, our ability to achieve profitability may be adversely impacted.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">Our current product development portfolio consists primarily of label expansion activities for Nabi-HB, BIVIGAM and ASCENIV, as well as expanding our IP estate with patents issued for <span style="font-style: italic;">S.








          Pneumoniae</span> hyperimmune IG. We have initiated small scale preclinical activities to potentially expand our current portfolio through new product development efforts or to in-license or acquire additional products and product candidates. If
        we are not successful in developing or acquiring additional products and product candidates, we will have to depend on our ability to successfully commercialize ASCENIV, as well as our ability to generate revenue from Nabi-HB, BIVIGAM, contract
        manufacturing, intermediate fractions and plasma attributable to the operations of ADMA BioCenters, to support our operations.</div>

      <div> <br />
      </div>

      <div style="font-style: italic; font-weight: bold;">Our ADMA BioCenters operations collect information from donors in the U.S. that subjects us to consumer and health privacy laws, which could create enforcement and litigation exposure if we fail to
        meet their requirements.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">Consumer privacy is highly protected by federal and state law.&#160; The Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), as amended by the Health Information Technology for Economic and Clinical
        Health Act of 2009 (&#8220;HITECH&#8221;), and their respective implementing regulations, impose, among other things, obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually
        identifiable health information held by covered entities and business associates. A &#8220;covered entity&#8221; is the primary type of HIPAA-regulated entity.&#160; Health plans/insurers, healthcare providers engaging in standard transactions (insurance/health
        plan claims and encounters, payment and remittance advice, claims status, eligibility, enrollment/disenrollment, referrals and authorizations, coordination of benefits and premium payments), and healthcare clearinghouses (switches that convert data
        between standard and non-standard data sets) are covered entities. A &#8220;business associate&#8221; provides services to covered entities (directly or as subcontractors to other business associates) involving arranging, creating, receiving, maintaining, or
        transmitting protected health information (&#8220;PHI&#8221;) on a covered entity&#8217;s behalf.&#160; In order to legally provide access to PHI to service providers, covered entities and business associates must enter into a &#8220;business associate agreement&#8221; (&#8220;BAA&#8221;) with
        the service provider PHI recipient. Among other things, HITECH made certain aspects of the HIPAA&#8217;s rules (notably the Security Rule) directly applicable to business associates &#8211; independent contractors or agents of covered entities that receive or
        obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to
        business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal court to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil
        actions. The HHS Office of Civil Rights (&#8220;OCR&#8221;) has increased its focus on compliance and continues to train state attorneys general for enforcement purposes. OCR has recently increased both its efforts to audit HIPAA compliance and its level of
        enforcement, with one recent penalty exceeding $5.0 million.</div>

      <div><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">52</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div style="text-indent: 36pt;">While we are not a covered entity or business associate subject to HIPAA, even when HIPAA does not apply, according to the U.S. Federal Trade Commission (the &#8220;FTC&#8221;), failing to take appropriate steps to keep consumers&#8217;
        personal information secure constitutes unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act, 15 U.S.C &#167; 45(a). The FTC expects a company&#8217;s data security measures to be reasonable and
        appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Medical data is considered sensitive data
        that merits stronger safeguards. The FTC&#8217;s guidance for appropriately securing consumers&#8217; personal information is similar to what is required by the HIPAA Security Rule.&#160; In addition, states impose a variety of laws protecting consumer information,
        with certain sensitive information such as HIV/Sexually Transmitted Disease status subject to heightened standards.&#160; In addition, federal and state privacy, data security, and breach notification laws, rules and regulations, and other laws apply to
        the collection, use and security of personal information, including social security number, driver&#8217;s license numbers, government identifiers, credit card and financial account numbers.&#160; Some state privacy and security laws apply more broadly than
        HIPAA and associated regulations. For example, California recently enacted legislation &#8211; the California Consumer Privacy Act, or CCPA &#8211; which went into effect January 1, 2020, and will be amended by the California Privacy Rights Act, effective
        January 1, 2023. The CCPA, among other things, creates new data privacy obligations for covered companies and provides new privacy rights to California residents, including the right to opt out of certain disclosures of their information. The CCPA
        also creates a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach. It remains unclear what, if any, modifications will be made to this legislation or how it
        will be interpreted. We could be subject to enforcement action and litigation exposure if we fail to adhere to these data privacy and security laws.</div>

      <div> <br />
      </div>

      <div style="font-style: italic; font-weight: bold;">The Perceptive Credit Facility is subject to acceleration in specified circumstances, which may result in Perceptive taking possession and disposing of any collateral.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">On February 11, 2019 (the &#8220;Perceptive Closing Date&#8221;), we entered into the Perceptive Credit Agreement with Perceptive Credit Holdings II, LP, as the lender and administrative agent (&#8220;Perceptive&#8221;). The Perceptive Credit
        Agreement, as amended, currently provides for a senior secured term loan facility in the principal amount of $100.0 million (the &#8220;Perceptive Credit Facility&#8221;), comprised of (i) a term loan made on the Perceptive Closing Date in the principal amount
        of $45.0 million, as evidenced by our issuance of a promissory note in favor of Perceptive on the Perceptive Closing Date (the &#8220;Perceptive Tranche I Loan&#8221;), (ii) a term loan in the principal amount of $27.5 million evidenced by our issuance of a
        promissory note in favor of Perceptive on May 3, 2019 (the &#8220;Perceptive Tranche II Loan&#8221;), (iii) a term loan in the principal amount of $12.5 million evidenced by our issuance of a promissory note in favor of Perceptive on March 20, 2020, (the
        &#8220;Perceptive Tranche III Loan&#8221;); and (iv) a term loan in the principal amount of $15 million evidenced by our issuance of a promissory note in favor of Perceptive on December 8, 2020 (the &#8220;Perceptive Tranche IV Loan,&#8221; and together with the
        Perceptive Tranche I Loan, the Perceptive Tranche II Loan and the Perceptive Tranche III Loan, the &#8220;Perceptive Loans&#8221;). The Perceptive Loans each have a maturity date of March 1, 2024, subject to acceleration pursuant to the Perceptive Credit
        Agreement, including upon an Event of Default (as defined in the Perceptive Credit Agreement). The Perceptive Loans are secured by substantially all of our assets, including our intellectual property. Events of Default include, among others,
        non-payment of principal, interest, or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross-defaults to material contracts and events constituting a change of
        control. In addition to an increase in the rate of interest on the Perceptive Loans of 4% per annum, the occurrence of an Event of Default could result in, among other things, the termination of commitments under the Perceptive Credit Facility, the
        declaration that all outstanding Loans are immediately due and payable in whole or in part, and Perceptive taking immediate possession of, and selling, any collateral securing the Perceptive Loans.</div>

      <div> <br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">53</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div>
        <div style="font-style: italic; font-weight: bold;">Developments by competitors may render our products or technologies obsolete or non-competitive.</div>

      </div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. Our current products and any future product we may develop will have to compete with
        other marketed therapies. In addition, other companies may pursue the development of pharmaceuticals that target the same diseases and conditions that we are targeting. We face competition from pharmaceutical and biotechnology companies in the U.S.
        and abroad. In addition, companies pursuing different but related fields represent substantial competition. Many of these organizations competing with us have substantially greater financial resources, larger research and development staffs and
        facilities, longer product development history in obtaining regulatory approvals and greater manufacturing and marketing capabilities than we do. These organizations also compete with us to attract qualified personnel and parties for acquisitions,
        joint ventures or other collaborations.</div>

      <div> <br />
      </div>

      <div style="font-style: italic; font-weight: bold;">If we are unable to protect our patents, trade secrets or other proprietary rights, if our patents are challenged or if our provisional patent applications do not get approved, our competitiveness
        and business prospects may be materially damaged.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">As we move forward in clinical development we are also uncovering novel aspects of our products and are drafting patents to cover our inventions.&#160; We rely on a combination of patent rights, trade secrets and
        nondisclosure and non-competition agreements to protect our proprietary intellectual property, and we will continue to do so. There can be no assurance that our patents, trade secret policies and practices or other agreements will adequately
        protect our intellectual property. Our issued patents may be challenged, found to be over-broad or otherwise invalidated in subsequent proceedings before courts or the U.S. Patent and Trademark Office. Even if enforceable, we cannot provide any
        assurances that they will provide significant protection from competition. The processes, systems, and/or security measures we use to preserve the integrity and confidentiality of our data and trade secrets may be breached, and we may not have
        adequate remedies as a result of any such breaches. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. There can be no assurance that the confidentiality, nondisclosure and non-competition
        agreements with employees, consultants and other parties with access to our proprietary information to protect our trade secrets, proprietary technology, processes and other proprietary rights, or any other security measures relating to such trade
        secrets, proprietary technology, processes and proprietary rights, will be adequate, will not be breached, that we will have adequate remedies for any breach, that others will not independently develop substantially equivalent proprietary
        information or that third parties will not otherwise gain access to our trade secrets or proprietary knowledge. To the extent that our consultants, contractors or collaborators use intellectual property owned by others in their work for us,
        disputes may arise as to the rights in related or resulting know-how and inventions.</div>

      <div><br />
      </div>

      <div style="font-style: italic; font-weight: bold;">We could lose market exclusivity of a product earlier than expected.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">In the pharmaceutical and biotechnology industries, the majority of an innovative product&#8217;s commercial value is realized during its market exclusivity period. In the U.S. and in some other countries, when market
        exclusivity expires and generic or biosimilar versions are approved and marketed or when biosimilars are introduced (even if only for a competing product), there are usually very substantial and rapid declines in a product&#8217;s revenues.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">Market exclusivity for our products is based upon patent rights and certain regulatory forms of exclusivity. The scope of our patent rights may vary from country to country and may also be dependent on the availability
        of meaningful legal remedies in a country. The failure to obtain patent and other intellectual property rights, or limitations on the use or loss of such rights, could be material to us. In some countries, basic patent protections for our products
        may not exist because certain countries did not historically offer the right to obtain specific types of patents and/or we (or our licensors) did not file in those markets. In addition, the patent environment can be unpredictable and the validity
        and enforceability of patents cannot be predicted with certainty. Absent relevant patent protection for a product, once the data exclusivity period expires, generic versions can be approved and marketed.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">Patent rights covering our products may become subject to patent litigation. In some cases, manufacturers may seek regulatory approval by submitting their own clinical trial data to obtain marketing approval or choose
        to launch a generic product &#8220;at risk&#8221; before the expiration of our patent rights/or before the final resolution of related patent litigation. Enforcement of claims in patent litigation can be very costly, time-consuming and no assurance can be
        given that we will prevail. In addition, any such litigation may divert our management&#8217;s attention from our core business and reduce the resources available for our clinical development, manufacturing and marketing activities, and consequently have
        a material and adverse effect on our business and prospects, regardless of the outcome. There is no assurance that ASCENIV, or any other of our products for which we are issued a patent, will enjoy market exclusivity for the full time period of the
        respective patent. </div>

      <div> <br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">54</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div style="font-style: italic; font-weight: bold;">Third parties could obtain patents that may require us to negotiate licenses to conduct our business, and there can be no assurance that the required licenses would be available on reasonable terms
        or at all.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">We may not be able to operate our business without infringing third-party patents. Numerous U.S. and foreign patents and pending patent applications owned by third parties exist in fields that relate to the development
        and commercialization of IG. In addition, many companies have employed intellectual property litigation as a way to gain a competitive advantage. It is possible that infringement claims may occur as the number of products and competitors in our
        market increases. In addition, to the extent that we gain greater visibility and market exposure as a public company, we face a greater risk of being the subject of intellectual property infringement claims. We cannot be certain that the conduct of
        our business does not and will not infringe intellectual property or other proprietary rights of others in the U.S. and in foreign jurisdictions. If our products, methods, processes and other technologies are found to infringe third-party patent
        rights, we could be prohibited from manufacturing and commercializing the infringing technology, process or product unless we obtain a license under the applicable third-party patent and pay royalties or are able to design around such patent. We
        may be unable to obtain a license on terms acceptable to us, or at all, and we may not be able to redesign our products or processes to avoid infringement. Even if we are able to redesign our products or processes to avoid an infringement claim,
        our efforts to design around the patent could require significant time, effort and expense and ultimately may lead to an inferior or more costly product and/or process. Any claim of infringement by a third party, even those without merit, could
        cause us to incur substantial costs defending against the claim and could distract our management from our business. Furthermore, if any such claim is successful, a court could order us to pay substantial damages, including compensatory damages for
        any infringement, plus prejudgment interest and could, in certain circumstances, treble the compensatory damages and award attorney fees. These damages could be substantial and could harm our reputation, business, financial condition and operating
        results. A court also could enter orders that temporarily, preliminarily or permanently prohibit us, our licensees, if any, or our customers from making, using, selling, offering to sell or importing one or more of our products or practicing our
        proprietary technologies or processes, or could enter an order mandating that we undertake certain remedial activities. Any of these events could seriously harm our business, operating results and financial condition.</div>

      <div><br />
      </div>

      <div style="font-style: italic; font-weight: bold;">If we are unable to successfully manage our growth, our business may be harmed.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">Our success will depend on the expansion of our commercial and manufacturing activities, supply of plasma and overall operations and the effective management of our growth, which will place a significant strain on our
        management and on our administrative, operational and financial resources. To manage this growth, we must expand our facilities, augment our operational, financial and management systems and hire and train additional qualified personnel. Our
        ability to accomplish each of these factors may be negatively impacted as a consequence of the COVID-19 pandemic. If we are unable to manage our growth effectively, our business could be harmed.</div>

      <div> <br />
      </div>

      <div style="font-style: italic; font-weight: bold;">The loss of one or more key members of our management team could adversely affect our business.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">Our performance is substantially dependent on the continued service and performance of our management team, who have extensive experience and specialized expertise in our business. In particular, the loss of Adam S.
        Grossman, our President and Chief Executive Officer, could adversely affect our business and operating results. We do not have &#8220;key person&#8221; life insurance policies for any members of our management team. We have employment agreements with each of
        our executive officers; however, the existence of an employment agreement does not guarantee retention of members of our management team and we may not be able to retain those individuals for the duration of or beyond the end of their respective
        terms. The loss of services of key personnel, or the inability to attract and retain additional qualified personnel, could result in delays in development or approval of our product candidates and diversion of management resources.</div>

      <div><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">55</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div>
        <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Cyberattacks and other security breaches could compromise our proprietary and confidential information, which could harm our business and reputation.</div>

      </div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">In the ordinary course of our business, we generate, collect and store proprietary information, including intellectual property and business information. The secure storage, maintenance, and transmission of and access
        to this information is important to our operations and reputation. Computer hackers may attempt to penetrate our computer systems and, if successful, misappropriate our proprietary and confidential information including e-mails and other electronic
        communications. Further, while many of our employees and certain suppliers with whom we do business operate in a remote working environment during the COVID-19 pandemic, the risk of cybersecurity attacks and data breaches, particularly through
        phishing attempts, may be increased as we and third parties with whom we interact leverage our IT infrastructure in unanticipated ways during the ongoing COVID-19 pandemic. In addition, an employee, contractor, or other third party with whom we do
        business may attempt to obtain such information, and may purposefully or inadvertently cause a breach involving such information. While we have certain safeguards in place to reduce the risk of and detect cyberattacks, including a Company-wide
        cybersecurity policy, our information technology networks and infrastructure may be vulnerable to unpermitted access by hackers or other breaches, or employee error or malfeasance. Any such compromise of our data security and access to, or public
        disclosure or loss of, confidential business or proprietary information could disrupt our operations, damage our reputation, provide our competitors with valuable information and subject us to additional costs, which could adversely affect our
        business.</div>

      <div><br />
      </div>

      <div style="font-style: italic; font-weight: bold;">If we are unable to hire and retain a substantial number of qualified personnel, our ability to sustain and grow our business may be harmed.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">Our success depends in part on our ability to attract, motivate, and retain a sufficient number of qualified employees across various areas of our operations, such as research and development, manufacturing operations,
        and sales, who understand and appreciate our strategy and culture and are able to contribute to our mission. We will need to hire additional qualified personnel with expertise in commercialization, sales, marketing, medical affairs, reimbursement,
        government regulation, formulation, quality control, manufacturing and finance and accounting. In particular, over the next 12-24 months, we expect to hire several new employees devoted to commercialization, sales, marketing, medical and scientific
        affairs, regulatory affairs, quality control, finance and general and operational management. Qualified individuals of the requisite caliber and number needed to fill these positions may be in short supply in some areas. We compete for qualified
        individuals with numerous biopharmaceutical companies, universities and other research institutions. Competition for such individuals is intense, and we cannot assure you that our search for such personnel will be successful, particularly if the
        COVID-19 pandemic causes significant changes in the competitive market for such personnel or travel restrictions related to COVID-19 prevent qualified personnel from applying for employment. If we are unable to hire and retain personnel capable of
        consistently performing at a high level, our business and operations could be materially adversely affected. Additionally, any material increases in existing employee turnover rates or increases in labor costs could have a material adverse effect
        on our business, financial condition or operating results.</div>

      <div style="text-indent: 36pt;"> <br />
      </div>

      <div style="font-style: italic; font-weight: bold;">We currently collect human blood plasma at our ADMA BioCenters facilities, and if we cannot maintain FDA approval for these facilities or obtain FDA approval for additional facilities that we create
        or acquire rights to, we may be adversely affected and may not be able to sell or use this human blood plasma for future commercial purposes.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">We intend to maintain FDA approval of our ADMA BioCenters collection facilities for the collection of human blood plasma and we may seek other governmental and regulatory approvals for these facilities. We also plan to
        grow through the building and licensing of additional ADMA BioCenters facilities in various regions of the U.S. Collection facilities are subject to FDA and potentially other governmental and regulatory inspections and extensive regulation,
        including compliance with current cGMP and blood standards, FDA and other government approvals, as applicable. Failure to comply with applicable governmental regulations or to receive applicable approvals for our future facilities may result in
        enforcement actions, such as adverse inspection reports, warning or untitled letters, product recalls or seizures, monetary sanctions, injunctions to halt manufacture and distribution of products, civil or criminal sanctions, costly litigation,
        refusal of regulatory authority approvals and licenses, restrictions on operations or withdrawal of existing approvals and licenses, any of which may significantly delay or suspend our operations for these locations, potentially having a materially
        adverse effect on our ability to manufacture our products or offer for sale plasma collected at the affected sites.</div>

      <div> <br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">56</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div>
        <div style="font-style: italic; font-weight: bold;">We manufacture our current marketed products, pipeline products, and products for third parties in our manufacturing and testing facilities, and if we or our vendors cannot maintain appropriate
          FDA status for these facilities, we may be adversely affected, and may not be able to sell, manufacture or commercialize these products.</div>

      </div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">There are no assurances we will be able to maintain compliance with all FDA or other regulations.&#160; Our third-party vendors may perform activities for themselves or other clients and we may not be privy to all
        regulatory findings or issues discovered by the FDA or other regulatory agencies. Such findings, which are out of our control, may adversely affect our ability to continue to work with these vendors, or our ability to release commercial drug
        product or perform necessary testing or other actions for us or our clients, which may be required in order to remain FDA compliant or to commercialize our products.</div>

      <div> <br />
      </div>

      <div style="font-style: italic; font-weight: bold;">We may incur substantial liabilities and may be required to limit commercialization of our products in response to product liability lawsuits.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">The testing and marketing of medical products entail an inherent risk of product liability. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be
        required to limit commercialization of our products. Even successful defense, however, could impair our results of operations. Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost to protect against
        potential product liability claims could prevent or inhibit the commercialization of pharmaceutical products we develop, either alone or with collaborators.</div>

      <div> <br />
      </div>

      <div style="font-style: italic; font-weight: bold;">Many of our business practices are subject to scrutiny by federal and state regulatory authorities, as well as to lawsuits brought by private citizens under federal and state laws. Failure to comply
        with applicable law or an adverse decision in lawsuits may result in adverse consequences to us.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">The laws governing our conduct in the U.S. are enforceable on the federal and state levels by criminal, civil and administrative penalties. Violations of laws such as the Federal Food, Drug, and Cosmetic Act, the
        Social Security Act (including the Anti-Kickback Statute), the Public Health Service Act and the civil and criminal Federal False Claims Act, the civil monetary penalty statute, requirements regarding the reporting and repayment of overpayments,
        other fraud and abuse laws and any regulations promulgated under the authority of the preceding, may result in jail sentences, fines or exclusion from federal and state programs, as may be determined by Medicare, Medicaid and HHS and other
        regulatory authorities as well as by the courts. Similarly, the violation of applicable laws, rules and regulations of states, including the State of Florida with respect to the manufacture and marketing of our products and product candidates may
        result in jail sentences, fines or exclusion from applicable state programs. There can be no assurance that our activities will not come under the scrutiny of federal and/or state regulators and other government authorities or that our practices
        will not be found to violate applicable laws, rules and regulations or prompt lawsuits by private citizen &#8220;relators&#8221; under federal or state false claims laws.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">For example, under the Anti-Kickback Statute and similar state laws and regulations, the offer or payment of anything of value for patient referrals, or in return for purchasing, leasing, ordering or arranging for or
        recommending the purchase, lease, or ordering of any time or service reimbursable in whole or in part by a federal healthcare program is prohibited.&#160; This places constraints on the marketing and promotion of products and on common business
        arrangements, such as discounted terms and volume incentives for customers in a position to recommend or choose products for patients, such as physicians and hospitals, and these practices can result in substantial legal penalties, including, among
        others, exclusion from the Medicare and Medicaid programs. Arrangements with referral sources such as purchasers, group purchasing organizations, physicians and pharmacists must be structured with care to comply with applicable requirements.
        Legislators and regulators may seek to further restrict the scope of financial relationships that are considered appropriate. For example, HHS recently promulgated a regulation that is effective in two phases.&#160; First, the regulation excludes from
        the definition of &#8220;remuneration&#8221; limited categories of (a) PBM rebates or other reductions in price to a plan sponsor under Medicare Part D or a Medicaid Managed Care Organization plan reflected in point-of sale reductions in price and (b) PBM
        service fees.&#160; Second, effective January 1, 2023, the regulation expressly provides that rebates to plan sponsors under Medicare Part D either directly to the plan sponsor under Medicare Part D, or indirectly through a pharmacy benefit manager will
        not be protected under the anti-kickback discount safe harbor.</div>

      <div><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">57</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div style="text-indent: 36pt;">Also, certain business practices, such as payments of consulting fees to healthcare providers, sponsorship of educational or research grants, charitable donations, interactions with healthcare providers that prescribe
        products for uses not approved by the FDA and financial support for continuing medical education programs, must be conducted within narrowly prescribed and controlled limits to avoid any possibility of wrongfully influencing healthcare providers to
        prescribe or purchase particular products or as a reward for past prescribing. Under the Patient Protection and Affordable Care Act (&#8220;ACA&#8221;) and the companion Health Care and Education Reconciliation Act, which together are referred to as the
        &#8220;Healthcare Reform Law,&#8221; payments and transfers of value by pharmaceutical manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with
        certain exceptions)&#160; to or at the request of covered recipients, such as, but limited to, physicians, physician assistants, nurse practitioners, clinical nurse specialists and certified registered nurse anesthetists and teaching hospitals, must be
        tracked and reported to CMS, and are publicly disclosed. Such &#8220;applicable manufacturers&#8221; are also required to report certain ownership interests held by physicians and their immediate family members. A number of states have similar laws in place.
        Additional and stricter prohibitions could be implemented by federal and state authorities. Where such practices have been found to be improper incentives to use such products, government investigations and assessments of penalties against
        manufacturers have resulted in substantial damages and fines. Many manufacturers have been required to enter into consent decrees or orders that prescribe allowable corporate conduct.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">Failure to satisfy requirements under the Federal Food, Drug, and Cosmetic Act can also result in penalties, as well as requirements to enter into consent decrees or orders that prescribe allowable corporate conduct.
        In addition, while regulatory authorities generally do not regulate physicians&#8217; discretion in their choice of treatments for their patients, they do restrict communications by manufacturers on unapproved uses of approved products or on the
        potential safety and efficacy of unapproved products in development. Companies in the U.S., Canada and the European Union cannot promote approved products for other indications that are not specifically approved by the competent regulatory
        authorities such as the FDA in the U.S., nor can companies promote unapproved products. In limited circumstances, companies may disseminate to physicians information regarding unapproved uses of approved products or results of studies involving
        investigational products. If such activities fail to comply with applicable regulations and guidelines of the various regulatory authorities, we may be subject to warnings from, or enforcement action by, these authorities. Furthermore, if such
        activities are prohibited, it may harm demand for our products. Promotion of unapproved drugs or devices or unapproved indications for a drug or device is a violation of the Federal Food, Drug, and Cosmetic Act and subjects us to civil and criminal
        sanctions. Furthermore, sanctions under the Federal False Claims Act have recently been brought against companies accused of promoting off-label uses of drugs, because such promotion induces the use and subsequent claims for reimbursement under
        Medicare and other federal programs. Similar actions for off-label promotion have been initiated by several states for Medicaid fraud. The Healthcare Reform Law significantly strengthened provisions of the Federal False Claims Act, the
        Anti-Kickback Statute that applies to Medicare and Medicaid, and other healthcare fraud provisions, leading to the possibility of greatly increased qui tam suits by relators for perceived violations. Violations or allegations of violations of the
        foregoing restrictions could materially and adversely affect our business.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">We are required to report detailed pricing information, net of included discounts, rebates and other concessions, to CMS for the purpose of calculating national reimbursement levels, certain federal prices and certain
        federal and state rebate obligations. Inaccurate or incomplete reporting of pricing information could result in liability under the False Claims Act, the federal Anti-Kickback Statute and various other laws, rules and regulations.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">We will need to establish systems for collecting and reporting this data accurately to CMS and institute a compliance program to assure that the information collected is complete in all respects. If we report pricing
        information that is not accurate to the federal government, we could be subject to fines and other sanctions that could adversely affect our business. If we choose to pursue clinical development and commercialization in the European Union or
        otherwise market and sell our products outside of the U.S., we must obtain and maintain regulatory approvals and comply with regulatory requirements in such jurisdictions. The approval procedures vary among countries in complexity and timing. We
        may not obtain approvals from regulatory authorities outside the U.S. on a timely basis, if at all, which would preclude us from commercializing products in those markets.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">In addition, some countries, particularly the countries of the European Union, regulate the pricing of prescription pharmaceuticals. In these countries, pricing discussions with governmental authorities can take
        considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to
        other available therapies. Such trials may be time-consuming and expensive and may not show an advantage in efficacy for our products. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at
        unsatisfactory levels, in either the U.S. or the European Union, we could be adversely affected.</div>

      <div> <br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">58</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div style="text-indent: 36pt;">Also, under the U.S. Foreign Corrupt Practices Act, the U.S. has increasingly focused on regulating the conduct by U.S. businesses occurring outside of the U.S., generally prohibiting remuneration to foreign officials
        for the purpose of obtaining or retaining business. To enhance compliance with applicable healthcare laws, and mitigate potential liability in the event of noncompliance, regulatory authorities such as the HHS Office of Inspector General (the
        &#8220;OIG&#8221;) have recommended the adoption and implementation of a comprehensive healthcare compliance program that generally contains the elements of an effective compliance and ethics program described in Section 8B2.1 of the U.S. Sentencing Commission
        Guidelines Manual. Increasing numbers of U.S.-based pharmaceutical companies have such programs. We will need to adopt healthcare compliance and ethics programs that would incorporate the OIG&#8217;s recommendations and train our employees. Such a
        program may be expensive and may not provide assurance that we will avoid compliance issues.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">We are also required to comply with the applicable laws, rules, regulations and permit requirements of the various states in which our business operates, including the State of Florida where our manufacturing facility
        is located.&#160; These regulations and permit requirements are not always in concert with applicable federal laws, rules and regulations regulating our business.&#160; Although compliant with applicable federal requirements, we may be required to comply
        with additional state laws, rules, regulations and permits.&#160; Failure to appropriately comply with such state requirements could result in temporary or long-term cessation of our manufacturing operations, as well as fines and other sanctions.&#160; Any
        such penalties may have a material adverse effect on our business and results of operations.</div>

      <div><br />
      </div>

      <div style="font-style: italic; font-weight: bold;">We are subject to extensive and rigorous governmental regulation, including the requirement of FDA and other federal, state and local business regulatory<span style="color: rgb(0, 0, 255);">&#160;</span>approval








        before our products and product candidates may be lawfully marketed, and our ability to obtain regulatory approval of our products and product candidates from the FDA in a timely manner, access the public markets and obtain necessary capital in
        order to properly capitalize and continue our operations may be hindered by inadequate funding for the FDA, the SEC and other state and local government agencies.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">Both before and after the approval of our products, our products, operations, facilities, suppliers and contract research organizations are subject to extensive regulation by federal, state and local governmental
        authorities in the U.S. and other countries, with regulations differing from country to country. In the U.S., the FDA regulates, among other things, the pre-clinical testing, clinical trials, manufacturing, safety, efficacy, potency, labeling,
        storage, record keeping, quality systems, advertising, promotion, sale and distribution of therapeutic products. Failure to comply with applicable requirements could result in, among other things, one or more of the following actions: notices of
        violation, untitled letters, warning letters, complete response letters, fines and other monetary penalties, unanticipated expenditures, delays in approval or refusal to approve a product or product candidate, product recall or seizure,
        interruption of manufacturing or clinical trials, operating restrictions, injunctions and criminal prosecution. Our products and product candidates cannot be lawfully marketed in the U.S. without FDA and other federal, state and local business
        regulatory approval. Any failure to receive the marketing approvals necessary to commercialize our product or product candidates could harm our business.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">Additionally, the ability of the FDA and other federal, state and local business regulatory agencies to review and approve products and product candidates can be affected by a variety of factors, including government
        budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the FDA and other federal, state and local business regulatory agencies
        have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political
        process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for products and product candidate submissions to be reviewed and/or approved by necessary government agencies, which
        would adversely affect our business. For example, over the last several years, including in December 2018 and January 2019, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and SEC, have had to
        furlough critical employees and stop critical activities. If a prolonged government shutdown reoccurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions and other reporting requirements
        which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</div>

      <div><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">59</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div style="font-style: italic; font-weight: bold;">The manufacturing processes for plasma-based biologics are complex and involve biological intermediates that are susceptible to contamination and impurities.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">Plasma is a raw material that is susceptible to damage and contamination and may contain human pathogens, any of which would render the plasma unsuitable as raw material for further manufacturing. For instance,
        improper storage of plasma, by us or third-party suppliers, may require us to destroy some of our raw material. If unsuitable plasma is not identified and discarded prior to the release of the plasma to the manufacturing process, it may be
        necessary to discard intermediate or finished product made from that plasma or to recall any finished product released to the market, resulting in a charge to cost of product revenue. The manufacture of our plasma products is an extremely complex
        process of fractionation, purification, testing, filling and finishing. Our products can become non-releasable or otherwise fail to meet our stringent specifications or regulatory agencies&#8217; specifications through a failure in one or more of these
        process steps. We may detect instances in which an unreleased product was produced without adherence to our manufacturing procedures or plasma used in our production process was not collected or stored in a compliant manner consistent with our cGMP
        or other regulations. Such an event of noncompliance would likely result in our determination that the implicated products should not be released or maybe replaced or withdrawn from the market and therefore should be destroyed. Once manufactured,
        our plasma-derived products must be handled carefully and kept at appropriate temperatures. Our failure, or the failure of third parties that supply, test, ship or distribute our products or product components to properly care for our products, may
        require that those products be destroyed. Even if handled properly, biologics may form or contain particulates or have other issues or problems after storage which may require products to be destroyed or recalled. While we expect to write off small
        amounts of work-in-progress in the ordinary course of business due to the complex nature of plasma, our processes and our products, unanticipated events may lead to write-offs and other costs materially in excess of our expectations and the
        reserves we have established for these purposes. Such write-offs and other costs could cause material fluctuations in our results of operations. Product or component quality issues may also result in regulatory enforcement actions, liability,
        corrective actions and recalls, among other actions, as described elsewhere in this annual report.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">Furthermore, contamination of our products could cause investors, consumers, or other third parties with whom we conduct business to lose confidence in the reliability of our manufacturing procedures, which could
        adversely affect our revenues. In addition, faulty or contaminated products that are unknowingly distributed could result in patient harm, threaten the reputation of our products and expose us to product liability damages and claims from companies
        for whom we do contract manufacturing.</div>

      <div> <br />
      </div>

      <div style="font-style: italic; font-weight: bold;">Our ability to continue to produce safe and effective products depends on the safety of our plasma supply, testing by third parties and the timing of receiving the testing results, and manufacturing
        processes against transmittable diseases.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">Despite overlapping safeguards, including the screening of donors and other steps to remove or inactivate viruses and other infectious disease-causing agents, the risk of transmissible disease through blood plasma
        products cannot be entirely eliminated. For example, since plasma-derived therapeutics involves the use and purification of human plasma, there has been concern raised about the risk of transmitting HIV, prions, West Nile virus, H1N1 virus or
        &#8220;swine flu&#8221; and other blood-borne pathogens through plasma-derived products. There are also concerns about the future transmission of H5N1 virus, or &#8220;bird flu.&#8221; In the 1980s, thousands of hemophiliacs worldwide were infected with HIV through the
        use of contaminated Factor VIII. Other producers of Factor VIII, though not us, were defendants in numerous lawsuits resulting from these infections. New infectious diseases emerge in the human population from time to time. If a new infectious
        disease has a period during which time the causative agent is present in the bloodstream but symptoms are not present, it is possible that plasma donations could be contaminated by that infectious agent. Typically, early in an outbreak of a new
        disease, tests for the causative agent do not exist. During this early phase, we must rely on screening of donors for behavioral risk factors or physical symptoms to reduce the risk of plasma contamination. Screening methods are generally less
        sensitive and specific than a direct test as a means of identifying potentially contaminated plasma units. During the early phase of an outbreak of a new infectious disease, our ability to manufacture safe products would depend on the manufacturing
        process&#8217; capacity to inactivate or remove the infectious agent. To the extent that a product&#8217;s manufacturing process is inadequate to inactivate or remove an infectious agent, our ability to manufacture and distribute that product would be
        impaired. If a new infectious disease were to emerge in the human population, such as COVID-19, or if there were a reemergence of an infectious disease, the regulatory and public health authorities could impose precautions to limit the transmission
        of the disease that would impair our ability to procure plasma, manufacture our products or both. Such precautionary measures could be taken before there is conclusive medical or scientific evidence that a disease poses a risk for plasma-derived
        products. In recent years, new testing and viral inactivation methods have been developed that more effectively detect and inactivate infectious viruses in collected plasma. There can be no assurance, however, that such new testing and inactivation
        methods will adequately screen for, and inactivate, infectious agents in the plasma used in the production of our products.</div>

      <div> <br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">60</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div style="font-style: italic; font-weight: bold;">We could become supply-constrained and our financial performance would suffer if we cannot obtain adequate quantities of FDA-approved source plasma with proper specifications or other necessary raw
        materials.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">In order for plasma to be used in the manufacturing of our products, the individual centers at which the plasma is collected must generally be licensed by the FDA and approved by the regulatory authorities of any
        country in which we may wish to commercialize our products. When we open a new plasma center, and on an ongoing basis after licensure, it must be inspected by the FDA for compliance with cGMP and other regulatory requirements. Therefore, even if we
        are able to construct new plasma collection centers to complement our current plasma collection facilities, an unsatisfactory inspection could prevent a new center from being licensed or risk the suspension or revocation of an existing license,
        among other enforcement actions. We do not and will not have adequate plasma to manufacture our products. Therefore, we are reliant on the purchase of plasma from third parties to manufacture our products. We can give no assurances that appropriate
        plasma will be available to us on commercially reasonable terms, or at all, to manufacture our products. Further, the COVID-19 pandemic has resulted in, and may continue to result in, significant constraints in raw material supply across various
        different industries, including the supply of plasma. It is possible that in the future, the COVID-19 pandemic and government responses thereto will have an adverse effect on our ability to source plasma from donors in quantity and quality
        sufficient for our manufacturing processes. In order to maintain a plasma center&#8217;s license, its operations must continue to conform to cGMP and other regulatory requirements. In the event that we determine that plasma was not collected in
        compliance with cGMP and other applicable regulatory requirements, we may be unable to use and may ultimately destroy plasma collected from that center, which would be recorded as a charge to cost of product revenue. Additionally, if non-compliance
        in the plasma collection process is identified after the impacted plasma has been pooled with compliant plasma from other sources, entire plasma pools, in-process intermediate materials and final products could be impacted. Consequently, we could
        experience significant inventory impairment provisions and write-offs which could adversely affect our business and financial results. We plan to increase our supplies of plasma for use in the manufacturing processes through increased purchases of
        plasma from third-party suppliers as well as collections from our existing ADMA BioCenters plasma collection facilities. This strategy is dependent upon our ability to maintain a cGMP compliant environment at our plasma collection facilities and to
        expand production and attract donors to our facilities. There is no assurance that the FDA will inspect and license any of our current or future unlicensed plasma collection facilities in a timely manner consistent with our production plans. If we
        misjudge the readiness of a center for an FDA inspection, we may lose credibility with the FDA and cause the FDA to more closely examine all of our operations. Such additional scrutiny could materially hamper our operations and our ability to
        increase plasma collections. Our ability to expand production and increase our plasma collection facilities to more efficient production levels may be affected by changes in the economic environment and population in selected regions where ADMA
        BioCenters operates its current or future plasma facilities, by the entry of competitive plasma centers into regions where ADMA BioCenters operates such centers, by misjudging the demographic potential of individual regions where ADMA BioCenters
        expects to expand production and attract new donors, by unexpected facility related challenges, or by unexpected management challenges at selected plasma facilities held by us from time to time.</div>

      <div> <br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">61</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div>
        <div style="font-style: italic; font-weight: bold;">Our ability to commercialize our products, alone or with collaborators, will depend in part upon the extent to which reimbursement will be available from governmental agencies, health
          administration authorities, private health maintenance organizations and health insurers and other healthcare payers, and also depends upon the approval, timing and representations by the FDA or other governmental authorities for our product
          candidates.</div>

      </div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">Our ability to generate product revenues will be diminished if our products sell for inadequate prices or patients are unable to obtain adequate levels of coverage. Significant uncertainty exists as to the
        reimbursement status of newly approved healthcare products, as well as to the timing, language, specifications and other details pertaining to the approval of such products. Healthcare payers, including Medicare, are challenging the prices charged
        for medical products and services. Government and other healthcare payers increasingly attempt to contain healthcare costs by limiting both coverage and the level of reimbursement for products. Even if one of our product candidates is approved by
        the FDA, insurance coverage may not be available, and reimbursement levels may be inadequate, to cover such product. If government and other healthcare payers do not provide adequate coverage and reimbursement levels for one of our products, once
        approved, market acceptance of such product could be reduced. Prices in many countries, including many in Europe, are subject to local regulation and certain pharmaceutical products, such as plasma-derived products, are subject to price controls in
        several of the world&#8217;s principal markets, including many countries within the European Union. In the U.S., where pricing levels for our products are substantially established by third-party payers, including Medicare, if payers reduce the amount of
        reimbursement for a product, it may cause groups or individuals dispensing the product to discontinue administration of the product, to administer lower doses, to substitute lower cost products or to seek additional price-related concessions. These
        actions could have a negative effect on our financial results, particularly in cases where our products command a premium price in the marketplace, or where changes in reimbursement induce a shift in the site of treatment. The existence of direct
        and indirect price controls and pressures over our products could materially adversely affect our financial prospects and performance.</div>

      <div> <br />
      </div>

      <div style="font-style: italic; font-weight: bold;">The new biosimilar pathway established as part of healthcare reform may make it easier for competitors to market biosimilar products.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">The Healthcare Reform Law introduced an abbreviated licensure pathway for biological products that are demonstrated to be biosimilar to an FDA-licensed biological product.&#160; A biological product may be demonstrated to
        be &#8220;biosimilar&#8221; if data shows that, among other things, the product is &#8220;highly similar&#8221; to an already-approved biological product, known as a reference product, and has no clinically meaningful differences in terms of safety and effectiveness from
        the reference product. The law provides that a biosimilar application may be submitted as soon as four years after the reference product is first licensed, and that the FDA may not make approval of an application effective until 12 years after the
        reference product was first licensed.&#160; Since the enactment of the law, the FDA has issued several guidance documents to assist sponsors of biosimilar products in preparing their approval applications. Moreover, in an effort to increase competition
        in the biologic product marketplace, Congress, the executive branch, and the FDA have taken certain legislative and regulatory steps. For example, in 2020 the FDA finalized a guidance to facilitate biologic product importation. The 2020 Further
        Consolidated Appropriations Act included provisions requiring that sponsors of approved biologic products provide samples of the approved products to persons developing biosimilar products within specified timeframes, in sufficient quantities, and
        on commercially reasonable market-based terms The FDA approved the first biosimilar product in 2015 and has since approved a number of biosimilars.&#160; As a result of the biosimilar pathway in the U.S., we expect in the future to face greater
        competition from biosimilar products, including a possible increase in patent challenges.</div>

      <div><br />
      </div>

      <div style="font-style: italic; font-weight: bold;">The implementation of the Healthcare Reform Law in the U.S. may adversely affect our business.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">Through the March 2010 adoption of the Healthcare Reform Law in the U.S., substantial changes are being made to the current system for paying for healthcare in the U.S., including programs to extend medical benefits to
        millions of individuals who currently lack insurance coverage. This reform establishes significant cost-saving measures with respect to several government healthcare programs, including Medicaid and Medicare Parts B and D, that may cover the cost
        of our future products, and these efforts could have a material adverse impact on our future financial prospects and performance. For example, in order for a manufacturer&#8217;s products to be reimbursed by federal funding under Medicaid, the
        manufacturer must enter into a Medicaid rebate agreement with the Secretary of HHS and pay certain rebates to the states based on utilization data provided by each state to the manufacturer and to CMS and pricing data provided by the manufacturer
        to the federal government. The states share these savings with the federal government, and sometimes implement their own additional supplemental rebate programs. Under the Medicaid drug rebate program, the rebate amount for most branded drug
        products was previously equal to a minimum of 15.1% of the Average Manufacturer Price (&#8220;AMP&#8221;) or the AMP less Best Price, whichever is greater. Effective January 1, 2010, the Healthcare Reform Law generally increased the size of the Medicaid
        rebates paid by manufacturers for single source and innovator multiple source (brand name) drug products from a minimum of 15.1% to a minimum of 23.1% of AMP, subject to certain exceptions. For non-innovator multiple source (generic) products, the
        rebate percentage was increased from a minimum of 11.0% to a minimum of 13.0% of AMP.&#160; In 2010, the Healthcare Reform Law also newly extended this rebate obligation to prescription drugs covered by Medicaid managed care organizations. These
        increases in required rebates may adversely affect our future financial prospects and performance. In order for a pharmaceutical product to receive federal reimbursement under the Medicare Part B and Medicaid programs or to be sold directly to U.S.
        government agencies, the manufacturer must extend discounts to entities eligible to participate in the 340B drug pricing program.&#160; The required 340B discount on a given product is calculated based on the AMP and Medicaid rebate amounts reported by
        the manufacturer.&#160; As the 340B drug pricing is determined based on AMP and Medicaid rebate data, the revisions to the Medicaid rebate formula and AMP definition described above could cause the required 340B discount to increase.</div>

      <div> <br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">62</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div style="text-indent: 36pt;">Effective in 2011, the Healthcare Reform Law imposed an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, apportioned among these entities
        according to their market share in certain government healthcare programs. These fees may adversely affect our future financial prospects and performance.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">The Healthcare Reform Law also created new rebate obligations for our products under Medicare Part D, a partial, voluntary prescription drug benefit created by the U.S. federal government primarily for persons 65 years
        old and over. The Part D drug program is administered through private insurers that contract with CMS. Beginning in 2011, the Healthcare Reform Law generally requires that in order for a drug manufacturer&#8217;s products to be reimbursed under Medicare
        Part D, the manufacturer must enter into a Medicare Coverage Gap Discount Program agreement with the Secretary of HHS, and reimburse each Medicare Part D plan sponsor an amount now equal to 70% savings for the manufacturer&#8217;s brand name drugs and
        biologics which the Part D plan sponsor has provided to its Medicare Part D beneficiaries who are in the &#8220;donut hole&#8221; (or a gap in Medicare Part D coverage for beneficiaries who have expended certain amounts for drugs). The Part D plan sponsor is
        responsible for calculating and providing the discount directly to its beneficiaries and for reporting these amounts paid to CMS&#8217;s contractor, which notifies drug manufacturers of the rebate amounts it must pay to each Part D plan sponsor. The
        rebate requirement could adversely affect our future financial performance, particularly if contracts with Part D plans cannot be favorably renegotiated or the Part D plan sponsors fail to accurately calculate payments due in a manner that
        overstates our rebate obligation. Regarding access to our products, the Healthcare Reform Law established and provided significant funding for a Patient-Centered Outcomes Research Institute to coordinate and fund Comparative Effectiveness Research
        (&#8220;CER&#8221;). While the stated intent of CER is to develop information to guide providers to the most efficacious therapies, outcomes of CER could influence the reimbursement or coverage for therapies that are determined to be less cost-effective than
        others. Should any of our products be determined to be less cost effective than alternative therapies, the levels of reimbursement for these products, or the willingness to reimburse at all, could be impacted, which could materially impact our
        future financial prospects and results.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">There have been repeated attempts by Congress to repeal or change the Healthcare Reform Law and there are ongoing legal challenges, including at the Supreme Court, which may contribute to the uncertainty of the ongoing
        implementation and impact of the law and also underscores the potential for additional reform going forward. We cannot assure that the law, as currently enacted or as amended in the future, will not adversely affect our business and financial
        results and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.&#160; Certain provisions of enacted or proposed legislative changes may negatively impact coverage
        and reimbursement of, or rebates paid by manufacturers for, healthcare items and services. We will continue to evaluate the effect that the Healthcare Reform Law and any potential changes may have on our business.</div>

      <div style="text-indent: 36pt;"> <br />
      </div>

      <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Corporate responsibility, specifically related to environmental, social and governance (&#8220;ESG&#8221;) matters, may impose additional costs and expose us to new risks.</div>

      <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;"> <br />
      </div>

      <div style="text-indent: 36pt;"><span style="color: rgb(0, 0, 0);">Public ESG and sustainability reporting is becoming more broadly expected by investors, stockholders and other third parties. Certain organizations that provide corporate governance
          and other corporate risk information to investors and stockholders have developed, and others may in the future develop, scores and ratings to evaluate companies and investment funds based upon ESG or &#8220;sustainability&#8221; metrics. Many investment
          funds focus on positive ESG business practices and sustainability scores when making investments and may consider a company&#8217;s ESG or sustainability scores as a reputational or other factor in making an investment decision. In addition, investors,
          particularly institutional investors, use these scores to benchmark companies against their peers and if a company is perceived as lagging, these investors may engage with such company to improve ESG disclosure or performance and may also make
          voting decisions, or take other actions, to hold these companies and their boards of directors accountable. Board diversity is an ESG topic that is, in particular, receiving heightened attention by investors, stockholders, lawmakers and listing
          exchanges. Certain states have passed laws requiring companies to meet certain gender and ethnic diversity requirements on their boards of directors. We may face reputational damage in the event our corporate responsibility initiatives or
          objectives, including with respect to board diversity, do not meet the standards set by our investors, stockholders, lawmakers, listing exchanges or other constituencies, or if we are unable to achieve an acceptable ESG or sustainability rating
          from third-party rating</span><span style="color: rgb(255, 0, 0);">&#160;</span><span style="color: rgb(0, 0, 0);">services. A low ESG or sustainability rating by a third-party rating service could also result in the exclusion of our common stock from
          consideration by certain investors who may elect to invest with our competition instead. Ongoing focus on corporate responsibility matters by investors and other parties as described above may impose additional costs or expose us to new risks.</span></div>

      <div><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">63</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div style="font-weight: bold;">Risks Relating to our Finances, Capital Requirements and Other Financial Matters</div>

      <div style="font-weight: bold;"> <br />
      </div>

      <div style="font-style: italic; font-weight: bold;">We require additional funding and may be unable to raise capital when needed, which would force us to delay, curtail or eliminate one or more of our research and development programs or
        commercialization efforts.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">Our operations have consumed substantial amounts of cash since inception. For the six months ended June 30, 2021 and 2020, we had negative cash flows from operations of $65.5 million and $45.9 million, respectively,
        and for the years ended December 31, 2020 and 2019, we had negative cash flows from operations of approximately $102.0 million and $76.2 million, respectively. We expect to continue to spend substantial amounts on procurement of raw material plasma
        and other raw materials necessary to scale up our manufacturing operations, commercial product launches, capacity expansion at the Boca Facility, building additional plasma collection facilities, product development, quality assurance, regulatory
        affairs and conducting clinical trials for our product candidates and purchasing clinical trial materials, some of which may be required by the FDA. In addition, our end-to-end production cycle from procurement of raw materials to commercial
        release of finished product can take between seven and 12 months or potentially longer, requiring substantial investments in raw material plasma and other manufacturing materials. We expect that we will not be able to generate a sufficient amount
        of product revenue to achieve profitability until the beginning of 2024 and, as a result, we expect that we will need to continue to finance our operations through additional equity or debt financings or corporate collaboration and licensing
        agreements.&#160; We currently anticipate, based upon our projected revenue and expenditures, that our current cash, cash equivalents and accounts receivable will be sufficient to fund our operations, as currently conducted, into the fourth quarter of
        2021. In order to have sufficient cash to fund our operations thereafter, we will need to raise additional equity or debt financing before the end of the fourth quarter of 2021. This time frame may change based upon how quickly we are able to
        execute on our operational initiatives and the various financing options that may be available to us in 2021. However, if the assumptions underlying our estimated expenses prove to be incorrect, we may have to raise additional capital sooner than
        we currently expect. Until such time, if ever, as we can generate a sufficient amount of product revenue to achieve profitability, we expect to continue to finance our operations through additional equity or debt financings or corporate
        collaboration and licensing arrangements. If we are unable to raise additional capital as needed, including due to widespread liquidity constraints or significant market instability that could result from the COVID-19 pandemic, we will have to
        delay, curtail or eliminate our commercialization efforts or our product development activities.</div>

      <div><br />
      </div>

      <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">We may not have cash available to us in amounts sufficient to enable us to make interest or principal payments on our indebtedness when due.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">The Perceptive Credit Facility provides for term loans of up to an aggregate principal amount of $100.0 million, all of which has been drawn down and is currently outstanding. Borrowings under the Perceptive Credit
        Facility bear interest at a rate per annum equal to 7.5% plus the greater of (i) one-month LIBOR and (ii) 3.5%; provided, however, that upon, and during the continuance of, an Event of Default, the interest rate will automatically increase by an
        additional 400 basis points. We are required to make monthly payments of interest during the term of the Perceptive Credit Facility of approximately $0.9 million, with all principal and unpaid interest due at maturity. The Perceptive Credit
        Facility has a maturity date of March 1, 2024, subject to acceleration pursuant to the Perceptive Credit Agreement, including upon an Event of Default. All of our obligations under the Perceptive Credit Facility are secured by a first-priority lien
        and security interest in substantially all of our and our subsidiaries&#8217; tangible and intangible assets, including intellectual property, and all of the equity interests in our subsidiaries.</div>

      <div><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">64</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div style="text-indent: 36pt;">Our current cash, cash equivalents and accounts receivable will not be sufficient to repay all of our current outstanding debt obligations as they mature. If we are unable to obtain additional financing and are
        otherwise unable to become profitable and generate cash from operations in the amounts necessary to repay our outstanding debt obligations when due, including as a result of the impact of the COVID-19 pandemic, our creditors would be able to
        accelerate all of the amounts due and, in the case of the Perceptive Credit Facility, seek to enforce their security interests, which could lead to our creditors taking immediate possession of and selling substantially all of our assets with no
        return provided to our stockholders.</div>

      <div> <br />
      </div>

      <div style="font-style: italic; font-weight: bold;">Raising additional funds by issuing securities or through licensing or lending arrangements may cause dilution to our existing stockholders, restrict our operations or require us to relinquish
        proprietary rights.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">To the extent that we raise additional capital by issuing equity securities, the share ownership of existing stockholders will be diluted. Any future debt financing may involve covenants that, among other restrictions,
        limit our ability to incur liens or additional debt, pay dividends, redeem or repurchase our common stock, make certain investments or engage in certain merger, consolidation or asset sale transactions. In addition, if we raise additional funds
        through licensing arrangements or the disposition of any of our assets, it may be necessary to relinquish potentially valuable rights to our product candidates or grant licenses on terms that are not favorable to us.</div>

      <div> <br />
      </div>

      <div style="font-style: italic; font-weight: bold;">Our cash and cash equivalents could be adversely affected if the financial institutions in which we hold our cash and cash equivalents fail.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">We regularly maintain cash balances at third-party financial institutions in excess of the Federal Deposit Insurance Corporation insurance limit. While we monitor the cash balances in our operating accounts on a daily
        basis and adjust the balances as appropriate, these balances could be impacted, and there could be a material adverse effect on our business, if one or more of the financial institutions with which we deposit cash fails or is subject to other
        adverse conditions in the financial or credit markets. To date, we have experienced no loss or lack of access to our invested cash or cash equivalents; however, we can provide no assurance that access to our invested cash and cash equivalents will
        not be impacted by adverse conditions in the financial and credit markets.</div>

      <div> <br />
      </div>

      <div style="font-style: italic; font-weight: bold;">If we fail to maintain proper and effective internal control over financial reporting in the future, our ability to produce accurate and timely financial statements could be impaired, which could
        harm our operating results, investors&#8217; views of us and, as a result, the value of our common stock.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 (the &#8220;Sarbanes-Oxley Act&#8221;) and related rules, our management is required to report on the effectiveness of our internal control over financial reporting. The
        rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a
        reporting company under the Exchange Act, we have been required to upgrade, and may need to implement further upgrades, to our financial, information and operating systems, implement additional financial and management controls, reporting systems
        and procedures and hire additional accounting and finance staff.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">Consequently, we have incurred increased costs related to our compliance with Section 404 of the Sarbanes-Oxley Act and will continue to do so. Our Audit Committee has retained the services of BDO, a Sarbanes-Oxley
        advisor, to assist with our internal control over financial reporting and information technology relating to Section 404. Moreover, if we are not able to comply with the requirements of Section 404 applicable to us in a timely manner, or if we or
        our independent registered public accounting firm identifies deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, the market price of our common stock could decline and we could be subject to
        sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources.</div>

      <div> <br />
      </div>

      <div style="font-style: italic; font-weight: bold;">Our ability to use our net operating loss carryforwards (&#8220;NOLs&#8221;) may be limited.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">We have incurred substantial losses during our history. As of December 31, 2020, we had federal and state NOLs of $239.8 million and $172.6 million, respectively. Federal and State NOLs of approximately $115.8 million
        and $90.0 million, respectively, will begin to expire at various dates beginning in 2027, if not limited by triggering events prior to such time. Under the provisions of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), changes in our
        ownership, in certain circumstances, will limit the amount of federal NOLs that can be utilized annually in the future to offset taxable income. In particular, Section 382 of the Code imposes limitations on a company&#8217;s ability to use NOLs upon
        certain changes in such ownership. If we are limited in our ability to use our NOLs in future years in which we have taxable income, we will pay more taxes than if we were able to fully utilize our NOLs. The Biotest Transaction on June 6, 2017
        resulted in a change in ownership of ADMA under Section 382 and, as a result, we were required to write off $57.6 million of federal NOLs. We may experience ownership changes in the future as a result of subsequent changes in our stock ownership
        that we cannot predict or control that could result in further limitations being placed on our ability to utilize our federal NOLs.</div>

      <div> <br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">65</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div style="font-weight: bold;">Risks Associated with our Common Stock</div>

      <div style="font-weight: bold;"> <br />
      </div>

      <div style="font-style: italic; font-weight: bold;">The market price of our common stock may be volatile and may fluctuate in a way that is disproportionate to our operating performance.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">Our stock price may experience substantial volatility as a result of a number of factors, including:</div>

      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>sales or potential sales of substantial amounts of our common stock;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>uncertainties in the equity markets related to the effects of the COVID-19 pandemic;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>delay or failure in initiating or completing preclinical or clinical trials or unsatisfactory results of these trials;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>delay in a decision by federal, state or local business regulatory authority;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>the timing of acceptance, third-party reimbursement and sales of BIVIGAM and ASCENIV;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>announcements about us or about our competitors, including clinical trial results, regulatory approvals or new product introductions;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>developments concerning our licensors or third-party vendors;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>litigation and other developments relating to our patents or other proprietary rights or those of our competitors;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>conditions in the pharmaceutical or biotechnology industries;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>governmental regulation and legislation;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>overall market volatility;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>variations in our anticipated or actual operating results; and</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>change in securities analysts&#8217; estimates of our performance, or our failure to meet analysts&#8217; expectations.</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <div>Many of these factors are beyond our control. The stock markets in general, and the market for pharmaceutical and biotechnology companies in particular, have historically experienced extreme price and volume fluctuations. These fluctuations
        often have been unrelated or disproportionate to the operating performance of these companies. These broad market and industry factors could reduce the market price of our common stock, regardless of our actual operating performance.</div>

      <div> <br />
      </div>

      <div style="font-style: italic; font-weight: bold;">Sales of a substantial number of shares of our common stock, or the perception that such sales may occur, may adversely affect the market price of our common stock.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">As of August 6, 2021, most of our 132,769,471 outstanding shares of common stock, as well as a substantial number of shares of our common stock underlying outstanding warrants, were available for sale in the public
        market, subject to certain restrictions with respect to sales of our common stock by our affiliates, either pursuant to Rule 144 under the Securities Act, or under effective registration statements. Sales of a substantial number of shares of our
        common stock, or the perception that such sales may occur, could cause the market price of our common stock to decline or adversely affect demand for our common stock.</div>

      <div><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">66</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div style="font-style: italic; font-weight: bold;">Our affiliates control a substantial amount of our shares of common stock. Provisions in our Second Amended and Restated Certificate of Incorporation (the &#8220;Certificate of Incorporation&#8221;), our
        Amended and Restated Bylaws (the &#8220;Bylaws&#8221;) and Delaware law might discourage, delay or prevent a change in control of our Company or changes in our management and, therefore, depress the trading price of our common stock.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">As of June 30, 2021, Perceptive, our directors and executive officers and their affiliates beneficially owned approximately 18% of the outstanding shares of our common stock. Provisions of our Certificate of
        Incorporation, our Bylaws and Delaware law may have the effect of deterring unsolicited takeovers or delaying or preventing a change in control of our Company or changes in our management, including transactions in which our stockholders might
        otherwise receive a premium for their shares over then current market prices. In addition, these provisions may limit the ability of stockholders to approve transactions that they may deem to be in their best interests. These provisions include:</div>

      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>the inability of stockholders to call special meetings;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>classification of our Board and limitation on filling of vacancies could make it more difficult for a third party to acquire, or discourage a third party from seeking to acquire control of our Company; and</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>authorization of the issuance of &#8220;blank check&#8221; preferred stock, with such designation rights and preferences as may be determined from time to time by the Board, without any need for action by stockholders.</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <div style="text-indent: 36pt;">In addition, Section 203 of the Delaware General Corporation Law prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person which together
        with its affiliates owns, or within the last three years, has owned 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is
        approved in a prescribed manner.&#160; The existence of the foregoing provisions and anti-takeover measures could limit the price that investors might be willing to pay in the future for shares of our common stock. They could also deter potential
        acquirers of our company, thereby reducing the likelihood that you could receive a premium for your common stock in an acquisition. In addition, as a result of the concentration of ownership of our shares of common stock, our stockholders may, from
        time to time, observe instances where there may be less liquidity in the public markets for our securities.</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt;">Our Board also recently adopted a short-term stockholder rights agreement with an expiration date of December 15, 2021 and an ownership trigger threshold of 10%. This stockholder rights agreement could render more
        difficult or discourage a merger, tender offer or assumption of control of the Company that is not approved by our Board. The rights agreement, however, should not interfere with any merger, tender or exchange offer or other business combination
        approved by our Board. In addition, the rights agreement does not prevent our Board from considering any offer that it considers to be in the best interest of the Company&#8217;s stockholders.</div>

      <div> <br />
      </div>

      <div style="font-style: italic; font-weight: bold;">We have never paid and do not intend to pay cash dividends in the foreseeable future. As a result, capital appreciation, if any, will be your sole source of gain.</div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">We have never paid cash dividends on any of our capital stock and we currently intend to retain future earnings, if any, to fund the development and growth of our business. In addition, the terms of existing and future
        debt agreements may preclude us from paying dividends. For example, the Perceptive Credit Agreement prohibits us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the
        foreseeable future.</div>

      <div> <br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">67</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div>
        <div style="font-style: italic; font-weight: bold;">If we fail to adhere to the strict listing requirements of the Nasdaq Global Market (&#8220;Nasdaq&#8221;), we may be subject to delisting. As a result, our stock price may decline and our common stock may be
          delisted.&#160; If our stock were no longer listed on Nasdaq, the liquidity of our securities likely would be impaired.</div>

      </div>

      <div> <br />
      </div>

      <div style="text-indent: 36pt;">Our Common Stock currently trades on the Nasdaq Global Market under the symbol &#8220;ADMA.&#8221; If we fail to adhere to Nasdaq&#8217;s strict listing criteria, including with respect to stock price, market capitalization and
        stockholders&#8217; equity, our stock may be delisted. This could potentially impair the liquidity of our securities not only in the number of shares that could be bought and sold at a given price, which may be depressed by the relative illiquidity, but
        also through delays in the timing of transactions and the potential reduction in media coverage. As a result, an investor might find it more difficult to dispose of our common stock. We believe that current and prospective investors would view an
        investment in our common stock more favorably if it continues to be listed on Nasdaq. Any failure at any time to meet the Nasdaq continued listing requirements could have an adverse impact on the value and trading activity of our common stock.
        Although we currently satisfy the listing criteria for Nasdaq, if our stock price declines dramatically, we could be at risk of failing to meet the Nasdaq continued listing criteria.</div>

      <div> <br />
      </div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Penny stock regulations may affect your ability to sell our common stock.</div>

      <div style="text-align: justify;"> <br />
      </div>

      <div style="text-indent: 36pt;">Because the price of our common stock currently trades below $5.00 per share, our common stock is subject to Rule 15g-9 under the Exchange Act, which imposes additional sales practice requirements on broker-dealers
        which sell these securities to persons other than established customers and accredited investors. Under these rules, broker-dealers who recommend penny stocks to persons other than established customers and &#8220;accredited investors&#8221; must make a
        special written suitability determination for the purchaser and receive the purchaser&#8217;s written agreement to a transaction prior to sale, which includes an acknowledgement that the purchaser&#8217;s financial situation, investment experience and
        investment objectives forming the basis for the broker-dealer&#8217;s suitability determination are accurately stated in such written agreement. Unless an exception is available, the regulations require the delivery, prior to any transaction involving a
        penny stock, of a disclosure schedule explaining the penny stock market and the associated risks. The additional burdens imposed upon broker-dealers by these requirements could discourage broker-dealers from effecting transactions in our common
        stock and may make it more difficult for holders of our common stock to sell shares to third parties or to otherwise dispose of them.</div>

      <div> <br />
      </div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Our Board may, without stockholder approval, issue and fix the terms of shares of preferred stock and issue additional shares of common stock adversely affecting the rights of
        holders of our common stock.</div>

      <div style="text-align: justify;"> <br />
      </div>

      <div style="text-indent: 36pt;">Our Certificate of Incorporation authorizes the issuance of up to 10,000,000 shares of &#8220;blank check&#8221; preferred stock, with such designation rights and preferences as may be determined from time to time by the Board.
        Currently, our Certificate of Incorporation authorizes the issuance of up to 300,000,000 shares of common stock. As of June 30, 2021, there were 151,054,617 shares remaining available for issuance, after giving effect to 12,997,322 shares of our
        common stock that were subject to outstanding stock options, Restricted Stock Units and warrants as of June 30, 2021 that may be issued by us without stockholder approval, as well as an additional 4,076,035 shares reserved for the future issuance
        of awards under our equity compensation plans.</div>

      <div><br />
      </div>

      <a id="Item2."><!--Anchor--></a>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 45pt; vertical-align: top; font-weight: bold;">Item 2.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Unregistered Sales of Equity Securities and Use of Proceeds.</div>
            </td>

  </tr>


</table>
      <div style="margin-left: 36pt;"> <br />
      </div>

      <div style="margin-left: 36pt;">None.</div>

      <div><br />
      </div>

      <a id="Item3."><!--Anchor--></a>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 45pt; vertical-align: top; font-weight: bold;">Item 3.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Defaults Upon Senior Securities.</div>
            </td>

  </tr>


</table>
      <div style="text-indent: 36pt;"> <br />
      </div>

      <div style="text-indent: 36pt;">None.</div>

      <div><br />
      </div>

      <a id="Item4."><!--Anchor--></a>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 45pt; vertical-align: top; font-weight: bold;">Item 4.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Mine Safety Disclosures.</div>
            </td>

  </tr>


</table>
      <div style="text-indent: 36pt;"> <br />
      </div>

      <div style="text-indent: 36pt;">Not applicable.</div>

      <div><br />
      </div>

      <a id="Item5."><!--Anchor--></a>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 45pt; vertical-align: top; font-weight: bold;">Item 5.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Other Information.</div>
            </td>

  </tr>


</table>
      <div style="text-indent: 36pt;"><br />
      </div>

      <div style="text-indent: 36pt;">
        <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On August 6, 2021, the Company entered into a Separation Agreement and Release (the &#8220;Separation Agreement&#8221;) with James Mond (&#8220;Mond&#8221;),
          following his voluntary resignation on June 8, 2021 (the &#8220;Separation Date&#8221;) from his former role as Chief Medical Officer and Chief Scientific Officer of the Company, as previously reported in the Company&#8217;s Current Report on Form 8-K filed with
          the SEC on June 14, 2021. Subject to the expiration of a revocation period, the Separation Agreement will become effective on August 12, 2021 (the &#8220;Effective Date&#8221;).</div>

        <div><br />
        </div>

        <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Under the terms of the Separation Agreement,&#160; Mond will receive approximately $0.8 million in certain separation benefits, subject to
          his continued compliance with the terms of the Separation Agreement, including: (i) salary continuation for a period of ten months beginning on August 1, 2021 through May 1, 2022 (the &#8220;Severance Period&#8221;); (ii) certain cash payments subject to
          customary and ordinary tax withholdings, as payments for bonus, the forfeiture of restricted stock units, reimbursement of certain expenses; (iii) an extension providing that, subject to the terms and conditions of the applicable plan or award
          agreement, Mond has twenty-four (24) months to exercise vested options from the Effective Date; (iv) at his election, the Company will reimburse Mond the same employer premium percentage contribution in effect on the Separation Date for continued
          health coverage under the Consolidated Omnibus Budget Reconciliation Act (COBRA) through the Severance Period; and (v) payment for accrued and unused paid time off.</div>

        <div><br />
        </div>

        <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to the Separation Agreement, Mond has agreed to cooperate with the Company during the Severance Period to assist with
          transition matters and among other items, has released all prior, existing or future claims he had, has or may have against the Company and has agreed to certain customary confidentiality, non-disparagement, work-product assignment, non-compete
          and non-solicitation provisions.</div>

        <div><br />
        </div>

        <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The foregoing description of the Separation Agreement does not purport to be complete and is qualified in its entirety by reference to
          the full text of the Separation Agreement, which is filed herewith as Exhibit 10.2.</div>

      </div>

      <div style="text-indent: 36pt;"><br />
      </div>

      <a id="Item6."><!--Anchor--></a>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 45pt; vertical-align: top; font-weight: bold;">Item 6.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Exhibits</div>
            </td>

  </tr>


</table>
      <div style="text-indent: 36pt;"> <br />
      </div>

      <div style="text-indent: 36pt;">See the Exhibit Index immediately following the signature page of this Quarterly Report on Form 10-Q.</div>

      <div style="text-indent: 36pt;"> <br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">68</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div style="text-align: center; font-weight: bold;"><a id="SIGNATURES"><!--Anchor--></a>SIGNATURES</div>

      <div style="text-align: center; font-weight: bold;"> <br />
      </div>

      <div style="text-indent: 36pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</div>

      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="vertical-align: top;" colspan="3">
              <div style="text-align: justify; font-weight: bold;">ADMA Biologics, Inc.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="vertical-align: top;" colspan="3">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify;">Date:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;August 11, 2021</div>
            </td>

    <td style="width: 3%; vertical-align: top;">
              <div style="text-align: justify;">By:</div>
            </td>

    <td style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
              <div>
                <div style="text-align: justify;">/s/ Adam S. Grossman</div>
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">
              <div style="text-align: justify;">Name:</div>
            </td>

    <td style="width: 42%; vertical-align: top;">
              <div style="text-align: justify;">Adam S. Grossman</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">
              <div style="text-align: justify;">Title:</div>
            </td>

    <td style="width: 42%; vertical-align: top;">
              <div style="text-align: justify;">President and Chief Executive Officer</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">&#160;</td>

    <td style="width: 42%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify;">Date:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;August 11, 2021</div>
            </td>

    <td style="width: 3%; vertical-align: top;">
              <div style="text-align: justify;">By:</div>
            </td>

    <td style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
              <div>
                <div style="text-align: justify;">/s/ Brian Lenz</div>
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">
              <div style="text-align: justify;">Name:</div>
            </td>

    <td style="width: 42%; vertical-align: top;">
              <div style="text-align: justify;">Brian Lenz</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">
              <div style="text-align: justify;">Title:</div>
            </td>

    <td style="width: 42%; vertical-align: top;">
              <div style="text-align: justify;">Executive Vice President and Chief Financial Officer</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">69</span></div>

        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 100%; font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></td>

  </tr>


</table>
        </div>

      </div>

      <div style="text-align: center; text-indent: 36pt; font-weight: bold;">EXHIBIT INDEX</div>

      <div style="text-align: center; text-indent: 36pt; font-weight: bold;"> <br />
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 12%; vertical-align: top;">
              <div><span style="text-decoration: underline;">Exhibit Number</span></div>
            </td>

    <td style="width: 88%; vertical-align: top;">
              <div><span style="text-decoration: underline;">Description</span></div>
            </td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top;">&#160;</td>

    <td style="width: 88%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1368514/000119380521000749/e620651_ex3-1.htm">3.1</a></div>
            </td>

    <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="color: rgb(0, 0, 0);">Certificate of Amendment of the Second Amended and Restated Certificate of Incorporation of ADMA Biologics, Inc., dated as of May 27, 2021 (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Current
                Report on Form 8-K filed with the SEC on May 28, 2021).</div>
            </td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top;">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1368514/000119380521000751/e620652_ex1-1.htm">10.1</a></div>
            </td>

    <td style="width: 88%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Open Market Sale Agreement<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">SM</sup>, dated May 28, 2021, by and between ADMA Biologics, Inc. and Jefferies LLC (incorporated by
                reference to Exhibit 1.1 of the Company&#8217;s Current Report on Form 8-K filed with the SEC on May 28, 2021).</div>
            </td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255);" rowspan="1">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="brhc10027771_ex10-2.htm">10.2*</a></div>
            </td>

    <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);" rowspan="1">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Separation Agreement and Release, dated August 6, 2021, by and between ADMA Biologics, Inc. and James Mond.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top;">
              <div><a href="brhc10027771_ex31-1.htm">31.1*</a></div>
            </td>

    <td style="width: 88%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="brhc10027771_ex31-2.htm">31.2*</a></div>
            </td>

    <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="color: rgb(0, 0, 0);">Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top;">
              <div><a href="brhc10027771_ex32-1.htm">32.1**</a></div>
            </td>

    <td style="width: 88%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Certification of Principal Executive Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="brhc10027771_ex32-2.htm">32.2**</a></div>
            </td>

    <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="color: rgb(0, 0, 0);">Certification of Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top;">
              <div>101*</div>
            </td>

    <td style="width: 88%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">The following materials from ADMA Biologics, Inc.&#8217;s Form 10-Q for the quarter ended June 30, 2021, formatted in Extensible Business Reporting Language (XBRL): (i) Condensed Consolidated Balance Sheets as of
                June 30, 2021 (Unaudited) and December 31, 2020, (ii) Condensed Consolidated Statements of Operations (Unaudited) for the three and six months ended June 30, 2021 and 2020, (iii) Condensed Consolidated Statements of Changes in Stockholders&#8217;
                Equity (Unaudited) for the three and six months ended June 30, 2021 and 2020, (iv) Condensed Consolidated Statements of Cash Flows (Unaudited) for the six months ended June 30, 2021 and 2020, and (v) Notes to (Unaudited) Condensed
                Consolidated Financial Statements.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>104</div>
            </td>

    <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="color: rgb(0, 0, 0);">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div>
        <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto 0px 0px; height: 2px; width: 18%; color: #000000; margin-left: 0px; margin-right: auto;" /></div>

      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top;">*</td>

    <td style="width: auto; vertical-align: top;">
              <div>Filed herewith.</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top;">**</td>

    <td style="width: auto; vertical-align: top;">
              <div>In accordance with SEC Release 33-8238, Exhibit 32.1 and 32.2 are being furnished and not filed.</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div><br /></div>

      <div style="text-align: center;"><span style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: 'Times New Roman';" class="DSPFPageNumber">70</span></div>

      <div style="text-align: center;">
<div><span style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: 'Times New Roman';" class="DSPFPageNumber"><br /></span></div>

        <hr style="height: 2px; color: #000000; background-color: #000000; border: none; margin-left: auto; margin-right: auto;" /></div>

    </div>


  </div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>2
<FILENAME>brhc10027771_ex10-2.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, LLC
         Document created using EDGARfilings PROfile 8.0.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <!--PROfilePageNumberReset%Num%1%%%-->


  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div style="font-weight: bold;">
      <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Exhibit 10.2</div>
    </div>
    <div>
      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><u>SEPARATION AGREEMENT AND RELEASE</u></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">THIS SEPARATION AGREEMENT AND RELEASE (the &#8220;Agreement&#8221;) is made and entered into by and between Dr. James Mond (hereafter &#8220;Employee&#8221;)
        and ADMA Biologics, Inc. on behalf of itself and each of its subsidiaries, affiliates, divisions, predecessors, successors, and assigns (hereinafter referred to collectively as the &#8220;Company&#8221; or &#8220;ADMA Biologics&#8221;).</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to the terms and conditions set forth herein and in consideration of the premises and mutual promises contained herein, it is
        agreed by and between Employee and the Company as follows:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">1.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>Separation Date</u></font>:&#160; Employee&#8217;s last date of employment with ADMA Biologics was June 8, 2021 (the &#8220;Separation Date&#8221;).&#160; Employee agrees and
          represents that from and after the Separation Date, Employee will not be, nor will Employee hold himself out as, an employee, consultant, affiliate or agent of ADMA Biologics. While not an employee of ADMA Biologics after the Separation Date,
          Employee agrees to abide by the confidentiality and other obligations of this Agreement as set forth herein.</font></div>
      <div>&#160;<br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">2.</font>&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>Separation Benefits</u></font>:&#160; In consideration of the releases and covenants given by Employee as set forth in this Agreement and Employee&#8217;s
          compliance therewith, and provided that Employee signs and does not revoke this Agreement and further complies with its terms and conditions, ADMA Biologics agrees as follows:</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>Salary Continuation</u></font>:&#160; For a period of ten (10) months beginning on August 1, 2021 through May 1, 2022 (the &#8220;Severance Period&#8221;), the Company will pay Employee
          on a monthly basis the equivalent of his monthly base salary subject to the tax withholdings used prior to the Separation Date (the &#8220;Severance Payments&#8221;) paid on the regularly scheduled payroll dates.&#160; The first Severance Payment will be made on
          the next regularly scheduled payroll date following the Effective Date of this Agreement. Severance Payments are contingent on Employee&#8217;s continued compliance with the terms of this Agreement including, but not limited to, cooperation pursuant to
          Section 8 below.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>Bonus Payment</u></font>:&#160; The Company will pay employee the total gross sum of $140,000.00, subject to the customary and ordinary tax withholdings, payable as follows:
          (1) $70,000.00 paid within 30 days of the Effective Date; and (2) $70,000.00 paid at the expiration of the Severance Period.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>Restricted Stock Unit Payment</u></font>: Employee forfeits all unvested restricted stock units and in lieu thereof the Company shall pay Employee the total gross sum of
          $175,000.00 subject to the customary and ordinary tax withholdings, payable as follows: (1) 87,500.00 paid within 30 days of the Effective Date; and (2) $87,500.00 paid at the expiration of the Severance Period.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>Exercise Extension</u></font>:&#160; Employee shall have twenty-four (24) months to exercise any stock option vested as of the Effective Date of this Agreement.&#160; All options
          remain otherwise subject to the terms and conditions of any plan document and/or grant agreement.</font></div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
        </font></div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">1</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>Repricing Participation</u></font>:&#160; In the event the Company&#8217;s Board of Directors approves a stock option exchange program or other repricing mechanism, then Employee&#8217;s
          vested stock options shall be, subject to the terms and conditions of the Company&#8217;s equity incentive plan, able to participate in any such program or repricing that occurs during the Severance Period.&#160; The options are otherwise subject to the
          terms and conditions of any plan document and/or grant agreement.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>Expense Reimbursement</u></font>: The Company agrees to reimburse Employee&#8217;s relocation expenses in the total gross sum $30,000.00, subject to the customary and ordinary
          tax withholdings, paid within 30 days of the Effective Date.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(g)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>Attorneys&#8217; Fees</u></font>:&#160; The Company will pay Employee&#8217;s legal fees and costs incurred in negotiating this Agreement in the total gross sum of $15,000.00, payable
          within 30 days of the Effective Date of this Agreement by a check made payable to Neuberger Quinn Gielen Rubin Gibber P.A., One South Street, 27th Floor, Baltimore, MD 21202.&#160; This payment will be reported as &#8220;miscellaneous&#8221; income on Forms 1099
          to be issued to Employee and Neuberger Quinn Gielen Rubin Gibber P.A.&#160; Employee&#8217;s counsel will provide the Company with fully executed W-9s for Neuberger Quinn Gielen Rubin Gibber P.A and Employee.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(h)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>COBRA</u></font>:&#160; If Employee timely elects continued health coverage under the Consolidated Omnibus Budget Reconciliation Act (COBRA), the Company agrees to reimburse
          Employee the same employer premium percentage contribution in effect on the Separation Date through the Severance Period, provided Employee remains eligible for COBRA benefits and does not qualify for health coverage under another employer during
          this period.&#160; Accordingly, Employee agrees to notify Company as soon as possible after Employee becomes eligible for health insurance coverage under another employer or ceases to be eligible for COBRA benefits.&#160; Notwithstanding the foregoing, if
          the payments made by the Company under this Section 2(h) would violate the nondiscrimination rules or result in the imposition of penalties under the Patient Protection and Affordable Care Act of 2010 and related regulations and guidance, the
          parties agree to reform this Section 2(h) as necessary to ensure compliance.&#160; Payment(s) under this Section will be made within fourteen (14) days of submission by Employee of proof of payment.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Employee acknowledges
          that Employee would not be entitled to receive the consideration set forth in this Section 2 absent execution of this Agreement and agrees that the amount of the consideration set forth herein is greater than any amount Employee is otherwise
          entitled to receive from ADMA Biologics, Inc. and/or the Releasees (as that term is defined below) under any law, contract, policy, promise, expectation, or otherwise, either as compensation, wages, commissions, incentives, accrued but unused
          vacation or paid time off, severance, benefits, reimbursements, damages, or otherwise.&#160; In the event the Internal Revenue Service, or any other state or local taxing entity, or any court or other tribunal of competent jurisdiction, determines
          that all or part of these payments are remuneration for which any taxes are due and owing by the Company, except the Company&#8217;s employer share/contribution, Employee shall be solely responsible for the payment of such taxes.&#160; Employee agrees not
          to make a claim against the Company for the payment of any such taxes, or for any related interest or penalties.&#160; Employee also agrees to indemnify the Company for any amounts paid, including, but not limited to, interest and penalties, in
          connection with any taxes that Employee may owe based on these payments.</font></div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
        </font></div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">2</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">3.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>Business Expense Reimbursement</u></font>:<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">&#160; </font>The
          Company will reimburse Employee for all approved and documented business expenses incurred prior to the Separation Date, provided that Employee submits to the Company prior to the Effective Date, an expense report with adequate documentation of
          such expenses in accordance with the Company&#8217;s policies.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">4.</font>&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>Other Rights and Benefits</u></font>:&#160; As of the Separation Date, Employee&#8217;s (i) accrual of paid time off, (ii) participation in any and all health,
          dental and prescription plans, and (iii) participation in any and all Life, AD&amp;D, long term disability, and 401(k) retirement savings plans will terminate.&#160; Employee&#8217;s execution of this Agreement shall not diminish any benefits vested
          pursuant to the terms of any Employee Retirement Income Security Act of 1974 (ERISA) employee pension or 401(k) benefit plan, which benefits shall continue to be subject to the terms of applicable plan documents.&#160;&#160; The Company shall pay Employee
          for 33.75 hours of vacation/PTO.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">5.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>Full Discharge of Obligations</u></font>:&#160; Employee understands and agrees that Employee is not entitled to, and will not receive, any payments or
          benefits of any kind (including but not limited to wages, bonus payments, incentive compensation payments, or other payments to which Employee otherwise might have been entitled) from the Company except as expressly set forth herein above.
          Employee further represents that Employee has or will receive all compensation, including salary payments, due and owing through the Separation Date.&#160; In addition, Employee understands and agrees that after the Separation Date, Employee will not
          accrue any further benefits under any of the Company&#8217;s applicable plans.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">6.</font>&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>Release</u></font>:&#160; As a material inducement to the Company to enter into this Agreement and to give Employee the benefits described above, Employee
          forever releases and discharges the Company and each of its predecessors, successors, assigns, partners, directors, officers, members, managers, stockholders, employees, representatives, attorneys, agents, divisions, subsidiaries, and affiliates
          (and the past and present partners, directors, officers, members, managers, stockholders, employees, representatives, attorneys and agents of such divisions, subsidiaries and affiliates), and all persons acting by, through, under, or in concert
          with any of them (hereinafter the &#8220;Releasees&#8221;), from any and all charges, complaints, claims, liabilities, obligations, promises, agreements, controversies, damages, actions, causes of action, suits, rights, demands, costs, losses, debts and
          expenses (including attorneys&#8217; fees and costs actually incurred) of any nature whatsoever, in law or equity, known or unknown, suspected or unsuspected, that Employee and Employee&#8217;s issue, heirs, representatives, successors, agents, executors,
          administrators and assigns ever had, now has or hereafter can, shall or may have for, upon, or by reason of any matter, cause or thing whatsoever through the date of this Agreement, including but not limited to any claims arising out of his
          employment by the Company and the cessation of such employment; any claims for unpaid wages, back pay, bonuses, incentive pay, vacation pay, legal fees, severance or other compensation; any claims arising under any contracts, express or implied,
          or any covenant of good faith and fair dealing, express or implied; any tort, including without limitation intentional infliction of emotional distress, defamation, fraud and breach of duty; any legal restrictions on the Company&#8217;s right to
          terminate employees; and any federal, state, local, or other governmental common law, statute, regulation, or ordinance, including without limitation: Title VII of the Civil Rights Act of 1964, the Civil Rights Act of 1991, the Age Discrimination
          in Employment Act of 1967, the Older Workers&#8217; Benefit Protection Act, the Genetic Information Nondiscrimination Act of 2008, the Worker and Adjustment Retraining Notification (&#8220;WARN&#8221;) Act, the Illinois WARN statutes, the New Jersey WARN statutes,
          the New Jersey Law Against Discrimination, the New Jersey Conscientious Employee Protection Act, the New Jersey Family Leave Act, the New Jersey Temporary Disability Benefits Law, the New Jersey Wage Payment Law, the New Jersey Wage and Hour Law,
          the New Jersey Workers&#8217; Compensation Law, the Americans with Disabilities Act, the Florida Whistleblower Protection Act, the Florida Workers&#8217; Compensation Retaliation provision, the Florida Minimum Wage Act, the Florida Constitution, the Florida
          Fair Housing Act, the Equal Pay Act, the Employee Retirement Income Security Act, the Rehabilitation Act of 1973, and the Family and Medical Leave Act of 1993, each of the foregoing as amended; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>provided, however</u></font>, that nothing contained herein shall serve to waive any (a) claims or rights that, pursuant to law, cannot be legally waived or subject to a release of this kind, such as claims for
          unemployment or workers&#8217; compensation benefits; (b) rights to vested benefits under any applicable retirement plans as of the Separation Date; (c) rights to vested stock options and rights arising under any stock option agreement and Company
          equity incentive plan; and/or (d) claims arising under or to enforce the terms of this Agreement. Moreover, nothing herein shall be construed to prohibit Employee from filing a charge with, or participating in any investigation or proceeding
          conducted by, the Equal Employment Opportunity Commission or a comparable state or local agency (&#8220;EEOC&#8221;); provided, however, that Employee agrees and covenants to waive his right to recover monetary damages in any such EEOC charge, complaint, or
          lawsuit filed by Employee or by any other person, organization, or other entity on Employee&#8217;s behalf with respect to the claims lawfully released by this Agreement.</font></div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
        </font></div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">3</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">7.</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>Representations</u></font>:</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The Company represents
          and acknowledges that it is not aware of any claim, if any, that it may have against Employee as of the signing of this Agreement.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(b)</font>&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Employee acknowledges
          that as an employee of the Company it has been Employee&#8217;s obligation to advise the Company completely and candidly of all facts of which Employee is aware that constitute or might constitute violations of the Company&#8217;s ethical standards or legal
          or regulatory obligations.&#160; Employee represents and warrants that Employee is not aware of any such facts or that Employee has previously advised the Company about any such facts. Employee further agrees to advise the Company in the future of all
          such facts that come to Employee&#8217;s attention; and</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Employee, for himself
          and Employee&#8217;s issue, heirs, representatives, successors, agents, executors, administrators, and assigns, represents and warrants that, to the fullest extent permitted by law, Employee has not filed any complaints or charges or lawsuits against
          the Company with any governmental agency or court.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">8.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>Cooperation</u></font>:&#160; Employee and the Company agree that certain matters in which Employee has been involved during his employment may require his
          cooperation with the Company in the future.&#160; Accordingly, to the extent reasonably requested by the Company and to help ensure a smooth and honorable transition from the Company, during business hours for the duration of the Severance Period,
          Employee agrees to cooperate with the Company upon its reasonable request to provide assistance via telephone, e-mail or in-person meetings in connection with any matters in which Employee was involved while employed by the Company.&#160; In
          particular, but without limitation, Employee agrees to make himself reasonably available via telephone, e-mail or in-person meetings during such period to the Company to respond to requests by the Company for information relating to scientific or
          intellectual property matters within the scope of Employee&#8217;s responsibility prior to the Separation Date, including with respect to Company patents, patent applications or other formal intellectual property related documents, any Company-related
          scholarly articles, any litigation, arbitration or governmental or regulatory inquiry or investigation, or similar proceeding, and to provide truthful testimony to any court, agency or other adjudicatory body.</font></div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
        </font></div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">4</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">9.</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>Confidentiality</u></font>:&#160; (a) Employee agrees not to disclose, divulge, publish, communicate, publicize, disseminate or otherwise reveal, either
          directly or indirectly, any Confidential Information (as defined below) to any person, natural or legal, who is not affiliated with the Company (i.e., employees, principal stockholders and directors), otherwise bound by an agreement with the
          Company or obligation of confidentiality for the benefit of the Company or in need of such information in connection with services to be provided for the benefit of the Company. The term "Confidential Information" means all information in any
          form relating to the past, present or future business affairs, including without limitation, research, development or business plans, operations or systems, of the Company or a person not a party to this Agreement whose information the Company
          has in its possession under obligations of confidentiality, which is disclosed by the Company to Employee or which is produced or developed while Employee is an owner of, employee or director of the Company. The term &#8220;Confidential Information&#8221;
          shall not include any information of the Company which becomes publicly known through no wrongful act of Employee or is received from a person not a party to this Agreement who is free to disclose it to Employee.&#160; To the fullest extent permitted
          by law, Employee further agrees not to divulge to anyone (other than the Company or any persons employed or designated by ADMA Biologics), publish, or make use of any such Confidential Information without the prior written consent of the
          Company.&#160; Employee (i) may make and retain electronic copies of his contact list and calendar and (ii) may retain any documentation relevant to and reasonably necessary to file his income tax returns.&#160; Employee&#8217;s obligations in this Section are
          in addition to any of Employee&#8217;s continuing obligations under the Confidentiality, Non-Disclosure, E-Mail, Telephone, Fax and Computer Policy and Agreement, provided to Employee when Employee began employment with the Company (&#8220;Confidentiality
          and Non-Disclosure Agreement&#8221;), as well as the Company&#8217;s Insider Trading Policy which continuing obligations remain in full force and effect and are expressly incorporated herein.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Nothing in this
          Agreement is intended to or shall preclude Employee from: (i) providing truthful testimony on any subject matter in response to a valid subpoena, court order, regulatory request or other judicial, administrative or legal process or otherwise as
          required by law, in which event Employee shall notify the Company of the anticipated testimony in writing, unless prohibited to do so by law, as promptly as practicable after receiving any such request and at least ten (10) business days prior to
          providing such testimony (or, if such notice is not possible under the circumstances, with as much prior notice as is possible) so that the Company may seek a protective order or other appropriate remedy; or (ii) reporting, without any prior
          authorization from, or notification to, the Company, possible violations of federal law or regulation to any governmental agency or entity, including but not limited to the Securities and Exchange Commission, the Department of Justice, Congress,
          and any agency Inspector General, or making other disclosures that are protected under the whistleblower provisions of federal law or regulation.&#160; If such a protective order or other remedy described in clause (i) of the foregoing sentence is not
          obtained, or the Company waives compliance with this Agreement, Employee shall furnish only that portion of such subject matter that is legally required and shall exercise all reasonable efforts to obtain reliable assurance that confidential
          treatment will be accorded to the subject matter to be disclosed.</font></div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
        </font></div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">5</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(c)</font>&#160;&#160;&#160; &#160; &#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Employee is hereby
          further notified in accordance with the Defend Trade Secrets Act of 2016 that Employee will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that: (i) is made in confidence
          to a federal, state, or local government official, either directly or indirectly, or to an attorney, solely for the purpose of reporting or investigating a suspected violation of law; or (ii) is made in a complaint or other document filed in a
          lawsuit or other proceeding, if such filing is made under seal.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Employee expressly
          agrees to keep secret and strictly confidential, the circumstances leading up to this Agreement except: (a) with the prior written consent of the Company; (b) to Employee&#8217;s attorney or tax preparers, provided such individuals are specifically
          instructed to maintain such information as confidential and agree to keep said information strictly confidential and not disclose it to others; or (c) as may be required by law, including in response to valid legal process or upon request by a
          government taxing authority or other government entity.&#160; Moreover, this Agreement and its terms shall not be used or disclosed in any court, arbitration or legal proceedings, except to enforce the provisions of this Agreement, in which case the
          Agreement shall be filed under seal.&#160; In the event that Employee is compelled to make disclosures related to any released party pursuant to a subpoena or other court process, or Employee has advance notice that a subpoena or other court process
          may result in the disclosure of confidential information, or Employee should reasonably conclude that a subpoena or other court process may result in the disclosure of Confidential Information, then Employee shall provide advance written notice
          of such compelled disclosure to the Company within sufficient time for the Company to object to disclosure.&#160; The Employee expressly agrees and acknowledges that the Company may publicly disclose the existence and terms of this Agreement,
          including through the Company&#8217;s filings with the Securities and Exchange Commission.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><a name="z_Hlk78962923"></a><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">10.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>Return of Company Property</u></font>:&#160; As of the Effective Date, Employee will have returned to the Company all
          Confidential Information, files, memoranda, and records, cardkey passes, door and file keys, computer access codes, software, corporate credit card, equipment, including cell phones and computers, and other property which he received, acquired,
          or prepared in connection with his employment with the Company, and any and all copies, duplicates, reproductions, synopses, and/or excerpts thereof (collectively, &#8220;Company Property&#8221;). Employee further agrees and certifies herein that by no later
          than the Effective Date, Employee has permanently and irrevocably deleted any and all intangible Company Property, including any Company emails or documents sent to, by or from any Company employee, including himself, which exists or is stored
          (i) in any e-mail account; (ii) in any &#8220;cloud&#8221; account; or (iii) on any computer, tablet, cellular phone or smartphone, the foregoing of which are accessible, controlled, or owned by him.&#160; The consideration detailed in Section 2 above is
          contingent on Employee&#8217;s compliance with his obligations under this Section.</font></div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
        </font></div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">6</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">11.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>Non-Disparagement</u></font>:&#160; Employee agrees not to directly or indirectly, or encourage others, to defame, disparage or criticize the Company, its
          business plan, procedures, products, services, development, finances, financial condition, capabilities or other aspect of its business, or any of its stockholders in any medium (whether oral, written, electronic or otherwise, whether currently
          existing or hereafter created), to any person or entity, without limitation in time. Nothing in this Agreement is intended to (a) preclude the Employee from making any truthful statement to the extent required by law or by any court, arbitrator,
          mediator or administrative or legislative body with actual or apparent jurisdiction to order such person to disclose or make accessible such information; or (b) unlawfully impair or interfere with Employee&#8217;s rights under Section 7 of the National
          Labor Relations Act.&#160; The Company agrees to instruct Adam Grossman and Brian Lenz to not directly or indirectly, or encourage others, to defame or disparage Employee in any medium (whether oral, written, electronic or otherwise).&#160; The parties
          understand that this provision is a material one.</font></div>
      <div><br>
      </div>
      <div style="text-align: left; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">12.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>Work Product Assignment</u></font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">: </font>Employee
          hereby assigns to the Company all of his right, title and interest in and to, and shall disclose promptly to the Company, any and all work product, developments, processes, inventions, ideas and discoveries, and works of authorship developed,
          discovered, improved, authored, derived, invented or acquired by Employee during the period of his employment by the Company (collectively, "Work Product"), whether or not during business hours, that are either related to the scope of Employee 's
          employment by the Company or make use, in any manner, to the dedicated resources of the Company, and agrees that such Work Product shall be and shall remain the exclusive property of the Company. The parties hereto understand that the term Work
          Product includes, but is not limited to, all work product developed, discovered, improved, authored, derived, invented or acquired by Employee that: (i) incorporates or reflects any Confidential information, (ii) relates to the business of the
          Company or the Company's actual or anticipated research and development with respect to Confidential Information, or (iii) results from any work performed by Employee for the Company. Work Product shall not include anything relating to a
          potential transaction or matter which involves the business of the Company as then conducted (or is related thereto, or a business the Company is then contemplating entering) and may be an investment or business opportunity or of prospective
          economic or competitive advantage to the Company, with respect to which the Board of Directors of the Company has made a determination not to pursue.</font></div>
      <div><br>
      </div>
      <div style="text-align: left; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">13.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>Non-Competition</u></font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">: </font>Employee absolutely
          and unconditionally covenants and agrees that, for the period commencing on the Separation Date through the period ending 12 months thereafter (the &#8220;Restrictive Period&#8221;), Employee will not, either directly or indirectly, solely or jointly with
          any other person or persons, as an employee, consultant or advisor, or as an individual proprietor, partner, stockholder, director, officer, joint venturer, investor, lender or in any other capacity (whether or not engaged in business for
          profit), engage or participate in a Competing Business (as defined below). Nothing herein contained shall, however, prohibit Employee&#8217;s acquisition or ownership of (i) stock or securities listed on a national or regional securities exchange or
          the Nasdaq Stock Market, so long as such investments, in the aggregate, in any particular business enterprise constitute less than five percent (5%) of the total issued and outstanding stock and securities of such enterprise or (ii) passive
          investment in units or other interests in private equity or hedge funds to similar investment vehicles. The term &#8220;Competing Business&#8221; means (i) the manufacture and sale of immune globulin intravenous (IGIV) and hyperimmune immunoglobulin (IG),
          (ii) plasma collection, (iii) the manufacture of plasma products competitive with products manufactured by or under development by the Company, (iv) the manufacture of vaccines to stimulate hyperimmune donors, and (v) any other specific business
          being conducted by the Company during the term of the Employee&#8217;s employment with the Company.&#160; Nothing herein shall restrict the ability of any of the Permitted Entities, as such term is used in Employee&#8217;s Amended and Restated Employment
          Agreement (which is otherwise superseded), to continue the conduct of their existing businesses.</font></div>
      <div style="text-align: left; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
        </font></div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">7</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">14.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>Non-Solicitation</u></font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">:&#160; </font>Employee
          absolutely and unconditionally covenants and agrees that, during the Restrictive Period, Employee will not, either directly or indirectly, for any reason, whether for Employee&#8217;s own account or for the account of any other person, natural or
          legal, without the prior written consent of the Company: (i) solicit, employ, deal with or otherwise interfere with any contract or relationship of the Company with any employee, officer, director or any independent contractor of the Company,
          while such person or entity is employed by or associated with the Company or in the case of former employees within one year of the termination of such person's employment with the Company during the Restrictive Period, unless such person was
          terminated without cause by the Company, (ii) solicit, accept, deal with or otherwise interfere with any contract or relationship of the Company with any independent contractor, customer, client or supplier of the Company or with any person,
          natural or legal the effect of which would have an adverse effect on the Company, or (iii) solicit or otherwise interfere with any existing or proposed contract between the Company and any other person, natural or legal.&#160; Other than responding to
          requests made pursuant to Section 8, Employee agrees not to contact or communicate with employees, directors or independent contractors of the Company except for personal reasons.&#160; Without limitation to the foregoing, Employee may continue to
          work with any independent contractor, customer, client or supplier of the Company, or with any person, natural or legal, who or which has had a previous relationship with any of the Permitted Entities, as such term is used in Employee&#8217;s Amended
          and Restated Employment Agreement (which is otherwise superseded),&#160; and which may continue to have such a relationship while honoring any commitments or obligations that it may have with the Company or with whom the Employee had a preexisting
          relationship prior to the Employee&#8217;s employment with the Company.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">15.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>Indemnification</u></font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">:</font>&#160; The Company shall
          abide by any preexisting obligations to indemnify Employee pursuant to the Company Charter.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">16.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>Rule of Ambiguities</u></font>:&#160; It is agreed and understood that the general rule that ambiguities are to be construed against the drafter shall not
          apply to this Agreement.&#160; In the event that any language in this Agreement is found or claimed to be ambiguous, each party shall have the same opportunity to present evidence as to the actual intent of the parties with respect to any such
          ambiguous language without any inference or presumption being drawn against the drafter.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">17.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>Severability</u></font>:&#160; It is the desire and intent of the parties that the provisions of this Agreement shall be enforced to the fullest extent
          permissible under the laws and public policies applied in each jurisdiction in which enforcement is sought.&#160; In the event that any one or more of the provisions of this Agreement shall be held to be invalid, illegal or unenforceable, the
          validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.&#160; Moreover, if any one or more of the provisions contained in this Agreement shall be held to be excessively broad as to
          duration, scope, activity or subject, such provisions shall be construed by limiting or reducing them so as to be enforceable to the maximum extent compatible with applicable law.</font></div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
        </font></div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">8</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">18.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>Non-Admission of Liability</u></font>:&#160; This Agreement is not, and shall not in any way be construed as, an admission by the Company that it has acted
          wrongfully with respect to Employee or any other person, or that Employee has any rights whatsoever against the Company except as set forth herein.&#160; The Company specifically disclaims any liability to or wrongful acts against Employee or any
          other person.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">19.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>Representation</u></font>:&#160; Employee acknowledges that he was advised by the Company to consult with an attorney of his own choosing concerning the
          waivers contained in this Agreement, that Employee retained Thomas M. Wood IV, Esq., and that the waivers Employee has made herein are knowing, conscious, and with full appreciation that Employee is forever foreclosed from pursuing any of the
          rights so waived.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">20.</font>&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>No Modification</u></font>:&#160; No waiver or modification of this Agreement or any term or provision hereof shall be binding unless it is in writing and
          signed by the parties hereto or their expressly authorized representatives.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">21.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>Choice of Law; Dispute Resolution</u></font>:&#160; This Agreement shall be construed in accordance with the laws of the State of Florida without regard to
          conflicts of law principles.&#160;&#160; Employee and the Company hereby submit to the exclusive jurisdiction of the state and federal courts located in Florida (and waive the defenses of lack of jurisdiction or inconvenient forum to the maintenance of any
          such action or proceeding in such venue) for any proceedings to obtain injunctive relief for a breach or threatened breach of any covenants herein.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">22.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>Injunctive Relief</u></font>:&#160; Employee agrees and acknowledges that the Company will be irreparably harmed by any breach, or threatened breach, by
          Employee of this Agreement and that monetary damages would be grossly inadequate.&#160; Accordingly, Employee agrees that in the event of a breach or threatened breach by Employee of this Agreement, the Company shall be entitled to immediate
          injunctive or other preliminary or equitable relief, as appropriate, in addition to all other remedies available at law and equity, without being required to post a bond.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">23.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>No Disclosure</u></font>:&#160; Other than as may be required by law, Employee agrees not to disclose to anyone, other than Employee&#8217;s immediate family,
          accountant, and attorney, the contents of this Agreement, the circumstances surrounding it, or its terms, conditions, and negotiation, including the dollar amounts set forth herein, and then only upon their express agreement not to disclose such
          subject matter to another person, except as required by law.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">24.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>Entire Agreement</u></font>:&#160; This Agreement sets forth the entire agreement between the parties hereto and fully supersedes and replaces any and all
          prior agreements, arrangements, or understandings (whether oral or written) between the parties hereto pertaining to the subject matter hereof.&#160; Employee acknowledges and agrees that in signing this Agreement, Employee has not relied upon any
          representation, promise, or inducement that is not expressly set forth in this Agreement.&#160; All prior written agreements between Employee and the Company remain in effect unless modified by the provisions herein.</font></div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
        </font></div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">9</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">25.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>Revocation Period; Effective Date</u></font>:&#160; Employee shall have a period of twenty-one (21) days from the date on which a copy of this Agreement has
          been delivered to Employee to consider whether to sign it.&#160; In the event that Employee elects to sign and return to the Company a copy of this Agreement, Employee has a period of seven (7) days following the date of Employee&#8217;s execution to revoke
          this Agreement (the &#8220;Revocation Period&#8221;) by delivering a written letter to ADMA Biologics, Inc., 5800 Park of Commerce Blvd., NW, Boca Raton, FL 33487, Attention: Kim Tripodo, Executive Director &amp; Head of Human Resources, within the
          Revocation Period notifying ADMA Biologics of Employee&#8217;s revocation.&#160; Employee further acknowledges and agrees that, in the event that Employee revokes this Agreement, the Agreement shall have no force or effect, and Employee shall have no right
          to receive any of the benefits provided for hereunder.&#160; Provided that Employee signs and does not revoke the Agreement as set forth above, it shall become effective on the eighth (8<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>) day following Employee&#8217;s execution of this
          Agreement (the &#8220;Effective Date&#8221;).&#160; Employee acknowledges and agrees that, in the event Employee does not sign this Agreement within such twenty-one (21) day period or revokes his consent during the additional seven (7) day period described above:
          (i) the Agreement shall have no force or effect and Employee&#8217;s last day of employment with the Company was the Separation Date.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">26.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>Voluntary Execution</u></font>:&#160; Employee hereby acknowledges that Employee has read and that Employee understands the foregoing Agreement and that
          Employee has affixed their signature hereto voluntarily and without coercion.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">27.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>Counterparts</u></font>:&#160; This Agreement may be executed in any number of counterparts, which together shall be effective as if they were a single
          document.&#160; Signatures on the Agreement transmitted by email or facsimile copy shall have the same force and effect as original signatures.</font></div>
      <div style="text-align: justify; text-indent: 36pt;"><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">28.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>Cost of Enforcement</u></font>:&#160; In the event of litigation involving this Agreement, the non-prevailing party shall reimburse the prevailing party for
          all costs and expenses, including reasonable attorneys&#8217; fees and expenses, incurred in connection with any such litigation or arbitration, including any appeal therefrom.</font></div>
      <div><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">PLEASE READ CAREFULLY. THIS SEPARATION AGREEMENT AND RELEASE INCLUDES A RELEASE OF KNOWN AND UNKNOWN CLAIMS.</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td style="vertical-align: top;" rowspan="1" colspan="2">
              <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">EMPLOYEE</div>
            </td>
            <td style="width: 5%; vertical-align: top; text-align: center;" rowspan="1" colspan="1">&#160;</td>
            <td style="vertical-align: top;" rowspan="1" colspan="2">
              <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">ADMA Biologics, Inc.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 5%; vertical-align: top;" rowspan="1" colspan="1">&#160;</td>
            <td style="width: 5%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 45%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">By:</div>
            </td>
            <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ James Mond</div>
            </td>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">By:</div>
            </td>
            <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ Adam Grossman</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 40%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 45%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Name:</div>
            </td>
            <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">James Mond</div>
            </td>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Name:</div>
            </td>
            <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Adam Grossman</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 40%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 45%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Title:</div>
            </td>
            <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Title:</div>
            </td>
            <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">President &amp; CEO</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 40%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 45%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Date:</div>
            </td>
            <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">August 4, 2021</div>
            </td>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Date:</div>
            </td>
            <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">August 6, 2021</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><br>
      </div>
      <div style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">10</font></div>
    </div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>brhc10027771_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, LLC
         Document created using EDGARfilings PROfile 8.0.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; text-indent: 36pt; font-weight: bold;">Exhibit 31.1</div>
      <div style="text-align: right; text-indent: 36pt; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; font-weight: bold;">CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER</div>
      <div style="text-align: center; font-weight: bold;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</div>
      <div style="text-align: justify;"> <br>
      </div>
      <div style="text-align: justify;">I, Adam S. Grossman, certify that:</div>
      <div style="text-align: justify;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z796635b8dc9c47918909bd999bf7b20c">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>I have reviewed this Quarterly Report on Form 10-Q of ADMA Biologics, Inc.;</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5c9d404559584470a330180132924999">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
                misleading with respect to the period covered by this report;</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z12c0fd0b31c1423f9d01ecea25e026f3">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">3.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and
                for, the periods presented in this report;</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6259aa81668d44a9a15b304f7308878e">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">4.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting
                (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z11ed8600787f450d9904594bb4679815">

          <tr>
            <td style="width: 45pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated
                subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zbb406eeba4c544848a09bd8afd9f2243">

          <tr>
            <td style="width: 45pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and
                the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4aff42e54a414d8a8dd94db4b61efa8c">

          <tr>
            <td style="width: 45pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">c)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by
                this report based on such evaluation; and</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z752e36fe4b76402a8a0265a4244c4e89">

          <tr>
            <td style="width: 45pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">d)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report)
                that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4c8f64f50e5641259c1f1ccee153f37d">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">5.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors
                (or persons performing the equivalent functions):</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z82048dc15697426ba7da1e24860df731">

          <tr>
            <td style="width: 45pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and
                report financial information; and</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z758fc17721e844ed994f1fabe57e24b3">

          <tr>
            <td style="width: 45pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zc88e498090644e02916e63c686e97a27">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div>Date: August 11, 2021</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div>By:</div>
            </td>
            <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div>/s/ Adam S. Grossman</div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div>Name:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div>Adam S. Grossman</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div>Title:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div>President and Chief Executive Officer</div>
              <div>(Principal Executive Officer)</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div> <br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>brhc10027771_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, LLC
         Document created using EDGARfilings PROfile 8.0.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" style="height: 4px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); margin-left: auto; margin-right: auto; border: medium none;">
    <div style="text-align: right; text-indent: 36pt; font-weight: bold;">Exhibit 31.2</div>
    <div style="text-align: right; text-indent: 36pt; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-weight: bold;">CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER</div>
    <div style="text-align: center; font-weight: bold;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: justify;">I, Brian Lenz, certify that:</div>
    <div style="text-align: justify;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">1.</td>
          <td style="width: auto; vertical-align: top;">
            <div>I have reviewed this Quarterly Report on Form 10-Q of ADMA Biologics, Inc.;</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">2.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
              misleading with respect to the period covered by this report;</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">3.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and
              for, the periods presented in this report;</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">4.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting
              (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 45pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">a)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated
              subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 45pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">b)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and
              the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 45pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">c)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this
              report based on such evaluation; and</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 45pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">d)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report)
              that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">5.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors
              (or persons performing the equivalent functions):</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 45pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">a)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report
              financial information; and</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 45pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">b)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div>Date: August 11, 2021</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div>By:</div>
          </td>
          <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>
              <div>/s/ Brian Lenz</div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 5%; vertical-align: top;">
            <div>Name:</div>
          </td>
          <td style="width: 45%; vertical-align: top;">
            <div>Brian Lenz</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 5%; vertical-align: top;">
            <div>Title:</div>
          </td>
          <td style="width: 45%; vertical-align: top;">
            <div>Executive Vice President and Chief Financial Officer</div>
            <div>(Principal Financial and Accounting Officer)</div>
          </td>
        </tr>

    </table>
    <br>
    <div><br>
    </div>
    <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>brhc10027771_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, LLC
         Document created using EDGARfilings PROfile 8.0.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; text-indent: 36pt; font-weight: bold;">Exhibit 32.1</div>
      <div style="text-align: right; text-indent: 36pt; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; font-weight: bold;">CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER</div>
      <div style="text-align: center; font-weight: bold;">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</div>
      <div><br>
      </div>
      <div>In connection with the Quarterly Report of ADMA Biologics, Inc., a Delaware corporation (the &#8220;Company&#8221;), on Form 10-Q for the quarter ended June 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I,
        Adam S. Grossman, President and Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">1.</td>
            <td style="width: auto; vertical-align: top;">
              <div>The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">2.</td>
            <td style="width: auto; vertical-align: top;">
              <div>The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div>Date: August 11, 2021</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div>By:</div>
            </td>
            <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div>/s/ Adam S. Grossman</div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div>Name:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div>Adam S. Grossman</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div>Title:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div>President and Chief Executive Officer</div>
              <div>(Principal Executive Officer)</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>brhc10027771_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, LLC
         Document created using EDGARfilings PROfile 8.0.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; text-indent: 36pt; font-weight: bold;">Exhibit 32.2<br>
        <br>
      </div>
      <div style="text-align: center; font-weight: bold;">CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER</div>
      <div style="text-align: center; font-weight: bold;">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</div>
      <div><br>
      </div>
      <div>In connection with the Quarterly Report of ADMA Biologics, Inc., a Delaware corporation (the &#8220;Company&#8221;), on Form 10-Q for the quarter ended June 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I,
        Brian Lenz, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">1.</td>
            <td style="width: auto; vertical-align: top;">
              <div>The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">2.</td>
            <td style="width: auto; vertical-align: top;">
              <div>The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div>Date: August 11, 2021</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div>By:</div>
            </td>
            <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div>/s/ Brian Lenz</div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div>Name:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div>Brian Lenz</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div>Title:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div>Executive Vice President and Chief Financial Officer</div>
              <div>(Principal Financial and Accounting Officer)</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>adma-20210630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 8.0.0.0 Broadridge-->
<xs:schema targetNamespace="http://admabiologics.com/20210630" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:adma="http://admabiologics.com/20210630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dei="http://xbrl.sec.gov/dei/2021">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="adma-20210630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="adma-20210630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="adma-20210630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="adma-20210630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://admabiologics.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
        <link:definition>010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" id="CondensedConsolidatedBalanceSheetsParenthetical">
        <!--Parent Role: CONDENSED CONSOLIDATED BALANCE SHEETS-->
        <link:definition>010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations" id="CondensedConsolidatedStatementsOfOperations">
        <link:definition>020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" id="CondensedConsolidatedStatementsOfChangesInStockholdersEquity">
        <link:definition>030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows" id="CondensedConsolidatedStatementsOfCashFlows">
        <link:definition>040000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/OrganizationAndBusiness" id="OrganizationAndBusiness">
        <link:definition>060100 - Disclosure - ORGANIZATION AND BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>060200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/Inventories" id="Inventories">
        <link:definition>060300 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/IntangibleAssets" id="IntangibleAssets">
        <link:definition>060400 - Disclosure - INTANGIBLE ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
        <link:definition>060500 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilities" id="AccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>060600 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/Debt" id="Debt">
        <link:definition>060700 - Disclosure - DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/StockholdersEquity" id="StockholdersEquity">
        <link:definition>060800 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
        <link:definition>060900 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/CommitmentAndContingencies" id="CommitmentAndContingencies">
        <link:definition>061000 - Disclosure - COMMITMENT AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/Segments" id="Segments">
        <link:definition>061100 - Disclosure - SEGMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/LeaseObligations" id="LeaseObligations">
        <link:definition>061200 - Disclosure - LEASE OBLIGATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation" id="SupplementalDisclosureOfCashFlowInformation">
        <link:definition>061300 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>061400 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <!--Parent Role: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>070200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
        <!--Parent Role: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>080200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/InventoriesTables" id="InventoriesTables">
        <!--Parent Role: INVENTORIES-->
        <link:definition>080300 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
        <!--Parent Role: INTANGIBLE ASSETS-->
        <link:definition>080400 - Disclosure - INTANGIBLE ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
        <!--Parent Role: PROPERTY AND EQUIPMENT-->
        <link:definition>080500 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" id="AccruedExpensesAndOtherCurrentLiabilitiesTables">
        <!--Parent Role: ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES-->
        <link:definition>080600 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/DebtTables" id="DebtTables">
        <!--Parent Role: DEBT-->
        <link:definition>080700 - Disclosure - DEBT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
        <!--Parent Role: STOCKHOLDERS' EQUITY-->
        <link:definition>080800 - Disclosure - STOCKHOLDERS EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SegmentsTables" id="SegmentsTables">
        <!--Parent Role: SEGMENTS-->
        <link:definition>081100 - Disclosure - SEGMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/LeaseObligationsTables" id="LeaseObligationsTables">
        <!--Parent Role: LEASE OBLIGATIONS-->
        <link:definition>081200 - Disclosure - LEASE OBLIGATIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables" id="SupplementalDisclosureOfCashFlowInformationTables">
        <!--Parent Role: SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION-->
        <link:definition>081300 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/OrganizationAndBusinessDetails" id="OrganizationAndBusinessDetails">
        <!--Parent Role: ORGANIZATION AND BUSINESS-->
        <link:definition>090100 - Disclosure - ORGANIZATION AND BUSINESS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails" id="SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails">
        <!--Parent Role: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>090200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails" id="SummaryOfSignificantAccountingPoliciesGoodwillDetails">
        <!--Parent Role: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>090202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails" id="SummaryOfSignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails">
        <!--Parent Role: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>090204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Impairment of Long-lived Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" id="SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails">
        <!--Parent Role: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>090206 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Revenue Recognition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetailsDefault" id="SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetailsDefault">
        <link:definition>090206 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Revenue Recognition (Details)Default</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesLossPerCommonShareDetails" id="SummaryOfSignificantAccountingPoliciesLossPerCommonShareDetails">
        <!--Parent Role: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>090208 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Loss per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails" id="SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails">
        <!--Parent Role: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>090210 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Stock-based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails" id="SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails">
        <!--Parent Role: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>090212 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/InventoriesDetails" id="InventoriesDetails">
        <!--Parent Role: INVENTORIES-->
        <link:definition>090300 - Disclosure - INVENTORIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/IntangibleAssetsDetails" id="IntangibleAssetsDetails">
        <!--Parent Role: INTANGIBLE ASSETS-->
        <link:definition>090400 - Disclosure - INTANGIBLE ASSETS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails" id="IntangibleAssetsFutureAggregateAmortizationExpenseDetails">
        <!--Parent Role: INTANGIBLE ASSETS-->
        <link:definition>090404 - Disclosure - INTANGIBLE ASSETS, Future Aggregate Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/PropertyAndEquipmentDetails" id="PropertyAndEquipmentDetails">
        <!--Parent Role: PROPERTY AND EQUIPMENT-->
        <link:definition>090500 - Disclosure - PROPERTY AND EQUIPMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" id="AccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <!--Parent Role: ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES-->
        <link:definition>090600 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/DebtDetails" id="DebtDetails">
        <!--Parent Role: DEBT-->
        <link:definition>090702 - Disclosure - DEBT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/StockholdersEquityPreferredStockDetails" id="StockholdersEquityPreferredStockDetails">
        <!--Parent Role: STOCKHOLDERS' EQUITY-->
        <link:definition>090800 - Disclosure - STOCKHOLDERS' EQUITY, Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/StockholdersEquityCommonStockDetails" id="StockholdersEquityCommonStockDetails">
        <!--Parent Role: STOCKHOLDERS' EQUITY-->
        <link:definition>090802 - Disclosure - STOCKHOLDERS' EQUITY, Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/StockholdersEquityWarrantsDetails" id="StockholdersEquityWarrantsDetails">
        <!--Parent Role: STOCKHOLDERS' EQUITY-->
        <link:definition>090804 - Disclosure - STOCKHOLDERS' EQUITY, Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails" id="StockholdersEquityEquityIncentivePlansDetails">
        <!--Parent Role: STOCKHOLDERS' EQUITY-->
        <link:definition>090806 - Disclosure - STOCKHOLDERS' EQUITY, Equity Incentive Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/RelatedPartyTransactionsDetails" id="RelatedPartyTransactionsDetails">
        <!--Parent Role: RELATED PARTY TRANSACTIONS-->
        <link:definition>090900 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
        <!--Parent Role: COMMITMENT AND CONTINGENCIES-->
        <link:definition>091000 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SegmentsDetails" id="SegmentsDetails">
        <!--Parent Role: SEGMENTS-->
        <link:definition>091100 - Disclosure - SEGMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/LeaseObligationsDetails" id="LeaseObligationsDetails">
        <!--Parent Role: LEASE OBLIGATIONS-->
        <link:definition>091200 - Disclosure - LEASE OBLIGATIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/LeaseObligationsDetailsCalc2" id="LeaseObligationsDetailsCalc2">
        <!--Parent Role: LEASE OBLIGATIONS (Details)-->
        <link:definition>091202 - Disclosure - LEASE OBLIGATIONS (Details) Calc 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails" id="SupplementalDisclosureOfCashFlowInformationDetails">
        <!--Parent Role: SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION-->
        <link:definition>091300 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SubsequentEventsDetails" id="SubsequentEventsDetails">
        <!--Parent Role: SUBSEQUENT EVENTS-->
        <link:definition>091400 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2021" schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xs:element name="JefferiesLLCMember" id="adma_JefferiesLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SaleAgreement2020Member" id="adma_SaleAgreement2020Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ProductCycleFromProcurementOfRawMaterialsToFinishedProduct" id="adma_ProductCycleFromProcurementOfRawMaterialsToFinishedProduct" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="WorkingCapital" id="adma_WorkingCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="SaleAgreement2021Member" id="adma_SaleAgreement2021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfFDALicensedPlasmaCollectionFacilities" id="adma_NumberOfFDALicensedPlasmaCollectionFacilities" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfFDAApprovedProduct" id="adma_NumberOfFDAApprovedProduct" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" id="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="SubsequentEventsSaleOfStockAbstract" id="adma_SubsequentEventsSaleOfStockAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AmortizationOfLicenseRevenue" id="adma_AmortizationOfLicenseRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="TaxesPaidOnVestedRestrictedStockUnits" id="adma_TaxesPaidOnVestedRestrictedStockUnits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="IncreaseDecreaseInDepositsAndOtherAssets" id="adma_IncreaseDecreaseInDepositsAndOtherAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="ADMABioManufacturingSegmentMember" id="adma_ADMABioManufacturingSegmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PlasmaCollectionCentersSegmentMember" id="adma_PlasmaCollectionCentersSegmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CostOfProductRevenueExcludingAmortizationExpense" id="adma_CostOfProductRevenueExcludingAmortizationExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="RightToIntermediatesMember" id="adma_RightToIntermediatesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" id="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares" id="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" id="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease" id="adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease" id="adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="OperatingLeasesRentExpense" id="adma_OperatingLeasesRentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="NumberOfNewPropertyLeases" id="adma_NumberOfNewPropertyLeases" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="OperatingLeaseIncrementalBorrowingRatePercent" id="adma_OperatingLeaseIncrementalBorrowingRatePercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DepositsAndOtherNoncurrentAssets" id="adma_DepositsAndOtherNoncurrentAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" id="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" id="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="ThreeCustomersMember" id="adma_ThreeCustomersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfCustomers" id="adma_NumberOfCustomers" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="SixCustomersMember" id="adma_SixCustomersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="EquityIncentivePlanMember" id="adma_EquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="EmployeesMember" id="adma_EmployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RestrictedStockUnitsAbstract" id="adma_RestrictedStockUnitsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="StockOptionsAbstract" id="adma_StockOptionsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="StockOptionSharesAbstract" id="adma_StockOptionSharesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockOptionsWeightedAverageExercisePriceAbstract" id="adma_StockOptionsWeightedAverageExercisePriceAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AccruedRebatesCurrent" id="adma_AccruedRebatesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="FiveCustomersMember" id="adma_FiveCustomersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="BiotestLicenseAgreementMember" id="adma_BiotestLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DeferredRevenueRemainingAmortizationPeriod" id="adma_DeferredRevenueRemainingAmortizationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DebtInstrumentTermOfVariableRate" id="adma_DebtInstrumentTermOfVariableRate" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PerceptiveCreditFacilityMember" id="adma_PerceptiveCreditFacilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PerceptiveCreditAgreementMember" id="adma_PerceptiveCreditAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SeniorNotesPayableBeforeDebtDiscount" id="adma_SeniorNotesPayableBeforeDebtDiscount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="RepaymentsOfDebtInterest" id="adma_RepaymentsOfDebtInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="PreferredSharePurchaseRightMember" id="adma_PreferredSharePurchaseRightMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="VendorCommitmentsAbstract" id="adma_VendorCommitmentsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PercentageOfInventoryPurchases" id="adma_PercentageOfInventoryPurchases" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfRenewalTerms" id="adma_NumberOfRenewalTerms" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PlasmaPurchaseAgreementRenewalPeriod" id="adma_PlasmaPurchaseAgreementRenewalPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PlasmaSupplyAgreementTerm" id="adma_PlasmaSupplyAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfPlasmaCollectionFacilities" id="adma_NumberOfPlasmaCollectionFacilities" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity" id="adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PercentageOfPlasmaPurchasePriceEqualToCost" id="adma_PercentageOfPlasmaPurchasePriceEqualToCost" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PlasmaPurchased" id="adma_PlasmaPurchased" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="PlasmaPurchaseAgreementOneMember" id="adma_PlasmaPurchaseAgreementOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PlasmaPurchaseAgreementTwoMember" id="adma_PlasmaPurchaseAgreementTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PlasmaPurchaseAgreementTerm" id="adma_PlasmaPurchaseAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="WarrantsAbstract" id="adma_WarrantsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="IndirectOwnershipMember" id="adma_IndirectOwnershipMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DirectOwnershipMember" id="adma_DirectOwnershipMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ChiefScientificOfficerAndChiefMedicalOfficerMember" id="adma_ChiefScientificOfficerAndChiefMedicalOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ViceChairmanMember" id="adma_ViceChairmanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PresidentAndChiefExecutiveOfficerMember" id="adma_PresidentAndChiefExecutiveOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ExecutiveVicePresidentAndChiefFinancialOfficerMember" id="adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PerceptiveCreditHoldingsIILPMember" id="adma_PerceptiveCreditHoldingsIILPMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement" id="adma_PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="MinimumPercentageOfCommonStockHeldByLender" id="adma_MinimumPercentageOfCommonStockHeldByLender" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="EstimatedPaymentForSeparationAndTransitionAgreement" id="adma_EstimatedPaymentForSeparationAndTransitionAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="ArethLLCMember" id="adma_ArethLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="GenesisBPSMember" id="adma_GenesisBPSMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="GrossProceedsFromIssuanceOfCommonStock" id="adma_GrossProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="SaleAgreementMember" id="adma_SaleAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SaleAgreement2020AmendedMember" id="adma_SaleAgreement2020AmendedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>adma-20210630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 8.0.0.0 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsDetailsCalc2" xlink:type="simple" xlink:href="adma-20210630.xsd#LeaseObligationsDetailsCalc2" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#LeaseObligationsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/DebtDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#DebtDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/PropertyAndEquipmentDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#PropertyAndEquipmentDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/InventoriesDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#InventoriesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="adma-20210630.xsd#CondensedConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="simple" xlink:href="adma-20210630.xsd#CondensedConsolidatedStatementsOfOperations" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="adma-20210630.xsd#CondensedConsolidatedBalanceSheets" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="calculation: AssetsCurrent to CashAndCashEquivalentsAtCarryingValue" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="AccountsReceivableNetCurrent" xlink:title="AccountsReceivableNetCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="AccountsReceivableNetCurrent" xlink:title="calculation: AssetsCurrent to AccountsReceivableNetCurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="calculation: AssetsCurrent to PrepaidExpenseAndOtherAssetsCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="InventoryNet" xlink:title="calculation: AssetsCurrent to InventoryNet" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="AssetsCurrent" xlink:title="calculation: Assets to AssetsCurrent" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_DepositsAndOtherNoncurrentAssets" xlink:label="DepositsAndOtherNoncurrentAssets" xlink:title="DepositsAndOtherNoncurrentAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="DepositsAndOtherNoncurrentAssets" xlink:title="calculation: Assets to DepositsAndOtherNoncurrentAssets" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="OperatingLeaseRightOfUseAsset" xlink:title="calculation: Assets to OperatingLeaseRightOfUseAsset" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="calculation: Assets to PropertyPlantAndEquipmentNet" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="Goodwill" xlink:title="calculation: Assets to Goodwill" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="IntangibleAssetsNetExcludingGoodwill" xlink:title="IntangibleAssetsNetExcludingGoodwill" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="IntangibleAssetsNetExcludingGoodwill" xlink:title="calculation: Assets to IntangibleAssetsNetExcludingGoodwill" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="PreferredStockValue" xlink:title="calculation: StockholdersEquity to PreferredStockValue" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="CommonStockValue" xlink:title="calculation: StockholdersEquity to CommonStockValue" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="calculation: StockholdersEquity to RetainedEarningsAccumulatedDeficit" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="AdditionalPaidInCapital" xlink:title="calculation: StockholdersEquity to AdditionalPaidInCapital" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="StockholdersEquity" xlink:title="calculation: LiabilitiesAndStockholdersEquity to StockholdersEquity" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="OperatingLeaseLiabilityNoncurrent" xlink:title="calculation: Liabilities to OperatingLeaseLiabilityNoncurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="calculation: LiabilitiesCurrent to OperatingLeaseLiabilityCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="AccruedLiabilitiesAndOtherLiabilities" xlink:title="AccruedLiabilitiesAndOtherLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccruedLiabilitiesAndOtherLiabilities" xlink:title="calculation: LiabilitiesCurrent to AccruedLiabilitiesAndOtherLiabilities" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="ContractWithCustomerLiabilityCurrent" xlink:title="ContractWithCustomerLiabilityCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="ContractWithCustomerLiabilityCurrent" xlink:title="calculation: LiabilitiesCurrent to ContractWithCustomerLiabilityCurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccountsPayableCurrent" xlink:title="calculation: LiabilitiesCurrent to AccountsPayableCurrent" order="4.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="LiabilitiesCurrent" xlink:title="calculation: Liabilities to LiabilitiesCurrent" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="OtherLiabilitiesNoncurrent" xlink:title="calculation: Liabilities to OtherLiabilitiesNoncurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="DeferredRevenueNoncurrent" xlink:title="DeferredRevenueNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="DeferredRevenueNoncurrent" xlink:title="calculation: Liabilities to DeferredRevenueNoncurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorLongTermNotes" xlink:label="SeniorLongTermNotes" xlink:title="SeniorLongTermNotes" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="SeniorLongTermNotes" xlink:title="calculation: Liabilities to SeniorLongTermNotes" order="4.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="Liabilities" xlink:title="calculation: LiabilitiesAndStockholdersEquity to Liabilities" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="InvestmentIncomeInterest" xlink:title="calculation: NonoperatingIncomeExpense to InvestmentIncomeInterest" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="InterestExpense" xlink:title="calculation: NonoperatingIncomeExpense to InterestExpense" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="OtherNonoperatingExpense" xlink:title="OtherNonoperatingExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="OtherNonoperatingExpense" xlink:title="calculation: NonoperatingIncomeExpense to OtherNonoperatingExpense" order="2.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="NonoperatingIncomeExpense" xlink:title="calculation: NetIncomeLoss to NonoperatingIncomeExpense" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="AmortizationOfIntangibleAssets" xlink:title="calculation: OperatingExpenses to AmortizationOfIntangibleAssets" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="SellingGeneralAndAdministrativeExpense" xlink:title="SellingGeneralAndAdministrativeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="SellingGeneralAndAdministrativeExpense" xlink:title="calculation: OperatingExpenses to SellingGeneralAndAdministrativeExpense" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="ResearchAndDevelopmentExpense" xlink:title="calculation: OperatingExpenses to ResearchAndDevelopmentExpense" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_CostOfProductRevenueExcludingAmortizationExpense" xlink:label="CostOfProductRevenueExcludingAmortizationExpense" xlink:title="CostOfProductRevenueExcludingAmortizationExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="CostOfProductRevenueExcludingAmortizationExpense" xlink:title="calculation: OperatingExpenses to CostOfProductRevenueExcludingAmortizationExpense" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="OtherCostAndExpenseOperating" xlink:title="OtherCostAndExpenseOperating" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="OtherCostAndExpenseOperating" xlink:title="calculation: OperatingExpenses to OtherCostAndExpenseOperating" order="3.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="OperatingExpenses" xlink:title="calculation: OperatingIncomeLoss to OperatingExpenses" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="calculation: OperatingIncomeLoss to RevenueFromContractWithCustomerExcludingAssessedTax" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="OperatingIncomeLoss" xlink:title="calculation: NetIncomeLoss to OperatingIncomeLoss" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to PaymentsToAcquirePropertyPlantAndEquipment" order="2.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to ProceedsFromSaleOfPropertyPlantAndEquipment" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInInvestingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect to NetCashProvidedByUsedInInvestingActivities" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="FinanceLeasePrincipalPayments" xlink:title="FinanceLeasePrincipalPayments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="FinanceLeasePrincipalPayments" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to FinanceLeasePrincipalPayments" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromIssuanceOfCommonStock" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_TaxesPaidOnVestedRestrictedStockUnits" xlink:label="TaxesPaidOnVestedRestrictedStockUnits" xlink:title="TaxesPaidOnVestedRestrictedStockUnits" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="TaxesPaidOnVestedRestrictedStockUnits" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to TaxesPaidOnVestedRestrictedStockUnits" order="3.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromStockOptionsExercised" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="ProceedsFromNotesPayable" xlink:title="ProceedsFromNotesPayable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromNotesPayable" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromNotesPayable" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect to NetCashProvidedByUsedInFinancingActivities" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="AmortizationOfDebtDiscountPremium" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to AmortizationOfDebtDiscountPremium" order="7.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_AmortizationOfLicenseRevenue" xlink:label="AmortizationOfLicenseRevenue" xlink:title="AmortizationOfLicenseRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="AmortizationOfLicenseRevenue" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to AmortizationOfLicenseRevenue" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccruedLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccruedLiabilities" order="13.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="3.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="IncreaseDecreaseInAccountsPayable" xlink:title="IncreaseDecreaseInAccountsPayable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccountsPayable" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccountsPayable" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="IncreaseDecreaseInDepositsAndOtherAssets" xlink:title="IncreaseDecreaseInDepositsAndOtherAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInDepositsAndOtherAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInDepositsAndOtherAssets" order="2.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="NetIncomeLoss" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to NetIncomeLoss" order="11.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="GainLossOnDispositionOfAssets" xlink:title="GainLossOnDispositionOfAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="GainLossOnDispositionOfAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to GainLossOnDispositionOfAssets" order="9.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="DepreciationAndAmortization" xlink:title="DepreciationAndAmortization" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="DepreciationAndAmortization" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to DepreciationAndAmortization" order="10.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="IncreaseDecreaseInInventories" xlink:title="IncreaseDecreaseInInventories" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInInventories" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInInventories" order="4.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="IncreaseDecreaseInAccountsReceivable" xlink:title="IncreaseDecreaseInAccountsReceivable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccountsReceivable" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccountsReceivable" order="5.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="ShareBasedCompensation" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to ShareBasedCompensation" order="8.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInOtherOperatingLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInOtherOperatingLiabilities" order="12.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect to NetCashProvidedByUsedInOperatingActivities" order="3.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/InventoriesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="InventoryRawMaterials" xlink:title="InventoryRawMaterials" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="InventoryNet" xlink:to="InventoryRawMaterials" xlink:title="calculation: InventoryNet to InventoryRawMaterials" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="InventoryWorkInProcess" xlink:title="InventoryWorkInProcess" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="InventoryNet" xlink:to="InventoryWorkInProcess" xlink:title="calculation: InventoryNet to InventoryWorkInProcess" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="InventoryFinishedGoods" xlink:title="InventoryFinishedGoods" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="InventoryNet" xlink:to="InventoryFinishedGoods" xlink:title="calculation: InventoryNet to InventoryFinishedGoods" order="2.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/PropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="calculation: PropertyPlantAndEquipmentNet to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="calculation: PropertyPlantAndEquipmentNet to PropertyPlantAndEquipmentGross" order="0.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="AccruedLiabilitiesAndOtherLiabilities" xlink:title="AccruedLiabilitiesAndOtherLiabilities" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_AccruedRebatesCurrent" xlink:label="AccruedRebatesCurrent" xlink:title="AccruedRebatesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesAndOtherLiabilities" xlink:to="AccruedRebatesCurrent" xlink:title="calculation: AccruedLiabilitiesAndOtherLiabilities to AccruedRebatesCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesAndOtherLiabilities" xlink:to="AccruedProfessionalFeesCurrent" xlink:title="calculation: AccruedLiabilitiesAndOtherLiabilities to AccruedProfessionalFeesCurrent" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="AccruedSalariesCurrent" xlink:title="AccruedSalariesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesAndOtherLiabilities" xlink:to="AccruedSalariesCurrent" xlink:title="calculation: AccruedLiabilitiesAndOtherLiabilities to AccruedSalariesCurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount" xlink:label="LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount" xlink:title="LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesAndOtherLiabilities" xlink:to="LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount" xlink:title="calculation: AccruedLiabilitiesAndOtherLiabilities to LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:label="SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:title="SupplementalUnemploymentBenefitsSeveranceBenefits" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesAndOtherLiabilities" xlink:to="SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:title="calculation: AccruedLiabilitiesAndOtherLiabilities to SupplementalUnemploymentBenefitsSeveranceBenefits" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="AccruedBonusesCurrent" xlink:title="AccruedBonusesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesAndOtherLiabilities" xlink:to="AccruedBonusesCurrent" xlink:title="calculation: AccruedLiabilitiesAndOtherLiabilities to AccruedBonusesCurrent" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="OtherAccruedLiabilitiesCurrent" xlink:title="OtherAccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesAndOtherLiabilities" xlink:to="OtherAccruedLiabilitiesCurrent" xlink:title="calculation: AccruedLiabilitiesAndOtherLiabilities to OtherAccruedLiabilitiesCurrent" order="6.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/DebtDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorLongTermNotes" xlink:label="SeniorLongTermNotes" xlink:title="SeniorLongTermNotes" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="DebtInstrumentUnamortizedDiscount" xlink:title="DebtInstrumentUnamortizedDiscount" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="SeniorLongTermNotes" xlink:to="DebtInstrumentUnamortizedDiscount" xlink:title="calculation: SeniorLongTermNotes to DebtInstrumentUnamortizedDiscount" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_SeniorNotesPayableBeforeDebtDiscount" xlink:label="SeniorNotesPayableBeforeDebtDiscount" xlink:title="SeniorNotesPayableBeforeDebtDiscount" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="SeniorLongTermNotes" xlink:to="SeniorNotesPayableBeforeDebtDiscount" xlink:title="calculation: SeniorLongTermNotes to SeniorNotesPayableBeforeDebtDiscount" order="0.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsDetailsCalc2">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="OperatingLeaseLiabilityNoncurrent" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to OperatingLeaseLiabilityNoncurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to OperatingLeaseLiabilityCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0.0" weight="1.0" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>adma-20210630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 8.0.0.0 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:t1="http://xbrl.org/2005/xbrldt">
  <link:roleRef roleURI="http://admabiologics.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#SubsequentEventsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#SupplementalDisclosureOfCashFlowInformationDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsDetailsCalc2" xlink:type="simple" xlink:href="adma-20210630.xsd#LeaseObligationsDetailsCalc2" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#LeaseObligationsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SegmentsDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#SegmentsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/CommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#CommitmentsAndContingenciesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#RelatedPartyTransactionsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#StockholdersEquityEquityIncentivePlansDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityWarrantsDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#StockholdersEquityWarrantsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityCommonStockDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#StockholdersEquityCommonStockDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityPreferredStockDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#StockholdersEquityPreferredStockDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/DebtDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#DebtDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/PropertyAndEquipmentDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#PropertyAndEquipmentDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#IntangibleAssetsFutureAggregateAmortizationExpenseDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssetsDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#IntangibleAssetsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/InventoriesDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#InventoriesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesLossPerCommonShareDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#SummaryOfSignificantAccountingPoliciesLossPerCommonShareDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetailsDefault" xlink:type="simple" xlink:href="adma-20210630.xsd#SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetailsDefault" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#SummaryOfSignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#SummaryOfSignificantAccountingPoliciesGoodwillDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/OrganizationAndBusinessDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#OrganizationAndBusinessDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables" xlink:type="simple" xlink:href="adma-20210630.xsd#SupplementalDisclosureOfCashFlowInformationTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsTables" xlink:type="simple" xlink:href="adma-20210630.xsd#LeaseObligationsTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/SegmentsTables" xlink:type="simple" xlink:href="adma-20210630.xsd#SegmentsTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="adma-20210630.xsd#StockholdersEquityTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/DebtTables" xlink:type="simple" xlink:href="adma-20210630.xsd#DebtTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="adma-20210630.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/PropertyAndEquipmentTables" xlink:type="simple" xlink:href="adma-20210630.xsd#PropertyAndEquipmentTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssetsTables" xlink:type="simple" xlink:href="adma-20210630.xsd#IntangibleAssetsTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/InventoriesTables" xlink:type="simple" xlink:href="adma-20210630.xsd#InventoriesTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="adma-20210630.xsd#SummaryOfSignificantAccountingPoliciesTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="adma-20210630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" />
  <link:roleRef roleURI="http://admabiologics.com/role/SubsequentEvents" xlink:type="simple" xlink:href="adma-20210630.xsd#SubsequentEvents" />
  <link:roleRef roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation" xlink:type="simple" xlink:href="adma-20210630.xsd#SupplementalDisclosureOfCashFlowInformation" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligations" xlink:type="simple" xlink:href="adma-20210630.xsd#LeaseObligations" />
  <link:roleRef roleURI="http://admabiologics.com/role/Segments" xlink:type="simple" xlink:href="adma-20210630.xsd#Segments" />
  <link:roleRef roleURI="http://admabiologics.com/role/CommitmentAndContingencies" xlink:type="simple" xlink:href="adma-20210630.xsd#CommitmentAndContingencies" />
  <link:roleRef roleURI="http://admabiologics.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="adma-20210630.xsd#RelatedPartyTransactions" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="adma-20210630.xsd#StockholdersEquity" />
  <link:roleRef roleURI="http://admabiologics.com/role/Debt" xlink:type="simple" xlink:href="adma-20210630.xsd#Debt" />
  <link:roleRef roleURI="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" xlink:href="adma-20210630.xsd#AccruedExpensesAndOtherCurrentLiabilities" />
  <link:roleRef roleURI="http://admabiologics.com/role/PropertyAndEquipment" xlink:type="simple" xlink:href="adma-20210630.xsd#PropertyAndEquipment" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssets" xlink:type="simple" xlink:href="adma-20210630.xsd#IntangibleAssets" />
  <link:roleRef roleURI="http://admabiologics.com/role/Inventories" xlink:type="simple" xlink:href="adma-20210630.xsd#Inventories" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="adma-20210630.xsd#SummaryOfSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://admabiologics.com/role/OrganizationAndBusiness" xlink:type="simple" xlink:href="adma-20210630.xsd#OrganizationAndBusiness" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="adma-20210630.xsd#CondensedConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" xlink:href="adma-20210630.xsd#CondensedConsolidatedStatementsOfChangesInStockholdersEquity" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="simple" xlink:href="adma-20210630.xsd#CondensedConsolidatedStatementsOfOperations" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="adma-20210630.xsd#CondensedConsolidatedBalanceSheetsParenthetical" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="adma-20210630.xsd#CondensedConsolidatedBalanceSheets" />
  <link:roleRef roleURI="http://admabiologics.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="adma-20210630.xsd#DocumentAndEntityInformation" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityListingsLineItems" xlink:label="EntityListingsLineItems" xlink:title="EntityListingsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="DocumentType" xlink:title="definition: EntityListingsLineItems to DocumentType" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="AmendmentFlag" xlink:title="definition: EntityListingsLineItems to AmendmentFlag" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="DocumentQuarterlyReport" xlink:title="DocumentQuarterlyReport" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="DocumentQuarterlyReport" xlink:title="definition: EntityListingsLineItems to DocumentQuarterlyReport" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="DocumentPeriodEndDate" xlink:title="definition: EntityListingsLineItems to DocumentPeriodEndDate" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="CurrentFiscalYearEndDate" xlink:title="definition: EntityListingsLineItems to CurrentFiscalYearEndDate" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="DocumentFiscalYearFocus" xlink:title="definition: EntityListingsLineItems to DocumentFiscalYearFocus" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="DocumentFiscalPeriodFocus" xlink:title="definition: EntityListingsLineItems to DocumentFiscalPeriodFocus" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="DocumentTransitionReport" xlink:title="DocumentTransitionReport" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="DocumentTransitionReport" xlink:title="definition: EntityListingsLineItems to DocumentTransitionReport" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityFileNumber" xlink:title="definition: EntityListingsLineItems to EntityFileNumber" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityRegistrantName" xlink:title="definition: EntityListingsLineItems to EntityRegistrantName" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityCentralIndexKey" xlink:title="definition: EntityListingsLineItems to EntityCentralIndexKey" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityIncorporationStateCountryCode" xlink:title="definition: EntityListingsLineItems to EntityIncorporationStateCountryCode" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityTaxIdentificationNumber" xlink:title="definition: EntityListingsLineItems to EntityTaxIdentificationNumber" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine1" xlink:title="definition: EntityListingsLineItems to EntityAddressAddressLine1" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressCityOrTown" xlink:title="definition: EntityListingsLineItems to EntityAddressCityOrTown" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressStateOrProvince" xlink:title="definition: EntityListingsLineItems to EntityAddressStateOrProvince" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressPostalZipCode" xlink:title="definition: EntityListingsLineItems to EntityAddressPostalZipCode" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="CityAreaCode" xlink:title="definition: EntityListingsLineItems to CityAreaCode" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="LocalPhoneNumber" xlink:title="definition: EntityListingsLineItems to LocalPhoneNumber" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="Security12bTitle" xlink:title="definition: EntityListingsLineItems to Security12bTitle" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="TradingSymbol" xlink:title="definition: EntityListingsLineItems to TradingSymbol" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="NoTradingSymbolFlag" xlink:title="definition: EntityListingsLineItems to NoTradingSymbolFlag" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="SecurityExchangeName" xlink:title="definition: EntityListingsLineItems to SecurityExchangeName" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityCurrentReportingStatus" xlink:title="definition: EntityListingsLineItems to EntityCurrentReportingStatus" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="EntityInteractiveDataCurrent" xlink:title="EntityInteractiveDataCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityInteractiveDataCurrent" xlink:title="definition: EntityListingsLineItems to EntityInteractiveDataCurrent" order="25.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityFilerCategory" xlink:title="definition: EntityListingsLineItems to EntityFilerCategory" order="26.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="EntitySmallBusiness" xlink:title="EntitySmallBusiness" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntitySmallBusiness" xlink:title="definition: EntityListingsLineItems to EntitySmallBusiness" order="27.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityEmergingGrowthCompany" xlink:title="definition: EntityListingsLineItems to EntityEmergingGrowthCompany" order="28.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="EntityShellCompany" xlink:title="EntityShellCompany" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityShellCompany" xlink:title="definition: EntityListingsLineItems to EntityShellCompany" order="29.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityCommonStockSharesOutstanding" xlink:title="definition: EntityListingsLineItems to EntityCommonStockSharesOutstanding" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityListingsTable" xlink:label="EntityListingsTable" xlink:title="EntityListingsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="EntityListingsLineItems" xlink:to="EntityListingsTable" xlink:title="definition: EntityListingsLineItems to EntityListingsTable" order="31.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="EntityListingsTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: EntityListingsTable to StatementClassOfStockAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain_2" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain_2" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="CommonStockMember" xlink:title="definition: ClassOfStockDomain to CommonStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PreferredSharePurchaseRightMember" xlink:label="PreferredSharePurchaseRightMember" xlink:title="PreferredSharePurchaseRightMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="PreferredSharePurchaseRightMember" xlink:title="definition: ClassOfStockDomain to PreferredSharePurchaseRightMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedBalanceSheets" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="RevenuesAbstract" xlink:title="RevenuesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="RevenuesAbstract" xlink:title="definition: StatementLineItems to RevenuesAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="CostsAndExpensesAbstract" xlink:title="CostsAndExpensesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CostsAndExpensesAbstract" xlink:title="definition: StatementLineItems to CostsAndExpensesAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="OperatingIncomeLoss" xlink:title="definition: StatementLineItems to OperatingIncomeLoss" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="NonoperatingIncomeExpenseAbstract" xlink:title="NonoperatingIncomeExpenseAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NonoperatingIncomeExpenseAbstract" xlink:title="definition: StatementLineItems to NonoperatingIncomeExpenseAbstract" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetIncomeLoss" xlink:title="definition: StatementLineItems to NetIncomeLoss" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="EarningsPerShareBasic" xlink:title="definition: StatementLineItems to EarningsPerShareBasic" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="EarningsPerShareDiluted" xlink:title="definition: StatementLineItems to EarningsPerShareDiluted" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:title="WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:title="definition: StatementLineItems to WeightedAverageNumberOfSharesOutstandingAbstract" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="definition: StatementLineItems to WeightedAverageNumberOfSharesOutstandingBasic" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="definition: StatementLineItems to WeightedAverageNumberOfDilutedSharesOutstanding" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="InvestmentIncomeInterest" xlink:title="definition: StatementLineItems to InvestmentIncomeInterest" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="InterestExpense" xlink:title="definition: StatementLineItems to InterestExpense" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="OtherNonoperatingExpense" xlink:title="OtherNonoperatingExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="OtherNonoperatingExpense" xlink:title="definition: StatementLineItems to OtherNonoperatingExpense" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NonoperatingIncomeExpense" xlink:title="definition: StatementLineItems to NonoperatingIncomeExpense" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_CostOfProductRevenueExcludingAmortizationExpense" xlink:label="CostOfProductRevenueExcludingAmortizationExpense" xlink:title="CostOfProductRevenueExcludingAmortizationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CostOfProductRevenueExcludingAmortizationExpense" xlink:title="definition: StatementLineItems to CostOfProductRevenueExcludingAmortizationExpense" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ResearchAndDevelopmentExpense" xlink:title="definition: StatementLineItems to ResearchAndDevelopmentExpense" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="OtherCostAndExpenseOperating" xlink:title="OtherCostAndExpenseOperating" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="OtherCostAndExpenseOperating" xlink:title="definition: StatementLineItems to OtherCostAndExpenseOperating" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AmortizationOfIntangibleAssets" xlink:title="definition: StatementLineItems to AmortizationOfIntangibleAssets" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="SellingGeneralAndAdministrativeExpense" xlink:title="SellingGeneralAndAdministrativeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SellingGeneralAndAdministrativeExpense" xlink:title="definition: StatementLineItems to SellingGeneralAndAdministrativeExpense" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="OperatingExpenses" xlink:title="definition: StatementLineItems to OperatingExpenses" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="definition: StatementLineItems to RevenueFromContractWithCustomerExcludingAssessedTax" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="22.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="ProductOrServiceAxis" xlink:title="definition: StatementTable to ProductOrServiceAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain_2" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain_2" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="ProductMember" xlink:title="ProductMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="ProductMember" xlink:title="definition: ProductsAndServicesDomain to ProductMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="LicenseAndServiceMember" xlink:title="LicenseAndServiceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="LicenseAndServiceMember" xlink:title="definition: ProductsAndServicesDomain to LicenseAndServiceMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="definition: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockholdersEquity" xlink:title="definition: StatementLineItems to StockholdersEquity" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SharesOutstanding" xlink:title="definition: StatementLineItems to SharesOutstanding" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="definition: StatementLineItems to AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" xlink:label="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" xlink:title="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" xlink:title="definition: StatementLineItems to VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares" xlink:label="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares" xlink:title="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares" xlink:title="definition: StatementLineItems to VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueNewIssues" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesNewIssues" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueStockOptionsExercised" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesStockOptionsExercised" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetIncomeLoss" xlink:title="definition: StatementLineItems to NetIncomeLoss" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="12.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: StatementTable to StatementEquityComponentsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="AdditionalPaidInCapitalMember" xlink:title="definition: EquityComponentDomain to AdditionalPaidInCapitalMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="RetainedEarningsMember" xlink:title="definition: EquityComponentDomain to RetainedEarningsMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/OrganizationAndBusiness" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/Inventories" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssets" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/PropertyAndEquipment" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilities" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/Debt" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquity" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/RelatedPartyTransactions" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CommitmentAndContingencies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/Segments" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligations" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SubsequentEvents" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/InventoriesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssetsTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/PropertyAndEquipmentTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/DebtTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SegmentsTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/OrganizationAndBusinessDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="SubsidiarySaleOfStockLineItems" xlink:title="SubsidiarySaleOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:label="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:title="ProceedsFromIssuanceOrSaleOfEquityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:title="definition: SubsidiarySaleOfStockLineItems to ProceedsFromIssuanceOrSaleOfEquityAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:label="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:title="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:title="definition: SubsidiarySaleOfStockLineItems to NumberOfPlasmaCollectionFacilitiesUnderDevelopment" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_NumberOfFDALicensedPlasmaCollectionFacilities" xlink:label="NumberOfFDALicensedPlasmaCollectionFacilities" xlink:title="NumberOfFDALicensedPlasmaCollectionFacilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="NumberOfFDALicensedPlasmaCollectionFacilities" xlink:title="definition: SubsidiarySaleOfStockLineItems to NumberOfFDALicensedPlasmaCollectionFacilities" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_NumberOfFDAApprovedProduct" xlink:label="NumberOfFDAApprovedProduct" xlink:title="NumberOfFDAApprovedProduct" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="NumberOfFDAApprovedProduct" xlink:title="definition: SubsidiarySaleOfStockLineItems to NumberOfFDAApprovedProduct" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_WorkingCapital" xlink:label="WorkingCapital" xlink:title="WorkingCapital" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="WorkingCapital" xlink:title="definition: SubsidiarySaleOfStockLineItems to WorkingCapital" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="CashEquivalentsAtCarryingValue" xlink:title="CashEquivalentsAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="CashEquivalentsAtCarryingValue" xlink:title="definition: SubsidiarySaleOfStockLineItems to CashEquivalentsAtCarryingValue" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ProductCycleFromProcurementOfRawMaterialsToFinishedProduct" xlink:label="ProductCycleFromProcurementOfRawMaterialsToFinishedProduct" xlink:title="ProductCycleFromProcurementOfRawMaterialsToFinishedProduct" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="ProductCycleFromProcurementOfRawMaterialsToFinishedProduct" xlink:title="definition: SubsidiarySaleOfStockLineItems to ProductCycleFromProcurementOfRawMaterialsToFinishedProduct" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="definition: SubsidiarySaleOfStockLineItems to RetainedEarningsAccumulatedDeficit" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="ProceedsFromIssuanceOrSaleOfEquity" xlink:title="ProceedsFromIssuanceOrSaleOfEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="ProceedsFromIssuanceOrSaleOfEquity" xlink:title="definition: SubsidiarySaleOfStockLineItems to ProceedsFromIssuanceOrSaleOfEquity" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonUnitIssuanceValue" xlink:label="CommonUnitIssuanceValue" xlink:title="CommonUnitIssuanceValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="CommonUnitIssuanceValue" xlink:title="definition: SubsidiarySaleOfStockLineItems to CommonUnitIssuanceValue" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="definition: SubsidiarySaleOfStockLineItems to StockIssuedDuringPeriodValueNewIssues" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:title="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:title="definition: SubsidiarySaleOfStockLineItems to SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="12.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="ConsolidatedEntitiesAxis" xlink:title="definition: SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable to ConsolidatedEntitiesAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain" xlink:title="definition: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain_2" xlink:title="ConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain_2" xlink:title="definition: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_JefferiesLLCMember" xlink:label="JefferiesLLCMember" xlink:title="JefferiesLLCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConsolidatedEntitiesDomain" xlink:to="JefferiesLLCMember" xlink:title="definition: ConsolidatedEntitiesDomain to JefferiesLLCMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable to TypeOfArrangementAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_SaleAgreement2020Member" xlink:label="SaleAgreement2020Member" xlink:title="SaleAgreement2020Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="SaleAgreement2020Member" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to SaleAgreement2020Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_SaleAgreement2021Member" xlink:label="SaleAgreement2021Member" xlink:title="SaleAgreement2021Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="SaleAgreement2021Member" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to SaleAgreement2021Member" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="RangeAxis" xlink:title="definition: SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable to RangeAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="SubsequentEventTypeAxis" xlink:title="definition: SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable to SubsequentEventTypeAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain_2" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain_2" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="definition: SubsequentEventTypeDomain to SubsequentEventMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="ConcentrationRiskLineItems" xlink:title="ConcentrationRiskLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetAbstract" xlink:label="AccountsReceivableNetAbstract" xlink:title="AccountsReceivableNetAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskLineItems" xlink:to="AccountsReceivableNetAbstract" xlink:title="definition: ConcentrationRiskLineItems to AccountsReceivableNetAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:label="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:title="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskLineItems" xlink:to="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:title="definition: ConcentrationRiskLineItems to AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_NumberOfCustomers" xlink:label="NumberOfCustomers" xlink:title="NumberOfCustomers" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskLineItems" xlink:to="NumberOfCustomers" xlink:title="definition: ConcentrationRiskLineItems to NumberOfCustomers" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskLineItems" xlink:to="ConcentrationRiskPercentage1" xlink:title="definition: ConcentrationRiskLineItems to ConcentrationRiskPercentage1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="ConcentrationRiskTable" xlink:title="ConcentrationRiskTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ConcentrationRiskLineItems" xlink:to="ConcentrationRiskTable" xlink:title="definition: ConcentrationRiskLineItems to ConcentrationRiskTable" order="5.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ConcentrationRiskTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="definition: ConcentrationRiskTable to ConcentrationRiskByBenchmarkAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain_2" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain_2" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="AccountsReceivableMember" xlink:title="AccountsReceivableMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="AccountsReceivableMember" xlink:title="definition: ConcentrationRiskBenchmarkDomain to AccountsReceivableMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ConcentrationRiskTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="definition: ConcentrationRiskTable to ConcentrationRiskByTypeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain_2" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain_2" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskTypeDomain" xlink:to="CustomerConcentrationRiskMember" xlink:title="definition: ConcentrationRiskTypeDomain to CustomerConcentrationRiskMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ConcentrationRiskTable" xlink:to="MajorCustomersAxis" xlink:title="definition: ConcentrationRiskTable to MajorCustomersAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain" xlink:title="NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain" xlink:title="definition: MajorCustomersAxis to NameOfMajorCustomerDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain_2" xlink:title="NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain_2" xlink:title="definition: MajorCustomersAxis to NameOfMajorCustomerDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_SixCustomersMember" xlink:label="SixCustomersMember" xlink:title="SixCustomersMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NameOfMajorCustomerDomain" xlink:to="SixCustomersMember" xlink:title="definition: NameOfMajorCustomerDomain to SixCustomersMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ThreeCustomersMember" xlink:label="ThreeCustomersMember" xlink:title="ThreeCustomersMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NameOfMajorCustomerDomain" xlink:to="ThreeCustomersMember" xlink:title="definition: NameOfMajorCustomerDomain to ThreeCustomersMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:title="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" xlink:title="RevenueFromContractWithCustomerAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="RevenueFromContractWithCustomerAbstract" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to RevenueFromContractWithCustomerAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_DeferredRevenueRemainingAmortizationPeriod" xlink:label="DeferredRevenueRemainingAmortizationPeriod" xlink:title="DeferredRevenueRemainingAmortizationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="DeferredRevenueRemainingAmortizationPeriod" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to DeferredRevenueRemainingAmortizationPeriod" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_NumberOfCustomers" xlink:label="NumberOfCustomers" xlink:title="NumberOfCustomers" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="NumberOfCustomers" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to NumberOfCustomers" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="ConcentrationRiskPercentage1" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to ConcentrationRiskPercentage1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:title="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" order="5.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to TypeOfArrangementAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_BiotestLicenseAgreementMember" xlink:label="BiotestLicenseAgreementMember" xlink:title="BiotestLicenseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="BiotestLicenseAgreementMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to BiotestLicenseAgreementMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="MajorCustomersAxis" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to MajorCustomersAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain" xlink:title="NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain" xlink:title="definition: MajorCustomersAxis to NameOfMajorCustomerDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain_2" xlink:title="NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain_2" xlink:title="definition: MajorCustomersAxis to NameOfMajorCustomerDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_FiveCustomersMember" xlink:label="FiveCustomersMember" xlink:title="FiveCustomersMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NameOfMajorCustomerDomain" xlink:to="FiveCustomersMember" xlink:title="definition: NameOfMajorCustomerDomain to FiveCustomersMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ThreeCustomersMember" xlink:label="ThreeCustomersMember" xlink:title="ThreeCustomersMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NameOfMajorCustomerDomain" xlink:to="ThreeCustomersMember" xlink:title="definition: NameOfMajorCustomerDomain to ThreeCustomersMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to ConcentrationRiskByBenchmarkAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain_2" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain_2" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="RevenueFromContractWithCustomerMember" xlink:title="RevenueFromContractWithCustomerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="RevenueFromContractWithCustomerMember" xlink:title="definition: ConcentrationRiskBenchmarkDomain to RevenueFromContractWithCustomerMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:label="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:title="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueFromContractWithCustomerMember" xlink:to="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:title="definition: RevenueFromContractWithCustomerMember to RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to ConcentrationRiskByTypeAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain_2" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain_2" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskTypeDomain" xlink:to="CustomerConcentrationRiskMember" xlink:title="definition: ConcentrationRiskTypeDomain to CustomerConcentrationRiskMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetailsDefault">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:title="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" xlink:title="RevenueFromContractWithCustomerAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="RevenueFromContractWithCustomerAbstract" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to RevenueFromContractWithCustomerAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_DeferredRevenueRemainingAmortizationPeriod" xlink:label="DeferredRevenueRemainingAmortizationPeriod" xlink:title="DeferredRevenueRemainingAmortizationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="DeferredRevenueRemainingAmortizationPeriod" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to DeferredRevenueRemainingAmortizationPeriod" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_NumberOfCustomers" xlink:label="NumberOfCustomers" xlink:title="NumberOfCustomers" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="NumberOfCustomers" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to NumberOfCustomers" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="ConcentrationRiskPercentage1" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to ConcentrationRiskPercentage1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:title="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" order="5.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to TypeOfArrangementAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_BiotestLicenseAgreementMember" xlink:label="BiotestLicenseAgreementMember" xlink:title="BiotestLicenseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="BiotestLicenseAgreementMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to BiotestLicenseAgreementMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="MajorCustomersAxis" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to MajorCustomersAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain" xlink:title="NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain" xlink:title="definition: MajorCustomersAxis to NameOfMajorCustomerDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain_2" xlink:title="NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain_2" xlink:title="definition: MajorCustomersAxis to NameOfMajorCustomerDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_FiveCustomersMember" xlink:label="FiveCustomersMember" xlink:title="FiveCustomersMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NameOfMajorCustomerDomain" xlink:to="FiveCustomersMember" xlink:title="definition: NameOfMajorCustomerDomain to FiveCustomersMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ThreeCustomersMember" xlink:label="ThreeCustomersMember" xlink:title="ThreeCustomersMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NameOfMajorCustomerDomain" xlink:to="ThreeCustomersMember" xlink:title="definition: NameOfMajorCustomerDomain to ThreeCustomersMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to ConcentrationRiskByBenchmarkAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain_2" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain_2" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="RevenueFromContractWithCustomerMember" xlink:title="RevenueFromContractWithCustomerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="RevenueFromContractWithCustomerMember" xlink:title="definition: ConcentrationRiskBenchmarkDomain to RevenueFromContractWithCustomerMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:label="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:title="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueFromContractWithCustomerMember" xlink:to="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:title="definition: RevenueFromContractWithCustomerMember to RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to ConcentrationRiskByTypeAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain_2" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain_2" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskTypeDomain" xlink:to="CustomerConcentrationRiskMember" xlink:title="definition: ConcentrationRiskTypeDomain to CustomerConcentrationRiskMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesLossPerCommonShareDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to EarningsPerShareDilutedOtherDisclosuresAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="definition: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain_2" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain_2" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to EmployeeStockOptionMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to RestrictedStockUnitsRSUMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="WarrantMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to WarrantMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/InventoriesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="FiniteLivedIntangibleAssetsLineItems" xlink:title="FiniteLivedIntangibleAssetsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="FiniteLivedIntangibleAssetsNetAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsNetAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="AmortizationOfIntangibleAssets" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to AmortizationOfIntangibleAssets" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="FiniteLivedIntangibleAssetsGross" xlink:title="FiniteLivedIntangibleAssetsGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsGross" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsGross" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsAccumulatedAmortization" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="FiniteLivedIntangibleAssetsNet" xlink:title="FiniteLivedIntangibleAssetsNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsNet" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsNet" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to ScheduleOfFiniteLivedIntangibleAssetsTable" order="6.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="definition: ScheduleOfFiniteLivedIntangibleAssetsTable to FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="definition: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain_2" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain_2" xlink:title="definition: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:label="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:title="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:title="definition: FiniteLivedIntangibleAssetsMajorClassNameDomain to TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_RightToIntermediatesMember" xlink:label="RightToIntermediatesMember" xlink:title="RightToIntermediatesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="RightToIntermediatesMember" xlink:title="definition: FiniteLivedIntangibleAssetsMajorClassNameDomain to RightToIntermediatesMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerContractsMember" xlink:label="CustomerContractsMember" xlink:title="CustomerContractsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="CustomerContractsMember" xlink:title="definition: FiniteLivedIntangibleAssetsMajorClassNameDomain to CustomerContractsMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/PropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="PropertyPlantAndEquipmentNetAbstract" xlink:title="PropertyPlantAndEquipmentNetAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentNetAbstract" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentNetAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentUsefulLife" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentUsefulLife" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="DepreciationDepletionAndAmortization" xlink:title="definition: PropertyPlantAndEquipmentLineItems to DepreciationDepletionAndAmortization" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentGross" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="definition: PropertyPlantAndEquipmentLineItems to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentNet" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="definition: PropertyPlantAndEquipmentLineItems to ScheduleOfPropertyPlantAndEquipmentTable" order="7.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="definition: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentByTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="ManufacturingFacilityMember" xlink:title="ManufacturingFacilityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="ManufacturingFacilityMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to ManufacturingFacilityMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="OfficeEquipmentMember" xlink:title="OfficeEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="OfficeEquipmentMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to OfficeEquipmentMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="FurnitureAndFixturesMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to FurnitureAndFixturesMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetUnderConstructionMember" xlink:label="AssetUnderConstructionMember" xlink:title="AssetUnderConstructionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="AssetUnderConstructionMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to AssetUnderConstructionMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="LeaseholdImprovementsMember" xlink:title="LeaseholdImprovementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LeaseholdImprovementsMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to LeaseholdImprovementsMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandMember" xlink:label="LandMember" xlink:title="LandMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LandMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to LandMember" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="BuildingAndBuildingImprovementsMember" xlink:title="BuildingAndBuildingImprovementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="BuildingAndBuildingImprovementsMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to BuildingAndBuildingImprovementsMember" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember" xlink:label="BuildingMember" xlink:title="BuildingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="BuildingMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to BuildingMember" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfPropertyPlantAndEquipmentTable to RangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/DebtDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="DebtInstrumentsAbstract" xlink:title="DebtInstrumentsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentsAbstract" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="NotesPayableAbstract" xlink:title="NotesPayableAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="NotesPayableAbstract" xlink:title="definition: DebtInstrumentLineItems to NotesPayableAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="DebtInstrumentMaturityDate" xlink:title="DebtInstrumentMaturityDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentMaturityDate" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentMaturityDate" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentInterestRateStatedPercentage" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_DebtInstrumentTermOfVariableRate" xlink:label="DebtInstrumentTermOfVariableRate" xlink:title="DebtInstrumentTermOfVariableRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTermOfVariableRate" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentTermOfVariableRate" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentBasisSpreadOnVariableRate1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="DebtInstrumentInterestRateIncreaseDecrease" xlink:title="DebtInstrumentInterestRateIncreaseDecrease" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentInterestRateIncreaseDecrease" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentInterestRateIncreaseDecrease" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="DebtInstrumentInterestRateEffectivePercentage" xlink:title="DebtInstrumentInterestRateEffectivePercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentInterestRateEffectivePercentage" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentInterestRateEffectivePercentage" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_RepaymentsOfDebtInterest" xlink:label="RepaymentsOfDebtInterest" xlink:title="RepaymentsOfDebtInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="RepaymentsOfDebtInterest" xlink:title="definition: DebtInstrumentLineItems to RepaymentsOfDebtInterest" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="Cash" xlink:title="Cash" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="Cash" xlink:title="definition: DebtInstrumentLineItems to Cash" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="definition: DebtInstrumentLineItems to RevenueFromContractWithCustomerExcludingAssessedTax" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_SeniorNotesPayableBeforeDebtDiscount" xlink:label="SeniorNotesPayableBeforeDebtDiscount" xlink:title="SeniorNotesPayableBeforeDebtDiscount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="SeniorNotesPayableBeforeDebtDiscount" xlink:title="definition: DebtInstrumentLineItems to SeniorNotesPayableBeforeDebtDiscount" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="DebtInstrumentUnamortizedDiscount" xlink:title="DebtInstrumentUnamortizedDiscount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentUnamortizedDiscount" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentUnamortizedDiscount" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorLongTermNotes" xlink:label="SeniorLongTermNotes" xlink:title="SeniorLongTermNotes" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="SeniorLongTermNotes" xlink:title="definition: DebtInstrumentLineItems to SeniorLongTermNotes" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTable" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentTable" order="15.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="LongtermDebtTypeAxis" xlink:title="definition: DebtInstrumentTable to LongtermDebtTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain" xlink:title="definition: LongtermDebtTypeAxis to LongtermDebtTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain_2" xlink:title="LongtermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain_2" xlink:title="definition: LongtermDebtTypeAxis to LongtermDebtTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="SeniorNotesMember" xlink:title="SeniorNotesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongtermDebtTypeDomain" xlink:to="SeniorNotesMember" xlink:title="definition: LongtermDebtTypeDomain to SeniorNotesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentAxis" xlink:title="definition: DebtInstrumentTable to DebtInstrumentAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain_2" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain_2" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PerceptiveCreditAgreementMember" xlink:label="PerceptiveCreditAgreementMember" xlink:title="PerceptiveCreditAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="PerceptiveCreditAgreementMember" xlink:title="definition: DebtInstrumentNameDomain to PerceptiveCreditAgreementMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PerceptiveCreditFacilityMember" xlink:label="PerceptiveCreditFacilityMember" xlink:title="PerceptiveCreditFacilityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="PerceptiveCreditFacilityMember" xlink:title="definition: DebtInstrumentNameDomain to PerceptiveCreditFacilityMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="VariableRateAxis" xlink:title="VariableRateAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="VariableRateAxis" xlink:title="definition: DebtInstrumentTable to VariableRateAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="VariableRateDomain" xlink:title="VariableRateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="VariableRateAxis" xlink:to="VariableRateDomain" xlink:title="definition: VariableRateAxis to VariableRateDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="VariableRateDomain_2" xlink:title="VariableRateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="VariableRateAxis" xlink:to="VariableRateDomain_2" xlink:title="definition: VariableRateAxis to VariableRateDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="LondonInterbankOfferedRateLIBORMember" xlink:title="LondonInterbankOfferedRateLIBORMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="VariableRateDomain" xlink:to="LondonInterbankOfferedRateLIBORMember" xlink:title="definition: VariableRateDomain to LondonInterbankOfferedRateLIBORMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="RangeAxis" xlink:title="definition: DebtInstrumentTable to RangeAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="StatementScenarioAxis" xlink:title="definition: DebtInstrumentTable to StatementScenarioAxis" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain_2" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain_2" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="ScenarioForecastMember" xlink:title="ScenarioForecastMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScenarioUnspecifiedDomain" xlink:to="ScenarioForecastMember" xlink:title="definition: ScenarioUnspecifiedDomain to ScenarioForecastMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityPreferredStockDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityCommonStockDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="definition: ClassOfStockLineItems to CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="CommonStockSharesAuthorized" xlink:title="definition: ClassOfStockLineItems to CommonStockSharesAuthorized" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="definition: ClassOfStockLineItems to CommonStockParOrStatedValuePerShare" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="CommonStockSharesOutstanding" xlink:title="definition: ClassOfStockLineItems to CommonStockSharesOutstanding" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="ClassOfWarrantOrRightOutstanding" xlink:title="definition: ClassOfStockLineItems to ClassOfWarrantOrRightOutstanding" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="definition: ClassOfStockLineItems to CommonStockCapitalSharesReservedForFutureIssuance" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="definition: ClassOfStockLineItems to StockIssuedDuringPeriodValueNewIssues" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="definition: ClassOfStockLineItems to StockIssuedDuringPeriodSharesNewIssues" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="definition: ClassOfStockLineItems to ProceedsFromIssuanceOfCommonStock" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_GrossProceedsFromIssuanceOfCommonStock" xlink:label="GrossProceedsFromIssuanceOfCommonStock" xlink:title="GrossProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="GrossProceedsFromIssuanceOfCommonStock" xlink:title="definition: ClassOfStockLineItems to GrossProceedsFromIssuanceOfCommonStock" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ClassOfStockLineItems" xlink:to="ScheduleOfStockByClassTable" xlink:title="definition: ClassOfStockLineItems to ScheduleOfStockByClassTable" order="11.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: ScheduleOfStockByClassTable to StatementEquityComponentsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: ScheduleOfStockByClassTable to TypeOfArrangementAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_SaleAgreementMember" xlink:label="SaleAgreementMember" xlink:title="SaleAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="SaleAgreementMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to SaleAgreementMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_SaleAgreement2020Member" xlink:label="SaleAgreement2020Member" xlink:title="SaleAgreement2020Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="SaleAgreement2020Member" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to SaleAgreement2020Member" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_SaleAgreement2020AmendedMember" xlink:label="SaleAgreement2020AmendedMember" xlink:title="SaleAgreement2020AmendedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="SaleAgreement2020AmendedMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to SaleAgreement2020AmendedMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_SaleAgreement2021Member" xlink:label="SaleAgreement2021Member" xlink:title="SaleAgreement2021Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="SaleAgreement2021Member" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to SaleAgreement2021Member" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="definition: ScheduleOfStockByClassTable to RelatedPartyTransactionsByRelatedPartyAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain_2" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain_2" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_JefferiesLLCMember" xlink:label="JefferiesLLCMember" xlink:title="JefferiesLLCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="JefferiesLLCMember" xlink:title="definition: RelatedPartyDomain to JefferiesLLCMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="SubsidiarySaleOfStockAxis" xlink:title="definition: ScheduleOfStockByClassTable to SubsidiarySaleOfStockAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain_2" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain_2" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="OverAllotmentOptionMember" xlink:title="OverAllotmentOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="OverAllotmentOptionMember" xlink:title="definition: SaleOfStockNameOfTransactionDomain to OverAllotmentOptionMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfStockByClassTable to RangeAxis" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityWarrantsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="ClassOfWarrantOrRightLineItems" xlink:title="ClassOfWarrantOrRightLineItems" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_WarrantsAbstract" xlink:label="WarrantsAbstract" xlink:title="WarrantsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="WarrantsAbstract" xlink:title="definition: ClassOfWarrantOrRightLineItems to WarrantsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantOrRightOutstanding" xlink:title="definition: ClassOfWarrantOrRightLineItems to ClassOfWarrantOrRightOutstanding" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="definition: ClassOfWarrantOrRightLineItems to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="ClassOfWarrantOrRightTable" xlink:title="ClassOfWarrantOrRightTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantOrRightTable" xlink:title="definition: ClassOfWarrantOrRightLineItems to ClassOfWarrantOrRightTable" order="4.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ClassOfWarrantOrRightTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: ClassOfWarrantOrRightTable to StatementEquityComponentsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_StockOptionsAbstract" xlink:label="StockOptionsAbstract" xlink:title="StockOptionsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="StockOptionsAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to StockOptionsAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_RestrictedStockUnitsAbstract" xlink:label="RestrictedStockUnitsAbstract" xlink:title="RestrictedStockUnitsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="RestrictedStockUnitsAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to RestrictedStockUnitsAbstract" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:title="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensation" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensation" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" order="25.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="26.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="27.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_StockOptionSharesAbstract" xlink:label="StockOptionSharesAbstract" xlink:title="StockOptionSharesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="StockOptionSharesAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to StockOptionSharesAbstract" order="28.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_StockOptionsWeightedAverageExercisePriceAbstract" xlink:label="StockOptionsWeightedAverageExercisePriceAbstract" xlink:title="StockOptionsWeightedAverageExercisePriceAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="StockOptionsWeightedAverageExercisePriceAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to StockOptionsWeightedAverageExercisePriceAbstract" order="29.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" order="31.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" order="32.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" order="33.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" order="34.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="35.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="36.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" order="37.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" order="38.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" order="39.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="41.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="42.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="43.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="44.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="45.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="46.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockUnitsRSUMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="PlanNameAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to PlanNameAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain_2" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain_2" xlink:title="definition: PlanNameAxis to PlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_EquityIncentivePlanMember" xlink:label="EquityIncentivePlanMember" xlink:title="EquityIncentivePlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="EquityIncentivePlanMember" xlink:title="definition: PlanNameDomain to EquityIncentivePlanMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="TitleOfIndividualAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to TitleOfIndividualAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="DirectorMember" xlink:title="DirectorMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="DirectorMember" xlink:title="definition: TitleOfIndividualWithRelationshipToEntityDomain to DirectorMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_EmployeesMember" xlink:label="EmployeesMember" xlink:title="EmployeesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="EmployeesMember" xlink:title="definition: TitleOfIndividualWithRelationshipToEntityDomain to EmployeesMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to RangeAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="IncomeStatementLocationAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to IncomeStatementLocationAxis" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain_2" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain_2" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="OperatingExpenseMember" xlink:title="OperatingExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="OperatingExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to OperatingExpenseMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="SellingGeneralAndAdministrativeExpensesMember" xlink:title="SellingGeneralAndAdministrativeExpensesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="SellingGeneralAndAdministrativeExpensesMember" xlink:title="definition: IncomeStatementLocationDomain to SellingGeneralAndAdministrativeExpensesMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="CostOfSalesMember" xlink:title="CostOfSalesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="CostOfSalesMember" xlink:title="definition: IncomeStatementLocationDomain to CostOfSalesMember" order="4.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="RelatedPartyTransactionLineItems" xlink:title="RelatedPartyTransactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:label="RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:title="RelatedPartyTransactionDueFromToRelatedPartyAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:title="definition: RelatedPartyTransactionLineItems to RelatedPartyTransactionDueFromToRelatedPartyAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:title="RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:title="definition: RelatedPartyTransactionLineItems to RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="RelatedPartyTransactionPurchasesFromRelatedParty" xlink:title="RelatedPartyTransactionPurchasesFromRelatedParty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="RelatedPartyTransactionPurchasesFromRelatedParty" xlink:title="definition: RelatedPartyTransactionLineItems to RelatedPartyTransactionPurchasesFromRelatedParty" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_EstimatedPaymentForSeparationAndTransitionAgreement" xlink:label="EstimatedPaymentForSeparationAndTransitionAgreement" xlink:title="EstimatedPaymentForSeparationAndTransitionAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="EstimatedPaymentForSeparationAndTransitionAgreement" xlink:title="definition: RelatedPartyTransactionLineItems to EstimatedPaymentForSeparationAndTransitionAgreement" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement" xlink:label="PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement" xlink:title="PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement" xlink:title="definition: RelatedPartyTransactionLineItems to PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_MinimumPercentageOfCommonStockHeldByLender" xlink:label="MinimumPercentageOfCommonStockHeldByLender" xlink:title="MinimumPercentageOfCommonStockHeldByLender" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="MinimumPercentageOfCommonStockHeldByLender" xlink:title="definition: RelatedPartyTransactionLineItems to MinimumPercentageOfCommonStockHeldByLender" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="definition: RelatedPartyTransactionLineItems to StockIssuedDuringPeriodSharesNewIssues" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="SharesIssuedPricePerShare" xlink:title="SharesIssuedPricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="SharesIssuedPricePerShare" xlink:title="definition: RelatedPartyTransactionLineItems to SharesIssuedPricePerShare" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="RelatedPartyTransactionLineItems" xlink:to="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="definition: RelatedPartyTransactionLineItems to ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="9.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="definition: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain_2" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain_2" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ArethLLCMember" xlink:label="ArethLLCMember" xlink:title="ArethLLCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="ArethLLCMember" xlink:title="definition: RelatedPartyDomain to ArethLLCMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_GenesisBPSMember" xlink:label="GenesisBPSMember" xlink:title="GenesisBPSMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="GenesisBPSMember" xlink:title="definition: RelatedPartyDomain to GenesisBPSMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="LineOfCreditFacilityAxis" xlink:title="LineOfCreditFacilityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="LineOfCreditFacilityAxis" xlink:title="definition: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to LineOfCreditFacilityAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="LineOfCreditFacilityLenderDomain" xlink:title="LineOfCreditFacilityLenderDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LineOfCreditFacilityAxis" xlink:to="LineOfCreditFacilityLenderDomain" xlink:title="definition: LineOfCreditFacilityAxis to LineOfCreditFacilityLenderDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="LineOfCreditFacilityLenderDomain_2" xlink:title="LineOfCreditFacilityLenderDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LineOfCreditFacilityAxis" xlink:to="LineOfCreditFacilityLenderDomain_2" xlink:title="definition: LineOfCreditFacilityAxis to LineOfCreditFacilityLenderDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PerceptiveCreditHoldingsIILPMember" xlink:label="PerceptiveCreditHoldingsIILPMember" xlink:title="PerceptiveCreditHoldingsIILPMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLenderDomain" xlink:to="PerceptiveCreditHoldingsIILPMember" xlink:title="definition: LineOfCreditFacilityLenderDomain to PerceptiveCreditHoldingsIILPMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="TitleOfIndividualAxis" xlink:title="definition: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to TitleOfIndividualAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ViceChairmanMember" xlink:label="ViceChairmanMember" xlink:title="ViceChairmanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ViceChairmanMember" xlink:title="definition: TitleOfIndividualWithRelationshipToEntityDomain to ViceChairmanMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="DirectorMember" xlink:title="DirectorMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="DirectorMember" xlink:title="definition: TitleOfIndividualWithRelationshipToEntityDomain to DirectorMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PresidentAndChiefExecutiveOfficerMember" xlink:label="PresidentAndChiefExecutiveOfficerMember" xlink:title="PresidentAndChiefExecutiveOfficerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="PresidentAndChiefExecutiveOfficerMember" xlink:title="definition: TitleOfIndividualWithRelationshipToEntityDomain to PresidentAndChiefExecutiveOfficerMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember" xlink:label="ExecutiveVicePresidentAndChiefFinancialOfficerMember" xlink:title="ExecutiveVicePresidentAndChiefFinancialOfficerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ExecutiveVicePresidentAndChiefFinancialOfficerMember" xlink:title="definition: TitleOfIndividualWithRelationshipToEntityDomain to ExecutiveVicePresidentAndChiefFinancialOfficerMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ChiefScientificOfficerAndChiefMedicalOfficerMember" xlink:label="ChiefScientificOfficerAndChiefMedicalOfficerMember" xlink:title="ChiefScientificOfficerAndChiefMedicalOfficerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ChiefScientificOfficerAndChiefMedicalOfficerMember" xlink:title="definition: TitleOfIndividualWithRelationshipToEntityDomain to ChiefScientificOfficerAndChiefMedicalOfficerMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis" xlink:label="OwnershipAxis" xlink:title="OwnershipAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="OwnershipAxis" xlink:title="definition: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to OwnershipAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain" xlink:title="OwnershipDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="OwnershipAxis" xlink:to="OwnershipDomain" xlink:title="definition: OwnershipAxis to OwnershipDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain_2" xlink:title="OwnershipDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="OwnershipAxis" xlink:to="OwnershipDomain_2" xlink:title="definition: OwnershipAxis to OwnershipDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_DirectOwnershipMember" xlink:label="DirectOwnershipMember" xlink:title="DirectOwnershipMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OwnershipDomain" xlink:to="DirectOwnershipMember" xlink:title="definition: OwnershipDomain to DirectOwnershipMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_IndirectOwnershipMember" xlink:label="IndirectOwnershipMember" xlink:title="IndirectOwnershipMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OwnershipDomain" xlink:to="IndirectOwnershipMember" xlink:title="definition: OwnershipDomain to IndirectOwnershipMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="LossContingenciesLineItems" xlink:title="LossContingenciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_VendorCommitmentsAbstract" xlink:label="VendorCommitmentsAbstract" xlink:title="VendorCommitmentsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="VendorCommitmentsAbstract" xlink:title="definition: LossContingenciesLineItems to VendorCommitmentsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_NumberOfPlasmaCollectionFacilities" xlink:label="NumberOfPlasmaCollectionFacilities" xlink:title="NumberOfPlasmaCollectionFacilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="NumberOfPlasmaCollectionFacilities" xlink:title="definition: LossContingenciesLineItems to NumberOfPlasmaCollectionFacilities" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_NumberOfRenewalTerms" xlink:label="NumberOfRenewalTerms" xlink:title="NumberOfRenewalTerms" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="NumberOfRenewalTerms" xlink:title="definition: LossContingenciesLineItems to NumberOfRenewalTerms" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PlasmaPurchaseAgreementRenewalPeriod" xlink:label="PlasmaPurchaseAgreementRenewalPeriod" xlink:title="PlasmaPurchaseAgreementRenewalPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="PlasmaPurchaseAgreementRenewalPeriod" xlink:title="definition: LossContingenciesLineItems to PlasmaPurchaseAgreementRenewalPeriod" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PlasmaPurchaseAgreementTerm" xlink:label="PlasmaPurchaseAgreementTerm" xlink:title="PlasmaPurchaseAgreementTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="PlasmaPurchaseAgreementTerm" xlink:title="definition: LossContingenciesLineItems to PlasmaPurchaseAgreementTerm" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity" xlink:label="NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity" xlink:title="NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity" xlink:title="definition: LossContingenciesLineItems to NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PercentageOfPlasmaPurchasePriceEqualToCost" xlink:label="PercentageOfPlasmaPurchasePriceEqualToCost" xlink:title="PercentageOfPlasmaPurchasePriceEqualToCost" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="PercentageOfPlasmaPurchasePriceEqualToCost" xlink:title="definition: LossContingenciesLineItems to PercentageOfPlasmaPurchasePriceEqualToCost" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PlasmaSupplyAgreementTerm" xlink:label="PlasmaSupplyAgreementTerm" xlink:title="PlasmaSupplyAgreementTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="PlasmaSupplyAgreementTerm" xlink:title="definition: LossContingenciesLineItems to PlasmaSupplyAgreementTerm" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PlasmaPurchased" xlink:label="PlasmaPurchased" xlink:title="PlasmaPurchased" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="PlasmaPurchased" xlink:title="definition: LossContingenciesLineItems to PlasmaPurchased" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PercentageOfInventoryPurchases" xlink:label="PercentageOfInventoryPurchases" xlink:title="PercentageOfInventoryPurchases" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="PercentageOfInventoryPurchases" xlink:title="definition: LossContingenciesLineItems to PercentageOfInventoryPurchases" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="LossContingenciesTable" xlink:title="LossContingenciesTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="LossContingenciesLineItems" xlink:to="LossContingenciesTable" xlink:title="definition: LossContingenciesLineItems to LossContingenciesTable" order="11.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LossContingenciesTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: LossContingenciesTable to TypeOfArrangementAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PlasmaPurchaseAgreementOneMember" xlink:label="PlasmaPurchaseAgreementOneMember" xlink:title="PlasmaPurchaseAgreementOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="PlasmaPurchaseAgreementOneMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to PlasmaPurchaseAgreementOneMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PlasmaPurchaseAgreementTwoMember" xlink:label="PlasmaPurchaseAgreementTwoMember" xlink:title="PlasmaPurchaseAgreementTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="PlasmaPurchaseAgreementTwoMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to PlasmaPurchaseAgreementTwoMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LossContingenciesTable" xlink:to="RangeAxis" xlink:title="definition: LossContingenciesTable to RangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SegmentsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="SegmentReportingInformationLineItems" xlink:title="SegmentReportingInformationLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:label="SegmentReportingInformationProfitLossAbstract" xlink:title="SegmentReportingInformationProfitLossAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="SegmentReportingInformationProfitLossAbstract" xlink:title="definition: SegmentReportingInformationLineItems to SegmentReportingInformationProfitLossAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_NumberOfFDALicensedPlasmaCollectionFacilities" xlink:label="NumberOfFDALicensedPlasmaCollectionFacilities" xlink:title="NumberOfFDALicensedPlasmaCollectionFacilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="NumberOfFDALicensedPlasmaCollectionFacilities" xlink:title="definition: SegmentReportingInformationLineItems to NumberOfFDALicensedPlasmaCollectionFacilities" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:label="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:title="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:title="definition: SegmentReportingInformationLineItems to NumberOfPlasmaCollectionFacilitiesUnderDevelopment" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="definition: SegmentReportingInformationLineItems to RevenueFromContractWithCustomerExcludingAssessedTax" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_CostOfProductRevenueExcludingAmortizationExpense" xlink:label="CostOfProductRevenueExcludingAmortizationExpense" xlink:title="CostOfProductRevenueExcludingAmortizationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="CostOfProductRevenueExcludingAmortizationExpense" xlink:title="definition: SegmentReportingInformationLineItems to CostOfProductRevenueExcludingAmortizationExpense" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="OperatingIncomeLoss" xlink:title="definition: SegmentReportingInformationLineItems to OperatingIncomeLoss" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="NonoperatingIncomeExpense" xlink:title="definition: SegmentReportingInformationLineItems to NonoperatingIncomeExpense" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="NetIncomeLoss" xlink:title="definition: SegmentReportingInformationLineItems to NetIncomeLoss" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="definition: SegmentReportingInformationLineItems to PaymentsToAcquirePropertyPlantAndEquipment" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="DepreciationAndAmortization" xlink:title="DepreciationAndAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="DepreciationAndAmortization" xlink:title="definition: SegmentReportingInformationLineItems to DepreciationAndAmortization" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="Assets" xlink:title="definition: SegmentReportingInformationLineItems to Assets" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="SegmentReportingInformationLineItems" xlink:to="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="definition: SegmentReportingInformationLineItems to ScheduleOfSegmentReportingInformationBySegmentTable" order="12.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="ConsolidationItemsAxis" xlink:title="ConsolidationItemsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="ConsolidationItemsAxis" xlink:title="definition: ScheduleOfSegmentReportingInformationBySegmentTable to ConsolidationItemsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="ConsolidationItemsDomain" xlink:title="ConsolidationItemsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConsolidationItemsAxis" xlink:to="ConsolidationItemsDomain" xlink:title="definition: ConsolidationItemsAxis to ConsolidationItemsDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="ConsolidationItemsDomain_2" xlink:title="ConsolidationItemsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConsolidationItemsAxis" xlink:to="ConsolidationItemsDomain_2" xlink:title="definition: ConsolidationItemsAxis to ConsolidationItemsDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="OperatingSegmentsMember" xlink:title="OperatingSegmentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConsolidationItemsDomain" xlink:to="OperatingSegmentsMember" xlink:title="definition: ConsolidationItemsDomain to OperatingSegmentsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="StatementBusinessSegmentsAxis" xlink:title="StatementBusinessSegmentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="StatementBusinessSegmentsAxis" xlink:title="definition: ScheduleOfSegmentReportingInformationBySegmentTable to StatementBusinessSegmentsAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain" xlink:title="SegmentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain" xlink:title="definition: StatementBusinessSegmentsAxis to SegmentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain_2" xlink:title="SegmentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain_2" xlink:title="definition: StatementBusinessSegmentsAxis to SegmentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ADMABioManufacturingSegmentMember" xlink:label="ADMABioManufacturingSegmentMember" xlink:title="ADMABioManufacturingSegmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentDomain" xlink:to="ADMABioManufacturingSegmentMember" xlink:title="definition: SegmentDomain to ADMABioManufacturingSegmentMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PlasmaCollectionCentersSegmentMember" xlink:label="PlasmaCollectionCentersSegmentMember" xlink:title="PlasmaCollectionCentersSegmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentDomain" xlink:to="PlasmaCollectionCentersSegmentMember" xlink:title="definition: SegmentDomain to PlasmaCollectionCentersSegmentMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateMember" xlink:label="CorporateMember" xlink:title="CorporateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentDomain" xlink:to="CorporateMember" xlink:title="definition: SegmentDomain to CorporateMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="StatementGeographicalAxis" xlink:title="StatementGeographicalAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="StatementGeographicalAxis" xlink:title="definition: ScheduleOfSegmentReportingInformationBySegmentTable to StatementGeographicalAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="SegmentGeographicalDomain" xlink:title="SegmentGeographicalDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementGeographicalAxis" xlink:to="SegmentGeographicalDomain" xlink:title="definition: StatementGeographicalAxis to SegmentGeographicalDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="SegmentGeographicalDomain_2" xlink:title="SegmentGeographicalDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementGeographicalAxis" xlink:to="SegmentGeographicalDomain_2" xlink:title="definition: StatementGeographicalAxis to SegmentGeographicalDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="US" xlink:title="US" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentGeographicalDomain" xlink:to="US" xlink:title="definition: SegmentGeographicalDomain to US" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember" xlink:label="NonUsMember" xlink:title="NonUsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentGeographicalDomain" xlink:to="NonUsMember" xlink:title="definition: SegmentGeographicalDomain to NonUsMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="LesseeLeaseDescriptionLineItems" xlink:title="LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="LesseeOperatingLeaseDescriptionAbstract" xlink:title="LesseeOperatingLeaseDescriptionAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseDescriptionAbstract" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseDescriptionAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="LesseeOperatingLeaseTermOfContract" xlink:title="LesseeOperatingLeaseTermOfContract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseTermOfContract" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseTermOfContract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="SecurityDeposit" xlink:title="SecurityDeposit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="SecurityDeposit" xlink:title="definition: LesseeLeaseDescriptionLineItems to SecurityDeposit" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRent" xlink:label="PaymentsForRent" xlink:title="PaymentsForRent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="PaymentsForRent" xlink:title="definition: LesseeLeaseDescriptionLineItems to PaymentsForRent" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_OperatingLeasesRentExpense" xlink:label="OperatingLeasesRentExpense" xlink:title="OperatingLeasesRentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeasesRentExpense" xlink:title="definition: LesseeLeaseDescriptionLineItems to OperatingLeasesRentExpense" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="LesseeLeaseDescriptionTable" xlink:title="LesseeLeaseDescriptionTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeLeaseDescriptionTable" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeLeaseDescriptionTable" order="6.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LesseeLeaseDescriptionTable" xlink:to="RangeAxis" xlink:title="definition: LesseeLeaseDescriptionTable to RangeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsDetailsCalc2" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_SubsequentEventsSaleOfStockAbstract" xlink:label="SubsequentEventsSaleOfStockAbstract" xlink:title="SubsequentEventsSaleOfStockAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="SubsequentEventsSaleOfStockAbstract" xlink:title="definition: SubsequentEventLineItems to SubsequentEventsSaleOfStockAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="definition: SubsequentEventLineItems to StockIssuedDuringPeriodSharesNewIssues" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="definition: SubsequentEventLineItems to ProceedsFromIssuanceOfCommonStock" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="SubsequentEventLineItems" xlink:to="SubsequentEventTable" xlink:title="definition: SubsequentEventLineItems to SubsequentEventTable" order="4.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventTypeAxis" xlink:title="definition: SubsequentEventTable to SubsequentEventTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain_2" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain_2" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="definition: SubsequentEventTypeDomain to SubsequentEventMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: SubsequentEventTable to TypeOfArrangementAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_SaleAgreement2020Member" xlink:label="SaleAgreement2020Member" xlink:title="SaleAgreement2020Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="SaleAgreement2020Member" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to SaleAgreement2020Member" order="1.0" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>adma-20210630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 8.0.0.0 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" id="us-gaap_AwardTypeAxis_lbl">Award Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:title="label: AwardTypeAxis to us-gaap_AwardTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:title="label: ArrangementsAndNonarrangementTransactionsMember to us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="us-gaap_AccountingPoliciesAbstract_lbl">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:title="label: AccountingPoliciesAbstract to us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:title="label: AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock to us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" xlink:title="label: AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock to us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="us-gaap_AccountsPayableCurrent_lbl">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:title="label: AccountsPayableCurrent to us-gaap_AccountsPayableCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetAbstract" xlink:label="AccountsReceivableNetAbstract" xlink:title="AccountsReceivableNetAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsReceivableNetAbstract_lbl" xml:lang="en-US" id="us-gaap_AccountsReceivableNetAbstract_lbl">Accounts Receivable [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableNetAbstract" xlink:to="us-gaap_AccountsReceivableNetAbstract_lbl" xlink:title="label: AccountsReceivableNetAbstract to us-gaap_AccountsReceivableNetAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="AccountsReceivableNetCurrent" xlink:title="AccountsReceivableNetCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" id="us-gaap_AccountsReceivableNetCurrent_lbl">Accounts receivable, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:title="label: AccountsReceivableNetCurrent to us-gaap_AccountsReceivableNetCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="AccountsReceivableMember" xlink:title="AccountsReceivableMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US" id="us-gaap_AccountsReceivableMember_lbl">Accounts Receivable [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" xlink:title="label: AccountsReceivableMember to us-gaap_AccountsReceivableMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="AccruedBonusesCurrent" xlink:title="AccruedBonusesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US" id="us-gaap_AccruedBonusesCurrent_lbl">Accrued incentives</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl" xlink:title="label: AccruedBonusesCurrent to us-gaap_AccruedBonusesCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" id="us-gaap_AccruedProfessionalFeesCurrent_lbl">Accrued distribution fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:title="label: AccruedProfessionalFeesCurrent to us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="AccruedSalariesCurrent" xlink:title="AccruedSalariesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US" id="us-gaap_AccruedSalariesCurrent_lbl">Accrued payroll</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl" xlink:title="label: AccruedSalariesCurrent to us-gaap_AccruedSalariesCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:title="AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl">Accrued Expenses and Other Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xlink:title="label: AccruedLiabilitiesAndOtherLiabilitiesAbstract to us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="AccruedLiabilitiesAndOtherLiabilities" xlink:title="AccruedLiabilitiesAndOtherLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl">Accrued expenses and other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:title="label: AccruedLiabilitiesAndOtherLiabilities to us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl1" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl1">Total accrued expenses and other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl1" xlink:title="label: AccruedLiabilitiesAndOtherLiabilities to us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl">Less: accumulated depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:title="label: AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment to us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xml:lang="en-US" id="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xlink:title="label: AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment to us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapital_lbl">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:title="label: AdditionalPaidInCapital to us-gaap_AdditionalPaidInCapital_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdditionalPaidInCapital_lbl1" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapital_lbl1">Additional Paid in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl1" xlink:title="label: AdditionalPaidInCapital to us-gaap_AdditionalPaidInCapital_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapitalMember_lbl">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:title="label: AdditionalPaidInCapitalMember to us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:title="label: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition to us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl1" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl1">APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl1" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition to us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" id="us-gaap_AmortizationOfDebtDiscountPremium_lbl">Amortization of debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:title="label: AmortizationOfDebtDiscountPremium to us-gaap_AmortizationOfDebtDiscountPremium_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" id="us-gaap_AmortizationOfIntangibleAssets_lbl">Amortization of intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:title="label: AmortizationOfIntangibleAssets to us-gaap_AmortizationOfIntangibleAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AmortizationOfIntangibleAssets_lbl1" xml:lang="en-US" id="us-gaap_AmortizationOfIntangibleAssets_lbl1">Amortization of intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl1" xlink:title="label: AmortizationOfIntangibleAssets to us-gaap_AmortizationOfIntangibleAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl">Potentially dilutive securities (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesNameDomain_lbl">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:title="label: AntidilutiveSecuritiesNameDomain to us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_lbl1" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesNameDomain_lbl1">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl1" xlink:title="label: AntidilutiveSecuritiesNameDomain to us-gaap_AntidilutiveSecuritiesNameDomain_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentChargesAbstract" xlink:label="AssetImpairmentChargesAbstract" xlink:title="AssetImpairmentChargesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetImpairmentChargesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetImpairmentChargesAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetImpairmentChargesAbstract_lbl">Impairment of Long-lived Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetImpairmentChargesAbstract" xlink:to="us-gaap_AssetImpairmentChargesAbstract_lbl" xlink:title="label: AssetImpairmentChargesAbstract to us-gaap_AssetImpairmentChargesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetUnderConstructionMember" xlink:label="AssetUnderConstructionMember" xlink:title="AssetUnderConstructionMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetUnderConstructionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetUnderConstructionMember_lbl" xml:lang="en-US" id="us-gaap_AssetUnderConstructionMember_lbl">Construction in Process [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetUnderConstructionMember" xlink:to="us-gaap_AssetUnderConstructionMember_lbl" xlink:title="label: AssetUnderConstructionMember to us-gaap_AssetUnderConstructionMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Assets_lbl" xml:lang="en-US" id="us-gaap_Assets_lbl">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets_lbl" xlink:title="label: Assets to us-gaap_Assets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets_lbl1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Assets_lbl1" xml:lang="en-US" id="us-gaap_Assets_lbl1">TOTAL ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets_lbl1" xlink:title="label: Assets to us-gaap_Assets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetsAbstract_lbl">ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsAbstract_lbl1" xml:lang="en-US" id="us-gaap_AssetsAbstract_lbl1">Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl1" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="us-gaap_AssetsCurrent_lbl">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrent_lbl1" xml:lang="en-US" id="us-gaap_AssetsCurrent_lbl1">Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl1" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetsCurrentAbstract_lbl">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:title="label: AssetsCurrentAbstract to us-gaap_AssetsCurrentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="BasisOfAccountingPolicyPolicyTextBlock" xlink:title="BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl">Basis of presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:title="label: BasisOfAccountingPolicyPolicyTextBlock to us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember" xlink:label="BuildingMember" xlink:title="BuildingMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BuildingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BuildingMember_lbl" xml:lang="en-US" id="us-gaap_BuildingMember_lbl">Building [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BuildingMember" xlink:to="us-gaap_BuildingMember_lbl" xlink:title="label: BuildingMember to us-gaap_BuildingMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="BuildingAndBuildingImprovementsMember" xlink:title="BuildingAndBuildingImprovementsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BuildingAndBuildingImprovementsMember_lbl" xml:lang="en-US" id="us-gaap_BuildingAndBuildingImprovementsMember_lbl">Buildings and Building Improvements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BuildingAndBuildingImprovementsMember" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember_lbl" xlink:title="label: BuildingAndBuildingImprovementsMember to us-gaap_BuildingAndBuildingImprovementsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl">Net (decrease) increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl1" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl1">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl1" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl">Cash and cash equivalents - beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1">Cash and cash equivalents - end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="Cash" xlink:title="Cash" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Cash_lbl" xml:lang="en-US" id="us-gaap_Cash_lbl">Cash balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Cash" xlink:to="us-gaap_Cash_lbl" xlink:title="label: Cash to us-gaap_Cash_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="CashEquivalentsAtCarryingValue" xlink:title="CashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="us-gaap_CashEquivalentsAtCarryingValue_lbl">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:title="label: CashEquivalentsAtCarryingValue to us-gaap_CashEquivalentsAtCarryingValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashEquivalentsAtCarryingValue_lbl1" xml:lang="en-US" id="us-gaap_CashEquivalentsAtCarryingValue_lbl1">Cash Equivalents, at Carrying Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl1" xlink:title="label: CashEquivalentsAtCarryingValue to us-gaap_CashEquivalentsAtCarryingValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:label="CashFlowSupplementalDisclosuresTextBlock" xlink:title="CashFlowSupplementalDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl" xml:lang="en-US" id="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashFlowSupplementalDisclosuresTextBlock" xlink:to="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl" xlink:title="label: CashFlowSupplementalDisclosuresTextBlock to us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="ClassOfWarrantOrRightTable" xlink:title="ClassOfWarrantOrRightTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightTable_lbl">Class of Warrant or Right [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:title="label: ClassOfWarrantOrRightTable to us-gaap_ClassOfWarrantOrRightTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="ClassOfWarrantOrRightLineItems" xlink:title="ClassOfWarrantOrRightLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightLineItems_lbl">Class of Warrant or Right [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:title="label: ClassOfWarrantOrRightLineItems to us-gaap_ClassOfWarrantOrRightLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" id="us-gaap_ClassOfStockLineItems_lbl">Class of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:title="label: ClassOfStockLineItems to us-gaap_ClassOfStockLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" id="us-gaap_ClassOfStockDomain_lbl">Class of Stock [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xlink:title="label: ClassOfStockDomain to us-gaap_ClassOfStockDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl">Weighted average exercise price of warrants (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:title="label: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 to us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xlink:title="label: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 to us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightOutstanding_lbl">Warrants outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:title="label: ClassOfWarrantOrRightOutstanding to us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ClassOfWarrantOrRightOutstanding_lbl1" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightOutstanding_lbl1">Warrants outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl1" xlink:title="label: ClassOfWarrantOrRightOutstanding to us-gaap_ClassOfWarrantOrRightOutstanding_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl">COMMITMENT AND CONTINGENCIES [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:title="label: CommitmentsAndContingenciesDisclosureAbstract to us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:title="label: CommitmentsAndContingenciesDisclosureTextBlock to us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" xlink:title="label: CommitmentsAndContingenciesDisclosureTextBlock to us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" id="us-gaap_CommitmentsAndContingencies_lbl">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:title="label: CommitmentsAndContingencies to us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingencies_lbl1" xml:lang="en-US" id="us-gaap_CommitmentsAndContingencies_lbl1">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl1" xlink:title="label: CommitmentsAndContingencies to us-gaap_CommitmentsAndContingencies_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonUnitIssuanceValue" xlink:label="CommonUnitIssuanceValue" xlink:title="CommonUnitIssuanceValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonUnitIssuanceValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonUnitIssuanceValue_lbl" xml:lang="en-US" id="us-gaap_CommonUnitIssuanceValue_lbl">Sales of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonUnitIssuanceValue" xlink:to="us-gaap_CommonUnitIssuanceValue_lbl" xlink:title="label: CommonUnitIssuanceValue to us-gaap_CommonUnitIssuanceValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" id="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl">Common stock, available for issuance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:title="label: CommonStockCapitalSharesReservedForFutureIssuance to us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" id="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl">Common Stock [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xlink:title="label: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="us-gaap_CommonStockMember_lbl">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:title="label: CommonStockMember to us-gaap_CommonStockMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesIssued_lbl">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:title="label: CommonStockSharesIssued to us-gaap_CommonStockSharesIssued_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="us-gaap_CommonStockParOrStatedValuePerShare_lbl">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:title="label: CommonStockParOrStatedValuePerShare to us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xml:lang="en-US" id="us-gaap_CommonStockParOrStatedValuePerShare_lbl1">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xlink:title="label: CommonStockParOrStatedValuePerShare to us-gaap_CommonStockParOrStatedValuePerShare_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="us-gaap_CommonStockValue_lbl">Common Stock - voting, $0.0001 par value, 300,000,000 and 150,000,000 shares authorized, 131,872,026 and 104,902,888 shares issued and outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:title="label: CommonStockValue to us-gaap_CommonStockValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesAuthorized_lbl">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:title="label: CommonStockSharesAuthorized to us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CommonStockSharesAuthorized_lbl1" xml:lang="en-US" id="us-gaap_CommonStockSharesAuthorized_lbl1">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl1" xlink:title="label: CommonStockSharesAuthorized to us-gaap_CommonStockSharesAuthorized_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesOutstanding_lbl">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:title="label: CommonStockSharesOutstanding to us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US" id="us-gaap_CommonStockSharesOutstanding_lbl1">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl1" xlink:title="label: CommonStockSharesOutstanding to us-gaap_CommonStockSharesOutstanding_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="ConcentrationRiskTable" xlink:title="ConcentrationRiskTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US" id="us-gaap_ConcentrationRiskTable_lbl">Schedule of Product Information [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xlink:title="label: ConcentrationRiskTable to us-gaap_ConcentrationRiskTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US" id="us-gaap_ConcentrationRiskTypeDomain_lbl">Concentration Risk Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:title="label: ConcentrationRiskTypeDomain to us-gaap_ConcentrationRiskTypeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" id="us-gaap_ConcentrationRiskPercentage1_lbl">Percentage of account receivables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:title="label: ConcentrationRiskPercentage1 to us-gaap_ConcentrationRiskPercentage1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ConcentrationRiskPercentage1_lbl1" xml:lang="en-US" id="us-gaap_ConcentrationRiskPercentage1_lbl1">Percentage of consolidated revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl1" xlink:title="label: ConcentrationRiskPercentage1 to us-gaap_ConcentrationRiskPercentage1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US" id="us-gaap_ConcentrationRiskBenchmarkDomain_lbl">Concentration Risk Benchmark [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:title="label: ConcentrationRiskBenchmarkDomain to us-gaap_ConcentrationRiskBenchmarkDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US" id="us-gaap_ConcentrationRiskByTypeAxis_lbl">Concentration Risk Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:title="label: ConcentrationRiskByTypeAxis to us-gaap_ConcentrationRiskByTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="ConcentrationRiskLineItems" xlink:title="ConcentrationRiskLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" id="us-gaap_ConcentrationRiskLineItems_lbl">Concentration Risk [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xlink:title="label: ConcentrationRiskLineItems to us-gaap_ConcentrationRiskLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US" id="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl">Concentration Risk Benchmark [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:title="label: ConcentrationRiskByBenchmarkAxis to us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="ContractWithCustomerLiabilityCurrent" xlink:title="ContractWithCustomerLiabilityCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US" id="us-gaap_ContractWithCustomerLiabilityCurrent_lbl">Current portion of deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:title="label: ContractWithCustomerLiabilityCurrent to us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateMember" xlink:label="CorporateMember" xlink:title="CorporateMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CorporateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CorporateMember_lbl" xml:lang="en-US" id="us-gaap_CorporateMember_lbl">Corporate [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CorporateMember" xlink:to="us-gaap_CorporateMember_lbl" xlink:title="label: CorporateMember to us-gaap_CorporateMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CorporateMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CorporateMember_lbl1" xml:lang="en-US" id="us-gaap_CorporateMember_lbl1">Corporate Segment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CorporateMember" xlink:to="us-gaap_CorporateMember_lbl1" xlink:title="label: CorporateMember to us-gaap_CorporateMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="CostOfSalesPolicyTextBlock" xlink:title="CostOfSalesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_CostOfSalesPolicyTextBlock_lbl">Cost of product revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl" xlink:title="label: CostOfSalesPolicyTextBlock to us-gaap_CostOfSalesPolicyTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="CostOfSalesMember" xlink:title="CostOfSalesMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostOfSalesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US" id="us-gaap_CostOfSalesMember_lbl">Cost of Product Revenue [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" xlink:title="label: CostOfSalesMember to us-gaap_CostOfSalesMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="CostsAndExpensesAbstract" xlink:title="CostsAndExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" id="us-gaap_CostsAndExpensesAbstract_lbl">OPERATING EXPENSES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl" xlink:title="label: CostsAndExpensesAbstract to us-gaap_CostsAndExpensesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerContractsMember" xlink:label="CustomerContractsMember" xlink:title="CustomerContractsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CustomerContractsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CustomerContractsMember_lbl" xml:lang="en-US" id="us-gaap_CustomerContractsMember_lbl">Customer Contract [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CustomerContractsMember" xlink:to="us-gaap_CustomerContractsMember_lbl" xlink:title="label: CustomerContractsMember to us-gaap_CustomerContractsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US" id="us-gaap_CustomerConcentrationRiskMember_lbl">Customer Concentration Risk [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:title="label: CustomerConcentrationRiskMember to us-gaap_CustomerConcentrationRiskMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl">Credit agreement, Interest rate provided</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:title="label: DebtInstrumentBasisSpreadOnVariableRate1 to us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="DebtInstrumentInterestRateIncreaseDecrease" xlink:title="DebtInstrumentInterestRateIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl">Increase basis points</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateIncreaseDecrease" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" xlink:title="label: DebtInstrumentInterestRateIncreaseDecrease to us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl1">Debt Instrument, Interest Rate, Increase (Decrease)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateIncreaseDecrease" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl1" xlink:title="label: DebtInstrumentInterestRateIncreaseDecrease to us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_DebtDisclosureAbstract_lbl">DEBT [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:title="label: DebtDisclosureAbstract to us-gaap_DebtDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentAxis_lbl">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:title="label: DebtInstrumentAxis to us-gaap_DebtInstrumentAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentTable_lbl">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:title="label: DebtInstrumentTable to us-gaap_DebtInstrumentTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentLineItems_lbl">Debt Instrument [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:title="label: DebtInstrumentLineItems to us-gaap_DebtInstrumentLineItems_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentLineItems_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentLineItems_lbl1">Debt Instrument [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl1" xlink:title="label: DebtInstrumentLineItems to us-gaap_DebtInstrumentLineItems_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="DebtInstrumentInterestRateEffectivePercentage" xlink:title="DebtInstrumentInterestRateEffectivePercentage" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl">Effective interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:title="label: DebtInstrumentInterestRateEffectivePercentage to us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="DebtInstrumentsAbstract" xlink:title="DebtInstrumentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentsAbstract_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentsAbstract_lbl">Debt Instruments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentsAbstract" xlink:to="us-gaap_DebtInstrumentsAbstract_lbl" xlink:title="label: DebtInstrumentsAbstract to us-gaap_DebtInstrumentsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl">Credit agreement, Interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:title="label: DebtInstrumentInterestRateStatedPercentage to us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="DebtInstrumentMaturityDate" xlink:title="DebtInstrumentMaturityDate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentMaturityDate_lbl">Maturity date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:title="label: DebtInstrumentMaturityDate to us-gaap_DebtInstrumentMaturityDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="DebtInstrumentUnamortizedDiscount" xlink:title="DebtInstrumentUnamortizedDiscount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentUnamortizedDiscount_lbl">Less: Debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:title="label: DebtInstrumentUnamortizedDiscount to us-gaap_DebtInstrumentUnamortizedDiscount_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentUnamortizedDiscount_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentUnamortizedDiscount_lbl1">Debt Instrument, Unamortized Discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl1" xlink:title="label: DebtInstrumentUnamortizedDiscount to us-gaap_DebtInstrumentUnamortizedDiscount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentNameDomain_lbl">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xlink:title="label: DebtInstrumentNameDomain to us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="DeferredRevenueNoncurrent" xlink:title="DeferredRevenueNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US" id="us-gaap_DeferredRevenueNoncurrent_lbl">Deferred revenue, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:title="label: DeferredRevenueNoncurrent to us-gaap_DeferredRevenueNoncurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" id="us-gaap_DepreciationDepletionAndAmortization_lbl">Depreciation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:title="label: DepreciationDepletionAndAmortization to us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DepreciationDepletionAndAmortization_lbl1" xml:lang="en-US" id="us-gaap_DepreciationDepletionAndAmortization_lbl1">Depreciation, Depletion and Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl1" xlink:title="label: DepreciationDepletionAndAmortization to us-gaap_DepreciationDepletionAndAmortization_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="DepreciationAndAmortization" xlink:title="DepreciationAndAmortization" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US" id="us-gaap_DepreciationAndAmortization_lbl">Depreciation and amortization expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:title="label: DepreciationAndAmortization to us-gaap_DepreciationAndAmortization_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DepreciationAndAmortization_lbl1" xml:lang="en-US" id="us-gaap_DepreciationAndAmortization_lbl1">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl1" xlink:title="label: DepreciationAndAmortization to us-gaap_DepreciationAndAmortization_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl">Loss Per Common Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" xlink:title="label: EarningsPerShareDilutedOtherDisclosuresAbstract to us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="EarningsPerSharePolicyTextBlock" xlink:title="EarningsPerSharePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_EarningsPerSharePolicyTextBlock_lbl">Loss per common share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:title="label: EarningsPerSharePolicyTextBlock to us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareBasic_lbl">BASIC LOSS PER COMMON SHARE (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:title="label: EarningsPerShareBasic to us-gaap_EarningsPerShareBasic_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareDiluted_lbl">DILUTED LOSS PER COMMON SHARE (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:title="label: EarningsPerShareDiluted to us-gaap_EarningsPerShareDiluted_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl">Unrecognized compensation expense recognition period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" id="us-gaap_EmployeeStockOptionMember_lbl">Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:title="label: EmployeeStockOptionMember to us-gaap_EmployeeStockOptionMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl">Unrecognized compensation expense, non option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl">Unrecognized compensation expense, stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="us-gaap_EquityComponentDomain_lbl">Equity Component [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xlink:title="label: EquityComponentDomain to us-gaap_EquityComponentDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityAbstract_lbl" xml:lang="en-US" id="us-gaap_EquityAbstract_lbl">STOCKHOLDERS' EQUITY [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:title="label: EquityAbstract to us-gaap_EquityAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="FairValueOfFinancialInstrumentsPolicy" xlink:title="FairValueOfFinancialInstrumentsPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" id="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl">Fair value of financial instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:title="label: FairValueOfFinancialInstrumentsPolicy to us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="FinanceLeasePrincipalPayments" xlink:title="FinanceLeasePrincipalPayments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US" id="us-gaap_FinanceLeasePrincipalPayments_lbl">Payments on finance lease obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:title="label: FinanceLeasePrincipalPayments to us-gaap_FinanceLeasePrincipalPayments_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeasePrincipalPayments_lbl1" xml:lang="en-US" id="us-gaap_FinanceLeasePrincipalPayments_lbl1">Finance Lease, Principal Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl1" xlink:title="label: FinanceLeasePrincipalPayments to us-gaap_FinanceLeasePrincipalPayments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="FiniteLivedIntangibleAssetsNetAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xlink:title="label: FiniteLivedIntangibleAssetsNetAbstract to us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl">Remaining of 2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl">Accumulated amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:title="label: FiniteLivedIntangibleAssetsAccumulatedAmortization to us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:title="label: FiniteLivedIntangibleAssetsMajorClassNameDomain to us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="FiniteLivedIntangibleAssetsLineItems" xlink:title="FiniteLivedIntangibleAssetsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:title="label: FiniteLivedIntangibleAssetsLineItems to us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:title="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl">Estimated Aggregate Amortization Expense [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xlink:title="label: FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract to us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="FiniteLivedIntangibleAssetsGross" xlink:title="FiniteLivedIntangibleAssetsGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsGross_lbl">Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:title="label: FiniteLivedIntangibleAssetsGross to us-gaap_FiniteLivedIntangibleAssetsGross_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl">Finite Lived Intangible Assets By Major Class Axis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:title="label: FiniteLivedIntangibleAssetsByMajorClassAxis to us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="FiniteLivedIntangibleAssetsNet" xlink:title="FiniteLivedIntangibleAssetsNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsNet_lbl">Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:title="label: FiniteLivedIntangibleAssetsNet to us-gaap_FiniteLivedIntangibleAssetsNet_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" id="us-gaap_FurnitureAndFixturesMember_lbl">Furniture and Fixtures [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:title="label: FurnitureAndFixturesMember to us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="GainLossOnDispositionOfAssets" xlink:title="GainLossOnDispositionOfAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_GainLossOnDispositionOfAssets_lbl" xml:lang="en-US" id="us-gaap_GainLossOnDispositionOfAssets_lbl">Loss on disposal of fixed assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl" xlink:title="label: GainLossOnDispositionOfAssets to us-gaap_GainLossOnDispositionOfAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GainLossOnDispositionOfAssets_lbl1" xml:lang="en-US" id="us-gaap_GainLossOnDispositionOfAssets_lbl1">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl1" xlink:title="label: GainLossOnDispositionOfAssets to us-gaap_GainLossOnDispositionOfAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Goodwill_lbl" xml:lang="en-US" id="us-gaap_Goodwill_lbl">Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Goodwill" xlink:to="us-gaap_Goodwill_lbl" xlink:title="label: Goodwill to us-gaap_Goodwill_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_Goodwill_lbl1" xml:lang="en-US" id="us-gaap_Goodwill_lbl1">Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Goodwill" xlink:to="us-gaap_Goodwill_lbl1" xlink:title="label: Goodwill to us-gaap_Goodwill_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:title="GoodwillAndIntangibleAssetsGoodwillPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xml:lang="en-US" id="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl">Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:title="label: GoodwillAndIntangibleAssetsGoodwillPolicy to us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl1" xml:lang="en-US" id="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl1">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl1" xlink:title="label: GoodwillAndIntangibleAssetsGoodwillPolicy to us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:label="GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:title="GoodwillImpairedAccumulatedImpairmentLossAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract_lbl" xml:lang="en-US" id="us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract_lbl">Goodwill [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:to="us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract_lbl" xlink:title="label: GoodwillImpairedAccumulatedImpairmentLossAbstract to us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract_lbl1" xml:lang="en-US" id="us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract_lbl1">Goodwill, Impaired, Accumulated Impairment Loss [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:to="us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract_lbl1" xlink:title="label: GoodwillImpairedAccumulatedImpairmentLossAbstract to us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="GoodwillImpairmentLoss" xlink:title="GoodwillImpairmentLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US" id="us-gaap_GoodwillImpairmentLoss_lbl">Impairment charges related to goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl" xlink:title="label: GoodwillImpairmentLoss to us-gaap_GoodwillImpairmentLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GoodwillImpairmentLoss_lbl1" xml:lang="en-US" id="us-gaap_GoodwillImpairmentLoss_lbl1">Goodwill, Impairment Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl1" xlink:title="label: GoodwillImpairmentLoss to us-gaap_GoodwillImpairmentLoss_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl">INTANGIBLE ASSETS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:title="label: GoodwillAndIntangibleAssetsDisclosureAbstract to us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US" id="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl">Impairment of long-lived assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:title="label: ImpairmentOfLongLivedAssetsHeldForUse to us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl1" xml:lang="en-US" id="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl1">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl1" xlink:title="label: ImpairmentOfLongLivedAssetsHeldForUse to us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:title="ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl">Impairment of long-lived assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xlink:title="label: ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock to us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementLocationDomain_lbl">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xlink:title="label: IncomeStatementLocationDomain to us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureAbstract_lbl">Income Taxes [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:title="label: IncomeTaxDisclosureAbstract to us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementLocationAxis_lbl">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:title="label: IncomeStatementLocationAxis to us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementAbstract_lbl">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:title="label: IncomeStatementAbstract to us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="IncomeTaxPolicyTextBlock" xlink:title="IncomeTaxPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxPolicyTextBlock_lbl">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:title="label: IncomeTaxPolicyTextBlock to us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="IncreaseDecreaseInAccountsReceivable" xlink:title="IncreaseDecreaseInAccountsReceivable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:title="label: IncreaseDecreaseInAccountsReceivable to us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1">Increase (Decrease) in Accounts Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1" xlink:title="label: IncreaseDecreaseInAccountsReceivable to us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="IncreaseDecreaseInAccountsPayable" xlink:title="IncreaseDecreaseInAccountsPayable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsPayable_lbl">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:title="label: IncreaseDecreaseInAccountsPayable to us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayable_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsPayable_lbl1">Increase (Decrease) in Accounts Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl1" xlink:title="label: IncreaseDecreaseInAccountsPayable to us-gaap_IncreaseDecreaseInAccountsPayable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:title="label: IncreaseDecreaseInAccruedLiabilities to us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="IncreaseDecreaseInInventories" xlink:title="IncreaseDecreaseInInventories" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInInventories_lbl">Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:title="label: IncreaseDecreaseInInventories to us-gaap_IncreaseDecreaseInInventories_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInInventories_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInInventories_lbl1">Increase (Decrease) in Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl1" xlink:title="label: IncreaseDecreaseInInventories to us-gaap_IncreaseDecreaseInInventories_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:title="label: IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInOtherOperatingLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl">Other current and non-current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:title="label: IncreaseDecreaseInOtherOperatingLiabilities to us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xlink:title="label: IncreaseDecreaseInStockholdersEquityRollForward to us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="IntangibleAssetsNetExcludingGoodwill" xlink:title="IntangibleAssetsNetExcludingGoodwill" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US" id="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl">Intangible assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:title="label: IntangibleAssetsNetExcludingGoodwill to us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="IntangibleAssetsDisclosureTextBlock" xlink:title="IntangibleAssetsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl">INTANGIBLE ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:title="label: IntangibleAssetsDisclosureTextBlock to us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_InterestExpense_lbl" xml:lang="en-US" id="us-gaap_InterestExpense_lbl">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:title="label: InterestExpense to us-gaap_InterestExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestExpense_lbl1" xml:lang="en-US" id="us-gaap_InterestExpense_lbl1">Interest Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpense" xlink:to="us-gaap_InterestExpense_lbl1" xlink:title="label: InterestExpense to us-gaap_InterestExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="InterestPaidNet" xlink:title="InterestPaidNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" id="us-gaap_InterestPaidNet_lbl">Cash paid for interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:title="label: InterestPaidNet to us-gaap_InterestPaidNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestPaidNet_lbl1" xml:lang="en-US" id="us-gaap_InterestPaidNet_lbl1">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl1" xlink:title="label: InterestPaidNet to us-gaap_InterestPaidNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="InventoryDisclosureAbstract" xlink:title="InventoryDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_InventoryDisclosureAbstract_lbl">INVENTORIES [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:title="label: InventoryDisclosureAbstract to us-gaap_InventoryDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="InventoryDisclosureTextBlock" xlink:title="InventoryDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_InventoryDisclosureTextBlock_lbl">INVENTORIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:title="label: InventoryDisclosureTextBlock to us-gaap_InventoryDisclosureTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="InventoryFinishedGoods" xlink:title="InventoryFinishedGoods" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US" id="us-gaap_InventoryFinishedGoods_lbl">Finished goods</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xlink:title="label: InventoryFinishedGoods to us-gaap_InventoryFinishedGoods_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="InventoryWorkInProcess" xlink:title="InventoryWorkInProcess" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US" id="us-gaap_InventoryWorkInProcess_lbl">Work-in-process</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl" xlink:title="label: InventoryWorkInProcess to us-gaap_InventoryWorkInProcess_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="InventoryPolicyTextBlock" xlink:title="InventoryPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_InventoryPolicyTextBlock_lbl">Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:title="label: InventoryPolicyTextBlock to us-gaap_InventoryPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_InventoryPolicyTextBlock_lbl1">Inventory, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl1" xlink:title="label: InventoryPolicyTextBlock to us-gaap_InventoryPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InventoryNet_lbl" xml:lang="en-US" id="us-gaap_InventoryNet_lbl">Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:title="label: InventoryNet to us-gaap_InventoryNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_InventoryNet_lbl1" xml:lang="en-US" id="us-gaap_InventoryNet_lbl1">Total inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryNet" xlink:to="us-gaap_InventoryNet_lbl1" xlink:title="label: InventoryNet to us-gaap_InventoryNet_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryNet_lbl2" xml:lang="en-US" id="us-gaap_InventoryNet_lbl2">Inventory, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryNet" xlink:to="us-gaap_InventoryNet_lbl2" xlink:title="label: InventoryNet to us-gaap_InventoryNet_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="InventoryRawMaterials" xlink:title="InventoryRawMaterials" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryRawMaterials_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US" id="us-gaap_InventoryRawMaterials_lbl">Raw materials</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl" xlink:title="label: InventoryRawMaterials to us-gaap_InventoryRawMaterials_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" id="us-gaap_InvestmentIncomeInterest_lbl">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xlink:title="label: InvestmentIncomeInterest to us-gaap_InvestmentIncomeInterest_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="LondonInterbankOfferedRateLIBORMember" xlink:title="LondonInterbankOfferedRateLIBORMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LondonInterbankOfferedRateLIBORMember_lbl" xml:lang="en-US" id="us-gaap_LondonInterbankOfferedRateLIBORMember_lbl">LIBOR [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LondonInterbankOfferedRateLIBORMember" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember_lbl" xlink:title="label: LondonInterbankOfferedRateLIBORMember to us-gaap_LondonInterbankOfferedRateLIBORMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="LesseeOperatingLeasesTextBlock" xlink:title="LesseeOperatingLeasesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeasesTextBlock_lbl">LEASE OBLIGATIONS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:title="label: LesseeOperatingLeasesTextBlock to us-gaap_LesseeOperatingLeasesTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl">Year ended December 31, 2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl">Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl">Total payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDue to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDue to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl">Less: imputed interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityUndiscountedExcessAmount to us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityUndiscountedExcessAmount to us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl">2026</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearFive to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearFour to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="LesseeOperatingLeaseTermOfContract" xlink:title="LesseeOperatingLeaseTermOfContract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseTermOfContract_lbl">Initial term of lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:title="label: LesseeOperatingLeaseTermOfContract to us-gaap_LesseeOperatingLeaseTermOfContract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl">Remainder of 2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear to us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearThree to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl1">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearThree to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl">Payments Under Lease Obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityMaturityTableTextBlock to us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearTwo to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl1">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearTwo to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="LesseeLeaseDescriptionTable" xlink:title="LesseeLeaseDescriptionTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" id="us-gaap_LesseeLeaseDescriptionTable_lbl">Lessee, Lease, Description [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:title="label: LesseeLeaseDescriptionTable to us-gaap_LesseeLeaseDescriptionTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="LesseeLeaseDescriptionLineItems" xlink:title="LesseeLeaseDescriptionLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" id="us-gaap_LesseeLeaseDescriptionLineItems_lbl">Lessee, Lease, Description [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:title="label: LesseeLeaseDescriptionLineItems to us-gaap_LesseeLeaseDescriptionLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="LesseeOperatingLeaseDescriptionAbstract" xlink:title="LesseeOperatingLeaseDescriptionAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl">Lease [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" xlink:title="label: LesseeOperatingLeaseDescriptionAbstract to us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US" id="us-gaap_LongtermDebtTypeAxis_lbl">Long-term Debt, Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xlink:title="label: LongtermDebtTypeAxis to us-gaap_LongtermDebtTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US" id="us-gaap_LongtermDebtTypeDomain_lbl">Long-term Debt, Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl" xlink:title="label: LongtermDebtTypeDomain to us-gaap_LongtermDebtTypeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandMember" xlink:label="LandMember" xlink:title="LandMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LandMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LandMember_lbl" xml:lang="en-US" id="us-gaap_LandMember_lbl">Land [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LandMember" xlink:to="us-gaap_LandMember_lbl" xlink:title="label: LandMember to us-gaap_LandMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="LeaseholdImprovementsMember" xlink:title="LeaseholdImprovementsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" id="us-gaap_LeaseholdImprovementsMember_lbl">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:title="label: LeaseholdImprovementsMember to us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LeasesAbstract_lbl" xml:lang="en-US" id="us-gaap_LeasesAbstract_lbl">LEASE OBLIGATIONS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xlink:title="label: LeasesAbstract to us-gaap_LeasesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Liabilities_lbl" xml:lang="en-US" id="us-gaap_Liabilities_lbl">TOTAL LIABILITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:title="label: Liabilities to us-gaap_Liabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Liabilities_lbl1" xml:lang="en-US" id="us-gaap_Liabilities_lbl1">Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="us-gaap_Liabilities_lbl1" xlink:title="label: Liabilities to us-gaap_Liabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity_lbl">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity_lbl1">Liabilities and Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent_lbl">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent_lbl1">Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl1" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesCurrentAbstract_lbl">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:title="label: LiabilitiesCurrentAbstract to us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount" xlink:label="LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount" xlink:title="LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount_lbl" xml:lang="en-US" id="us-gaap_LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount_lbl">Accrued testing</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount" xlink:to="us-gaap_LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount_lbl" xlink:title="label: LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount to us-gaap_LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="LicenseAndServiceMember" xlink:title="LicenseAndServiceMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US" id="us-gaap_LicenseAndServiceMember_lbl">License Revenue [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicenseAndServiceMember" xlink:to="us-gaap_LicenseAndServiceMember_lbl" xlink:title="label: LicenseAndServiceMember to us-gaap_LicenseAndServiceMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="LineOfCreditFacilityAxis" xlink:title="LineOfCreditFacilityAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LineOfCreditFacilityAxis_lbl" xml:lang="en-US" id="us-gaap_LineOfCreditFacilityAxis_lbl">Lender Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis_lbl" xlink:title="label: LineOfCreditFacilityAxis to us-gaap_LineOfCreditFacilityAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="LineOfCreditFacilityLenderDomain" xlink:title="LineOfCreditFacilityLenderDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xml:lang="en-US" id="us-gaap_LineOfCreditFacilityLenderDomain_lbl">Line of Credit Facility, Lender [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditFacilityLenderDomain" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xlink:title="label: LineOfCreditFacilityLenderDomain to us-gaap_LineOfCreditFacilityLenderDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="LongTermDebtTextBlock" xlink:title="LongTermDebtTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US" id="us-gaap_LongTermDebtTextBlock_lbl">DEBT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" xlink:title="label: LongTermDebtTextBlock to us-gaap_LongTermDebtTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="LossContingenciesLineItems" xlink:title="LossContingenciesLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US" id="us-gaap_LossContingenciesLineItems_lbl">Contingencies [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:title="label: LossContingenciesLineItems to us-gaap_LossContingenciesLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="LossContingenciesTable" xlink:title="LossContingenciesTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US" id="us-gaap_LossContingenciesTable_lbl">Contingencies [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:title="label: LossContingenciesTable to us-gaap_LossContingenciesTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="ManufacturingFacilityMember" xlink:title="ManufacturingFacilityMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ManufacturingFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ManufacturingFacilityMember_lbl" xml:lang="en-US" id="us-gaap_ManufacturingFacilityMember_lbl">Manufacturing and Laboratory Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ManufacturingFacilityMember" xlink:to="us-gaap_ManufacturingFacilityMember_lbl" xlink:title="label: ManufacturingFacilityMember to us-gaap_ManufacturingFacilityMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:title="label: NetCashProvidedByUsedInFinancingActivities to us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInFinancingActivities to us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:title="label: NetCashProvidedByUsedInOperatingActivities to us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInOperatingActivities to us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl">Net cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:title="label: NetCashProvidedByUsedInInvestingActivities to us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInInvestingActivities to us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl1">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetIncomeLoss_lbl2" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl2">NET LOSS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl2" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetIncomeLoss_lbl3" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl3">Net Income (Loss) Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl3" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl">Recent Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:title="label: NewAccountingPronouncementsPolicyPolicyTextBlock to us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember" xlink:label="NonUsMember" xlink:title="NonUsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NonUsMember_lbl" xml:lang="en-US" id="us-gaap_NonUsMember_lbl">International [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonUsMember" xlink:to="us-gaap_NonUsMember_lbl" xlink:title="label: NonUsMember to us-gaap_NonUsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="NoncashInvestingAndFinancingItemsAbstract" xlink:title="NoncashInvestingAndFinancingItemsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US" id="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl">Non-cash Financing and Investing Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:title="label: NoncashInvestingAndFinancingItemsAbstract to us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpense_lbl">Interest and other expense, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:title="label: NonoperatingIncomeExpense to us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NonoperatingIncomeExpense_lbl1" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpense_lbl1">Other expense, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl1" xlink:title="label: NonoperatingIncomeExpense to us-gaap_NonoperatingIncomeExpense_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NonoperatingIncomeExpense_lbl2" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpense_lbl2">Nonoperating Income (Expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl2" xlink:title="label: NonoperatingIncomeExpense to us-gaap_NonoperatingIncomeExpense_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="NonoperatingIncomeExpenseAbstract" xlink:title="NonoperatingIncomeExpenseAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpenseAbstract_lbl">OTHER INCOME (EXPENSE):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:title="label: NonoperatingIncomeExpenseAbstract to us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="NotesPayableAbstract" xlink:title="NotesPayableAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NotesPayableAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NotesPayableAbstract_lbl" xml:lang="en-US" id="us-gaap_NotesPayableAbstract_lbl">Senior Notes Payable [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NotesPayableAbstract" xlink:to="us-gaap_NotesPayableAbstract_lbl" xlink:title="label: NotesPayableAbstract to us-gaap_NotesPayableAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="OverAllotmentOptionMember" xlink:title="OverAllotmentOptionMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US" id="us-gaap_OverAllotmentOptionMember_lbl">Underwritten Public Offering [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" xlink:title="label: OverAllotmentOptionMember to us-gaap_OverAllotmentOptionMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="OfficeEquipmentMember" xlink:title="OfficeEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US" id="us-gaap_OfficeEquipmentMember_lbl">Office Equipment and Computer Software [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xlink:title="label: OfficeEquipmentMember to us-gaap_OfficeEquipmentMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityCurrent_lbl">Current portion of lease obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:title="label: OperatingLeaseLiabilityCurrent to us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityCurrent_lbl1">Current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xlink:title="label: OperatingLeaseLiabilityCurrent to us-gaap_OperatingLeaseLiabilityCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl">Lease obligations, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:title="label: OperatingLeaseLiabilityNoncurrent to us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1">Balance at June 30, 2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xlink:title="label: OperatingLeaseLiabilityNoncurrent to us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl">Payments Under Lease Obligations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:title="label: OperatingLeaseLiabilitiesPaymentsDueAbstract to us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="OperatingLeasePayments" xlink:title="OperatingLeasePayments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" id="us-gaap_OperatingLeasePayments_lbl">Cash payments for lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:title="label: OperatingLeasePayments to us-gaap_OperatingLeasePayments_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeasePayments_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeasePayments_lbl1">Operating Lease, Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl1" xlink:title="label: OperatingLeasePayments to us-gaap_OperatingLeasePayments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseRightOfUseAsset_lbl">Right to use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:title="label: OperatingLeaseRightOfUseAsset to us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="OperatingLeaseExpense" xlink:title="OperatingLeaseExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseExpense_lbl">Aggregate lease expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:title="label: OperatingLeaseExpense to us-gaap_OperatingLeaseExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseExpense_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseExpense_lbl1">Operating Lease, Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl1" xlink:title="label: OperatingLeaseExpense to us-gaap_OperatingLeaseExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:title="OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl">Weighted average remaining term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:title="label: OperatingLeaseWeightedAverageRemainingLeaseTerm1 to us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" xlink:title="OperatingLeaseLiability" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseLiability_lbl">Operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:title="label: OperatingLeaseLiability to us-gaap_OperatingLeaseLiability_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="OperatingSegmentsMember" xlink:title="OperatingSegmentsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingSegmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingSegmentsMember_lbl" xml:lang="en-US" id="us-gaap_OperatingSegmentsMember_lbl">Operating Segments [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingSegmentsMember" xlink:to="us-gaap_OperatingSegmentsMember_lbl" xlink:title="label: OperatingSegmentsMember to us-gaap_OperatingSegmentsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="OperatingExpenseMember" xlink:title="OperatingExpenseMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingExpenseMember_lbl" xml:lang="en-US" id="us-gaap_OperatingExpenseMember_lbl">Plasma Center Operating Expenses [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenseMember" xlink:to="us-gaap_OperatingExpenseMember_lbl" xlink:title="label: OperatingExpenseMember to us-gaap_OperatingExpenseMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" id="us-gaap_OperatingExpenses_lbl">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:title="label: OperatingExpenses to us-gaap_OperatingExpenses_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingExpenses_lbl1" xml:lang="en-US" id="us-gaap_OperatingExpenses_lbl1">Operating Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl1" xlink:title="label: OperatingExpenses to us-gaap_OperatingExpenses_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss_lbl">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OperatingIncomeLoss_lbl1" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss_lbl1">LOSS FROM OPERATIONS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl1" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingIncomeLoss_lbl2" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss_lbl2">Operating Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl2" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl">ORGANIZATION AND BUSINESS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock to us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl">ORGANIZATION AND BUSINESS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="OtherCostAndExpenseOperating" xlink:title="OtherCostAndExpenseOperating" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherCostAndExpenseOperating_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherCostAndExpenseOperating_lbl" xml:lang="en-US" id="us-gaap_OtherCostAndExpenseOperating_lbl">Plasma center operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherCostAndExpenseOperating" xlink:to="us-gaap_OtherCostAndExpenseOperating_lbl" xlink:title="label: OtherCostAndExpenseOperating to us-gaap_OtherCostAndExpenseOperating_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="us-gaap_OtherLiabilitiesNoncurrent_lbl">Other non-current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:title="label: OtherLiabilitiesNoncurrent to us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="OtherNonoperatingExpense" xlink:title="OtherNonoperatingExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US" id="us-gaap_OtherNonoperatingExpense_lbl">Other expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" xlink:title="label: OtherNonoperatingExpense to us-gaap_OtherNonoperatingExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherNonoperatingExpense_lbl1" xml:lang="en-US" id="us-gaap_OtherNonoperatingExpense_lbl1">Other Nonoperating Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl1" xlink:title="label: OtherNonoperatingExpense to us-gaap_OtherNonoperatingExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="OtherAccruedLiabilitiesCurrent" xlink:title="OtherAccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_OtherAccruedLiabilitiesCurrent_lbl">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:title="label: OtherAccruedLiabilitiesCurrent to us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" id="us-gaap_PayablesAndAccrualsAbstract_lbl">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:title="label: PayablesAndAccrualsAbstract to us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRent" xlink:label="PaymentsForRent" xlink:title="PaymentsForRent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsForRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PaymentsForRent_lbl" xml:lang="en-US" id="us-gaap_PaymentsForRent_lbl">Rental payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl" xlink:title="label: PaymentsForRent to us-gaap_PaymentsForRent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsForRent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsForRent_lbl1" xml:lang="en-US" id="us-gaap_PaymentsForRent_lbl1">Payments for Rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl1" xlink:title="label: PaymentsForRent to us-gaap_PaymentsForRent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl">Capital expenditures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xml:lang="en-US" id="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1">Purchase of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl2" xml:lang="en-US" id="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl2">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl2" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" id="us-gaap_PlanNameDomain_lbl">Plan Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xlink:title="label: PlanNameDomain to us-gaap_PlanNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" id="us-gaap_PlanNameAxis_lbl">Plan Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:title="label: PlanNameAxis to us-gaap_PlanNameAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance" xlink:label="PreferredStockCapitalSharesReservedForFutureIssuance" xlink:title="PreferredStockCapitalSharesReservedForFutureIssuance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" id="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl">Preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl" xlink:title="label: PreferredStockCapitalSharesReservedForFutureIssuance to us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl1" xml:lang="en-US" id="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl1">Preferred Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl1" xlink:title="label: PreferredStockCapitalSharesReservedForFutureIssuance to us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" id="us-gaap_PreferredStockValue_lbl">Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:title="label: PreferredStockValue to us-gaap_PreferredStockValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="us-gaap_PreferredStockSharesAuthorized_lbl">Preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:title="label: PreferredStockSharesAuthorized to us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="us-gaap_PreferredStockParOrStatedValuePerShare_lbl">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:title="label: PreferredStockParOrStatedValuePerShare to us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_PreferredStockParOrStatedValuePerShare_lbl1" xml:lang="en-US" id="us-gaap_PreferredStockParOrStatedValuePerShare_lbl1">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl1" xlink:title="label: PreferredStockParOrStatedValuePerShare to us-gaap_PreferredStockParOrStatedValuePerShare_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_PreferredStockSharesOutstanding_lbl">Preferred stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:title="label: PreferredStockSharesOutstanding to us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_PreferredStockSharesOutstanding_lbl1" xml:lang="en-US" id="us-gaap_PreferredStockSharesOutstanding_lbl1">Preferred stock, outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl1" xlink:title="label: PreferredStockSharesOutstanding to us-gaap_PreferredStockSharesOutstanding_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="us-gaap_PreferredStockSharesIssued_lbl">Preferred stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:title="label: PreferredStockSharesIssued to us-gaap_PreferredStockSharesIssued_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" id="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl">Preferred Stock [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xlink:title="label: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" id="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:title="label: PrepaidExpenseAndOtherAssetsCurrent to us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:label="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:title="ProceedsFromIssuanceOrSaleOfEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl">Organization and Business [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl" xlink:title="label: ProceedsFromIssuanceOrSaleOfEquityAbstract to us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl1">Proceeds from Issuance or Sale of Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl1" xlink:title="label: ProceedsFromIssuanceOrSaleOfEquityAbstract to us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="ProceedsFromIssuanceOrSaleOfEquity" xlink:title="ProceedsFromIssuanceOrSaleOfEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl">Proceeds from sales of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:title="label: ProceedsFromIssuanceOrSaleOfEquity to us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl">Proceeds from issuance of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:title="label: ProceedsFromIssuanceOfCommonStock to us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1">Proceeds from issuance of common stock, net of offering expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xlink:title="label: ProceedsFromIssuanceOfCommonStock to us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="ProceedsFromNotesPayable" xlink:title="ProceedsFromNotesPayable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromNotesPayable_lbl">Proceeds from issuance of note payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xlink:title="label: ProceedsFromNotesPayable to us-gaap_ProceedsFromNotesPayable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl">Proceeds from the sale of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:title="label: ProceedsFromSaleOfPropertyPlantAndEquipment to us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromStockOptionsExercised_lbl">Proceeds from the exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:title="label: ProceedsFromStockOptionsExercised to us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="ProductMember" xlink:title="ProductMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProductMember_lbl" xml:lang="en-US" id="us-gaap_ProductMember_lbl">Product Revenue [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProductMember" xlink:to="us-gaap_ProductMember_lbl" xlink:title="label: ProductMember to us-gaap_ProductMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentLineItems_lbl">Property, Plant and Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:title="label: PropertyPlantAndEquipmentLineItems to us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl">PROPERTY AND EQUIPMENT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:title="label: PropertyPlantAndEquipmentDisclosureTextBlock to us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl">Estimated useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:title="label: PropertyPlantAndEquipmentUsefulLife to us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1">Property, Plant and Equipment, Useful Life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" xlink:title="label: PropertyPlantAndEquipmentUsefulLife to us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentAbstract_lbl">PROPERTY AND EQUIPMENT [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:title="label: PropertyPlantAndEquipmentAbstract to us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="PropertyPlantAndEquipmentTextBlock" xlink:title="PropertyPlantAndEquipmentTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:title="label: PropertyPlantAndEquipmentTextBlock to us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" xlink:title="label: PropertyPlantAndEquipmentTextBlock to us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl">Property Plant And Equipment By Type Axis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:title="label: PropertyPlantAndEquipmentByTypeAxis to us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:title="label: PropertyPlantAndEquipmentTypeDomain to us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNet_lbl">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:title="label: PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNet_lbl1">Total property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xlink:title="label: PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentGross_lbl">Property, plant and equipments, gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:title="label: PropertyPlantAndEquipmentGross to us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="PropertyPlantAndEquipmentNetAbstract" xlink:title="PropertyPlantAndEquipmentNetAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl">Property, Plant and Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xlink:title="label: PropertyPlantAndEquipmentNetAbstract to us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:title="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" id="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl">Right-to-use assets in exchange for lease obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:title="label: RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability to us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl1" xml:lang="en-US" id="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl1">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl1" xlink:title="label: RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability to us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="ReceivablesPolicyTextBlock" xlink:title="ReceivablesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_ReceivablesPolicyTextBlock_lbl">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:title="label: ReceivablesPolicyTextBlock to us-gaap_ReceivablesPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ReceivablesPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ReceivablesPolicyTextBlock_lbl1">Receivable [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl1" xlink:title="label: ReceivablesPolicyTextBlock to us-gaap_ReceivablesPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" xlink:title="RelatedPartyTransactionsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsAbstract_lbl">RELATED PARTY TRANSACTIONS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:title="label: RelatedPartyTransactionsAbstract to us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="RelatedPartyTransactionLineItems" xlink:title="RelatedPartyTransactionLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionLineItems_lbl">Related Party Transaction [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:title="label: RelatedPartyTransactionLineItems to us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:label="RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:title="RelatedPartyTransactionDueFromToRelatedPartyAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_lbl">Related Party Transactions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_lbl" xlink:title="label: RelatedPartyTransactionDueFromToRelatedPartyAbstract to us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_lbl1" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_lbl1">Related Party Transaction, Due from (to) Related Party [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_lbl1" xlink:title="label: RelatedPartyTransactionDueFromToRelatedPartyAbstract to us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:title="RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl">Rent expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:title="label: RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty to us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl">Related Party [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:title="label: RelatedPartyTransactionsByRelatedPartyAxis to us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl1" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl1">Related Party [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl1" xlink:title="label: RelatedPartyTransactionsByRelatedPartyAxis to us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="RelatedPartyTransactionsDisclosureTextBlock" xlink:title="RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl">RELATED PARTY TRANSACTIONS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:title="label: RelatedPartyTransactionsDisclosureTextBlock to us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl1">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl1" xlink:title="label: RelatedPartyTransactionsDisclosureTextBlock to us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="RelatedPartyTransactionPurchasesFromRelatedParty" xlink:title="RelatedPartyTransactionPurchasesFromRelatedParty" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl">Purchased materials amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xlink:title="label: RelatedPartyTransactionPurchasesFromRelatedParty to us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl1" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl1">Related Party Transaction, Purchases from Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl1" xlink:title="label: RelatedPartyTransactionPurchasesFromRelatedParty to us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyDomain_lbl">Related Party [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xlink:title="label: RelatedPartyDomain to us-gaap_RelatedPartyDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpense_lbl">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:title="label: ResearchAndDevelopmentExpense to us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpenseMember_lbl">Research and Development [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:title="label: ResearchAndDevelopmentExpenseMember to us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" id="us-gaap_RestrictedStockUnitsRSUMember_lbl">Restricted Stock Units [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:title="label: RestrictedStockUnitsRSUMember to us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RestrictedStockUnitsRSUMember_lbl1" xml:lang="en-US" id="us-gaap_RestrictedStockUnitsRSUMember_lbl1">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl1" xlink:title="label: RestrictedStockUnitsRSUMember to us-gaap_RestrictedStockUnitsRSUMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" id="us-gaap_RetainedEarningsMember_lbl">Accumulated Deficit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:title="label: RetainedEarningsMember to us-gaap_RetainedEarningsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="us-gaap_RetainedEarningsAccumulatedDeficit_lbl">Cumulative losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:title="label: RetainedEarningsAccumulatedDeficit to us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" xml:lang="en-US" id="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" xlink:title="label: RetainedEarningsAccumulatedDeficit to us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="RevenueFromContractWithCustomerMember" xlink:title="RevenueFromContractWithCustomerMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueFromContractWithCustomerMember_lbl" xml:lang="en-US" id="us-gaap_RevenueFromContractWithCustomerMember_lbl">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerMember" xlink:to="us-gaap_RevenueFromContractWithCustomerMember_lbl" xlink:title="label: RevenueFromContractWithCustomerMember to us-gaap_RevenueFromContractWithCustomerMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" xlink:title="RevenueFromContractWithCustomerAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US" id="us-gaap_RevenueFromContractWithCustomerAbstract_lbl">Revenue Recognition [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:title="label: RevenueFromContractWithCustomerAbstract to us-gaap_RevenueFromContractWithCustomerAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:title="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_lbl" xml:lang="en-US" id="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_lbl">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_lbl" xlink:title="label: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:title="RevenueFromExternalCustomersByGeographicAreasTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl">Net Revenues According to Geographic Area</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" xlink:title="label: RevenueFromExternalCustomersByGeographicAreasTableTextBlock to us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:title="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_lbl" xml:lang="en-US" id="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_lbl">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_lbl" xlink:title="label: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" id="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl">Revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:title="label: RevenueFromContractWithCustomerExcludingAssessedTax to us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl1" xml:lang="en-US" id="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl1">Total revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl1" xlink:title="label: RevenueFromContractWithCustomerExcludingAssessedTax to us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:label="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:title="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_lbl" xml:lang="en-US" id="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_lbl">Revenues [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_lbl" xlink:title="label: RevenueFromContractWithCustomerProductAndServiceBenchmarkMember to us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_lbl1" xml:lang="en-US" id="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_lbl1">Revenue from Contract with Customer, Product and Service Benchmark [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_lbl1" xlink:title="label: RevenueFromContractWithCustomerProductAndServiceBenchmarkMember to us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="RevenueRecognitionPolicyTextBlock" xlink:title="RevenueRecognitionPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_RevenueRecognitionPolicyTextBlock_lbl">Revenue recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:title="label: RevenueRecognitionPolicyTextBlock to us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="RevenuesAbstract" xlink:title="RevenuesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" id="us-gaap_RevenuesAbstract_lbl">REVENUES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xlink:title="label: RevenuesAbstract to us-gaap_RevenuesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl">Weighted average remaining contractual life of stock options, expected to vest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl">Expected term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl">Weighted average remaining contractual life of stock options, outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl">Weighted average remaining contractual life of stock options, exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:title="ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl">Intangible Asset Future Aggregate Amortization Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:title="label: ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock to us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" id="us-gaap_SaleOfStockNameOfTransactionDomain_lbl">Sale of Stock [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:title="label: SaleOfStockNameOfTransactionDomain to us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl">Schedule of Assumptions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:title="label: ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock to us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl">Schedule of Option Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:title="label: ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock to us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="ScheduleOfInventoryCurrentTableTextBlock" xlink:title="ScheduleOfInventoryCurrentTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl">Components of Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:title="label: ScheduleOfInventoryCurrentTableTextBlock to us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:title="ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl">Schedule of Unvested RSU Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" xlink:title="label: ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock to us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:label="ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:title="ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl">Schedule of Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:title="label: ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock to us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl1">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl1" xlink:title="label: ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock to us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:title="ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl">Schedule of Stock-Based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:title="label: ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock to us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:title="ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl">Accrued Expenses and Other Current Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:title="label: ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock to us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl1">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl1" xlink:title="label: ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock to us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:title="label: ScheduleOfFiniteLivedIntangibleAssetsTable to us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:title="ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl">Supplemental Cash Flow Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:title="label: ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock to us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="ScheduleOfDebtTableTextBlock" xlink:title="ScheduleOfDebtTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfDebtTableTextBlock_lbl">Summary of Outstanding Senior Notes Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:title="label: ScheduleOfDebtTableTextBlock to us-gaap_ScheduleOfDebtTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl">Calculation of Diluted Loss Per Common Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:title="label: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl">Property, Plant and Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:title="label: ScheduleOfPropertyPlantAndEquipmentTable to us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:title="label: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:title="label: ScheduleOfSegmentReportingInformationBySegmentTable to us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:title="ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl">Summarized Financial Information Concerning Reportable Segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:title="label: ScheduleOfSegmentReportingInformationBySegmentTextBlock to us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfStockByClassTable_lbl">Schedule of Stock by Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:title="label: ScheduleOfStockByClassTable to us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="SecurityDeposit" xlink:title="SecurityDeposit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SecurityDeposit_lbl" xml:lang="en-US" id="us-gaap_SecurityDeposit_lbl">Security deposit and initial payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" xlink:title="label: SecurityDeposit to us-gaap_SecurityDeposit_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain" xlink:title="SegmentDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentDomain_lbl" xml:lang="en-US" id="us-gaap_SegmentDomain_lbl">Segments [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl" xlink:title="label: SegmentDomain to us-gaap_SegmentDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="SegmentReportingInformationLineItems" xlink:title="SegmentReportingInformationLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US" id="us-gaap_SegmentReportingInformationLineItems_lbl">Segment Reporting Information [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:title="label: SegmentReportingInformationLineItems to us-gaap_SegmentReportingInformationLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:label="SegmentReportingInformationProfitLossAbstract" xlink:title="SegmentReportingInformationProfitLossAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationProfitLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingInformationProfitLossAbstract_lbl" xml:lang="en-US" id="us-gaap_SegmentReportingInformationProfitLossAbstract_lbl">Segment Reporting Information [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="us-gaap_SegmentReportingInformationProfitLossAbstract_lbl" xlink:title="label: SegmentReportingInformationProfitLossAbstract to us-gaap_SegmentReportingInformationProfitLossAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US" id="us-gaap_SegmentReportingAbstract_lbl">SEGMENTS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:title="label: SegmentReportingAbstract to us-gaap_SegmentReportingAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="SegmentReportingDisclosureTextBlock" xlink:title="SegmentReportingDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_SegmentReportingDisclosureTextBlock_lbl">SEGMENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:title="label: SegmentReportingDisclosureTextBlock to us-gaap_SegmentReportingDisclosureTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="SellingGeneralAndAdministrativeExpensesMember" xlink:title="SellingGeneralAndAdministrativeExpensesMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" id="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl">Selling, General and Administrative [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:title="label: SellingGeneralAndAdministrativeExpensesMember to us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="SellingGeneralAndAdministrativeExpense" xlink:title="SellingGeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="us-gaap_SellingGeneralAndAdministrativeExpense_lbl">Selling, general and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:title="label: SellingGeneralAndAdministrativeExpense to us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="SeniorNotesMember" xlink:title="SeniorNotesMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SeniorNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SeniorNotesMember_lbl" xml:lang="en-US" id="us-gaap_SeniorNotesMember_lbl">Senior Notes [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeniorNotesMember" xlink:to="us-gaap_SeniorNotesMember_lbl" xlink:title="label: SeniorNotesMember to us-gaap_SeniorNotesMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorLongTermNotes" xlink:label="SeniorLongTermNotes" xlink:title="SeniorLongTermNotes" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SeniorLongTermNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SeniorLongTermNotes_lbl" xml:lang="en-US" id="us-gaap_SeniorLongTermNotes_lbl">Senior notes payable, net of discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeniorLongTermNotes" xlink:to="us-gaap_SeniorLongTermNotes_lbl" xlink:title="label: SeniorLongTermNotes to us-gaap_SeniorLongTermNotes_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SeniorLongTermNotes_lbl1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_SeniorLongTermNotes_lbl1" xml:lang="en-US" id="us-gaap_SeniorLongTermNotes_lbl1">Senior notes payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeniorLongTermNotes" xlink:to="us-gaap_SeniorLongTermNotes_lbl1" xlink:title="label: SeniorLongTermNotes to us-gaap_SeniorLongTermNotes_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl">Equity incentive plans, vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1">Restricted stock units vested over a period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl">Number of stock options granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl">Unvested RSU, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationAbstract_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationAbstract_lbl">Stock-based Compensation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract_lbl" xlink:title="label: ShareBasedCompensationAbstract to us-gaap_ShareBasedCompensationAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl">Equity incentive plans, term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensation_lbl">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:title="label: ShareBasedCompensation to us-gaap_ShareBasedCompensation_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensation_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensation_lbl1">Total stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl1" xlink:title="label: ShareBasedCompensation to us-gaap_ShareBasedCompensation_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensation_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensation_lbl2">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl2" xlink:title="label: ShareBasedCompensation to us-gaap_ShareBasedCompensation_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl">Forfeited, Weighted average grant date fair value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl">Number of restricted stock units granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl">Dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl">Unvested, Weighted average grant date fair value, beginning balance (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1">Unvested, Weighted average grant date fair value, ending balance (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl">Forfeited (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl">Unvested RSU, Shares [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl">Vested, Weighted average grant date fair value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl">Granted, Weighted average grant date fair value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl">Ending balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1">Beginning balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl">Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl">Granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl">Vested (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl">Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl">Options exercisable, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl">Options exercisable (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl">Volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl">Options outstanding, vested and expected to vest, weighted average exercise price, ending balance (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl1">Options outstanding, vested and expected to vest, weighted average exercise price, beginning balance (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl2">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl">Options outstanding, vested and expected to vest, ending balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl1">Options outstanding, vested and expected to vest, beginning balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl2">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_lbl">Stock Options, Vested and Expected to Vest [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl">Award Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:title="label: ShareBasedCompensationOptionAndIncentivePlansPolicy to us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xlink:title="label: ShareBasedCompensationOptionAndIncentivePlansPolicy to us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:title="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_lbl">Total stock-based compensation expense, Amount [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_lbl" xlink:title="label: ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract to us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="SharesIssuedPricePerShare" xlink:title="SharesIssuedPricePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" id="us-gaap_SharesIssuedPricePerShare_lbl">Public offering price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:title="label: SharesIssuedPricePerShare to us-gaap_SharesIssuedPricePerShare_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_SharesOutstanding_lbl">Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US" id="us-gaap_SharesOutstanding_lbl1">Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharesOutstanding_lbl2" xml:lang="en-US" id="us-gaap_SharesOutstanding_lbl2">Shares, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl2" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="SignificantAccountingPoliciesTextBlock" xlink:title="SignificantAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="us-gaap_SignificantAccountingPoliciesTextBlock_lbl">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:title="label: SignificantAccountingPoliciesTextBlock to us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfFinancialPositionAbstract_lbl">CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:title="label: StatementOfFinancialPositionAbstract to us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" id="us-gaap_StatementClassOfStockAxis_lbl">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:title="label: StatementClassOfStockAxis to us-gaap_StatementClassOfStockAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="StatementBusinessSegmentsAxis" xlink:title="StatementBusinessSegmentsAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US" id="us-gaap_StatementBusinessSegmentsAxis_lbl">Segments [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:title="label: StatementBusinessSegmentsAxis to us-gaap_StatementBusinessSegmentsAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementTable_lbl" xml:lang="en-US" id="us-gaap_StatementTable_lbl">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:title="label: StatementTable to us-gaap_StatementTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="us-gaap_StatementLineItems_lbl">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:title="label: StatementLineItems to us-gaap_StatementLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfCashFlowsAbstract_lbl">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:title="label: StatementOfCashFlowsAbstract to us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="us-gaap_StatementEquityComponentsAxis_lbl">Equity Components [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:title="label: StatementEquityComponentsAxis to us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfStockholdersEquityAbstract_lbl">CONDENSED CONSOLIDATED STATEMENTS' OF CHANGES IN STOCKHOLDERS EQUITY [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:title="label: StatementOfStockholdersEquityAbstract to us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl">Exercise of stock options (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl">Common stock shares sold under sale agreement (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:title="label: StockIssuedDuringPeriodSharesNewIssues to us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1">Issuance of common stock, net of offering expenses (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesNewIssues to us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl2" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl2">Common stock shares sold during the period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl2" xlink:title="label: StockIssuedDuringPeriodSharesNewIssues to us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl">Exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:title="label: StockIssuedDuringPeriodValueStockOptionsExercised to us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl">Issuance of common stock, net of offering expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:title="label: StockIssuedDuringPeriodValueNewIssues to us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1">Common stock issuable under agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1" xlink:title="label: StockIssuedDuringPeriodValueNewIssues to us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl1">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl2">TOTAL STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquity_lbl3" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl3">Stockholders' Equity Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl3" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl">STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:title="label: StockholdersEquityNoteDisclosureTextBlock to us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityAbstract_lbl">STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:title="label: StockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockholdersEquityAbstract_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquityAbstract_lbl1">STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl1" xlink:title="label: StockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityAbstract_lbl2" xml:lang="en-US" id="us-gaap_StockholdersEquityAbstract_lbl2">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl2" xlink:title="label: StockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventMember_lbl">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:title="label: SubsequentEventMember to us-gaap_SubsequentEventMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventTypeDomain_lbl">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xlink:title="label: SubsequentEventTypeDomain to us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventLineItems_lbl">Subsequent Event [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:title="label: SubsequentEventLineItems to us-gaap_SubsequentEventLineItems_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventLineItems_lbl1" xml:lang="en-US" id="us-gaap_SubsequentEventLineItems_lbl1">Subsequent Event [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl1" xlink:title="label: SubsequentEventLineItems to us-gaap_SubsequentEventLineItems_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventTypeAxis_lbl">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:title="label: SubsequentEventTypeAxis to us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventsAbstract_lbl">SUBSEQUENT EVENTS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:title="label: SubsequentEventsAbstract to us-gaap_SubsequentEventsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventTable_lbl">Subsequent Event [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:title="label: SubsequentEventTable to us-gaap_SubsequentEventTable_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTable_lbl1" xml:lang="en-US" id="us-gaap_SubsequentEventTable_lbl1">Subsequent Event [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl1" xlink:title="label: SubsequentEventTable to us-gaap_SubsequentEventTable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="SubsequentEventsTextBlock" xlink:title="SubsequentEventsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventsTextBlock_lbl">SUBSEQUENT EVENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:title="label: SubsequentEventsTextBlock to us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" id="us-gaap_SubsidiarySaleOfStockAxis_lbl">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:title="label: SubsidiarySaleOfStockAxis to us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="SubsidiarySaleOfStockLineItems" xlink:title="SubsidiarySaleOfStockLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" id="us-gaap_SubsidiarySaleOfStockLineItems_lbl">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:title="label: SubsidiarySaleOfStockLineItems to us-gaap_SubsidiarySaleOfStockLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:title="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US" id="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:title="label: SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable to us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:label="SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:title="SupplementalUnemploymentBenefitsSeveranceBenefits" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_lbl" xml:lang="en-US" id="us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_lbl">Accrued severance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:to="us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_lbl" xlink:title="label: SupplementalUnemploymentBenefitsSeveranceBenefits to us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_lbl1" xml:lang="en-US" id="us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_lbl1">Supplemental Unemployment Benefits, Severance Benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:to="us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_lbl1" xlink:title="label: SupplementalUnemploymentBenefitsSeveranceBenefits to us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" id="us-gaap_SupplementalCashFlowInformationAbstract_lbl">SUPPLEMENTAL CASH FLOW INFORMATION [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:title="label: SupplementalCashFlowInformationAbstract to us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="SupplementalCashFlowElementsAbstract" xlink:title="SupplementalCashFlowElementsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xml:lang="en-US" id="us-gaap_SupplementalCashFlowElementsAbstract_lbl">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xlink:title="label: SupplementalCashFlowElementsAbstract to us-gaap_SupplementalCashFlowElementsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="us-gaap_TypeOfArrangementAxis_lbl">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:title="label: TypeOfArrangementAxis to us-gaap_TypeOfArrangementAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="UnrecognizedTaxBenefits" xlink:title="UnrecognizedTaxBenefits" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" id="us-gaap_UnrecognizedTaxBenefits_lbl">Unrecognized tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:title="label: UnrecognizedTaxBenefits to us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="us-gaap_UseOfEstimates_lbl">Use of estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:title="label: UseOfEstimates to us-gaap_UseOfEstimates_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="VariableRateAxis" xlink:title="VariableRateAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_VariableRateAxis_lbl" xml:lang="en-US" id="us-gaap_VariableRateAxis_lbl">Variable Rate [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" xlink:title="label: VariableRateAxis to us-gaap_VariableRateAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="VariableRateDomain" xlink:title="VariableRateDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_VariableRateDomain_lbl" xml:lang="en-US" id="us-gaap_VariableRateDomain_lbl">Variable Rate [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl" xlink:title="label: VariableRateDomain to us-gaap_VariableRateDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WarrantMember_lbl" xml:lang="en-US" id="us-gaap_WarrantMember_lbl">Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:title="label: WarrantMember to us-gaap_WarrantMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl">Diluted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:title="label: WeightedAverageNumberOfDilutedSharesOutstanding to us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl">Basic (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:title="label: WeightedAverageNumberOfSharesOutstandingBasic to us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:title="WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl">WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:title="label: WeightedAverageNumberOfSharesOutstandingAbstract to us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:label xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ConsolidatedEntitiesDomain_lbl" xml:lang="en-US" id="srt_ConsolidatedEntitiesDomain_lbl">Consolidated Entities [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl" xlink:title="label: ConsolidatedEntitiesDomain to srt_ConsolidatedEntitiesDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:label xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ConsolidatedEntitiesAxis_lbl" xml:lang="en-US" id="srt_ConsolidatedEntitiesAxis_lbl">Consolidated Entities Axis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl" xlink:title="label: ConsolidatedEntitiesAxis to srt_ConsolidatedEntitiesAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="ConsolidationItemsDomain" xlink:title="ConsolidationItemsDomain" />
    <link:label xlink:type="resource" xlink:label="srt_ConsolidationItemsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ConsolidationItemsDomain_lbl" xml:lang="en-US" id="srt_ConsolidationItemsDomain_lbl">Consolidation Items [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidationItemsDomain" xlink:to="srt_ConsolidationItemsDomain_lbl" xlink:title="label: ConsolidationItemsDomain to srt_ConsolidationItemsDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="ConsolidationItemsAxis" xlink:title="ConsolidationItemsAxis" />
    <link:label xlink:type="resource" xlink:label="srt_ConsolidationItemsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ConsolidationItemsAxis_lbl" xml:lang="en-US" id="srt_ConsolidationItemsAxis_lbl">Consolidation Items [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsAxis_lbl" xlink:title="label: ConsolidationItemsAxis to srt_ConsolidationItemsAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="DirectorMember" xlink:title="DirectorMember" />
    <link:label xlink:type="resource" xlink:label="srt_DirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="srt_DirectorMember_lbl" xml:lang="en-US" id="srt_DirectorMember_lbl">Directors [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DirectorMember" xlink:to="srt_DirectorMember_lbl" xlink:title="label: DirectorMember to srt_DirectorMember_lbl" />
    <link:label xlink:type="resource" xlink:label="srt_DirectorMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_DirectorMember_lbl1" xml:lang="en-US" id="srt_DirectorMember_lbl1">Lawrence P. Guiheen [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DirectorMember" xlink:to="srt_DirectorMember_lbl1" xlink:title="label: DirectorMember to srt_DirectorMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:label xlink:type="resource" xlink:label="srt_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_MajorCustomersAxis_lbl" xml:lang="en-US" id="srt_MajorCustomersAxis_lbl">Customer [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xlink:title="label: MajorCustomersAxis to srt_MajorCustomersAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:label xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_MaximumMember_lbl" xml:lang="en-US" id="srt_MaximumMember_lbl">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:title="label: MaximumMember to srt_MaximumMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:label xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_MinimumMember_lbl" xml:lang="en-US" id="srt_MinimumMember_lbl">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:title="label: MinimumMember to srt_MinimumMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain" xlink:title="NameOfMajorCustomerDomain" />
    <link:label xlink:type="resource" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US" id="srt_NameOfMajorCustomerDomain_lbl">Customer [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl" xlink:title="label: NameOfMajorCustomerDomain to srt_NameOfMajorCustomerDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain" xlink:title="OwnershipDomain" />
    <link:label xlink:type="resource" xlink:label="srt_OwnershipDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_OwnershipDomain_lbl" xml:lang="en-US" id="srt_OwnershipDomain_lbl">Ownership [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl" xlink:title="label: OwnershipDomain to srt_OwnershipDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis" xlink:label="OwnershipAxis" xlink:title="OwnershipAxis" />
    <link:label xlink:type="resource" xlink:label="srt_OwnershipAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_OwnershipAxis_lbl" xml:lang="en-US" id="srt_OwnershipAxis_lbl">Ownership [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl" xlink:title="label: OwnershipAxis to srt_OwnershipAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:label xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US" id="srt_ProductsAndServicesDomain_lbl">Product and Service [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" xlink:title="label: ProductsAndServicesDomain to srt_ProductsAndServicesDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:label xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ProductOrServiceAxis_lbl" xml:lang="en-US" id="srt_ProductOrServiceAxis_lbl">Product and Service [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:title="label: ProductOrServiceAxis to srt_ProductOrServiceAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:label xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_RangeMember_lbl" xml:lang="en-US" id="srt_RangeMember_lbl">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeMember" xlink:to="srt_RangeMember_lbl" xlink:title="label: RangeMember to srt_RangeMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:label xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="srt_RangeAxis_lbl" xml:lang="en-US" id="srt_RangeAxis_lbl">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:title="label: RangeAxis to srt_RangeAxis_lbl" />
    <link:label xlink:type="resource" xlink:label="srt_RangeAxis_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_RangeAxis_lbl1" xml:lang="en-US" id="srt_RangeAxis_lbl1">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeAxis" xlink:to="srt_RangeAxis_lbl1" xlink:title="label: RangeAxis to srt_RangeAxis_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="ScenarioForecastMember" xlink:title="ScenarioForecastMember" />
    <link:label xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ScenarioForecastMember_lbl" xml:lang="en-US" id="srt_ScenarioForecastMember_lbl">Forecast [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl" xlink:title="label: ScenarioForecastMember to srt_ScenarioForecastMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:label xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" id="srt_ScenarioUnspecifiedDomain_lbl">Scenario [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xlink:title="label: ScenarioUnspecifiedDomain to srt_ScenarioUnspecifiedDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="SegmentGeographicalDomain" xlink:title="SegmentGeographicalDomain" />
    <link:label xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US" id="srt_SegmentGeographicalDomain_lbl">Geographical [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" xlink:title="label: SegmentGeographicalDomain to srt_SegmentGeographicalDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:label xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_StatementScenarioAxis_lbl" xml:lang="en-US" id="srt_StatementScenarioAxis_lbl">Scenario [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xlink:title="label: StatementScenarioAxis to srt_StatementScenarioAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="StatementGeographicalAxis" xlink:title="StatementGeographicalAxis" />
    <link:label xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_StatementGeographicalAxis_lbl" xml:lang="en-US" id="srt_StatementGeographicalAxis_lbl">Geographical [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:title="label: StatementGeographicalAxis to srt_StatementGeographicalAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:label xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" id="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl">Title of Individual [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:title="label: TitleOfIndividualWithRelationshipToEntityDomain to srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:label xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US" id="srt_TitleOfIndividualAxis_lbl">Title of Individual [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:title="label: TitleOfIndividualAxis to srt_TitleOfIndividualAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="US" xlink:title="US" />
    <link:label xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="country_US_lbl" xml:lang="en-US" id="country_US_lbl">United States [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="US" xlink:to="country_US_lbl" xlink:title="label: US to country_US_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="DocumentQuarterlyReport" xlink:title="DocumentQuarterlyReport" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US" id="dei_DocumentQuarterlyReport_lbl">Document Quarterly Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:title="label: DocumentQuarterlyReport to dei_DocumentQuarterlyReport_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="DocumentTransitionReport" xlink:title="DocumentTransitionReport" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentTransitionReport_lbl" xml:lang="en-US" id="dei_DocumentTransitionReport_lbl">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:title="label: DocumentTransitionReport to dei_DocumentTransitionReport_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="EntityInteractiveDataCurrent" xlink:title="EntityInteractiveDataCurrent" />
    <link:label xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" id="dei_EntityInteractiveDataCurrent_lbl">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:title="label: EntityInteractiveDataCurrent to dei_EntityInteractiveDataCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="dei_CurrentFiscalYearEndDate_lbl">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:title="label: CurrentFiscalYearEndDate to dei_CurrentFiscalYearEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" id="dei_EntityCurrentReportingStatus_lbl">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:title="label: EntityCurrentReportingStatus to dei_EntityCurrentReportingStatus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="EntityShellCompany" xlink:title="EntityShellCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityShellCompany_lbl" xml:lang="en-US" id="dei_EntityShellCompany_lbl">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:title="label: EntityShellCompany to dei_EntityShellCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="dei_EntityFilerCategory_lbl">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:title="label: EntityFilerCategory to dei_EntityFilerCategory_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="EntitySmallBusiness" xlink:title="EntitySmallBusiness" />
    <link:label xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntitySmallBusiness_lbl" xml:lang="en-US" id="dei_EntitySmallBusiness_lbl">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:title="label: EntitySmallBusiness to dei_EntitySmallBusiness_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address City Or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityListingsTable" xlink:label="EntityListingsTable" xlink:title="EntityListingsTable" />
    <link:label xlink:type="resource" xlink:label="dei_EntityListingsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityListingsTable_lbl" xml:lang="en-US" id="dei_EntityListingsTable_lbl">Entity Listings [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityListingsTable" xlink:to="dei_EntityListingsTable_lbl" xlink:title="label: EntityListingsTable to dei_EntityListingsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityListingsLineItems" xlink:label="EntityListingsLineItems" xlink:title="EntityListingsLineItems" />
    <link:label xlink:type="resource" xlink:label="dei_EntityListingsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityListingsLineItems_lbl" xml:lang="en-US" id="dei_EntityListingsLineItems_lbl">Entity Listings [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityListingsLineItems" xlink:to="dei_EntityListingsLineItems_lbl" xlink:title="label: EntityListingsLineItems to dei_EntityListingsLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US" id="dei_NoTradingSymbolFlag_lbl">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="dei_EntityCommonStockSharesOutstanding_lbl">Entity Common Stock Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:title="label: EntityCommonStockSharesOutstanding to dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_JefferiesLLCMember" xlink:label="JefferiesLLCMember" xlink:title="JefferiesLLCMember" />
    <link:label xlink:type="resource" xlink:label="adma_JefferiesLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_JefferiesLLCMember_lbl" xml:lang="en-US" id="adma_JefferiesLLCMember_lbl">Entity owned or controlled by another entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JefferiesLLCMember" xlink:to="adma_JefferiesLLCMember_lbl" xlink:title="label: JefferiesLLCMember to adma_JefferiesLLCMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_JefferiesLLCMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_JefferiesLLCMember_lbl1" xml:lang="en-US" id="adma_JefferiesLLCMember_lbl1">Jefferies LLC [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JefferiesLLCMember" xlink:to="adma_JefferiesLLCMember_lbl1" xlink:title="label: JefferiesLLCMember to adma_JefferiesLLCMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_JefferiesLLCMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_JefferiesLLCMember_lbl2" xml:lang="en-US" id="adma_JefferiesLLCMember_lbl2">Jefferies [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JefferiesLLCMember" xlink:to="adma_JefferiesLLCMember_lbl2" xlink:title="label: JefferiesLLCMember to adma_JefferiesLLCMember_lbl2" />
    <link:label xlink:type="resource" xlink:label="adma_JefferiesLLCMember_lbl3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="adma_JefferiesLLCMember_lbl3" xml:lang="en-US" id="adma_JefferiesLLCMember_lbl3">Jefferies LLC [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JefferiesLLCMember" xlink:to="adma_JefferiesLLCMember_lbl3" xlink:title="label: JefferiesLLCMember to adma_JefferiesLLCMember_lbl3" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_SaleAgreement2020Member" xlink:label="SaleAgreement2020Member" xlink:title="SaleAgreement2020Member" />
    <link:label xlink:type="resource" xlink:label="adma_SaleAgreement2020Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_SaleAgreement2020Member_lbl" xml:lang="en-US" id="adma_SaleAgreement2020Member_lbl">An agreement of sale constitutes the terms and conditions of sale of a property by the seller to the buyer during the previous fiscal period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleAgreement2020Member" xlink:to="adma_SaleAgreement2020Member_lbl" xlink:title="label: SaleAgreement2020Member to adma_SaleAgreement2020Member_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_SaleAgreement2020Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_SaleAgreement2020Member_lbl1" xml:lang="en-US" id="adma_SaleAgreement2020Member_lbl1">Sale Agreement 2020 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleAgreement2020Member" xlink:to="adma_SaleAgreement2020Member_lbl1" xlink:title="label: SaleAgreement2020Member to adma_SaleAgreement2020Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_SaleAgreement2020Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_SaleAgreement2020Member_lbl2" xml:lang="en-US" id="adma_SaleAgreement2020Member_lbl2">2020 Sale Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleAgreement2020Member" xlink:to="adma_SaleAgreement2020Member_lbl2" xlink:title="label: SaleAgreement2020Member to adma_SaleAgreement2020Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ProductCycleFromProcurementOfRawMaterialsToFinishedProduct" xlink:label="ProductCycleFromProcurementOfRawMaterialsToFinishedProduct" xlink:title="ProductCycleFromProcurementOfRawMaterialsToFinishedProduct" />
    <link:label xlink:type="resource" xlink:label="adma_ProductCycleFromProcurementOfRawMaterialsToFinishedProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ProductCycleFromProcurementOfRawMaterialsToFinishedProduct_lbl" xml:lang="en-US" id="adma_ProductCycleFromProcurementOfRawMaterialsToFinishedProduct_lbl">Production cycle from procurement of raw materials to commercial release of finished product.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProductCycleFromProcurementOfRawMaterialsToFinishedProduct" xlink:to="adma_ProductCycleFromProcurementOfRawMaterialsToFinishedProduct_lbl" xlink:title="label: ProductCycleFromProcurementOfRawMaterialsToFinishedProduct to adma_ProductCycleFromProcurementOfRawMaterialsToFinishedProduct_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ProductCycleFromProcurementOfRawMaterialsToFinishedProduct_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ProductCycleFromProcurementOfRawMaterialsToFinishedProduct_lbl1" xml:lang="en-US" id="adma_ProductCycleFromProcurementOfRawMaterialsToFinishedProduct_lbl1">Product Cycle from Procurement of Raw Materials to Finished Product</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProductCycleFromProcurementOfRawMaterialsToFinishedProduct" xlink:to="adma_ProductCycleFromProcurementOfRawMaterialsToFinishedProduct_lbl1" xlink:title="label: ProductCycleFromProcurementOfRawMaterialsToFinishedProduct to adma_ProductCycleFromProcurementOfRawMaterialsToFinishedProduct_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ProductCycleFromProcurementOfRawMaterialsToFinishedProduct_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ProductCycleFromProcurementOfRawMaterialsToFinishedProduct_lbl2" xml:lang="en-US" id="adma_ProductCycleFromProcurementOfRawMaterialsToFinishedProduct_lbl2">Production cycle from procurement of raw materials to release of finished product</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProductCycleFromProcurementOfRawMaterialsToFinishedProduct" xlink:to="adma_ProductCycleFromProcurementOfRawMaterialsToFinishedProduct_lbl2" xlink:title="label: ProductCycleFromProcurementOfRawMaterialsToFinishedProduct to adma_ProductCycleFromProcurementOfRawMaterialsToFinishedProduct_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_WorkingCapital" xlink:label="WorkingCapital" xlink:title="WorkingCapital" />
    <link:label xlink:type="resource" xlink:label="adma_WorkingCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_WorkingCapital_lbl" xml:lang="en-US" id="adma_WorkingCapital_lbl">The amount of difference between current assets and liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WorkingCapital" xlink:to="adma_WorkingCapital_lbl" xlink:title="label: WorkingCapital to adma_WorkingCapital_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_WorkingCapital_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_WorkingCapital_lbl1" xml:lang="en-US" id="adma_WorkingCapital_lbl1">Working Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WorkingCapital" xlink:to="adma_WorkingCapital_lbl1" xlink:title="label: WorkingCapital to adma_WorkingCapital_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_WorkingCapital_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_WorkingCapital_lbl2" xml:lang="en-US" id="adma_WorkingCapital_lbl2">Working capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WorkingCapital" xlink:to="adma_WorkingCapital_lbl2" xlink:title="label: WorkingCapital to adma_WorkingCapital_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_SaleAgreement2021Member" xlink:label="SaleAgreement2021Member" xlink:title="SaleAgreement2021Member" />
    <link:label xlink:type="resource" xlink:label="adma_SaleAgreement2021Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_SaleAgreement2021Member_lbl" xml:lang="en-US" id="adma_SaleAgreement2021Member_lbl">An agreement of sale constitutes the terms and conditions of sale of a property by the seller to the buyer during the current fiscal period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleAgreement2021Member" xlink:to="adma_SaleAgreement2021Member_lbl" xlink:title="label: SaleAgreement2021Member to adma_SaleAgreement2021Member_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_SaleAgreement2021Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_SaleAgreement2021Member_lbl1" xml:lang="en-US" id="adma_SaleAgreement2021Member_lbl1">Sale Agreement 2021 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleAgreement2021Member" xlink:to="adma_SaleAgreement2021Member_lbl1" xlink:title="label: SaleAgreement2021Member to adma_SaleAgreement2021Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_SaleAgreement2021Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_SaleAgreement2021Member_lbl2" xml:lang="en-US" id="adma_SaleAgreement2021Member_lbl2">2021 Sale Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleAgreement2021Member" xlink:to="adma_SaleAgreement2021Member_lbl2" xlink:title="label: SaleAgreement2021Member to adma_SaleAgreement2021Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_NumberOfFDALicensedPlasmaCollectionFacilities" xlink:label="NumberOfFDALicensedPlasmaCollectionFacilities" xlink:title="NumberOfFDALicensedPlasmaCollectionFacilities" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl" xml:lang="en-US" id="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl">Number of plasma collection facilities having FDA license.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFDALicensedPlasmaCollectionFacilities" xlink:to="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl" xlink:title="label: NumberOfFDALicensedPlasmaCollectionFacilities to adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl1" xml:lang="en-US" id="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl1">Number of FDA-Licensed Plasma Collection Facilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFDALicensedPlasmaCollectionFacilities" xlink:to="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl1" xlink:title="label: NumberOfFDALicensedPlasmaCollectionFacilities to adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl2" xml:lang="en-US" id="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl2">Number of FDA-licensed plasma collection facilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFDALicensedPlasmaCollectionFacilities" xlink:to="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl2" xlink:title="label: NumberOfFDALicensedPlasmaCollectionFacilities to adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_NumberOfFDAApprovedProduct" xlink:label="NumberOfFDAApprovedProduct" xlink:title="NumberOfFDAApprovedProduct" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfFDAApprovedProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfFDAApprovedProduct_lbl" xml:lang="en-US" id="adma_NumberOfFDAApprovedProduct_lbl">Number of products approved by FDA.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFDAApprovedProduct" xlink:to="adma_NumberOfFDAApprovedProduct_lbl" xlink:title="label: NumberOfFDAApprovedProduct to adma_NumberOfFDAApprovedProduct_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfFDAApprovedProduct_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfFDAApprovedProduct_lbl1" xml:lang="en-US" id="adma_NumberOfFDAApprovedProduct_lbl1">Number of FDA Approved Product</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFDAApprovedProduct" xlink:to="adma_NumberOfFDAApprovedProduct_lbl1" xlink:title="label: NumberOfFDAApprovedProduct to adma_NumberOfFDAApprovedProduct_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfFDAApprovedProduct_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_NumberOfFDAApprovedProduct_lbl2" xml:lang="en-US" id="adma_NumberOfFDAApprovedProduct_lbl2">Number of FDA approved product</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFDAApprovedProduct" xlink:to="adma_NumberOfFDAApprovedProduct_lbl2" xlink:title="label: NumberOfFDAApprovedProduct to adma_NumberOfFDAApprovedProduct_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:label="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:title="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl" xml:lang="en-US" id="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl">Number of plasma collection facilities under various stages of development.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:to="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl" xlink:title="label: NumberOfPlasmaCollectionFacilitiesUnderDevelopment to adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl1" xml:lang="en-US" id="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl1">Number of Plasma Collection Facilities Under Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:to="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl1" xlink:title="label: NumberOfPlasmaCollectionFacilitiesUnderDevelopment to adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl2" xml:lang="en-US" id="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl2">Number of plasma collection facilities under development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:to="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl2" xlink:title="label: NumberOfPlasmaCollectionFacilitiesUnderDevelopment to adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_SubsequentEventsSaleOfStockAbstract" xlink:label="SubsequentEventsSaleOfStockAbstract" xlink:title="SubsequentEventsSaleOfStockAbstract" />
    <link:label xlink:type="resource" xlink:label="adma_SubsequentEventsSaleOfStockAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_SubsequentEventsSaleOfStockAbstract_lbl1" xml:lang="en-US" id="adma_SubsequentEventsSaleOfStockAbstract_lbl1">Subsequent Events, Sale of Stock [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsSaleOfStockAbstract" xlink:to="adma_SubsequentEventsSaleOfStockAbstract_lbl1" xlink:title="label: SubsequentEventsSaleOfStockAbstract to adma_SubsequentEventsSaleOfStockAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_SubsequentEventsSaleOfStockAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_SubsequentEventsSaleOfStockAbstract_lbl2" xml:lang="en-US" id="adma_SubsequentEventsSaleOfStockAbstract_lbl2">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsSaleOfStockAbstract" xlink:to="adma_SubsequentEventsSaleOfStockAbstract_lbl2" xlink:title="label: SubsequentEventsSaleOfStockAbstract to adma_SubsequentEventsSaleOfStockAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_AmortizationOfLicenseRevenue" xlink:label="AmortizationOfLicenseRevenue" xlink:title="AmortizationOfLicenseRevenue" />
    <link:label xlink:type="resource" xlink:label="adma_AmortizationOfLicenseRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_AmortizationOfLicenseRevenue_lbl" xml:lang="en-US" id="adma_AmortizationOfLicenseRevenue_lbl">Amount of noncash revenue related to amortization of license revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfLicenseRevenue" xlink:to="adma_AmortizationOfLicenseRevenue_lbl" xlink:title="label: AmortizationOfLicenseRevenue to adma_AmortizationOfLicenseRevenue_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_AmortizationOfLicenseRevenue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_AmortizationOfLicenseRevenue_lbl1" xml:lang="en-US" id="adma_AmortizationOfLicenseRevenue_lbl1">Amortization of License Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfLicenseRevenue" xlink:to="adma_AmortizationOfLicenseRevenue_lbl1" xlink:title="label: AmortizationOfLicenseRevenue to adma_AmortizationOfLicenseRevenue_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_AmortizationOfLicenseRevenue_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_AmortizationOfLicenseRevenue_lbl2" xml:lang="en-US" id="adma_AmortizationOfLicenseRevenue_lbl2">Amortization of license revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfLicenseRevenue" xlink:to="adma_AmortizationOfLicenseRevenue_lbl2" xlink:title="label: AmortizationOfLicenseRevenue to adma_AmortizationOfLicenseRevenue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_TaxesPaidOnVestedRestrictedStockUnits" xlink:label="TaxesPaidOnVestedRestrictedStockUnits" xlink:title="TaxesPaidOnVestedRestrictedStockUnits" />
    <link:label xlink:type="resource" xlink:label="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl" xml:lang="en-US" id="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl">Amount of cash outflow related to taxes on vested Restricted Stock Units.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxesPaidOnVestedRestrictedStockUnits" xlink:to="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl" xlink:title="label: TaxesPaidOnVestedRestrictedStockUnits to adma_TaxesPaidOnVestedRestrictedStockUnits_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl1" xml:lang="en-US" id="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl1">Taxes Paid on Vested Restricted Stock Units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxesPaidOnVestedRestrictedStockUnits" xlink:to="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl1" xlink:title="label: TaxesPaidOnVestedRestrictedStockUnits to adma_TaxesPaidOnVestedRestrictedStockUnits_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl2" xml:lang="en-US" id="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl2">Taxes paid on vested Restricted Stock Units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxesPaidOnVestedRestrictedStockUnits" xlink:to="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl2" xlink:title="label: TaxesPaidOnVestedRestrictedStockUnits to adma_TaxesPaidOnVestedRestrictedStockUnits_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="IncreaseDecreaseInDepositsAndOtherAssets" xlink:title="IncreaseDecreaseInDepositsAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl" xml:lang="en-US" id="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl">Amount of increase (decrease) in deposits and operating assets classified as other.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInDepositsAndOtherAssets" xlink:to="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl" xlink:title="label: IncreaseDecreaseInDepositsAndOtherAssets to adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl1" xml:lang="en-US" id="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl1">Increase Decrease in Deposits and Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInDepositsAndOtherAssets" xlink:to="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl1" xlink:title="label: IncreaseDecreaseInDepositsAndOtherAssets to adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl2" xml:lang="en-US" id="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl2">Deposits and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInDepositsAndOtherAssets" xlink:to="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl2" xlink:title="label: IncreaseDecreaseInDepositsAndOtherAssets to adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ADMABioManufacturingSegmentMember" xlink:label="ADMABioManufacturingSegmentMember" xlink:title="ADMABioManufacturingSegmentMember" />
    <link:label xlink:type="resource" xlink:label="adma_ADMABioManufacturingSegmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ADMABioManufacturingSegmentMember_lbl" xml:lang="en-US" id="adma_ADMABioManufacturingSegmentMember_lbl">Component of ADMA BioManufacturing that usually provides financial, operational and administrative support and is considered an operating segment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ADMABioManufacturingSegmentMember" xlink:to="adma_ADMABioManufacturingSegmentMember_lbl" xlink:title="label: ADMABioManufacturingSegmentMember to adma_ADMABioManufacturingSegmentMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ADMABioManufacturingSegmentMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ADMABioManufacturingSegmentMember_lbl1" xml:lang="en-US" id="adma_ADMABioManufacturingSegmentMember_lbl1">ADMA BioManufacturing Segment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ADMABioManufacturingSegmentMember" xlink:to="adma_ADMABioManufacturingSegmentMember_lbl1" xlink:title="label: ADMABioManufacturingSegmentMember to adma_ADMABioManufacturingSegmentMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ADMABioManufacturingSegmentMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ADMABioManufacturingSegmentMember_lbl2" xml:lang="en-US" id="adma_ADMABioManufacturingSegmentMember_lbl2">ADMA BioManufacturing [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ADMABioManufacturingSegmentMember" xlink:to="adma_ADMABioManufacturingSegmentMember_lbl2" xlink:title="label: ADMABioManufacturingSegmentMember to adma_ADMABioManufacturingSegmentMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PlasmaCollectionCentersSegmentMember" xlink:label="PlasmaCollectionCentersSegmentMember" xlink:title="PlasmaCollectionCentersSegmentMember" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaCollectionCentersSegmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PlasmaCollectionCentersSegmentMember_lbl" xml:lang="en-US" id="adma_PlasmaCollectionCentersSegmentMember_lbl">Component of Plasma Collection Centers segment that usually provides financial, operational and administrative support and is considered an operating segment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaCollectionCentersSegmentMember" xlink:to="adma_PlasmaCollectionCentersSegmentMember_lbl" xlink:title="label: PlasmaCollectionCentersSegmentMember to adma_PlasmaCollectionCentersSegmentMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaCollectionCentersSegmentMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PlasmaCollectionCentersSegmentMember_lbl1" xml:lang="en-US" id="adma_PlasmaCollectionCentersSegmentMember_lbl1">Plasma Collection Centers Segment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaCollectionCentersSegmentMember" xlink:to="adma_PlasmaCollectionCentersSegmentMember_lbl1" xlink:title="label: PlasmaCollectionCentersSegmentMember to adma_PlasmaCollectionCentersSegmentMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaCollectionCentersSegmentMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PlasmaCollectionCentersSegmentMember_lbl2" xml:lang="en-US" id="adma_PlasmaCollectionCentersSegmentMember_lbl2">Plasma Collection Centers [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaCollectionCentersSegmentMember" xlink:to="adma_PlasmaCollectionCentersSegmentMember_lbl2" xlink:title="label: PlasmaCollectionCentersSegmentMember to adma_PlasmaCollectionCentersSegmentMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_CostOfProductRevenueExcludingAmortizationExpense" xlink:label="CostOfProductRevenueExcludingAmortizationExpense" xlink:title="CostOfProductRevenueExcludingAmortizationExpense" />
    <link:label xlink:type="resource" xlink:label="adma_CostOfProductRevenueExcludingAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_CostOfProductRevenueExcludingAmortizationExpense_lbl" xml:lang="en-US" id="adma_CostOfProductRevenueExcludingAmortizationExpense_lbl">Cost of product sold and service rendered, excluding amortization expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfProductRevenueExcludingAmortizationExpense" xlink:to="adma_CostOfProductRevenueExcludingAmortizationExpense_lbl" xlink:title="label: CostOfProductRevenueExcludingAmortizationExpense to adma_CostOfProductRevenueExcludingAmortizationExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_CostOfProductRevenueExcludingAmortizationExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_CostOfProductRevenueExcludingAmortizationExpense_lbl1" xml:lang="en-US" id="adma_CostOfProductRevenueExcludingAmortizationExpense_lbl1">Cost of Product Revenue, Excluding Amortization Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfProductRevenueExcludingAmortizationExpense" xlink:to="adma_CostOfProductRevenueExcludingAmortizationExpense_lbl1" xlink:title="label: CostOfProductRevenueExcludingAmortizationExpense to adma_CostOfProductRevenueExcludingAmortizationExpense_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_CostOfProductRevenueExcludingAmortizationExpense_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="adma_CostOfProductRevenueExcludingAmortizationExpense_lbl2" xml:lang="en-US" id="adma_CostOfProductRevenueExcludingAmortizationExpense_lbl2">Cost of product revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfProductRevenueExcludingAmortizationExpense" xlink:to="adma_CostOfProductRevenueExcludingAmortizationExpense_lbl2" xlink:title="label: CostOfProductRevenueExcludingAmortizationExpense to adma_CostOfProductRevenueExcludingAmortizationExpense_lbl2" />
    <link:label xlink:type="resource" xlink:label="adma_CostOfProductRevenueExcludingAmortizationExpense_lbl3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_CostOfProductRevenueExcludingAmortizationExpense_lbl3" xml:lang="en-US" id="adma_CostOfProductRevenueExcludingAmortizationExpense_lbl3">Cost of product revenue (exclusive of amortization expense shown below)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfProductRevenueExcludingAmortizationExpense" xlink:to="adma_CostOfProductRevenueExcludingAmortizationExpense_lbl3" xlink:title="label: CostOfProductRevenueExcludingAmortizationExpense to adma_CostOfProductRevenueExcludingAmortizationExpense_lbl3" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_RightToIntermediatesMember" xlink:label="RightToIntermediatesMember" xlink:title="RightToIntermediatesMember" />
    <link:label xlink:type="resource" xlink:label="adma_RightToIntermediatesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_RightToIntermediatesMember_lbl" xml:lang="en-US" id="adma_RightToIntermediatesMember_lbl">Entity's established relationships with its customers through contracts.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RightToIntermediatesMember" xlink:to="adma_RightToIntermediatesMember_lbl" xlink:title="label: RightToIntermediatesMember to adma_RightToIntermediatesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_RightToIntermediatesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_RightToIntermediatesMember_lbl1" xml:lang="en-US" id="adma_RightToIntermediatesMember_lbl1">Right to intermediates [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RightToIntermediatesMember" xlink:to="adma_RightToIntermediatesMember_lbl1" xlink:title="label: RightToIntermediatesMember to adma_RightToIntermediatesMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_RightToIntermediatesMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_RightToIntermediatesMember_lbl2" xml:lang="en-US" id="adma_RightToIntermediatesMember_lbl2">Right to Intermediates [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RightToIntermediatesMember" xlink:to="adma_RightToIntermediatesMember_lbl2" xlink:title="label: RightToIntermediatesMember to adma_RightToIntermediatesMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:label="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:title="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" />
    <link:label xlink:type="resource" xlink:label="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl" xml:lang="en-US" id="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl">Entity's established relationships with its customers through contracts.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:to="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl" xlink:title="label: TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember to adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl1" xml:lang="en-US" id="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl1">Trademark and other intangible rights related to Nabi-HB [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:to="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl1" xlink:title="label: TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember to adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl2" xml:lang="en-US" id="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl2">Trademark and Other Intangible Rights Related to Nabi-HB [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:to="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl2" xlink:title="label: TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember to adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares" xlink:label="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares" xlink:title="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares" />
    <link:label xlink:type="resource" xlink:label="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares_lbl" xml:lang="en-US" id="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares_lbl">Number of shares issued during the period related to Restricted Stock Awards, net of shares withheld to cover grantees' income tax liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares" xlink:to="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares_lbl" xlink:title="label: VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares to adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares_lbl1" xml:lang="en-US" id="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares_lbl1">Vesting of Restricted Stock Units, net of shares withheld for taxes and retired, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares" xlink:to="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares_lbl1" xlink:title="label: VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares to adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares_lbl2" xml:lang="en-US" id="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares_lbl2">Vesting of Restricted Stock Units, net of shares withheld for taxes and retired (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares" xlink:to="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares_lbl2" xlink:title="label: VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares to adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" xlink:label="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" xlink:title="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" />
    <link:label xlink:type="resource" xlink:label="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount_lbl" xml:lang="en-US" id="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount_lbl">Value of stock related to Restricted Stock Awards issued during the period, net of shares withheld to cover grantees' income tax liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" xlink:to="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount_lbl" xlink:title="label: VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount to adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount_lbl1" xml:lang="en-US" id="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount_lbl1">Vesting of Restricted Stock Units, net of shares withheld for taxes and retired, amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" xlink:to="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount_lbl1" xlink:title="label: VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount to adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount_lbl2" xml:lang="en-US" id="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount_lbl2">Vesting of Restricted Stock Units, net of shares withheld for taxes and retired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" xlink:to="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount_lbl2" xlink:title="label: VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount to adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease" xlink:label="LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease" xlink:title="LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease" />
    <link:label xlink:type="resource" xlink:label="adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease_lbl" xml:lang="en-US" id="adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease_lbl">Lease liability recognized in connection with property lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease" xlink:to="adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease_lbl" xlink:title="label: LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease to adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease_lbl1" xml:lang="en-US" id="adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease_lbl1">Lessee Operating Lease Liabilities Related to Property Lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease" xlink:to="adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease to adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease_lbl2" xml:lang="en-US" id="adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease_lbl2">Lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease" xlink:to="adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease_lbl2" xlink:title="label: LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease to adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease" xlink:label="LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease" xlink:title="LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease" />
    <link:label xlink:type="resource" xlink:label="adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease_lbl" xml:lang="en-US" id="adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease_lbl">Right to use assets recognized in connection with property lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease" xlink:to="adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease_lbl" xlink:title="label: LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease to adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease_lbl1" xml:lang="en-US" id="adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease_lbl1">Lessee, Operating Lease, Right-of-Use Asset Related to Property Lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease" xlink:to="adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease_lbl1" xlink:title="label: LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease to adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease_lbl2" xml:lang="en-US" id="adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease_lbl2">Right to use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease" xlink:to="adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease_lbl2" xlink:title="label: LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease to adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_OperatingLeasesRentExpense" xlink:label="OperatingLeasesRentExpense" xlink:title="OperatingLeasesRentExpense" />
    <link:label xlink:type="resource" xlink:label="adma_OperatingLeasesRentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_OperatingLeasesRentExpense_lbl" xml:lang="en-US" id="adma_OperatingLeasesRentExpense_lbl">Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesRentExpense" xlink:to="adma_OperatingLeasesRentExpense_lbl" xlink:title="label: OperatingLeasesRentExpense to adma_OperatingLeasesRentExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_OperatingLeasesRentExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_OperatingLeasesRentExpense_lbl1" xml:lang="en-US" id="adma_OperatingLeasesRentExpense_lbl1">Operating Leases, Rent Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesRentExpense" xlink:to="adma_OperatingLeasesRentExpense_lbl1" xlink:title="label: OperatingLeasesRentExpense to adma_OperatingLeasesRentExpense_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_OperatingLeasesRentExpense_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_OperatingLeasesRentExpense_lbl2" xml:lang="en-US" id="adma_OperatingLeasesRentExpense_lbl2">Rental expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesRentExpense" xlink:to="adma_OperatingLeasesRentExpense_lbl2" xlink:title="label: OperatingLeasesRentExpense to adma_OperatingLeasesRentExpense_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_NumberOfNewPropertyLeases" xlink:label="NumberOfNewPropertyLeases" xlink:title="NumberOfNewPropertyLeases" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfNewPropertyLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfNewPropertyLeases_lbl" xml:lang="en-US" id="adma_NumberOfNewPropertyLeases_lbl">Number of new property leases related to additional plasma collection facilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfNewPropertyLeases" xlink:to="adma_NumberOfNewPropertyLeases_lbl" xlink:title="label: NumberOfNewPropertyLeases to adma_NumberOfNewPropertyLeases_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfNewPropertyLeases_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfNewPropertyLeases_lbl1" xml:lang="en-US" id="adma_NumberOfNewPropertyLeases_lbl1">Number of New Property Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfNewPropertyLeases" xlink:to="adma_NumberOfNewPropertyLeases_lbl1" xlink:title="label: NumberOfNewPropertyLeases to adma_NumberOfNewPropertyLeases_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfNewPropertyLeases_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_NumberOfNewPropertyLeases_lbl2" xml:lang="en-US" id="adma_NumberOfNewPropertyLeases_lbl2">Number of new property leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfNewPropertyLeases" xlink:to="adma_NumberOfNewPropertyLeases_lbl2" xlink:title="label: NumberOfNewPropertyLeases to adma_NumberOfNewPropertyLeases_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_OperatingLeaseIncrementalBorrowingRatePercent" xlink:label="OperatingLeaseIncrementalBorrowingRatePercent" xlink:title="OperatingLeaseIncrementalBorrowingRatePercent" />
    <link:label xlink:type="resource" xlink:label="adma_OperatingLeaseIncrementalBorrowingRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_OperatingLeaseIncrementalBorrowingRatePercent_lbl" xml:lang="en-US" id="adma_OperatingLeaseIncrementalBorrowingRatePercent_lbl">Weighted average incremental borrowing rate for operating lease calculated at point in time.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseIncrementalBorrowingRatePercent" xlink:to="adma_OperatingLeaseIncrementalBorrowingRatePercent_lbl" xlink:title="label: OperatingLeaseIncrementalBorrowingRatePercent to adma_OperatingLeaseIncrementalBorrowingRatePercent_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_OperatingLeaseIncrementalBorrowingRatePercent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_OperatingLeaseIncrementalBorrowingRatePercent_lbl1" xml:lang="en-US" id="adma_OperatingLeaseIncrementalBorrowingRatePercent_lbl1">Operating Lease Incremental Borrowing Rate Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseIncrementalBorrowingRatePercent" xlink:to="adma_OperatingLeaseIncrementalBorrowingRatePercent_lbl1" xlink:title="label: OperatingLeaseIncrementalBorrowingRatePercent to adma_OperatingLeaseIncrementalBorrowingRatePercent_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_OperatingLeaseIncrementalBorrowingRatePercent_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_OperatingLeaseIncrementalBorrowingRatePercent_lbl2" xml:lang="en-US" id="adma_OperatingLeaseIncrementalBorrowingRatePercent_lbl2">Incremental borrowing rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseIncrementalBorrowingRatePercent" xlink:to="adma_OperatingLeaseIncrementalBorrowingRatePercent_lbl2" xlink:title="label: OperatingLeaseIncrementalBorrowingRatePercent to adma_OperatingLeaseIncrementalBorrowingRatePercent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_DepositsAndOtherNoncurrentAssets" xlink:label="DepositsAndOtherNoncurrentAssets" xlink:title="DepositsAndOtherNoncurrentAssets" />
    <link:label xlink:type="resource" xlink:label="adma_DepositsAndOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_DepositsAndOtherNoncurrentAssets_lbl" xml:lang="en-US" id="adma_DepositsAndOtherNoncurrentAssets_lbl">Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and amount of noncurrent assets classified as other.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepositsAndOtherNoncurrentAssets" xlink:to="adma_DepositsAndOtherNoncurrentAssets_lbl" xlink:title="label: DepositsAndOtherNoncurrentAssets to adma_DepositsAndOtherNoncurrentAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_DepositsAndOtherNoncurrentAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_DepositsAndOtherNoncurrentAssets_lbl1" xml:lang="en-US" id="adma_DepositsAndOtherNoncurrentAssets_lbl1">Deposits and Other Noncurrent Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepositsAndOtherNoncurrentAssets" xlink:to="adma_DepositsAndOtherNoncurrentAssets_lbl1" xlink:title="label: DepositsAndOtherNoncurrentAssets to adma_DepositsAndOtherNoncurrentAssets_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_DepositsAndOtherNoncurrentAssets_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_DepositsAndOtherNoncurrentAssets_lbl2" xml:lang="en-US" id="adma_DepositsAndOtherNoncurrentAssets_lbl2">Deposits and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepositsAndOtherNoncurrentAssets" xlink:to="adma_DepositsAndOtherNoncurrentAssets_lbl2" xlink:title="label: DepositsAndOtherNoncurrentAssets to adma_DepositsAndOtherNoncurrentAssets_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:label="EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:title="EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" />
    <link:label xlink:type="resource" xlink:label="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" id="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl">Amount of equipment acquired in a noncash (or part noncash) acquisition and reflected in accounts payable and accrued liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:to="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl" xlink:title="label: EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities to adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl1" xml:lang="en-US" id="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl1">Equipment Acquired Reflected in Accounts Payable and Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:to="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl1" xlink:title="label: EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities to adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl2" xml:lang="en-US" id="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl2">Equipment acquired reflected in accounts payable and accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:to="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl2" xlink:title="label: EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities to adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:label="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:title="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" />
    <link:label xlink:type="resource" xlink:label="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl" xml:lang="en-US" id="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl">Amount of allowance for contractual credits and doubtful accounts.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:to="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl" xlink:title="label: AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts to adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl1" xml:lang="en-US" id="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl1">Accounts Receivable, Allowance for Contractual Credits and Doubtful Accounts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:to="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl1" xlink:title="label: AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts to adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl2" xml:lang="en-US" id="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl2">Accounts receivable, allowances for contractual credits and doubtful accounts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:to="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl2" xlink:title="label: AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts to adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ThreeCustomersMember" xlink:label="ThreeCustomersMember" xlink:title="ThreeCustomersMember" />
    <link:label xlink:type="resource" xlink:label="adma_ThreeCustomersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ThreeCustomersMember_lbl" xml:lang="en-US" id="adma_ThreeCustomersMember_lbl">Information about number of customers accounting for a percentage of consolidated revenues.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ThreeCustomersMember" xlink:to="adma_ThreeCustomersMember_lbl" xlink:title="label: ThreeCustomersMember to adma_ThreeCustomersMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ThreeCustomersMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ThreeCustomersMember_lbl1" xml:lang="en-US" id="adma_ThreeCustomersMember_lbl1">Three Customers [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ThreeCustomersMember" xlink:to="adma_ThreeCustomersMember_lbl1" xlink:title="label: ThreeCustomersMember to adma_ThreeCustomersMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_NumberOfCustomers" xlink:label="NumberOfCustomers" xlink:title="NumberOfCustomers" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfCustomers_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfCustomers_lbl" xml:lang="en-US" id="adma_NumberOfCustomers_lbl">Number of customers accounted for company's total accounts receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfCustomers" xlink:to="adma_NumberOfCustomers_lbl" xlink:title="label: NumberOfCustomers to adma_NumberOfCustomers_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfCustomers_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfCustomers_lbl1" xml:lang="en-US" id="adma_NumberOfCustomers_lbl1">Number of Customers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfCustomers" xlink:to="adma_NumberOfCustomers_lbl1" xlink:title="label: NumberOfCustomers to adma_NumberOfCustomers_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfCustomers_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_NumberOfCustomers_lbl2" xml:lang="en-US" id="adma_NumberOfCustomers_lbl2">Number of customers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfCustomers" xlink:to="adma_NumberOfCustomers_lbl2" xlink:title="label: NumberOfCustomers to adma_NumberOfCustomers_lbl2" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfCustomers_lbl3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="adma_NumberOfCustomers_lbl3" xml:lang="en-US" id="adma_NumberOfCustomers_lbl3">Number of customers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfCustomers" xlink:to="adma_NumberOfCustomers_lbl3" xlink:title="label: NumberOfCustomers to adma_NumberOfCustomers_lbl3" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_SixCustomersMember" xlink:label="SixCustomersMember" xlink:title="SixCustomersMember" />
    <link:label xlink:type="resource" xlink:label="adma_SixCustomersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_SixCustomersMember_lbl" xml:lang="en-US" id="adma_SixCustomersMember_lbl">Information about number of customers accounting for a percentage of consolidated revenues.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SixCustomersMember" xlink:to="adma_SixCustomersMember_lbl" xlink:title="label: SixCustomersMember to adma_SixCustomersMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_SixCustomersMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_SixCustomersMember_lbl1" xml:lang="en-US" id="adma_SixCustomersMember_lbl1">Six Customers [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SixCustomersMember" xlink:to="adma_SixCustomersMember_lbl1" xlink:title="label: SixCustomersMember to adma_SixCustomersMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_EquityIncentivePlanMember" xlink:label="EquityIncentivePlanMember" xlink:title="EquityIncentivePlanMember" />
    <link:label xlink:type="resource" xlink:label="adma_EquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_EquityIncentivePlanMember_lbl" xml:lang="en-US" id="adma_EquityIncentivePlanMember_lbl">Equity compensation is often a significant portion of the total compensation paid to employees and other service providers.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlanMember" xlink:to="adma_EquityIncentivePlanMember_lbl" xlink:title="label: EquityIncentivePlanMember to adma_EquityIncentivePlanMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_EquityIncentivePlanMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_EquityIncentivePlanMember_lbl1" xml:lang="en-US" id="adma_EquityIncentivePlanMember_lbl1">Equity Incentive Plans [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlanMember" xlink:to="adma_EquityIncentivePlanMember_lbl1" xlink:title="label: EquityIncentivePlanMember to adma_EquityIncentivePlanMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_EmployeesMember" xlink:label="EmployeesMember" xlink:title="EmployeesMember" />
    <link:label xlink:type="resource" xlink:label="adma_EmployeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_EmployeesMember_lbl" xml:lang="en-US" id="adma_EmployeesMember_lbl">A group of person working with the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeesMember" xlink:to="adma_EmployeesMember_lbl" xlink:title="label: EmployeesMember to adma_EmployeesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_EmployeesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_EmployeesMember_lbl1" xml:lang="en-US" id="adma_EmployeesMember_lbl1">Employees [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeesMember" xlink:to="adma_EmployeesMember_lbl1" xlink:title="label: EmployeesMember to adma_EmployeesMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_RestrictedStockUnitsAbstract" xlink:label="RestrictedStockUnitsAbstract" xlink:title="RestrictedStockUnitsAbstract" />
    <link:label xlink:type="resource" xlink:label="adma_RestrictedStockUnitsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_RestrictedStockUnitsAbstract_lbl1" xml:lang="en-US" id="adma_RestrictedStockUnitsAbstract_lbl1">Restricted Stock Units [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockUnitsAbstract" xlink:to="adma_RestrictedStockUnitsAbstract_lbl1" xlink:title="label: RestrictedStockUnitsAbstract to adma_RestrictedStockUnitsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl">The shares value withheld by the Company to cover employees' tax liabilities under share-based payment arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Shares Value Withheld for Employees Tax Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl2" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl2">Amount of shares withheld for tax withholding obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl">The number of shares withheld by the Company to cover employees' tax liabilities under share-based payment arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Shares Withheld for Employees Tax Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl2" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl2">Shares withheld for tax withholding obligation (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_StockOptionsAbstract" xlink:label="StockOptionsAbstract" xlink:title="StockOptionsAbstract" />
    <link:label xlink:type="resource" xlink:label="adma_StockOptionsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_StockOptionsAbstract_lbl1" xml:lang="en-US" id="adma_StockOptionsAbstract_lbl1">Stock Options [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionsAbstract" xlink:to="adma_StockOptionsAbstract_lbl1" xlink:title="label: StockOptionsAbstract to adma_StockOptionsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_StockOptionSharesAbstract" xlink:label="StockOptionSharesAbstract" xlink:title="StockOptionSharesAbstract" />
    <link:label xlink:type="resource" xlink:label="adma_StockOptionSharesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_StockOptionSharesAbstract_lbl1" xml:lang="en-US" id="adma_StockOptionSharesAbstract_lbl1">Stock Option, Shares [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionSharesAbstract" xlink:to="adma_StockOptionSharesAbstract_lbl1" xlink:title="label: StockOptionSharesAbstract to adma_StockOptionSharesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl">Number of shares under fully vested and expected to vest options for which rights to exercise lapsed.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Expired, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl2" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl2">Expired (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl">Number of shares under fully vested and expected to vest options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Forfeited, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl2" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl2">Forfeited (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl">Number of shares under fully vested and expected to vest options that were exercised during the current period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercised, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl2" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl2">Exercised (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl">Number of shares under fully vested and expected to vest options that were granted during the current period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Granted, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl2" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl2">Granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_StockOptionsWeightedAverageExercisePriceAbstract" xlink:label="StockOptionsWeightedAverageExercisePriceAbstract" xlink:title="StockOptionsWeightedAverageExercisePriceAbstract" />
    <link:label xlink:type="resource" xlink:label="adma_StockOptionsWeightedAverageExercisePriceAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_StockOptionsWeightedAverageExercisePriceAbstract_lbl1" xml:lang="en-US" id="adma_StockOptionsWeightedAverageExercisePriceAbstract_lbl1">Stock Options, Weighted Average Exercise Price [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionsWeightedAverageExercisePriceAbstract" xlink:to="adma_StockOptionsWeightedAverageExercisePriceAbstract_lbl1" xlink:title="label: StockOptionsWeightedAverageExercisePriceAbstract to adma_StockOptionsWeightedAverageExercisePriceAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl">Weighted-average exercise price, for fully vested and expected to vest that were not exercised or put into effect as a result of the occurrence of a terminating event.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Forfeited, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl2" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl2">Forfeited, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl">Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercised.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercised, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl2" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl2">Exercised, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl">Weighted-average exercise price, for fully vested and expected to vest that were expired.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Expired, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl2" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl2">Expired, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl">Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest granted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Granted, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl2" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl2">Granted, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_AccruedRebatesCurrent" xlink:label="AccruedRebatesCurrent" xlink:title="AccruedRebatesCurrent" />
    <link:label xlink:type="resource" xlink:label="adma_AccruedRebatesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_AccruedRebatesCurrent_lbl" xml:lang="en-US" id="adma_AccruedRebatesCurrent_lbl">Carrying value as of the balance sheet date of rebates for Medicaid or other third parties related to sale of product.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedRebatesCurrent" xlink:to="adma_AccruedRebatesCurrent_lbl" xlink:title="label: AccruedRebatesCurrent to adma_AccruedRebatesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_AccruedRebatesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_AccruedRebatesCurrent_lbl1" xml:lang="en-US" id="adma_AccruedRebatesCurrent_lbl1">Accrued Rebates, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedRebatesCurrent" xlink:to="adma_AccruedRebatesCurrent_lbl1" xlink:title="label: AccruedRebatesCurrent to adma_AccruedRebatesCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_AccruedRebatesCurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_AccruedRebatesCurrent_lbl2" xml:lang="en-US" id="adma_AccruedRebatesCurrent_lbl2">Accrued rebates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedRebatesCurrent" xlink:to="adma_AccruedRebatesCurrent_lbl2" xlink:title="label: AccruedRebatesCurrent to adma_AccruedRebatesCurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_FiveCustomersMember" xlink:label="FiveCustomersMember" xlink:title="FiveCustomersMember" />
    <link:label xlink:type="resource" xlink:label="adma_FiveCustomersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_FiveCustomersMember_lbl" xml:lang="en-US" id="adma_FiveCustomersMember_lbl">Information about number of customers accounting for a percentage of consolidated revenues.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiveCustomersMember" xlink:to="adma_FiveCustomersMember_lbl" xlink:title="label: FiveCustomersMember to adma_FiveCustomersMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_FiveCustomersMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_FiveCustomersMember_lbl1" xml:lang="en-US" id="adma_FiveCustomersMember_lbl1">Five Customers [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiveCustomersMember" xlink:to="adma_FiveCustomersMember_lbl1" xlink:title="label: FiveCustomersMember to adma_FiveCustomersMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_BiotestLicenseAgreementMember" xlink:label="BiotestLicenseAgreementMember" xlink:title="BiotestLicenseAgreementMember" />
    <link:label xlink:type="resource" xlink:label="adma_BiotestLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_BiotestLicenseAgreementMember_lbl" xml:lang="en-US" id="adma_BiotestLicenseAgreementMember_lbl">Name of license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BiotestLicenseAgreementMember" xlink:to="adma_BiotestLicenseAgreementMember_lbl" xlink:title="label: BiotestLicenseAgreementMember to adma_BiotestLicenseAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_BiotestLicenseAgreementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_BiotestLicenseAgreementMember_lbl1" xml:lang="en-US" id="adma_BiotestLicenseAgreementMember_lbl1">Biotest License Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BiotestLicenseAgreementMember" xlink:to="adma_BiotestLicenseAgreementMember_lbl1" xlink:title="label: BiotestLicenseAgreementMember to adma_BiotestLicenseAgreementMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_DeferredRevenueRemainingAmortizationPeriod" xlink:label="DeferredRevenueRemainingAmortizationPeriod" xlink:title="DeferredRevenueRemainingAmortizationPeriod" />
    <link:label xlink:type="resource" xlink:label="adma_DeferredRevenueRemainingAmortizationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_DeferredRevenueRemainingAmortizationPeriod_lbl" xml:lang="en-US" id="adma_DeferredRevenueRemainingAmortizationPeriod_lbl">Remaining amortization period of deferred revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenueRemainingAmortizationPeriod" xlink:to="adma_DeferredRevenueRemainingAmortizationPeriod_lbl" xlink:title="label: DeferredRevenueRemainingAmortizationPeriod to adma_DeferredRevenueRemainingAmortizationPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_DeferredRevenueRemainingAmortizationPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_DeferredRevenueRemainingAmortizationPeriod_lbl1" xml:lang="en-US" id="adma_DeferredRevenueRemainingAmortizationPeriod_lbl1">Amortization period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenueRemainingAmortizationPeriod" xlink:to="adma_DeferredRevenueRemainingAmortizationPeriod_lbl1" xlink:title="label: DeferredRevenueRemainingAmortizationPeriod to adma_DeferredRevenueRemainingAmortizationPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_DebtInstrumentTermOfVariableRate" xlink:label="DebtInstrumentTermOfVariableRate" xlink:title="DebtInstrumentTermOfVariableRate" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentTermOfVariableRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_DebtInstrumentTermOfVariableRate_lbl" xml:lang="en-US" id="adma_DebtInstrumentTermOfVariableRate_lbl">Term of the interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTermOfVariableRate" xlink:to="adma_DebtInstrumentTermOfVariableRate_lbl" xlink:title="label: DebtInstrumentTermOfVariableRate to adma_DebtInstrumentTermOfVariableRate_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentTermOfVariableRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_DebtInstrumentTermOfVariableRate_lbl1" xml:lang="en-US" id="adma_DebtInstrumentTermOfVariableRate_lbl1">Debt Instrument, Term of Variable Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTermOfVariableRate" xlink:to="adma_DebtInstrumentTermOfVariableRate_lbl1" xlink:title="label: DebtInstrumentTermOfVariableRate to adma_DebtInstrumentTermOfVariableRate_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentTermOfVariableRate_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_DebtInstrumentTermOfVariableRate_lbl2" xml:lang="en-US" id="adma_DebtInstrumentTermOfVariableRate_lbl2">Term of variable rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTermOfVariableRate" xlink:to="adma_DebtInstrumentTermOfVariableRate_lbl2" xlink:title="label: DebtInstrumentTermOfVariableRate to adma_DebtInstrumentTermOfVariableRate_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PerceptiveCreditFacilityMember" xlink:label="PerceptiveCreditFacilityMember" xlink:title="PerceptiveCreditFacilityMember" />
    <link:label xlink:type="resource" xlink:label="adma_PerceptiveCreditFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PerceptiveCreditFacilityMember_lbl" xml:lang="en-US" id="adma_PerceptiveCreditFacilityMember_lbl">Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount from lender.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PerceptiveCreditFacilityMember" xlink:to="adma_PerceptiveCreditFacilityMember_lbl" xlink:title="label: PerceptiveCreditFacilityMember to adma_PerceptiveCreditFacilityMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PerceptiveCreditFacilityMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PerceptiveCreditFacilityMember_lbl1" xml:lang="en-US" id="adma_PerceptiveCreditFacilityMember_lbl1">Perceptive Credit Facility [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PerceptiveCreditFacilityMember" xlink:to="adma_PerceptiveCreditFacilityMember_lbl1" xlink:title="label: PerceptiveCreditFacilityMember to adma_PerceptiveCreditFacilityMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PerceptiveCreditFacilityMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PerceptiveCreditFacilityMember_lbl2" xml:lang="en-US" id="adma_PerceptiveCreditFacilityMember_lbl2">Perceptive Credit Facility [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PerceptiveCreditFacilityMember" xlink:to="adma_PerceptiveCreditFacilityMember_lbl2" xlink:title="label: PerceptiveCreditFacilityMember to adma_PerceptiveCreditFacilityMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PerceptiveCreditAgreementMember" xlink:label="PerceptiveCreditAgreementMember" xlink:title="PerceptiveCreditAgreementMember" />
    <link:label xlink:type="resource" xlink:label="adma_PerceptiveCreditAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PerceptiveCreditAgreementMember_lbl" xml:lang="en-US" id="adma_PerceptiveCreditAgreementMember_lbl">A Perceptive credit agreement is a legally-binding contract documenting the terms of a loan agreement; it is made between a person or party borrowing money and a lender.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PerceptiveCreditAgreementMember" xlink:to="adma_PerceptiveCreditAgreementMember_lbl" xlink:title="label: PerceptiveCreditAgreementMember to adma_PerceptiveCreditAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PerceptiveCreditAgreementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PerceptiveCreditAgreementMember_lbl1" xml:lang="en-US" id="adma_PerceptiveCreditAgreementMember_lbl1">Perceptive Credit Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PerceptiveCreditAgreementMember" xlink:to="adma_PerceptiveCreditAgreementMember_lbl1" xlink:title="label: PerceptiveCreditAgreementMember to adma_PerceptiveCreditAgreementMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PerceptiveCreditAgreementMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PerceptiveCreditAgreementMember_lbl2" xml:lang="en-US" id="adma_PerceptiveCreditAgreementMember_lbl2">Perceptive Credit Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PerceptiveCreditAgreementMember" xlink:to="adma_PerceptiveCreditAgreementMember_lbl2" xlink:title="label: PerceptiveCreditAgreementMember to adma_PerceptiveCreditAgreementMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_SeniorNotesPayableBeforeDebtDiscount" xlink:label="SeniorNotesPayableBeforeDebtDiscount" xlink:title="SeniorNotesPayableBeforeDebtDiscount" />
    <link:label xlink:type="resource" xlink:label="adma_SeniorNotesPayableBeforeDebtDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_SeniorNotesPayableBeforeDebtDiscount_lbl" xml:lang="en-US" id="adma_SeniorNotesPayableBeforeDebtDiscount_lbl">Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding debt discount and current portion.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeniorNotesPayableBeforeDebtDiscount" xlink:to="adma_SeniorNotesPayableBeforeDebtDiscount_lbl" xlink:title="label: SeniorNotesPayableBeforeDebtDiscount to adma_SeniorNotesPayableBeforeDebtDiscount_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_SeniorNotesPayableBeforeDebtDiscount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_SeniorNotesPayableBeforeDebtDiscount_lbl1" xml:lang="en-US" id="adma_SeniorNotesPayableBeforeDebtDiscount_lbl1">Senior Notes Payable Before Debt Discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeniorNotesPayableBeforeDebtDiscount" xlink:to="adma_SeniorNotesPayableBeforeDebtDiscount_lbl1" xlink:title="label: SeniorNotesPayableBeforeDebtDiscount to adma_SeniorNotesPayableBeforeDebtDiscount_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_SeniorNotesPayableBeforeDebtDiscount_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_SeniorNotesPayableBeforeDebtDiscount_lbl2" xml:lang="en-US" id="adma_SeniorNotesPayableBeforeDebtDiscount_lbl2">Notes payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeniorNotesPayableBeforeDebtDiscount" xlink:to="adma_SeniorNotesPayableBeforeDebtDiscount_lbl2" xlink:title="label: SeniorNotesPayableBeforeDebtDiscount to adma_SeniorNotesPayableBeforeDebtDiscount_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_RepaymentsOfDebtInterest" xlink:label="RepaymentsOfDebtInterest" xlink:title="RepaymentsOfDebtInterest" />
    <link:label xlink:type="resource" xlink:label="adma_RepaymentsOfDebtInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_RepaymentsOfDebtInterest_lbl" xml:lang="en-US" id="adma_RepaymentsOfDebtInterest_lbl">The cash outflow during the period from the repayment of aggregate short-term and long-term debt interest.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfDebtInterest" xlink:to="adma_RepaymentsOfDebtInterest_lbl" xlink:title="label: RepaymentsOfDebtInterest to adma_RepaymentsOfDebtInterest_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_RepaymentsOfDebtInterest_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_RepaymentsOfDebtInterest_lbl1" xml:lang="en-US" id="adma_RepaymentsOfDebtInterest_lbl1">Payments of Debt, Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfDebtInterest" xlink:to="adma_RepaymentsOfDebtInterest_lbl1" xlink:title="label: RepaymentsOfDebtInterest to adma_RepaymentsOfDebtInterest_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_RepaymentsOfDebtInterest_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_RepaymentsOfDebtInterest_lbl2" xml:lang="en-US" id="adma_RepaymentsOfDebtInterest_lbl2">Payments of debt interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfDebtInterest" xlink:to="adma_RepaymentsOfDebtInterest_lbl2" xlink:title="label: RepaymentsOfDebtInterest to adma_RepaymentsOfDebtInterest_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PreferredSharePurchaseRightMember" xlink:label="PreferredSharePurchaseRightMember" xlink:title="PreferredSharePurchaseRightMember" />
    <link:label xlink:type="resource" xlink:label="adma_PreferredSharePurchaseRightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PreferredSharePurchaseRightMember_lbl" xml:lang="en-US" id="adma_PreferredSharePurchaseRightMember_lbl">The right of the existing shareholder to buy additional shares in proportion to the number of shares already owned.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredSharePurchaseRightMember" xlink:to="adma_PreferredSharePurchaseRightMember_lbl" xlink:title="label: PreferredSharePurchaseRightMember to adma_PreferredSharePurchaseRightMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PreferredSharePurchaseRightMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PreferredSharePurchaseRightMember_lbl1" xml:lang="en-US" id="adma_PreferredSharePurchaseRightMember_lbl1">Preferred Share Purchase Right [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredSharePurchaseRightMember" xlink:to="adma_PreferredSharePurchaseRightMember_lbl1" xlink:title="label: PreferredSharePurchaseRightMember to adma_PreferredSharePurchaseRightMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PreferredSharePurchaseRightMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PreferredSharePurchaseRightMember_lbl2" xml:lang="en-US" id="adma_PreferredSharePurchaseRightMember_lbl2">Preferred Share Purchase Right [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredSharePurchaseRightMember" xlink:to="adma_PreferredSharePurchaseRightMember_lbl2" xlink:title="label: PreferredSharePurchaseRightMember to adma_PreferredSharePurchaseRightMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_VendorCommitmentsAbstract" xlink:label="VendorCommitmentsAbstract" xlink:title="VendorCommitmentsAbstract" />
    <link:label xlink:type="resource" xlink:label="adma_VendorCommitmentsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_VendorCommitmentsAbstract_lbl1" xml:lang="en-US" id="adma_VendorCommitmentsAbstract_lbl1">Vendor Commitments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VendorCommitmentsAbstract" xlink:to="adma_VendorCommitmentsAbstract_lbl1" xlink:title="label: VendorCommitmentsAbstract to adma_VendorCommitmentsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PercentageOfInventoryPurchases" xlink:label="PercentageOfInventoryPurchases" xlink:title="PercentageOfInventoryPurchases" />
    <link:label xlink:type="resource" xlink:label="adma_PercentageOfInventoryPurchases_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PercentageOfInventoryPurchases_lbl" xml:lang="en-US" id="adma_PercentageOfInventoryPurchases_lbl">Percentage of inventory purchases related to raw material plasma.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfInventoryPurchases" xlink:to="adma_PercentageOfInventoryPurchases_lbl" xlink:title="label: PercentageOfInventoryPurchases to adma_PercentageOfInventoryPurchases_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PercentageOfInventoryPurchases_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PercentageOfInventoryPurchases_lbl1" xml:lang="en-US" id="adma_PercentageOfInventoryPurchases_lbl1">Percentage of Inventory Purchases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfInventoryPurchases" xlink:to="adma_PercentageOfInventoryPurchases_lbl1" xlink:title="label: PercentageOfInventoryPurchases to adma_PercentageOfInventoryPurchases_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PercentageOfInventoryPurchases_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PercentageOfInventoryPurchases_lbl2" xml:lang="en-US" id="adma_PercentageOfInventoryPurchases_lbl2">Percentage of inventory purchases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfInventoryPurchases" xlink:to="adma_PercentageOfInventoryPurchases_lbl2" xlink:title="label: PercentageOfInventoryPurchases to adma_PercentageOfInventoryPurchases_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_NumberOfRenewalTerms" xlink:label="NumberOfRenewalTerms" xlink:title="NumberOfRenewalTerms" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfRenewalTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfRenewalTerms_lbl" xml:lang="en-US" id="adma_NumberOfRenewalTerms_lbl">Number of renewal terms to extend purchase agreement, if agreed to by the parties.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfRenewalTerms" xlink:to="adma_NumberOfRenewalTerms_lbl" xlink:title="label: NumberOfRenewalTerms to adma_NumberOfRenewalTerms_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfRenewalTerms_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfRenewalTerms_lbl1" xml:lang="en-US" id="adma_NumberOfRenewalTerms_lbl1">Number of Renewal Terms</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfRenewalTerms" xlink:to="adma_NumberOfRenewalTerms_lbl1" xlink:title="label: NumberOfRenewalTerms to adma_NumberOfRenewalTerms_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfRenewalTerms_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_NumberOfRenewalTerms_lbl2" xml:lang="en-US" id="adma_NumberOfRenewalTerms_lbl2">Number of renewal terms</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfRenewalTerms" xlink:to="adma_NumberOfRenewalTerms_lbl2" xlink:title="label: NumberOfRenewalTerms to adma_NumberOfRenewalTerms_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PlasmaPurchaseAgreementRenewalPeriod" xlink:label="PlasmaPurchaseAgreementRenewalPeriod" xlink:title="PlasmaPurchaseAgreementRenewalPeriod" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl" xml:lang="en-US" id="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl">Plasma purchase agreement renewal period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchaseAgreementRenewalPeriod" xlink:to="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl" xlink:title="label: PlasmaPurchaseAgreementRenewalPeriod to adma_PlasmaPurchaseAgreementRenewalPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl1" xml:lang="en-US" id="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl1">Plasma Purchase Agreement Renewal Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchaseAgreementRenewalPeriod" xlink:to="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl1" xlink:title="label: PlasmaPurchaseAgreementRenewalPeriod to adma_PlasmaPurchaseAgreementRenewalPeriod_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl2" xml:lang="en-US" id="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl2">Plasma purchase agreement renewal period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchaseAgreementRenewalPeriod" xlink:to="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl2" xlink:title="label: PlasmaPurchaseAgreementRenewalPeriod to adma_PlasmaPurchaseAgreementRenewalPeriod_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PlasmaSupplyAgreementTerm" xlink:label="PlasmaSupplyAgreementTerm" xlink:title="PlasmaSupplyAgreementTerm" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaSupplyAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PlasmaSupplyAgreementTerm_lbl" xml:lang="en-US" id="adma_PlasmaSupplyAgreementTerm_lbl">Plasma supply agreement term period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaSupplyAgreementTerm" xlink:to="adma_PlasmaSupplyAgreementTerm_lbl" xlink:title="label: PlasmaSupplyAgreementTerm to adma_PlasmaSupplyAgreementTerm_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaSupplyAgreementTerm_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PlasmaSupplyAgreementTerm_lbl1" xml:lang="en-US" id="adma_PlasmaSupplyAgreementTerm_lbl1">Plasma supply agreement term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaSupplyAgreementTerm" xlink:to="adma_PlasmaSupplyAgreementTerm_lbl1" xlink:title="label: PlasmaSupplyAgreementTerm to adma_PlasmaSupplyAgreementTerm_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaSupplyAgreementTerm_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PlasmaSupplyAgreementTerm_lbl2" xml:lang="en-US" id="adma_PlasmaSupplyAgreementTerm_lbl2">Plasma supply agreement term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaSupplyAgreementTerm" xlink:to="adma_PlasmaSupplyAgreementTerm_lbl2" xlink:title="label: PlasmaSupplyAgreementTerm to adma_PlasmaSupplyAgreementTerm_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_NumberOfPlasmaCollectionFacilities" xlink:label="NumberOfPlasmaCollectionFacilities" xlink:title="NumberOfPlasmaCollectionFacilities" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfPlasmaCollectionFacilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfPlasmaCollectionFacilities_lbl" xml:lang="en-US" id="adma_NumberOfPlasmaCollectionFacilities_lbl">Number of wholly-owned plasma collection facilities of the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPlasmaCollectionFacilities" xlink:to="adma_NumberOfPlasmaCollectionFacilities_lbl" xlink:title="label: NumberOfPlasmaCollectionFacilities to adma_NumberOfPlasmaCollectionFacilities_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfPlasmaCollectionFacilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfPlasmaCollectionFacilities_lbl1" xml:lang="en-US" id="adma_NumberOfPlasmaCollectionFacilities_lbl1">Number of Plasma Collection Facilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPlasmaCollectionFacilities" xlink:to="adma_NumberOfPlasmaCollectionFacilities_lbl1" xlink:title="label: NumberOfPlasmaCollectionFacilities to adma_NumberOfPlasmaCollectionFacilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfPlasmaCollectionFacilities_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_NumberOfPlasmaCollectionFacilities_lbl2" xml:lang="en-US" id="adma_NumberOfPlasmaCollectionFacilities_lbl2">Number of plasma collection facilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPlasmaCollectionFacilities" xlink:to="adma_NumberOfPlasmaCollectionFacilities_lbl2" xlink:title="label: NumberOfPlasmaCollectionFacilities to adma_NumberOfPlasmaCollectionFacilities_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity" xlink:label="NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity" xlink:title="NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity_lbl" xml:lang="en-US" id="adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity_lbl">Number of plasma collection centers that company may purchase RSV plasma.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity" xlink:to="adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity_lbl" xlink:title="label: NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity to adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity_lbl1" xml:lang="en-US" id="adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity_lbl1">Number of Plasma Collection Centers Transferred to Acquired Entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity" xlink:to="adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity_lbl1" xlink:title="label: NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity to adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity_lbl2" xml:lang="en-US" id="adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity_lbl2">Number of plasma collection centers transferred to BPC</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity" xlink:to="adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity_lbl2" xlink:title="label: NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity to adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PercentageOfPlasmaPurchasePriceEqualToCost" xlink:label="PercentageOfPlasmaPurchasePriceEqualToCost" xlink:title="PercentageOfPlasmaPurchasePriceEqualToCost" />
    <link:label xlink:type="resource" xlink:label="adma_PercentageOfPlasmaPurchasePriceEqualToCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PercentageOfPlasmaPurchasePriceEqualToCost_lbl" xml:lang="en-US" id="adma_PercentageOfPlasmaPurchasePriceEqualToCost_lbl">Percentage of plasma purchase price equal to cost purchased from collection centers.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfPlasmaPurchasePriceEqualToCost" xlink:to="adma_PercentageOfPlasmaPurchasePriceEqualToCost_lbl" xlink:title="label: PercentageOfPlasmaPurchasePriceEqualToCost to adma_PercentageOfPlasmaPurchasePriceEqualToCost_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PercentageOfPlasmaPurchasePriceEqualToCost_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PercentageOfPlasmaPurchasePriceEqualToCost_lbl1" xml:lang="en-US" id="adma_PercentageOfPlasmaPurchasePriceEqualToCost_lbl1">Percentage of Plasma Purchase Price Equal to Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfPlasmaPurchasePriceEqualToCost" xlink:to="adma_PercentageOfPlasmaPurchasePriceEqualToCost_lbl1" xlink:title="label: PercentageOfPlasmaPurchasePriceEqualToCost to adma_PercentageOfPlasmaPurchasePriceEqualToCost_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PercentageOfPlasmaPurchasePriceEqualToCost_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PercentageOfPlasmaPurchasePriceEqualToCost_lbl2" xml:lang="en-US" id="adma_PercentageOfPlasmaPurchasePriceEqualToCost_lbl2">Percentage of plasma purchase price equal to cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfPlasmaPurchasePriceEqualToCost" xlink:to="adma_PercentageOfPlasmaPurchasePriceEqualToCost_lbl2" xlink:title="label: PercentageOfPlasmaPurchasePriceEqualToCost to adma_PercentageOfPlasmaPurchasePriceEqualToCost_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PlasmaPurchased" xlink:label="PlasmaPurchased" xlink:title="PlasmaPurchased" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PlasmaPurchased_lbl" xml:lang="en-US" id="adma_PlasmaPurchased_lbl">Amount of plasma purchased during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchased" xlink:to="adma_PlasmaPurchased_lbl" xlink:title="label: PlasmaPurchased to adma_PlasmaPurchased_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchased_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PlasmaPurchased_lbl1" xml:lang="en-US" id="adma_PlasmaPurchased_lbl1">Plasma Purchased</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchased" xlink:to="adma_PlasmaPurchased_lbl1" xlink:title="label: PlasmaPurchased to adma_PlasmaPurchased_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchased_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PlasmaPurchased_lbl2" xml:lang="en-US" id="adma_PlasmaPurchased_lbl2">Plasma purchased from Grifols</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchased" xlink:to="adma_PlasmaPurchased_lbl2" xlink:title="label: PlasmaPurchased to adma_PlasmaPurchased_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PlasmaPurchaseAgreementOneMember" xlink:label="PlasmaPurchaseAgreementOneMember" xlink:title="PlasmaPurchaseAgreementOneMember" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchaseAgreementOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PlasmaPurchaseAgreementOneMember_lbl" xml:lang="en-US" id="adma_PlasmaPurchaseAgreementOneMember_lbl">Plasma purchase agreement to purchase plasma containing antibodies to RSV to be used in the manufacture of ASCENIV.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchaseAgreementOneMember" xlink:to="adma_PlasmaPurchaseAgreementOneMember_lbl" xlink:title="label: PlasmaPurchaseAgreementOneMember to adma_PlasmaPurchaseAgreementOneMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchaseAgreementOneMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PlasmaPurchaseAgreementOneMember_lbl1" xml:lang="en-US" id="adma_PlasmaPurchaseAgreementOneMember_lbl1">Plasma Purchase Agreement One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchaseAgreementOneMember" xlink:to="adma_PlasmaPurchaseAgreementOneMember_lbl1" xlink:title="label: PlasmaPurchaseAgreementOneMember to adma_PlasmaPurchaseAgreementOneMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchaseAgreementOneMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PlasmaPurchaseAgreementOneMember_lbl2" xml:lang="en-US" id="adma_PlasmaPurchaseAgreementOneMember_lbl2">2011 Plasma Purchase Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchaseAgreementOneMember" xlink:to="adma_PlasmaPurchaseAgreementOneMember_lbl2" xlink:title="label: PlasmaPurchaseAgreementOneMember to adma_PlasmaPurchaseAgreementOneMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PlasmaPurchaseAgreementTwoMember" xlink:label="PlasmaPurchaseAgreementTwoMember" xlink:title="PlasmaPurchaseAgreementTwoMember" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchaseAgreementTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PlasmaPurchaseAgreementTwoMember_lbl" xml:lang="en-US" id="adma_PlasmaPurchaseAgreementTwoMember_lbl">Plasma purchase agreement to purchase normal source plasma ("NSP").</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchaseAgreementTwoMember" xlink:to="adma_PlasmaPurchaseAgreementTwoMember_lbl" xlink:title="label: PlasmaPurchaseAgreementTwoMember to adma_PlasmaPurchaseAgreementTwoMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchaseAgreementTwoMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PlasmaPurchaseAgreementTwoMember_lbl1" xml:lang="en-US" id="adma_PlasmaPurchaseAgreementTwoMember_lbl1">Plasma Purchase Agreement Two [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchaseAgreementTwoMember" xlink:to="adma_PlasmaPurchaseAgreementTwoMember_lbl1" xlink:title="label: PlasmaPurchaseAgreementTwoMember to adma_PlasmaPurchaseAgreementTwoMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchaseAgreementTwoMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PlasmaPurchaseAgreementTwoMember_lbl2" xml:lang="en-US" id="adma_PlasmaPurchaseAgreementTwoMember_lbl2">2017 Plasma Purchase Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchaseAgreementTwoMember" xlink:to="adma_PlasmaPurchaseAgreementTwoMember_lbl2" xlink:title="label: PlasmaPurchaseAgreementTwoMember to adma_PlasmaPurchaseAgreementTwoMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PlasmaPurchaseAgreementTerm" xlink:label="PlasmaPurchaseAgreementTerm" xlink:title="PlasmaPurchaseAgreementTerm" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchaseAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PlasmaPurchaseAgreementTerm_lbl" xml:lang="en-US" id="adma_PlasmaPurchaseAgreementTerm_lbl">Plasma purchase agreement term, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchaseAgreementTerm" xlink:to="adma_PlasmaPurchaseAgreementTerm_lbl" xlink:title="label: PlasmaPurchaseAgreementTerm to adma_PlasmaPurchaseAgreementTerm_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchaseAgreementTerm_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PlasmaPurchaseAgreementTerm_lbl1" xml:lang="en-US" id="adma_PlasmaPurchaseAgreementTerm_lbl1">Plasma Purchase Agreement Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchaseAgreementTerm" xlink:to="adma_PlasmaPurchaseAgreementTerm_lbl1" xlink:title="label: PlasmaPurchaseAgreementTerm to adma_PlasmaPurchaseAgreementTerm_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchaseAgreementTerm_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PlasmaPurchaseAgreementTerm_lbl2" xml:lang="en-US" id="adma_PlasmaPurchaseAgreementTerm_lbl2">Plasma purchase agreement term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchaseAgreementTerm" xlink:to="adma_PlasmaPurchaseAgreementTerm_lbl2" xlink:title="label: PlasmaPurchaseAgreementTerm to adma_PlasmaPurchaseAgreementTerm_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_WarrantsAbstract" xlink:label="WarrantsAbstract" xlink:title="WarrantsAbstract" />
    <link:label xlink:type="resource" xlink:label="adma_WarrantsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_WarrantsAbstract_lbl1" xml:lang="en-US" id="adma_WarrantsAbstract_lbl1">Warrants [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAbstract" xlink:to="adma_WarrantsAbstract_lbl1" xlink:title="label: WarrantsAbstract to adma_WarrantsAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_WarrantsAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_WarrantsAbstract_lbl2" xml:lang="en-US" id="adma_WarrantsAbstract_lbl2">Warrants [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAbstract" xlink:to="adma_WarrantsAbstract_lbl2" xlink:title="label: WarrantsAbstract to adma_WarrantsAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_IndirectOwnershipMember" xlink:label="IndirectOwnershipMember" xlink:title="IndirectOwnershipMember" />
    <link:label xlink:type="resource" xlink:label="adma_IndirectOwnershipMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_IndirectOwnershipMember_lbl" xml:lang="en-US" id="adma_IndirectOwnershipMember_lbl">Indirect Ownership means an interest in an entity that has direct or indirect ownership interest in the Applicant. The amount of indirect ownership in the Applicant that is held by any other entity is determined by multiplying the percentage of ownership interest at each level.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IndirectOwnershipMember" xlink:to="adma_IndirectOwnershipMember_lbl" xlink:title="label: IndirectOwnershipMember to adma_IndirectOwnershipMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_IndirectOwnershipMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_IndirectOwnershipMember_lbl1" xml:lang="en-US" id="adma_IndirectOwnershipMember_lbl1">Indirect Ownership [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IndirectOwnershipMember" xlink:to="adma_IndirectOwnershipMember_lbl1" xlink:title="label: IndirectOwnershipMember to adma_IndirectOwnershipMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_IndirectOwnershipMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_IndirectOwnershipMember_lbl2" xml:lang="en-US" id="adma_IndirectOwnershipMember_lbl2">Indirect [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IndirectOwnershipMember" xlink:to="adma_IndirectOwnershipMember_lbl2" xlink:title="label: IndirectOwnershipMember to adma_IndirectOwnershipMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_DirectOwnershipMember" xlink:label="DirectOwnershipMember" xlink:title="DirectOwnershipMember" />
    <link:label xlink:type="resource" xlink:label="adma_DirectOwnershipMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_DirectOwnershipMember_lbl" xml:lang="en-US" id="adma_DirectOwnershipMember_lbl">Direct owner refers to individuals and entities who directly own shares or are partners in any legal entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DirectOwnershipMember" xlink:to="adma_DirectOwnershipMember_lbl" xlink:title="label: DirectOwnershipMember to adma_DirectOwnershipMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_DirectOwnershipMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_DirectOwnershipMember_lbl1" xml:lang="en-US" id="adma_DirectOwnershipMember_lbl1">Direct Ownership [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DirectOwnershipMember" xlink:to="adma_DirectOwnershipMember_lbl1" xlink:title="label: DirectOwnershipMember to adma_DirectOwnershipMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_DirectOwnershipMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_DirectOwnershipMember_lbl2" xml:lang="en-US" id="adma_DirectOwnershipMember_lbl2">Direct [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DirectOwnershipMember" xlink:to="adma_DirectOwnershipMember_lbl2" xlink:title="label: DirectOwnershipMember to adma_DirectOwnershipMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ChiefScientificOfficerAndChiefMedicalOfficerMember" xlink:label="ChiefScientificOfficerAndChiefMedicalOfficerMember" xlink:title="ChiefScientificOfficerAndChiefMedicalOfficerMember" />
    <link:label xlink:type="resource" xlink:label="adma_ChiefScientificOfficerAndChiefMedicalOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ChiefScientificOfficerAndChiefMedicalOfficerMember_lbl" xml:lang="en-US" id="adma_ChiefScientificOfficerAndChiefMedicalOfficerMember_lbl">Person with designation of chief scientific officer and chief medical officer.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChiefScientificOfficerAndChiefMedicalOfficerMember" xlink:to="adma_ChiefScientificOfficerAndChiefMedicalOfficerMember_lbl" xlink:title="label: ChiefScientificOfficerAndChiefMedicalOfficerMember to adma_ChiefScientificOfficerAndChiefMedicalOfficerMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ChiefScientificOfficerAndChiefMedicalOfficerMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ChiefScientificOfficerAndChiefMedicalOfficerMember_lbl1" xml:lang="en-US" id="adma_ChiefScientificOfficerAndChiefMedicalOfficerMember_lbl1">Chief Scientific Officer and Chief Medical Officer [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChiefScientificOfficerAndChiefMedicalOfficerMember" xlink:to="adma_ChiefScientificOfficerAndChiefMedicalOfficerMember_lbl1" xlink:title="label: ChiefScientificOfficerAndChiefMedicalOfficerMember to adma_ChiefScientificOfficerAndChiefMedicalOfficerMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ChiefScientificOfficerAndChiefMedicalOfficerMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ChiefScientificOfficerAndChiefMedicalOfficerMember_lbl2" xml:lang="en-US" id="adma_ChiefScientificOfficerAndChiefMedicalOfficerMember_lbl2">Dr. James Mond [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChiefScientificOfficerAndChiefMedicalOfficerMember" xlink:to="adma_ChiefScientificOfficerAndChiefMedicalOfficerMember_lbl2" xlink:title="label: ChiefScientificOfficerAndChiefMedicalOfficerMember to adma_ChiefScientificOfficerAndChiefMedicalOfficerMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ViceChairmanMember" xlink:label="ViceChairmanMember" xlink:title="ViceChairmanMember" />
    <link:label xlink:type="resource" xlink:label="adma_ViceChairmanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ViceChairmanMember_lbl" xml:lang="en-US" id="adma_ViceChairmanMember_lbl">Person who acts for and assists a chairman.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ViceChairmanMember" xlink:to="adma_ViceChairmanMember_lbl" xlink:title="label: ViceChairmanMember to adma_ViceChairmanMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ViceChairmanMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ViceChairmanMember_lbl1" xml:lang="en-US" id="adma_ViceChairmanMember_lbl1">Vice Chairman [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ViceChairmanMember" xlink:to="adma_ViceChairmanMember_lbl1" xlink:title="label: ViceChairmanMember to adma_ViceChairmanMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ViceChairmanMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ViceChairmanMember_lbl2" xml:lang="en-US" id="adma_ViceChairmanMember_lbl2">Dr. Grossman [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ViceChairmanMember" xlink:to="adma_ViceChairmanMember_lbl2" xlink:title="label: ViceChairmanMember to adma_ViceChairmanMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PresidentAndChiefExecutiveOfficerMember" xlink:label="PresidentAndChiefExecutiveOfficerMember" xlink:title="PresidentAndChiefExecutiveOfficerMember" />
    <link:label xlink:type="resource" xlink:label="adma_PresidentAndChiefExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PresidentAndChiefExecutiveOfficerMember_lbl" xml:lang="en-US" id="adma_PresidentAndChiefExecutiveOfficerMember_lbl">Person with designation of president and chief executive officer.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PresidentAndChiefExecutiveOfficerMember" xlink:to="adma_PresidentAndChiefExecutiveOfficerMember_lbl" xlink:title="label: PresidentAndChiefExecutiveOfficerMember to adma_PresidentAndChiefExecutiveOfficerMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PresidentAndChiefExecutiveOfficerMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PresidentAndChiefExecutiveOfficerMember_lbl1" xml:lang="en-US" id="adma_PresidentAndChiefExecutiveOfficerMember_lbl1">President and Chief Executive Officer [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PresidentAndChiefExecutiveOfficerMember" xlink:to="adma_PresidentAndChiefExecutiveOfficerMember_lbl1" xlink:title="label: PresidentAndChiefExecutiveOfficerMember to adma_PresidentAndChiefExecutiveOfficerMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PresidentAndChiefExecutiveOfficerMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PresidentAndChiefExecutiveOfficerMember_lbl2" xml:lang="en-US" id="adma_PresidentAndChiefExecutiveOfficerMember_lbl2">Mr. Grossman [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PresidentAndChiefExecutiveOfficerMember" xlink:to="adma_PresidentAndChiefExecutiveOfficerMember_lbl2" xlink:title="label: PresidentAndChiefExecutiveOfficerMember to adma_PresidentAndChiefExecutiveOfficerMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember" xlink:label="ExecutiveVicePresidentAndChiefFinancialOfficerMember" xlink:title="ExecutiveVicePresidentAndChiefFinancialOfficerMember" />
    <link:label xlink:type="resource" xlink:label="adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember_lbl" xml:lang="en-US" id="adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember_lbl">Person with designation of executive vice president and chief financial officer.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExecutiveVicePresidentAndChiefFinancialOfficerMember" xlink:to="adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember_lbl" xlink:title="label: ExecutiveVicePresidentAndChiefFinancialOfficerMember to adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember_lbl1" xml:lang="en-US" id="adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember_lbl1">Executive Vice President and Chief Financial Officer [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExecutiveVicePresidentAndChiefFinancialOfficerMember" xlink:to="adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember_lbl1" xlink:title="label: ExecutiveVicePresidentAndChiefFinancialOfficerMember to adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember_lbl2" xml:lang="en-US" id="adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember_lbl2">Brian Lenz [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExecutiveVicePresidentAndChiefFinancialOfficerMember" xlink:to="adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember_lbl2" xlink:title="label: ExecutiveVicePresidentAndChiefFinancialOfficerMember to adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PerceptiveCreditHoldingsIILPMember" xlink:label="PerceptiveCreditHoldingsIILPMember" xlink:title="PerceptiveCreditHoldingsIILPMember" />
    <link:label xlink:type="resource" xlink:label="adma_PerceptiveCreditHoldingsIILPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PerceptiveCreditHoldingsIILPMember_lbl" xml:lang="en-US" id="adma_PerceptiveCreditHoldingsIILPMember_lbl">Name of the Lender in credit facility agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PerceptiveCreditHoldingsIILPMember" xlink:to="adma_PerceptiveCreditHoldingsIILPMember_lbl" xlink:title="label: PerceptiveCreditHoldingsIILPMember to adma_PerceptiveCreditHoldingsIILPMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PerceptiveCreditHoldingsIILPMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PerceptiveCreditHoldingsIILPMember_lbl1" xml:lang="en-US" id="adma_PerceptiveCreditHoldingsIILPMember_lbl1">Perceptive Credit Holdings II, LP [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PerceptiveCreditHoldingsIILPMember" xlink:to="adma_PerceptiveCreditHoldingsIILPMember_lbl1" xlink:title="label: PerceptiveCreditHoldingsIILPMember to adma_PerceptiveCreditHoldingsIILPMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PerceptiveCreditHoldingsIILPMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PerceptiveCreditHoldingsIILPMember_lbl2" xml:lang="en-US" id="adma_PerceptiveCreditHoldingsIILPMember_lbl2">Perceptive [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PerceptiveCreditHoldingsIILPMember" xlink:to="adma_PerceptiveCreditHoldingsIILPMember_lbl2" xlink:title="label: PerceptiveCreditHoldingsIILPMember to adma_PerceptiveCreditHoldingsIILPMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement" xlink:label="PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement" xlink:title="PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement" />
    <link:label xlink:type="resource" xlink:label="adma_PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement_lbl" xml:lang="en-US" id="adma_PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement_lbl">Period of scheduled installments for separation and transition agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement" xlink:to="adma_PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement_lbl" xlink:title="label: PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement to adma_PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement_lbl1" xml:lang="en-US" id="adma_PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement_lbl1">Period of Scheduled Installments for Separation and Transition Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement" xlink:to="adma_PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement_lbl1" xlink:title="label: PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement to adma_PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement_lbl2" xml:lang="en-US" id="adma_PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement_lbl2">Period of scheduled installments for separation and transition agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement" xlink:to="adma_PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement_lbl2" xlink:title="label: PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement to adma_PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_MinimumPercentageOfCommonStockHeldByLender" xlink:label="MinimumPercentageOfCommonStockHeldByLender" xlink:title="MinimumPercentageOfCommonStockHeldByLender" />
    <link:label xlink:type="resource" xlink:label="adma_MinimumPercentageOfCommonStockHeldByLender_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_MinimumPercentageOfCommonStockHeldByLender_lbl" xml:lang="en-US" id="adma_MinimumPercentageOfCommonStockHeldByLender_lbl">Minimum percentage of common stock held by lender and administrative agent of credit facility.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumPercentageOfCommonStockHeldByLender" xlink:to="adma_MinimumPercentageOfCommonStockHeldByLender_lbl" xlink:title="label: MinimumPercentageOfCommonStockHeldByLender to adma_MinimumPercentageOfCommonStockHeldByLender_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_MinimumPercentageOfCommonStockHeldByLender_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_MinimumPercentageOfCommonStockHeldByLender_lbl1" xml:lang="en-US" id="adma_MinimumPercentageOfCommonStockHeldByLender_lbl1">Minimum Percentage of Common Stock held by Lender</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumPercentageOfCommonStockHeldByLender" xlink:to="adma_MinimumPercentageOfCommonStockHeldByLender_lbl1" xlink:title="label: MinimumPercentageOfCommonStockHeldByLender to adma_MinimumPercentageOfCommonStockHeldByLender_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_MinimumPercentageOfCommonStockHeldByLender_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_MinimumPercentageOfCommonStockHeldByLender_lbl2" xml:lang="en-US" id="adma_MinimumPercentageOfCommonStockHeldByLender_lbl2">Minimum percentage of common stock held by lender</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumPercentageOfCommonStockHeldByLender" xlink:to="adma_MinimumPercentageOfCommonStockHeldByLender_lbl2" xlink:title="label: MinimumPercentageOfCommonStockHeldByLender to adma_MinimumPercentageOfCommonStockHeldByLender_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_EstimatedPaymentForSeparationAndTransitionAgreement" xlink:label="EstimatedPaymentForSeparationAndTransitionAgreement" xlink:title="EstimatedPaymentForSeparationAndTransitionAgreement" />
    <link:label xlink:type="resource" xlink:label="adma_EstimatedPaymentForSeparationAndTransitionAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_EstimatedPaymentForSeparationAndTransitionAgreement_lbl" xml:lang="en-US" id="adma_EstimatedPaymentForSeparationAndTransitionAgreement_lbl">Amount of estimated lability of payment for separation and transition agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EstimatedPaymentForSeparationAndTransitionAgreement" xlink:to="adma_EstimatedPaymentForSeparationAndTransitionAgreement_lbl" xlink:title="label: EstimatedPaymentForSeparationAndTransitionAgreement to adma_EstimatedPaymentForSeparationAndTransitionAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_EstimatedPaymentForSeparationAndTransitionAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_EstimatedPaymentForSeparationAndTransitionAgreement_lbl1" xml:lang="en-US" id="adma_EstimatedPaymentForSeparationAndTransitionAgreement_lbl1">Estimated Payment for Separation and Transition Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EstimatedPaymentForSeparationAndTransitionAgreement" xlink:to="adma_EstimatedPaymentForSeparationAndTransitionAgreement_lbl1" xlink:title="label: EstimatedPaymentForSeparationAndTransitionAgreement to adma_EstimatedPaymentForSeparationAndTransitionAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_EstimatedPaymentForSeparationAndTransitionAgreement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_EstimatedPaymentForSeparationAndTransitionAgreement_lbl2" xml:lang="en-US" id="adma_EstimatedPaymentForSeparationAndTransitionAgreement_lbl2">Estimated payment for separation and transition agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EstimatedPaymentForSeparationAndTransitionAgreement" xlink:to="adma_EstimatedPaymentForSeparationAndTransitionAgreement_lbl2" xlink:title="label: EstimatedPaymentForSeparationAndTransitionAgreement to adma_EstimatedPaymentForSeparationAndTransitionAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ArethLLCMember" xlink:label="ArethLLCMember" xlink:title="ArethLLCMember" />
    <link:label xlink:type="resource" xlink:label="adma_ArethLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ArethLLCMember_lbl" xml:lang="en-US" id="adma_ArethLLCMember_lbl">Name of the entity associated with related party.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ArethLLCMember" xlink:to="adma_ArethLLCMember_lbl" xlink:title="label: ArethLLCMember to adma_ArethLLCMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ArethLLCMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ArethLLCMember_lbl1" xml:lang="en-US" id="adma_ArethLLCMember_lbl1">Areth, LLC [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ArethLLCMember" xlink:to="adma_ArethLLCMember_lbl1" xlink:title="label: ArethLLCMember to adma_ArethLLCMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_GenesisBPSMember" xlink:label="GenesisBPSMember" xlink:title="GenesisBPSMember" />
    <link:label xlink:type="resource" xlink:label="adma_GenesisBPSMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_GenesisBPSMember_lbl" xml:lang="en-US" id="adma_GenesisBPSMember_lbl">Name of the entity associated with related party.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GenesisBPSMember" xlink:to="adma_GenesisBPSMember_lbl" xlink:title="label: GenesisBPSMember to adma_GenesisBPSMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_GenesisBPSMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_GenesisBPSMember_lbl1" xml:lang="en-US" id="adma_GenesisBPSMember_lbl1">GenesisBPS [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GenesisBPSMember" xlink:to="adma_GenesisBPSMember_lbl1" xlink:title="label: GenesisBPSMember to adma_GenesisBPSMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_GenesisBPSMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_GenesisBPSMember_lbl2" xml:lang="en-US" id="adma_GenesisBPSMember_lbl2">Genesis [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GenesisBPSMember" xlink:to="adma_GenesisBPSMember_lbl2" xlink:title="label: GenesisBPSMember to adma_GenesisBPSMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_GrossProceedsFromIssuanceOfCommonStock" xlink:label="GrossProceedsFromIssuanceOfCommonStock" xlink:title="GrossProceedsFromIssuanceOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="adma_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_GrossProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="adma_GrossProceedsFromIssuanceOfCommonStock_lbl">The amount of gross proceeds from issuance of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrossProceedsFromIssuanceOfCommonStock" xlink:to="adma_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:title="label: GrossProceedsFromIssuanceOfCommonStock to adma_GrossProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_GrossProceedsFromIssuanceOfCommonStock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_GrossProceedsFromIssuanceOfCommonStock_lbl1" xml:lang="en-US" id="adma_GrossProceedsFromIssuanceOfCommonStock_lbl1">Gross Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrossProceedsFromIssuanceOfCommonStock" xlink:to="adma_GrossProceedsFromIssuanceOfCommonStock_lbl1" xlink:title="label: GrossProceedsFromIssuanceOfCommonStock to adma_GrossProceedsFromIssuanceOfCommonStock_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_GrossProceedsFromIssuanceOfCommonStock_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="adma_GrossProceedsFromIssuanceOfCommonStock_lbl2" xml:lang="en-US" id="adma_GrossProceedsFromIssuanceOfCommonStock_lbl2">Gross proceeds from issuance of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrossProceedsFromIssuanceOfCommonStock" xlink:to="adma_GrossProceedsFromIssuanceOfCommonStock_lbl2" xlink:title="label: GrossProceedsFromIssuanceOfCommonStock to adma_GrossProceedsFromIssuanceOfCommonStock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_SaleAgreementMember" xlink:label="SaleAgreementMember" xlink:title="SaleAgreementMember" />
    <link:label xlink:type="resource" xlink:label="adma_SaleAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_SaleAgreementMember_lbl" xml:lang="en-US" id="adma_SaleAgreementMember_lbl">An agreement of sale constitutes the terms and conditions of sale of a property by the seller to the buyer.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleAgreementMember" xlink:to="adma_SaleAgreementMember_lbl" xlink:title="label: SaleAgreementMember to adma_SaleAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_SaleAgreementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_SaleAgreementMember_lbl1" xml:lang="en-US" id="adma_SaleAgreementMember_lbl1">Sale Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleAgreementMember" xlink:to="adma_SaleAgreementMember_lbl1" xlink:title="label: SaleAgreementMember to adma_SaleAgreementMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_SaleAgreementMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="adma_SaleAgreementMember_lbl2" xml:lang="en-US" id="adma_SaleAgreementMember_lbl2">Sale Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleAgreementMember" xlink:to="adma_SaleAgreementMember_lbl2" xlink:title="label: SaleAgreementMember to adma_SaleAgreementMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_SaleAgreement2020AmendedMember" xlink:label="SaleAgreement2020AmendedMember" xlink:title="SaleAgreement2020AmendedMember" />
    <link:label xlink:type="resource" xlink:label="adma_SaleAgreement2020AmendedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_SaleAgreement2020AmendedMember_lbl" xml:lang="en-US" id="adma_SaleAgreement2020AmendedMember_lbl">An agreement of sale constitutes the terms and conditions of sale of a property by the seller to the buyer, as amended during the previous fiscal period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleAgreement2020AmendedMember" xlink:to="adma_SaleAgreement2020AmendedMember_lbl" xlink:title="label: SaleAgreement2020AmendedMember to adma_SaleAgreement2020AmendedMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_SaleAgreement2020AmendedMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_SaleAgreement2020AmendedMember_lbl1" xml:lang="en-US" id="adma_SaleAgreement2020AmendedMember_lbl1">Sale Agreement 2020, Amended [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleAgreement2020AmendedMember" xlink:to="adma_SaleAgreement2020AmendedMember_lbl1" xlink:title="label: SaleAgreement2020AmendedMember to adma_SaleAgreement2020AmendedMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_SaleAgreement2020AmendedMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_SaleAgreement2020AmendedMember_lbl2" xml:lang="en-US" id="adma_SaleAgreement2020AmendedMember_lbl2">2020 Sale Agreement, As Amended [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleAgreement2020AmendedMember" xlink:to="adma_SaleAgreement2020AmendedMember_lbl2" xlink:title="label: SaleAgreement2020AmendedMember to adma_SaleAgreement2020AmendedMember_lbl2" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>adma-20210630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 8.0.0.0 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://admabiologics.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#SubsequentEventsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#SupplementalDisclosureOfCashFlowInformationDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsDetailsCalc2" xlink:type="simple" xlink:href="adma-20210630.xsd#LeaseObligationsDetailsCalc2" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#LeaseObligationsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SegmentsDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#SegmentsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/CommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#CommitmentsAndContingenciesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#RelatedPartyTransactionsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#StockholdersEquityEquityIncentivePlansDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityWarrantsDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#StockholdersEquityWarrantsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityCommonStockDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#StockholdersEquityCommonStockDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityPreferredStockDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#StockholdersEquityPreferredStockDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/DebtDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#DebtDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/PropertyAndEquipmentDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#PropertyAndEquipmentDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#IntangibleAssetsFutureAggregateAmortizationExpenseDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssetsDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#IntangibleAssetsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/InventoriesDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#InventoriesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesLossPerCommonShareDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#SummaryOfSignificantAccountingPoliciesLossPerCommonShareDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#SummaryOfSignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#SummaryOfSignificantAccountingPoliciesGoodwillDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/OrganizationAndBusinessDetails" xlink:type="simple" xlink:href="adma-20210630.xsd#OrganizationAndBusinessDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables" xlink:type="simple" xlink:href="adma-20210630.xsd#SupplementalDisclosureOfCashFlowInformationTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsTables" xlink:type="simple" xlink:href="adma-20210630.xsd#LeaseObligationsTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/SegmentsTables" xlink:type="simple" xlink:href="adma-20210630.xsd#SegmentsTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="adma-20210630.xsd#StockholdersEquityTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/DebtTables" xlink:type="simple" xlink:href="adma-20210630.xsd#DebtTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="adma-20210630.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/PropertyAndEquipmentTables" xlink:type="simple" xlink:href="adma-20210630.xsd#PropertyAndEquipmentTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssetsTables" xlink:type="simple" xlink:href="adma-20210630.xsd#IntangibleAssetsTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/InventoriesTables" xlink:type="simple" xlink:href="adma-20210630.xsd#InventoriesTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="adma-20210630.xsd#SummaryOfSignificantAccountingPoliciesTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="adma-20210630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" />
  <link:roleRef roleURI="http://admabiologics.com/role/SubsequentEvents" xlink:type="simple" xlink:href="adma-20210630.xsd#SubsequentEvents" />
  <link:roleRef roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation" xlink:type="simple" xlink:href="adma-20210630.xsd#SupplementalDisclosureOfCashFlowInformation" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligations" xlink:type="simple" xlink:href="adma-20210630.xsd#LeaseObligations" />
  <link:roleRef roleURI="http://admabiologics.com/role/Segments" xlink:type="simple" xlink:href="adma-20210630.xsd#Segments" />
  <link:roleRef roleURI="http://admabiologics.com/role/CommitmentAndContingencies" xlink:type="simple" xlink:href="adma-20210630.xsd#CommitmentAndContingencies" />
  <link:roleRef roleURI="http://admabiologics.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="adma-20210630.xsd#RelatedPartyTransactions" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="adma-20210630.xsd#StockholdersEquity" />
  <link:roleRef roleURI="http://admabiologics.com/role/Debt" xlink:type="simple" xlink:href="adma-20210630.xsd#Debt" />
  <link:roleRef roleURI="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" xlink:href="adma-20210630.xsd#AccruedExpensesAndOtherCurrentLiabilities" />
  <link:roleRef roleURI="http://admabiologics.com/role/PropertyAndEquipment" xlink:type="simple" xlink:href="adma-20210630.xsd#PropertyAndEquipment" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssets" xlink:type="simple" xlink:href="adma-20210630.xsd#IntangibleAssets" />
  <link:roleRef roleURI="http://admabiologics.com/role/Inventories" xlink:type="simple" xlink:href="adma-20210630.xsd#Inventories" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="adma-20210630.xsd#SummaryOfSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://admabiologics.com/role/OrganizationAndBusiness" xlink:type="simple" xlink:href="adma-20210630.xsd#OrganizationAndBusiness" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="adma-20210630.xsd#CondensedConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" xlink:href="adma-20210630.xsd#CondensedConsolidatedStatementsOfChangesInStockholdersEquity" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="simple" xlink:href="adma-20210630.xsd#CondensedConsolidatedStatementsOfOperations" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="adma-20210630.xsd#CondensedConsolidatedBalanceSheetsParenthetical" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="adma-20210630.xsd#CondensedConsolidatedBalanceSheets" />
  <link:roleRef roleURI="http://admabiologics.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="adma-20210630.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityListingsTable" xlink:label="EntityListingsTable" xlink:title="EntityListingsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="CommonStockMember" xlink:title="presentation: ClassOfStockDomain to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PreferredSharePurchaseRightMember" xlink:label="PreferredSharePurchaseRightMember" xlink:title="PreferredSharePurchaseRightMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="PreferredSharePurchaseRightMember" xlink:title="presentation: ClassOfStockDomain to PreferredSharePurchaseRightMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: EntityListingsTable to StatementClassOfStockAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityListingsLineItems" xlink:label="EntityListingsLineItems" xlink:title="EntityListingsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="DocumentType" xlink:title="presentation: EntityListingsLineItems to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="AmendmentFlag" xlink:title="presentation: EntityListingsLineItems to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="DocumentQuarterlyReport" xlink:title="DocumentQuarterlyReport" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="DocumentQuarterlyReport" xlink:title="presentation: EntityListingsLineItems to DocumentQuarterlyReport" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: EntityListingsLineItems to DocumentPeriodEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="CurrentFiscalYearEndDate" xlink:title="presentation: EntityListingsLineItems to CurrentFiscalYearEndDate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: EntityListingsLineItems to DocumentFiscalYearFocus" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: EntityListingsLineItems to DocumentFiscalPeriodFocus" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="DocumentTransitionReport" xlink:title="DocumentTransitionReport" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="DocumentTransitionReport" xlink:title="presentation: EntityListingsLineItems to DocumentTransitionReport" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityFileNumber" xlink:title="presentation: EntityListingsLineItems to EntityFileNumber" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityRegistrantName" xlink:title="presentation: EntityListingsLineItems to EntityRegistrantName" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityCentralIndexKey" xlink:title="presentation: EntityListingsLineItems to EntityCentralIndexKey" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: EntityListingsLineItems to EntityIncorporationStateCountryCode" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: EntityListingsLineItems to EntityTaxIdentificationNumber" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: EntityListingsLineItems to EntityAddressAddressLine1" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: EntityListingsLineItems to EntityAddressCityOrTown" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: EntityListingsLineItems to EntityAddressStateOrProvince" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: EntityListingsLineItems to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="CityAreaCode" xlink:title="presentation: EntityListingsLineItems to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="LocalPhoneNumber" xlink:title="presentation: EntityListingsLineItems to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="Security12bTitle" xlink:title="presentation: EntityListingsLineItems to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="TradingSymbol" xlink:title="presentation: EntityListingsLineItems to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: EntityListingsLineItems to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="SecurityExchangeName" xlink:title="presentation: EntityListingsLineItems to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityCurrentReportingStatus" xlink:title="presentation: EntityListingsLineItems to EntityCurrentReportingStatus" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="EntityInteractiveDataCurrent" xlink:title="EntityInteractiveDataCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityInteractiveDataCurrent" xlink:title="presentation: EntityListingsLineItems to EntityInteractiveDataCurrent" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityFilerCategory" xlink:title="presentation: EntityListingsLineItems to EntityFilerCategory" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="EntitySmallBusiness" xlink:title="EntitySmallBusiness" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntitySmallBusiness" xlink:title="presentation: EntityListingsLineItems to EntitySmallBusiness" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: EntityListingsLineItems to EntityEmergingGrowthCompany" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="EntityShellCompany" xlink:title="EntityShellCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityShellCompany" xlink:title="presentation: EntityListingsLineItems to EntityShellCompany" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityCommonStockSharesOutstanding" xlink:title="presentation: EntityListingsLineItems to EntityCommonStockSharesOutstanding" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsTable" xlink:to="EntityListingsLineItems" xlink:title="presentation: EntityListingsTable to EntityListingsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityListingsTable" xlink:title="presentation: CoverAbstract to EntityListingsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: AssetsCurrentAbstract to CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="AccountsReceivableNetCurrent" xlink:title="AccountsReceivableNetCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="AccountsReceivableNetCurrent" xlink:title="presentation: AssetsCurrentAbstract to AccountsReceivableNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="InventoryNet" xlink:title="presentation: AssetsCurrentAbstract to InventoryNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to PrepaidExpenseAndOtherAssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="AssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to AssetsCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: AssetsCurrentAbstract to PropertyPlantAndEquipmentNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="IntangibleAssetsNetExcludingGoodwill" xlink:title="IntangibleAssetsNetExcludingGoodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="IntangibleAssetsNetExcludingGoodwill" xlink:title="presentation: AssetsCurrentAbstract to IntangibleAssetsNetExcludingGoodwill" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="Goodwill" xlink:title="presentation: AssetsCurrentAbstract to Goodwill" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="OperatingLeaseRightOfUseAsset" xlink:title="presentation: AssetsCurrentAbstract to OperatingLeaseRightOfUseAsset" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_DepositsAndOtherNoncurrentAssets" xlink:label="DepositsAndOtherNoncurrentAssets" xlink:title="DepositsAndOtherNoncurrentAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="DepositsAndOtherNoncurrentAssets" xlink:title="presentation: AssetsCurrentAbstract to DepositsAndOtherNoncurrentAssets" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="Assets" xlink:title="presentation: AssetsCurrentAbstract to Assets" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="AssetsCurrentAbstract" xlink:title="presentation: AssetsAbstract to AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="AssetsAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccountsPayableCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="AccruedLiabilitiesAndOtherLiabilities" xlink:title="AccruedLiabilitiesAndOtherLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccruedLiabilitiesAndOtherLiabilities" xlink:title="presentation: LiabilitiesCurrentAbstract to AccruedLiabilitiesAndOtherLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="ContractWithCustomerLiabilityCurrent" xlink:title="ContractWithCustomerLiabilityCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="ContractWithCustomerLiabilityCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to ContractWithCustomerLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to OperatingLeaseLiabilityCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to LiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesCurrentAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorLongTermNotes" xlink:label="SeniorLongTermNotes" xlink:title="SeniorLongTermNotes" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="SeniorLongTermNotes" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to SeniorLongTermNotes" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="DeferredRevenueNoncurrent" xlink:title="DeferredRevenueNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="DeferredRevenueNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to DeferredRevenueNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="OperatingLeaseLiabilityNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to OperatingLeaseLiabilityNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="OtherLiabilitiesNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to OtherLiabilitiesNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="Liabilities" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to Liabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="CommitmentsAndContingencies" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to CommitmentsAndContingencies" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockValue" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockValue" xlink:title="presentation: StockholdersEquityAbstract to CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="AdditionalPaidInCapital" xlink:title="presentation: StockholdersEquityAbstract to AdditionalPaidInCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="presentation: StockholdersEquityAbstract to RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="StockholdersEquity" xlink:title="presentation: StockholdersEquityAbstract to StockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to StockholdersEquityAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesAndStockholdersEquity" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesAndStockholdersEquity" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to LiabilitiesAndStockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockParOrStatedValuePerShare" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockSharesAuthorized" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockSharesIssued" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockSharesOutstanding" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="presentation: StockholdersEquityAbstract to CommonStockParOrStatedValuePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesAuthorized" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesIssued" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesOutstanding" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to StockholdersEquityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="ProductMember" xlink:title="ProductMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="ProductMember" xlink:title="presentation: ProductsAndServicesDomain to ProductMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="LicenseAndServiceMember" xlink:title="LicenseAndServiceMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="LicenseAndServiceMember" xlink:title="presentation: ProductsAndServicesDomain to LicenseAndServiceMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="presentation: ProductOrServiceAxis to ProductsAndServicesDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="ProductOrServiceAxis" xlink:title="presentation: StatementTable to ProductOrServiceAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="RevenuesAbstract" xlink:title="RevenuesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesAbstract" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="presentation: RevenuesAbstract to RevenueFromContractWithCustomerExcludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="RevenuesAbstract" xlink:title="presentation: StatementLineItems to RevenuesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="CostsAndExpensesAbstract" xlink:title="CostsAndExpensesAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_CostOfProductRevenueExcludingAmortizationExpense" xlink:label="CostOfProductRevenueExcludingAmortizationExpense" xlink:title="CostOfProductRevenueExcludingAmortizationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="CostOfProductRevenueExcludingAmortizationExpense" xlink:title="presentation: CostsAndExpensesAbstract to CostOfProductRevenueExcludingAmortizationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="ResearchAndDevelopmentExpense" xlink:title="presentation: CostsAndExpensesAbstract to ResearchAndDevelopmentExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="OtherCostAndExpenseOperating" xlink:title="OtherCostAndExpenseOperating" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="OtherCostAndExpenseOperating" xlink:title="presentation: CostsAndExpensesAbstract to OtherCostAndExpenseOperating" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="AmortizationOfIntangibleAssets" xlink:title="presentation: CostsAndExpensesAbstract to AmortizationOfIntangibleAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="SellingGeneralAndAdministrativeExpense" xlink:title="SellingGeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="SellingGeneralAndAdministrativeExpense" xlink:title="presentation: CostsAndExpensesAbstract to SellingGeneralAndAdministrativeExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="OperatingExpenses" xlink:title="presentation: CostsAndExpensesAbstract to OperatingExpenses" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="CostsAndExpensesAbstract" xlink:title="presentation: StatementLineItems to CostsAndExpensesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="OperatingIncomeLoss" xlink:title="presentation: StatementLineItems to OperatingIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="NonoperatingIncomeExpenseAbstract" xlink:title="NonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="InvestmentIncomeInterest" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to InvestmentIncomeInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="InterestExpense" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to InterestExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="OtherNonoperatingExpense" xlink:title="OtherNonoperatingExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="OtherNonoperatingExpense" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to OtherNonoperatingExpense" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="NonoperatingIncomeExpense" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to NonoperatingIncomeExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="NonoperatingIncomeExpenseAbstract" xlink:title="presentation: StatementLineItems to NonoperatingIncomeExpenseAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="NetIncomeLoss" xlink:title="presentation: StatementLineItems to NetIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="EarningsPerShareBasic" xlink:title="presentation: StatementLineItems to EarningsPerShareBasic" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="EarningsPerShareDiluted" xlink:title="presentation: StatementLineItems to EarningsPerShareDiluted" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:title="WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="presentation: WeightedAverageNumberOfSharesOutstandingAbstract to WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="presentation: WeightedAverageNumberOfSharesOutstandingAbstract to WeightedAverageNumberOfDilutedSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:title="presentation: StatementLineItems to WeightedAverageNumberOfSharesOutstandingAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="StatementTable" xlink:title="presentation: IncomeStatementAbstract to StatementTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="CommonStockMember" xlink:title="presentation: StatementEquityComponentsAxis to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="AdditionalPaidInCapitalMember" xlink:title="presentation: StatementEquityComponentsAxis to AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="RetainedEarningsMember" xlink:title="presentation: StatementEquityComponentsAxis to RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: StatementTable to StatementEquityComponentsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquity" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="SharesOutstanding" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" xlink:label="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" xlink:title="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares" xlink:label="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares" xlink:title="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueNewIssues" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesNewIssues" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueStockOptionsExercised" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesStockOptionsExercised" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="NetIncomeLoss" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to NetIncomeLoss" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity_2" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquity_2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquity" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding_2" xlink:title="SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="SharesOutstanding_2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to SharesOutstanding" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="presentation: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfStockholdersEquityAbstract to StatementTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="DepreciationAndAmortization" xlink:title="DepreciationAndAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="DepreciationAndAmortization" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to DepreciationAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="GainLossOnDispositionOfAssets" xlink:title="GainLossOnDispositionOfAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GainLossOnDispositionOfAssets" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to GainLossOnDispositionOfAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ShareBasedCompensation" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ShareBasedCompensation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfDebtDiscountPremium" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfDebtDiscountPremium" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_AmortizationOfLicenseRevenue" xlink:label="AmortizationOfLicenseRevenue" xlink:title="AmortizationOfLicenseRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfLicenseRevenue" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfLicenseRevenue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="IncreaseDecreaseInAccountsReceivable" xlink:title="IncreaseDecreaseInAccountsReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsReceivable" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="IncreaseDecreaseInInventories" xlink:title="IncreaseDecreaseInInventories" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInInventories" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInInventories" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="IncreaseDecreaseInDepositsAndOtherAssets" xlink:title="IncreaseDecreaseInDepositsAndOtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInDepositsAndOtherAssets" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInDepositsAndOtherAssets" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="IncreaseDecreaseInAccountsPayable" xlink:title="IncreaseDecreaseInAccountsPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsPayable" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsPayable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccruedLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccruedLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInOtherOperatingLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInOtherOperatingLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to NetCashProvidedByUsedInOperatingActivities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to ProceedsFromSaleOfPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivities" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to NetCashProvidedByUsedInInvestingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromIssuanceOfCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromStockOptionsExercised" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_TaxesPaidOnVestedRestrictedStockUnits" xlink:label="TaxesPaidOnVestedRestrictedStockUnits" xlink:title="TaxesPaidOnVestedRestrictedStockUnits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="TaxesPaidOnVestedRestrictedStockUnits" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to TaxesPaidOnVestedRestrictedStockUnits" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="ProceedsFromNotesPayable" xlink:title="ProceedsFromNotesPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromNotesPayable" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromNotesPayable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="FinanceLeasePrincipalPayments" xlink:title="FinanceLeasePrincipalPayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="FinanceLeasePrincipalPayments" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to FinanceLeasePrincipalPayments" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to NetCashProvidedByUsedInFinancingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/OrganizationAndBusiness">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPolicies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="SignificantAccountingPoliciesTextBlock" xlink:title="SignificantAccountingPoliciesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="SignificantAccountingPoliciesTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/Inventories">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="InventoryDisclosureAbstract" xlink:title="InventoryDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="InventoryDisclosureTextBlock" xlink:title="InventoryDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="InventoryDisclosureTextBlock" xlink:title="presentation: InventoryDisclosureAbstract to InventoryDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="IntangibleAssetsDisclosureTextBlock" xlink:title="IntangibleAssetsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="IntangibleAssetsDisclosureTextBlock" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to IntangibleAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/PropertyAndEquipment">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilities">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="presentation: PayablesAndAccrualsAbstract to AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/Debt">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="LongTermDebtTextBlock" xlink:title="LongTermDebtTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="LongTermDebtTextBlock" xlink:title="presentation: DebtDisclosureAbstract to LongTermDebtTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="StockholdersEquityNoteDisclosureTextBlock" xlink:title="presentation: EquityAbstract to StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/RelatedPartyTransactions">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" xlink:title="RelatedPartyTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="RelatedPartyTransactionsDisclosureTextBlock" xlink:title="RelatedPartyTransactionsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyTransactionsDisclosureTextBlock" xlink:title="presentation: RelatedPartyTransactionsAbstract to RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CommitmentAndContingencies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/Segments">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="SegmentReportingDisclosureTextBlock" xlink:title="SegmentReportingDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="SegmentReportingDisclosureTextBlock" xlink:title="presentation: SegmentReportingAbstract to SegmentReportingDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="LesseeOperatingLeasesTextBlock" xlink:title="LesseeOperatingLeasesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeOperatingLeasesTextBlock" xlink:title="presentation: LeasesAbstract to LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="SupplementalCashFlowElementsAbstract" xlink:title="SupplementalCashFlowElementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:label="CashFlowSupplementalDisclosuresTextBlock" xlink:title="CashFlowSupplementalDisclosuresTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowElementsAbstract" xlink:to="CashFlowSupplementalDisclosuresTextBlock" xlink:title="presentation: SupplementalCashFlowElementsAbstract to CashFlowSupplementalDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SubsequentEvents">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="SubsequentEventsTextBlock" xlink:title="SubsequentEventsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="SubsequentEventsTextBlock" xlink:title="presentation: SubsequentEventsAbstract to SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="BasisOfAccountingPolicyPolicyTextBlock" xlink:title="BasisOfAccountingPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="BasisOfAccountingPolicyPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to BasisOfAccountingPolicyPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="UseOfEstimates" xlink:title="presentation: AccountingPoliciesAbstract to UseOfEstimates" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="FairValueOfFinancialInstrumentsPolicy" xlink:title="FairValueOfFinancialInstrumentsPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="FairValueOfFinancialInstrumentsPolicy" xlink:title="presentation: AccountingPoliciesAbstract to FairValueOfFinancialInstrumentsPolicy" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="ReceivablesPolicyTextBlock" xlink:title="ReceivablesPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ReceivablesPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to ReceivablesPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="InventoryPolicyTextBlock" xlink:title="InventoryPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="InventoryPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to InventoryPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:title="GoodwillAndIntangibleAssetsGoodwillPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:title="presentation: AccountingPoliciesAbstract to GoodwillAndIntangibleAssetsGoodwillPolicy" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:title="ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="RevenueRecognitionPolicyTextBlock" xlink:title="RevenueRecognitionPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="RevenueRecognitionPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to RevenueRecognitionPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="CostOfSalesPolicyTextBlock" xlink:title="CostOfSalesPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="CostOfSalesPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to CostOfSalesPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="EarningsPerSharePolicyTextBlock" xlink:title="EarningsPerSharePolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="EarningsPerSharePolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to EarningsPerSharePolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="presentation: AccountingPoliciesAbstract to ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="IncomeTaxPolicyTextBlock" xlink:title="IncomeTaxPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="IncomeTaxPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to IncomeTaxPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to NewAccountingPronouncementsPolicyPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/InventoriesTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="InventoryDisclosureAbstract" xlink:title="InventoryDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="ScheduleOfInventoryCurrentTableTextBlock" xlink:title="ScheduleOfInventoryCurrentTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="ScheduleOfInventoryCurrentTableTextBlock" xlink:title="presentation: InventoryDisclosureAbstract to ScheduleOfInventoryCurrentTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssetsTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:label="ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:title="ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:title="ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/PropertyAndEquipmentTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="PropertyPlantAndEquipmentTextBlock" xlink:title="PropertyPlantAndEquipmentTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="PropertyPlantAndEquipmentTextBlock" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:title="ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:title="presentation: PayablesAndAccrualsAbstract to ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/DebtTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="ScheduleOfDebtTableTextBlock" xlink:title="ScheduleOfDebtTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="ScheduleOfDebtTableTextBlock" xlink:title="presentation: DebtDisclosureAbstract to ScheduleOfDebtTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="presentation: EquityAbstract to ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="presentation: EquityAbstract to ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:title="ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:title="presentation: EquityAbstract to ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:title="ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:title="presentation: EquityAbstract to ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SegmentsTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:title="ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:title="presentation: SegmentReportingAbstract to ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:title="RevenueFromExternalCustomersByGeographicAreasTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:title="presentation: SegmentReportingAbstract to RevenueFromExternalCustomersByGeographicAreasTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="presentation: LeasesAbstract to LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="SupplementalCashFlowElementsAbstract" xlink:title="SupplementalCashFlowElementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:title="ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowElementsAbstract" xlink:to="ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:title="presentation: SupplementalCashFlowElementsAbstract to ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/OrganizationAndBusinessDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:title="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_JefferiesLLCMember" xlink:label="JefferiesLLCMember" xlink:title="JefferiesLLCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedEntitiesDomain" xlink:to="JefferiesLLCMember" xlink:title="presentation: ConsolidatedEntitiesDomain to JefferiesLLCMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain" xlink:title="presentation: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="ConsolidatedEntitiesAxis" xlink:title="presentation: SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable to ConsolidatedEntitiesAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_SaleAgreement2020Member" xlink:label="SaleAgreement2020Member" xlink:title="SaleAgreement2020Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="SaleAgreement2020Member" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to SaleAgreement2020Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_SaleAgreement2021Member" xlink:label="SaleAgreement2021Member" xlink:title="SaleAgreement2021Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="SaleAgreement2021Member" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to SaleAgreement2021Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable to TypeOfArrangementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="RangeAxis" xlink:title="presentation: SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable to RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="presentation: SubsequentEventTypeDomain to SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="presentation: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="SubsequentEventTypeAxis" xlink:title="presentation: SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable to SubsequentEventTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="SubsidiarySaleOfStockLineItems" xlink:title="SubsidiarySaleOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:label="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:title="ProceedsFromIssuanceOrSaleOfEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:label="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:title="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:title="presentation: ProceedsFromIssuanceOrSaleOfEquityAbstract to NumberOfPlasmaCollectionFacilitiesUnderDevelopment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_NumberOfFDALicensedPlasmaCollectionFacilities" xlink:label="NumberOfFDALicensedPlasmaCollectionFacilities" xlink:title="NumberOfFDALicensedPlasmaCollectionFacilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="NumberOfFDALicensedPlasmaCollectionFacilities" xlink:title="presentation: ProceedsFromIssuanceOrSaleOfEquityAbstract to NumberOfFDALicensedPlasmaCollectionFacilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_NumberOfFDAApprovedProduct" xlink:label="NumberOfFDAApprovedProduct" xlink:title="NumberOfFDAApprovedProduct" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="NumberOfFDAApprovedProduct" xlink:title="presentation: ProceedsFromIssuanceOrSaleOfEquityAbstract to NumberOfFDAApprovedProduct" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_WorkingCapital" xlink:label="WorkingCapital" xlink:title="WorkingCapital" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="WorkingCapital" xlink:title="presentation: ProceedsFromIssuanceOrSaleOfEquityAbstract to WorkingCapital" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="CashEquivalentsAtCarryingValue" xlink:title="CashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="CashEquivalentsAtCarryingValue" xlink:title="presentation: ProceedsFromIssuanceOrSaleOfEquityAbstract to CashEquivalentsAtCarryingValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ProductCycleFromProcurementOfRawMaterialsToFinishedProduct" xlink:label="ProductCycleFromProcurementOfRawMaterialsToFinishedProduct" xlink:title="ProductCycleFromProcurementOfRawMaterialsToFinishedProduct" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="ProductCycleFromProcurementOfRawMaterialsToFinishedProduct" xlink:title="presentation: ProceedsFromIssuanceOrSaleOfEquityAbstract to ProductCycleFromProcurementOfRawMaterialsToFinishedProduct" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="presentation: ProceedsFromIssuanceOrSaleOfEquityAbstract to RetainedEarningsAccumulatedDeficit" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="ProceedsFromIssuanceOrSaleOfEquity" xlink:title="ProceedsFromIssuanceOrSaleOfEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="ProceedsFromIssuanceOrSaleOfEquity" xlink:title="presentation: ProceedsFromIssuanceOrSaleOfEquityAbstract to ProceedsFromIssuanceOrSaleOfEquity" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonUnitIssuanceValue" xlink:label="CommonUnitIssuanceValue" xlink:title="CommonUnitIssuanceValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="CommonUnitIssuanceValue" xlink:title="presentation: ProceedsFromIssuanceOrSaleOfEquityAbstract to CommonUnitIssuanceValue" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="presentation: ProceedsFromIssuanceOrSaleOfEquityAbstract to StockIssuedDuringPeriodValueNewIssues" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:title="presentation: SubsidiarySaleOfStockLineItems to ProceedsFromIssuanceOrSaleOfEquityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="SubsidiarySaleOfStockLineItems" xlink:title="presentation: SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable to SubsidiarySaleOfStockLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="ConcentrationRiskTable" xlink:title="ConcentrationRiskTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="AccountsReceivableMember" xlink:title="AccountsReceivableMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="AccountsReceivableMember" xlink:title="presentation: ConcentrationRiskBenchmarkDomain to AccountsReceivableMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="presentation: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="presentation: ConcentrationRiskTable to ConcentrationRiskByBenchmarkAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskTypeDomain" xlink:to="CustomerConcentrationRiskMember" xlink:title="presentation: ConcentrationRiskTypeDomain to CustomerConcentrationRiskMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="presentation: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="presentation: ConcentrationRiskTable to ConcentrationRiskByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain" xlink:title="NameOfMajorCustomerDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_SixCustomersMember" xlink:label="SixCustomersMember" xlink:title="SixCustomersMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NameOfMajorCustomerDomain" xlink:to="SixCustomersMember" xlink:title="presentation: NameOfMajorCustomerDomain to SixCustomersMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ThreeCustomersMember" xlink:label="ThreeCustomersMember" xlink:title="ThreeCustomersMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NameOfMajorCustomerDomain" xlink:to="ThreeCustomersMember" xlink:title="presentation: NameOfMajorCustomerDomain to ThreeCustomersMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain" xlink:title="presentation: MajorCustomersAxis to NameOfMajorCustomerDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskTable" xlink:to="MajorCustomersAxis" xlink:title="presentation: ConcentrationRiskTable to MajorCustomersAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="ConcentrationRiskLineItems" xlink:title="ConcentrationRiskLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetAbstract" xlink:label="AccountsReceivableNetAbstract" xlink:title="AccountsReceivableNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:label="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:title="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsReceivableNetAbstract" xlink:to="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:title="presentation: AccountsReceivableNetAbstract to AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_NumberOfCustomers" xlink:label="NumberOfCustomers" xlink:title="NumberOfCustomers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsReceivableNetAbstract" xlink:to="NumberOfCustomers" xlink:title="presentation: AccountsReceivableNetAbstract to NumberOfCustomers" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsReceivableNetAbstract" xlink:to="ConcentrationRiskPercentage1" xlink:title="presentation: AccountsReceivableNetAbstract to ConcentrationRiskPercentage1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskLineItems" xlink:to="AccountsReceivableNetAbstract" xlink:title="presentation: ConcentrationRiskLineItems to AccountsReceivableNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskTable" xlink:to="ConcentrationRiskLineItems" xlink:title="presentation: ConcentrationRiskTable to ConcentrationRiskLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ConcentrationRiskTable" xlink:title="presentation: AccountingPoliciesAbstract to ConcentrationRiskTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:label="GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:title="GoodwillImpairedAccumulatedImpairmentLossAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:to="Goodwill" xlink:title="presentation: GoodwillImpairedAccumulatedImpairmentLossAbstract to Goodwill" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="GoodwillImpairmentLoss" xlink:title="GoodwillImpairmentLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:to="GoodwillImpairmentLoss" xlink:title="presentation: GoodwillImpairedAccumulatedImpairmentLossAbstract to GoodwillImpairmentLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:title="presentation: AccountingPoliciesAbstract to GoodwillImpairedAccumulatedImpairmentLossAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentChargesAbstract" xlink:label="AssetImpairmentChargesAbstract" xlink:title="AssetImpairmentChargesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetImpairmentChargesAbstract" xlink:to="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="presentation: AssetImpairmentChargesAbstract to ImpairmentOfLongLivedAssetsHeldForUse" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="AssetImpairmentChargesAbstract" xlink:title="presentation: AccountingPoliciesAbstract to AssetImpairmentChargesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:title="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_BiotestLicenseAgreementMember" xlink:label="BiotestLicenseAgreementMember" xlink:title="BiotestLicenseAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="BiotestLicenseAgreementMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to BiotestLicenseAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to TypeOfArrangementAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain" xlink:title="NameOfMajorCustomerDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_FiveCustomersMember" xlink:label="FiveCustomersMember" xlink:title="FiveCustomersMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NameOfMajorCustomerDomain" xlink:to="FiveCustomersMember" xlink:title="presentation: NameOfMajorCustomerDomain to FiveCustomersMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ThreeCustomersMember" xlink:label="ThreeCustomersMember" xlink:title="ThreeCustomersMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NameOfMajorCustomerDomain" xlink:to="ThreeCustomersMember" xlink:title="presentation: NameOfMajorCustomerDomain to ThreeCustomersMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain" xlink:title="presentation: MajorCustomersAxis to NameOfMajorCustomerDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="MajorCustomersAxis" xlink:title="presentation: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to MajorCustomersAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="RevenueFromContractWithCustomerMember" xlink:title="RevenueFromContractWithCustomerMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:label="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:title="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerMember" xlink:to="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:title="presentation: RevenueFromContractWithCustomerMember to RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="RevenueFromContractWithCustomerMember" xlink:title="presentation: ConcentrationRiskBenchmarkDomain to RevenueFromContractWithCustomerMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="presentation: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="presentation: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to ConcentrationRiskByBenchmarkAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskTypeDomain" xlink:to="CustomerConcentrationRiskMember" xlink:title="presentation: ConcentrationRiskTypeDomain to CustomerConcentrationRiskMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="presentation: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="presentation: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to ConcentrationRiskByTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:title="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" xlink:title="RevenueFromContractWithCustomerAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_DeferredRevenueRemainingAmortizationPeriod" xlink:label="DeferredRevenueRemainingAmortizationPeriod" xlink:title="DeferredRevenueRemainingAmortizationPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="DeferredRevenueRemainingAmortizationPeriod" xlink:title="presentation: RevenueFromContractWithCustomerAbstract to DeferredRevenueRemainingAmortizationPeriod" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_NumberOfCustomers" xlink:label="NumberOfCustomers" xlink:title="NumberOfCustomers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="NumberOfCustomers" xlink:title="presentation: RevenueFromContractWithCustomerAbstract to NumberOfCustomers" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="ConcentrationRiskPercentage1" xlink:title="presentation: RevenueFromContractWithCustomerAbstract to ConcentrationRiskPercentage1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="RevenueFromContractWithCustomerAbstract" xlink:title="presentation: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to RevenueFromContractWithCustomerAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:title="presentation: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:title="presentation: AccountingPoliciesAbstract to RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesLossPerCommonShareDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="WarrantMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to WarrantMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="presentation: EarningsPerShareDilutedOtherDisclosuresAbstract to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to EarningsPerShareDilutedOtherDisclosuresAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="presentation: AccountingPoliciesAbstract to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="presentation: ShareBasedCompensationAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:title="presentation: ShareBasedCompensationAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ShareBasedCompensationAbstract" xlink:title="presentation: AccountingPoliciesAbstract to ShareBasedCompensationAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="UnrecognizedTaxBenefits" xlink:title="UnrecognizedTaxBenefits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="UnrecognizedTaxBenefits" xlink:title="presentation: IncomeTaxDisclosureAbstract to UnrecognizedTaxBenefits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="IncomeTaxDisclosureAbstract" xlink:title="presentation: AccountingPoliciesAbstract to IncomeTaxDisclosureAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/InventoriesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="InventoryDisclosureAbstract" xlink:title="InventoryDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="InventoryRawMaterials" xlink:title="InventoryRawMaterials" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="InventoryRawMaterials" xlink:title="presentation: InventoryDisclosureAbstract to InventoryRawMaterials" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="InventoryWorkInProcess" xlink:title="InventoryWorkInProcess" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="InventoryWorkInProcess" xlink:title="presentation: InventoryDisclosureAbstract to InventoryWorkInProcess" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="InventoryFinishedGoods" xlink:title="InventoryFinishedGoods" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="InventoryFinishedGoods" xlink:title="presentation: InventoryDisclosureAbstract to InventoryFinishedGoods" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="InventoryNet" xlink:title="presentation: InventoryDisclosureAbstract to InventoryNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:label="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:title="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:title="presentation: FiniteLivedIntangibleAssetsMajorClassNameDomain to TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_RightToIntermediatesMember" xlink:label="RightToIntermediatesMember" xlink:title="RightToIntermediatesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="RightToIntermediatesMember" xlink:title="presentation: FiniteLivedIntangibleAssetsMajorClassNameDomain to RightToIntermediatesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerContractsMember" xlink:label="CustomerContractsMember" xlink:title="CustomerContractsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="CustomerContractsMember" xlink:title="presentation: FiniteLivedIntangibleAssetsMajorClassNameDomain to CustomerContractsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="presentation: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="presentation: ScheduleOfFiniteLivedIntangibleAssetsTable to FiniteLivedIntangibleAssetsByMajorClassAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="FiniteLivedIntangibleAssetsLineItems" xlink:title="FiniteLivedIntangibleAssetsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="FiniteLivedIntangibleAssetsNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="FiniteLivedIntangibleAssetsGross" xlink:title="FiniteLivedIntangibleAssetsGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="FiniteLivedIntangibleAssetsGross" xlink:title="presentation: FiniteLivedIntangibleAssetsNetAbstract to FiniteLivedIntangibleAssetsGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="presentation: FiniteLivedIntangibleAssetsNetAbstract to FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="FiniteLivedIntangibleAssetsNet" xlink:title="FiniteLivedIntangibleAssetsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="FiniteLivedIntangibleAssetsNet" xlink:title="presentation: FiniteLivedIntangibleAssetsNetAbstract to FiniteLivedIntangibleAssetsNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="presentation: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="AmortizationOfIntangibleAssets" xlink:title="presentation: FiniteLivedIntangibleAssetsLineItems to AmortizationOfIntangibleAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="FiniteLivedIntangibleAssetsLineItems" xlink:title="presentation: ScheduleOfFiniteLivedIntangibleAssetsTable to FiniteLivedIntangibleAssetsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to ScheduleOfFiniteLivedIntangibleAssetsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:title="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:title="presentation: FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract to FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:title="presentation: FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract to FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:title="presentation: FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract to FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:title="presentation: FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract to FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/PropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="ManufacturingFacilityMember" xlink:title="ManufacturingFacilityMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="ManufacturingFacilityMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to ManufacturingFacilityMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="OfficeEquipmentMember" xlink:title="OfficeEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="OfficeEquipmentMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to OfficeEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="FurnitureAndFixturesMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to FurnitureAndFixturesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetUnderConstructionMember" xlink:label="AssetUnderConstructionMember" xlink:title="AssetUnderConstructionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="AssetUnderConstructionMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to AssetUnderConstructionMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="LeaseholdImprovementsMember" xlink:title="LeaseholdImprovementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LeaseholdImprovementsMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to LeaseholdImprovementsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandMember" xlink:label="LandMember" xlink:title="LandMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LandMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to LandMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="BuildingAndBuildingImprovementsMember" xlink:title="BuildingAndBuildingImprovementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="BuildingAndBuildingImprovementsMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to BuildingAndBuildingImprovementsMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember" xlink:label="BuildingMember" xlink:title="BuildingMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="BuildingMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to BuildingMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="presentation: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentByTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="PropertyPlantAndEquipmentNetAbstract" xlink:title="PropertyPlantAndEquipmentNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentNetAbstract" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="presentation: PropertyPlantAndEquipmentNetAbstract to PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentNetAbstract" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="presentation: PropertyPlantAndEquipmentNetAbstract to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentNetAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: PropertyPlantAndEquipmentNetAbstract to PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentNetAbstract" xlink:title="presentation: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentUsefulLife" xlink:title="presentation: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentUsefulLife" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="DepreciationDepletionAndAmortization" xlink:title="presentation: PropertyPlantAndEquipmentLineItems to DepreciationDepletionAndAmortization" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentLineItems" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to ScheduleOfPropertyPlantAndEquipmentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:title="AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_AccruedRebatesCurrent" xlink:label="AccruedRebatesCurrent" xlink:title="AccruedRebatesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="AccruedRebatesCurrent" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to AccruedRebatesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="AccruedProfessionalFeesCurrent" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to AccruedProfessionalFeesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="AccruedSalariesCurrent" xlink:title="AccruedSalariesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="AccruedSalariesCurrent" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to AccruedSalariesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount" xlink:label="LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount" xlink:title="LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="AccruedBonusesCurrent" xlink:title="AccruedBonusesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="AccruedBonusesCurrent" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to AccruedBonusesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:label="SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:title="SupplementalUnemploymentBenefitsSeveranceBenefits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to SupplementalUnemploymentBenefitsSeveranceBenefits" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="OtherAccruedLiabilitiesCurrent" xlink:title="OtherAccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="OtherAccruedLiabilitiesCurrent" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to OtherAccruedLiabilitiesCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="AccruedLiabilitiesAndOtherLiabilities" xlink:title="AccruedLiabilitiesAndOtherLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="AccruedLiabilitiesAndOtherLiabilities" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to AccruedLiabilitiesAndOtherLiabilities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:title="presentation: PayablesAndAccrualsAbstract to AccruedLiabilitiesAndOtherLiabilitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/DebtDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="SeniorNotesMember" xlink:title="SeniorNotesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeDomain" xlink:to="SeniorNotesMember" xlink:title="presentation: LongtermDebtTypeDomain to SeniorNotesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain" xlink:title="presentation: LongtermDebtTypeAxis to LongtermDebtTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="LongtermDebtTypeAxis" xlink:title="presentation: DebtInstrumentTable to LongtermDebtTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PerceptiveCreditAgreementMember" xlink:label="PerceptiveCreditAgreementMember" xlink:title="PerceptiveCreditAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="PerceptiveCreditAgreementMember" xlink:title="presentation: DebtInstrumentNameDomain to PerceptiveCreditAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PerceptiveCreditFacilityMember" xlink:label="PerceptiveCreditFacilityMember" xlink:title="PerceptiveCreditFacilityMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="PerceptiveCreditFacilityMember" xlink:title="presentation: DebtInstrumentNameDomain to PerceptiveCreditFacilityMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="presentation: DebtInstrumentAxis to DebtInstrumentNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentAxis" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="VariableRateAxis" xlink:title="VariableRateAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="VariableRateDomain" xlink:title="VariableRateDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="LondonInterbankOfferedRateLIBORMember" xlink:title="LondonInterbankOfferedRateLIBORMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VariableRateDomain" xlink:to="LondonInterbankOfferedRateLIBORMember" xlink:title="presentation: VariableRateDomain to LondonInterbankOfferedRateLIBORMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VariableRateAxis" xlink:to="VariableRateDomain" xlink:title="presentation: VariableRateAxis to VariableRateDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="VariableRateAxis" xlink:title="presentation: DebtInstrumentTable to VariableRateAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="RangeAxis" xlink:title="presentation: DebtInstrumentTable to RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="ScenarioForecastMember" xlink:title="ScenarioForecastMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScenarioUnspecifiedDomain" xlink:to="ScenarioForecastMember" xlink:title="presentation: ScenarioUnspecifiedDomain to ScenarioForecastMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="presentation: StatementScenarioAxis to ScenarioUnspecifiedDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="StatementScenarioAxis" xlink:title="presentation: DebtInstrumentTable to StatementScenarioAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="DebtInstrumentsAbstract" xlink:title="DebtInstrumentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="NotesPayableAbstract" xlink:title="NotesPayableAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_SeniorNotesPayableBeforeDebtDiscount" xlink:label="SeniorNotesPayableBeforeDebtDiscount" xlink:title="SeniorNotesPayableBeforeDebtDiscount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableAbstract" xlink:to="SeniorNotesPayableBeforeDebtDiscount" xlink:title="presentation: NotesPayableAbstract to SeniorNotesPayableBeforeDebtDiscount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="DebtInstrumentUnamortizedDiscount" xlink:title="DebtInstrumentUnamortizedDiscount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableAbstract" xlink:to="DebtInstrumentUnamortizedDiscount" xlink:title="presentation: NotesPayableAbstract to DebtInstrumentUnamortizedDiscount" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorLongTermNotes" xlink:label="SeniorLongTermNotes" xlink:title="SeniorLongTermNotes" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableAbstract" xlink:to="SeniorLongTermNotes" xlink:title="presentation: NotesPayableAbstract to SeniorLongTermNotes" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="NotesPayableAbstract" xlink:title="presentation: DebtInstrumentsAbstract to NotesPayableAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="DebtInstrumentMaturityDate" xlink:title="DebtInstrumentMaturityDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentMaturityDate" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentMaturityDate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentInterestRateStatedPercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_DebtInstrumentTermOfVariableRate" xlink:label="DebtInstrumentTermOfVariableRate" xlink:title="DebtInstrumentTermOfVariableRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentTermOfVariableRate" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentTermOfVariableRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentBasisSpreadOnVariableRate1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="DebtInstrumentInterestRateIncreaseDecrease" xlink:title="DebtInstrumentInterestRateIncreaseDecrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentInterestRateIncreaseDecrease" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentInterestRateIncreaseDecrease" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="DebtInstrumentInterestRateEffectivePercentage" xlink:title="DebtInstrumentInterestRateEffectivePercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentInterestRateEffectivePercentage" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentInterestRateEffectivePercentage" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_RepaymentsOfDebtInterest" xlink:label="RepaymentsOfDebtInterest" xlink:title="RepaymentsOfDebtInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="RepaymentsOfDebtInterest" xlink:title="presentation: DebtInstrumentsAbstract to RepaymentsOfDebtInterest" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="Cash" xlink:title="Cash" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="Cash" xlink:title="presentation: DebtInstrumentsAbstract to Cash" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="presentation: DebtInstrumentsAbstract to RevenueFromContractWithCustomerExcludingAssessedTax" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentsAbstract" xlink:title="presentation: DebtInstrumentLineItems to DebtInstrumentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentLineItems" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="DebtInstrumentTable" xlink:title="presentation: DebtDisclosureAbstract to DebtInstrumentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityPreferredStockDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance" xlink:label="PreferredStockCapitalSharesReservedForFutureIssuance" xlink:title="PreferredStockCapitalSharesReservedForFutureIssuance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="PreferredStockCapitalSharesReservedForFutureIssuance" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to PreferredStockCapitalSharesReservedForFutureIssuance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="PreferredStockParOrStatedValuePerShare" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to PreferredStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="PreferredStockSharesOutstanding" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to PreferredStockSharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="presentation: EquityAbstract to PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityCommonStockDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="presentation: EquityComponentDomain to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: ScheduleOfStockByClassTable to StatementEquityComponentsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_SaleAgreementMember" xlink:label="SaleAgreementMember" xlink:title="SaleAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="SaleAgreementMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to SaleAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_SaleAgreement2020Member" xlink:label="SaleAgreement2020Member" xlink:title="SaleAgreement2020Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="SaleAgreement2020Member" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to SaleAgreement2020Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_SaleAgreement2020AmendedMember" xlink:label="SaleAgreement2020AmendedMember" xlink:title="SaleAgreement2020AmendedMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="SaleAgreement2020AmendedMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to SaleAgreement2020AmendedMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_SaleAgreement2021Member" xlink:label="SaleAgreement2021Member" xlink:title="SaleAgreement2021Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="SaleAgreement2021Member" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to SaleAgreement2021Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: ScheduleOfStockByClassTable to TypeOfArrangementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_JefferiesLLCMember" xlink:label="JefferiesLLCMember" xlink:title="JefferiesLLCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="JefferiesLLCMember" xlink:title="presentation: RelatedPartyDomain to JefferiesLLCMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="presentation: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="presentation: ScheduleOfStockByClassTable to RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="OverAllotmentOptionMember" xlink:title="OverAllotmentOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="OverAllotmentOptionMember" xlink:title="presentation: SaleOfStockNameOfTransactionDomain to OverAllotmentOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="presentation: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="SubsidiarySaleOfStockAxis" xlink:title="presentation: ScheduleOfStockByClassTable to SubsidiarySaleOfStockAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfStockByClassTable to RangeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="CommonStockSharesAuthorized" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to CommonStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to CommonStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="CommonStockSharesOutstanding" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to CommonStockSharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="ClassOfWarrantOrRightOutstanding" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to ClassOfWarrantOrRightOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to CommonStockCapitalSharesReservedForFutureIssuance" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to StockIssuedDuringPeriodValueNewIssues" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to StockIssuedDuringPeriodSharesNewIssues" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to ProceedsFromIssuanceOfCommonStock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_GrossProceedsFromIssuanceOfCommonStock" xlink:label="GrossProceedsFromIssuanceOfCommonStock" xlink:title="GrossProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="GrossProceedsFromIssuanceOfCommonStock" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to GrossProceedsFromIssuanceOfCommonStock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockLineItems" xlink:to="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="presentation: ClassOfStockLineItems to CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="ClassOfStockLineItems" xlink:title="presentation: ScheduleOfStockByClassTable to ClassOfStockLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ScheduleOfStockByClassTable" xlink:title="presentation: EquityAbstract to ScheduleOfStockByClassTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityWarrantsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="ClassOfWarrantOrRightTable" xlink:title="ClassOfWarrantOrRightTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="presentation: EquityComponentDomain to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: ClassOfWarrantOrRightTable to StatementEquityComponentsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="ClassOfWarrantOrRightLineItems" xlink:title="ClassOfWarrantOrRightLineItems" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_WarrantsAbstract" xlink:label="WarrantsAbstract" xlink:title="WarrantsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAbstract" xlink:to="ClassOfWarrantOrRightOutstanding" xlink:title="presentation: WarrantsAbstract to ClassOfWarrantOrRightOutstanding" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAbstract" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="presentation: WarrantsAbstract to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="WarrantsAbstract" xlink:title="presentation: ClassOfWarrantOrRightLineItems to WarrantsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightTable" xlink:to="ClassOfWarrantOrRightLineItems" xlink:title="presentation: ClassOfWarrantOrRightTable to ClassOfWarrantOrRightLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ClassOfWarrantOrRightTable" xlink:title="presentation: EquityAbstract to ClassOfWarrantOrRightTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_EquityIncentivePlanMember" xlink:label="EquityIncentivePlanMember" xlink:title="EquityIncentivePlanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="EquityIncentivePlanMember" xlink:title="presentation: PlanNameDomain to EquityIncentivePlanMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="presentation: PlanNameAxis to PlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="PlanNameAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to PlanNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="DirectorMember" xlink:title="DirectorMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="DirectorMember" xlink:title="presentation: TitleOfIndividualWithRelationshipToEntityDomain to DirectorMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_EmployeesMember" xlink:label="EmployeesMember" xlink:title="EmployeesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="EmployeesMember" xlink:title="presentation: TitleOfIndividualWithRelationshipToEntityDomain to EmployeesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="presentation: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="TitleOfIndividualAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to TitleOfIndividualAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="OperatingExpenseMember" xlink:title="OperatingExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="OperatingExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to OperatingExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="SellingGeneralAndAdministrativeExpensesMember" xlink:title="SellingGeneralAndAdministrativeExpensesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="SellingGeneralAndAdministrativeExpensesMember" xlink:title="presentation: IncomeStatementLocationDomain to SellingGeneralAndAdministrativeExpensesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="CostOfSalesMember" xlink:title="CostOfSalesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="CostOfSalesMember" xlink:title="presentation: IncomeStatementLocationDomain to CostOfSalesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="presentation: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="IncomeStatementLocationAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to IncomeStatementLocationAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_StockOptionsAbstract" xlink:label="StockOptionsAbstract" xlink:title="StockOptionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="presentation: StockOptionsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="presentation: StockOptionsAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="presentation: StockOptionsAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="presentation: StockOptionsAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_StockOptionSharesAbstract" xlink:label="StockOptionSharesAbstract" xlink:title="StockOptionSharesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionSharesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="presentation: StockOptionSharesAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionSharesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:title="presentation: StockOptionSharesAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionSharesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:title="presentation: StockOptionSharesAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionSharesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:title="presentation: StockOptionSharesAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionSharesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:title="presentation: StockOptionSharesAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionSharesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2" xlink:title="presentation: StockOptionSharesAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionSharesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="presentation: StockOptionSharesAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="StockOptionSharesAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract to StockOptionSharesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_StockOptionsWeightedAverageExercisePriceAbstract" xlink:label="StockOptionsWeightedAverageExercisePriceAbstract" xlink:title="StockOptionsWeightedAverageExercisePriceAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsWeightedAverageExercisePriceAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="presentation: StockOptionsWeightedAverageExercisePriceAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsWeightedAverageExercisePriceAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:title="presentation: StockOptionsWeightedAverageExercisePriceAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsWeightedAverageExercisePriceAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:title="presentation: StockOptionsWeightedAverageExercisePriceAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsWeightedAverageExercisePriceAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:title="presentation: StockOptionsWeightedAverageExercisePriceAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsWeightedAverageExercisePriceAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:title="presentation: StockOptionsWeightedAverageExercisePriceAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsWeightedAverageExercisePriceAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2" xlink:title="presentation: StockOptionsWeightedAverageExercisePriceAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsWeightedAverageExercisePriceAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="presentation: StockOptionsWeightedAverageExercisePriceAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="StockOptionsWeightedAverageExercisePriceAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract to StockOptionsWeightedAverageExercisePriceAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:title="presentation: StockOptionsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="presentation: StockOptionsAbstract to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="presentation: StockOptionsAbstract to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="StockOptionsAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to StockOptionsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_RestrictedStockUnitsAbstract" xlink:label="RestrictedStockUnitsAbstract" xlink:title="RestrictedStockUnitsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockUnitsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:title="presentation: RestrictedStockUnitsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockUnitsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="presentation: RestrictedStockUnitsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockUnitsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:title="presentation: RestrictedStockUnitsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockUnitsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:title="presentation: RestrictedStockUnitsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockUnitsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="presentation: RestrictedStockUnitsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockUnitsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="presentation: RestrictedStockUnitsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockUnitsAbstract" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="presentation: RestrictedStockUnitsAbstract to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="RestrictedStockUnitsAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to RestrictedStockUnitsAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:title="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="ShareBasedCompensation" xlink:title="presentation: ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract to ShareBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: EquityAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" xlink:title="RelatedPartyTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ArethLLCMember" xlink:label="ArethLLCMember" xlink:title="ArethLLCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="ArethLLCMember" xlink:title="presentation: RelatedPartyDomain to ArethLLCMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_GenesisBPSMember" xlink:label="GenesisBPSMember" xlink:title="GenesisBPSMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="GenesisBPSMember" xlink:title="presentation: RelatedPartyDomain to GenesisBPSMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="presentation: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RelatedPartyTransactionsByRelatedPartyAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="LineOfCreditFacilityAxis" xlink:title="LineOfCreditFacilityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="LineOfCreditFacilityLenderDomain" xlink:title="LineOfCreditFacilityLenderDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PerceptiveCreditHoldingsIILPMember" xlink:label="PerceptiveCreditHoldingsIILPMember" xlink:title="PerceptiveCreditHoldingsIILPMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityLenderDomain" xlink:to="PerceptiveCreditHoldingsIILPMember" xlink:title="presentation: LineOfCreditFacilityLenderDomain to PerceptiveCreditHoldingsIILPMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityAxis" xlink:to="LineOfCreditFacilityLenderDomain" xlink:title="presentation: LineOfCreditFacilityAxis to LineOfCreditFacilityLenderDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="LineOfCreditFacilityAxis" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to LineOfCreditFacilityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ViceChairmanMember" xlink:label="ViceChairmanMember" xlink:title="ViceChairmanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ViceChairmanMember" xlink:title="presentation: TitleOfIndividualWithRelationshipToEntityDomain to ViceChairmanMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="DirectorMember" xlink:title="DirectorMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="DirectorMember" xlink:title="presentation: TitleOfIndividualWithRelationshipToEntityDomain to DirectorMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PresidentAndChiefExecutiveOfficerMember" xlink:label="PresidentAndChiefExecutiveOfficerMember" xlink:title="PresidentAndChiefExecutiveOfficerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="PresidentAndChiefExecutiveOfficerMember" xlink:title="presentation: TitleOfIndividualWithRelationshipToEntityDomain to PresidentAndChiefExecutiveOfficerMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember" xlink:label="ExecutiveVicePresidentAndChiefFinancialOfficerMember" xlink:title="ExecutiveVicePresidentAndChiefFinancialOfficerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ExecutiveVicePresidentAndChiefFinancialOfficerMember" xlink:title="presentation: TitleOfIndividualWithRelationshipToEntityDomain to ExecutiveVicePresidentAndChiefFinancialOfficerMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ChiefScientificOfficerAndChiefMedicalOfficerMember" xlink:label="ChiefScientificOfficerAndChiefMedicalOfficerMember" xlink:title="ChiefScientificOfficerAndChiefMedicalOfficerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ChiefScientificOfficerAndChiefMedicalOfficerMember" xlink:title="presentation: TitleOfIndividualWithRelationshipToEntityDomain to ChiefScientificOfficerAndChiefMedicalOfficerMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="presentation: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="TitleOfIndividualAxis" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to TitleOfIndividualAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis" xlink:label="OwnershipAxis" xlink:title="OwnershipAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain" xlink:title="OwnershipDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_DirectOwnershipMember" xlink:label="DirectOwnershipMember" xlink:title="DirectOwnershipMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OwnershipDomain" xlink:to="DirectOwnershipMember" xlink:title="presentation: OwnershipDomain to DirectOwnershipMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_IndirectOwnershipMember" xlink:label="IndirectOwnershipMember" xlink:title="IndirectOwnershipMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OwnershipDomain" xlink:to="IndirectOwnershipMember" xlink:title="presentation: OwnershipDomain to IndirectOwnershipMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OwnershipAxis" xlink:to="OwnershipDomain" xlink:title="presentation: OwnershipAxis to OwnershipDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="OwnershipAxis" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to OwnershipAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="RelatedPartyTransactionLineItems" xlink:title="RelatedPartyTransactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:label="RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:title="RelatedPartyTransactionDueFromToRelatedPartyAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:title="RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:title="presentation: RelatedPartyTransactionDueFromToRelatedPartyAbstract to RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="RelatedPartyTransactionPurchasesFromRelatedParty" xlink:title="RelatedPartyTransactionPurchasesFromRelatedParty" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="RelatedPartyTransactionPurchasesFromRelatedParty" xlink:title="presentation: RelatedPartyTransactionDueFromToRelatedPartyAbstract to RelatedPartyTransactionPurchasesFromRelatedParty" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_EstimatedPaymentForSeparationAndTransitionAgreement" xlink:label="EstimatedPaymentForSeparationAndTransitionAgreement" xlink:title="EstimatedPaymentForSeparationAndTransitionAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="EstimatedPaymentForSeparationAndTransitionAgreement" xlink:title="presentation: RelatedPartyTransactionDueFromToRelatedPartyAbstract to EstimatedPaymentForSeparationAndTransitionAgreement" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement" xlink:label="PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement" xlink:title="PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement" xlink:title="presentation: RelatedPartyTransactionDueFromToRelatedPartyAbstract to PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_MinimumPercentageOfCommonStockHeldByLender" xlink:label="MinimumPercentageOfCommonStockHeldByLender" xlink:title="MinimumPercentageOfCommonStockHeldByLender" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="MinimumPercentageOfCommonStockHeldByLender" xlink:title="presentation: RelatedPartyTransactionDueFromToRelatedPartyAbstract to MinimumPercentageOfCommonStockHeldByLender" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="presentation: RelatedPartyTransactionDueFromToRelatedPartyAbstract to StockIssuedDuringPeriodSharesNewIssues" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="SharesIssuedPricePerShare" xlink:title="SharesIssuedPricePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="SharesIssuedPricePerShare" xlink:title="presentation: RelatedPartyTransactionDueFromToRelatedPartyAbstract to SharesIssuedPricePerShare" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionLineItems" xlink:to="RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:title="presentation: RelatedPartyTransactionLineItems to RelatedPartyTransactionDueFromToRelatedPartyAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RelatedPartyTransactionLineItems" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RelatedPartyTransactionLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="presentation: RelatedPartyTransactionsAbstract to ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="LossContingenciesTable" xlink:title="LossContingenciesTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PlasmaPurchaseAgreementOneMember" xlink:label="PlasmaPurchaseAgreementOneMember" xlink:title="PlasmaPurchaseAgreementOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="PlasmaPurchaseAgreementOneMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to PlasmaPurchaseAgreementOneMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PlasmaPurchaseAgreementTwoMember" xlink:label="PlasmaPurchaseAgreementTwoMember" xlink:title="PlasmaPurchaseAgreementTwoMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="PlasmaPurchaseAgreementTwoMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to PlasmaPurchaseAgreementTwoMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: LossContingenciesTable to TypeOfArrangementAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="RangeAxis" xlink:title="presentation: LossContingenciesTable to RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="LossContingenciesLineItems" xlink:title="LossContingenciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_VendorCommitmentsAbstract" xlink:label="VendorCommitmentsAbstract" xlink:title="VendorCommitmentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_NumberOfPlasmaCollectionFacilities" xlink:label="NumberOfPlasmaCollectionFacilities" xlink:title="NumberOfPlasmaCollectionFacilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VendorCommitmentsAbstract" xlink:to="NumberOfPlasmaCollectionFacilities" xlink:title="presentation: VendorCommitmentsAbstract to NumberOfPlasmaCollectionFacilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_NumberOfRenewalTerms" xlink:label="NumberOfRenewalTerms" xlink:title="NumberOfRenewalTerms" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VendorCommitmentsAbstract" xlink:to="NumberOfRenewalTerms" xlink:title="presentation: VendorCommitmentsAbstract to NumberOfRenewalTerms" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PlasmaPurchaseAgreementRenewalPeriod" xlink:label="PlasmaPurchaseAgreementRenewalPeriod" xlink:title="PlasmaPurchaseAgreementRenewalPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VendorCommitmentsAbstract" xlink:to="PlasmaPurchaseAgreementRenewalPeriod" xlink:title="presentation: VendorCommitmentsAbstract to PlasmaPurchaseAgreementRenewalPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PlasmaPurchaseAgreementTerm" xlink:label="PlasmaPurchaseAgreementTerm" xlink:title="PlasmaPurchaseAgreementTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VendorCommitmentsAbstract" xlink:to="PlasmaPurchaseAgreementTerm" xlink:title="presentation: VendorCommitmentsAbstract to PlasmaPurchaseAgreementTerm" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity" xlink:label="NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity" xlink:title="NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VendorCommitmentsAbstract" xlink:to="NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity" xlink:title="presentation: VendorCommitmentsAbstract to NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PercentageOfPlasmaPurchasePriceEqualToCost" xlink:label="PercentageOfPlasmaPurchasePriceEqualToCost" xlink:title="PercentageOfPlasmaPurchasePriceEqualToCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VendorCommitmentsAbstract" xlink:to="PercentageOfPlasmaPurchasePriceEqualToCost" xlink:title="presentation: VendorCommitmentsAbstract to PercentageOfPlasmaPurchasePriceEqualToCost" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PlasmaSupplyAgreementTerm" xlink:label="PlasmaSupplyAgreementTerm" xlink:title="PlasmaSupplyAgreementTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VendorCommitmentsAbstract" xlink:to="PlasmaSupplyAgreementTerm" xlink:title="presentation: VendorCommitmentsAbstract to PlasmaSupplyAgreementTerm" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PlasmaPurchased" xlink:label="PlasmaPurchased" xlink:title="PlasmaPurchased" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VendorCommitmentsAbstract" xlink:to="PlasmaPurchased" xlink:title="presentation: VendorCommitmentsAbstract to PlasmaPurchased" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PercentageOfInventoryPurchases" xlink:label="PercentageOfInventoryPurchases" xlink:title="PercentageOfInventoryPurchases" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VendorCommitmentsAbstract" xlink:to="PercentageOfInventoryPurchases" xlink:title="presentation: VendorCommitmentsAbstract to PercentageOfInventoryPurchases" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesLineItems" xlink:to="VendorCommitmentsAbstract" xlink:title="presentation: LossContingenciesLineItems to VendorCommitmentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="LossContingenciesLineItems" xlink:title="presentation: LossContingenciesTable to LossContingenciesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="LossContingenciesTable" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to LossContingenciesTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SegmentsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="ConsolidationItemsAxis" xlink:title="ConsolidationItemsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="ConsolidationItemsDomain" xlink:title="ConsolidationItemsDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="OperatingSegmentsMember" xlink:title="OperatingSegmentsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidationItemsDomain" xlink:to="OperatingSegmentsMember" xlink:title="presentation: ConsolidationItemsDomain to OperatingSegmentsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidationItemsAxis" xlink:to="ConsolidationItemsDomain" xlink:title="presentation: ConsolidationItemsAxis to ConsolidationItemsDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="ConsolidationItemsAxis" xlink:title="presentation: ScheduleOfSegmentReportingInformationBySegmentTable to ConsolidationItemsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="StatementBusinessSegmentsAxis" xlink:title="StatementBusinessSegmentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain" xlink:title="SegmentDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_ADMABioManufacturingSegmentMember" xlink:label="ADMABioManufacturingSegmentMember" xlink:title="ADMABioManufacturingSegmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentDomain" xlink:to="ADMABioManufacturingSegmentMember" xlink:title="presentation: SegmentDomain to ADMABioManufacturingSegmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_PlasmaCollectionCentersSegmentMember" xlink:label="PlasmaCollectionCentersSegmentMember" xlink:title="PlasmaCollectionCentersSegmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentDomain" xlink:to="PlasmaCollectionCentersSegmentMember" xlink:title="presentation: SegmentDomain to PlasmaCollectionCentersSegmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateMember" xlink:label="CorporateMember" xlink:title="CorporateMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentDomain" xlink:to="CorporateMember" xlink:title="presentation: SegmentDomain to CorporateMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain" xlink:title="presentation: StatementBusinessSegmentsAxis to SegmentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="StatementBusinessSegmentsAxis" xlink:title="presentation: ScheduleOfSegmentReportingInformationBySegmentTable to StatementBusinessSegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="StatementGeographicalAxis" xlink:title="StatementGeographicalAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="SegmentGeographicalDomain" xlink:title="SegmentGeographicalDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="US" xlink:title="US" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentGeographicalDomain" xlink:to="US" xlink:title="presentation: SegmentGeographicalDomain to US" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember" xlink:label="NonUsMember" xlink:title="NonUsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentGeographicalDomain" xlink:to="NonUsMember" xlink:title="presentation: SegmentGeographicalDomain to NonUsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementGeographicalAxis" xlink:to="SegmentGeographicalDomain" xlink:title="presentation: StatementGeographicalAxis to SegmentGeographicalDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="StatementGeographicalAxis" xlink:title="presentation: ScheduleOfSegmentReportingInformationBySegmentTable to StatementGeographicalAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="SegmentReportingInformationLineItems" xlink:title="SegmentReportingInformationLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:label="SegmentReportingInformationProfitLossAbstract" xlink:title="SegmentReportingInformationProfitLossAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_NumberOfFDALicensedPlasmaCollectionFacilities" xlink:label="NumberOfFDALicensedPlasmaCollectionFacilities" xlink:title="NumberOfFDALicensedPlasmaCollectionFacilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="NumberOfFDALicensedPlasmaCollectionFacilities" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to NumberOfFDALicensedPlasmaCollectionFacilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:label="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:title="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to NumberOfPlasmaCollectionFacilitiesUnderDevelopment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to RevenueFromContractWithCustomerExcludingAssessedTax" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_CostOfProductRevenueExcludingAmortizationExpense" xlink:label="CostOfProductRevenueExcludingAmortizationExpense" xlink:title="CostOfProductRevenueExcludingAmortizationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="CostOfProductRevenueExcludingAmortizationExpense" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to CostOfProductRevenueExcludingAmortizationExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="OperatingIncomeLoss" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to OperatingIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="NonoperatingIncomeExpense" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to NonoperatingIncomeExpense" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to NetIncomeLoss" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to PaymentsToAcquirePropertyPlantAndEquipment" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="DepreciationAndAmortization" xlink:title="DepreciationAndAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="DepreciationAndAmortization" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to DepreciationAndAmortization" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="Assets" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to Assets" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationLineItems" xlink:to="SegmentReportingInformationProfitLossAbstract" xlink:title="presentation: SegmentReportingInformationLineItems to SegmentReportingInformationProfitLossAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="SegmentReportingInformationLineItems" xlink:title="presentation: ScheduleOfSegmentReportingInformationBySegmentTable to SegmentReportingInformationLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="presentation: SegmentReportingAbstract to ScheduleOfSegmentReportingInformationBySegmentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_OperatingLeaseIncrementalBorrowingRatePercent" xlink:label="OperatingLeaseIncrementalBorrowingRatePercent" xlink:title="OperatingLeaseIncrementalBorrowingRatePercent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="OperatingLeaseIncrementalBorrowingRatePercent" xlink:title="presentation: LeasesAbstract to OperatingLeaseIncrementalBorrowingRatePercent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="OperatingLeaseExpense" xlink:title="OperatingLeaseExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="OperatingLeaseExpense" xlink:title="presentation: LeasesAbstract to OperatingLeaseExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="OperatingLeasePayments" xlink:title="OperatingLeasePayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="OperatingLeasePayments" xlink:title="presentation: LeasesAbstract to OperatingLeasePayments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease" xlink:label="LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease" xlink:title="LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease" xlink:title="presentation: LeasesAbstract to LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease" xlink:label="LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease" xlink:title="LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease" xlink:title="presentation: LeasesAbstract to LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_NumberOfNewPropertyLeases" xlink:label="NumberOfNewPropertyLeases" xlink:title="NumberOfNewPropertyLeases" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="NumberOfNewPropertyLeases" xlink:title="presentation: LeasesAbstract to NumberOfNewPropertyLeases" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" xlink:title="OperatingLeaseLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="OperatingLeaseLiability" xlink:title="presentation: LeasesAbstract to OperatingLeaseLiability" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:title="OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:title="presentation: LeasesAbstract to OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to OperatingLeaseLiabilityCurrent" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="OperatingLeaseLiabilityNoncurrent" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to OperatingLeaseLiabilityNoncurrent" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="presentation: LeasesAbstract to OperatingLeaseLiabilitiesPaymentsDueAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="LesseeLeaseDescriptionTable" xlink:title="LesseeLeaseDescriptionTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionTable" xlink:to="RangeAxis" xlink:title="presentation: LesseeLeaseDescriptionTable to RangeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="LesseeLeaseDescriptionLineItems" xlink:title="LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="LesseeOperatingLeaseDescriptionAbstract" xlink:title="LesseeOperatingLeaseDescriptionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="LesseeOperatingLeaseTermOfContract" xlink:title="LesseeOperatingLeaseTermOfContract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="LesseeOperatingLeaseTermOfContract" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to LesseeOperatingLeaseTermOfContract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="SecurityDeposit" xlink:title="SecurityDeposit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="SecurityDeposit" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to SecurityDeposit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRent" xlink:label="PaymentsForRent" xlink:title="PaymentsForRent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="PaymentsForRent" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to PaymentsForRent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_OperatingLeasesRentExpense" xlink:label="OperatingLeasesRentExpense" xlink:title="OperatingLeasesRentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="OperatingLeasesRentExpense" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to OperatingLeasesRentExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseDescriptionAbstract" xlink:title="presentation: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseDescriptionAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionTable" xlink:to="LesseeLeaseDescriptionLineItems" xlink:title="presentation: LesseeLeaseDescriptionTable to LesseeLeaseDescriptionLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeLeaseDescriptionTable" xlink:title="presentation: LeasesAbstract to LesseeLeaseDescriptionTable" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsDetailsCalc2" />
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="SupplementalCashFlowElementsAbstract" xlink:title="SupplementalCashFlowElementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="InterestPaidNet" xlink:title="InterestPaidNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="InterestPaidNet" xlink:title="presentation: SupplementalCashFlowInformationAbstract to InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="NoncashInvestingAndFinancingItemsAbstract" xlink:title="NoncashInvestingAndFinancingItemsAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:label="EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:title="EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:title="presentation: NoncashInvestingAndFinancingItemsAbstract to EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:title="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:title="presentation: NoncashInvestingAndFinancingItemsAbstract to RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="NoncashInvestingAndFinancingItemsAbstract" xlink:title="presentation: SupplementalCashFlowInformationAbstract to NoncashInvestingAndFinancingItemsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowElementsAbstract" xlink:to="SupplementalCashFlowInformationAbstract" xlink:title="presentation: SupplementalCashFlowElementsAbstract to SupplementalCashFlowInformationAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="presentation: SubsequentEventTypeDomain to SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="presentation: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventTypeAxis" xlink:title="presentation: SubsequentEventTable to SubsequentEventTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_SaleAgreement2020Member" xlink:label="SaleAgreement2020Member" xlink:title="SaleAgreement2020Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="SaleAgreement2020Member" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to SaleAgreement2020Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: SubsequentEventTable to TypeOfArrangementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:loc xlink:type="locator" xlink:href="adma-20210630.xsd#adma_SubsequentEventsSaleOfStockAbstract" xlink:label="SubsequentEventsSaleOfStockAbstract" xlink:title="SubsequentEventsSaleOfStockAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsSaleOfStockAbstract" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="presentation: SubsequentEventsSaleOfStockAbstract to StockIssuedDuringPeriodSharesNewIssues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsSaleOfStockAbstract" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="presentation: SubsequentEventsSaleOfStockAbstract to ProceedsFromIssuanceOfCommonStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="SubsequentEventsSaleOfStockAbstract" xlink:title="presentation: SubsequentEventLineItems to SubsequentEventsSaleOfStockAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventLineItems" xlink:title="presentation: SubsequentEventTable to SubsequentEventLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="SubsequentEventTable" xlink:title="presentation: SubsequentEventsAbstract to SubsequentEventTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>brhc10027771_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:adma="http://admabiologics.com/20210630"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="adma-20210630.xsd" xlink:type="simple"/>
    <context id="c20210101to20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210630_StatementClassOfStockAxis_PreferredSharePurchaseRightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adma:PreferredSharePurchaseRightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210630_StatementClassOfStockAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20210806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2021-08-06</instant>
        </period>
    </context>
    <context id="c20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20200401to20200630_ProductOrServiceAxis_LicenseAndServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210630_ProductOrServiceAxis_LicenseAndServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20200401to20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c20210401to20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20200101to20200630_ProductOrServiceAxis_LicenseAndServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c20210401to20210630_ProductOrServiceAxis_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20200101to20200630_ProductOrServiceAxis_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210630_ProductOrServiceAxis_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20210401to20210630_ProductOrServiceAxis_LicenseAndServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20200401to20200630_ProductOrServiceAxis_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c20200101to20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20201231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20191231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20201231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20201231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20200101to20200331_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="c20210401to20210630_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20200101to20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="c20200401to20200630_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c20200101to20200331_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="c20210101to20210331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c20200101to20200331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="c20210101to20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c20210101to20210331_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c20210101to20210331_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c20210401to20210630_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20210401to20210630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20200401to20200630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c20200401to20200630_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c20200331_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="c20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c20200331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="c20210331_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c20200630_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="c20210630_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c20210331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c20200630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c20200630_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c20210630_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c20210630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c20200331_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="c20210331_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c20210101to20210630_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210630_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210630_ConsolidatedEntitiesAxis_JefferiesLLCMember_TypeOfArrangementAxis_SaleAgreement2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">adma:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:SaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20210731to20210731_ConsolidatedEntitiesAxis_JefferiesLLCMember_SubsequentEventTypeAxis_SubsequentEventMember_TypeOfArrangementAxis_SaleAgreement2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">adma:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:SaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-31</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c20210811_ConsolidatedEntitiesAxis_JefferiesLLCMember_SubsequentEventTypeAxis_SubsequentEventMember_TypeOfArrangementAxis_SaleAgreement2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">adma:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:SaleAgreement2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-11</instant>
        </period>
    </context>
    <context id="c20210528to20210528_ConsolidatedEntitiesAxis_JefferiesLLCMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_SaleAgreement2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">adma:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:SaleAgreement2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-28</startDate>
            <endDate>2021-05-28</endDate>
        </period>
    </context>
    <context id="c20210101to20210630_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_SixCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:SixCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20200101to20201231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_ThreeCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c20210101to20210630_TypeOfArrangementAxis_BiotestLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:BiotestLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20200101to20200630_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_ThreeCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210630_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_FiveCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:FiveCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20200101to20200630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c20200101to20200630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20200101to20200630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c20201231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">adma:TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20201231_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerContractsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20201231_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">adma:RightToIntermediatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20210630_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">adma:TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c20210630_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerContractsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c20210630_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">adma:RightToIntermediatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c20210630_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c20201231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20210630_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c20201231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20210630_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c20201231_PropertyPlantAndEquipmentByTypeAxis_LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20210630_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c20210630_PropertyPlantAndEquipmentByTypeAxis_AssetUnderConstructionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c20201231_PropertyPlantAndEquipmentByTypeAxis_AssetUnderConstructionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20210630_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c20201231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20210630_PropertyPlantAndEquipmentByTypeAxis_LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c20201231_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20201231_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20210101to20210630_PropertyPlantAndEquipmentByTypeAxis_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20210630_DebtInstrumentAxis_PerceptiveCreditAgreementMember_LongtermDebtTypeAxis_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:PerceptiveCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c20210101to20210630_DebtInstrumentAxis_PerceptiveCreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:PerceptiveCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20210630_DebtInstrumentAxis_PerceptiveCreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:PerceptiveCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c20210101to20210630_DebtInstrumentAxis_PerceptiveCreditAgreementMember_VariableRateAxis_LondonInterbankOfferedRateLIBORMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:PerceptiveCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20210630_DebtInstrumentAxis_PerceptiveCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:PerceptiveCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c20210630_DebtInstrumentAxis_PerceptiveCreditAgreementMember_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:PerceptiveCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c20211001to20211231_DebtInstrumentAxis_PerceptiveCreditAgreementMember_StatementScenarioAxis_ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:PerceptiveCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20190401to20190630_DebtInstrumentAxis_PerceptiveCreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:PerceptiveCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c20200805to20200805_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_JefferiesLLCMember_TypeOfArrangementAxis_SaleAgreement2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adma:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:SaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-05</startDate>
            <endDate>2020-08-05</endDate>
        </period>
    </context>
    <context id="c20210203to20210203_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_JefferiesLLCMember_TypeOfArrangementAxis_SaleAgreement2020AmendedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adma:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:SaleAgreement2020AmendedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-03</startDate>
            <endDate>2021-02-03</endDate>
        </period>
    </context>
    <context id="c20210528to20210528_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_JefferiesLLCMember_TypeOfArrangementAxis_SaleAgreement2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adma:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:SaleAgreement2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-28</startDate>
            <endDate>2021-05-28</endDate>
        </period>
    </context>
    <context id="c20200211to20200211_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-11</startDate>
            <endDate>2020-02-11</endDate>
        </period>
    </context>
    <context id="c20200221to20200221_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-21</startDate>
            <endDate>2020-02-21</endDate>
        </period>
    </context>
    <context id="c20210528to20210528_RelatedPartyTransactionsByRelatedPartyAxis_JefferiesLLCMember_StatementEquityComponentsAxis_CommonStockMember_TypeOfArrangementAxis_SaleAgreement2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adma:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:SaleAgreement2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-28</startDate>
            <endDate>2021-05-28</endDate>
        </period>
    </context>
    <context id="c20210101to20210630_RelatedPartyTransactionsByRelatedPartyAxis_JefferiesLLCMember_StatementEquityComponentsAxis_CommonStockMember_TypeOfArrangementAxis_SaleAgreement2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adma:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:SaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210630_RelatedPartyTransactionsByRelatedPartyAxis_JefferiesLLCMember_TypeOfArrangementAxis_SaleAgreement2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adma:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:SaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20200101to20200630_SubsidiarySaleOfStockAxis_OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c20200221to20200221_SubsidiarySaleOfStockAxis_OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-21</startDate>
            <endDate>2020-02-21</endDate>
        </period>
    </context>
    <context id="c20200211to20200211_SubsidiarySaleOfStockAxis_OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-11</startDate>
            <endDate>2020-02-11</endDate>
        </period>
    </context>
    <context id="c20200101to20200630_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20200101to20200630_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20200101to20200630_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c20201231_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20210630_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c20210630_PlanNameAxis_EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c20210101to20210630_PlanNameAxis_EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210630_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210630_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20200101to20200630_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c20200101to20200630_AwardTypeAxis_RestrictedStockUnitsRSUMember_TitleOfIndividualAxis_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210630_AwardTypeAxis_RestrictedStockUnitsRSUMember_TitleOfIndividualAxis_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20210630_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c20201231_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20210630_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c20200101to20200630_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c20200401to20200630_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c20200101to20200630_IncomeStatementLocationAxis_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c20210401to20210630_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20210401to20210630_IncomeStatementLocationAxis_OperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20200401to20200630_IncomeStatementLocationAxis_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210630_IncomeStatementLocationAxis_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20200101to20200630_IncomeStatementLocationAxis_OperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c20210401to20210630_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210630_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210630_IncomeStatementLocationAxis_OperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20200101to20200630_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210630_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20200401to20200630_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c20210401to20210630_IncomeStatementLocationAxis_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20200401to20200630_IncomeStatementLocationAxis_OperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210630_RelatedPartyTransactionsByRelatedPartyAxis_ArethLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adma:ArethLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20200401to20200630_RelatedPartyTransactionsByRelatedPartyAxis_ArethLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adma:ArethLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210630_RelatedPartyTransactionsByRelatedPartyAxis_GenesisBPSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adma:GenesisBPSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20210630_TitleOfIndividualAxis_ChiefScientificOfficerAndChiefMedicalOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:ChiefScientificOfficerAndChiefMedicalOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c20210101to20210630_TitleOfIndividualAxis_ChiefScientificOfficerAndChiefMedicalOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:ChiefScientificOfficerAndChiefMedicalOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210630_LineOfCreditFacilityAxis_PerceptiveCreditHoldingsIILPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adma:PerceptiveCreditHoldingsIILPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20200211to20200211_TitleOfIndividualAxis_ExecutiveVicePresidentAndChiefFinancialOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:ExecutiveVicePresidentAndChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-11</startDate>
            <endDate>2020-02-11</endDate>
        </period>
    </context>
    <context id="c20200211to20200211_OwnershipAxis_IndirectOwnershipMember_TitleOfIndividualAxis_PresidentAndChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">adma:IndirectOwnershipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:PresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-11</startDate>
            <endDate>2020-02-11</endDate>
        </period>
    </context>
    <context id="c20200211to20200211_TitleOfIndividualAxis_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-11</startDate>
            <endDate>2020-02-11</endDate>
        </period>
    </context>
    <context id="c20200211to20200211_TitleOfIndividualAxis_ChiefScientificOfficerAndChiefMedicalOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:ChiefScientificOfficerAndChiefMedicalOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-11</startDate>
            <endDate>2020-02-11</endDate>
        </period>
    </context>
    <context id="c20200211to20200211_OwnershipAxis_IndirectOwnershipMember_TitleOfIndividualAxis_ViceChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">adma:IndirectOwnershipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:ViceChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-11</startDate>
            <endDate>2020-02-11</endDate>
        </period>
    </context>
    <context id="c20200211to20200211_OwnershipAxis_DirectOwnershipMember_TitleOfIndividualAxis_PresidentAndChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">adma:DirectOwnershipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:PresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-11</startDate>
            <endDate>2020-02-11</endDate>
        </period>
    </context>
    <context id="c20200211to20200211_OwnershipAxis_DirectOwnershipMember_TitleOfIndividualAxis_ViceChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">adma:DirectOwnershipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:ViceChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-11</startDate>
            <endDate>2020-02-11</endDate>
        </period>
    </context>
    <context id="c20200211to20200211_LineOfCreditFacilityAxis_PerceptiveCreditHoldingsIILPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adma:PerceptiveCreditHoldingsIILPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-11</startDate>
            <endDate>2020-02-11</endDate>
        </period>
    </context>
    <context id="c20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2020-02-11</instant>
        </period>
    </context>
    <context id="c20210101to20210630_RangeAxis_MaximumMember_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:PlasmaPurchaseAgreementOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210630_TypeOfArrangementAxis_PlasmaPurchaseAgreementTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:PlasmaPurchaseAgreementTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210630_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:PlasmaPurchaseAgreementOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20200101to20200630_StatementGeographicalAxis_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c20200401to20200630_StatementGeographicalAxis_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c20210401to20210630_StatementGeographicalAxis_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20200101to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c20200101to20200630_StatementGeographicalAxis_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210630_StatementGeographicalAxis_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210630_StatementBusinessSegmentsAxis_CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20200401to20200630_StatementGeographicalAxis_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210630_StatementGeographicalAxis_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20200401to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c20210401to20210630_StatementGeographicalAxis_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20210401to20210630_StatementBusinessSegmentsAxis_CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20200401to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c20200101to20200630_StatementBusinessSegmentsAxis_CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20200401to20200630_StatementBusinessSegmentsAxis_CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c20210101to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20210401to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20210401to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c20200101to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c20200630_StatementBusinessSegmentsAxis_CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c20210630_StatementBusinessSegmentsAxis_CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c20210611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2021-06-11</instant>
        </period>
    </context>
    <context id="c20210611to20210611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2021-06-11</startDate>
            <endDate>2021-06-11</endDate>
        </period>
    </context>
    <context id="c20210611to20210611_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-11</startDate>
            <endDate>2021-06-11</endDate>
        </period>
    </context>
    <context id="c20210611to20210611_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-11</startDate>
            <endDate>2021-06-11</endDate>
        </period>
    </context>
    <context id="c20210726to20210726_SubsequentEventTypeAxis_SubsequentEventMember_TypeOfArrangementAxis_SaleAgreement2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:SaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-26</startDate>
            <endDate>2021-07-26</endDate>
        </period>
    </context>
    <unit id="U001">
        <measure>shares</measure>
    </unit>
    <unit id="U002">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U003">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U004">
        <measure>adma:Facility</measure>
    </unit>
    <unit id="U005">
        <measure>adma:Product</measure>
    </unit>
    <unit id="U006">
        <measure>adma:Customer</measure>
    </unit>
    <unit id="U007">
        <measure>pure</measure>
    </unit>
    <unit id="U008">
        <measure>adma:Term</measure>
    </unit>
    <unit id="U009">
        <measure>adma:Center</measure>
    </unit>
    <unit id="U010">
        <measure>adma:Lease</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="c20210101to20210630"
      id="Fact_16424b7faa9c4ba5bb45066a3d70235f">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="c20210101to20210630"
      id="Fact_839f2a878e96425d9b939d239048597d">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="c20210101to20210630"
      id="Fact_eb8baaf1209d4130afd8ba98681be698">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="c20210101to20210630"
      id="Fact_ea22fb2f847741208d9b9ce9ad800fdd">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="c20210101to20210630"
      id="Fact_ef7dde1ce93a40ba84fb284a01d64bbb">0001368514</dei:EntityCentralIndexKey>
    <dei:NoTradingSymbolFlag
      contextRef="c20210101to20210630_StatementClassOfStockAxis_PreferredSharePurchaseRightMember"
      id="Fact_273b8602e1574290ac4ea428a0ea6a9d">true</dei:NoTradingSymbolFlag>
    <adma:ProductCycleFromProcurementOfRawMaterialsToFinishedProduct
      contextRef="c20210101to20210630_RangeAxis_MinimumMember"
      id="Fact_53babb8f6d26472fabf16dec51a6b0a4">P7M</adma:ProductCycleFromProcurementOfRawMaterialsToFinishedProduct>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="c20210101to20210630_RangeAxis_MinimumMember"
      id="Fact_06457f177efa4ffeb98a18387724a0a7">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <adma:PercentageOfPlasmaPurchasePriceEqualToCost
      contextRef="c20210101to20210630_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember"
      decimals="2"
      id="Fact_5246f96bd6684b0493a757c543cd5bb9"
      unitRef="U007">0.05</adma:PercentageOfPlasmaPurchasePriceEqualToCost>
    <dei:DocumentType
      contextRef="c20210101to20210630"
      id="Fact_033967c9224a464b8818a92ef4f84a4c">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="c20210101to20210630"
      id="Fact_28c9642f73b84cfcb0abd89387439186">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="c20210101to20210630"
      id="Fact_c92e4fb6011347e081b1b8f2f7e152b7">2021-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="c20210101to20210630"
      id="Fact_82be25f2344e4cecb6fb902ef07b03c7">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="c20210101to20210630"
      id="Fact_a7733ef3c9f94a9eb4e5090d28e21308">001-36728</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="c20210101to20210630"
      id="Fact_4e3b8851bf5a4c1db6ab22389e3dacf0">ADMA BIOLOGICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20210101to20210630"
      id="Fact_2c65d664fa1d41158edc92593db858b6">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20210101to20210630"
      id="Fact_2d94e7af1ef2412ca4c53c36e330d2ba">56-2590442</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20210101to20210630"
      id="Fact_3b835463acaa486594d507a02c794254">465 State Route 17</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="c20210101to20210630"
      id="Fact_6c478f3fc81b4b89a9164eaf2c2a3258">Ramsey</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20210101to20210630"
      id="Fact_afd523726cef40e39c573246e1749b4a">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20210101to20210630"
      id="Fact_f93f7ff9c83b4d96880e0e3f2fbb4463">07446</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20210101to20210630"
      id="Fact_a49f4345d22646d6a9b5463f34355e41">201</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20210101to20210630"
      id="Fact_328de645c50c4759acbcf986cf4be9e7">478-5552</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="c20210101to20210630_StatementClassOfStockAxis_CommonStockMember"
      id="Fact_255e93c0795b443b8555a4b4253f53a9">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20210101to20210630_StatementClassOfStockAxis_CommonStockMember"
      id="Fact_db81a98acb5c42dab261aeb63c5d84a4">ADMA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20210101to20210630_StatementClassOfStockAxis_CommonStockMember"
      id="Fact_77ebb6fc7cec469fb7876b0d25642940">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="c20210101to20210630_StatementClassOfStockAxis_PreferredSharePurchaseRightMember"
      id="Fact_3fb4218939f542f0b71a21aa93994cbf">Preferred Share Purchase Right</dei:Security12bTitle>
    <dei:SecurityExchangeName
      contextRef="c20210101to20210630_StatementClassOfStockAxis_PreferredSharePurchaseRightMember"
      id="Fact_4ef94fc09dc54db9890867f97eb33f17">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="c20210101to20210630"
      id="Fact_c2eb97aba99a4893a4e4613d16713d43">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="c20210101to20210630"
      id="Fact_bf74f7d1cc724e39a9f6851adf25e2ec">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="c20210101to20210630"
      id="Fact_679ceb9e5c6848738efae54d6110b8c3">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="c20210101to20210630"
      id="Fact_1f02ca5c210e408cb232a16fc5b1e12f">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20210101to20210630"
      id="Fact_f7b4a4a5e7c54dbba9b3e16d18380d16">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="c20210101to20210630"
      id="Fact_bb41edf2dd4b4d8484c4ce87a072dc58">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c20210806"
      decimals="INF"
      id="Fact_616a2568cd2442b09691d90e8acecee9"
      unitRef="U001">132769471</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20210630"
      decimals="0"
      id="Fact_2433aaa0f77c4c2088cd8707941d7e68"
      unitRef="U002">42408958</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20201231"
      decimals="0"
      id="Fact_9cbd99f142bc49918de54d35b82c9d7f"
      unitRef="U002">55921152</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="c20210630"
      decimals="0"
      id="Fact_a65a3741507a430fb1245c9c1f8d85e2"
      unitRef="U002">23544594</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="c20201231"
      decimals="0"
      id="Fact_86347a9c044b48f19dc559a37403ea87"
      unitRef="U002">13237290</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="c20210630"
      decimals="0"
      id="Fact_9142fbb79b634d9da8f751e35db17e72"
      unitRef="U002">99699743</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="c20201231"
      decimals="0"
      id="Fact_c733c840f9854e208bc854b08f2bbeeb"
      unitRef="U002">81535599</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="c20210630"
      decimals="0"
      id="Fact_a5421b8588ca4ecfadbf6cbaacc9c7b6"
      unitRef="U002">5701863</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="c20201231"
      decimals="0"
      id="Fact_9177520ab36c49ea97cd19a1c968df92"
      unitRef="U002">3046466</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="c20210630"
      decimals="0"
      id="Fact_f0a49f8ce9bd4d899b3db3c19e04efdd"
      unitRef="U002">171355158</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="c20201231"
      decimals="0"
      id="Fact_f45b3271b441455cb2105680565b129e"
      unitRef="U002">153740507</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20210630"
      decimals="0"
      id="Fact_d8c833d9f27b421dbaa3e2b268ca0bab"
      unitRef="U002">46486980</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20201231"
      decimals="0"
      id="Fact_c7aaf9819ea84e03bf8722ce95af85af"
      unitRef="U002">41593090</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="c20210630"
      decimals="0"
      id="Fact_f17de370315f4091b0f89c2e84d973d1"
      unitRef="U002">2086445</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="c20201231"
      decimals="0"
      id="Fact_0514a0e23bdc4d0ea5e717bdf3754926"
      unitRef="U002">2444121</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="c20210630"
      decimals="0"
      id="Fact_769d5f0c97eb4064bdb43ac410530a21"
      unitRef="U002">3529509</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="c20201231"
      decimals="0"
      id="Fact_146dfcca9c3e49fa9b8a31f975e6acc2"
      unitRef="U002">3529509</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c20210630"
      decimals="0"
      id="Fact_bbc32b4cc98043e9a94ba4f7220fb722"
      unitRef="U002">6829040</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c20201231"
      decimals="0"
      id="Fact_6dd902973f4846a4bb1c1594e27f8f57"
      unitRef="U002">4259191</us-gaap:OperatingLeaseRightOfUseAsset>
    <adma:DepositsAndOtherNoncurrentAssets
      contextRef="c20210630"
      decimals="0"
      id="Fact_fdb7387d5b0a4d048c2f6366a42a0e3e"
      unitRef="U002">2526660</adma:DepositsAndOtherNoncurrentAssets>
    <adma:DepositsAndOtherNoncurrentAssets
      contextRef="c20201231"
      decimals="0"
      id="Fact_a50743018b6247889bc69ddeeb66ade6"
      unitRef="U002">2106976</adma:DepositsAndOtherNoncurrentAssets>
    <us-gaap:Assets
      contextRef="c20210630"
      decimals="0"
      id="Fact_c2f9187a8f1347b180e4de1c4e0650a0"
      unitRef="U002">232813792</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20201231"
      decimals="0"
      id="Fact_7667a4f3673d4a5c8f4ea222c3c2efa1"
      unitRef="U002">207673394</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="c20210630"
      decimals="0"
      id="Fact_7dde0dfcef624d98a7c818296df97379"
      unitRef="U002">6167465</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="c20201231"
      decimals="0"
      id="Fact_79f8959f51c440058a2b2ae73dcbf97b"
      unitRef="U002">11073708</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="c20210630"
      decimals="0"
      id="Fact_dd0f579f43084bb2aa500ce0cc36df30"
      unitRef="U002">11490239</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="c20201231"
      decimals="0"
      id="Fact_0e9ccf6016784da8a8b04f3a1af923c3"
      unitRef="U002">8365143</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="c20210630"
      decimals="0"
      id="Fact_717f5016a22d44e788a7623ed89d02dc"
      unitRef="U002">142834</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="c20201231"
      decimals="0"
      id="Fact_f9a0da175433427abcd2517ac58e7ac3"
      unitRef="U002">142834</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c20210630"
      decimals="0"
      id="Fact_e15d10dae4084e71835cb788dda3105c"
      unitRef="U002">385858</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c20201231"
      decimals="0"
      id="Fact_133ea3e3d3ae4a4c84dea5f17daf07ff"
      unitRef="U002">365682</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="c20210630"
      decimals="0"
      id="Fact_e040cd8f2ecf4ad193d82978ff855ac5"
      unitRef="U002">18186396</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="c20201231"
      decimals="0"
      id="Fact_df082a6c52ae4c43b80203fb015af4c8"
      unitRef="U002">19947367</us-gaap:LiabilitiesCurrent>
    <us-gaap:SeniorLongTermNotes
      contextRef="c20210630"
      decimals="0"
      id="Fact_5dbbafa983e447648edea5d160779986"
      unitRef="U002">93877017</us-gaap:SeniorLongTermNotes>
    <us-gaap:SeniorLongTermNotes
      contextRef="c20201231"
      decimals="0"
      id="Fact_a253f9727f7042bdb255854fc1f4cc07"
      unitRef="U002">92968866</us-gaap:SeniorLongTermNotes>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="c20210630"
      decimals="0"
      id="Fact_c6a34d215f70489cb00ad0517bb21b35"
      unitRef="U002">2047281</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="c20201231"
      decimals="0"
      id="Fact_c686e6297dea4e4d93efce7816cca250"
      unitRef="U002">2118698</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c20210630"
      decimals="0"
      id="Fact_67604891dc8248dba7f483ed9d867778"
      unitRef="U002">7073415</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c20201231"
      decimals="0"
      id="Fact_c7f10b40133643d19d8ee5f69eb7ddd7"
      unitRef="U002">4334151</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="c20210630"
      decimals="0"
      id="Fact_1425725201a64a6b81c6061265b988a6"
      unitRef="U002">36151</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="c20201231"
      decimals="0"
      id="Fact_019efd73590a4e5fb4700d5a202f9ba9"
      unitRef="U002">54886</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="c20210630"
      decimals="0"
      id="Fact_4b09c740ef954edab33c4b39d9ffc56e"
      unitRef="U002">121220260</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="c20201231"
      decimals="0"
      id="Fact_95d12ad8d1e64b189d1268bbd917203d"
      unitRef="U002">119423968</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c20210630"
      id="Fact_9109aae765d343688bd225ff5a0745fd"
      unitRef="U002"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c20201231"
      id="Fact_cd2a31ec8a274e85bda554fc0b8b2bc8"
      unitRef="U002"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c20201231"
      decimals="4"
      id="Fact_4b322bc4ff9047ada11d276fba00f032"
      unitRef="U003">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c20210630"
      decimals="4"
      id="Fact_6fc4cd5d6f0b44aba187135f7f5f2546"
      unitRef="U003">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c20201231"
      decimals="0"
      id="Fact_c51731a3209d45bc9c438cd58e2594ec"
      unitRef="U001">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c20210630"
      decimals="0"
      id="Fact_6460774f302542369b031f1439c51371"
      unitRef="U001">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c20201231"
      decimals="INF"
      id="Fact_7357d7c8b24b4172b404e8fb73377a70"
      unitRef="U001">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c20210630"
      decimals="INF"
      id="Fact_6a23abbcd48d427490a73e11ae49d3bd"
      unitRef="U001">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c20201231"
      decimals="INF"
      id="Fact_985ef26e70de4d438886de20409f6e62"
      unitRef="U001">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c20210630"
      decimals="INF"
      id="Fact_65817be99e324befbc84fa32051df194"
      unitRef="U001">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="c20210630"
      decimals="0"
      id="Fact_32421b2e655449bc95407ba53997b2dd"
      unitRef="U002">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="c20201231"
      decimals="0"
      id="Fact_1b0624f0760d4befb7bf3f49d8cdc325"
      unitRef="U002">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20201231"
      decimals="4"
      id="Fact_772895fcdb8948edaa197e1a3cbda00b"
      unitRef="U003">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20210630"
      decimals="4"
      id="Fact_0b9116e5ffd647cd91be96bc28d8ec95"
      unitRef="U003">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20210630"
      decimals="0"
      id="Fact_e17fd8ff3db44d0db345255c9de5d29c"
      unitRef="U001">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20201231"
      decimals="0"
      id="Fact_a33bbef49e4c4c0c9b8a70c07e1a3c1f"
      unitRef="U001">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20210630"
      decimals="0"
      id="Fact_be2280b446274185893dcebcbf2be1f3"
      unitRef="U001">131872026</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20210630"
      decimals="0"
      id="Fact_a47a04445e0a40c0ac5864df134f7b0a"
      unitRef="U001">131872026</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20201231"
      decimals="0"
      id="Fact_6acdb1cf62784deea606e18a567d8916"
      unitRef="U001">104902888</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20201231"
      decimals="0"
      id="Fact_4889dba395554041a519d29516e511d1"
      unitRef="U001">104902888</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="c20210630"
      decimals="0"
      id="Fact_58134c88742643e59d1016963f21fc5a"
      unitRef="U002">13187</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="c20201231"
      decimals="0"
      id="Fact_a9deedc4c75a4eca9914e129648a18c2"
      unitRef="U002">10490</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="c20210630"
      decimals="0"
      id="Fact_c293fe47874d4c80ae1b7165eead05cc"
      unitRef="U002">489330692</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="c20201231"
      decimals="0"
      id="Fact_393b6c347b684f7c93234fece20c7a2e"
      unitRef="U002">428704039</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c20210630"
      decimals="0"
      id="Fact_670ee4f1c7ce4252ae8b84b63c0b3e46"
      unitRef="U002">-377750347</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c20201231"
      decimals="0"
      id="Fact_4f86c6a8492a4d20b20ca60fb4d5913a"
      unitRef="U002">-340465103</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="c20210630"
      decimals="0"
      id="Fact_1a6712ef74b145788070fef039c2ef2d"
      unitRef="U002">111593532</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20201231"
      decimals="0"
      id="Fact_3acf9855c6604de4b9fef2d7902b6e9c"
      unitRef="U002">88249426</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="c20210630"
      decimals="0"
      id="Fact_b55ab3549e7148a98c2fb93694e5d4ad"
      unitRef="U002">232813792</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="c20201231"
      decimals="0"
      id="Fact_cceb9a747e2849a3a60625fde7c5ccf2"
      unitRef="U002">207673394</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20210401to20210630_ProductOrServiceAxis_ProductMember"
      decimals="0"
      id="Fact_c6b6bce5012d4eb49231fb67e6fe8add"
      unitRef="U002">17794881</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20200401to20200630_ProductOrServiceAxis_ProductMember"
      decimals="0"
      id="Fact_8b8a95af880c4848a5335ff17ee4cd83"
      unitRef="U002">7751885</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20210101to20210630_ProductOrServiceAxis_ProductMember"
      decimals="0"
      id="Fact_6ebf9c66719342d1b1c57fc4895ddbbf"
      unitRef="U002">33807791</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20200101to20200630_ProductOrServiceAxis_ProductMember"
      decimals="0"
      id="Fact_d6a310fe1fb64e42b233075d83db32fd"
      unitRef="U002">17915921</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20210401to20210630_ProductOrServiceAxis_LicenseAndServiceMember"
      decimals="0"
      id="Fact_638d48f759d843b986cc623c094eade2"
      unitRef="U002">35709</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20200401to20200630_ProductOrServiceAxis_LicenseAndServiceMember"
      decimals="0"
      id="Fact_67ca54a911714c0a9189ca6cb5a32515"
      unitRef="U002">35709</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20210101to20210630_ProductOrServiceAxis_LicenseAndServiceMember"
      decimals="0"
      id="Fact_448a203311114732b7548e69af691b06"
      unitRef="U002">71417</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20200101to20200630_ProductOrServiceAxis_LicenseAndServiceMember"
      decimals="0"
      id="Fact_77bb68ea3ea1472895b5bbcc786d04a8"
      unitRef="U002">71417</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20210401to20210630"
      decimals="0"
      id="Fact_8c80cfc03fa74e58958a9587696524f5"
      unitRef="U002">17830590</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20200401to20200630"
      decimals="0"
      id="Fact_d65c68a297bb40a6abc800115fd3e089"
      unitRef="U002">7787594</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_db1c99d55665420f861dc5da714d74f6"
      unitRef="U002">33879208</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_5276c028bca94dea939e43baf7116995"
      unitRef="U002">17987338</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <adma:CostOfProductRevenueExcludingAmortizationExpense
      contextRef="c20210401to20210630"
      decimals="0"
      id="Fact_2a32a17bf1c04120a3956c557c29a5e1"
      unitRef="U002">18832624</adma:CostOfProductRevenueExcludingAmortizationExpense>
    <adma:CostOfProductRevenueExcludingAmortizationExpense
      contextRef="c20200401to20200630"
      decimals="0"
      id="Fact_8185b8bd22884c3797aaa65583bc5c0d"
      unitRef="U002">13495629</adma:CostOfProductRevenueExcludingAmortizationExpense>
    <adma:CostOfProductRevenueExcludingAmortizationExpense
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_6a7985388ce14d67b72b256e7c011084"
      unitRef="U002">36602746</adma:CostOfProductRevenueExcludingAmortizationExpense>
    <adma:CostOfProductRevenueExcludingAmortizationExpense
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_fab689db4ac34073a3eccd5aa0fdb6a4"
      unitRef="U002">30324855</adma:CostOfProductRevenueExcludingAmortizationExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20210401to20210630"
      decimals="0"
      id="Fact_76fd52e789af4a42ada5afe548ae34ca"
      unitRef="U002">1158866</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20200401to20200630"
      decimals="0"
      id="Fact_538c4a8ac16743929e2629256f082196"
      unitRef="U002">1656420</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_767d365ccb6e4f8a941c3e2bf80e5305"
      unitRef="U002">2146515</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_3978299636d3471ba982778fb79b6d7f"
      unitRef="U002">3185158</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="c20210401to20210630"
      decimals="0"
      id="Fact_2508b08896b84f05ad8886a40f7a89c2"
      unitRef="U002">2803326</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="c20200401to20200630"
      decimals="0"
      id="Fact_52fbac27372245c1845f8f60f81b05dc"
      unitRef="U002">877902</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_f95713b8e2534090b79a2181f9f873de"
      unitRef="U002">5045669</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_67e7731d006e4d6194d461677b19b7a7"
      unitRef="U002">1378546</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="c20210401to20210630"
      decimals="0"
      id="Fact_68d14fb4cdbc4d52bef5ca7b73bae20b"
      unitRef="U002">178838</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="c20200401to20200630"
      decimals="0"
      id="Fact_f5817a3d25a9452f8064504e0a6ad533"
      unitRef="U002">178838</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_e047b89e58ce483392bb4e610b6699ab"
      unitRef="U002">357676</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_86f686ac3c8944008b56a6e12dec6117"
      unitRef="U002">357676</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="c20210401to20210630"
      decimals="0"
      id="Fact_d15b4b179ab441fe9251ccd2c2a696fb"
      unitRef="U002">10438168</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="c20200401to20200630"
      decimals="0"
      id="Fact_bb8adde31d404947b7945ee85af00d37"
      unitRef="U002">8702630</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_d1a168e6e11f401184561b77d9ad0a24"
      unitRef="U002">20472083</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_0ae9a0b15ed14b248b6ad733e1240f4a"
      unitRef="U002">16634714</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="c20210401to20210630"
      decimals="0"
      id="Fact_f58f61080187486cb5d586586e7c4a2a"
      unitRef="U002">33411822</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="c20200401to20200630"
      decimals="0"
      id="Fact_2bb5a41ed61441d79b84be8f5aa9af0e"
      unitRef="U002">24911419</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_829a82c7dd954db2b1c95648aa88c175"
      unitRef="U002">64624689</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_b791a46855dc487d86f347326cd93297"
      unitRef="U002">51880949</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20210401to20210630"
      decimals="0"
      id="Fact_9905cc735ec943c78fde9b7157776e2f"
      unitRef="U002">-15581232</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20200401to20200630"
      decimals="0"
      id="Fact_7ccce697ae9746d696a1b2909639981d"
      unitRef="U002">-17123825</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_3d55c702be5d4b7289ed0dfcd1bbd61c"
      unitRef="U002">-30745481</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_e3db1982360a453da28f6cb67140efc7"
      unitRef="U002">-33893611</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="c20210401to20210630"
      decimals="0"
      id="Fact_e55d7714fff74a22a9e1abdc4c73dd92"
      unitRef="U002">5926</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="c20200401to20200630"
      decimals="0"
      id="Fact_3665c88c4a624fd0b89c4ea358fc88d7"
      unitRef="U002">19411</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_3983f011cf9c44c2b31e921ee99a3c71"
      unitRef="U002">27985</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_5d0ca20aa1ca4d6f8b95e4d9dde57be9"
      unitRef="U002">267479</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="c20210401to20210630"
      decimals="0"
      id="Fact_a71ce3062d4b4766935dbad0677878b9"
      unitRef="U002">3246680</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="c20200401to20200630"
      decimals="0"
      id="Fact_49f9029bdfea42409552df53f24b26c9"
      unitRef="U002">3067306</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_ae318561cdb542efba63f477ea144d24"
      unitRef="U002">6442430</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_de970281193a47b3a8597ec3af3e3f43"
      unitRef="U002">5784397</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="c20210401to20210630"
      decimals="0"
      id="Fact_3c85d6b811a84eeebac14ccc274b24ce"
      unitRef="U002">83317</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="c20200401to20200630"
      decimals="0"
      id="Fact_d87fb0a9fd664540a55938448c6dc318"
      unitRef="U002">6371</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_897e5502eb4941bb9bb5bc25680f05e7"
      unitRef="U002">125318</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_4b207b7d0347476683916641fb38cd62"
      unitRef="U002">12792</us-gaap:OtherNonoperatingExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20210401to20210630"
      decimals="0"
      id="Fact_b922c5a89fdd43df81e81fd831e92aee"
      unitRef="U002">-3324071</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20200401to20200630"
      decimals="0"
      id="Fact_e13d75cb9d9247dba7d6ebc9bbd1d554"
      unitRef="U002">-3054266</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_c24f7f1c9c08401ca83a2922629bf451"
      unitRef="U002">-6539763</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_15362ef7299a48d5b7e06be643481db3"
      unitRef="U002">-5529710</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="c20210401to20210630"
      decimals="0"
      id="Fact_68a96a78aa6d416585ca6b454281fac2"
      unitRef="U002">-18905303</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20200401to20200630"
      decimals="0"
      id="Fact_80d68c6beb7f4bd0a0041e1773a29226"
      unitRef="U002">-20178091</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_a6c25bda09c94616b5d74178043a2d99"
      unitRef="U002">-37285244</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_368890b0c61546a488d23fc526638660"
      unitRef="U002">-39423321</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20210401to20210630"
      decimals="2"
      id="Fact_1767fd2ea00b4462b2287acdd39f05a3"
      unitRef="U003">-0.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20210401to20210630"
      decimals="2"
      id="Fact_02e2b4857360489c945db42e05ffd436"
      unitRef="U003">-0.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20200401to20200630"
      decimals="2"
      id="Fact_a486c19f3fdf440aaff7ba2317905801"
      unitRef="U003">-0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20200401to20200630"
      decimals="2"
      id="Fact_7761f59e984a497ba9d69362f54febdf"
      unitRef="U003">-0.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20210101to20210630"
      decimals="2"
      id="Fact_74ac9617cd87418ba63abfdfdf6233ce"
      unitRef="U003">-0.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20210101to20210630"
      decimals="2"
      id="Fact_10b9fb718a51441fa6a1439efe4ed952"
      unitRef="U003">-0.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20200101to20200630"
      decimals="2"
      id="Fact_ba3f9da89374448dbee1b2cfe53a211d"
      unitRef="U003">-0.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20200101to20200630"
      decimals="2"
      id="Fact_00022220cc2441389dbb2915aa6793c4"
      unitRef="U003">-0.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20210401to20210630"
      decimals="0"
      id="Fact_96e3128f83b7487380c8b5b70089ff97"
      unitRef="U001">127416126</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20210401to20210630"
      decimals="0"
      id="Fact_c276c4c49cca42a7b83987aaf34ef168"
      unitRef="U001">127416126</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20200401to20200630"
      decimals="0"
      id="Fact_c4eb368859cd47a9958f1d90fe5371a6"
      unitRef="U001">86347467</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20200401to20200630"
      decimals="0"
      id="Fact_997d6212b374457ebe5c352b4ae66f9a"
      unitRef="U001">86347467</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_9b47bdc675484b8dac471b4fa61d9e21"
      unitRef="U001">121571501</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_5c0c0d319b0346c2ad6b398b656c4519"
      unitRef="U001">121571501</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_d26d1cb38b874fa999335c65fd03d99b"
      unitRef="U001">80064641</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_be62392da41f437abc039947c0b7eb74"
      unitRef="U001">80064641</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="c20201231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_d9bb0eac3ebb4b438bf5b4a5f361df8f"
      unitRef="U001">104902888</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20201231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_a416aadadf354cd1a73ce97bfc0a6f99"
      unitRef="U002">10490</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20201231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_2d81533587df46d7927c7c09c5ab56c2"
      unitRef="U002">428704039</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20201231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_31c5976c53964850a0a9a217ef48dd3d"
      unitRef="U002">-340465103</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20201231"
      decimals="0"
      id="Fact_3b63271b81644b3ca62cc53dca107351"
      unitRef="U002">88249426</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20210101to20210331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_17e33565766842c6bedcd987230ca868"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20210101to20210331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_43764f7d695b490882c0f1f46ce6173d"
      unitRef="U002">781397</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20210101to20210331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_6ed615c81846454f9853e8777ae40da1"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20210101to20210331"
      decimals="0"
      id="Fact_4a68e1ea3a574b7a9cdde3ba16e13931"
      unitRef="U002">781397</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares
      contextRef="c20210101to20210331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_7d65e85c9377477ea19162a214a34d60"
      unitRef="U001">61385</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount
      contextRef="c20210101to20210331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_f1393b46fc2846d994eb32052518cd62"
      unitRef="U002">6</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount
      contextRef="c20210101to20210331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_c540f22d1ae34c53aa80d9959d74dd70"
      unitRef="U002">-59317</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount
      contextRef="c20210101to20210331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_e18b5f8c8db2487485a6965e0f4efbad"
      unitRef="U002">0</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount
      contextRef="c20210101to20210331"
      decimals="0"
      id="Fact_22796e2d74e04038bf14989404237ac7"
      unitRef="U002">-59311</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20210101to20210331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_fd4ec9d5d5804992a6b24579d1e47fa5"
      unitRef="U001">18080708</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20210101to20210331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_60628656272d4120bbbb68dd625c873a"
      unitRef="U002">1808</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20210101to20210331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_3744968e8ea84782b579ce927fc5b296"
      unitRef="U002">41910707</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20210101to20210331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_22a616d6162e423ea9de10dc025543b0"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20210101to20210331"
      decimals="0"
      id="Fact_dd70fabfa4124ea08591b315695f73f8"
      unitRef="U002">41912515</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="c20210101to20210331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_bdb5aab902734720af630acea4eaed7f"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210101to20210331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_223a6581262f404aa77d5c9642c5da73"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210101to20210331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_b60a607c72f3446f93ca39f04d80db0e"
      unitRef="U002">-18379941</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210101to20210331"
      decimals="0"
      id="Fact_90820523ce2148689e9f144e4f634cab"
      unitRef="U002">-18379941</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20210331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_847da51dd20c4b85922257084a19d0b6"
      unitRef="U001">123044981</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20210331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_aec245a25df645cba1bf26b341923cd8"
      unitRef="U002">12304</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20210331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_b9f5179391c44efdac9eec358175fd56"
      unitRef="U002">471336826</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20210331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_4225c99cae7b428d99ef3ced0ad03892"
      unitRef="U002">-358845044</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20210331"
      decimals="0"
      id="Fact_c5935e1d84324fc8834083db0335567c"
      unitRef="U002">112504086</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20210401to20210630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_7f8bd3c091a84861b0b5c6a5f33a4311"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20210401to20210630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_f46421f936c044fb93d56d5b70b4c43b"
      unitRef="U002">805189</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20210401to20210630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_eda8e36eeddc44adb5ab109a861a6e86"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20210401to20210630"
      decimals="0"
      id="Fact_21914908bd2d4036a4aa4f5a2804d071"
      unitRef="U002">805189</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20210401to20210630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_748aedb12326479a8d9fdd991add8f90"
      unitRef="U001">8827045</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20210401to20210630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_a311ab818c7f47e3bf13e9022be29184"
      unitRef="U002">883</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20210401to20210630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_cc5497e825fc4eaa836eeb14726f3db2"
      unitRef="U002">17188677</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20210401to20210630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_9b37d6321fcb48bcb9ad6f502e2ab32f"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20210401to20210630"
      decimals="0"
      id="Fact_2dc6488fa7b4499399a89a3928fb53aa"
      unitRef="U002">17189560</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="c20210401to20210630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_747d7c814aea453bb5dce71090b09422"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210401to20210630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_561c9623e978431bb8fc5f7f64bc45aa"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210401to20210630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_b9779245840e40bf8166ccf6d93169f2"
      unitRef="U002">-18905303</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210401to20210630"
      decimals="0"
      id="Fact_835408b616034d9faa76f9df5b43151d"
      unitRef="U002">-18905303</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20210630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_3315d84d6afd4fda99947163488f5872"
      unitRef="U001">131872026</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20210630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_f10b5fac998d4e33bd27c1c3e494347e"
      unitRef="U002">13187</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20210630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_e357f33876e94c35a9221bb458c4aa7f"
      unitRef="U002">489330692</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20210630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_15179b67f8df4031899f0b4543d4867c"
      unitRef="U002">-377750347</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20210630"
      decimals="0"
      id="Fact_de3b06ca2b0e4c0d9be8a02c29fb68dd"
      unitRef="U002">111593532</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c20191231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_e3af723878b24acf8d021cd279f9b6c3"
      unitRef="U001">59318355</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20191231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_d26666681ce04244a40a267d760c23dd"
      unitRef="U002">5932</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20191231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_df1f6f2f177046ff9b8aa1e09cbba7e2"
      unitRef="U002">290903772</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20191231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_58a9cf00c013468f9a1d263e058c4a0a"
      unitRef="U002">-264716555</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20191231"
      decimals="0"
      id="Fact_5881244e5fc4452cb44683e94e1cfe0a"
      unitRef="U002">26193149</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20200101to20200331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_a0ffbe2cf56b498884f12792290356d7"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20200101to20200331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_dcf771f123cf4f5e87c0eb4dd0f0c56c"
      unitRef="U002">676548</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20200101to20200331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_d0b4768edbfe4ffdbb56616e9701cc30"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20200101to20200331"
      decimals="0"
      id="Fact_5d5ac49545fd4fa898b3cb5f31c0c623"
      unitRef="U002">676548</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20200101to20200331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_ada50275eda24bfb94e747a548220fdf"
      unitRef="U001">27025000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20200101to20200331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_559c7123223145dda85c5bf8a5ddc05e"
      unitRef="U002">2703</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20200101to20200331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_75980879834e4eacb1498bf6445393cd"
      unitRef="U002">88701336</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20200101to20200331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_4b5f381ebbee41a2bbd901a1fa1ed789"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20200101to20200331"
      decimals="0"
      id="Fact_c0c1f109bdcb42e5a7019aff7a7bd8da"
      unitRef="U002">88704039</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20200101to20200331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_2d24d454ca15479eb0b5dc26fa6a0ef1"
      unitRef="U001">1958</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20200101to20200331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_7ee7f9f7dcc04c41ad8ba65b848acc13"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20200101to20200331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_f43acf3260c345cda98068846c5d85dc"
      unitRef="U002">7177</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20200101to20200331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_c8be8287c06d41c3aae0bd855a7a993b"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20200101to20200331"
      decimals="0"
      id="Fact_0da0e3b660b441ebac8de6b209478ec3"
      unitRef="U002">7177</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="c20200101to20200331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_ed05126635fe445baf1a05e06f893314"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20200101to20200331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_83a6894d51aa43599197d6f50eb13745"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20200101to20200331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_c310bbb136464734a0ab7bd10fbbb1cd"
      unitRef="U002">-19245230</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20200101to20200331"
      decimals="0"
      id="Fact_a0fb27d99e6449ef9d1c54766adf5484"
      unitRef="U002">-19245230</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20200331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_f1bd0ca111954cab850c2557cf0bfdda"
      unitRef="U001">86345313</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20200331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_355e50adcdc74fc3956641f095cbc781"
      unitRef="U002">8635</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20200331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_eac31b33353f4162a66b494f67bacaac"
      unitRef="U002">380288833</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20200331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_aa870c133a754af2adaed679adff1350"
      unitRef="U002">-283961785</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20200331"
      decimals="0"
      id="Fact_1a2bd3a2b89e491e989cf408beb63542"
      unitRef="U002">96335683</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20200401to20200630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_f271dccbb78b4cd6bb8e7c2621787fcf"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20200401to20200630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_52083d1b4e6f438bb9063656ee4d015c"
      unitRef="U002">715608</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20200401to20200630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_a964ffa25c9447ff9923e847dc22a1c7"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20200401to20200630"
      decimals="0"
      id="Fact_6065b0c5d0904ad7b42761ae3c5c8dca"
      unitRef="U002">715608</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20200401to20200630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_5f5e340dc1aa462ebae9aaf7b25ea3d7"
      unitRef="U001">4668</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20200401to20200630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_db6d541c60bd42969d3de03622f25b9a"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20200401to20200630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_1fa37fb7d6314366bba755b0f92a5ddb"
      unitRef="U002">6255</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20200401to20200630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_a4a8496a5f6a455480e7b139af04fda2"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20200401to20200630"
      decimals="0"
      id="Fact_75f1f9a4a4ca4064abffe062bb3a1cb9"
      unitRef="U002">6255</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="c20200401to20200630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_be478214ac9d4e638d8686d690010837"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20200401to20200630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_187697f3f9274e038e26f859a8abdfc2"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20200401to20200630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_23137b069bad49d496494f37e43889b4"
      unitRef="U002">-20178091</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20200401to20200630"
      decimals="0"
      id="Fact_36da3705617f483d985618c936fe9438"
      unitRef="U002">-20178091</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20200630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_bb5bad4b835247aea9472bb73090d4ab"
      unitRef="U001">86349981</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20200630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_03be9aa3ae29435096e5d69ef2a7d78d"
      unitRef="U002">8635</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20200630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_26202f5d634d4717a2becb5d57f8aa79"
      unitRef="U002">381010696</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20200630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_001f6983a47045c3becedc4948db400d"
      unitRef="U002">-304139876</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20200630"
      decimals="0"
      id="Fact_773acc9bd45a493a81c90eea013a9f4c"
      unitRef="U002">76879455</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_63479501b6734fa9b4bafb7d53a92ae4"
      unitRef="U002">-37285244</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_554cda1cba654604bbccaaebde7db98c"
      unitRef="U002">-39423321</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_83080cccdd6c41ebbae85287f51e38d5"
      unitRef="U002">2555622</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_ca7370b0b19e46f99b974659c5ad04e6"
      unitRef="U002">1674490</us-gaap:DepreciationAndAmortization>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_515262ae94b843ba8af2bd8952c28fa5"
      unitRef="U002">-78135</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_68fa0d6ea69d4931b29a903cca06f2d5"
      unitRef="U002">-3518</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:ShareBasedCompensation
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_8d5c2bb295224d419c3420694af40e45"
      unitRef="U002">1586586</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_670daf81ec0e4ae59184cfe715be7bcc"
      unitRef="U002">1392156</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_fd92d9f44d34479786a5d68a3983d2af"
      unitRef="U002">908151</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_f13bdc7f5a914f4084b4953436f3654d"
      unitRef="U002">874732</us-gaap:AmortizationOfDebtDiscountPremium>
    <adma:AmortizationOfLicenseRevenue
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_3e57e53903a545c1ac13b4b75ab07fce"
      unitRef="U002">-71417</adma:AmortizationOfLicenseRevenue>
    <adma:AmortizationOfLicenseRevenue
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_89a9d124aac042ee93e9b2e64f0875e0"
      unitRef="U002">-71417</adma:AmortizationOfLicenseRevenue>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_1dd109c39b304e7c91c47847eb964c36"
      unitRef="U002">10307304</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_9b8f4c75f5734cdc85490f66d98fe227"
      unitRef="U002">3044246</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_264d1acc9c834f019a733c35d2177df8"
      unitRef="U002">18164144</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_a9b6140c5d234afdb8706bbbf1d75f35"
      unitRef="U002">2936614</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_f5acef387bce4b40a96171dd2a65c78a"
      unitRef="U002">2655397</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_c77b61709a1d49c7b5267b2f15dde1bc"
      unitRef="U002">2159834</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <adma:IncreaseDecreaseInDepositsAndOtherAssets
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_b1d73d329b954767897f8f303d9ffebf"
      unitRef="U002">144657</adma:IncreaseDecreaseInDepositsAndOtherAssets>
    <adma:IncreaseDecreaseInDepositsAndOtherAssets
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_bf9008a7b96d42e0a6fa92a97ab7c4a8"
      unitRef="U002">283195</adma:IncreaseDecreaseInDepositsAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_3f886d78219940d3ae9eb541eb90c632"
      unitRef="U002">-4906244</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_5bbf598ffc494351b32f0efe70ce5fee"
      unitRef="U002">-2264932</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_40dbe8521d1446c6936e91f772fa3bf3"
      unitRef="U002">2980534</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_fd95dbec2e6c4bf48dfad93fd19f3ed9"
      unitRef="U002">399295</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_f25bbf8593734543b01b1dfd3ea1038e"
      unitRef="U002">-65984</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_973d5a4d2ef14b7abe9ed0af9a9d952f"
      unitRef="U002">-92067</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_6cfe9408e8844ab9b40d95553100bcca"
      unitRef="U002">-65491363</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_a0dea6324de24915a75e5abd788855e6"
      unitRef="U002">-45931435</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_b1f5fe8caf7047798637405d4650fbb9"
      unitRef="U002">7046735</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_4e1c44f0ac144022bf9d800076d23a3a"
      unitRef="U002">6243284</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_6797a2378adb4390a83c89996c6db0aa"
      unitRef="U002">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_319349c6d12d469ea5b228d443c43f4e"
      unitRef="U002">2000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_8b1af39671aa45ceb09f7ef327d9e32a"
      unitRef="U002">-7046735</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_d8843976a13c448cafd94324f9287089"
      unitRef="U002">-6241284</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_336dc76cd6de47ed99aa178e48304f19"
      unitRef="U002">59102075</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_06d204f867994332ab5b936e4c9ddb74"
      unitRef="U002">88704039</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_e1a434839c5c4e438182727f622e3fb7"
      unitRef="U002">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_946f591d558d46f9bea90b6cd5f7f278"
      unitRef="U002">13432</us-gaap:ProceedsFromStockOptionsExercised>
    <adma:TaxesPaidOnVestedRestrictedStockUnits
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_d32a8fddbec241f5ab3ae2c5cfadb6a4"
      unitRef="U002">59311</adma:TaxesPaidOnVestedRestrictedStockUnits>
    <adma:TaxesPaidOnVestedRestrictedStockUnits
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_f2f6799b325341b3a9d32f52e87bc068"
      unitRef="U002">0</adma:TaxesPaidOnVestedRestrictedStockUnits>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_daafaa6a38a548018b49111022183f8d"
      unitRef="U002">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_e7be14b72a6c429caeb899de0f038105"
      unitRef="U002">12500000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_32e891ca8de644d3b4189b5bb7913221"
      unitRef="U002">16860</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_ae409d8f4bc74c5ebf7a79249c40adb1"
      unitRef="U002">15765</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_69272294317744fcbfbcc384392b85ee"
      unitRef="U002">59025904</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_d0382ac483a34ed6abd49cbd4df0a0eb"
      unitRef="U002">101201706</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_45c3b87b315a4c698252bde2791e3307"
      unitRef="U002">-13512194</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_79454785ed50456da17cfe72739aa946"
      unitRef="U002">49028987</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20201231"
      decimals="0"
      id="Fact_b2be9221ca3942a0b45e4f329506aeb1"
      unitRef="U002">55921152</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20191231"
      decimals="0"
      id="Fact_2bd75314b7494603aa085ca7d4edf16b"
      unitRef="U002">26752135</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20210630"
      decimals="0"
      id="Fact_ab8dcca17d114290a2011513bb272e45"
      unitRef="U002">42408958</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20200630"
      decimals="0"
      id="Fact_2c2c2920b7a9492c8d90f7f638ebc74e"
      unitRef="U002">75781122</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="c20210101to20210630"
      id="Text_88329a42a4ee4d0fa66d0bad3c26ba8f">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;ORGANIZATION AND BUSINESS&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;ADMA Biologics, Inc. (&#x201c;ADMA&#x201d; or the &#x201c;Company&#x201d;) is an end-to-end commercial
            biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The
            Company&#x2019;s targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 33.75pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;ADMA operates through its wholly-owned subsidiaries ADMA BioManufacturing, LLC (&#x201c;ADMA
            BioManufacturing&#x201d;) and ADMA BioCenters Georgia Inc. (&#x201c;ADMA BioCenters&#x201d;). ADMA BioManufacturing was formed in January 2017 to facilitate the acquisition of the Biotest Therapy Business Unit (&#x201c;BTBU&#x201d;) from BPC Plasma, Inc. (formerly Biotest
            Pharmaceuticals Corporation) (&#x201c;BPC&#x201d; and, together with Biotest AG, &#x201c;Biotest&#x201d;) on June 6, 2017. The acquisition included certain assets (the &#x201c;Biotest Assets&#x201d;) of BTBU, which included the FDA-licensed BIVIGAM and Nabi-HB immunoglobulin products,
            and an FDA-licensed plasma fractionation manufacturing facility located in Boca Raton, FL (the &#x201c;Boca Facility&#x201d;) (the &#x201c;Biotest Transaction&#x201d;). BTBU had previously been the Company&#x2019;s third-party contract manufacturer. ADMA BioCenters is the
            Company&#x2019;s source plasma collection business with eight plasma collection facilities in various stages of approval and development
            located throughout the U.S., two of which hold an approved license with the U.S. Food and Drug Administration (the &#x201c;FDA&#x201d;) while a
            third facility has a Biologics License Application (&#x201c;BLA&#x201d;) pending FDA approval.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 33.75pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The Company has three FDA-approved products, all of which are currently marketed and commercially available: (i) BIVIGAM (Immune Globulin Intravenous, Human), an Intravenous Immune Globulin (&#x201c;IVIG&#x201d;)
            product indicated for the treatment of Primary Humoral Immunodeficiency (&#x201c;PI&#x201d;), also known as Primary Immunodeficiency Disease (&#x201c;PIDD&#x201d;), and for which the Company received FDA approval on May 9, 2019 and commenced commercial sales in August
            2019; (ii) ASCENIV (Immune Globulin Intravenous, Human &#x2013; slra 10% Liquid), an IVIG product indicated for the treatment of PI, for which the Company received FDA approval on April 1, 2019 and commenced first commercial sales in October 2019; and
            (iii) Nabi-HB (Hepatitis B Immune Globulin, Human), which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen (&#x201c;HBsAg&#x201d;) and other listed exposures to Hepatitis B. In addition to its commercially
            available immunoglobulin products, the Company provides contract manufacturing and laboratory services for certain clients and generates revenues from the sale of intermediate by-products that result from the immunoglobulin production process.
            The Company seeks to develop a pipeline of plasma-derived therapeutics, and its products and product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients with or at risk for certain
            infectious diseases.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 33.75pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;As of June 30, 2021, the Company had working capital of $153.2 million, including $42.4
            million of cash and cash equivalents. Based upon the Company&#x2019;s current projected revenue and expenditures, including capital expenditures and continued implementation of the Company&#x2019;s commercialization and expansion activities, the Company&#x2019;s
            management currently believes that its cash, cash equivalents, projected revenue and accounts receivable will be sufficient to fund ADMA&#x2019;s operations, as currently conducted, into the fourth quarter of 2021. In order to have sufficient cash to
            fund its operations thereafter, the Company anticipates it will need to raise additional capital before the end of the fourth quarter of 2021. These estimates may change based upon several factors, including the success of the Company&#x2019;s
            commercial sales of its products, manufacturing ramp-up activities, the acceptability of ADMA&#x2019;s immune globulin products by physicians, patients or payers and the various financing options that may be available to the Company. In addition, the
            Company&#x2019;s end-to-end production cycle from procurement of raw materials to commercial release of finished product can take between &lt;span style="-sec-ix-hidden:Fact_53babb8f6d26472fabf16dec51a6b0a4"&gt;seven&lt;/span&gt;
            and 12 months or potentially longer, requiring substantial investments in raw material plasma and other manufacturing materials. The
            Company currently has no firm commitments for additional financing, and there can be no assurance that the Company will be able to secure additional financing on terms that are acceptable to the Company, or at all. Furthermore, if the Company&#x2019;s
            assumptions underlying its estimated expenses and revenues are incorrect, it may have to raise additional capital sooner than currently anticipated.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
              &lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Due to numerous risks and uncertainties associated with FDA review, inspections and approvals related to the
            Company&#x2019;s products or the labeled indications of such products, ongoing compliance requirements and capacity expansion efforts at the Company&#x2019;s Boca Facility and future commercialization of the Company&#x2019;s products, including the Company&#x2019;s
            ability to obtain adequate quantities of FDA-approved plasma with proper specifications on acceptable terms for use in the Company&#x2019;s manufacturing process, as well as the additional uncertainties surrounding the COVID-19 pandemic (see Note 10),
            the Company is unable to estimate with certainty the amounts of increased capital outlays and operating expenditures required to fund its commercial and development activities. The Company&#x2019;s current estimates may be subject to change as
            circumstances regarding its business requirements evolve. Failure to secure any necessary financing in a timely manner and on commercially reasonable terms could have a material adverse effect on the Company&#x2019;s business plan and financial
            performance and it could be forced to delay or discontinue its commercialization, product development or clinical activities or delay or discontinue the approval efforts for any of the Company&#x2019;s products or product candidates. The Company has
            reported cumulative losses since inception in June 2004 through June 30, 2021 of $377.8 million. As such, these factors raise
            substantial doubt about the Company&#x2019;s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments related to the recoverability and classification of asset carrying amounts and the
            classification of liabilities that might be necessary from the outcome of this uncertainty.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The Company may decide to raise capital through public or private equity offerings or debt financings, or
            obtain a bank credit facility or enter into corporate collaboration and licensing arrangements. The sale of additional equity or debt securities, if convertible, could result in dilution to the Company&#x2019;s existing stockholders and, in such
            event, the market value of its common stock may decline. The incurrence of additional indebtedness would result in increased fixed obligations and could also result in covenants that would restrict the Company&#x2019;s operations or other financing
            alternatives. In addition, the Company is exploring additional contract manufacturing arrangements and other business development opportunities, which may provide additional liquidity to the Company.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;During the six months ended June 30, 2021, the Company raised $59.1 million from the open market sale agreement dated August 5, 2020, as amended, (the &#x201c;2020 Sale Agreement&#x201d;) with Jefferies LLC (&#x201c;Jefferies&#x201d;), pursuant to which the
            Company could offer and sell, from time to time, at its option, through or to Jefferies, shares of the Company&#x2019;s common stock (see Note 8). In July of 2021, the Company raised an additional $1.5 million under the 2020 Sale Agreement, and the Company has reached the maximum amount of funds that can be raised under the 2020 Sale Agreement.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;On May 28, 2021, the Company entered into a new Open Market Sale AgreementSM (the &#x201c;2021 Sale Agreement&#x201d;) with
            Jefferies, pursuant to which the Company may offer and sell, from time to time, at its option, through or to Jefferies, up to an aggregate of $50,000,000
            of shares of the Company&#x2019;s common stock. As of August 11, 2021, there have been no sales of common stock under the 2021 Sale
            Agreement.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;There can be no assurance that the Company&#x2019;s approved products will be commercially viable, or that research
            and development, plant capacity expansion, plasma center build-outs or other capital improvements will be successfully completed or that any product developed in the future will be approved. The Company is subject to risks common to companies
            in the biotechnology and pharmaceutical manufacturing industries including, but not limited to, dependence on collaborative arrangements, development by the Company or its competitors of new technological innovations, dependence on key
            personnel, protection of proprietary technology, and compliance with FDA and other governmental regulations and approval requirements.&lt;/div&gt;
</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <adma:NumberOfPlasmaCollectionFacilitiesUnderDevelopment
      contextRef="c20210101to20210630"
      decimals="INF"
      id="Fact_031fdfc61f444092b07221fedfa54d04"
      unitRef="U004">8</adma:NumberOfPlasmaCollectionFacilitiesUnderDevelopment>
    <adma:NumberOfFDALicensedPlasmaCollectionFacilities
      contextRef="c20210101to20210630"
      decimals="INF"
      id="Fact_5b60fa18617a487692f8cc703f2d5d9a"
      unitRef="U004">2</adma:NumberOfFDALicensedPlasmaCollectionFacilities>
    <adma:NumberOfFDAApprovedProduct
      contextRef="c20210101to20210630"
      decimals="INF"
      id="Fact_53446129f2e5474f80608ef59aff3c5e"
      unitRef="U005">3</adma:NumberOfFDAApprovedProduct>
    <adma:WorkingCapital
      contextRef="c20210630"
      decimals="-5"
      id="Fact_8194587f8e614d498f3b7f84de810705"
      unitRef="U002">153200000</adma:WorkingCapital>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c20210630"
      decimals="-5"
      id="Fact_683cefc756784e1583e970c2928e0af1"
      unitRef="U002">42400000</us-gaap:CashEquivalentsAtCarryingValue>
    <adma:ProductCycleFromProcurementOfRawMaterialsToFinishedProduct
      contextRef="c20210101to20210630_RangeAxis_MaximumMember"
      id="Fact_a74ad2c25ec64e86b81e16715fdc49b2">P12M</adma:ProductCycleFromProcurementOfRawMaterialsToFinishedProduct>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c20210630"
      decimals="-5"
      id="Fact_d1886db912c74841aa633cd5372f7284"
      unitRef="U002">-377800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="c20210101to20210630_ConsolidatedEntitiesAxis_JefferiesLLCMember_TypeOfArrangementAxis_SaleAgreement2020Member"
      decimals="-5"
      id="Fact_7fa614f8e0e54f74a221311d32613a6d"
      unitRef="U002">59100000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="c20210731to20210731_ConsolidatedEntitiesAxis_JefferiesLLCMember_SubsequentEventTypeAxis_SubsequentEventMember_TypeOfArrangementAxis_SaleAgreement2020Member"
      decimals="-5"
      id="Fact_904e693f7e3f4c1983c50b867b469a54"
      unitRef="U002">1500000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20210528to20210528_ConsolidatedEntitiesAxis_JefferiesLLCMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_SaleAgreement2021Member"
      decimals="0"
      id="Fact_2b5f8c6009ab40e6aec57a77b9348a52"
      unitRef="U002">50000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:CommonUnitIssuanceValue
      contextRef="c20210811_ConsolidatedEntitiesAxis_JefferiesLLCMember_SubsequentEventTypeAxis_SubsequentEventMember_TypeOfArrangementAxis_SaleAgreement2021Member"
      decimals="-6"
      id="Fact_54f8eb44153d4d7ab3546705cb597f69"
      unitRef="U002">0</us-gaap:CommonUnitIssuanceValue>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="c20210101to20210630"
      id="Text_de030162bc8b448998134934872398f9">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Basis of presentation&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with
            accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards
            Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;).&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the
            annual audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2020 included in the Company&#x2019;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on March
            25, 2021.&#160; The accompanying consolidated balance sheet as of December 31, 2020 was derived from the audited financial statements as of and for the year ended December 31, 2020. These condensed consolidated interim financial statements have been
            prepared in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X, and therefore omit or condense certain footnotes and other information normally included in complete consolidated financial statements prepared in
            accordance with U.S. GAAP. All intercompany balances and transactions have been eliminated in consolidation.&#160; In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all normal and recurring
            adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company&#x2019;s financial position as of June 30, 2021 and its results of operations, changes
            in equity and cash flows for the three and six months ended June 30, 2021.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;During the three and six months ended June 30, 2021 and 2020, comprehensive loss was equal to the net loss
            amounts presented for the respective periods in the accompanying condensed consolidated statements of operations.&#160;&#160; Operating results for interim periods are not necessarily indicative of the results that may be expected for the full fiscal
            year.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The preparation of financial statements requires management to make estimates and assumptions that affect the
            reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ
            from those estimates. Significant estimates include the realizable value of accounts receivable, valuation of inventory, assumptions used in projecting future liquidity and capital requirements, assumptions used in the fair value of awards
            granted under the Company&#x2019;s equity incentive plans and warrants issued in connection with the issuance of notes payable and the valuation allowance for the Company&#x2019;s deferred tax assets.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Fair value of financial instruments&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The carrying amounts of certain of the Company&#x2019;s financial instruments, including cash and cash equivalents,
            accounts receivable and accounts payable, are shown at cost which approximates fair value due to the short-term nature of these instruments.&#160; The debt outstanding under the Company&#x2019;s senior secured term loan (see Note 7) approximates fair value
            due to the variable interest rate on this debt.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt;&lt;span style="text-decoration: underline;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accounts receivable&lt;br/&gt;
              &lt;/span&gt;&lt;/span&gt; &lt;span style="text-decoration: underline;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt;&lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accounts receivable is reported at realizable value, net of allowances for contractual credits and doubtful
            accounts in the amount of $0.2 million and $0.1 million at June 30, 2021 and December 31, 2020, respectively, which are recognized in the period the related revenue is recorded. &lt;span style="color: rgb(33, 37, 41);"&gt;The Company
              extends credit to its customers based upon an evaluation of each customer&#x2019;s financial condition and credit history. Evaluations of the financial condition and associated credit risk of customers are performed on an ongoing basis.&lt;/span&gt; Based
            on these evaluations, the Company has concluded that its credit risk is minimal. At June 30, 2021, six customers accounted for an
            aggregate of 94% of the Company&#x2019;s total accounts receivable, and at December 31, 2020, three customers accounted for approximately 92% of the
            Company&#x2019;s total accounts receivable.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Inventories&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Raw materials inventory consists of various materials purchased from suppliers,
            including normal source plasma, used in the production of the Company&#x2019;s products. Work-in-process and finished goods inventories (see Note 3) reflect the cost of raw materials as well as costs for direct and indirect labor, primarily salaries,
            wages and benefits for applicable employees, as well as an allocation of overhead costs related to the Boca Facility including utilities, property taxes, general repairs and maintenance, consumable supplies and depreciation. The allocation of
            Boca Facility overhead to inventory is generally based upon the estimated square footage of the Boca Facility that is used in the production of the Company&#x2019;s products relative to the total square footage of the facility.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 33.75pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Inventories, including plasma intended for resale and plasma intended for internal
            use in the Company&#x2019;s manufacturing, commercialization or research and development activities, are carried at the lower of cost or net realizable value determined by the first-in, first-out method. Net realizable value is generally determined
            based upon the consideration the Company expects to receive when the inventory is sold, less costs to deliver the inventory to the recipient. The estimates for net realizable value of inventory are based on contractual terms or upon historical
            experience and certain other assumptions, and the Company believes that such assumptions are reasonable. Inventory is periodically reviewed to ensure that its carrying value does not exceed its net realizable value, and adjustments are recorded
            to write down such inventory, with a corresponding charge to cost of product revenue, when the carrying value or historical cost exceeds its estimated net realizable value. In addition, costs associated with the production of conformance or
            engineering lots that would not qualify as immediately available for commercial sale are charged to cost of product revenue and not capitalized into inventory.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company.&#160;
            Goodwill at June 30, 2021 and December 31, 2020 was $3.5 million.&#160; All of the Company&#x2019;s goodwill is attributable to its ADMA
            BioManufacturing business segment and is related to the 2017 Biotest Transaction.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Goodwill is not amortized but is assessed for impairment on an annual basis or more frequently if impairment
            indicators exist. The Company has the option to perform a qualitative assessment of goodwill to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill and
            other intangible assets. If the Company concludes that this is the case, then it must perform a goodwill impairment test by comparing the fair value of the reporting unit to its carrying value. An impairment charge is recorded to the extent the
            reporting unit&#x2019;s carrying value exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. The Company performs its annual goodwill impairment test as of October 1 of each year.&#160; The Company&#x2019;s annual
            goodwill impairment test as of October 1, 2020 did not result in a goodwill impairment charge, and the Company did not record
            any impairment charges related to goodwill for the three and six months ended June 30, 2021 and 2020.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The Company assesses the recoverability of its long-lived assets, which include property and equipment and
            finite-lived intangible assets, whenever significant events or changes in circumstances indicate impairment may have occurred. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to
            its carrying amount to determine whether the asset&#x2019;s carrying value is recoverable. Any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a charge to operating results. For
            the three and six months ended June 30, 2021 and 2020, the Company determined that there was no impairment of its long-lived
            assets.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Revenue recognition&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Revenues for the three and six months ended June 30, 2021 and 2020 are comprised of (i) revenues from the
            sale of the Company&#x2019;s immunoglobulin products, BIVIGAM, ASCENIV and Nabi-HB, (ii) product revenues from the sale of human plasma collected through the Company&#x2019;s Plasma Collection Centers business segment, (iii) contract manufacturing and
            laboratory services revenue, (iv) revenues from the sale of intermediate by-products; and (v) license and other revenues primarily attributable to the out-licensing of ASCENIV to Biotest in 2012 to market and sell this product in Europe and
            selected countries in North Africa and the Middle East. Biotest has provided the Company with certain services and financial payments in accordance with the related Biotest license agreement and is obligated to pay the Company certain amounts
            in the future if certain milestones are achieved. Deferred revenue is amortized into income over the term of the Biotest license, representing a period of approximately 22 years.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Product revenue is recognized when the customer is deemed to have control over the product. Control is
            determined based on when the product is shipped or delivered and title passes to the customer. Revenue is recorded in an amount that reflects the consideration the Company expects to receive in exchange. Revenue from the sale of the Company&#x2019;s
            immunoglobulin products is recognized when the product reaches the customer&#x2019;s destination, and is recorded net of estimated rebates, price protection arrangements and customer incentives, including prompt pay discounts, wholesaler chargebacks
            and other wholesaler fees. These estimates are based on historical experience and certain other assumptions, and the Company believes that such estimates are reasonable. For revenues associated with contract manufacturing and the sale of
            intermediates, control transfers to the customer and the performance obligation is satisfied when the customer takes possession of the product from the Boca Facility or from a third-party warehouse that is utilized by the Company.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Product revenues from the sale of human plasma collected at the Company&#x2019;s plasma collection centers are
            recognized at the time control of the product has been transferred to the customer, which generally occurs at the time of shipment. Product revenues are recognized at the time of delivery if the Company retains control of the product during
            shipment.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;For the six months ended June 30, 2021, five customers represented an aggregate of 85% of the Company&#x2019;s
            consolidated revenues. For the six months ended June 30, 2020, three customers represented an aggregate of 81% of the Company&#x2019;s consolidated revenues.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Cost of product revenue&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cost of product revenue includes costs associated with the manufacture of the Company&#x2019;s FDA approved
            products, intermediates and the sale of human source plasma, as well as expenses related to conformance batch production, process development and scientific and technical operations when these operations are attributable to marketed products.
            When the activities of these operations are attributable to new products in development, the expenses are classified as research and development expenses.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Loss per common share&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Basic loss per common share is computed by dividing net loss attributable to common
              stockholders by the weighted average number of shares of common stock outstanding during the period.&#160; Diluted loss per common share is calculated by dividing net loss attributable to common stockholders, as adjusted for the effect of dilutive
              securities, if any, by the weighted average number of shares of common stock and dilutive common stock outstanding during the period. Potentially dilutive common stock includes the shares of common stock issuable upon the exercise of
              outstanding stock options and warrants, using the treasury stock method. Potentially dilutive common stock is excluded from the diluted loss per common share computation to the extent that it would be anti-dilutive. As a result, no
              potentially dilutive securities are included in the computation of any of the accompanying diluted loss per share amounts in the accompanying condensed consolidated financial statements as the Company reported a net loss for all periods
              presented. &lt;/span&gt;&lt;span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;For the six months ended June 30, 2021 and 2020, the following securities were excluded
              from the calculation of diluted loss per common share because of their anti-dilutive effects:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;For the Six Months Ended June 30,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2021&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2020&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Stock options&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;7,783,029&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;6,801,779&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Restricted stock units&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;686,133&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;326,000&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Warrants&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,528,160&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,138,160&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;12,997,322&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;9,265,939&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The Company follows recognized accounting guidance which requires all equity-based payments, including grants
            of stock options, to be recognized in the statement of operations as compensation expense based on their fair values at the date of grant. Compensation expense related to awards to employees and directors with service-based vesting conditions
            is recognized on a straight-line basis over the associated vesting period of the award based on the grant date fair value of the award. Stock options granted under the Company&#x2019;s equity incentive plans generally have a four-year vesting period and a term of 10
            years. Pursuant to ASU No. 2016-09, &lt;span style="font-style: italic;"&gt;Improvements to Employee Share-Based Payment Accounting (Topic 718)&lt;/span&gt;, the Company has elected not to establish a forfeiture rate, as stock-based compensation expense
            related to forfeitures of unvested stock options is fully reversed at the time of forfeiture.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events
            that have been included in the consolidated financial statements or its tax returns. Under this method, deferred tax assets and liabilities are recognized for the temporary differences between the tax bases of assets and liabilities and their
            respective financial reporting amounts at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. The Company records a valuation allowance on its deferred tax assets if it is more likely than not
            that the Company will not generate sufficient taxable income to utilize its deferred tax assets. The Company is subject to income tax examinations by major taxing authorities for all tax years since 2016 and for previous periods as it relates
            to the Company&#x2019;s net operating loss carryforwards.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;In accordance with U.S. GAAP, the Company is required to determine whether a tax position of the Company is
            more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit to be recognized is
            measured as the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. Derecognition of a tax benefit previously recognized could result in the Company recording a tax liability that would reduce
            net assets. Based on its analysis, the Company has determined that it has not incurred any liability for unrecognized tax benefits as of June 30, 2021 and December 31, 2020, and during the three and six months ended June 30, 2021 and 2020, the
            Company recognized no adjustments for uncertain tax positions.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="text-decoration: underline;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt;&lt;span style="text-decoration: underline;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;span style="font-style: italic;"&gt;Financial Instruments &#x2013;
              Credit Losses (Topic 326)&lt;/span&gt; (&#x201c;ASU 2016-13&#x201d;), which requires financial assets to be presented at the net amount expected to be collected, with an allowance for credit losses to be deducted from the amortized cost basis of the financial
            asset such that the net carrying value of the asset is presented as the amount expected to be collected. Under ASU 2016-13, the entity&#x2019;s statement of operations is required to reflect the measurement of credit losses for newly recognized
            financial assets, as well as expected increases or decreases in expected credit losses that have taken place during the period. For public business entities, ASU 2016-13 is effective for fiscal years beginning after December 15, 2019.&#160; The
            Company adopted ASU 2016-13 on January 1, 2020, and the adoption of this update did not have a significant impact on the Company&#x2019;s consolidated financial statements.&lt;/div&gt;
</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="c20210101to20210630"
      id="Text_1b842d491338428ea527247b3dcb683e">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Basis of presentation&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with
            accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards
            Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;).&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the
            annual audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2020 included in the Company&#x2019;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on March
            25, 2021.&#160; The accompanying consolidated balance sheet as of December 31, 2020 was derived from the audited financial statements as of and for the year ended December 31, 2020. These condensed consolidated interim financial statements have been
            prepared in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X, and therefore omit or condense certain footnotes and other information normally included in complete consolidated financial statements prepared in
            accordance with U.S. GAAP. All intercompany balances and transactions have been eliminated in consolidation.&#160; In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all normal and recurring
            adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company&#x2019;s financial position as of June 30, 2021 and its results of operations, changes
            in equity and cash flows for the three and six months ended June 30, 2021.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;During the three and six months ended June 30, 2021 and 2020, comprehensive loss was equal to the net loss
            amounts presented for the respective periods in the accompanying condensed consolidated statements of operations.&#160;&#160; Operating results for interim periods are not necessarily indicative of the results that may be expected for the full fiscal
            year.&lt;/div&gt;
</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="c20210101to20210630"
      id="Text_8dc991838e454edf8db537076279b401">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The preparation of financial statements requires management to make estimates and assumptions that affect the
            reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ
            from those estimates. Significant estimates include the realizable value of accounts receivable, valuation of inventory, assumptions used in projecting future liquidity and capital requirements, assumptions used in the fair value of awards
            granted under the Company&#x2019;s equity incentive plans and warrants issued in connection with the issuance of notes payable and the valuation allowance for the Company&#x2019;s deferred tax assets.&lt;/div&gt;
</us-gaap:UseOfEstimates>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="c20210101to20210630"
      id="Text_960edfd623ae41ecbb40cabb46d04a99">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Fair value of financial instruments&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The carrying amounts of certain of the Company&#x2019;s financial instruments, including cash and cash equivalents,
            accounts receivable and accounts payable, are shown at cost which approximates fair value due to the short-term nature of these instruments.&#160; The debt outstanding under the Company&#x2019;s senior secured term loan (see Note 7) approximates fair value
            due to the variable interest rate on this debt.&lt;/div&gt;
</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="c20210101to20210630"
      id="Text_1d7ad30ef88342e895d372c263a22966">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt;&lt;span style="text-decoration: underline;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accounts receivable&lt;br/&gt;
              &lt;/span&gt;&lt;/span&gt; &lt;span style="text-decoration: underline;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt;&lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accounts receivable is reported at realizable value, net of allowances for contractual credits and doubtful
            accounts in the amount of $0.2 million and $0.1 million at June 30, 2021 and December 31, 2020, respectively, which are recognized in the period the related revenue is recorded. &lt;span style="color: rgb(33, 37, 41);"&gt;The Company
              extends credit to its customers based upon an evaluation of each customer&#x2019;s financial condition and credit history. Evaluations of the financial condition and associated credit risk of customers are performed on an ongoing basis.&lt;/span&gt; Based
            on these evaluations, the Company has concluded that its credit risk is minimal. At June 30, 2021, six customers accounted for an
            aggregate of 94% of the Company&#x2019;s total accounts receivable, and at December 31, 2020, three customers accounted for approximately 92% of the
            Company&#x2019;s total accounts receivable.&lt;/div&gt;
</us-gaap:ReceivablesPolicyTextBlock>
    <adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts
      contextRef="c20210630"
      decimals="-5"
      id="Fact_f9aeec2ee42b4158ae576a190462cc87"
      unitRef="U002">200000</adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts>
    <adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts
      contextRef="c20201231"
      decimals="-5"
      id="Fact_84ebdf5555a34034a92a8e0b907d7a7b"
      unitRef="U002">100000</adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts>
    <adma:NumberOfCustomers
      contextRef="c20210101to20210630_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_SixCustomersMember"
      decimals="INF"
      id="Fact_765cd720dbb84638856e02caa4ffe34a"
      unitRef="U006">6</adma:NumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20210101to20210630_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_SixCustomersMember"
      decimals="2"
      id="Fact_edc6bca224f9451fa65d0b352bcb7705"
      unitRef="U007">0.94</us-gaap:ConcentrationRiskPercentage1>
    <adma:NumberOfCustomers
      contextRef="c20200101to20201231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_ThreeCustomersMember"
      decimals="INF"
      id="Fact_b817f141c32e420796bf77d976d87774"
      unitRef="U006">3</adma:NumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20200101to20201231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_ThreeCustomersMember"
      decimals="2"
      id="Fact_de0c4115bbb6401695d47ca7588242d3"
      unitRef="U007">0.92</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="c20210101to20210630"
      id="Text_a6c7a7396fa04bec80b800afedb33d14">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Inventories&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Raw materials inventory consists of various materials purchased from suppliers,
            including normal source plasma, used in the production of the Company&#x2019;s products. Work-in-process and finished goods inventories (see Note 3) reflect the cost of raw materials as well as costs for direct and indirect labor, primarily salaries,
            wages and benefits for applicable employees, as well as an allocation of overhead costs related to the Boca Facility including utilities, property taxes, general repairs and maintenance, consumable supplies and depreciation. The allocation of
            Boca Facility overhead to inventory is generally based upon the estimated square footage of the Boca Facility that is used in the production of the Company&#x2019;s products relative to the total square footage of the facility.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 33.75pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Inventories, including plasma intended for resale and plasma intended for internal
            use in the Company&#x2019;s manufacturing, commercialization or research and development activities, are carried at the lower of cost or net realizable value determined by the first-in, first-out method. Net realizable value is generally determined
            based upon the consideration the Company expects to receive when the inventory is sold, less costs to deliver the inventory to the recipient. The estimates for net realizable value of inventory are based on contractual terms or upon historical
            experience and certain other assumptions, and the Company believes that such assumptions are reasonable. Inventory is periodically reviewed to ensure that its carrying value does not exceed its net realizable value, and adjustments are recorded
            to write down such inventory, with a corresponding charge to cost of product revenue, when the carrying value or historical cost exceeds its estimated net realizable value. In addition, costs associated with the production of conformance or
            engineering lots that would not qualify as immediately available for commercial sale are charged to cost of product revenue and not capitalized into inventory.&lt;/div&gt;
</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="c20210101to20210630"
      id="Text_0213f3d0f66b495f8215943a938312e6">
&lt;div&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company.&#160;
            Goodwill at June 30, 2021 and December 31, 2020 was $3.5 million.&#160; All of the Company&#x2019;s goodwill is attributable to its ADMA
            BioManufacturing business segment and is related to the 2017 Biotest Transaction.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Goodwill is not amortized but is assessed for impairment on an annual basis or more frequently if impairment
            indicators exist. The Company has the option to perform a qualitative assessment of goodwill to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill and
            other intangible assets. If the Company concludes that this is the case, then it must perform a goodwill impairment test by comparing the fair value of the reporting unit to its carrying value. An impairment charge is recorded to the extent the
            reporting unit&#x2019;s carrying value exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. The Company performs its annual goodwill impairment test as of October 1 of each year.&#160; The Company&#x2019;s annual
            goodwill impairment test as of October 1, 2020 did not result in a goodwill impairment charge, and the Company did not record
            any impairment charges related to goodwill for the three and six months ended June 30, 2021 and 2020.&lt;/div&gt;
</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:Goodwill
      contextRef="c20201231"
      decimals="-5"
      id="Fact_b434950da0d244eaad6af314e31a9db9"
      unitRef="U002">3500000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="c20210630"
      decimals="-5"
      id="Fact_7f97a79b2f634754a8c1448c59e2341a"
      unitRef="U002">3500000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="c20200401to20200630"
      decimals="0"
      id="Fact_e31e614ea2a64555ae55c0a1b239e03a"
      unitRef="U002">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="c20210401to20210630"
      decimals="0"
      id="Fact_dfda9694a19f4e86a27c7afab7dc7e6c"
      unitRef="U002">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_348a1fcf4d2041fabe9cce687927ae5a"
      unitRef="U002">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_22300304dbf44f7ba1de021402ff3e09"
      unitRef="U002">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock
      contextRef="c20210101to20210630"
      id="Text_545ada14f0fa4349907835c9c9451111">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The Company assesses the recoverability of its long-lived assets, which include property and equipment and
            finite-lived intangible assets, whenever significant events or changes in circumstances indicate impairment may have occurred. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to
            its carrying amount to determine whether the asset&#x2019;s carrying value is recoverable. Any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a charge to operating results. For
            the three and six months ended June 30, 2021 and 2020, the Company determined that there was no impairment of its long-lived
            assets.&lt;/div&gt;
</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_b88a7b3f103d48d7b059500d9c92ccc3"
      unitRef="U002">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_96ed18fd4f4b42e0af74efd7954eaa00"
      unitRef="U002">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="c20200401to20200630"
      decimals="0"
      id="Fact_5c5ca898bfdc4ff0bb699939d6742007"
      unitRef="U002">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="c20210401to20210630"
      decimals="0"
      id="Fact_2d3b3bcd432d4fbab2c7e374d2e45ecf"
      unitRef="U002">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="c20210101to20210630"
      id="Text_3fb205bcaf1f40118c3c5793f85cc5d1">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Revenue recognition&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Revenues for the three and six months ended June 30, 2021 and 2020 are comprised of (i) revenues from the
            sale of the Company&#x2019;s immunoglobulin products, BIVIGAM, ASCENIV and Nabi-HB, (ii) product revenues from the sale of human plasma collected through the Company&#x2019;s Plasma Collection Centers business segment, (iii) contract manufacturing and
            laboratory services revenue, (iv) revenues from the sale of intermediate by-products; and (v) license and other revenues primarily attributable to the out-licensing of ASCENIV to Biotest in 2012 to market and sell this product in Europe and
            selected countries in North Africa and the Middle East. Biotest has provided the Company with certain services and financial payments in accordance with the related Biotest license agreement and is obligated to pay the Company certain amounts
            in the future if certain milestones are achieved. Deferred revenue is amortized into income over the term of the Biotest license, representing a period of approximately 22 years.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Product revenue is recognized when the customer is deemed to have control over the product. Control is
            determined based on when the product is shipped or delivered and title passes to the customer. Revenue is recorded in an amount that reflects the consideration the Company expects to receive in exchange. Revenue from the sale of the Company&#x2019;s
            immunoglobulin products is recognized when the product reaches the customer&#x2019;s destination, and is recorded net of estimated rebates, price protection arrangements and customer incentives, including prompt pay discounts, wholesaler chargebacks
            and other wholesaler fees. These estimates are based on historical experience and certain other assumptions, and the Company believes that such estimates are reasonable. For revenues associated with contract manufacturing and the sale of
            intermediates, control transfers to the customer and the performance obligation is satisfied when the customer takes possession of the product from the Boca Facility or from a third-party warehouse that is utilized by the Company.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Product revenues from the sale of human plasma collected at the Company&#x2019;s plasma collection centers are
            recognized at the time control of the product has been transferred to the customer, which generally occurs at the time of shipment. Product revenues are recognized at the time of delivery if the Company retains control of the product during
            shipment.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;For the six months ended June 30, 2021, five customers represented an aggregate of 85% of the Company&#x2019;s
            consolidated revenues. For the six months ended June 30, 2020, three customers represented an aggregate of 81% of the Company&#x2019;s consolidated revenues.&lt;/div&gt;
</us-gaap:RevenueRecognitionPolicyTextBlock>
    <adma:DeferredRevenueRemainingAmortizationPeriod
      contextRef="c20210101to20210630_TypeOfArrangementAxis_BiotestLicenseAgreementMember"
      id="Fact_857680b06654436294bb045b3513be50">P22Y</adma:DeferredRevenueRemainingAmortizationPeriod>
    <adma:NumberOfCustomers
      contextRef="c20210101to20210630_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_FiveCustomersMember"
      decimals="INF"
      id="Fact_6c016d3e373a407eaa468742a38c5e1a"
      unitRef="U006">5</adma:NumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20210101to20210630_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_FiveCustomersMember"
      decimals="2"
      id="Fact_a402f527b8204294ac484dab5b668fce"
      unitRef="U007">0.85</us-gaap:ConcentrationRiskPercentage1>
    <adma:NumberOfCustomers
      contextRef="c20200101to20200630_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_ThreeCustomersMember"
      decimals="INF"
      id="Fact_3643058089f94682a7543f7e2fa227ad"
      unitRef="U006">3</adma:NumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20200101to20200630_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_ThreeCustomersMember"
      decimals="2"
      id="Fact_23eb3ddb24b747e7a24a0fae2e7a662c"
      unitRef="U007">0.81</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="c20210101to20210630"
      id="Text_6ca79cd1448e48568dbd38122f71c2fe">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Cost of product revenue&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cost of product revenue includes costs associated with the manufacture of the Company&#x2019;s FDA approved
            products, intermediates and the sale of human source plasma, as well as expenses related to conformance batch production, process development and scientific and technical operations when these operations are attributable to marketed products.
            When the activities of these operations are attributable to new products in development, the expenses are classified as research and development expenses.&lt;/div&gt;
</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="c20210101to20210630"
      id="Text_be7a6a17aee344fd8c382498d5806f8b">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Loss per common share&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Basic loss per common share is computed by dividing net loss attributable to common
              stockholders by the weighted average number of shares of common stock outstanding during the period.&#160; Diluted loss per common share is calculated by dividing net loss attributable to common stockholders, as adjusted for the effect of dilutive
              securities, if any, by the weighted average number of shares of common stock and dilutive common stock outstanding during the period. Potentially dilutive common stock includes the shares of common stock issuable upon the exercise of
              outstanding stock options and warrants, using the treasury stock method. Potentially dilutive common stock is excluded from the diluted loss per common share computation to the extent that it would be anti-dilutive. As a result, no
              potentially dilutive securities are included in the computation of any of the accompanying diluted loss per share amounts in the accompanying condensed consolidated financial statements as the Company reported a net loss for all periods
              presented. &lt;/span&gt;&lt;span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;For the six months ended June 30, 2021 and 2020, the following securities were excluded
              from the calculation of diluted loss per common share because of their anti-dilutive effects:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;For the Six Months Ended June 30,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2021&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2020&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Stock options&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;7,783,029&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;6,801,779&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Restricted stock units&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;686,133&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;326,000&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Warrants&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,528,160&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,138,160&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;12,997,322&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;9,265,939&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;
</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="c20210101to20210630"
      id="Text_757dcc9acfdb4a958e5767203abe6501">&lt;span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;For the six months ended June 30, 2021 and 2020, the following securities were excluded
              from the calculation of diluted loss per common share because of their anti-dilutive effects:&lt;/span&gt;&lt;/span&gt;
&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;For the Six Months Ended June 30,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2021&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2020&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Stock options&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;7,783,029&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;6,801,779&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Restricted stock units&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;686,133&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;326,000&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Warrants&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,528,160&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,138,160&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;12,997,322&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;9,265,939&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;
</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20210101to20210630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_b0ec6bf02b9047e1a6f5aa1e08fe7cc2"
      unitRef="U001">7783029</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20200101to20200630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_2a90e1ec001d476b82a56367acf2351e"
      unitRef="U001">6801779</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20210101to20210630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_ec18de2ae8a34627b01b6dbdd0e7979f"
      unitRef="U001">686133</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20200101to20200630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_7a9b7f19451047629e553fa815cbbb51"
      unitRef="U001">326000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20210101to20210630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"
      decimals="0"
      id="Fact_621ea809f9864d42a1ee1d82dcb8797d"
      unitRef="U001">4528160</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20200101to20200630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"
      decimals="0"
      id="Fact_770481d06bd54b60a45601bc9c2e513a"
      unitRef="U001">2138160</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_7fe5fe5656f1444389acb0cb53dcb606"
      unitRef="U001">12997322</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_40e4366bc5774e05902dc05e2a065031"
      unitRef="U001">9265939</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="c20210101to20210630"
      id="Text_1186b39f37a3449d98632bcb312117f8">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The Company follows recognized accounting guidance which requires all equity-based payments, including grants
            of stock options, to be recognized in the statement of operations as compensation expense based on their fair values at the date of grant. Compensation expense related to awards to employees and directors with service-based vesting conditions
            is recognized on a straight-line basis over the associated vesting period of the award based on the grant date fair value of the award. Stock options granted under the Company&#x2019;s equity incentive plans generally have a four-year vesting period and a term of 10
            years. Pursuant to ASU No. 2016-09, &lt;span style="font-style: italic;"&gt;Improvements to Employee Share-Based Payment Accounting (Topic 718)&lt;/span&gt;, the Company has elected not to establish a forfeiture rate, as stock-based compensation expense
            related to forfeitures of unvested stock options is fully reversed at the time of forfeiture.&lt;/div&gt;
</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="c20210101to20210630"
      id="Fact_7ddccfe384494a22b332c087d24df9f7">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="c20210101to20210630"
      id="Fact_f10cd9d6deb6466294dac26bbf9e6e8b">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="c20210101to20210630"
      id="Text_4e76a2f0cb524e40a7bd3220a1b1553c">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events
            that have been included in the consolidated financial statements or its tax returns. Under this method, deferred tax assets and liabilities are recognized for the temporary differences between the tax bases of assets and liabilities and their
            respective financial reporting amounts at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. The Company records a valuation allowance on its deferred tax assets if it is more likely than not
            that the Company will not generate sufficient taxable income to utilize its deferred tax assets. The Company is subject to income tax examinations by major taxing authorities for all tax years since 2016 and for previous periods as it relates
            to the Company&#x2019;s net operating loss carryforwards.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;In accordance with U.S. GAAP, the Company is required to determine whether a tax position of the Company is
            more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit to be recognized is
            measured as the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. Derecognition of a tax benefit previously recognized could result in the Company recording a tax liability that would reduce
            net assets. Based on its analysis, the Company has determined that it has not incurred any liability for unrecognized tax benefits as of June 30, 2021 and December 31, 2020, and during the three and six months ended June 30, 2021 and 2020, the
            Company recognized no adjustments for uncertain tax positions.&lt;/div&gt;
</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="c20201231"
      decimals="0"
      id="Fact_9336d6533c59498c84a77fc670792924"
      unitRef="U002">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="c20210630"
      decimals="0"
      id="Fact_264d67f0fcb9482d8b477f062519733e"
      unitRef="U002">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="c20210101to20210630"
      id="Text_5d994092f5414d759c1e66c8cee1a148">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="text-decoration: underline;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt;&lt;span style="text-decoration: underline;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;span style="font-style: italic;"&gt;Financial Instruments &#x2013;
              Credit Losses (Topic 326)&lt;/span&gt; (&#x201c;ASU 2016-13&#x201d;), which requires financial assets to be presented at the net amount expected to be collected, with an allowance for credit losses to be deducted from the amortized cost basis of the financial
            asset such that the net carrying value of the asset is presented as the amount expected to be collected. Under ASU 2016-13, the entity&#x2019;s statement of operations is required to reflect the measurement of credit losses for newly recognized
            financial assets, as well as expected increases or decreases in expected credit losses that have taken place during the period. For public business entities, ASU 2016-13 is effective for fiscal years beginning after December 15, 2019.&#160; The
            Company adopted ASU 2016-13 on January 1, 2020, and the adoption of this update did not have a significant impact on the Company&#x2019;s consolidated financial statements.&lt;/div&gt;
</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="c20210101to20210630"
      id="Text_b0ac280d826c42309d29f504917785df">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;INVENTORIES&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The following table provides the components of inventories:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="margin-left: 13.5pt;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;June 30,&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2021&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;December 31,&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2020&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Raw materials&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;33,058,221&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;32,044,393&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Work-in-process&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;49,163,125&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;30,293,288&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Finished goods&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;17,478,397&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;19,197,918&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total inventories&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;99,699,743&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;81,535,599&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Raw materials includes plasma and other materials expected to be used in the production of BIVIGAM, ASCENIV
            and Nabi-HB, as there are alternative uses for these materials that provide a probable future benefit or will be consumed in the production of goods expected to be available for sale. All other activities and materials associated with the
            production of inventories used in research and development activities are expensed as incurred.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Work-in-process inventory primarily consists of bulk drug substance and unlabeled filled vials of the
            Company&#x2019;s immunoglobulin products. Finished goods inventory is comprised of immunoglobulin product inventory and related intermediates that are available for commercial sale, as well as plasma collected at the Company&#x2019;s plasma collection
            centers which is expected to be sold to third-party customers.&lt;/div&gt;
</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="c20210101to20210630"
      id="Text_bf83d86f9e0a4222991cdbebd88801ef">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The following table provides the components of inventories:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="margin-left: 13.5pt;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;June 30,&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2021&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;December 31,&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2020&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Raw materials&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;33,058,221&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;32,044,393&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Work-in-process&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;49,163,125&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;30,293,288&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Finished goods&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;17,478,397&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;19,197,918&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total inventories&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;99,699,743&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;81,535,599&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;
</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="c20210630"
      decimals="0"
      id="Fact_527fb3c30e30438ba359a2e8c79a1475"
      unitRef="U002">33058221</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="c20201231"
      decimals="0"
      id="Fact_c91f1d76395840c0aeebf90392124dc9"
      unitRef="U002">32044393</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="c20210630"
      decimals="0"
      id="Fact_49addd6918df4b1e863be6f5dde00376"
      unitRef="U002">49163125</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="c20201231"
      decimals="0"
      id="Fact_d877f0887a244d41b83e05fbbabbddcd"
      unitRef="U002">30293288</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="c20210630"
      decimals="0"
      id="Fact_3b8a7bf4100a4172987bd7851d7d4a45"
      unitRef="U002">17478397</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="c20201231"
      decimals="0"
      id="Fact_b237f9c9645a40c49ea0cb93d7710d48"
      unitRef="U002">19197918</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="c20210630"
      decimals="0"
      id="Fact_57c803b6a4bb4e8ba71f2165eec17864"
      unitRef="U002">99699743</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="c20201231"
      decimals="0"
      id="Fact_372d280e8bd34d0b8512003fa601b468"
      unitRef="U002">81535599</us-gaap:InventoryNet>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="c20210101to20210630"
      id="Text_f46b388b3a2a480ca88f823b8eb2cec7">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;INTANGIBLE ASSETS&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Intangible assets at June 30, 2021 and December 31, 2020 consist of the following:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;June 30, 2021&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;December 31, 2020&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; Cost&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accumulated&lt;/div&gt;
                    &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; Amortization&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cost&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accumulated&lt;/div&gt;
                    &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; Amortization&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Trademark and other intangible rights related to Nabi-HB&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,100,046&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,391,693&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,708,353&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,100,046&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,098,833&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,001,213&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 28%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Rights to intermediates&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;907,421&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;529,329&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;378,092&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;907,421&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;464,513&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;442,908&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 28%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Customer contract&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,076,557&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,076,557&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,076,557&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,076,557&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 28%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;6,084,024&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,997,579&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,086,445&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;6,084,024&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,639,903&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,444,121&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;All of the Company&#x2019;s intangible assets were acquired in the Biotest Transaction. Amortization
              expense related to these intangible assets was $0.2 million for the three months ended June 30, 2021 and 2020, and $0.4 million for the six months ended June 30, 2021 and 2020. &lt;/span&gt;&lt;span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Estimated aggregate future aggregate amortization expense is expected to be as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-indent: 0pt;"&gt;2021&lt;/span&gt;&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;357,676&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-indent: 0pt;"&gt;2022&lt;/span&gt;&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;715,352&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-indent: 0pt;"&gt;2023&lt;/span&gt;&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;715,352&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-indent: 0pt;"&gt;2024&lt;/span&gt;&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;298,065&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="c20210101to20210630"
      id="Text_198a34bb24c64972a597f9e24fef66c1">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Intangible assets at June 30, 2021 and December 31, 2020 consist of the following:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;June 30, 2021&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;December 31, 2020&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; Cost&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accumulated&lt;/div&gt;
                    &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; Amortization&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cost&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accumulated&lt;/div&gt;
                    &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; Amortization&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Trademark and other intangible rights related to Nabi-HB&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,100,046&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,391,693&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,708,353&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,100,046&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,098,833&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,001,213&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 28%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Rights to intermediates&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;907,421&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;529,329&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;378,092&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;907,421&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;464,513&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;442,908&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 28%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Customer contract&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,076,557&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,076,557&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,076,557&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,076,557&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 28%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;6,084,024&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,997,579&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,086,445&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;6,084,024&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,639,903&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,444,121&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;
</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c20210630_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember"
      decimals="0"
      id="Fact_b74a0adb91f14351a69efe85b7e9b490"
      unitRef="U002">4100046</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="c20210630_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember"
      decimals="0"
      id="Fact_f04c3df0a90d4d2da160ecb87eca7b72"
      unitRef="U002">2391693</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="c20210630_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember"
      decimals="0"
      id="Fact_c45bd005ea3a4821bffc1f02b555fdb4"
      unitRef="U002">1708353</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c20201231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember"
      decimals="0"
      id="Fact_05ec63b4278e4094a58ff967b9ce000e"
      unitRef="U002">4100046</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="c20201231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember"
      decimals="0"
      id="Fact_3da2219f23704774a076f9d1d0de7a2f"
      unitRef="U002">2098833</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="c20201231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember"
      decimals="0"
      id="Fact_222f3d5a7ca64bcbaa739ce2e2bc3214"
      unitRef="U002">2001213</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c20210630_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember"
      decimals="0"
      id="Fact_9f936fcb17f94a1e94fd804c9eb3d970"
      unitRef="U002">907421</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="c20210630_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember"
      decimals="0"
      id="Fact_d8ca3b23ad2b4770a6e405cda9bdaa69"
      unitRef="U002">529329</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="c20210630_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember"
      decimals="0"
      id="Fact_6e69768fd81141c2b77ffd4c111a4be3"
      unitRef="U002">378092</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c20201231_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember"
      decimals="0"
      id="Fact_f08ccb63aac04056983b5606be749f78"
      unitRef="U002">907421</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="c20201231_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember"
      decimals="0"
      id="Fact_9818fee6ac224c78a2cb73df8f524a69"
      unitRef="U002">464513</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="c20201231_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember"
      decimals="0"
      id="Fact_e6dc8e27792043cc8f15faaa9ffcc955"
      unitRef="U002">442908</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c20210630_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerContractsMember"
      decimals="0"
      id="Fact_e9baa7920fc7409b9dd3e88df8fe62da"
      unitRef="U002">1076557</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="c20210630_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerContractsMember"
      decimals="0"
      id="Fact_d82744dc45ab4156bbc6d6fda450d25d"
      unitRef="U002">1076557</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="c20210630_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerContractsMember"
      decimals="0"
      id="Fact_3dfa6bad96f94faba0a3c8f0714215b5"
      unitRef="U002">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c20201231_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerContractsMember"
      decimals="0"
      id="Fact_e7550bdc6f73474cbf0c1d255987c9aa"
      unitRef="U002">1076557</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="c20201231_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerContractsMember"
      decimals="0"
      id="Fact_f81925b8a5114ac792c0180d9360e2ce"
      unitRef="U002">1076557</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="c20201231_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerContractsMember"
      decimals="0"
      id="Fact_9e8c4929136c421094a1829b18fa2f9d"
      unitRef="U002">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c20210630"
      decimals="0"
      id="Fact_ad182d01a2714b15b2d466dd4b3af2e7"
      unitRef="U002">6084024</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="c20210630"
      decimals="0"
      id="Fact_2b7ff99af9dc465d911a5b351025c0ee"
      unitRef="U002">3997579</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="c20210630"
      decimals="0"
      id="Fact_e8bc8743842c4af0934be2b2c577dc21"
      unitRef="U002">2086445</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c20201231"
      decimals="0"
      id="Fact_e7b354c296cf43ca848a8fad4d297f4c"
      unitRef="U002">6084024</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="c20201231"
      decimals="0"
      id="Fact_df23fa5c8baa45dbbf157c82d571d810"
      unitRef="U002">3639903</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="c20201231"
      decimals="0"
      id="Fact_ec316a666c42447da6f184f02ec1d192"
      unitRef="U002">2444121</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="c20210401to20210630"
      decimals="-5"
      id="Fact_126ef81d669f4b68a75963df73aac867"
      unitRef="U002">200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="c20200401to20200630"
      decimals="-5"
      id="Fact_094ae4a5baeb47f1bab1494afc054b89"
      unitRef="U002">200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="c20200101to20200630"
      decimals="-5"
      id="Fact_2d31f285567d43e5885f5c63c793961f"
      unitRef="U002">400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="c20210101to20210630"
      decimals="-5"
      id="Fact_18c87486451e45cba6cb8bdaaa56dafa"
      unitRef="U002">400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="c20210101to20210630"
      id="Text_fb3841ea63e849d5b88c7023ee6513dd">&lt;span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Estimated aggregate future aggregate amortization expense is expected to be as follows:&lt;/span&gt;&lt;/span&gt;
&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-indent: 0pt;"&gt;2021&lt;/span&gt;&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;357,676&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-indent: 0pt;"&gt;2022&lt;/span&gt;&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;715,352&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-indent: 0pt;"&gt;2023&lt;/span&gt;&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;715,352&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-indent: 0pt;"&gt;2024&lt;/span&gt;&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;298,065&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="c20210630"
      decimals="0"
      id="Fact_5cd6d93ee2044a628addb65369d7fbfa"
      unitRef="U002">357676</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths
      contextRef="c20210630"
      decimals="0"
      id="Fact_1c9b4833806b4a96a67f46d9cd97cff9"
      unitRef="U002">715352</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo
      contextRef="c20210630"
      decimals="0"
      id="Fact_1f34843077c64ef685398928a3bcd416"
      unitRef="U002">715352</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree
      contextRef="c20210630"
      decimals="0"
      id="Fact_646e20b3cf9e4e31bf1c6458a0933022"
      unitRef="U002">298065</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="c20210101to20210630"
      id="Text_c58c1d3b3a2e40808b659d66e69f3c99">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Property and equipment and related accumulated depreciation are summarized as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;June 30, 2021&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;December 31, 2020&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Manufacturing and laboratory equipment&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;15,082,205&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;14,468,874&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Office equipment and computer software&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,649,504&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,253,528&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Furniture and fixtures&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,516,729&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,039,398&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Construction in process&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,966,844&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,336,557&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Leasehold improvements&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;7,192,820&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,272,490&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Land&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,339,441&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,339,441&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Buildings and building improvements&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;18,694,960&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;17,746,744&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 76%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;57,442,503&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;50,457,032&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Less: Accumulated depreciation&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(10,955,523&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(8,863,942&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total property and equipment, net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;46,486,980&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;41,593,090&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Fixed assets are stated at cost less accumulated depreciation. Depreciation is calculated using the
            straight-line method over the asset&#x2019;s estimated useful life.&#160; Land is not depreciated. The buildings were assigned a useful life of 30
            years. Property and equipment other than land and buildings have useful lives ranging from &lt;span style="-sec-ix-hidden:Fact_06457f177efa4ffeb98a18387724a0a7"&gt;three&lt;/span&gt; to 10 years.&#160; Leasehold improvements are amortized over the lesser of the lease term or their estimated useful lives.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The Company recorded depreciation expense on property and equipment for
              the three and six months ended June 30, 2021 of $1.1 million and $2.2 million, respectively. Depreciation expense for the three and six months ended June 30, 2020 was $&lt;/span&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;0.7&lt;span style="color: rgb(0, 0, 0);"&gt; million and $&lt;/span&gt;1.3&lt;span style="color: rgb(0, 0, 0);"&gt; million, respectively. &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="c20210101to20210630"
      id="Text_593a680e06f44efe9f78af2c2597bdb7">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Property and equipment and related accumulated depreciation are summarized as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;June 30, 2021&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;December 31, 2020&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Manufacturing and laboratory equipment&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;15,082,205&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;14,468,874&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Office equipment and computer software&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,649,504&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,253,528&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Furniture and fixtures&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,516,729&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,039,398&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Construction in process&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,966,844&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,336,557&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Leasehold improvements&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;7,192,820&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,272,490&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Land&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,339,441&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,339,441&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Buildings and building improvements&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;18,694,960&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;17,746,744&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 76%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;57,442,503&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;50,457,032&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Less: Accumulated depreciation&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(10,955,523&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(8,863,942&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total property and equipment, net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;46,486,980&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;41,593,090&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;
</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20210630_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember"
      decimals="0"
      id="Fact_2c175418a7654108a35345494fed389b"
      unitRef="U002">15082205</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20201231_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember"
      decimals="0"
      id="Fact_8cba11ac5dca42ebbee1f55fbe870d6d"
      unitRef="U002">14468874</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20210630_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember"
      decimals="0"
      id="Fact_ce36a24b8da847389b97fd90b9107ccd"
      unitRef="U002">3649504</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20201231_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember"
      decimals="0"
      id="Fact_7ca07f41969344bd80d925df529cbd5d"
      unitRef="U002">3253528</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20210630_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember"
      decimals="0"
      id="Fact_27112b2cb5ff4b2da9776b7697d1a5ad"
      unitRef="U002">2516729</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20201231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember"
      decimals="0"
      id="Fact_34b55090808d4bf394ae2cb8f50c2966"
      unitRef="U002">2039398</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20210630_PropertyPlantAndEquipmentByTypeAxis_AssetUnderConstructionMember"
      decimals="0"
      id="Fact_29ceb6fa9d39489db0cf1098bdaad041"
      unitRef="U002">5966844</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20201231_PropertyPlantAndEquipmentByTypeAxis_AssetUnderConstructionMember"
      decimals="0"
      id="Fact_97c9612ab90e4868aea08a592737f1bf"
      unitRef="U002">3336557</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20210630_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember"
      decimals="0"
      id="Fact_abf87fa5832444288db4b83e78b9e240"
      unitRef="U002">7192820</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20201231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember"
      decimals="0"
      id="Fact_90acb1fabb98443a8822d116a7aab696"
      unitRef="U002">5272490</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20210630_PropertyPlantAndEquipmentByTypeAxis_LandMember"
      decimals="0"
      id="Fact_c7fd96371e8348b38ee74fc91f97cd5d"
      unitRef="U002">4339441</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20201231_PropertyPlantAndEquipmentByTypeAxis_LandMember"
      decimals="0"
      id="Fact_2b574a0687864c23be2876fb4fba62a5"
      unitRef="U002">4339441</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20210630_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember"
      decimals="0"
      id="Fact_88a5d5b0a39b422b96872750efcab8de"
      unitRef="U002">18694960</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20201231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember"
      decimals="0"
      id="Fact_4b9ea9c832d34abe929900ca57b624eb"
      unitRef="U002">17746744</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20210630"
      decimals="0"
      id="Fact_886726622550403ca500ad1258afaac1"
      unitRef="U002">57442503</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20201231"
      decimals="0"
      id="Fact_9f5497c16d8c4e68aa79c6656e6a6730"
      unitRef="U002">50457032</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="c20210630"
      decimals="0"
      id="Fact_3dafb370d28944dfb131b254fabc764c"
      unitRef="U002">10955523</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="c20201231"
      decimals="0"
      id="Fact_ea9b4bd62db146a788e9e6a03c72c668"
      unitRef="U002">8863942</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20210630"
      decimals="0"
      id="Fact_e69006edba5847bfb29ccdc0d305b696"
      unitRef="U002">46486980</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20201231"
      decimals="0"
      id="Fact_44a51fb982e84ac5ac15122a73ebacb8"
      unitRef="U002">41593090</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="c20210101to20210630_PropertyPlantAndEquipmentByTypeAxis_BuildingMember"
      id="Fact_2eda57c5d24c4eb7acbd922f12b25dbc">P30Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="c20210101to20210630_RangeAxis_MaximumMember"
      id="Fact_cc1f606ddd494dffa9ad6acccd5a597d">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="c20210401to20210630"
      decimals="-5"
      id="Fact_f716318d759641b1acde06129bb9ac20"
      unitRef="U002">1100000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="c20210101to20210630"
      decimals="-5"
      id="Fact_782f2e7922a049bdad707d58e720385e"
      unitRef="U002">2200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="c20200401to20200630"
      decimals="-5"
      id="Fact_9fd2b8dee66f4085bbf00d395bced584"
      unitRef="U002">700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="c20200101to20200630"
      decimals="-5"
      id="Fact_e15d4f50beb74ea6a2f9fbec788cab35"
      unitRef="U002">1300000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="c20210101to20210630"
      id="Text_ba86dceeeabc4c1dba19c743f8d13860">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;6.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accrued expenses and other current liabilities at June 30, 2021 and December 31, 2020 are as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;June 30, 2021&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;December 31, 2020&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accrued rebates&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,721,888&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,604,245&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accrued distribution fees&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,928,901&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;828,120&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accrued payroll&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;691,483&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;734,972&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accrued testing&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,673,120&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;779,660&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accrued incentives&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,539,491&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,210,884&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accrued severance&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;789,534&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Other&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,145,822&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;207,262&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total accrued expenses and other current liabilities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;11,490,239&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;8,365,143&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="c20210101to20210630"
      id="Text_d77cd9f2ea5a4f698f33265e16548c2e">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accrued expenses and other current liabilities at June 30, 2021 and December 31, 2020 are as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;June 30, 2021&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;December 31, 2020&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accrued rebates&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,721,888&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,604,245&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accrued distribution fees&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,928,901&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;828,120&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accrued payroll&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;691,483&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;734,972&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accrued testing&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,673,120&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;779,660&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accrued incentives&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,539,491&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,210,884&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accrued severance&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;789,534&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Other&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,145,822&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;207,262&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total accrued expenses and other current liabilities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;11,490,239&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;8,365,143&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <adma:AccruedRebatesCurrent
      contextRef="c20210630"
      decimals="0"
      id="Fact_41c719c528e3459b8888bf240ee1370b"
      unitRef="U002">3721888</adma:AccruedRebatesCurrent>
    <adma:AccruedRebatesCurrent
      contextRef="c20201231"
      decimals="0"
      id="Fact_92b4f4d3a4154dc793ed280e77a11237"
      unitRef="U002">2604245</adma:AccruedRebatesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="c20210630"
      decimals="0"
      id="Fact_4e8dfa15482644c58393790fe4d1d054"
      unitRef="U002">1928901</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="c20201231"
      decimals="0"
      id="Fact_5762360155e34e158cb27077438c22e8"
      unitRef="U002">828120</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="c20210630"
      decimals="0"
      id="Fact_c224df12c2be46269ccfd33516d7e0e3"
      unitRef="U002">691483</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="c20201231"
      decimals="0"
      id="Fact_da196edb37ff435ab593c23547539135"
      unitRef="U002">734972</us-gaap:AccruedSalariesCurrent>
    <us-gaap:LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount
      contextRef="c20210630"
      decimals="0"
      id="Fact_f48292f4d7244ed8b6d47d74be964607"
      unitRef="U002">1673120</us-gaap:LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount>
    <us-gaap:LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount
      contextRef="c20201231"
      decimals="0"
      id="Fact_8529173c98994f1abb50fb3eb52717d0"
      unitRef="U002">779660</us-gaap:LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount>
    <us-gaap:AccruedBonusesCurrent
      contextRef="c20210630"
      decimals="0"
      id="Fact_9d669b64b2344ea1a4e63074c6b5a396"
      unitRef="U002">1539491</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="c20201231"
      decimals="0"
      id="Fact_e4e50ddd301a417892b184780cf5cbc4"
      unitRef="U002">3210884</us-gaap:AccruedBonusesCurrent>
    <us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits
      contextRef="c20210630"
      decimals="0"
      id="Fact_96c1df4e7d034e639c610076ae10d654"
      unitRef="U002">789534</us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits>
    <us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits
      contextRef="c20201231"
      decimals="0"
      id="Fact_a65570df1969408ab1cf0cf9b9602316"
      unitRef="U002">0</us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="c20210630"
      decimals="0"
      id="Fact_63d31af9e52b401b88c919f89b33e1e9"
      unitRef="U002">1145822</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="c20201231"
      decimals="0"
      id="Fact_8ca45eeb425540e88e381605a7215d38"
      unitRef="U002">207262</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="c20210630"
      decimals="0"
      id="Fact_631d7514e524465abb18a1af67f3c8d2"
      unitRef="U002">11490239</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="c20201231"
      decimals="0"
      id="Fact_840dc4a07dab4a4c9bb1c89eec064a01"
      unitRef="U002">8365143</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:LongTermDebtTextBlock
      contextRef="c20210101to20210630"
      id="Text_8d67bee99c5242b6b262160cf53a6e8e">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: bold;"&gt;7.&lt;/span&gt;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;DEBT&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;A summary of outstanding senior notes payable is as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="margin-left: 13.5pt;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;June 30, 2021&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;December 31, 2020&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Notes payable&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;100,000,000&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;100,000,000&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Less:&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Debt discount&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(6,122,983&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(7,031,134&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Senior notes payable&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;93,877,017&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;92,968,866&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Under the Credit Agreement and Guaranty, as amended from time to time, (the &#x201c;Perceptive Credit Agreement&#x201d;)
            with Perceptive Credit Holdings II, LP, as the lender and administrative agent (&#x201c;Perceptive&#x201d;), the Company has a principal balance outstanding to Perceptive in the form of senior secured notes payable to Perceptive aggregating to $100.0 million with a maturity date of March 1, 2024
            (the &#x201c;Maturity Date&#x201d;), subject to acceleration pursuant to the Perceptive Credit Agreement, including upon an Event of Default (as defined in the Perceptive Credit Agreement). On the Maturity Date, the Company will pay Perceptive the entire
            outstanding principal amount and any accrued and unpaid interest thereon. Prior to the Maturity Date, there are no scheduled principal payments due under the Perceptive Credit Agreement.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Borrowings under the Perceptive Credit Agreement bear interest at a rate per annum equal to 7.5% plus the greater of (i) one-month
            LIBOR and (ii) 3.5%; provided, however, that upon, and during the continuance of, an Event of Default, the interest rate will
            automatically increase by an additional 400 basis points. Accrued interest is payable to Perceptive on the last day of each month
            during the term of the Perceptive Credit Facility. The rate of interest in effect as of June 30, 2021 was 11.0%, and the Company
            paid interest to Perceptive during the six months ended June 30, 2021 and 2020 in the amount of $5.5 million and $4.4 million, respectively.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;All of the Company&#x2019;s obligations under the Perceptive Credit Agreement are secured by a first-priority lien
            and security interest in substantially all of the Company&#x2019;s tangible and intangible assets, including intellectual property and all of the equity interests in the Company&#x2019;s subsidiaries. The Perceptive Credit Agreement contains certain
            representations and warranties, affirmative covenants, negative covenants and conditions that are customarily required for similar financings. The negative covenants restrict or limit the ability of the Company and its subsidiaries to, among
            other things and subject to certain exceptions contained in the Perceptive Credit Agreement, incur new indebtedness; create liens on assets; engage in certain fundamental corporate changes, such as mergers or acquisitions, or changes to the
            Company&#x2019;s or its subsidiaries&#x2019; business activities; make certain Investments or Restricted Payments (each as defined in the Perceptive Credit Agreement); change its fiscal year; pay dividends; repay other certain indebtedness; engage in certain
            affiliate transactions; or enter into, amend or terminate any other agreements that have the impact of restricting the Company&#x2019;s ability to make loan repayments under the Perceptive Credit Agreement. In addition, the Company must (i) at all
            times prior to the Maturity Date maintain a minimum cash balance of $3.0 million; and (ii) as of the last day of each fiscal quarter
            commencing with the fiscal quarter ended June 30, 2019, report revenues for the trailing 12-month period that exceed the amounts set forth in the Perceptive Credit Agreement, which range from $7.0 million for the fiscal quarter ended June 30, 2019 to $55.0
            million for the fiscal quarter ending December 31, 2021. At June 30, 2021, the Company was in compliance with all of the covenants contained in the Perceptive Credit Agreement.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;As a result of the fees paid to Perceptive and the value of the warrants issued to Perceptive under the terms
            of the Perceptive Credit Agreement, the Company recognized an aggregate discount on the senior secured notes in the amount of $7.1
            million.&#160; The Company records debt discount as a reduction to the face amount of the debt, and the debt discount is amortized as interest expense over the life of the debt using the interest method. Based on the fair value of the Perceptive
            Warrants and the aggregate amount of fees and expenses associated with obtaining the Perceptive Credit Facility, the effective interest rate on senior secured notes payable to Perceptive as of June 30, 2021 was approximately 13.7%.&lt;/div&gt;
</us-gaap:LongTermDebtTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="c20210101to20210630"
      id="Text_fb30672c877d44ed80eab25761383540">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;A summary of outstanding senior notes payable is as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="margin-left: 13.5pt;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;June 30, 2021&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;December 31, 2020&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Notes payable&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;100,000,000&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;100,000,000&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Less:&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Debt discount&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(6,122,983&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(7,031,134&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Senior notes payable&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;93,877,017&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;92,968,866&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;
</us-gaap:ScheduleOfDebtTableTextBlock>
    <adma:SeniorNotesPayableBeforeDebtDiscount
      contextRef="c20210630"
      decimals="0"
      id="Fact_426c94243fae42a8aecdc9e76c6b85ee"
      unitRef="U002">100000000</adma:SeniorNotesPayableBeforeDebtDiscount>
    <adma:SeniorNotesPayableBeforeDebtDiscount
      contextRef="c20201231"
      decimals="0"
      id="Fact_ac74dcba15724b1f8d31cb1d092ad7ff"
      unitRef="U002">100000000</adma:SeniorNotesPayableBeforeDebtDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="c20210630"
      decimals="0"
      id="Fact_a0d8dbbcdd1b41eaaff2142b0edd0dec"
      unitRef="U002">6122983</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="c20201231"
      decimals="0"
      id="Fact_cf0b794cdbd644d69b39a85037a9a545"
      unitRef="U002">7031134</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:SeniorLongTermNotes
      contextRef="c20210630"
      decimals="0"
      id="Fact_196eed8e93bd42ae8e604d0fe5983056"
      unitRef="U002">93877017</us-gaap:SeniorLongTermNotes>
    <us-gaap:SeniorLongTermNotes
      contextRef="c20201231"
      decimals="0"
      id="Fact_d0c973068df44ba28d11289e6042d38b"
      unitRef="U002">92968866</us-gaap:SeniorLongTermNotes>
    <adma:SeniorNotesPayableBeforeDebtDiscount
      contextRef="c20210630"
      decimals="-5"
      id="Fact_a23b41f8c71149a4846efc0a28fbec3d"
      unitRef="U002">100000000.0</adma:SeniorNotesPayableBeforeDebtDiscount>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="c20210101to20210630_DebtInstrumentAxis_PerceptiveCreditAgreementMember"
      id="Fact_997dbbe710f34278ae764df98710adc4">2024-03-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20210630_DebtInstrumentAxis_PerceptiveCreditAgreementMember"
      decimals="3"
      id="Fact_71a6c33b844b4f26b4410e9e5ee20a8d"
      unitRef="U007">0.075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <adma:DebtInstrumentTermOfVariableRate
      contextRef="c20210101to20210630_DebtInstrumentAxis_PerceptiveCreditAgreementMember_VariableRateAxis_LondonInterbankOfferedRateLIBORMember"
      id="Fact_70198b365427459c80621e18d8e6f833">P1M</adma:DebtInstrumentTermOfVariableRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c20210101to20210630_DebtInstrumentAxis_PerceptiveCreditAgreementMember"
      decimals="3"
      id="Fact_415e8037cec142609c8ca4d26ee55a15"
      unitRef="U007">0.035</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="c20210101to20210630_DebtInstrumentAxis_PerceptiveCreditAgreementMember"
      decimals="4"
      id="Fact_2535d04d809b4f8dbe59fb4300b3c382"
      unitRef="U007">0.0400</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c20210630_DebtInstrumentAxis_PerceptiveCreditAgreementMember"
      decimals="3"
      id="Fact_d5ae3613281c49479cf1fb971850b1fa"
      unitRef="U007">0.110</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <adma:RepaymentsOfDebtInterest
      contextRef="c20210101to20210630"
      decimals="-5"
      id="Fact_527de7a16f914970bc63b8b09f7a7e8f"
      unitRef="U002">5500000</adma:RepaymentsOfDebtInterest>
    <adma:RepaymentsOfDebtInterest
      contextRef="c20200101to20200630"
      decimals="-5"
      id="Fact_d8c4a4c19e3e4b7baf69b6e92c551cef"
      unitRef="U002">4400000</adma:RepaymentsOfDebtInterest>
    <us-gaap:Cash
      contextRef="c20210630_DebtInstrumentAxis_PerceptiveCreditAgreementMember_RangeAxis_MinimumMember"
      decimals="-5"
      id="Fact_d19f99d6554c40f5b8f68c652ad6323a"
      unitRef="U002">3000000.0</us-gaap:Cash>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190401to20190630_DebtInstrumentAxis_PerceptiveCreditAgreementMember"
      decimals="-5"
      id="Fact_c0c5e4c7214941ef947393646fe1969a"
      unitRef="U002">7000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20211001to20211231_DebtInstrumentAxis_PerceptiveCreditAgreementMember_StatementScenarioAxis_ScenarioForecastMember"
      decimals="-5"
      id="Fact_b2afe6436376469abcd97a1fcf0b289f"
      unitRef="U002">55000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="c20210630_DebtInstrumentAxis_PerceptiveCreditAgreementMember_LongtermDebtTypeAxis_SeniorNotesMember"
      decimals="-5"
      id="Fact_34f2d5303d594b4abaec127ecc9bb4c5"
      unitRef="U002">7100000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c20210630_DebtInstrumentAxis_PerceptiveCreditFacilityMember"
      decimals="3"
      id="Fact_fa9f8fb29b884d6ebbf5a8426109f80c"
      unitRef="U007">0.137</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="c20210101to20210630"
      id="Text_5ecaf0c606624acda2de24059b4958ef">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;8.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The Company is currently authorized to issue up to 10 million shares of preferred stock, $0.0001, par
            value per share.&#160; There were no shares of preferred stock outstanding at June 30, 2021 and December 31, 2020.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;As of June 30, 2021 and December 31, 2020, the Company was authorized to issue 300,000,000 and 150,000,000 shares,
            respectively, of its common stock, $0.0001 par value per share, and 131,872,026 and 104,902,888 shares of common stock were
            outstanding as of June 30, 2021 and December 31, 2020, respectively. On May 27, 2021, the Company&#x2019;s stockholders approved an amendment to the Company&#x2019;s certificate of incorporation which increased the number of shares of common stock that the
            Company is authorized to issue from 150,000,000 to 300,000,000. After giving effect to the 17,073,357 shares reserved for
            outstanding warrants and awards issued or reserved for future issuance under the Company&#x2019;s equity incentive plans, as of June 30, 2021 there were 151,054,617
            shares of common stock available for issuance.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;On August 5, 2020, the Company entered into the 2020 Sale Agreement with Jefferies (see Note 1), pursuant to
            which the Company could offer and sell, from time to time, at its option, through or to Jefferies, up to an aggregate of $50 million
            of shares of the Company&#x2019;s common stock. On November 5, 2020 and February 3, 2021, the Company and Jefferies amended the 2020 Sale Agreement to provide for increases in the aggregate offering amount under the Sale Agreement such that the
            Company could sell shares having an aggregate offering price of up to $105.4 million under the 2020 Sale Agreement, as amended.
            During the six months ended June 30, 2021, the Company issued and sold 26,907,753 shares of common stock under the 2020 Sale
            Agreement and received net proceeds of $59.1 million (see Note 14).&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;On May 28, 2021, the Company entered into the 2021 Sale Agreement with Jefferies, pursuant to which the
            Company may offer and sell, from time to time, at its option, through or to Jefferies, up to an aggregate of $50,000,000 of shares of
            the Company&#x2019;s common stock. As of the date of this report, there have been no sales of common stock under this agreement.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;On February 11, 2020, the Company completed an underwritten public offering of 23,500,000 shares of its common stock for gross proceeds of $82.3 million. On February 21, 2020, the Company sold an additional 3,525,000 shares pursuant to
            the underwriters&#x2019; exercise of their option to purchase additional shares of the Company&#x2019;s common stock for additional gross proceeds of $12.3
            million. The Company received net proceeds, after underwriting discounts and other expenses associated with the offering, of approximately $88.7
            million.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Warrants&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;At June 30, 2021 and December 31, 2020, the Company had outstanding warrants to purchase an aggregate of 4,528,160 shares of common stock, with a weighted average exercise price of $2.82 per share and expiration dates ranging between June 2022 and December 2030.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Equity Incentive Plans&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The fair value of stock options granted under the Company&#x2019;s 2007 Employee Stock Option Plan
              (the &#x201c;2007 Plan&#x201d;) and the ADMA Biologics, Inc. 2014 Omnibus Incentive Compensation Plan, as amended and restated (the &#x201c;2014 Plan&#x201d;), was determined on the date of grant using the Black-Scholes option valuation model. The Black-Scholes model
              was developed for use in estimating the fair value of publicly traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of certain subjective assumptions including
              the expected stock price volatility. The stock options granted to employees and directors have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the
              fair value estimate. &lt;/span&gt;&lt;span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The following assumptions were used to determine the fair value of options granted during the six months ended June 30, 2021 and
              2020:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 76%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Six Months Ended June 30,&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 76%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;"&gt;&#160;&lt;/td&gt;

    &lt;td style="width: 11%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2021&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;"&gt;&#160;&lt;/td&gt;

    &lt;td style="width: 11%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2020&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 76%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Expected term&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 11%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5.5 - 6.3 years&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 2%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;"&gt;&#160;&lt;/td&gt;

    &lt;td style="width: 11%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5.5 - 6.3 years&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 76%; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Volatility&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 11%; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0);"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;69%&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;"&gt;&#160;&lt;/td&gt;

    &lt;td style="width: 11%; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;62-67%&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 76%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Dividend yield&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 11%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0);"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;0.0&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 2%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;"&gt;&#160;&lt;/td&gt;

    &lt;td style="width: 11%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0);"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;0.0&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 76%; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Risk-free interest rate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 11%; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;0.80-1.14%&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;"&gt;&#160;&lt;/td&gt;

    &lt;td style="width: 11%; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;0.38-1.68%&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;During the six months ended June 30, 2021 and 2020, the Company granted options to purchase an aggregate of 1,658,050 and 1,232,500 shares of
            common stock, respectively, to its directors, employees and certain third-party service providers.&#160; The weighted average remaining contractual life of stock options outstanding and expected to vest at June 30, 2021 is 6.5 years. The weighted average remaining contractual life of stock options exercisable at June 30, 2021 is 5.2 years.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;A summary of the Company&#x2019;s option activity under the 2007 Plan and 2014 Plan and related information is as
            follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Shares&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Weighted &lt;/div&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Average &lt;/div&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Exercise Price&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Options outstanding, vested and expected to vest at &lt;span style="text-indent: 0pt;"&gt;December 31, 2020&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;6,922,931&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4.40&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Forfeited&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(404,782&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2.96&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Expired&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(393,170&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5.03&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Granted&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,658,050&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2.26&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Exercised&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Options outstanding, vested and expected to vest at &lt;span style="text-indent: 0pt;"&gt;June 30, 2021&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;7,783,029&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3.98&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Options exercisable&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,011,506&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4.70&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;As of June 30, 2021, the Company had $4.2 million of unrecognized compensation expense related to options granted under the Company&#x2019;s equity incentive plans, which is expected to be recognized over a
            weighted-average period of 2.6 years.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;During the six months ended June 30, 2021 and 2020, the Company granted Restricted Stock Units
              (&#x201c;RSUs&#x201d;) representing an aggregate of 542,244 and 341,000 shares, respectively, to certain management employees of the Company and to members of its Board of Directors.&#160; The RSUs vest annually over a period of four years for employees and semi-annually over a period of one year
              for directors. During the six months ended June 30, 2021, 87,750 shares vested in connection with grants of RSUs. With respect to
              these vested RSUs, 26,365 shares valued at approximately $59,000 were withheld by the Company to cover employees&#x2019; tax liabilities.&#160; On March 25, 2021, these shares were retired by the Company and were no longer outstanding as of
              June 30, 2021. &lt;/span&gt;&lt;span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;A summary of the Company&#x2019;s unvested RSU activity and related information is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Shares&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Weighted &lt;/div&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Average Grant &lt;/div&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Date Fair Value&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Balance at &lt;span style="text-indent: 0pt;"&gt;December 31, 2020&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;326,000&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2.81&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Granted&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;542,244&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2.29&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Vested&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(87,750&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2.81&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Forfeited&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(94,361&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2.53&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Balance at &lt;span style="text-indent: 0pt;"&gt;June 30, 2021&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;686,133&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2.44&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;As of June 30, 2021, the Company had $1.5 million of unrecognized compensation expense related to unvested RSUs granted under the Company&#x2019;s equity incentive plans, which is expected to be recognized over a
            weighted-average period of 3.3 years.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total stock-based compensation expense for all awards granted under the Company&#x2019;s equity incentive plans for
            the three months and six months June 30, 2021 and 2020 is as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Three Months Ended June 30,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Six Months Ended June 30,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2021&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2020&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2021&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2020&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Research and development&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;42,479&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;105,029&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;147,706&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;198,603&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Plasma center operating expenses&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;13,637&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;8,510&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;24,455&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;15,754&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Selling, general and administrative&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;665,836&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;539,256&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,254,327&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,063,145&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cost of product revenue&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;83,237&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;62,813&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;160,098&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;114,654&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total stock-based compensation expense&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;805,189&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;715,608&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,586,586&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,392,156&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance
      contextRef="c20201231"
      decimals="-6"
      id="Fact_c5aa594bdfcb46bfa703964d238bb7f8"
      unitRef="U001">10000000</us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance
      contextRef="c20210630"
      decimals="-6"
      id="Fact_1ad471244f8c4ba5926dc35ad53497fe"
      unitRef="U001">10000000</us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c20201231"
      decimals="4"
      id="Fact_e36989c2f28b42ffac930f2acc7e1d4f"
      unitRef="U003">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c20210630"
      decimals="4"
      id="Fact_9bcd923836844f3abcc769beaeabdff5"
      unitRef="U003">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c20210630"
      decimals="INF"
      id="Fact_97e658641dcb4b7f9dca22d60dfaf5e4"
      unitRef="U001">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c20201231"
      decimals="INF"
      id="Fact_19bfc313615040bb85ce5867d4ac3efd"
      unitRef="U001">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20210630"
      decimals="0"
      id="Fact_fbe414bac83745e6ad1110a42acecff8"
      unitRef="U001">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20201231"
      decimals="0"
      id="Fact_2dadc6e251d24d74bc9986e1a1f7fac7"
      unitRef="U001">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20201231"
      decimals="4"
      id="Fact_6ef668dd62dc4ef480ed001d88561df6"
      unitRef="U003">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20210630"
      decimals="4"
      id="Fact_04a74998a0984a49a5af7a4bfad67177"
      unitRef="U003">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20210630"
      decimals="0"
      id="Fact_38e8a93c07b5453d8a170b3d478b634c"
      unitRef="U001">131872026</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20201231"
      decimals="0"
      id="Fact_892dbb4ab68b46b6abdaf0ff14f819b7"
      unitRef="U001">104902888</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20201231"
      decimals="0"
      id="Fact_7e235e82dd864a4d98893080a0d7837c"
      unitRef="U001">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20210630"
      decimals="0"
      id="Fact_e687281a5dd24d3d9545d7aff01b2a02"
      unitRef="U001">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20210630"
      decimals="0"
      id="Fact_609e8f2aaaa44cc1ba336f385f70492b"
      unitRef="U001">17073357</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c20210630"
      decimals="0"
      id="Fact_a76d8c0cb3984d619cb711388866cde1"
      unitRef="U001">151054617</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20200805to20200805_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_JefferiesLLCMember_TypeOfArrangementAxis_SaleAgreement2020Member"
      decimals="-6"
      id="Fact_0624939f9c364750afc0261249f6abc5"
      unitRef="U002">50000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20210203to20210203_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_JefferiesLLCMember_TypeOfArrangementAxis_SaleAgreement2020AmendedMember"
      decimals="-5"
      id="Fact_ca0e1654006c4321a19940c35947789d"
      unitRef="U002">105400000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20210101to20210630_RelatedPartyTransactionsByRelatedPartyAxis_JefferiesLLCMember_StatementEquityComponentsAxis_CommonStockMember_TypeOfArrangementAxis_SaleAgreement2020Member"
      decimals="0"
      id="Fact_df5f1367f1544c4781aec18b980fbf9c"
      unitRef="U001">26907753</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20210101to20210630_RelatedPartyTransactionsByRelatedPartyAxis_JefferiesLLCMember_TypeOfArrangementAxis_SaleAgreement2020Member"
      decimals="-5"
      id="Fact_4ac97b4d67644fd6a1c840d883712cb5"
      unitRef="U002">59100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20210528to20210528_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_JefferiesLLCMember_TypeOfArrangementAxis_SaleAgreement2021Member"
      decimals="0"
      id="Fact_b679a94569664fd58e5a715fd5b6d4fd"
      unitRef="U002">50000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20210528to20210528_RelatedPartyTransactionsByRelatedPartyAxis_JefferiesLLCMember_StatementEquityComponentsAxis_CommonStockMember_TypeOfArrangementAxis_SaleAgreement2021Member"
      decimals="0"
      id="Fact_c031d491bd0c4ae58175758b8a8a4f63"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20200211to20200211_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_OverAllotmentOptionMember"
      decimals="0"
      id="Fact_3e2137fe01974a86aae52632190fc8ea"
      unitRef="U001">23500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <adma:GrossProceedsFromIssuanceOfCommonStock
      contextRef="c20200211to20200211_SubsidiarySaleOfStockAxis_OverAllotmentOptionMember"
      decimals="-5"
      id="Fact_c6d0703b6702455c8deeb5b76de102f9"
      unitRef="U002">82300000</adma:GrossProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20200221to20200221_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_OverAllotmentOptionMember"
      decimals="0"
      id="Fact_ae569f4bd5f04ccc9fde7d1768d8949a"
      unitRef="U001">3525000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <adma:GrossProceedsFromIssuanceOfCommonStock
      contextRef="c20200221to20200221_SubsidiarySaleOfStockAxis_OverAllotmentOptionMember"
      decimals="-5"
      id="Fact_e9c6139b17ae468fb494b59f32b45208"
      unitRef="U002">12300000</adma:GrossProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20200101to20200630_SubsidiarySaleOfStockAxis_OverAllotmentOptionMember"
      decimals="-5"
      id="Fact_b3efc90e12fc4d219a2ce4c739007e15"
      unitRef="U002">88700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20201231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_94055a98035b4bb7815626bb0cfb6b28"
      unitRef="U001">4528160</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20210630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_4ab5c5b6c61e49949e55285d6d03cd5a"
      unitRef="U001">4528160</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20201231"
      decimals="2"
      id="Fact_7fd9294b987d41aebddb5af01ff37603"
      unitRef="U003">2.82</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20210630"
      decimals="2"
      id="Fact_17bd2f089463449db84d64eca81952e5"
      unitRef="U003">2.82</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="c20210101to20210630"
      id="Text_91b9573094e44c8f81d6558493652ebe">&lt;span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The following assumptions were used to determine the fair value of options granted during the six months ended June 30, 2021 and
              2020:&lt;/span&gt;&lt;/span&gt;
&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 76%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Six Months Ended June 30,&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 76%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;"&gt;&#160;&lt;/td&gt;

    &lt;td style="width: 11%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2021&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;"&gt;&#160;&lt;/td&gt;

    &lt;td style="width: 11%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2020&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 76%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Expected term&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 11%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5.5 - 6.3 years&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 2%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;"&gt;&#160;&lt;/td&gt;

    &lt;td style="width: 11%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5.5 - 6.3 years&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 76%; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Volatility&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 11%; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0);"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;69%&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;"&gt;&#160;&lt;/td&gt;

    &lt;td style="width: 11%; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;62-67%&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 76%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Dividend yield&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 11%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0);"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;0.0&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 2%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;"&gt;&#160;&lt;/td&gt;

    &lt;td style="width: 11%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0);"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;0.0&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 76%; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Risk-free interest rate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 11%; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;0.80-1.14%&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;"&gt;&#160;&lt;/td&gt;

    &lt;td style="width: 11%; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;0.38-1.68%&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember"
      id="Fact_5edf98fab3ad43ab82420efb6e1f88a3">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember"
      id="Fact_9e70bc64a9b14ef393eb3cb4673cbc40">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20200101to20200630_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember"
      id="Fact_82911ce5e15f4821b44e3caf8324b3bc">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20200101to20200630_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember"
      id="Fact_8b7d7a0570ab4f47b408a03ecc8bc56c">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_ad066e76b55c4b67a4eb36af8aadb867"
      unitRef="U007">0.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20200101to20200630_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember"
      decimals="2"
      id="Fact_6fb81de8910d4f539abbb569f6255b7d"
      unitRef="U007">0.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20200101to20200630_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember"
      decimals="2"
      id="Fact_7a16b951e74846119f293c15500da749"
      unitRef="U007">0.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="1"
      id="Fact_fd89e78d74314c60b53e29b568086538"
      unitRef="U007">0.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20200101to20200630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="1"
      id="Fact_b374b1b991414d1088806c8b9310de71"
      unitRef="U007">0.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember"
      decimals="4"
      id="Fact_ef870433a43140ebbc855ce35f51a777"
      unitRef="U007">0.0080</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember"
      decimals="4"
      id="Fact_47ec553d5f724fbdb139d0cc2cc65cdf"
      unitRef="U007">0.0114</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20200101to20200630_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember"
      decimals="4"
      id="Fact_ede93fe1e9614961b990935fb83abb6b"
      unitRef="U007">0.0038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20200101to20200630_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember"
      decimals="4"
      id="Fact_a278f9a847e0442faf3737a6b734083d"
      unitRef="U007">0.0168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_9a863e3b6df846ccb70b653113a30c5b"
      unitRef="U001">1658050</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20200101to20200630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_34e621b3a0fd4079a653ba92d67a1236"
      unitRef="U001">1232500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_56a3149d760a408698cc2f034d26596f">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_4ddbd46632bb40558d9b037ddbea7242">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_85c3b4b12b8545aa8048145d06a68fd0">P5Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="c20210101to20210630"
      id="Text_619c0196e81947b1af4e026299b00e41">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;A summary of the Company&#x2019;s option activity under the 2007 Plan and 2014 Plan and related information is as
            follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Shares&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Weighted &lt;/div&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Average &lt;/div&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Exercise Price&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Options outstanding, vested and expected to vest at &lt;span style="text-indent: 0pt;"&gt;December 31, 2020&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;6,922,931&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4.40&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Forfeited&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(404,782&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2.96&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Expired&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(393,170&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5.03&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Granted&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,658,050&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2.26&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Exercised&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Options outstanding, vested and expected to vest at &lt;span style="text-indent: 0pt;"&gt;June 30, 2021&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;7,783,029&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3.98&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Options exercisable&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,011,506&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4.70&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c20201231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_ea8f15b425764c1bb03bc6a367fa5b4e"
      unitRef="U001">6922931</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c20201231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_b13b66e0829c4bb0b7cf3bdcf4fcbc76"
      unitRef="U003">4.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber
      contextRef="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_bd7c4eadc2124e45bbc1207e1d8e2ba0"
      unitRef="U001">404782</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice
      contextRef="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_d58cf233c30340a6a898ea61e63bd45f"
      unitRef="U003">2.96</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber
      contextRef="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_e66c935a897e4138b3469bc93318fb4c"
      unitRef="U001">393170</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice
      contextRef="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_7d5a8e9cedb44f5ea692c0c5bb625d62"
      unitRef="U003">5.03</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber
      contextRef="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_ab385a0e551e46f58d6483b01d16b73a"
      unitRef="U001">1658050</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice
      contextRef="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_b5d0ac4aaea24b33b2572704ab3a0dc9"
      unitRef="U003">2.26</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber
      contextRef="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact_6cd0d2b1621a4365a91bf3bd957b4139"
      unitRef="U001">0</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice
      contextRef="c20210101to20210630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_cf1448c48af64fc0af18979954090f55"
      unitRef="U003">0</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c20210630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_889f0f5da755432ea3a68571727c3373"
      unitRef="U001">7783029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c20210630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_b9a866771bc04c69a8cf81f13048dcd4"
      unitRef="U003">3.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c20210630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_e7a0611b1645413fa8560e6ec3495e3f"
      unitRef="U001">5011506</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c20210630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_d742804623e64614b4bbf7a422304d21"
      unitRef="U003">4.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="c20210630_PlanNameAxis_EquityIncentivePlanMember"
      decimals="-5"
      id="Fact_1a21ba963e8b49448a47c789cd3a755d"
      unitRef="U002">4200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="c20210101to20210630_PlanNameAxis_EquityIncentivePlanMember"
      id="Fact_db6ada0c0ca04a6c9df4ab4ff22cd30f">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="c20210101to20210630_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_52106f1da4e743719003af625beae328"
      unitRef="U001">542244</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="c20200101to20200630_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_db6c614af7f6450c9436ad2f0eea2cdb"
      unitRef="U001">341000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="c20210101to20210630_AwardTypeAxis_RestrictedStockUnitsRSUMember_TitleOfIndividualAxis_EmployeesMember"
      id="Fact_b71ea04f229f41969fe4c9b644c3292f">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="c20200101to20200630_AwardTypeAxis_RestrictedStockUnitsRSUMember_TitleOfIndividualAxis_DirectorMember"
      id="Fact_9bb71f6432c045b49d53acf3c82f1e61">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c20210101to20210630_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_04a3b07706fe432582ddb53265fcfc82"
      unitRef="U001">87750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities
      contextRef="c20210630_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_46a45c70c9f94cbab27714bc53a46f1f"
      unitRef="U001">26365</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities
      contextRef="c20210630_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_249dad5be0ef43cfbf11f69e0c1daf16"
      unitRef="U002">59000</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities>
    <us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock
      contextRef="c20210101to20210630"
      id="Text_9064e357ffdc4f8c83da8e349b856923">&lt;span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;A summary of the Company&#x2019;s unvested RSU activity and related information is as follows:&lt;/span&gt;&lt;/span&gt;
&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Shares&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Weighted &lt;/div&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Average Grant &lt;/div&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Date Fair Value&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Balance at &lt;span style="text-indent: 0pt;"&gt;December 31, 2020&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;326,000&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2.81&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Granted&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;542,244&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2.29&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Vested&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(87,750&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2.81&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Forfeited&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(94,361&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2.53&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Balance at &lt;span style="text-indent: 0pt;"&gt;June 30, 2021&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;686,133&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2.44&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;
</us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20201231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_9f291a1ddb1645be91d4c6c39295d9e4"
      unitRef="U001">326000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c20201231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_59e9040d6bfe4fdeb429f3bcdea8b1f7"
      unitRef="U003">2.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20210101to20210630_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_285a9b6a5ee54fbca06e460e6a8547e8"
      unitRef="U001">542244</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20210101to20210630_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_ec2a54b9e83f47f7a1b7b2e842dd6ff1"
      unitRef="U003">2.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c20210101to20210630_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_2278cf3e6210456e91e8f373baa263e7"
      unitRef="U001">87750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20210101to20210630_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_01d47564bb49418793ef24b7fc7fc677"
      unitRef="U003">2.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c20210101to20210630_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_0bdf5d82f6ec4e44a8043d7999652c89"
      unitRef="U001">94361</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c20210101to20210630_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_394462b201c64639864ebe0264f32f79"
      unitRef="U003">2.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20210630_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_d1555e70654f4816bcd2f5ab41e38fbe"
      unitRef="U001">686133</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c20210630_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_650c2683a07a4150b6bfe43c3ddb7360"
      unitRef="U003">2.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="c20210630_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlanMember"
      decimals="-5"
      id="Fact_60932583165846a4a1dcb7b0e18d9dc6"
      unitRef="U002">1500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="c20210101to20210630_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlanMember"
      id="Fact_d9adf9839e1349b2820ba9d8c3f649f7">P3Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="c20210101to20210630"
      id="Text_0cfebe5db0554c4a8d6b82f250a91866">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total stock-based compensation expense for all awards granted under the Company&#x2019;s equity incentive plans for
            the three months and six months June 30, 2021 and 2020 is as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Three Months Ended June 30,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Six Months Ended June 30,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2021&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2020&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2021&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2020&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Research and development&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;42,479&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;105,029&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;147,706&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;198,603&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Plasma center operating expenses&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;13,637&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;8,510&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;24,455&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;15,754&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Selling, general and administrative&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;665,836&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;539,256&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,254,327&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,063,145&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cost of product revenue&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;83,237&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;62,813&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;160,098&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;114,654&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total stock-based compensation expense&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;805,189&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;715,608&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,586,586&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,392,156&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="c20210401to20210630_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact_4eda738beddb43309201bb54037ea840"
      unitRef="U002">42479</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20200401to20200630_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact_068bde74ca224e78bb8c8b06165001ac"
      unitRef="U002">105029</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20210101to20210630_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact_8052c309b0c54548807b8917fe7aa9e2"
      unitRef="U002">147706</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20200101to20200630_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact_1800b76e29ce4394a1537c2b88d68ca2"
      unitRef="U002">198603</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20210401to20210630_IncomeStatementLocationAxis_OperatingExpenseMember"
      decimals="0"
      id="Fact_8c9c0d9e22814f22bc4b9481df49ebea"
      unitRef="U002">13637</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20200401to20200630_IncomeStatementLocationAxis_OperatingExpenseMember"
      decimals="0"
      id="Fact_89ca7c80b1f244a5aacd30dfaac7645c"
      unitRef="U002">8510</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20210101to20210630_IncomeStatementLocationAxis_OperatingExpenseMember"
      decimals="0"
      id="Fact_1f338f5df25a4e98be337f8f2240f5e6"
      unitRef="U002">24455</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20200101to20200630_IncomeStatementLocationAxis_OperatingExpenseMember"
      decimals="0"
      id="Fact_23b5d12a1548435581fc2948d2fd0fdd"
      unitRef="U002">15754</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20210401to20210630_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember"
      decimals="0"
      id="Fact_d577bc8150264676b5285009e23c514f"
      unitRef="U002">665836</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20200401to20200630_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember"
      decimals="0"
      id="Fact_8de38773fea74aac9a7782e57641746c"
      unitRef="U002">539256</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20210101to20210630_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember"
      decimals="0"
      id="Fact_ff4281f5bb6b47419b7f2a3093453f92"
      unitRef="U002">1254327</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20200101to20200630_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember"
      decimals="0"
      id="Fact_79f40c9ecf0844158915f5b875cc5516"
      unitRef="U002">1063145</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20210401to20210630_IncomeStatementLocationAxis_CostOfSalesMember"
      decimals="0"
      id="Fact_ce5e93afa4d04b8d9855a0357f68826c"
      unitRef="U002">83237</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20200401to20200630_IncomeStatementLocationAxis_CostOfSalesMember"
      decimals="0"
      id="Fact_d31bcf3745014e309a50b6b7b9b29d8b"
      unitRef="U002">62813</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20210101to20210630_IncomeStatementLocationAxis_CostOfSalesMember"
      decimals="0"
      id="Fact_527aa9f6c9e3476b81b8e2e790edb21c"
      unitRef="U002">160098</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20200101to20200630_IncomeStatementLocationAxis_CostOfSalesMember"
      decimals="0"
      id="Fact_44d4a848daf943f0b6e5603d85cef6e2"
      unitRef="U002">114654</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20210401to20210630"
      decimals="0"
      id="Fact_f06354f639ec4a8fab7466422660f0ed"
      unitRef="U002">805189</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20200401to20200630"
      decimals="0"
      id="Fact_902844a26e7e4564a1da2a0b3f356af8"
      unitRef="U002">715608</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_fd29e4724bb14396bc57cbd17699b6f8"
      unitRef="U002">1586586</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_31f2f180abc84b0b9177a182dbb7fd5b"
      unitRef="U002">1392156</us-gaap:ShareBasedCompensation>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="c20210101to20210630"
      id="Text_5a916556c61144a7b4a413e35522597b">
&lt;div&gt;  &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;9.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
              &lt;div style="font-weight: bold;"&gt;RELATED PARTY TRANSACTIONS&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The Company leases an office building and equipment from Areth, LLC (&#x201c;Areth&#x201d;)
        pursuant to an agreement for services effective as of January 1, 2016, as amended from time to time. Rent expense for the six months ended June 30, 2021 and 2020 amounted to $60,000. Areth is a company controlled by Dr. Jerrold B. Grossman, the Vice Chairman of the Company&#x2019;s Board of Directors, and Adam S. Grossman, the Company&#x2019;s President and Chief Executive
        Officer. The Company also reimburses Areth for office and building related (common area) expenses, equipment and certain other operational expenses, which were not material to the consolidated financial statements for the six months ended June 30,
        2021 and 2020. In addition, during the six months ended June 30, 2021, the Company purchased certain specialized medical equipment and services related to the Company&#x2019;s plasma collection centers, as well as personal protective equipment, from
        GenesisBPS and its affiliates (&#x201c;Genesis&#x201d;), in the amount of $0.1 million. This amount was immaterial to the consolidated financial
        statements for the three and six months ended June 30, 2020. Dr. Grossman and Adam Grossman each own shares of Genesis.&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;See Note 7 for a discussion of the Company&#x2019;s credit facility and related
        transactions with Perceptive, a holder of more than 10% of the Company&#x2019;s common stock.&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;During the three and six months ended June 30, 2021, in connection with the
        resignation of Dr. James Mond, the Company&#x2019;s former Chief Scientific and Medical Officer, the Company recognized an expense and corresponding liability in the amount of $0.8 million for estimated payments to be made under a separation and transition agreement with Dr. Mond. Such payments are to be made in scheduled installments over a period of 10 months.&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;In connection with the February 2020 public offering of the Company&#x2019;s common stock
        (see Note 8) on February 11, 2020: (i) Perceptive Advisors, a principal stockholder of ADMA, purchased 4,563,700 shares of common stock
        through one of its affiliates, (ii) Dr. Grossman purchased 22,857 shares of common stock directly and 22,857 shares indirectly through an entity he controls, (iii) Lawrence P. Guiheen, a director of the Company, purchased 20,000 shares of&#160; common stock, (iv) Mr. Grossman purchased 28,571 shares of common stock directly and 57,143 shares indirectly through an
        entity he controls, (v) Brian Lenz, the Company&#x2019;s Executive Vice President and Chief Financial Officer, purchased 7,142 shares of common
        stock, and (vi) Dr. Mond purchased 4,285 shares of common stock, all at the public offering price of $3.50 per share.&lt;/div&gt;
</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="c20200401to20200630_RelatedPartyTransactionsByRelatedPartyAxis_ArethLLCMember"
      decimals="0"
      id="Fact_a9f446d85fae4468aad8e2d50fc874df"
      unitRef="U002">60000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="c20210101to20210630_RelatedPartyTransactionsByRelatedPartyAxis_ArethLLCMember"
      decimals="0"
      id="Fact_a6195e61567642eb81ff62f2ac428fb4"
      unitRef="U002">60000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="c20210101to20210630_RelatedPartyTransactionsByRelatedPartyAxis_GenesisBPSMember"
      decimals="-5"
      id="Fact_930ecdcad9a045e8acb8af5082cd322f"
      unitRef="U002">100000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <adma:MinimumPercentageOfCommonStockHeldByLender
      contextRef="c20210101to20210630_LineOfCreditFacilityAxis_PerceptiveCreditHoldingsIILPMember"
      decimals="2"
      id="Fact_076b3e912eeb4dfe923cba4c36e297ba"
      unitRef="U007">0.10</adma:MinimumPercentageOfCommonStockHeldByLender>
    <adma:EstimatedPaymentForSeparationAndTransitionAgreement
      contextRef="c20210630_TitleOfIndividualAxis_ChiefScientificOfficerAndChiefMedicalOfficerMember"
      decimals="-5"
      id="Fact_1c591dbf551e47ebb5b2b2a98f5fe6b0"
      unitRef="U002">800000</adma:EstimatedPaymentForSeparationAndTransitionAgreement>
    <adma:PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement
      contextRef="c20210101to20210630_TitleOfIndividualAxis_ChiefScientificOfficerAndChiefMedicalOfficerMember"
      id="Fact_3c123bf3cf6a47889223bad5d1a551f7">P10M</adma:PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20200211to20200211_LineOfCreditFacilityAxis_PerceptiveCreditHoldingsIILPMember"
      decimals="0"
      id="Fact_6c5c3081b5ab4e5583b80dd3026f5058"
      unitRef="U001">4563700</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20200211to20200211_OwnershipAxis_DirectOwnershipMember_TitleOfIndividualAxis_ViceChairmanMember"
      decimals="0"
      id="Fact_7301eca8f8b4426d9797a04af09d874a"
      unitRef="U001">22857</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20200211to20200211_OwnershipAxis_IndirectOwnershipMember_TitleOfIndividualAxis_ViceChairmanMember"
      decimals="0"
      id="Fact_de3a3eb50f9348dbaa217f788d07533a"
      unitRef="U001">22857</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20200211to20200211_TitleOfIndividualAxis_DirectorMember"
      decimals="0"
      id="Fact_685ef449357a45e392ddeea0af0734a2"
      unitRef="U001">20000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20200211to20200211_OwnershipAxis_DirectOwnershipMember_TitleOfIndividualAxis_PresidentAndChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_fa4447f60ca849d784bcb626adef07e7"
      unitRef="U001">28571</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20200211to20200211_OwnershipAxis_IndirectOwnershipMember_TitleOfIndividualAxis_PresidentAndChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_0242745a2a7e41c89c2580a8cb1e895f"
      unitRef="U001">57143</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20200211to20200211_TitleOfIndividualAxis_ExecutiveVicePresidentAndChiefFinancialOfficerMember"
      decimals="0"
      id="Fact_b65e7014a7ed4fb89df91f010f237325"
      unitRef="U001">7142</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20200211to20200211_TitleOfIndividualAxis_ChiefScientificOfficerAndChiefMedicalOfficerMember"
      decimals="0"
      id="Fact_5f8c1f6dd3b54f349397811cee30fdc1"
      unitRef="U001">4285</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c20200211"
      decimals="2"
      id="Fact_2520ee9bdc27461c823af005133a484b"
      unitRef="U003">3.50</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="c20210101to20210630"
      id="Text_4473a060a68a403d939a6af745d8e9bf">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;10.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;General Legal Matters&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;From time to time the Company is or may become subject to certain legal proceedings and claims arising in
            connection with the normal course of its business. Management does not expect that the outcome of any such claims or actions will have a material effect on the Company&#x2019;s liquidity, results of operations or financial condition.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;COVID-19 Pandemic&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The Company continues to monitor the ongoing developments related to the COVID-19 pandemic, including the
            emergence of the Delta variant and other resistant strains of the coronavirus, and its impacts to the Company&#x2019;s commercial and manufacturing operations and plasma collection facilities, including collections of source plasma, procurement of raw
            materials and packaging materials, a portion of which are sourced internationally, and the testing of finished drug product that is required prior to its availability for commercial sale.&#160; A substantial portion of such testing has historically
            been performed by contract laboratories outside the United States.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The Company had experienced some delays with final drug product release testing by third-party vendors. In
            response to these delays, the Company added additional release testing laboratories to its FDA-approved consortium listed in its drug approval documents which the Company believes has adequately addressed this issue. In addition, due to a
            combination of previous state and local &#x201c;shelter-in-place&#x201d; orders, as well as government stimulus packages, persisting social distancing measures and varying roll-outs of vaccinations by state, the Company has experienced lower than normal
            donor collections at its FDA approved plasma collection centers. The Company was also subject to delays in shipments of source plasma from its contracted third-party suppliers, as well as delays in deliveries for personal protective equipment,
            reagents and other non-plasma raw materials and supplies used in the manufacture and distribution of its products. The Company is also subject to supply chain delays as a result of certain of its suppliers diverting significant resources
            towards the rapid development and distribution of COVID-19 vaccines and, as a result, the Company may elect to carry more raw materials inventory than it has in the past. The COVID-19 pandemic has also impacted, to a certain degree, the
            Company&#x2019;s customer engagement initiatives, whereby ADMA&#x2019;s sales and medical affairs field personnel have faced difficulties communicating directly with physicians and other healthcare professionals, as well as the cancellation or postponement
            of a number of key scientific and medical meetings, further limiting the Company&#x2019;s ability to communicate with potential customers.&#160; The Company has implemented a comprehensive suite of virtual engagement initiatives, however, clinician
            engagement has been reduced due to rapidly evolving COVID-19 priorities at U.S. medical centers.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The pandemic could also impact the Company&#x2019;s ability to interact with the FDA or other regulatory authorities
            and may result in delays in the conduct of inspections or review of pending applications or submissions.&#160; During the second quarter of 2021, the Company was notified by the FDA that its submission for the approval of its in-house fill-finish
            process utilizing a recently installed aseptic filling machine will require a site inspection, either in person or virtually, of the Boca Facility. Although the inspection was completed in July of 2021, the FDA&#x2019;s review of the Company&#x2019;s
            regulatory filing with respect to its in-house fill-finish process and new aseptic filling machine remains ongoing. Although the Company anticipates receiving regulatory approval of this submission in the second half of 2021, no assurances can
            be provided as to the timing for completion of this FDA review or any other regulatory submissions or applications that may be impacted by restrictions related to COVID-19.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Notwithstanding the foregoing, the COVID-19 pandemic to date has not had a material impact on the Company&#x2019;s
            financial condition or results of operations, and the Company does not believe that its production operations at the Boca Facility, the Company&#x2019;s contract fill/finishers or its plasma collection facilities have been significantly impacted by
            the COVID-19 pandemic. As a result, the Company does not anticipate and has not experienced any material impairments with respect to any of its long-lived assets, including the Company&#x2019;s property and equipment, goodwill or intangible assets.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Although the COVID-19 pandemic has not, to date, materially adversely impacted the Company&#x2019;s capital and
            financial resources, because the Company is unable to determine the ultimate severity or duration of the pandemic or its long-term effects on, among other things, the global, national or local economies, the capital and credit markets or the
            Company&#x2019;s workforce, customers or our suppliers, at this time the Company is unable to predict whether COVID-19 will have a material adverse impact on the Company&#x2019;s business, financial condition, liquidity and results of operations.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Vendor Commitments&lt;/span&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Pursuant to the terms of a plasma purchase agreement with BPC dated as of November 17, 2011 (the &#x201c;2011 Plasma
            Purchase Agreement&#x201d;), the Company agreed to purchase from BPC an annual minimum volume of source plasma containing antibodies to RSV to be used in the manufacture of ASCENIV. The Company must purchase a to-be-determined and agreed upon annual
            minimum volume from BPC, but may also collect high-titer RSV plasma from up to five wholly-owned ADMA plasma collection facilities.&#160;
            During 2015, the Company and BPC amended the 2011 Plasma Purchase Agreement to allow the Company the ability to collect its raw material RSV high-titer plasma from other third-party collection organizations, thus allowing the Company to expand
            its reach for raw material supply as it executes its commercialization plans for ASCENIV. Unless terminated earlier, the 2011 Plasma Purchase Agreement expires in June 2027, after which it may be renewed for two additional five-year periods if
            agreed to by the parties. As part of the closing of the Biotest Transaction, the parties amended the 2011 Plasma Purchase Agreement to extend the initial term through the ten-year anniversary of the closing date of the Biotest Transaction. On December 10, 2018, BPC assigned its rights and obligations under the 2011 Plasma Purchase Agreement
            to Grifols Worldwide Operations Limited (&#x201c;Grifols&#x201d;) as its successor-in-interest, effective January 1, 2019. On January 1, 2019, Grifols and the Company entered into an additional amendment to the 2011 Plasma Purchase Agreement for the purchase
            of source plasma containing antibodies to RSV from Grifols. Pursuant to this amendment, until January 1, 2022, the Company may purchase RSV plasma from Grifols from the two plasma collection centers that were transferred to BPC on January 1, 2019 at a price equal to cost plus &lt;span style="-sec-ix-hidden:Fact_5246f96bd6684b0493a757c543cd5bb9"&gt;five percent&lt;/span&gt; (5%) (without any additional increase due to
            inflation).&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;On June 6, 2017, the Company and BPC entered into a Plasma Supply Agreement pursuant to which BPC supplies,
            on an exclusive basis subject to certain exceptions, to ADMA BioManufacturing an annual minimum volume of hyperimmune plasma that contain antibodies to the Hepatitis B virus for the manufacture of Nabi-HB. The Plasma Supply Agreement has a 10-year term. On July 19, 2018, the Company and BPC entered into an amendment to the Plasma Supply Agreement to provide, among other things, that in
            the event BPC elects not to supply in excess of ADMA BioManufacturing&#x2019;s specified amount of Hepatitis B plasma and ADMA BioManufacturing is unable to secure Hepatitis B plasma from a third party at a price that is within a low double- digit
            percentage of the price that ADMA BioManufacturing pays to BPC, then BPC shall reimburse ADMA BioManufacturing for the difference in price ADMA BioManufacturing incurs. On December 10, 2018, BPC assigned its rights and obligations under the
            Plasma Supply Agreement to Grifols, effective January 1, 2019.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;On June 6, 2017, the Company and BPC entered into a Plasma Purchase Agreement (the &#x201c;2017 Plasma Purchase
            Agreement&#x201d;), pursuant to which ADMA BioManufacturing purchases normal source plasma (&#x201c;NSP&#x201d;) from BPC at agreed upon annual quantities and prices. The 2017 Plasma Purchase Agreement has an initial term of five years after which the 2017 Plasma Purchase Agreement may be renewed for additional two terms of two years each upon the mutual written consent
            of the parties. On July 19, 2018, the Company and BPC entered into an amendment to the 2017 Plasma Purchase Agreement to, among other things, provide agreed upon amounts of normal source plasma to be supplied by BPC to ADMA BioManufacturing in
            calendar year 2019 at a specified price per liter, provided that ADMA BioManufacturing delivers a valid purchase order to BPC. Additionally, pursuant to the amendment to the 2017 Plasma Purchase Agreement, BPC agreed that, for calendar years
            2020 and 2021, it shall supply no less than a high double-digit percentage of ADMA BioManufacturing&#x2019;s requested NSP amounts, provided that such requested NSP amounts are within an agreed range, at a price per liter to be mutually determined.
            Furthermore, pursuant to the amendment to the 2017 Plasma Purchase Agreement, in the event BPC fails to supply ADMA BioManufacturing with at least a high double-digit percentage of ADMA BioManufacturing&#x2019;s requested NSP amounts, BPC shall
            promptly reimburse ADMA BioManufacturing the difference in price ADMA BioManufacturing incurs due to BPC&#x2019;s election not to supply NSP to ADMA BioManufacturing in such amounts as requested. On December 10, 2018, BPC assigned its rights and
            obligations under the Plasma Purchase Agreement to Grifols, effective January 1, 2019. &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Effective as of May 12, 2021, the Company and Grifols amended the foregoing 2017 Plasma Purchase Agreement
            whereby, among other things, the term of the agreement was extended through December 31, 2022, while certain historical provisions were deleted. In order to maintain a reliable supply of raw material plasma thereafter, the Company is in
            late-stage discussion with multiple third-party suppliers of NSP to supplement the 2017 Plasma Purchase Agreement, and the Company has also increased the number of planned plasma collection center buildouts and is continuing to increase its
            plasma collection capabilities at its ADMA BioCenters plasma collection centers business segment.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The Company purchases substantially all of its raw material plasma from Grifols. For the six months ended
            June 30, 2021, plasma purchases from Grifols totaled $17.5 million, or approximately 67% of the Company&#x2019;s total inventory purchases. For the six months ended June 30, 2020, plasma purchases from Grifols totaled approximately $3.7 million, representing approximately 42%
            of the Company&#x2019;s total inventory purchases.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Post-marketing commitments&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;In connection with the approval of the BLA for BIVIGAM, on December 19, 2012 Biotest committed to perform two
            additional post-marketing studies, a pediatric study to evaluate the efficacy and safety of BIVIGAM in children and adolescents, and a post-authorization safety study to further assess the potential risk of hypotension and hepatic and renal
            impairment in BIVIGAM-treated patients with primary humoral immunodeficiency. These studies are still pending completion. ADMA has assumed the remaining obligations, and the costs of the studies will be expensed as incurred as research and
            development expenses. The Company currently expects both studies to be completed by June of 2023.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;In connection with the FDA&#x2019;s approval of ASCENIV on April 1, 2019, the Company is required to perform a
            pediatric study to evaluate the safety and efficacy of ASCENIV in children and adolescents. This study is required to be completed by June of 2023.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Employment contracts&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The Company has entered into employment agreements with its executive management team consisting of its
            President and Chief Executive Officer, its Executive Vice President and Chief Financial Officer and its former Executive Vice President, Chief Medical Officer and Chief Scientific Officer (see Note 9).&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Other commitments&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;In the normal course of business, the Company enters into contracts that contain a variety of
            indemnifications with its employees, licensors, suppliers and service providers. Further, the Company indemnifies its directors and officers who are, or were, serving at the Company&#x2019;s request in such capacities. The Company&#x2019;s maximum exposure
            under these arrangements is unknown as of June 30, 2021. The Company does not anticipate recognizing any significant losses relating to these arrangements.&lt;/div&gt;
</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <adma:NumberOfPlasmaCollectionFacilities
      contextRef="c20210101to20210630_RangeAxis_MaximumMember_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember"
      decimals="INF"
      id="Fact_b33ebe7530f64ca79944eab87543e97f"
      unitRef="U004">5</adma:NumberOfPlasmaCollectionFacilities>
    <adma:NumberOfRenewalTerms
      contextRef="c20210101to20210630_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember"
      decimals="INF"
      id="Fact_cd0f2988af684e7f8be59f723f6d5173"
      unitRef="U008">2</adma:NumberOfRenewalTerms>
    <adma:PlasmaPurchaseAgreementRenewalPeriod
      contextRef="c20210101to20210630_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember"
      id="Fact_bd444cd37f7d4ec2864a55bfe0fc8b53">P5Y</adma:PlasmaPurchaseAgreementRenewalPeriod>
    <adma:PlasmaPurchaseAgreementTerm
      contextRef="c20210101to20210630_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember"
      id="Fact_154a6679de8742529d07e173a0eb9df1">P10Y</adma:PlasmaPurchaseAgreementTerm>
    <adma:NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity
      contextRef="c20210101to20210630_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember"
      decimals="INF"
      id="Fact_09607613950449249b7874965f3117e6"
      unitRef="U009">2</adma:NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity>
    <adma:PercentageOfPlasmaPurchasePriceEqualToCost
      contextRef="c20210101to20210630_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember"
      decimals="2"
      id="Fact_49e49dd196b747b0b14c4d6ff565c0e5"
      unitRef="U007">0.05</adma:PercentageOfPlasmaPurchasePriceEqualToCost>
    <adma:PlasmaSupplyAgreementTerm
      contextRef="c20210101to20210630"
      id="Fact_16e928c73936497e9671b24c15058dcb">P10Y</adma:PlasmaSupplyAgreementTerm>
    <adma:PlasmaPurchaseAgreementTerm
      contextRef="c20210101to20210630_TypeOfArrangementAxis_PlasmaPurchaseAgreementTwoMember"
      id="Fact_c862859f2f82402abb7ffbc9f7baf6b2">P5Y</adma:PlasmaPurchaseAgreementTerm>
    <adma:NumberOfRenewalTerms
      contextRef="c20210101to20210630_TypeOfArrangementAxis_PlasmaPurchaseAgreementTwoMember"
      decimals="INF"
      id="Fact_39c91351233f47078d751e840bede949"
      unitRef="U008">2</adma:NumberOfRenewalTerms>
    <adma:PlasmaPurchaseAgreementRenewalPeriod
      contextRef="c20210101to20210630_TypeOfArrangementAxis_PlasmaPurchaseAgreementTwoMember"
      id="Fact_61c43110ee71417197d470c73cbc2f61">P2Y</adma:PlasmaPurchaseAgreementRenewalPeriod>
    <adma:PlasmaPurchased
      contextRef="c20210101to20210630"
      decimals="-5"
      id="Fact_e13a7f9200884c7798b1b56f08e18a1b"
      unitRef="U002">17500000</adma:PlasmaPurchased>
    <adma:PercentageOfInventoryPurchases
      contextRef="c20210101to20210630"
      decimals="2"
      id="Fact_f9457417f6294b45bab493bbd898f6eb"
      unitRef="U007">0.67</adma:PercentageOfInventoryPurchases>
    <adma:PlasmaPurchased
      contextRef="c20200101to20200630"
      decimals="-5"
      id="Fact_2ce551695d83498999ab429a7903556b"
      unitRef="U002">3700000</adma:PlasmaPurchased>
    <adma:PercentageOfInventoryPurchases
      contextRef="c20200101to20200630"
      decimals="2"
      id="Fact_bf5d072f454542b29774e6d6f63f0f3c"
      unitRef="U007">0.42</adma:PercentageOfInventoryPurchases>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="c20210101to20210630"
      id="Text_8d577c5a49fb4883907c94d4289126da">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;11.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;SEGMENTS&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The Company is engaged in the manufacture, marketing and development of specialty
              plasma-derived biologics.&#160; The Company&#x2019;s ADMA BioManufacturing segment reflects the Company&#x2019;s immunoglobulin manufacturing, commercial and development operations in Boca Raton, FL, acquired on June 6, 2017 (see Note 1).&#160; The Plasma Collection
              Centers segment as of June 30, 2021 consists of eight&lt;span style="color: rgb(0, 0, 0);"&gt; plasma collection facilities in various
                stages of approval and development located throughout the U.S., two of which hold an approved license with the FDA while a third
                facility has a BLA pending FDA approval&lt;/span&gt;. The Corporate segment includes general and administrative overhead expenses. The Company defines its segments as those business units whose operating results are regularly reviewed by the
              chief operating decision maker (&#x201c;CODM&#x201d;) to analyze performance and allocate resources. The Company&#x2019;s CODM is its President and Chief Executive Officer.&#160; &lt;/span&gt;&lt;span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Summarized financial information concerning reportable segments is shown in the following tables:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Three Months Ended June 30, 2021&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;ADMA &lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;BioManufacturing&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Plasma Collection &lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Centers&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Corporate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Consolidated&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Revenues&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;16,347,880&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,447,001&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;35,709&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;17,830,590&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cost of product revenue&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;17,382,292&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,450,332&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;18,832,624&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Loss from operations&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(8,337,405&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(2,794,219&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(4,449,608&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(15,581,232&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Interest and other expense, net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(78,793&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(366&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(3,244,912&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(3,324,071&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Net loss&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(8,416,198&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(2,794,585&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(7,694,520&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(18,905,303&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Depreciation and amortization expense&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,055,537&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;268,927&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,530&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,325,994&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total assets&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;169,799,509&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;20,593,411&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;42,420,872&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;232,813,792&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Three Months Ended June 30, 2020&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;ADMA &lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;BioManufacturing&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Plasma Collection &lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Centers&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Corporate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Consolidated&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Revenues&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;6,502,865&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,249,020&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;35,709&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;7,787,594&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cost of product revenue&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;12,237,141&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,258,488&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;13,495,629&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Loss from operations&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(12,852,835&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(919,309&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(3,351,681&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(17,123,825&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Interest and other expense, net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(235,442&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(33&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(2,818,791&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(3,054,266&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Net loss&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(13,088,277&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(919,342&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(6,170,472&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(20,178,091&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Depreciation and amortization expense&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;772,241&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;111,106&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,305&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;885,652&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total assets&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;109,105,418&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;7,542,486&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;74,893,664&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;191,541,568&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Six Months Ended June 30, 2021&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;ADMA &lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;BioManufacturing&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Plasma Collection &lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Centers&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Corporate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Consolidated&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Revenues&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;29,768,923&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,038,868&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;71,417&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;33,879,208&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cost of product revenue&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;32,832,049&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,770,697&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;36,602,746&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Loss from operations&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(17,843,093&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(4,765,060&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(8,137,328&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(30,745,481&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Interest and other expense, net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(100,307&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(750&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(6,438,706&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(6,539,763&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Net loss&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(17,943,400&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(4,765,810&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(14,576,034&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(37,285,244&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Capital expenditures&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,725,432&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,321,303&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;7,046,735&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Depreciation and amortization expense&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,065,307&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;486,918&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,397&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,555,622&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Six Months Ended June 30, 2020&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;ADMA &lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;BioManufacturing&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Plasma Collection &lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Centers&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Corporate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Consolidated&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Revenues&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;14,246,139&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,669,782&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;71,417&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;17,987,338&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cost of product revenue&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;26,689,094&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,635,761&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;30,324,855&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Loss from operations&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(25,328,980&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(1,376,464&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(7,188,167&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(33,893,611&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Interest and other expense, net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(474,314&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(33&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(5,055,363&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(5,529,710&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Net loss&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(25,803,294&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(1,376,497&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(12,243,530&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(39,423,321&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Capital expenditures&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,064,494&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,178,790&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;6,243,284&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Depreciation and amortization expense&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,447,214&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;222,395&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,881&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,674,490&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Net revenues according to geographic area, based on the location of where the product is shipped, is as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Three Months Ended June 30,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Six Months Ended June 30,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2021&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2020&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2021&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2020&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;United States&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;15,424,839&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;6,797,170&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;29,102,848&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;15,453,443&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;International&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,405,751&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;990,424&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,776,360&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,533,895&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total revenues&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;17,830,590&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;7,787,594&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;33,879,208&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;17,987,338&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:SegmentReportingDisclosureTextBlock>
    <adma:NumberOfPlasmaCollectionFacilitiesUnderDevelopment
      contextRef="c20200401to20200630"
      decimals="INF"
      id="Fact_5b21556d4509456ba68c97b32273b4cc"
      unitRef="U004">8</adma:NumberOfPlasmaCollectionFacilitiesUnderDevelopment>
    <adma:NumberOfFDALicensedPlasmaCollectionFacilities
      contextRef="c20200401to20200630"
      decimals="INF"
      id="Fact_33fbe50105da48769d80171e0051861a"
      unitRef="U004">2</adma:NumberOfFDALicensedPlasmaCollectionFacilities>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="c20210101to20210630"
      id="Text_60d8002bb1ba4c9dae45985bc0826d46">&lt;span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Summarized financial information concerning reportable segments is shown in the following tables:&lt;/span&gt;&lt;/span&gt;
&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Three Months Ended June 30, 2021&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;ADMA &lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;BioManufacturing&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Plasma Collection &lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Centers&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Corporate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Consolidated&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Revenues&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;16,347,880&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,447,001&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;35,709&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;17,830,590&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cost of product revenue&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;17,382,292&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,450,332&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;18,832,624&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Loss from operations&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(8,337,405&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(2,794,219&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(4,449,608&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(15,581,232&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Interest and other expense, net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(78,793&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(366&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(3,244,912&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(3,324,071&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Net loss&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(8,416,198&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(2,794,585&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(7,694,520&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(18,905,303&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Depreciation and amortization expense&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,055,537&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;268,927&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,530&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,325,994&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total assets&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;169,799,509&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;20,593,411&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;42,420,872&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;232,813,792&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Three Months Ended June 30, 2020&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;ADMA &lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;BioManufacturing&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Plasma Collection &lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Centers&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Corporate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Consolidated&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Revenues&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;6,502,865&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,249,020&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;35,709&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;7,787,594&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cost of product revenue&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;12,237,141&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,258,488&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;13,495,629&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Loss from operations&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(12,852,835&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(919,309&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(3,351,681&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(17,123,825&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Interest and other expense, net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(235,442&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(33&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(2,818,791&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(3,054,266&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Net loss&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(13,088,277&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(919,342&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(6,170,472&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(20,178,091&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Depreciation and amortization expense&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;772,241&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;111,106&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,305&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;885,652&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total assets&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;109,105,418&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;7,542,486&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;74,893,664&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;191,541,568&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Six Months Ended June 30, 2021&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;ADMA &lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;BioManufacturing&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Plasma Collection &lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Centers&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Corporate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Consolidated&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Revenues&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;29,768,923&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,038,868&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;71,417&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;33,879,208&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cost of product revenue&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;32,832,049&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,770,697&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;36,602,746&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Loss from operations&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(17,843,093&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(4,765,060&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(8,137,328&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(30,745,481&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Interest and other expense, net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(100,307&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(750&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(6,438,706&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(6,539,763&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Net loss&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(17,943,400&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(4,765,810&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(14,576,034&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(37,285,244&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Capital expenditures&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,725,432&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,321,303&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;7,046,735&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Depreciation and amortization expense&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,065,307&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;486,918&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,397&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,555,622&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Six Months Ended June 30, 2020&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;ADMA &lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;BioManufacturing&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Plasma Collection &lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Centers&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Corporate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Consolidated&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Revenues&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;14,246,139&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,669,782&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;71,417&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;17,987,338&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cost of product revenue&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;26,689,094&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,635,761&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;30,324,855&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Loss from operations&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(25,328,980&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(1,376,464&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(7,188,167&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(33,893,611&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Interest and other expense, net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(474,314&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(33&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(5,055,363&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(5,529,710&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Net loss&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(25,803,294&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(1,376,497&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(12,243,530&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(39,423,321&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Capital expenditures&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,064,494&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,178,790&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;6,243,284&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Depreciation and amortization expense&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,447,214&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;222,395&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,881&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,674,490&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;
</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20210401to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_ae1c75b0729e4cbfb0a427c5be32a760"
      unitRef="U002">16347880</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20210401to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_95b70e099c4e423d85e40aa146a5bec4"
      unitRef="U002">1447001</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20210401to20210630_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_06762faffeaf4e3ea01d3b53a6a8ed2c"
      unitRef="U002">35709</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20210401to20210630"
      decimals="0"
      id="Fact_2dd128bf08e84ba5abf16d064978cf4f"
      unitRef="U002">17830590</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <adma:CostOfProductRevenueExcludingAmortizationExpense
      contextRef="c20210401to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_8de7963e2ac44672b43e8b9fc2156ea6"
      unitRef="U002">17382292</adma:CostOfProductRevenueExcludingAmortizationExpense>
    <adma:CostOfProductRevenueExcludingAmortizationExpense
      contextRef="c20210401to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_a53f1721e88a42209e8ec339dd36c7b0"
      unitRef="U002">1450332</adma:CostOfProductRevenueExcludingAmortizationExpense>
    <adma:CostOfProductRevenueExcludingAmortizationExpense
      contextRef="c20210401to20210630_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_1f47b0219955494aa209928542cb938f"
      unitRef="U002">0</adma:CostOfProductRevenueExcludingAmortizationExpense>
    <adma:CostOfProductRevenueExcludingAmortizationExpense
      contextRef="c20210401to20210630"
      decimals="0"
      id="Fact_ca655c81584547f5aa550e879116b76c"
      unitRef="U002">18832624</adma:CostOfProductRevenueExcludingAmortizationExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20210401to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_379bae2ec882470e9ad94f8a0aed251d"
      unitRef="U002">-8337405</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20210401to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_aaedc1affee34a2c976877e84fc0b40e"
      unitRef="U002">-2794219</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20210401to20210630_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_df288b615af344aa91265912c29e3735"
      unitRef="U002">-4449608</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20210401to20210630"
      decimals="0"
      id="Fact_3aafa734f2fd4824bac227b1e9891e85"
      unitRef="U002">-15581232</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20210401to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_d64818b968b444079ff1d1e4b4697635"
      unitRef="U002">-78793</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20210401to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_c210a840dbd84dff8bfdab767dca7f46"
      unitRef="U002">-366</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20210401to20210630_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_04049f47d71a411181325b41df32532f"
      unitRef="U002">-3244912</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20210401to20210630"
      decimals="0"
      id="Fact_c0fde8a54f92458a99da16ca0196b102"
      unitRef="U002">-3324071</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="c20210401to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_2bd65dbd2e684d5886e999cd8a038829"
      unitRef="U002">-8416198</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210401to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_e997cbcf60bb41ecad269fdffc78a4e4"
      unitRef="U002">-2794585</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210401to20210630_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_4bc5f9089edc48c281e4002739100f3f"
      unitRef="U002">-7694520</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210401to20210630"
      decimals="0"
      id="Fact_5574c96dac93447590c434a50a70fe35"
      unitRef="U002">-18905303</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20210401to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_0cc343456a8f4422b5aab8961275070f"
      unitRef="U002">1055537</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20210401to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_1fe0211261664fbca018ab5ed05ff062"
      unitRef="U002">268927</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20210401to20210630_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_8f90ba44e0814c8b9adeac0fd1cdb262"
      unitRef="U002">1530</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20210401to20210630"
      decimals="0"
      id="Fact_4597ba4a88ab43c8a6925e697cfafb2a"
      unitRef="U002">1325994</us-gaap:DepreciationAndAmortization>
    <us-gaap:Assets
      contextRef="c20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_3d1dab999b794b89be0b2864ae3c8ff8"
      unitRef="U002">169799509</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_b94eab1d4ead4861b4cb7896f3aedd5e"
      unitRef="U002">20593411</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20210630_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_3cfc6da68b704c18bd0a33b4376a7850"
      unitRef="U002">42420872</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20210630"
      decimals="0"
      id="Fact_e6586a6c74534f2280c04e02109eaae9"
      unitRef="U002">232813792</us-gaap:Assets>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20200401to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_d1e869cfcddb49e68d4f3b9d72de0c60"
      unitRef="U002">6502865</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20200401to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_919188437b8e4eab9c859ccd18a76bd1"
      unitRef="U002">1249020</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20200401to20200630_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_3d4fe5cb9580473abb529b3a4af8a48b"
      unitRef="U002">35709</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20200401to20200630"
      decimals="0"
      id="Fact_d3da14b3ed27439fa431ac9be573413c"
      unitRef="U002">7787594</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <adma:CostOfProductRevenueExcludingAmortizationExpense
      contextRef="c20200401to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_6bd825dc85474598a355acba8adb7212"
      unitRef="U002">12237141</adma:CostOfProductRevenueExcludingAmortizationExpense>
    <adma:CostOfProductRevenueExcludingAmortizationExpense
      contextRef="c20200401to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_d6b8d3a23c3847058ac39ec8c93e07ad"
      unitRef="U002">1258488</adma:CostOfProductRevenueExcludingAmortizationExpense>
    <adma:CostOfProductRevenueExcludingAmortizationExpense
      contextRef="c20200401to20200630_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_815230690e6a4dedae0c563300efbd30"
      unitRef="U002">0</adma:CostOfProductRevenueExcludingAmortizationExpense>
    <adma:CostOfProductRevenueExcludingAmortizationExpense
      contextRef="c20200401to20200630"
      decimals="0"
      id="Fact_0cb7543aed154282a6e07a4098862233"
      unitRef="U002">13495629</adma:CostOfProductRevenueExcludingAmortizationExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20200401to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_012aaf74b020413eb79be5d9ab6ebde6"
      unitRef="U002">-12852835</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20200401to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_066b344e579949b290e89e0897363f1a"
      unitRef="U002">-919309</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20200401to20200630_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_af3c4ab624d947548dfb9cf0b75b29a0"
      unitRef="U002">-3351681</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20200401to20200630"
      decimals="0"
      id="Fact_db34f3b87a5243c7850c1ebdea0d6bd0"
      unitRef="U002">-17123825</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20200401to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_73c610a4bde24815b96f93771c7755a4"
      unitRef="U002">-235442</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20200401to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_5ddaaa2a14fe489eae438033eee641c6"
      unitRef="U002">-33</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20200401to20200630_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_08f8eaa3080847cba11b20ab9754e39e"
      unitRef="U002">-2818791</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20200401to20200630"
      decimals="0"
      id="Fact_89e5b67257db4e48b62558a8d09186a2"
      unitRef="U002">-3054266</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="c20200401to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_8dc56ff8b0f74e1eb31638271140e992"
      unitRef="U002">-13088277</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20200401to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_c7edeeb3eccd409da562712fa1b17670"
      unitRef="U002">-919342</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20200401to20200630_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_ed12451a4741446eb999f331e1e3a705"
      unitRef="U002">-6170472</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20200401to20200630"
      decimals="0"
      id="Fact_fa1a1de237ec4ff2a15df70ff5080748"
      unitRef="U002">-20178091</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20200401to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_26e3c6fa23db4307830401c0d2cd2ff5"
      unitRef="U002">772241</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20200401to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_10df16f25d7e4f7e972d23cd2008a179"
      unitRef="U002">111106</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20200401to20200630_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_322aaf735c43488597a0f2a07efd5312"
      unitRef="U002">2305</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20200401to20200630"
      decimals="0"
      id="Fact_33ea992828464d0fa2ab135c75a337e4"
      unitRef="U002">885652</us-gaap:DepreciationAndAmortization>
    <us-gaap:Assets
      contextRef="c20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_33aff3ac442c46d39e1a88624d8e583a"
      unitRef="U002">109105418</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_1e74fd07d19549d1b3bc474bf24610d8"
      unitRef="U002">7542486</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20200630_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_a6ae6d38638c410cbedeb2930f3ea0b9"
      unitRef="U002">74893664</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20200630"
      decimals="0"
      id="Fact_97a5c8458ede46b6814e9cbe56104cc2"
      unitRef="U002">191541568</us-gaap:Assets>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20210101to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_3ab5f431d03b4f78bc9734f9897f9f67"
      unitRef="U002">29768923</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20210101to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_b30ffe3d585e4044b4b7163d73a929d6"
      unitRef="U002">4038868</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20210101to20210630_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_6a27e923eaff4dec8944a7aa940cf91a"
      unitRef="U002">71417</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_72443bf3928047929fd2a257d544cc95"
      unitRef="U002">33879208</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <adma:CostOfProductRevenueExcludingAmortizationExpense
      contextRef="c20210101to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_1521869f85a1481f960992d9a0e00c71"
      unitRef="U002">32832049</adma:CostOfProductRevenueExcludingAmortizationExpense>
    <adma:CostOfProductRevenueExcludingAmortizationExpense
      contextRef="c20210101to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_9504c3ab7e184ffe95e03db32facda55"
      unitRef="U002">3770697</adma:CostOfProductRevenueExcludingAmortizationExpense>
    <adma:CostOfProductRevenueExcludingAmortizationExpense
      contextRef="c20210101to20210630_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_6d83529879bd46d1abedb8aeb301839a"
      unitRef="U002">0</adma:CostOfProductRevenueExcludingAmortizationExpense>
    <adma:CostOfProductRevenueExcludingAmortizationExpense
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_e59c3b150072466590cc1dae1bed13e4"
      unitRef="U002">36602746</adma:CostOfProductRevenueExcludingAmortizationExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20210101to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_374190270ce846a4b1fc4542b03b6e88"
      unitRef="U002">-17843093</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20210101to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_f681a186b05342d991e34d3128f712ad"
      unitRef="U002">-4765060</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20210101to20210630_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_5ac0246d4fdd417db97375fcaf86dd11"
      unitRef="U002">-8137328</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_bd04bd6906714c24afcddbd1b74cc3a2"
      unitRef="U002">-30745481</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20210101to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_375bed906a0741788807c00c52acdc8a"
      unitRef="U002">-100307</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20210101to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_4efbe8afa0484b88a0668e67418f8a1f"
      unitRef="U002">-750</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20210101to20210630_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_cd5089278e2147828470899dfba34d17"
      unitRef="U002">-6438706</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_2c08d8a61f88442c8a0e85a1cee81d63"
      unitRef="U002">-6539763</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="c20210101to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_0fc8899947b24c0194e9b89ae980b43e"
      unitRef="U002">-17943400</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210101to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_e9eae77e48c049a6b8959280cfd4c300"
      unitRef="U002">-4765810</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210101to20210630_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_e3b19c997d0e4d9bacbe3243d47ce532"
      unitRef="U002">-14576034</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_52ec4bcdb7f544d7bfa8b4e3a77491b9"
      unitRef="U002">-37285244</us-gaap:NetIncomeLoss>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c20210101to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_69b65294fa574c90b7d74090351578c7"
      unitRef="U002">2725432</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c20210101to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_2c0282d5eb0e46f68feb3b7a07577acf"
      unitRef="U002">4321303</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c20210101to20210630_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_00c72cfa1be4474087363482a932f869"
      unitRef="U002">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_696a0fe939c54fd3a622c9b41550059c"
      unitRef="U002">7046735</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20210101to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_896faca845534b52ab99a7118e15c4fd"
      unitRef="U002">2065307</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20210101to20210630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_8ae5d23a3a524c83abab20ecbee93836"
      unitRef="U002">486918</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20210101to20210630_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_766c62fd9b264ccd977ecf4844522155"
      unitRef="U002">3397</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_c4ab21db3ff84910a4176349fa65c7a4"
      unitRef="U002">2555622</us-gaap:DepreciationAndAmortization>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20200101to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_e57197a3dcbd412fbdc1da9760c3dc3d"
      unitRef="U002">14246139</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20200101to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_c51449ee90044d2facd637a7236782b9"
      unitRef="U002">3669782</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20200101to20200630_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_629aa179aee149a6966d1e752a620817"
      unitRef="U002">71417</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_ee44bec8b61e481b8b3914f623fcdd6b"
      unitRef="U002">17987338</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <adma:CostOfProductRevenueExcludingAmortizationExpense
      contextRef="c20200101to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_a11aefe6c5794446909e5fac319983fc"
      unitRef="U002">26689094</adma:CostOfProductRevenueExcludingAmortizationExpense>
    <adma:CostOfProductRevenueExcludingAmortizationExpense
      contextRef="c20200101to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_c1bd7b7212434c488051c4969c276635"
      unitRef="U002">3635761</adma:CostOfProductRevenueExcludingAmortizationExpense>
    <adma:CostOfProductRevenueExcludingAmortizationExpense
      contextRef="c20200101to20200630_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_d49337d2aba0426ca7dfce7efa7a1628"
      unitRef="U002">0</adma:CostOfProductRevenueExcludingAmortizationExpense>
    <adma:CostOfProductRevenueExcludingAmortizationExpense
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_2f487d658251437a854b0f2c68b0d29a"
      unitRef="U002">30324855</adma:CostOfProductRevenueExcludingAmortizationExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20200101to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_9e43e18a60b840208ca6fa9acc420446"
      unitRef="U002">-25328980</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20200101to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_b497c4d62cdb43fbbbd59007acdc0321"
      unitRef="U002">-1376464</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20200101to20200630_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_6b928b5a2adc4f5fb5797fab368a4a1a"
      unitRef="U002">-7188167</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_0d29e9b50ded430bb671128fe99b5aa4"
      unitRef="U002">-33893611</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20200101to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_a752336d52c14ef69ddc237159c8c765"
      unitRef="U002">-474314</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20200101to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_5a36b52d2f294d818245eb531de47414"
      unitRef="U002">-33</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20200101to20200630_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_076b884726fa4ccab5c2ada606024aaa"
      unitRef="U002">-5055363</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_b7bb527c783a4c049106f91c751257ba"
      unitRef="U002">-5529710</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="c20200101to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_baf135c6f83240f19cc86c8520ca7d23"
      unitRef="U002">-25803294</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20200101to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_7b5e57735097442f90e91bbd7a27cca5"
      unitRef="U002">-1376497</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20200101to20200630_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_bd889d441c96474ab4a35f732be98f9b"
      unitRef="U002">-12243530</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_f4ed534b73634c48a9110ac6c5c0f9b6"
      unitRef="U002">-39423321</us-gaap:NetIncomeLoss>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c20200101to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_7986b159db8c46588ea249ec61b1cd37"
      unitRef="U002">5064494</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c20200101to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_39247938dfc148a1888052cb95a37498"
      unitRef="U002">1178790</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c20200101to20200630_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_ec6cac1af74d458f864c529a503aef33"
      unitRef="U002">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_449830af87464ac8a543cf1f9e7732e9"
      unitRef="U002">6243284</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20200101to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_f51a4d5117514dc28f99aa645c521339"
      unitRef="U002">1447214</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20200101to20200630_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_0b56dbb3cc6044cc8ee576ce2f766f76"
      unitRef="U002">222395</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20200101to20200630_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_784b25dae90b4d92b5e812c66599f825"
      unitRef="U002">4881</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_bf0602743bd34654ae529575e7582c05"
      unitRef="U002">1674490</us-gaap:DepreciationAndAmortization>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="c20210101to20210630"
      id="Text_cb3457db51a845d5ad4ccf3d19e66190">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Net revenues according to geographic area, based on the location of where the product is shipped, is as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Three Months Ended June 30,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Six Months Ended June 30,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2021&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2020&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2021&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2020&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;United States&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;15,424,839&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;6,797,170&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;29,102,848&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;15,453,443&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;International&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,405,751&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;990,424&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,776,360&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,533,895&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total revenues&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;17,830,590&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;7,787,594&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;33,879,208&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;17,987,338&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20210401to20210630_StatementGeographicalAxis_US"
      decimals="0"
      id="Fact_3be7c03acc98435db1922b60348cf52f"
      unitRef="U002">15424839</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20200401to20200630_StatementGeographicalAxis_US"
      decimals="0"
      id="Fact_655c63533d814f2dbe2d6fe1563aead1"
      unitRef="U002">6797170</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20210101to20210630_StatementGeographicalAxis_US"
      decimals="0"
      id="Fact_91155d91098d4509b25ab5126c8ea6d4"
      unitRef="U002">29102848</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20200101to20200630_StatementGeographicalAxis_US"
      decimals="0"
      id="Fact_5e72e2fc55cb432da3023ec4422fc3c3"
      unitRef="U002">15453443</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20210401to20210630_StatementGeographicalAxis_NonUsMember"
      decimals="0"
      id="Fact_934c36b3b9be445ba641a3e697d1e312"
      unitRef="U002">2405751</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20200401to20200630_StatementGeographicalAxis_NonUsMember"
      decimals="0"
      id="Fact_0c71ba040dc54f4ba5c485595fd44e72"
      unitRef="U002">990424</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20210101to20210630_StatementGeographicalAxis_NonUsMember"
      decimals="0"
      id="Fact_bde3589b805a4f6b8377e9743eda474e"
      unitRef="U002">4776360</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20200101to20200630_StatementGeographicalAxis_NonUsMember"
      decimals="0"
      id="Fact_ef6fd07674c1435392453ab99b844b8f"
      unitRef="U002">2533895</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20210401to20210630"
      decimals="0"
      id="Fact_b206710de84f43feb4e52545a510fe99"
      unitRef="U002">17830590</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20200401to20200630"
      decimals="0"
      id="Fact_e86732b3d7a04748acea12c95f6087ba"
      unitRef="U002">7787594</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_3ac0675c69844d78babc6cce46372846"
      unitRef="U002">33879208</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_cc3862e422004e83b3a0e34cc3dd8040"
      unitRef="U002">17987338</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="c20210101to20210630"
      id="Text_1ecd1dbe03aa49dc9cdb7a437126c258">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;12.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;LEASE OBLIGATIONS&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The Company leases certain properties and equipment for its ADMA BioCenters subsidiary and certain equipment
            for its ADMA BioManufacturing subsidiary, which leases provide the right to use the underlying assets and require lease payments through the respective lease terms which expire at various dates through 2032. The Company&#x2019;s lease agreements do
            not contain any material residual value guarantees or material restrictive covenants.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The Company determines if an arrangement is an operating lease at inception. Leases with an initial term of
            12 months or less are not recorded on the balance sheet. All other leases are recorded on the balance sheet with assets representing the right to use the underlying asset for the lease term and lease liabilities representing the obligation to
            make lease payments arising from the lease. Right-to-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term and include options to extend or terminate the
            lease when they are reasonably certain to be exercised. The present value of the lease payments is determined using the Company&#x2019;s incremental borrowing rate of 13%. The Company&#x2019;s lease expense is recognized on a straight-line basis over the lease term and is reflected in Plasma center operating expenses and Selling, general and administrative expenses. Aggregate lease
            expense for the Company&#x2019;s leases for the three months ended June 30, 2021 and 2020 was approximately $0.4 million and $0.1 million, respectively. Aggregate lease expense for the six months ended June 30, 2021 and 2020 was approximately $0.7 million and $0.2 million,
            respectively. Cash paid for the Company&#x2019;s leases for the three months ended June 30, 2021 and 2020 was approximately $0.3 million and
            $0.1 million, respectively. Cash paid for the Company&#x2019;s leases for the six months ended June 30, 2021 and 2020 was approximately $0.5 million and $0.2 million,
            respectively.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;During the six months ended June 30, 2021, the Company recognized additional right to use
              assets and corresponding lease liabilities of $2.8 million in connection with three new property leases where the Company intends to open additional plasma collection facilities. Including a finance lease the Company entered into in June 2018, the
              Company has aggregate lease liabilities of $7.5 million and $4.7 million as of June 30, 2021 and December 31, 2020, respectively, which are comprised primarily of the leases for the Company&#x2019;s plasma collection centers and an
              administrative office lease related to the Company&#x2019;s ADMA BioCenters subsidiary.&#160; The Company&#x2019;s operating leases have a weighted average remaining term of 9.3 years. &lt;/span&gt;&lt;span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Scheduled payments under the Company&#x2019;s lease obligations are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 48%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Remainder of &lt;span style="text-indent: 0pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;595,836&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 48%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Year ended December 31, &lt;span style="text-indent: 0pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 40%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,512,443&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 48%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-indent: 0pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,526,406&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 48%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-indent: 0pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 40%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,399,474&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 48%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-indent: 0pt;"&gt;2025&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,405,411&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 48%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-indent: 0pt;"&gt;2026&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 40%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,137,321&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 48%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Thereafter&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 40%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,486,813&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 48%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total payments&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 40%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;13,063,704&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 48%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Less: imputed interest&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(5,604,431&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 48%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Current portion&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 40%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(385,858&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 48%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Balance at &lt;span style="text-indent: 0pt;"&gt;June 30, 2021&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 40%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;7,073,415&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;On June 11, 2021, t&lt;span style="color: rgb(0, 0, 0);"&gt;he Company entered into an additional property lease
              that the Company intends to use to store certain inventory for its ADMA BioManufacturing business segment. The Company has not taken possession of this leased property and its lease commencement date has not been determined. &lt;/span&gt;With the
            exception of a security deposit and six months&#x2019; rent totaling $0.3 million, no payments have been made under this lease. The initial term of the lease is for 90 months with monthly rental payments varying between approximately $14,000 and $24,000, including common area maintenance charges.&lt;/div&gt;
</us-gaap:LesseeOperatingLeasesTextBlock>
    <adma:OperatingLeaseIncrementalBorrowingRatePercent
      contextRef="c20210401to20210630"
      decimals="2"
      id="Fact_55f7c5cf48ad42f4b337ce7a4d017e14"
      unitRef="U007">0.13</adma:OperatingLeaseIncrementalBorrowingRatePercent>
    <us-gaap:OperatingLeaseExpense
      contextRef="c20210401to20210630"
      decimals="-5"
      id="Fact_79a67d3de81f41eba8d0cabf7a711f31"
      unitRef="U002">400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="c20200401to20200630"
      decimals="-5"
      id="Fact_2950ddff1a244f5a935ea7b3fba4d3b5"
      unitRef="U002">100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="c20210101to20210630"
      decimals="-5"
      id="Fact_5e1ff401ac144b29b2225e07025e7977"
      unitRef="U002">700000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="c20200101to20200630"
      decimals="-5"
      id="Fact_9d1d11ce4ecf4240b7f78c8e5600da83"
      unitRef="U002">200000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeasePayments
      contextRef="c20210401to20210630"
      decimals="-5"
      id="Fact_5fcf9a4488304ff9adc75ef83548bcec"
      unitRef="U002">300000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="c20200401to20200630"
      decimals="-5"
      id="Fact_8f6d66f8a87c4cbf9deff8322abbd383"
      unitRef="U002">100000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="c20210101to20210630"
      decimals="-5"
      id="Fact_b3749ff97e2746ee94b36869f1c8f445"
      unitRef="U002">500000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="c20200101to20200630"
      decimals="-5"
      id="Fact_80cc06cc7a6c4501962cdaf1c7a109d3"
      unitRef="U002">200000</us-gaap:OperatingLeasePayments>
    <adma:LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease
      contextRef="c20210630"
      decimals="-5"
      id="Fact_7ddb5248b3974999814e3cb7041345cd"
      unitRef="U002">2800000</adma:LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease>
    <adma:LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease
      contextRef="c20210630"
      decimals="-5"
      id="Fact_f33de3af181348d0a55e1d293d68e667"
      unitRef="U002">2800000</adma:LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease>
    <adma:NumberOfNewPropertyLeases
      contextRef="c20210401to20210630"
      decimals="INF"
      id="Fact_d8f980828b604e928ffea165a0541d60"
      unitRef="U010">3</adma:NumberOfNewPropertyLeases>
    <us-gaap:OperatingLeaseLiability
      contextRef="c20210630"
      decimals="-5"
      id="Fact_28418e11f07a4d819a967a6f2df610b0"
      unitRef="U002">7500000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="c20201231"
      decimals="-5"
      id="Fact_c6374a3f65244a51bd16c6fe2907ed62"
      unitRef="U002">4700000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="c20210630"
      id="Fact_07f24cbb2eba4271a2b57ab63c059442">P9Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="c20210101to20210630"
      id="Text_94a9bedf8b6049e3ba04fbd1b3835c75">&lt;span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Scheduled payments under the Company&#x2019;s lease obligations are as follows:&lt;/span&gt;&lt;/span&gt;
&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 48%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Remainder of &lt;span style="text-indent: 0pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;595,836&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 48%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Year ended December 31, &lt;span style="text-indent: 0pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 40%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,512,443&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 48%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-indent: 0pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,526,406&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 48%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-indent: 0pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 40%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,399,474&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 48%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-indent: 0pt;"&gt;2025&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,405,411&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 48%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-indent: 0pt;"&gt;2026&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 40%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,137,321&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 48%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Thereafter&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 40%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,486,813&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 48%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total payments&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 40%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;13,063,704&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 48%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Less: imputed interest&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(5,604,431&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 48%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Current portion&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 40%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(385,858&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 48%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Balance at &lt;span style="text-indent: 0pt;"&gt;June 30, 2021&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 40%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;7,073,415&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;
</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="c20210630"
      decimals="0"
      id="Fact_66f213eca6d44cb88c0b1718466616cf"
      unitRef="U002">595836</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="c20210630"
      decimals="0"
      id="Fact_7c8b32caf496451fba6675db1dbd1fda"
      unitRef="U002">1512443</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="c20210630"
      decimals="0"
      id="Fact_904cea01c7094440b74d69d4c87502c8"
      unitRef="U002">1526406</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="c20210630"
      decimals="0"
      id="Fact_13b215c1860f47b88f7ad7eb2f84541d"
      unitRef="U002">1399474</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="c20210630"
      decimals="0"
      id="Fact_2819ea5750b84ff7a2279b1aab503e97"
      unitRef="U002">1405411</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="c20210630"
      decimals="0"
      id="Fact_02e8c9ec86b94978b3a81e393d521819"
      unitRef="U002">1137321</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="c20210630"
      decimals="0"
      id="Fact_86f24fd93c434a2fa625e61fee723e49"
      unitRef="U002">5486813</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="c20210630"
      decimals="0"
      id="Fact_e6a8d527af1f413c8d87428916b1d905"
      unitRef="U002">13063704</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="c20210630"
      decimals="0"
      id="Fact_e0286a846fb24f23b3ce53d86f82a2be"
      unitRef="U002">5604431</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c20210630"
      decimals="0"
      id="Fact_2d8a1e09b09a480abb1ca603f79b06eb"
      unitRef="U002">385858</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c20210630"
      decimals="0"
      id="Fact_8b9a3b111481466d9c27264ae42c9a63"
      unitRef="U002">7073415</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:SecurityDeposit
      contextRef="c20210611"
      decimals="-5"
      id="Fact_f0734cb11db541cea2f2c4c4037abaa4"
      unitRef="U002">300000</us-gaap:SecurityDeposit>
    <us-gaap:PaymentsForRent
      contextRef="c20210611to20210611"
      decimals="-6"
      id="Fact_2b378f1f903c4993921b1cba57f103c3"
      unitRef="U002">0</us-gaap:PaymentsForRent>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="c20210611"
      id="Fact_c8279d913ea8459c8eb764d7f7d2ea77">P90M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <adma:OperatingLeasesRentExpense
      contextRef="c20210611to20210611_RangeAxis_MinimumMember"
      decimals="0"
      id="Fact_0254b898c7cc480c9992720c7844b774"
      unitRef="U002">14000</adma:OperatingLeasesRentExpense>
    <adma:OperatingLeasesRentExpense
      contextRef="c20210611to20210611_RangeAxis_MaximumMember"
      decimals="0"
      id="Fact_512a993ac40442848d38e304afab3c0f"
      unitRef="U002">24000</adma:OperatingLeasesRentExpense>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock
      contextRef="c20210101to20210630"
      id="Text_673ec408ded04a738b2e6188e9f26692">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;13.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Supplemental cash flow information for the six months ended June 30, 2021 and 2020 is as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2021&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2020&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;SUPPLEMENTAL CASH FLOW INFORMATION:&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cash paid for interest&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,534,279&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,192,165&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Non-cash Financing and Investing Activities:&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Equipment acquired reflected in accounts payable and accrued liabilities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,005,546&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,228,000&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Right-to-use assets in exchange for lease obligations&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,844,875&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,723,594&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="c20210101to20210630"
      id="Text_35fb1c620ab44388bdc46b9d5e9dccc2">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Supplemental cash flow information for the six months ended June 30, 2021 and 2020 is as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2021&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2020&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;SUPPLEMENTAL CASH FLOW INFORMATION:&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cash paid for interest&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,534,279&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,192,165&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Non-cash Financing and Investing Activities:&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Equipment acquired reflected in accounts payable and accrued liabilities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,005,546&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,228,000&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Right-to-use assets in exchange for lease obligations&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,844,875&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,723,594&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:InterestPaidNet
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_b9753325c53b44fdb9ba648f102d2d5a"
      unitRef="U002">5534279</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_26c4ccfe76504ce68892f30a85ee6a80"
      unitRef="U002">4192165</us-gaap:InterestPaidNet>
    <adma:EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_69359f1938dd4e358eba137ab827292d"
      unitRef="U002">1005546</adma:EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities>
    <adma:EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_10c7c926bd5149fb8b311b6fef8fa8a7"
      unitRef="U002">1228000</adma:EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c20210101to20210630"
      decimals="0"
      id="Fact_193554f3777e425caef57031b10aef16"
      unitRef="U002">2844875</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c20200101to20200630"
      decimals="0"
      id="Fact_7e89ae4268604b5bb6750e178340f566"
      unitRef="U002">1723594</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="c20210101to20210630"
      id="Text_b1e5371a9f6b4e368821fb3a9ed0e8a0">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;14.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                &lt;div style="font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;On July 26, 2021, the Company sold an additional 897,445 shares of its common stock under the 2020 Sale Agreement and received net proceeds of approximately $1.5 million, which represents the remaining amount that could be raised under the 2020 Sale Agreement as of June 30, 2021. In accordance with terms of the 2020 Sale
          Agreement, the 2020 Sale Agreement automatically terminated upon the foregoing sale of common stock.&lt;/div&gt;
</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20210726to20210726_SubsequentEventTypeAxis_SubsequentEventMember_TypeOfArrangementAxis_SaleAgreement2020Member"
      decimals="0"
      id="Fact_4bbf2096b4f142e99188b23c01ba5eab"
      unitRef="U001">897445</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20210726to20210726_SubsequentEventTypeAxis_SubsequentEventMember_TypeOfArrangementAxis_SaleAgreement2020Member"
      decimals="-5"
      id="Fact_d456b238d9a04e3ca364d7da466e37aa"
      unitRef="U002">1500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045469400488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Aug. 06, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ADMA BIOLOGICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001368514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">56-2590442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Line One</a></td>
<td class="text">465 State Route 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Ramsey<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">478-5552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,769,471<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ADMA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adma_PreferredSharePurchaseRightMember', window );">Preferred Share Purchase Right [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Preferred Share Purchase Right<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_NoTradingSymbolFlag', window );">No Trading Symbol Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_NoTradingSymbolFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a security having no trading symbol.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_NoTradingSymbolFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adma_PreferredSharePurchaseRightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adma_PreferredSharePurchaseRightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045468730136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 42,408,958<span></span>
</td>
<td class="nump">$ 55,921,152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">23,544,594<span></span>
</td>
<td class="nump">13,237,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">99,699,743<span></span>
</td>
<td class="nump">81,535,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,701,863<span></span>
</td>
<td class="nump">3,046,466<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">171,355,158<span></span>
</td>
<td class="nump">153,740,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">46,486,980<span></span>
</td>
<td class="nump">41,593,090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">2,086,445<span></span>
</td>
<td class="nump">2,444,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">3,529,509<span></span>
</td>
<td class="nump">3,529,509<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right to use assets</a></td>
<td class="nump">6,829,040<span></span>
</td>
<td class="nump">4,259,191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_DepositsAndOtherNoncurrentAssets', window );">Deposits and other assets</a></td>
<td class="nump">2,526,660<span></span>
</td>
<td class="nump">2,106,976<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">232,813,792<span></span>
</td>
<td class="nump">207,673,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">6,167,465<span></span>
</td>
<td class="nump">11,073,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">11,490,239<span></span>
</td>
<td class="nump">8,365,143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="nump">142,834<span></span>
</td>
<td class="nump">142,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease obligations</a></td>
<td class="nump">385,858<span></span>
</td>
<td class="nump">365,682<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">18,186,396<span></span>
</td>
<td class="nump">19,947,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorLongTermNotes', window );">Senior notes payable, net of discount</a></td>
<td class="nump">93,877,017<span></span>
</td>
<td class="nump">92,968,866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">2,047,281<span></span>
</td>
<td class="nump">2,118,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease obligations, net of current portion</a></td>
<td class="nump">7,073,415<span></span>
</td>
<td class="nump">4,334,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">36,151<span></span>
</td>
<td class="nump">54,886<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">121,220,260<span></span>
</td>
<td class="nump">119,423,968<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock - voting, $0.0001 par value, 300,000,000 and 150,000,000 shares authorized, 131,872,026 and 104,902,888 shares issued and outstanding</a></td>
<td class="nump">13,187<span></span>
</td>
<td class="nump">10,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">489,330,692<span></span>
</td>
<td class="nump">428,704,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(377,750,347)<span></span>
</td>
<td class="num">(340,465,103)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS' EQUITY</a></td>
<td class="nump">111,593,532<span></span>
</td>
<td class="nump">88,249,426<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
<td class="nump">$ 232,813,792<span></span>
</td>
<td class="nump">$ 207,673,394<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_DepositsAndOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_DepositsAndOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorLongTermNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorLongTermNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045389733128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">131,872,026<span></span>
</td>
<td class="nump">104,902,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">131,872,026<span></span>
</td>
<td class="nump">104,902,888<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045388465208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 17,830,590<span></span>
</td>
<td class="nump">$ 7,787,594<span></span>
</td>
<td class="nump">$ 33,879,208<span></span>
</td>
<td class="nump">$ 17,987,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>OPERATING EXPENSES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_CostOfProductRevenueExcludingAmortizationExpense', window );">Cost of product revenue (exclusive of amortization expense shown below)</a></td>
<td class="nump">18,832,624<span></span>
</td>
<td class="nump">13,495,629<span></span>
</td>
<td class="nump">36,602,746<span></span>
</td>
<td class="nump">30,324,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,158,866<span></span>
</td>
<td class="nump">1,656,420<span></span>
</td>
<td class="nump">2,146,515<span></span>
</td>
<td class="nump">3,185,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Plasma center operating expenses</a></td>
<td class="nump">2,803,326<span></span>
</td>
<td class="nump">877,902<span></span>
</td>
<td class="nump">5,045,669<span></span>
</td>
<td class="nump">1,378,546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">178,838<span></span>
</td>
<td class="nump">178,838<span></span>
</td>
<td class="nump">357,676<span></span>
</td>
<td class="nump">357,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">10,438,168<span></span>
</td>
<td class="nump">8,702,630<span></span>
</td>
<td class="nump">20,472,083<span></span>
</td>
<td class="nump">16,634,714<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">33,411,822<span></span>
</td>
<td class="nump">24,911,419<span></span>
</td>
<td class="nump">64,624,689<span></span>
</td>
<td class="nump">51,880,949<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">LOSS FROM OPERATIONS</a></td>
<td class="num">(15,581,232)<span></span>
</td>
<td class="num">(17,123,825)<span></span>
</td>
<td class="num">(30,745,481)<span></span>
</td>
<td class="num">(33,893,611)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME (EXPENSE):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">5,926<span></span>
</td>
<td class="nump">19,411<span></span>
</td>
<td class="nump">27,985<span></span>
</td>
<td class="nump">267,479<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(3,246,680)<span></span>
</td>
<td class="num">(3,067,306)<span></span>
</td>
<td class="num">(6,442,430)<span></span>
</td>
<td class="num">(5,784,397)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other expense</a></td>
<td class="num">(83,317)<span></span>
</td>
<td class="num">(6,371)<span></span>
</td>
<td class="num">(125,318)<span></span>
</td>
<td class="num">(12,792)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(3,324,071)<span></span>
</td>
<td class="num">(3,054,266)<span></span>
</td>
<td class="num">(6,539,763)<span></span>
</td>
<td class="num">(5,529,710)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (18,905,303)<span></span>
</td>
<td class="num">$ (20,178,091)<span></span>
</td>
<td class="num">$ (37,285,244)<span></span>
</td>
<td class="num">$ (39,423,321)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">BASIC LOSS PER COMMON SHARE (in dollars per share)</a></td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.31)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">DILUTED LOSS PER COMMON SHARE (in dollars per share)</a></td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.31)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">127,416,126<span></span>
</td>
<td class="nump">86,347,467<span></span>
</td>
<td class="nump">121,571,501<span></span>
</td>
<td class="nump">80,064,641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">127,416,126<span></span>
</td>
<td class="nump">86,347,467<span></span>
</td>
<td class="nump">121,571,501<span></span>
</td>
<td class="nump">80,064,641<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 17,794,881<span></span>
</td>
<td class="nump">$ 7,751,885<span></span>
</td>
<td class="nump">$ 33,807,791<span></span>
</td>
<td class="nump">$ 17,915,921<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 35,709<span></span>
</td>
<td class="nump">$ 35,709<span></span>
</td>
<td class="nump">$ 71,417<span></span>
</td>
<td class="nump">$ 71,417<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_CostOfProductRevenueExcludingAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of product sold and service rendered, excluding amortization expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_CostOfProductRevenueExcludingAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045384373304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 5,932<span></span>
</td>
<td class="nump">$ 290,903,772<span></span>
</td>
<td class="num">$ (264,716,555)<span></span>
</td>
<td class="nump">$ 26,193,149<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">59,318,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">676,548<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">676,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering expenses</a></td>
<td class="nump">$ 2,703<span></span>
</td>
<td class="nump">88,701,336<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">88,704,039<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering expenses (in shares)</a></td>
<td class="nump">27,025,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">7,177<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">1,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(19,245,230)<span></span>
</td>
<td class="num">(19,245,230)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2020</a></td>
<td class="nump">$ 8,635<span></span>
</td>
<td class="nump">380,288,833<span></span>
</td>
<td class="num">(283,961,785)<span></span>
</td>
<td class="nump">96,335,683<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2020</a></td>
<td class="nump">86,345,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 5,932<span></span>
</td>
<td class="nump">290,903,772<span></span>
</td>
<td class="num">(264,716,555)<span></span>
</td>
<td class="nump">26,193,149<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">59,318,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,423,321)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2020</a></td>
<td class="nump">$ 8,635<span></span>
</td>
<td class="nump">381,010,696<span></span>
</td>
<td class="num">(304,139,876)<span></span>
</td>
<td class="nump">76,879,455<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2020</a></td>
<td class="nump">86,349,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2020</a></td>
<td class="nump">$ 8,635<span></span>
</td>
<td class="nump">380,288,833<span></span>
</td>
<td class="num">(283,961,785)<span></span>
</td>
<td class="nump">96,335,683<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2020</a></td>
<td class="nump">86,345,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">715,608<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">715,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">6,255<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">4,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(20,178,091)<span></span>
</td>
<td class="num">(20,178,091)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2020</a></td>
<td class="nump">$ 8,635<span></span>
</td>
<td class="nump">381,010,696<span></span>
</td>
<td class="num">(304,139,876)<span></span>
</td>
<td class="nump">76,879,455<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2020</a></td>
<td class="nump">86,349,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 10,490<span></span>
</td>
<td class="nump">428,704,039<span></span>
</td>
<td class="num">(340,465,103)<span></span>
</td>
<td class="nump">88,249,426<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">104,902,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">781,397<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">781,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount', window );">Vesting of Restricted Stock Units, net of shares withheld for taxes and retired</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="num">(59,317)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(59,311)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares', window );">Vesting of Restricted Stock Units, net of shares withheld for taxes and retired (in shares)</a></td>
<td class="nump">61,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering expenses</a></td>
<td class="nump">$ 1,808<span></span>
</td>
<td class="nump">41,910,707<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">41,912,515<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering expenses (in shares)</a></td>
<td class="nump">18,080,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(18,379,941)<span></span>
</td>
<td class="num">(18,379,941)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2021</a></td>
<td class="nump">$ 12,304<span></span>
</td>
<td class="nump">471,336,826<span></span>
</td>
<td class="num">(358,845,044)<span></span>
</td>
<td class="nump">112,504,086<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2021</a></td>
<td class="nump">123,044,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 10,490<span></span>
</td>
<td class="nump">428,704,039<span></span>
</td>
<td class="num">(340,465,103)<span></span>
</td>
<td class="nump">88,249,426<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">104,902,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,285,244)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2021</a></td>
<td class="nump">$ 13,187<span></span>
</td>
<td class="nump">489,330,692<span></span>
</td>
<td class="num">(377,750,347)<span></span>
</td>
<td class="nump">111,593,532<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2021</a></td>
<td class="nump">131,872,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2021</a></td>
<td class="nump">$ 12,304<span></span>
</td>
<td class="nump">471,336,826<span></span>
</td>
<td class="num">(358,845,044)<span></span>
</td>
<td class="nump">112,504,086<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2021</a></td>
<td class="nump">123,044,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">805,189<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">805,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering expenses</a></td>
<td class="nump">$ 883<span></span>
</td>
<td class="nump">17,188,677<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,189,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering expenses (in shares)</a></td>
<td class="nump">8,827,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(18,905,303)<span></span>
</td>
<td class="num">(18,905,303)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2021</a></td>
<td class="nump">$ 13,187<span></span>
</td>
<td class="nump">$ 489,330,692<span></span>
</td>
<td class="num">$ (377,750,347)<span></span>
</td>
<td class="nump">$ 111,593,532<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2021</a></td>
<td class="nump">131,872,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of shares withheld to cover grantees' income tax liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of shares withheld to cover grantees' income tax liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045468836328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (37,285,244)<span></span>
</td>
<td class="num">$ (39,423,321)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,555,622<span></span>
</td>
<td class="nump">1,674,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">78,135<span></span>
</td>
<td class="nump">3,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">1,586,586<span></span>
</td>
<td class="nump">1,392,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">908,151<span></span>
</td>
<td class="nump">874,732<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_AmortizationOfLicenseRevenue', window );">Amortization of license revenue</a></td>
<td class="num">(71,417)<span></span>
</td>
<td class="num">(71,417)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(10,307,304)<span></span>
</td>
<td class="num">(3,044,246)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(18,164,144)<span></span>
</td>
<td class="num">(2,936,614)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(2,655,397)<span></span>
</td>
<td class="num">(2,159,834)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_IncreaseDecreaseInDepositsAndOtherAssets', window );">Deposits and other assets</a></td>
<td class="num">(144,657)<span></span>
</td>
<td class="num">(283,195)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(4,906,244)<span></span>
</td>
<td class="num">(2,264,932)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">2,980,534<span></span>
</td>
<td class="nump">399,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other current and non-current liabilities</a></td>
<td class="num">(65,984)<span></span>
</td>
<td class="num">(92,067)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(65,491,363)<span></span>
</td>
<td class="num">(45,931,435)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(7,046,735)<span></span>
</td>
<td class="num">(6,243,284)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from the sale of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(7,046,735)<span></span>
</td>
<td class="num">(6,241,284)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering expenses</a></td>
<td class="nump">59,102,075<span></span>
</td>
<td class="nump">88,704,039<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_TaxesPaidOnVestedRestrictedStockUnits', window );">Taxes paid on vested Restricted Stock Units</a></td>
<td class="num">(59,311)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of note payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments on finance lease obligations</a></td>
<td class="num">(16,860)<span></span>
</td>
<td class="num">(15,765)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">59,025,904<span></span>
</td>
<td class="nump">101,201,706<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(13,512,194)<span></span>
</td>
<td class="nump">49,028,987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents - beginning of period</a></td>
<td class="nump">55,921,152<span></span>
</td>
<td class="nump">26,752,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents - end of period</a></td>
<td class="nump">$ 42,408,958<span></span>
</td>
<td class="nump">$ 75,781,122<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_AmortizationOfLicenseRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash revenue related to amortization of license revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_AmortizationOfLicenseRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_IncreaseDecreaseInDepositsAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deposits and operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_IncreaseDecreaseInDepositsAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_TaxesPaidOnVestedRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow related to taxes on vested Restricted Stock Units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_TaxesPaidOnVestedRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2443-110228<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045382585464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND BUSINESS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>ORGANIZATION AND BUSINESS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND BUSINESS</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">ORGANIZATION AND BUSINESS</span></div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">ADMA Biologics, Inc. (&#8220;ADMA&#8221; or the &#8220;Company&#8221;) is an end-to-end commercial
            biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The
            Company&#8217;s targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 33.75pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">ADMA operates through its wholly-owned subsidiaries ADMA BioManufacturing, LLC (&#8220;ADMA
            BioManufacturing&#8221;) and ADMA BioCenters Georgia Inc. (&#8220;ADMA BioCenters&#8221;). ADMA BioManufacturing was formed in January 2017 to facilitate the acquisition of the Biotest Therapy Business Unit (&#8220;BTBU&#8221;) from BPC Plasma, Inc. (formerly Biotest
            Pharmaceuticals Corporation) (&#8220;BPC&#8221; and, together with Biotest AG, &#8220;Biotest&#8221;) on June 6, 2017. The acquisition included certain assets (the &#8220;Biotest Assets&#8221;) of BTBU, which included the FDA-licensed BIVIGAM and Nabi-HB immunoglobulin products,
            and an FDA-licensed plasma fractionation manufacturing facility located in Boca Raton, FL (the &#8220;Boca Facility&#8221;) (the &#8220;Biotest Transaction&#8221;). BTBU had previously been the Company&#8217;s third-party contract manufacturer. ADMA BioCenters is the
            Company&#8217;s source plasma collection business with eight plasma collection facilities in various stages of approval and development
            located throughout the U.S., two of which hold an approved license with the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) while a
            third facility has a Biologics License Application (&#8220;BLA&#8221;) pending FDA approval.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 33.75pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The Company has three FDA-approved products, all of which are currently marketed and commercially available: (i) BIVIGAM (Immune Globulin Intravenous, Human), an Intravenous Immune Globulin (&#8220;IVIG&#8221;)
            product indicated for the treatment of Primary Humoral Immunodeficiency (&#8220;PI&#8221;), also known as Primary Immunodeficiency Disease (&#8220;PIDD&#8221;), and for which the Company received FDA approval on May 9, 2019 and commenced commercial sales in August
            2019; (ii) ASCENIV (Immune Globulin Intravenous, Human &#8211; slra 10% Liquid), an IVIG product indicated for the treatment of PI, for which the Company received FDA approval on April 1, 2019 and commenced first commercial sales in October 2019; and
            (iii) Nabi-HB (Hepatitis B Immune Globulin, Human), which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen (&#8220;HBsAg&#8221;) and other listed exposures to Hepatitis B. In addition to its commercially
            available immunoglobulin products, the Company provides contract manufacturing and laboratory services for certain clients and generates revenues from the sale of intermediate by-products that result from the immunoglobulin production process.
            The Company seeks to develop a pipeline of plasma-derived therapeutics, and its products and product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients with or at risk for certain
            infectious diseases.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 33.75pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">As of June 30, 2021, the Company had working capital of $153.2 million, including $42.4
            million of cash and cash equivalents. Based upon the Company&#8217;s current projected revenue and expenditures, including capital expenditures and continued implementation of the Company&#8217;s commercialization and expansion activities, the Company&#8217;s
            management currently believes that its cash, cash equivalents, projected revenue and accounts receivable will be sufficient to fund ADMA&#8217;s operations, as currently conducted, into the fourth quarter of 2021. In order to have sufficient cash to
            fund its operations thereafter, the Company anticipates it will need to raise additional capital before the end of the fourth quarter of 2021. These estimates may change based upon several factors, including the success of the Company&#8217;s
            commercial sales of its products, manufacturing ramp-up activities, the acceptability of ADMA&#8217;s immune globulin products by physicians, patients or payers and the various financing options that may be available to the Company. In addition, the
            Company&#8217;s end-to-end production cycle from procurement of raw materials to commercial release of finished product can take between <span style="-sec-ix-hidden:Fact_53babb8f6d26472fabf16dec51a6b0a4">seven</span>
            and 12 months or potentially longer, requiring substantial investments in raw material plasma and other manufacturing materials. The
            Company currently has no firm commitments for additional financing, and there can be no assurance that the Company will be able to secure additional financing on terms that are acceptable to the Company, or at all. Furthermore, if the Company&#8217;s
            assumptions underlying its estimated expenses and revenues are incorrect, it may have to raise additional capital sooner than currently anticipated.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><br/>
              </div>

<div><br/></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Due to numerous risks and uncertainties associated with FDA review, inspections and approvals related to the
            Company&#8217;s products or the labeled indications of such products, ongoing compliance requirements and capacity expansion efforts at the Company&#8217;s Boca Facility and future commercialization of the Company&#8217;s products, including the Company&#8217;s
            ability to obtain adequate quantities of FDA-approved plasma with proper specifications on acceptable terms for use in the Company&#8217;s manufacturing process, as well as the additional uncertainties surrounding the COVID-19 pandemic (see Note 10),
            the Company is unable to estimate with certainty the amounts of increased capital outlays and operating expenditures required to fund its commercial and development activities. The Company&#8217;s current estimates may be subject to change as
            circumstances regarding its business requirements evolve. Failure to secure any necessary financing in a timely manner and on commercially reasonable terms could have a material adverse effect on the Company&#8217;s business plan and financial
            performance and it could be forced to delay or discontinue its commercialization, product development or clinical activities or delay or discontinue the approval efforts for any of the Company&#8217;s products or product candidates. The Company has
            reported cumulative losses since inception in June 2004 through June 30, 2021 of $377.8 million. As such, these factors raise
            substantial doubt about the Company&#8217;s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments related to the recoverability and classification of asset carrying amounts and the
            classification of liabilities that might be necessary from the outcome of this uncertainty.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The Company may decide to raise capital through public or private equity offerings or debt financings, or
            obtain a bank credit facility or enter into corporate collaboration and licensing arrangements. The sale of additional equity or debt securities, if convertible, could result in dilution to the Company&#8217;s existing stockholders and, in such
            event, the market value of its common stock may decline. The incurrence of additional indebtedness would result in increased fixed obligations and could also result in covenants that would restrict the Company&#8217;s operations or other financing
            alternatives. In addition, the Company is exploring additional contract manufacturing arrangements and other business development opportunities, which may provide additional liquidity to the Company.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">During the six months ended June 30, 2021, the Company raised $59.1 million from the open market sale agreement dated August 5, 2020, as amended, (the &#8220;2020 Sale Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;), pursuant to which the
            Company could offer and sell, from time to time, at its option, through or to Jefferies, shares of the Company&#8217;s common stock (see Note 8). In July of 2021, the Company raised an additional $1.5 million under the 2020 Sale Agreement, and the Company has reached the maximum amount of funds that can be raised under the 2020 Sale Agreement.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">On May 28, 2021, the Company entered into a new Open Market Sale AgreementSM (the &#8220;2021 Sale Agreement&#8221;) with
            Jefferies, pursuant to which the Company may offer and sell, from time to time, at its option, through or to Jefferies, up to an aggregate of $50,000,000
            of shares of the Company&#8217;s common stock. As of August 11, 2021, there have been no sales of common stock under the 2021 Sale
            Agreement.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">There can be no assurance that the Company&#8217;s approved products will be commercially viable, or that research
            and development, plant capacity expansion, plasma center build-outs or other capital improvements will be successfully completed or that any product developed in the future will be approved. The Company is subject to risks common to companies
            in the biotechnology and pharmaceutical manufacturing industries including, but not limited to, dependence on collaborative arrangements, development by the Company or its competitors of new technological innovations, dependence on key
            personnel, protection of proprietary technology, and compliance with FDA and other governmental regulations and approval requirements.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045384184344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Basis of presentation</span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with
            accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards
            Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (the &#8220;FASB&#8221;).</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the
            annual audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2020 included in the Company&#8217;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on March
            25, 2021.&#160; The accompanying consolidated balance sheet as of December 31, 2020 was derived from the audited financial statements as of and for the year ended December 31, 2020. These condensed consolidated interim financial statements have been
            prepared in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X, and therefore omit or condense certain footnotes and other information normally included in complete consolidated financial statements prepared in
            accordance with U.S. GAAP. All intercompany balances and transactions have been eliminated in consolidation.&#160; In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all normal and recurring
            adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company&#8217;s financial position as of June 30, 2021 and its results of operations, changes
            in equity and cash flows for the three and six months ended June 30, 2021.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">During the three and six months ended June 30, 2021 and 2020, comprehensive loss was equal to the net loss
            amounts presented for the respective periods in the accompanying condensed consolidated statements of operations.&#160;&#160; Operating results for interim periods are not necessarily indicative of the results that may be expected for the full fiscal
            year.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Use of estimates</span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The preparation of financial statements requires management to make estimates and assumptions that affect the
            reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ
            from those estimates. Significant estimates include the realizable value of accounts receivable, valuation of inventory, assumptions used in projecting future liquidity and capital requirements, assumptions used in the fair value of awards
            granted under the Company&#8217;s equity incentive plans and warrants issued in connection with the issuance of notes payable and the valuation allowance for the Company&#8217;s deferred tax assets.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Fair value of financial instruments</span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The carrying amounts of certain of the Company&#8217;s financial instruments, including cash and cash equivalents,
            accounts receivable and accounts payable, are shown at cost which approximates fair value due to the short-term nature of these instruments.&#160; The debt outstanding under the Company&#8217;s senior secured term loan (see Note 7) approximates fair value
            due to the variable interest rate on this debt.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"><span style="text-decoration: underline;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Accounts receivable<br/>
              </span></span> <span style="text-decoration: underline;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span></span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Accounts receivable is reported at realizable value, net of allowances for contractual credits and doubtful
            accounts in the amount of $0.2 million and $0.1 million at June 30, 2021 and December 31, 2020, respectively, which are recognized in the period the related revenue is recorded. <span style="color: rgb(33, 37, 41);">The Company
              extends credit to its customers based upon an evaluation of each customer&#8217;s financial condition and credit history. Evaluations of the financial condition and associated credit risk of customers are performed on an ongoing basis.</span> Based
            on these evaluations, the Company has concluded that its credit risk is minimal. At June 30, 2021, six customers accounted for an
            aggregate of 94% of the Company&#8217;s total accounts receivable, and at December 31, 2020, three customers accounted for approximately 92% of the
            Company&#8217;s total accounts receivable.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Inventories</span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Raw materials inventory consists of various materials purchased from suppliers,
            including normal source plasma, used in the production of the Company&#8217;s products. Work-in-process and finished goods inventories (see Note 3) reflect the cost of raw materials as well as costs for direct and indirect labor, primarily salaries,
            wages and benefits for applicable employees, as well as an allocation of overhead costs related to the Boca Facility including utilities, property taxes, general repairs and maintenance, consumable supplies and depreciation. The allocation of
            Boca Facility overhead to inventory is generally based upon the estimated square footage of the Boca Facility that is used in the production of the Company&#8217;s products relative to the total square footage of the facility.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 33.75pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Inventories, including plasma intended for resale and plasma intended for internal
            use in the Company&#8217;s manufacturing, commercialization or research and development activities, are carried at the lower of cost or net realizable value determined by the first-in, first-out method. Net realizable value is generally determined
            based upon the consideration the Company expects to receive when the inventory is sold, less costs to deliver the inventory to the recipient. The estimates for net realizable value of inventory are based on contractual terms or upon historical
            experience and certain other assumptions, and the Company believes that such assumptions are reasonable. Inventory is periodically reviewed to ensure that its carrying value does not exceed its net realizable value, and adjustments are recorded
            to write down such inventory, with a corresponding charge to cost of product revenue, when the carrying value or historical cost exceeds its estimated net realizable value. In addition, costs associated with the production of conformance or
            engineering lots that would not qualify as immediately available for commercial sale are charged to cost of product revenue and not capitalized into inventory.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Goodwill</span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company.&#160;
            Goodwill at June 30, 2021 and December 31, 2020 was $3.5 million.&#160; All of the Company&#8217;s goodwill is attributable to its ADMA
            BioManufacturing business segment and is related to the 2017 Biotest Transaction.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Goodwill is not amortized but is assessed for impairment on an annual basis or more frequently if impairment
            indicators exist. The Company has the option to perform a qualitative assessment of goodwill to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill and
            other intangible assets. If the Company concludes that this is the case, then it must perform a goodwill impairment test by comparing the fair value of the reporting unit to its carrying value. An impairment charge is recorded to the extent the
            reporting unit&#8217;s carrying value exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. The Company performs its annual goodwill impairment test as of October 1 of each year.&#160; The Company&#8217;s annual
            goodwill impairment test as of October 1, 2020 did not result in a goodwill impairment charge, and the Company did not record
            any impairment charges related to goodwill for the three and six months ended June 30, 2021 and 2020.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Impairment of long-lived assets</span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The Company assesses the recoverability of its long-lived assets, which include property and equipment and
            finite-lived intangible assets, whenever significant events or changes in circumstances indicate impairment may have occurred. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to
            its carrying amount to determine whether the asset&#8217;s carrying value is recoverable. Any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a charge to operating results. For
            the three and six months ended June 30, 2021 and 2020, the Company determined that there was no impairment of its long-lived
            assets.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Revenue recognition</span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Revenues for the three and six months ended June 30, 2021 and 2020 are comprised of (i) revenues from the
            sale of the Company&#8217;s immunoglobulin products, BIVIGAM, ASCENIV and Nabi-HB, (ii) product revenues from the sale of human plasma collected through the Company&#8217;s Plasma Collection Centers business segment, (iii) contract manufacturing and
            laboratory services revenue, (iv) revenues from the sale of intermediate by-products; and (v) license and other revenues primarily attributable to the out-licensing of ASCENIV to Biotest in 2012 to market and sell this product in Europe and
            selected countries in North Africa and the Middle East. Biotest has provided the Company with certain services and financial payments in accordance with the related Biotest license agreement and is obligated to pay the Company certain amounts
            in the future if certain milestones are achieved. Deferred revenue is amortized into income over the term of the Biotest license, representing a period of approximately 22 years.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Product revenue is recognized when the customer is deemed to have control over the product. Control is
            determined based on when the product is shipped or delivered and title passes to the customer. Revenue is recorded in an amount that reflects the consideration the Company expects to receive in exchange. Revenue from the sale of the Company&#8217;s
            immunoglobulin products is recognized when the product reaches the customer&#8217;s destination, and is recorded net of estimated rebates, price protection arrangements and customer incentives, including prompt pay discounts, wholesaler chargebacks
            and other wholesaler fees. These estimates are based on historical experience and certain other assumptions, and the Company believes that such estimates are reasonable. For revenues associated with contract manufacturing and the sale of
            intermediates, control transfers to the customer and the performance obligation is satisfied when the customer takes possession of the product from the Boca Facility or from a third-party warehouse that is utilized by the Company.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Product revenues from the sale of human plasma collected at the Company&#8217;s plasma collection centers are
            recognized at the time control of the product has been transferred to the customer, which generally occurs at the time of shipment. Product revenues are recognized at the time of delivery if the Company retains control of the product during
            shipment.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">For the six months ended June 30, 2021, five customers represented an aggregate of 85% of the Company&#8217;s
            consolidated revenues. For the six months ended June 30, 2020, three customers represented an aggregate of 81% of the Company&#8217;s consolidated revenues.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">
          </span></div>

<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Cost of product revenue</span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue includes costs associated with the manufacture of the Company&#8217;s FDA approved
            products, intermediates and the sale of human source plasma, as well as expenses related to conformance batch production, process development and scientific and technical operations when these operations are attributable to marketed products.
            When the activities of these operations are attributable to new products in development, the expenses are classified as research and development expenses.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Loss per common share</span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="color: rgb(0, 0, 0); font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Basic loss per common share is computed by dividing net loss attributable to common
              stockholders by the weighted average number of shares of common stock outstanding during the period.&#160; Diluted loss per common share is calculated by dividing net loss attributable to common stockholders, as adjusted for the effect of dilutive
              securities, if any, by the weighted average number of shares of common stock and dilutive common stock outstanding during the period. Potentially dilutive common stock includes the shares of common stock issuable upon the exercise of
              outstanding stock options and warrants, using the treasury stock method. Potentially dilutive common stock is excluded from the diluted loss per common share computation to the extent that it would be anti-dilutive. As a result, no
              potentially dilutive securities are included in the computation of any of the accompanying diluted loss per share amounts in the accompanying condensed consolidated financial statements as the Company reported a net loss for all periods
              presented. </span><span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">For the six months ended June 30, 2021 and 2020, the following securities were excluded
              from the calculation of diluted loss per common share because of their anti-dilutive effects:</span></span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">For the Six Months Ended June 30,</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2021<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2020<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Stock options</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">7,783,029</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">6,801,779</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Restricted stock units</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">686,133</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">326,000</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Warrants</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">4,528,160</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2,138,160</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">12,997,322</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">9,265,939</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">
          </span></div>

<div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Stock-based compensation</span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="color: rgb(0, 0, 0); font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The Company follows recognized accounting guidance which requires all equity-based payments, including grants
            of stock options, to be recognized in the statement of operations as compensation expense based on their fair values at the date of grant. Compensation expense related to awards to employees and directors with service-based vesting conditions
            is recognized on a straight-line basis over the associated vesting period of the award based on the grant date fair value of the award. Stock options granted under the Company&#8217;s equity incentive plans generally have a four-year vesting period and a term of 10
            years. Pursuant to ASU No. 2016-09, <span style="font-style: italic;">Improvements to Employee Share-Based Payment Accounting (Topic 718)</span>, the Company has elected not to establish a forfeiture rate, as stock-based compensation expense
            related to forfeitures of unvested stock options is fully reversed at the time of forfeiture.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Income Taxes</span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="color: rgb(0, 0, 0); font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events
            that have been included in the consolidated financial statements or its tax returns. Under this method, deferred tax assets and liabilities are recognized for the temporary differences between the tax bases of assets and liabilities and their
            respective financial reporting amounts at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. The Company records a valuation allowance on its deferred tax assets if it is more likely than not
            that the Company will not generate sufficient taxable income to utilize its deferred tax assets. The Company is subject to income tax examinations by major taxing authorities for all tax years since 2016 and for previous periods as it relates
            to the Company&#8217;s net operating loss carryforwards.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">In accordance with U.S. GAAP, the Company is required to determine whether a tax position of the Company is
            more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit to be recognized is
            measured as the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. Derecognition of a tax benefit previously recognized could result in the Company recording a tax liability that would reduce
            net assets. Based on its analysis, the Company has determined that it has not incurred any liability for unrecognized tax benefits as of June 30, 2021 and December 31, 2020, and during the three and six months ended June 30, 2021 and 2020, the
            Company recognized no adjustments for uncertain tax positions.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Recent Accounting Pronouncements</span></div>

<div><span style="text-decoration: underline;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></span></div>

<div style="font-style: italic;"><span style="text-decoration: underline;"> </span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">In June 2016, the FASB issued ASU No. 2016-13, <span style="font-style: italic;">Financial Instruments &#8211;
              Credit Losses (Topic 326)</span> (&#8220;ASU 2016-13&#8221;), which requires financial assets to be presented at the net amount expected to be collected, with an allowance for credit losses to be deducted from the amortized cost basis of the financial
            asset such that the net carrying value of the asset is presented as the amount expected to be collected. Under ASU 2016-13, the entity&#8217;s statement of operations is required to reflect the measurement of credit losses for newly recognized
            financial assets, as well as expected increases or decreases in expected credit losses that have taken place during the period. For public business entities, ASU 2016-13 is effective for fiscal years beginning after December 15, 2019.&#160; The
            Company adopted ASU 2016-13 on January 1, 2020, and the adoption of this update did not have a significant impact on the Company&#8217;s consolidated financial statements.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045382563496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">3.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">INVENTORIES</span></div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The following table provides the components of inventories:</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="margin-left: 13.5pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">June 30,</span></div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2021<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">December 31,</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2020<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Raw materials</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">33,058,221</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">32,044,393</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Work-in-process</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">49,163,125</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">30,293,288</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Finished goods</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">17,478,397</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">19,197,918</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Total inventories</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">99,699,743</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">81,535,599</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Raw materials includes plasma and other materials expected to be used in the production of BIVIGAM, ASCENIV
            and Nabi-HB, as there are alternative uses for these materials that provide a probable future benefit or will be consumed in the production of goods expected to be available for sale. All other activities and materials associated with the
            production of inventories used in research and development activities are expensed as incurred.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Work-in-process inventory primarily consists of bulk drug substance and unlabeled filled vials of the
            Company&#8217;s immunoglobulin products. Finished goods inventory is comprised of immunoglobulin product inventory and related intermediates that are available for commercial sale, as well as plasma collected at the Company&#8217;s plasma collection
            centers which is expected to be sold to third-party customers.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045384184344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>INTANGIBLE ASSETS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">4.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">INTANGIBLE ASSETS</span></div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Intangible assets at June 30, 2021 and December 31, 2020 consist of the following:</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">June 30, 2021</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">December 31, 2020</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> Cost</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">
                    <div style="color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Accumulated</div>
                    <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> Amortization</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Net</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Cost</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">
                    <div style="color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Accumulated</div>
                    <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> Amortization</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Net</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Trademark and other intangible rights related to Nabi-HB</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">4,100,046</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2,391,693</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,708,353</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">4,100,046</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2,098,833</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2,001,213</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 28%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Rights to intermediates</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">907,421</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">529,329</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">378,092</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">907,421</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">464,513</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">442,908</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 28%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Customer contract</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,076,557</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,076,557</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,076,557</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,076,557</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 28%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">6,084,024</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">3,997,579</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2,086,445</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">6,084,024</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">3,639,903</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2,444,121</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">All of the Company&#8217;s intangible assets were acquired in the Biotest Transaction. Amortization
              expense related to these intangible assets was $0.2 million for the three months ended June 30, 2021 and 2020, and $0.4 million for the six months ended June 30, 2021 and 2020. </span><span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Estimated aggregate future aggregate amortization expense is expected to be as follows:</span></span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">2021</span><br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">357,676</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">2022</span><br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">715,352</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">2023</span><br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">715,352</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">2024</span><br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">298,065</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045382585464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">5.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">PROPERTY AND EQUIPMENT</span></div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Property and equipment and related accumulated depreciation are summarized as follows:</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">June 30, 2021</span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">December 31, 2020</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Manufacturing and laboratory equipment</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">15,082,205</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">14,468,874</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Office equipment and computer software</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">3,649,504</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">3,253,528</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Furniture and fixtures</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2,516,729</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2,039,398</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Construction in process</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">5,966,844</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">3,336,557</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Leasehold improvements</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">7,192,820</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">5,272,490</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Land</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">4,339,441</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">4,339,441</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Buildings and building improvements</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">18,694,960</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">17,746,744</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 76%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">57,442,503</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">50,457,032</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Less: Accumulated depreciation</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(10,955,523</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(8,863,942</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Total property and equipment, net</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">46,486,980</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">41,593,090</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Fixed assets are stated at cost less accumulated depreciation. Depreciation is calculated using the
            straight-line method over the asset&#8217;s estimated useful life.&#160; Land is not depreciated. The buildings were assigned a useful life of 30
            years. Property and equipment other than land and buildings have useful lives ranging from <span style="-sec-ix-hidden:Fact_06457f177efa4ffeb98a18387724a0a7">three</span> to 10 years.&#160; Leasehold improvements are amortized over the lesser of the lease term or their estimated useful lives.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The Company recorded depreciation expense on property and equipment for
              the three and six months ended June 30, 2021 of $1.1 million and $2.2 million, respectively. Depreciation expense for the three and six months ended June 30, 2020 was $</span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">0.7<span style="color: rgb(0, 0, 0);"> million and $</span>1.3<span style="color: rgb(0, 0, 0);"> million, respectively. </span></span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045383965752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">6.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued expenses and other current liabilities at June 30, 2021 and December 31, 2020 are as follows:</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">June 30, 2021</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">December 31, 2020</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued rebates</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">3,721,888</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2,604,245</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued distribution fees</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,928,901</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">828,120</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued payroll</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">691,483</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">734,972</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued testing</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,673,120</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">779,660</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued incentives</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,539,491</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">3,210,884</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued severance</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">789,534</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Other</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,145,822</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">207,262</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Total accrued expenses and other current liabilities</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">11,490,239</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">8,365,143</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045382675416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>DEBT [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">DEBT</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="font-weight: bold;">7.</span></td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">DEBT</span></div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">A summary of outstanding senior notes payable is as follows:</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="margin-left: 13.5pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">June 30, 2021</span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">December 31, 2020</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Notes payable</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">100,000,000</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">100,000,000</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Less:</div>
                </td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Debt discount</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(6,122,983</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(7,031,134</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Senior notes payable</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">93,877,017</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">92,968,866</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Under the Credit Agreement and Guaranty, as amended from time to time, (the &#8220;Perceptive Credit Agreement&#8221;)
            with Perceptive Credit Holdings II, LP, as the lender and administrative agent (&#8220;Perceptive&#8221;), the Company has a principal balance outstanding to Perceptive in the form of senior secured notes payable to Perceptive aggregating to $100.0 million with a maturity date of March 1, 2024
            (the &#8220;Maturity Date&#8221;), subject to acceleration pursuant to the Perceptive Credit Agreement, including upon an Event of Default (as defined in the Perceptive Credit Agreement). On the Maturity Date, the Company will pay Perceptive the entire
            outstanding principal amount and any accrued and unpaid interest thereon. Prior to the Maturity Date, there are no scheduled principal payments due under the Perceptive Credit Agreement.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Borrowings under the Perceptive Credit Agreement bear interest at a rate per annum equal to 7.5% plus the greater of (i) one-month
            LIBOR and (ii) 3.5%; provided, however, that upon, and during the continuance of, an Event of Default, the interest rate will
            automatically increase by an additional 400 basis points. Accrued interest is payable to Perceptive on the last day of each month
            during the term of the Perceptive Credit Facility. The rate of interest in effect as of June 30, 2021 was 11.0%, and the Company
            paid interest to Perceptive during the six months ended June 30, 2021 and 2020 in the amount of $5.5 million and $4.4 million, respectively.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">All of the Company&#8217;s obligations under the Perceptive Credit Agreement are secured by a first-priority lien
            and security interest in substantially all of the Company&#8217;s tangible and intangible assets, including intellectual property and all of the equity interests in the Company&#8217;s subsidiaries. The Perceptive Credit Agreement contains certain
            representations and warranties, affirmative covenants, negative covenants and conditions that are customarily required for similar financings. The negative covenants restrict or limit the ability of the Company and its subsidiaries to, among
            other things and subject to certain exceptions contained in the Perceptive Credit Agreement, incur new indebtedness; create liens on assets; engage in certain fundamental corporate changes, such as mergers or acquisitions, or changes to the
            Company&#8217;s or its subsidiaries&#8217; business activities; make certain Investments or Restricted Payments (each as defined in the Perceptive Credit Agreement); change its fiscal year; pay dividends; repay other certain indebtedness; engage in certain
            affiliate transactions; or enter into, amend or terminate any other agreements that have the impact of restricting the Company&#8217;s ability to make loan repayments under the Perceptive Credit Agreement. In addition, the Company must (i) at all
            times prior to the Maturity Date maintain a minimum cash balance of $3.0 million; and (ii) as of the last day of each fiscal quarter
            commencing with the fiscal quarter ended June 30, 2019, report revenues for the trailing 12-month period that exceed the amounts set forth in the Perceptive Credit Agreement, which range from $7.0 million for the fiscal quarter ended June 30, 2019 to $55.0
            million for the fiscal quarter ending December 31, 2021. At June 30, 2021, the Company was in compliance with all of the covenants contained in the Perceptive Credit Agreement.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">As a result of the fees paid to Perceptive and the value of the warrants issued to Perceptive under the terms
            of the Perceptive Credit Agreement, the Company recognized an aggregate discount on the senior secured notes in the amount of $7.1
            million.&#160; The Company records debt discount as a reduction to the face amount of the debt, and the debt discount is amortized as interest expense over the life of the debt using the interest method. Based on the fair value of the Perceptive
            Warrants and the aggregate amount of fees and expenses associated with obtaining the Perceptive Credit Facility, the effective interest rate on senior secured notes payable to Perceptive as of June 30, 2021 was approximately 13.7%.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045382755384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">8.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">STOCKHOLDERS&#8217; EQUITY</span></div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Preferred Stock</span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The Company is currently authorized to issue up to 10 million shares of preferred stock, $0.0001, par
            value per share.&#160; There were no shares of preferred stock outstanding at June 30, 2021 and December 31, 2020.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Common Stock</span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">As of June 30, 2021 and December 31, 2020, the Company was authorized to issue 300,000,000 and 150,000,000 shares,
            respectively, of its common stock, $0.0001 par value per share, and 131,872,026 and 104,902,888 shares of common stock were
            outstanding as of June 30, 2021 and December 31, 2020, respectively. On May 27, 2021, the Company&#8217;s stockholders approved an amendment to the Company&#8217;s certificate of incorporation which increased the number of shares of common stock that the
            Company is authorized to issue from 150,000,000 to 300,000,000. After giving effect to the 17,073,357 shares reserved for
            outstanding warrants and awards issued or reserved for future issuance under the Company&#8217;s equity incentive plans, as of June 30, 2021 there were 151,054,617
            shares of common stock available for issuance.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">On August 5, 2020, the Company entered into the 2020 Sale Agreement with Jefferies (see Note 1), pursuant to
            which the Company could offer and sell, from time to time, at its option, through or to Jefferies, up to an aggregate of $50 million
            of shares of the Company&#8217;s common stock. On November 5, 2020 and February 3, 2021, the Company and Jefferies amended the 2020 Sale Agreement to provide for increases in the aggregate offering amount under the Sale Agreement such that the
            Company could sell shares having an aggregate offering price of up to $105.4 million under the 2020 Sale Agreement, as amended.
            During the six months ended June 30, 2021, the Company issued and sold 26,907,753 shares of common stock under the 2020 Sale
            Agreement and received net proceeds of $59.1 million (see Note 14).</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">On May 28, 2021, the Company entered into the 2021 Sale Agreement with Jefferies, pursuant to which the
            Company may offer and sell, from time to time, at its option, through or to Jefferies, up to an aggregate of $50,000,000 of shares of
            the Company&#8217;s common stock. As of the date of this report, there have been no sales of common stock under this agreement.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">On February 11, 2020, the Company completed an underwritten public offering of 23,500,000 shares of its common stock for gross proceeds of $82.3 million. On February 21, 2020, the Company sold an additional 3,525,000 shares pursuant to
            the underwriters&#8217; exercise of their option to purchase additional shares of the Company&#8217;s common stock for additional gross proceeds of $12.3
            million. The Company received net proceeds, after underwriting discounts and other expenses associated with the offering, of approximately $88.7
            million.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Warrants</span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">At June 30, 2021 and December 31, 2020, the Company had outstanding warrants to purchase an aggregate of 4,528,160 shares of common stock, with a weighted average exercise price of $2.82 per share and expiration dates ranging between June 2022 and December 2030.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Equity Incentive Plans</span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The fair value of stock options granted under the Company&#8217;s 2007 Employee Stock Option Plan
              (the &#8220;2007 Plan&#8221;) and the ADMA Biologics, Inc. 2014 Omnibus Incentive Compensation Plan, as amended and restated (the &#8220;2014 Plan&#8221;), was determined on the date of grant using the Black-Scholes option valuation model. The Black-Scholes model
              was developed for use in estimating the fair value of publicly traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of certain subjective assumptions including
              the expected stock price volatility. The stock options granted to employees and directors have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the
              fair value estimate. </span><span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The following assumptions were used to determine the fair value of options granted during the six months ended June 30, 2021 and
              2020:</span></span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 76%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Six Months Ended June 30,</div>
                </td>

  </tr>

  <tr>

    <td style="width: 76%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td style="width: 11%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2021<br/>
                    </span> </div>
                </td>

    <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td style="width: 11%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2020<br/>
                    </span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 76%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Expected term</div>
                </td>

    <td style="width: 11%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">5.5 - 6.3 years</div>
                </td>

    <td style="width: 2%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td style="width: 11%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">5.5 - 6.3 years</div>
                </td>

  </tr>

  <tr>

    <td style="width: 76%; vertical-align: bottom; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Volatility</div>
                </td>

    <td style="width: 11%; vertical-align: bottom; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">69%<br/>
                    </span> </div>
                </td>

    <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td style="width: 11%; vertical-align: bottom; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">62-67%</div>
                </td>

  </tr>

  <tr>

    <td style="width: 76%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Dividend yield</div>
                </td>

    <td style="width: 11%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">0.0<br/>
                    </span> </div>
                </td>

    <td style="width: 2%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td style="width: 11%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">0.0<br/>
                    </span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 76%; vertical-align: bottom; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Risk-free interest rate</div>
                </td>

    <td style="width: 11%; vertical-align: bottom; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">0.80-1.14%</div>
                </td>

    <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td style="width: 11%; vertical-align: bottom; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">0.38-1.68%</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">During the six months ended June 30, 2021 and 2020, the Company granted options to purchase an aggregate of 1,658,050 and 1,232,500 shares of
            common stock, respectively, to its directors, employees and certain third-party service providers.&#160; The weighted average remaining contractual life of stock options outstanding and expected to vest at June 30, 2021 is 6.5 years. The weighted average remaining contractual life of stock options exercisable at June 30, 2021 is 5.2 years.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">A summary of the Company&#8217;s option activity under the 2007 Plan and 2014 Plan and related information is as
            follows:</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Shares</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Weighted </div>
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Average </div>
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Exercise Price</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Options outstanding, vested and expected to vest at <span style="text-indent: 0pt;">December 31, 2020</span></div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">6,922,931</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">4.40</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Forfeited</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(404,782</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2.96</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Expired</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(393,170</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">5.03</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Granted</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,658,050</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2.26</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Exercised</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Options outstanding, vested and expected to vest at <span style="text-indent: 0pt;">June 30, 2021</span></div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">7,783,029</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">3.98</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Options exercisable</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">5,011,506</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">4.70</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">As of June 30, 2021, the Company had $4.2 million of unrecognized compensation expense related to options granted under the Company&#8217;s equity incentive plans, which is expected to be recognized over a
            weighted-average period of 2.6 years.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">During the six months ended June 30, 2021 and 2020, the Company granted Restricted Stock Units
              (&#8220;RSUs&#8221;) representing an aggregate of 542,244 and 341,000 shares, respectively, to certain management employees of the Company and to members of its Board of Directors.&#160; The RSUs vest annually over a period of four years for employees and semi-annually over a period of one year
              for directors. During the six months ended June 30, 2021, 87,750 shares vested in connection with grants of RSUs. With respect to
              these vested RSUs, 26,365 shares valued at approximately $59,000 were withheld by the Company to cover employees&#8217; tax liabilities.&#160; On March 25, 2021, these shares were retired by the Company and were no longer outstanding as of
              June 30, 2021. </span><span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">A summary of the Company&#8217;s unvested RSU activity and related information is as follows:</span></span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Shares</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Weighted </div>
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Average Grant </div>
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Date Fair Value</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Balance at <span style="text-indent: 0pt;">December 31, 2020</span></div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">326,000</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2.81</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Granted</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">542,244</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2.29</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Vested</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(87,750</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2.81</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Forfeited</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(94,361</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2.53</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Balance at <span style="text-indent: 0pt;">June 30, 2021</span></div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">686,133</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2.44</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">As of June 30, 2021, the Company had $1.5 million of unrecognized compensation expense related to unvested RSUs granted under the Company&#8217;s equity incentive plans, which is expected to be recognized over a
            weighted-average period of 3.3 years.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Total stock-based compensation expense for all awards granted under the Company&#8217;s equity incentive plans for
            the three months and six months June 30, 2021 and 2020 is as follows:</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Three Months Ended June 30,</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Six Months Ended June 30,</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2021<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2020<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2021<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2020<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Research and development</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">42,479</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">105,029</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">147,706</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">198,603</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Plasma center operating expenses</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">13,637</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">8,510</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">24,455</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">15,754</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Selling, general and administrative</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">665,836</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">539,256</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,254,327</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,063,145</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">83,237</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">62,813</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">160,098</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">114,654</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Total stock-based compensation expense</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">805,189</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">715,608</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,586,586</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,392,156</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045382709800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text">
<div>  <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">9.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">RELATED PARTY TRANSACTIONS</div>
            </td>

  </tr>


</table>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </span> </div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company leases an office building and equipment from Areth, LLC (&#8220;Areth&#8221;)
        pursuant to an agreement for services effective as of January 1, 2016, as amended from time to time. Rent expense for the six months ended June 30, 2021 and 2020 amounted to $60,000. Areth is a company controlled by Dr. Jerrold B. Grossman, the Vice Chairman of the Company&#8217;s Board of Directors, and Adam S. Grossman, the Company&#8217;s President and Chief Executive
        Officer. The Company also reimburses Areth for office and building related (common area) expenses, equipment and certain other operational expenses, which were not material to the consolidated financial statements for the six months ended June 30,
        2021 and 2020. In addition, during the six months ended June 30, 2021, the Company purchased certain specialized medical equipment and services related to the Company&#8217;s plasma collection centers, as well as personal protective equipment, from
        GenesisBPS and its affiliates (&#8220;Genesis&#8221;), in the amount of $0.1 million. This amount was immaterial to the consolidated financial
        statements for the three and six months ended June 30, 2020. Dr. Grossman and Adam Grossman each own shares of Genesis.</div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </span> </div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">See Note 7 for a discussion of the Company&#8217;s credit facility and related
        transactions with Perceptive, a holder of more than 10% of the Company&#8217;s common stock.</div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </span> </div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">During the three and six months ended June 30, 2021, in connection with the
        resignation of Dr. James Mond, the Company&#8217;s former Chief Scientific and Medical Officer, the Company recognized an expense and corresponding liability in the amount of $0.8 million for estimated payments to be made under a separation and transition agreement with Dr. Mond. Such payments are to be made in scheduled installments over a period of 10 months.</div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </span> </div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In connection with the February 2020 public offering of the Company&#8217;s common stock
        (see Note 8) on February 11, 2020: (i) Perceptive Advisors, a principal stockholder of ADMA, purchased 4,563,700 shares of common stock
        through one of its affiliates, (ii) Dr. Grossman purchased 22,857 shares of common stock directly and 22,857 shares indirectly through an entity he controls, (iii) Lawrence P. Guiheen, a director of the Company, purchased 20,000 shares of&#160; common stock, (iv) Mr. Grossman purchased 28,571 shares of common stock directly and 57,143 shares indirectly through an
        entity he controls, (v) Brian Lenz, the Company&#8217;s Executive Vice President and Chief Financial Officer, purchased 7,142 shares of common
        stock, and (vi) Dr. Mond purchased 4,285 shares of common stock, all at the public offering price of $3.50 per share.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045382636536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENT AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENT AND CONTINGENCIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">10.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">COMMITMENTS AND CONTINGENCIES</span></div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">General Legal Matters</span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">From time to time the Company is or may become subject to certain legal proceedings and claims arising in
            connection with the normal course of its business. Management does not expect that the outcome of any such claims or actions will have a material effect on the Company&#8217;s liquidity, results of operations or financial condition.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">COVID-19 Pandemic</span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The Company continues to monitor the ongoing developments related to the COVID-19 pandemic, including the
            emergence of the Delta variant and other resistant strains of the coronavirus, and its impacts to the Company&#8217;s commercial and manufacturing operations and plasma collection facilities, including collections of source plasma, procurement of raw
            materials and packaging materials, a portion of which are sourced internationally, and the testing of finished drug product that is required prior to its availability for commercial sale.&#160; A substantial portion of such testing has historically
            been performed by contract laboratories outside the United States.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The Company had experienced some delays with final drug product release testing by third-party vendors. In
            response to these delays, the Company added additional release testing laboratories to its FDA-approved consortium listed in its drug approval documents which the Company believes has adequately addressed this issue. In addition, due to a
            combination of previous state and local &#8220;shelter-in-place&#8221; orders, as well as government stimulus packages, persisting social distancing measures and varying roll-outs of vaccinations by state, the Company has experienced lower than normal
            donor collections at its FDA approved plasma collection centers. The Company was also subject to delays in shipments of source plasma from its contracted third-party suppliers, as well as delays in deliveries for personal protective equipment,
            reagents and other non-plasma raw materials and supplies used in the manufacture and distribution of its products. The Company is also subject to supply chain delays as a result of certain of its suppliers diverting significant resources
            towards the rapid development and distribution of COVID-19 vaccines and, as a result, the Company may elect to carry more raw materials inventory than it has in the past. The COVID-19 pandemic has also impacted, to a certain degree, the
            Company&#8217;s customer engagement initiatives, whereby ADMA&#8217;s sales and medical affairs field personnel have faced difficulties communicating directly with physicians and other healthcare professionals, as well as the cancellation or postponement
            of a number of key scientific and medical meetings, further limiting the Company&#8217;s ability to communicate with potential customers.&#160; The Company has implemented a comprehensive suite of virtual engagement initiatives, however, clinician
            engagement has been reduced due to rapidly evolving COVID-19 priorities at U.S. medical centers.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The pandemic could also impact the Company&#8217;s ability to interact with the FDA or other regulatory authorities
            and may result in delays in the conduct of inspections or review of pending applications or submissions.&#160; During the second quarter of 2021, the Company was notified by the FDA that its submission for the approval of its in-house fill-finish
            process utilizing a recently installed aseptic filling machine will require a site inspection, either in person or virtually, of the Boca Facility. Although the inspection was completed in July of 2021, the FDA&#8217;s review of the Company&#8217;s
            regulatory filing with respect to its in-house fill-finish process and new aseptic filling machine remains ongoing. Although the Company anticipates receiving regulatory approval of this submission in the second half of 2021, no assurances can
            be provided as to the timing for completion of this FDA review or any other regulatory submissions or applications that may be impacted by restrictions related to COVID-19.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Notwithstanding the foregoing, the COVID-19 pandemic to date has not had a material impact on the Company&#8217;s
            financial condition or results of operations, and the Company does not believe that its production operations at the Boca Facility, the Company&#8217;s contract fill/finishers or its plasma collection facilities have been significantly impacted by
            the COVID-19 pandemic. As a result, the Company does not anticipate and has not experienced any material impairments with respect to any of its long-lived assets, including the Company&#8217;s property and equipment, goodwill or intangible assets.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Although the COVID-19 pandemic has not, to date, materially adversely impacted the Company&#8217;s capital and
            financial resources, because the Company is unable to determine the ultimate severity or duration of the pandemic or its long-term effects on, among other things, the global, national or local economies, the capital and credit markets or the
            Company&#8217;s workforce, customers or our suppliers, at this time the Company is unable to predict whether COVID-19 will have a material adverse impact on the Company&#8217;s business, financial condition, liquidity and results of operations.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Vendor Commitments</span><br/>
            </span> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Pursuant to the terms of a plasma purchase agreement with BPC dated as of November 17, 2011 (the &#8220;2011 Plasma
            Purchase Agreement&#8221;), the Company agreed to purchase from BPC an annual minimum volume of source plasma containing antibodies to RSV to be used in the manufacture of ASCENIV. The Company must purchase a to-be-determined and agreed upon annual
            minimum volume from BPC, but may also collect high-titer RSV plasma from up to five wholly-owned ADMA plasma collection facilities.&#160;
            During 2015, the Company and BPC amended the 2011 Plasma Purchase Agreement to allow the Company the ability to collect its raw material RSV high-titer plasma from other third-party collection organizations, thus allowing the Company to expand
            its reach for raw material supply as it executes its commercialization plans for ASCENIV. Unless terminated earlier, the 2011 Plasma Purchase Agreement expires in June 2027, after which it may be renewed for two additional five-year periods if
            agreed to by the parties. As part of the closing of the Biotest Transaction, the parties amended the 2011 Plasma Purchase Agreement to extend the initial term through the ten-year anniversary of the closing date of the Biotest Transaction. On December 10, 2018, BPC assigned its rights and obligations under the 2011 Plasma Purchase Agreement
            to Grifols Worldwide Operations Limited (&#8220;Grifols&#8221;) as its successor-in-interest, effective January 1, 2019. On January 1, 2019, Grifols and the Company entered into an additional amendment to the 2011 Plasma Purchase Agreement for the purchase
            of source plasma containing antibodies to RSV from Grifols. Pursuant to this amendment, until January 1, 2022, the Company may purchase RSV plasma from Grifols from the two plasma collection centers that were transferred to BPC on January 1, 2019 at a price equal to cost plus <span style="-sec-ix-hidden:Fact_5246f96bd6684b0493a757c543cd5bb9">five percent</span> (5%) (without any additional increase due to
            inflation).</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">On June 6, 2017, the Company and BPC entered into a Plasma Supply Agreement pursuant to which BPC supplies,
            on an exclusive basis subject to certain exceptions, to ADMA BioManufacturing an annual minimum volume of hyperimmune plasma that contain antibodies to the Hepatitis B virus for the manufacture of Nabi-HB. The Plasma Supply Agreement has a 10-year term. On July 19, 2018, the Company and BPC entered into an amendment to the Plasma Supply Agreement to provide, among other things, that in
            the event BPC elects not to supply in excess of ADMA BioManufacturing&#8217;s specified amount of Hepatitis B plasma and ADMA BioManufacturing is unable to secure Hepatitis B plasma from a third party at a price that is within a low double- digit
            percentage of the price that ADMA BioManufacturing pays to BPC, then BPC shall reimburse ADMA BioManufacturing for the difference in price ADMA BioManufacturing incurs. On December 10, 2018, BPC assigned its rights and obligations under the
            Plasma Supply Agreement to Grifols, effective January 1, 2019.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">On June 6, 2017, the Company and BPC entered into a Plasma Purchase Agreement (the &#8220;2017 Plasma Purchase
            Agreement&#8221;), pursuant to which ADMA BioManufacturing purchases normal source plasma (&#8220;NSP&#8221;) from BPC at agreed upon annual quantities and prices. The 2017 Plasma Purchase Agreement has an initial term of five years after which the 2017 Plasma Purchase Agreement may be renewed for additional two terms of two years each upon the mutual written consent
            of the parties. On July 19, 2018, the Company and BPC entered into an amendment to the 2017 Plasma Purchase Agreement to, among other things, provide agreed upon amounts of normal source plasma to be supplied by BPC to ADMA BioManufacturing in
            calendar year 2019 at a specified price per liter, provided that ADMA BioManufacturing delivers a valid purchase order to BPC. Additionally, pursuant to the amendment to the 2017 Plasma Purchase Agreement, BPC agreed that, for calendar years
            2020 and 2021, it shall supply no less than a high double-digit percentage of ADMA BioManufacturing&#8217;s requested NSP amounts, provided that such requested NSP amounts are within an agreed range, at a price per liter to be mutually determined.
            Furthermore, pursuant to the amendment to the 2017 Plasma Purchase Agreement, in the event BPC fails to supply ADMA BioManufacturing with at least a high double-digit percentage of ADMA BioManufacturing&#8217;s requested NSP amounts, BPC shall
            promptly reimburse ADMA BioManufacturing the difference in price ADMA BioManufacturing incurs due to BPC&#8217;s election not to supply NSP to ADMA BioManufacturing in such amounts as requested. On December 10, 2018, BPC assigned its rights and
            obligations under the Plasma Purchase Agreement to Grifols, effective January 1, 2019. </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Effective as of May 12, 2021, the Company and Grifols amended the foregoing 2017 Plasma Purchase Agreement
            whereby, among other things, the term of the agreement was extended through December 31, 2022, while certain historical provisions were deleted. In order to maintain a reliable supply of raw material plasma thereafter, the Company is in
            late-stage discussion with multiple third-party suppliers of NSP to supplement the 2017 Plasma Purchase Agreement, and the Company has also increased the number of planned plasma collection center buildouts and is continuing to increase its
            plasma collection capabilities at its ADMA BioCenters plasma collection centers business segment.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The Company purchases substantially all of its raw material plasma from Grifols. For the six months ended
            June 30, 2021, plasma purchases from Grifols totaled $17.5 million, or approximately 67% of the Company&#8217;s total inventory purchases. For the six months ended June 30, 2020, plasma purchases from Grifols totaled approximately $3.7 million, representing approximately 42%
            of the Company&#8217;s total inventory purchases.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Post-marketing commitments</span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">In connection with the approval of the BLA for BIVIGAM, on December 19, 2012 Biotest committed to perform two
            additional post-marketing studies, a pediatric study to evaluate the efficacy and safety of BIVIGAM in children and adolescents, and a post-authorization safety study to further assess the potential risk of hypotension and hepatic and renal
            impairment in BIVIGAM-treated patients with primary humoral immunodeficiency. These studies are still pending completion. ADMA has assumed the remaining obligations, and the costs of the studies will be expensed as incurred as research and
            development expenses. The Company currently expects both studies to be completed by June of 2023.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">In connection with the FDA&#8217;s approval of ASCENIV on April 1, 2019, the Company is required to perform a
            pediatric study to evaluate the safety and efficacy of ASCENIV in children and adolescents. This study is required to be completed by June of 2023.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Employment contracts</span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The Company has entered into employment agreements with its executive management team consisting of its
            President and Chief Executive Officer, its Executive Vice President and Chief Financial Officer and its former Executive Vice President, Chief Medical Officer and Chief Scientific Officer (see Note 9).</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Other commitments</span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">In the normal course of business, the Company enters into contracts that contain a variety of
            indemnifications with its employees, licensors, suppliers and service providers. Further, the Company indemnifies its directors and officers who are, or were, serving at the Company&#8217;s request in such capacities. The Company&#8217;s maximum exposure
            under these arrangements is unknown as of June 30, 2021. The Company does not anticipate recognizing any significant losses relating to these arrangements.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045384697768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>SEGMENTS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENTS</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">11.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">SEGMENTS</span></div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The Company is engaged in the manufacture, marketing and development of specialty
              plasma-derived biologics.&#160; The Company&#8217;s ADMA BioManufacturing segment reflects the Company&#8217;s immunoglobulin manufacturing, commercial and development operations in Boca Raton, FL, acquired on June 6, 2017 (see Note 1).&#160; The Plasma Collection
              Centers segment as of June 30, 2021 consists of eight<span style="color: rgb(0, 0, 0);"> plasma collection facilities in various
                stages of approval and development located throughout the U.S., two of which hold an approved license with the FDA while a third
                facility has a BLA pending FDA approval</span>. The Corporate segment includes general and administrative overhead expenses. The Company defines its segments as those business units whose operating results are regularly reviewed by the
              chief operating decision maker (&#8220;CODM&#8221;) to analyze performance and allocate resources. The Company&#8217;s CODM is its President and Chief Executive Officer.&#160; </span><span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Summarized financial information concerning reportable segments is shown in the following tables:</span></span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Three Months Ended June 30, 2021</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">ADMA </div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">BioManufacturing</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Plasma Collection </div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Centers</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Corporate</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Consolidated</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Revenues</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">16,347,880</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,447,001</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">35,709</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">17,830,590</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">17,382,292</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,450,332</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">18,832,624</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Loss from operations</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(8,337,405</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(2,794,219</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(4,449,608</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(15,581,232</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Interest and other expense, net</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(78,793</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(366</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(3,244,912</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(3,324,071</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Net loss</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(8,416,198</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(2,794,585</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(7,694,520</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(18,905,303</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Depreciation and amortization expense</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,055,537</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">268,927</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,530</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,325,994</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Total assets</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">169,799,509</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">20,593,411</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">42,420,872</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">232,813,792</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Three Months Ended June 30, 2020</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">ADMA </div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">BioManufacturing</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Plasma Collection </div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Centers</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Corporate</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Consolidated</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Revenues</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">6,502,865</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,249,020</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">35,709</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">7,787,594</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">12,237,141</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,258,488</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">13,495,629</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Loss from operations</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(12,852,835</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(919,309</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(3,351,681</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(17,123,825</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Interest and other expense, net</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(235,442</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(33</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(2,818,791</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(3,054,266</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Net loss</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(13,088,277</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(919,342</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(6,170,472</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(20,178,091</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Depreciation and amortization expense</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">772,241</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">111,106</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2,305</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">885,652</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Total assets</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">109,105,418</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">7,542,486</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">74,893,664</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">191,541,568</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Six Months Ended June 30, 2021</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">ADMA </div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">BioManufacturing</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Plasma Collection </div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Centers</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Corporate</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Consolidated</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Revenues</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">29,768,923</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">4,038,868</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">71,417</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">33,879,208</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">32,832,049</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">3,770,697</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">36,602,746</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Loss from operations</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(17,843,093</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(4,765,060</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(8,137,328</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(30,745,481</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Interest and other expense, net</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(100,307</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(750</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(6,438,706</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(6,539,763</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Net loss</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(17,943,400</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(4,765,810</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(14,576,034</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(37,285,244</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Capital expenditures</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2,725,432</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">4,321,303</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">7,046,735</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Depreciation and amortization expense</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2,065,307</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">486,918</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">3,397</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2,555,622</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Six Months Ended June 30, 2020</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">ADMA </div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">BioManufacturing</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Plasma Collection </div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Centers</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Corporate</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Consolidated</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Revenues</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">14,246,139</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">3,669,782</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">71,417</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">17,987,338</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">26,689,094</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">3,635,761</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">30,324,855</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Loss from operations</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(25,328,980</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(1,376,464</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(7,188,167</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(33,893,611</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Interest and other expense, net</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(474,314</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(33</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(5,055,363</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(5,529,710</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Net loss</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(25,803,294</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(1,376,497</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(12,243,530</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(39,423,321</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Capital expenditures</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">5,064,494</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,178,790</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">6,243,284</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Depreciation and amortization expense</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,447,214</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">222,395</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">4,881</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,674,490</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Net revenues according to geographic area, based on the location of where the product is shipped, is as follows:</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Three Months Ended June 30,</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Six Months Ended June 30,</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2021<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2020<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2021<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2020<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">United States</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">15,424,839</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">6,797,170</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">29,102,848</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">15,453,443</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">International</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2,405,751</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">990,424</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">4,776,360</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2,533,895</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Total revenues</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">17,830,590</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">7,787,594</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">33,879,208</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">17,987,338</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045384738056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASE OBLIGATIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASE OBLIGATIONS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASE OBLIGATIONS</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">12.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">LEASE OBLIGATIONS</span></div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The Company leases certain properties and equipment for its ADMA BioCenters subsidiary and certain equipment
            for its ADMA BioManufacturing subsidiary, which leases provide the right to use the underlying assets and require lease payments through the respective lease terms which expire at various dates through 2032. The Company&#8217;s lease agreements do
            not contain any material residual value guarantees or material restrictive covenants.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The Company determines if an arrangement is an operating lease at inception. Leases with an initial term of
            12 months or less are not recorded on the balance sheet. All other leases are recorded on the balance sheet with assets representing the right to use the underlying asset for the lease term and lease liabilities representing the obligation to
            make lease payments arising from the lease. Right-to-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term and include options to extend or terminate the
            lease when they are reasonably certain to be exercised. The present value of the lease payments is determined using the Company&#8217;s incremental borrowing rate of 13%. The Company&#8217;s lease expense is recognized on a straight-line basis over the lease term and is reflected in Plasma center operating expenses and Selling, general and administrative expenses. Aggregate lease
            expense for the Company&#8217;s leases for the three months ended June 30, 2021 and 2020 was approximately $0.4 million and $0.1 million, respectively. Aggregate lease expense for the six months ended June 30, 2021 and 2020 was approximately $0.7 million and $0.2 million,
            respectively. Cash paid for the Company&#8217;s leases for the three months ended June 30, 2021 and 2020 was approximately $0.3 million and
            $0.1 million, respectively. Cash paid for the Company&#8217;s leases for the six months ended June 30, 2021 and 2020 was approximately $0.5 million and $0.2 million,
            respectively.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">During the six months ended June 30, 2021, the Company recognized additional right to use
              assets and corresponding lease liabilities of $2.8 million in connection with three new property leases where the Company intends to open additional plasma collection facilities. Including a finance lease the Company entered into in June 2018, the
              Company has aggregate lease liabilities of $7.5 million and $4.7 million as of June 30, 2021 and December 31, 2020, respectively, which are comprised primarily of the leases for the Company&#8217;s plasma collection centers and an
              administrative office lease related to the Company&#8217;s ADMA BioCenters subsidiary.&#160; The Company&#8217;s operating leases have a weighted average remaining term of 9.3 years. </span><span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Scheduled payments under the Company&#8217;s lease obligations are as follows:</span></span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; width: 48%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Remainder of <span style="text-indent: 0pt;">2021</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">595,836</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 48%; white-space: nowrap;" valign="bottom">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Year ended December 31, <span style="text-indent: 0pt;">2022</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 40%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,512,443</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 48%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">2023</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,526,406</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 48%; white-space: nowrap;" valign="bottom">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">2024</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 40%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,399,474</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 48%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">2025</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,405,411</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 48%; white-space: nowrap;" valign="bottom">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">2026</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 40%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,137,321</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 48%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Thereafter</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 40%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">5,486,813</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 48%; white-space: nowrap;" valign="bottom">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Total payments</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 40%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">13,063,704</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 48%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Less: imputed interest</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(5,604,431</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 48%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Current portion</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 40%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(385,858</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 48%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Balance at <span style="text-indent: 0pt;">June 30, 2021</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 40%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">7,073,415</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">On June 11, 2021, t<span style="color: rgb(0, 0, 0);">he Company entered into an additional property lease
              that the Company intends to use to store certain inventory for its ADMA BioManufacturing business segment. The Company has not taken possession of this leased property and its lease commencement date has not been determined. </span>With the
            exception of a security deposit and six months&#8217; rent totaling $0.3 million, no payments have been made under this lease. The initial term of the lease is for 90 months with monthly rental payments varying between approximately $14,000 and $24,000, including common area maintenance charges.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045382525528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">13.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</span></div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Supplemental cash flow information for the six months ended June 30, 2021 and 2020 is as follows:</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2021<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2020<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">SUPPLEMENTAL CASH FLOW INFORMATION:</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Cash paid for interest</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">5,534,279</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">4,192,165</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Non-cash Financing and Investing Activities:</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Equipment acquired reflected in accounts payable and accrued liabilities</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,005,546</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,228,000</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Right-to-use assets in exchange for lease obligations</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2,844,875</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,723,594</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -URI http://asc.fasb.org/topic&amp;trid=2134446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045384308008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">14.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">SUBSEQUENT EVENTS</span></div>
              </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
          </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">On July 26, 2021, the Company sold an additional 897,445 shares of its common stock under the 2020 Sale Agreement and received net proceeds of approximately $1.5 million, which represents the remaining amount that could be raised under the 2020 Sale Agreement as of June 30, 2021. In accordance with terms of the 2020 Sale
          Agreement, the 2020 Sale Agreement automatically terminated upon the foregoing sale of common stock.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045468824936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Basis of presentation</span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with
            accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards
            Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (the &#8220;FASB&#8221;).</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the
            annual audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2020 included in the Company&#8217;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on March
            25, 2021.&#160; The accompanying consolidated balance sheet as of December 31, 2020 was derived from the audited financial statements as of and for the year ended December 31, 2020. These condensed consolidated interim financial statements have been
            prepared in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X, and therefore omit or condense certain footnotes and other information normally included in complete consolidated financial statements prepared in
            accordance with U.S. GAAP. All intercompany balances and transactions have been eliminated in consolidation.&#160; In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all normal and recurring
            adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company&#8217;s financial position as of June 30, 2021 and its results of operations, changes
            in equity and cash flows for the three and six months ended June 30, 2021.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">During the three and six months ended June 30, 2021 and 2020, comprehensive loss was equal to the net loss
            amounts presented for the respective periods in the accompanying condensed consolidated statements of operations.&#160;&#160; Operating results for interim periods are not necessarily indicative of the results that may be expected for the full fiscal
            year.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Use of estimates</span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The preparation of financial statements requires management to make estimates and assumptions that affect the
            reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ
            from those estimates. Significant estimates include the realizable value of accounts receivable, valuation of inventory, assumptions used in projecting future liquidity and capital requirements, assumptions used in the fair value of awards
            granted under the Company&#8217;s equity incentive plans and warrants issued in connection with the issuance of notes payable and the valuation allowance for the Company&#8217;s deferred tax assets.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value of financial instruments</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Fair value of financial instruments</span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The carrying amounts of certain of the Company&#8217;s financial instruments, including cash and cash equivalents,
            accounts receivable and accounts payable, are shown at cost which approximates fair value due to the short-term nature of these instruments.&#160; The debt outstanding under the Company&#8217;s senior secured term loan (see Note 7) approximates fair value
            due to the variable interest rate on this debt.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts receivable</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"><span style="text-decoration: underline;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Accounts receivable<br/>
              </span></span> <span style="text-decoration: underline;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span></span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Accounts receivable is reported at realizable value, net of allowances for contractual credits and doubtful
            accounts in the amount of $0.2 million and $0.1 million at June 30, 2021 and December 31, 2020, respectively, which are recognized in the period the related revenue is recorded. <span style="color: rgb(33, 37, 41);">The Company
              extends credit to its customers based upon an evaluation of each customer&#8217;s financial condition and credit history. Evaluations of the financial condition and associated credit risk of customers are performed on an ongoing basis.</span> Based
            on these evaluations, the Company has concluded that its credit risk is minimal. At June 30, 2021, six customers accounted for an
            aggregate of 94% of the Company&#8217;s total accounts receivable, and at December 31, 2020, three customers accounted for approximately 92% of the
            Company&#8217;s total accounts receivable.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Inventories</span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Raw materials inventory consists of various materials purchased from suppliers,
            including normal source plasma, used in the production of the Company&#8217;s products. Work-in-process and finished goods inventories (see Note 3) reflect the cost of raw materials as well as costs for direct and indirect labor, primarily salaries,
            wages and benefits for applicable employees, as well as an allocation of overhead costs related to the Boca Facility including utilities, property taxes, general repairs and maintenance, consumable supplies and depreciation. The allocation of
            Boca Facility overhead to inventory is generally based upon the estimated square footage of the Boca Facility that is used in the production of the Company&#8217;s products relative to the total square footage of the facility.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 33.75pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Inventories, including plasma intended for resale and plasma intended for internal
            use in the Company&#8217;s manufacturing, commercialization or research and development activities, are carried at the lower of cost or net realizable value determined by the first-in, first-out method. Net realizable value is generally determined
            based upon the consideration the Company expects to receive when the inventory is sold, less costs to deliver the inventory to the recipient. The estimates for net realizable value of inventory are based on contractual terms or upon historical
            experience and certain other assumptions, and the Company believes that such assumptions are reasonable. Inventory is periodically reviewed to ensure that its carrying value does not exceed its net realizable value, and adjustments are recorded
            to write down such inventory, with a corresponding charge to cost of product revenue, when the carrying value or historical cost exceeds its estimated net realizable value. In addition, costs associated with the production of conformance or
            engineering lots that would not qualify as immediately available for commercial sale are charged to cost of product revenue and not capitalized into inventory.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text">
<div>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Goodwill</span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company.&#160;
            Goodwill at June 30, 2021 and December 31, 2020 was $3.5 million.&#160; All of the Company&#8217;s goodwill is attributable to its ADMA
            BioManufacturing business segment and is related to the 2017 Biotest Transaction.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Goodwill is not amortized but is assessed for impairment on an annual basis or more frequently if impairment
            indicators exist. The Company has the option to perform a qualitative assessment of goodwill to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill and
            other intangible assets. If the Company concludes that this is the case, then it must perform a goodwill impairment test by comparing the fair value of the reporting unit to its carrying value. An impairment charge is recorded to the extent the
            reporting unit&#8217;s carrying value exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. The Company performs its annual goodwill impairment test as of October 1 of each year.&#160; The Company&#8217;s annual
            goodwill impairment test as of October 1, 2020 did not result in a goodwill impairment charge, and the Company did not record
            any impairment charges related to goodwill for the three and six months ended June 30, 2021 and 2020.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Impairment of long-lived assets</span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The Company assesses the recoverability of its long-lived assets, which include property and equipment and
            finite-lived intangible assets, whenever significant events or changes in circumstances indicate impairment may have occurred. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to
            its carrying amount to determine whether the asset&#8217;s carrying value is recoverable. Any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a charge to operating results. For
            the three and six months ended June 30, 2021 and 2020, the Company determined that there was no impairment of its long-lived
            assets.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Revenue recognition</span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Revenues for the three and six months ended June 30, 2021 and 2020 are comprised of (i) revenues from the
            sale of the Company&#8217;s immunoglobulin products, BIVIGAM, ASCENIV and Nabi-HB, (ii) product revenues from the sale of human plasma collected through the Company&#8217;s Plasma Collection Centers business segment, (iii) contract manufacturing and
            laboratory services revenue, (iv) revenues from the sale of intermediate by-products; and (v) license and other revenues primarily attributable to the out-licensing of ASCENIV to Biotest in 2012 to market and sell this product in Europe and
            selected countries in North Africa and the Middle East. Biotest has provided the Company with certain services and financial payments in accordance with the related Biotest license agreement and is obligated to pay the Company certain amounts
            in the future if certain milestones are achieved. Deferred revenue is amortized into income over the term of the Biotest license, representing a period of approximately 22 years.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Product revenue is recognized when the customer is deemed to have control over the product. Control is
            determined based on when the product is shipped or delivered and title passes to the customer. Revenue is recorded in an amount that reflects the consideration the Company expects to receive in exchange. Revenue from the sale of the Company&#8217;s
            immunoglobulin products is recognized when the product reaches the customer&#8217;s destination, and is recorded net of estimated rebates, price protection arrangements and customer incentives, including prompt pay discounts, wholesaler chargebacks
            and other wholesaler fees. These estimates are based on historical experience and certain other assumptions, and the Company believes that such estimates are reasonable. For revenues associated with contract manufacturing and the sale of
            intermediates, control transfers to the customer and the performance obligation is satisfied when the customer takes possession of the product from the Boca Facility or from a third-party warehouse that is utilized by the Company.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Product revenues from the sale of human plasma collected at the Company&#8217;s plasma collection centers are
            recognized at the time control of the product has been transferred to the customer, which generally occurs at the time of shipment. Product revenues are recognized at the time of delivery if the Company retains control of the product during
            shipment.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">For the six months ended June 30, 2021, five customers represented an aggregate of 85% of the Company&#8217;s
            consolidated revenues. For the six months ended June 30, 2020, three customers represented an aggregate of 81% of the Company&#8217;s consolidated revenues.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of product revenue</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">
          </span></div>

<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Cost of product revenue</span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue includes costs associated with the manufacture of the Company&#8217;s FDA approved
            products, intermediates and the sale of human source plasma, as well as expenses related to conformance batch production, process development and scientific and technical operations when these operations are attributable to marketed products.
            When the activities of these operations are attributable to new products in development, the expenses are classified as research and development expenses.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per common share</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Loss per common share</span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="color: rgb(0, 0, 0); font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Basic loss per common share is computed by dividing net loss attributable to common
              stockholders by the weighted average number of shares of common stock outstanding during the period.&#160; Diluted loss per common share is calculated by dividing net loss attributable to common stockholders, as adjusted for the effect of dilutive
              securities, if any, by the weighted average number of shares of common stock and dilutive common stock outstanding during the period. Potentially dilutive common stock includes the shares of common stock issuable upon the exercise of
              outstanding stock options and warrants, using the treasury stock method. Potentially dilutive common stock is excluded from the diluted loss per common share computation to the extent that it would be anti-dilutive. As a result, no
              potentially dilutive securities are included in the computation of any of the accompanying diluted loss per share amounts in the accompanying condensed consolidated financial statements as the Company reported a net loss for all periods
              presented. </span><span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">For the six months ended June 30, 2021 and 2020, the following securities were excluded
              from the calculation of diluted loss per common share because of their anti-dilutive effects:</span></span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">For the Six Months Ended June 30,</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2021<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2020<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Stock options</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">7,783,029</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">6,801,779</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Restricted stock units</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">686,133</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">326,000</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Warrants</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">4,528,160</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2,138,160</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">12,997,322</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">9,265,939</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based compensation</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">
          </span></div>

<div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Stock-based compensation</span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="color: rgb(0, 0, 0); font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The Company follows recognized accounting guidance which requires all equity-based payments, including grants
            of stock options, to be recognized in the statement of operations as compensation expense based on their fair values at the date of grant. Compensation expense related to awards to employees and directors with service-based vesting conditions
            is recognized on a straight-line basis over the associated vesting period of the award based on the grant date fair value of the award. Stock options granted under the Company&#8217;s equity incentive plans generally have a four-year vesting period and a term of 10
            years. Pursuant to ASU No. 2016-09, <span style="font-style: italic;">Improvements to Employee Share-Based Payment Accounting (Topic 718)</span>, the Company has elected not to establish a forfeiture rate, as stock-based compensation expense
            related to forfeitures of unvested stock options is fully reversed at the time of forfeiture.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Income Taxes</span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="color: rgb(0, 0, 0); font-style: italic;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events
            that have been included in the consolidated financial statements or its tax returns. Under this method, deferred tax assets and liabilities are recognized for the temporary differences between the tax bases of assets and liabilities and their
            respective financial reporting amounts at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. The Company records a valuation allowance on its deferred tax assets if it is more likely than not
            that the Company will not generate sufficient taxable income to utilize its deferred tax assets. The Company is subject to income tax examinations by major taxing authorities for all tax years since 2016 and for previous periods as it relates
            to the Company&#8217;s net operating loss carryforwards.</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">In accordance with U.S. GAAP, the Company is required to determine whether a tax position of the Company is
            more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit to be recognized is
            measured as the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. Derecognition of a tax benefit previously recognized could result in the Company recording a tax liability that would reduce
            net assets. Based on its analysis, the Company has determined that it has not incurred any liability for unrecognized tax benefits as of June 30, 2021 and December 31, 2020, and during the three and six months ended June 30, 2021 and 2020, the
            Company recognized no adjustments for uncertain tax positions.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Recent Accounting Pronouncements</span></div>

<div><span style="text-decoration: underline;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></span></div>

<div style="font-style: italic;"><span style="text-decoration: underline;"> </span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">In June 2016, the FASB issued ASU No. 2016-13, <span style="font-style: italic;">Financial Instruments &#8211;
              Credit Losses (Topic 326)</span> (&#8220;ASU 2016-13&#8221;), which requires financial assets to be presented at the net amount expected to be collected, with an allowance for credit losses to be deducted from the amortized cost basis of the financial
            asset such that the net carrying value of the asset is presented as the amount expected to be collected. Under ASU 2016-13, the entity&#8217;s statement of operations is required to reflect the measurement of credit losses for newly recognized
            financial assets, as well as expected increases or decreases in expected credit losses that have taken place during the period. For public business entities, ASU 2016-13 is effective for fiscal years beginning after December 15, 2019.&#160; The
            Company adopted ASU 2016-13 on January 1, 2020, and the adoption of this update did not have a significant impact on the Company&#8217;s consolidated financial statements.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI http://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045384279128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Calculation of Diluted Loss Per Common Share</a></td>
<td class="text"><span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">For the six months ended June 30, 2021 and 2020, the following securities were excluded
              from the calculation of diluted loss per common share because of their anti-dilutive effects:</span></span>
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">For the Six Months Ended June 30,</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2021<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2020<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Stock options</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">7,783,029</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">6,801,779</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Restricted stock units</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">686,133</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">326,000</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Warrants</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">4,528,160</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2,138,160</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">12,997,322</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">9,265,939</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045382619960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Components of Inventory</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The following table provides the components of inventories:</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="margin-left: 13.5pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">June 30,</span></div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2021<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">December 31,</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2020<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Raw materials</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">33,058,221</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">32,044,393</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Work-in-process</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">49,163,125</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">30,293,288</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Finished goods</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">17,478,397</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">19,197,918</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Total inventories</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">99,699,743</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">81,535,599</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045382656792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>INTANGIBLE ASSETS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Intangible assets at June 30, 2021 and December 31, 2020 consist of the following:</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">June 30, 2021</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">December 31, 2020</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> Cost</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">
                    <div style="color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Accumulated</div>
                    <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> Amortization</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Net</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Cost</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">
                    <div style="color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Accumulated</div>
                    <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> Amortization</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Net</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Trademark and other intangible rights related to Nabi-HB</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">4,100,046</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2,391,693</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,708,353</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">4,100,046</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2,098,833</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2,001,213</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 28%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Rights to intermediates</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">907,421</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">529,329</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">378,092</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">907,421</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">464,513</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">442,908</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 28%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Customer contract</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,076,557</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,076,557</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,076,557</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,076,557</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 28%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">6,084,024</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">3,997,579</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2,086,445</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">6,084,024</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">3,639,903</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2,444,121</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Intangible Asset Future Aggregate Amortization Expense</a></td>
<td class="text"><span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Estimated aggregate future aggregate amortization expense is expected to be as follows:</span></span>
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">2021</span><br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">357,676</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">2022</span><br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">715,352</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">2023</span><br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">715,352</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">2024</span><br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">298,065</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045382684184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Property and equipment and related accumulated depreciation are summarized as follows:</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">June 30, 2021</span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">December 31, 2020</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Manufacturing and laboratory equipment</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">15,082,205</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">14,468,874</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Office equipment and computer software</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">3,649,504</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">3,253,528</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Furniture and fixtures</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2,516,729</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2,039,398</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Construction in process</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">5,966,844</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">3,336,557</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Leasehold improvements</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">7,192,820</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">5,272,490</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Land</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">4,339,441</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">4,339,441</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Buildings and building improvements</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">18,694,960</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">17,746,744</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 76%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">57,442,503</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">50,457,032</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Less: Accumulated depreciation</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(10,955,523</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(8,863,942</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Total property and equipment, net</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">46,486,980</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">41,593,090</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045382606536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued expenses and other current liabilities at June 30, 2021 and December 31, 2020 are as follows:</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">June 30, 2021</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">December 31, 2020</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued rebates</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">3,721,888</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2,604,245</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued distribution fees</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,928,901</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">828,120</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued payroll</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">691,483</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">734,972</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued testing</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,673,120</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">779,660</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued incentives</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,539,491</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">3,210,884</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued severance</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">789,534</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Other</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,145,822</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">207,262</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Total accrued expenses and other current liabilities</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">11,490,239</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">8,365,143</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045505176168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>DEBT [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Summary of Outstanding Senior Notes Payable</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">A summary of outstanding senior notes payable is as follows:</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="margin-left: 13.5pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">June 30, 2021</span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">December 31, 2020</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Notes payable</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">100,000,000</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">100,000,000</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Less:</div>
                </td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Debt discount</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(6,122,983</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(7,031,134</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Senior notes payable</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">93,877,017</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">92,968,866</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045388902072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions</a></td>
<td class="text"><span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">The following assumptions were used to determine the fair value of options granted during the six months ended June 30, 2021 and
              2020:</span></span>
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 76%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Six Months Ended June 30,</div>
                </td>

  </tr>

  <tr>

    <td style="width: 76%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td style="width: 11%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2021<br/>
                    </span> </div>
                </td>

    <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td style="width: 11%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2020<br/>
                    </span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 76%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Expected term</div>
                </td>

    <td style="width: 11%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">5.5 - 6.3 years</div>
                </td>

    <td style="width: 2%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td style="width: 11%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">5.5 - 6.3 years</div>
                </td>

  </tr>

  <tr>

    <td style="width: 76%; vertical-align: bottom; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Volatility</div>
                </td>

    <td style="width: 11%; vertical-align: bottom; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">69%<br/>
                    </span> </div>
                </td>

    <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td style="width: 11%; vertical-align: bottom; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">62-67%</div>
                </td>

  </tr>

  <tr>

    <td style="width: 76%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Dividend yield</div>
                </td>

    <td style="width: 11%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">0.0<br/>
                    </span> </div>
                </td>

    <td style="width: 2%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td style="width: 11%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">0.0<br/>
                    </span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 76%; vertical-align: bottom; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Risk-free interest rate</div>
                </td>

    <td style="width: 11%; vertical-align: bottom; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">0.80-1.14%</div>
                </td>

    <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td style="width: 11%; vertical-align: bottom; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">0.38-1.68%</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Option Activity</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">A summary of the Company&#8217;s option activity under the 2007 Plan and 2014 Plan and related information is as
            follows:</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Shares</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Weighted </div>
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Average </div>
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Exercise Price</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Options outstanding, vested and expected to vest at <span style="text-indent: 0pt;">December 31, 2020</span></div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">6,922,931</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">4.40</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Forfeited</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(404,782</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2.96</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Expired</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(393,170</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">5.03</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Granted</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,658,050</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2.26</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Exercised</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Options outstanding, vested and expected to vest at <span style="text-indent: 0pt;">June 30, 2021</span></div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">7,783,029</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">3.98</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Options exercisable</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">5,011,506</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">4.70</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock', window );">Schedule of Unvested RSU Activity</a></td>
<td class="text"><span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">A summary of the Company&#8217;s unvested RSU activity and related information is as follows:</span></span>
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Shares</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Weighted </div>
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Average Grant </div>
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Date Fair Value</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Balance at <span style="text-indent: 0pt;">December 31, 2020</span></div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">326,000</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2.81</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Granted</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">542,244</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2.29</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Vested</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(87,750</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2.81</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Forfeited</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(94,361</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2.53</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Balance at <span style="text-indent: 0pt;">June 30, 2021</span></div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">686,133</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2.44</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Total stock-based compensation expense for all awards granted under the Company&#8217;s equity incentive plans for
            the three months and six months June 30, 2021 and 2020 is as follows:</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Three Months Ended June 30,</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Six Months Ended June 30,</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2021<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2020<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2021<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2020<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Research and development</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">42,479</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">105,029</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">147,706</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">198,603</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Plasma center operating expenses</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">13,637</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">8,510</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">24,455</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">15,754</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Selling, general and administrative</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">665,836</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">539,256</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,254,327</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,063,145</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">83,237</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">62,813</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">160,098</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">114,654</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Total stock-based compensation expense</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">805,189</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">715,608</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,586,586</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,392,156</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in restricted stock units (RSUs).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045384098856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>SEGMENTS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Summarized Financial Information Concerning Reportable Segments</a></td>
<td class="text"><span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Summarized financial information concerning reportable segments is shown in the following tables:</span></span>
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Three Months Ended June 30, 2021</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">ADMA </div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">BioManufacturing</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Plasma Collection </div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Centers</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Corporate</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Consolidated</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Revenues</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">16,347,880</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,447,001</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">35,709</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">17,830,590</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">17,382,292</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,450,332</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">18,832,624</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Loss from operations</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(8,337,405</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(2,794,219</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(4,449,608</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(15,581,232</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Interest and other expense, net</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(78,793</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(366</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(3,244,912</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(3,324,071</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Net loss</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(8,416,198</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(2,794,585</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(7,694,520</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(18,905,303</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Depreciation and amortization expense</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,055,537</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">268,927</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,530</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,325,994</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Total assets</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">169,799,509</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">20,593,411</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">42,420,872</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">232,813,792</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Three Months Ended June 30, 2020</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">ADMA </div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">BioManufacturing</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Plasma Collection </div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Centers</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Corporate</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Consolidated</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Revenues</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">6,502,865</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,249,020</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">35,709</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">7,787,594</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">12,237,141</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,258,488</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">13,495,629</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Loss from operations</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(12,852,835</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(919,309</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(3,351,681</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(17,123,825</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Interest and other expense, net</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(235,442</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(33</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(2,818,791</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(3,054,266</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Net loss</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(13,088,277</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(919,342</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(6,170,472</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(20,178,091</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Depreciation and amortization expense</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">772,241</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">111,106</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2,305</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">885,652</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Total assets</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">109,105,418</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">7,542,486</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">74,893,664</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">191,541,568</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Six Months Ended June 30, 2021</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">ADMA </div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">BioManufacturing</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Plasma Collection </div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Centers</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Corporate</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Consolidated</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Revenues</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">29,768,923</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">4,038,868</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">71,417</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">33,879,208</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">32,832,049</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">3,770,697</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">36,602,746</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Loss from operations</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(17,843,093</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(4,765,060</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(8,137,328</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(30,745,481</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Interest and other expense, net</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(100,307</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(750</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(6,438,706</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(6,539,763</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Net loss</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(17,943,400</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(4,765,810</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(14,576,034</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(37,285,244</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Capital expenditures</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2,725,432</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">4,321,303</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">7,046,735</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Depreciation and amortization expense</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2,065,307</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">486,918</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">3,397</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2,555,622</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Six Months Ended June 30, 2020</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">ADMA </div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">BioManufacturing</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Plasma Collection </div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Centers</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Corporate</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Consolidated</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Revenues</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">14,246,139</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">3,669,782</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">71,417</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">17,987,338</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">26,689,094</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">3,635,761</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">30,324,855</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Loss from operations</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(25,328,980</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(1,376,464</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(7,188,167</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(33,893,611</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Interest and other expense, net</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(474,314</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(33</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(5,055,363</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(5,529,710</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Net loss</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(25,803,294</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(1,376,497</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(12,243,530</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(39,423,321</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Capital expenditures</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">5,064,494</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,178,790</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">6,243,284</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Depreciation and amortization expense</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,447,214</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">222,395</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">4,881</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,674,490</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Net Revenues According to Geographic Area</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Net revenues according to geographic area, based on the location of where the product is shipped, is as follows:</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Three Months Ended June 30,</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Six Months Ended June 30,</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2021<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2020<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2021<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2020<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">United States</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">15,424,839</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">6,797,170</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">29,102,848</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">15,453,443</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">International</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2,405,751</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">990,424</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">4,776,360</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2,533,895</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Total revenues</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">17,830,590</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">7,787,594</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">33,879,208</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">17,987,338</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045382562664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASE OBLIGATIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASE OBLIGATIONS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Payments Under Lease Obligations</a></td>
<td class="text"><span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Scheduled payments under the Company&#8217;s lease obligations are as follows:</span></span>
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; width: 48%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Remainder of <span style="text-indent: 0pt;">2021</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">595,836</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 48%; white-space: nowrap;" valign="bottom">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Year ended December 31, <span style="text-indent: 0pt;">2022</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 40%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,512,443</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 48%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">2023</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,526,406</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 48%; white-space: nowrap;" valign="bottom">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">2024</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 40%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,399,474</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 48%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">2025</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,405,411</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 48%; white-space: nowrap;" valign="bottom">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">2026</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 40%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,137,321</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 48%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Thereafter</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 40%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">5,486,813</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 48%; white-space: nowrap;" valign="bottom">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Total payments</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 40%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">13,063,704</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 48%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Less: imputed interest</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(5,604,431</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 48%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Current portion</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 40%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">(385,858</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 48%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Balance at <span style="text-indent: 0pt;">June 30, 2021</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 40%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">7,073,415</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045382616056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Supplemental Cash Flow Information</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Supplemental cash flow information for the six months ended June 30, 2021 and 2020 is as follows:</div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2021<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2020<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">SUPPLEMENTAL CASH FLOW INFORMATION:</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Cash paid for interest</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">5,534,279</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">4,192,165</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Non-cash Financing and Investing Activities:</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Equipment acquired reflected in accounts payable and accrued liabilities</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,005,546</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,228,000</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">Right-to-use assets in exchange for lease obligations</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">2,844,875</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none;">1,723,594</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045389369224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND BUSINESS (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 28, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>Facility</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>Facility </div>
<div>Product</div>
</th>
<th class="th">
<div>Aug. 11, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract', window );"><strong>Organization and Business [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment', window );">Number of Plasma Collection Facilities Under Development | Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_NumberOfFDALicensedPlasmaCollectionFacilities', window );">Number of FDA-Licensed Plasma Collection Facilities | Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_NumberOfFDAApprovedProduct', window );">Number of FDA approved product | Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_WorkingCapital', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 153,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 153,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Cumulative losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(377,750,347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (377,750,347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (340,465,103)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issuable under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,189,560<span></span>
</td>
<td class="nump">$ 41,912,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,704,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract', window );"><strong>Organization and Business [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_ProductCycleFromProcurementOfRawMaterialsToFinishedProduct', window );">Production cycle from procurement of raw materials to release of finished product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract', window );"><strong>Organization and Business [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_ProductCycleFromProcurementOfRawMaterialsToFinishedProduct', window );">Production cycle from procurement of raw materials to release of finished product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=adma_JefferiesLLCMember', window );">Jefferies [Member] | 2020 Sale Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract', window );"><strong>Organization and Business [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from sales of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=adma_JefferiesLLCMember', window );">Jefferies [Member] | 2020 Sale Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract', window );"><strong>Organization and Business [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from sales of common stock</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=adma_JefferiesLLCMember', window );">Jefferies [Member] | 2021 Sale Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract', window );"><strong>Organization and Business [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonUnitIssuanceValue', window );">Sales of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=adma_JefferiesLLCMember', window );">Jefferies [Member] | 2021 Sale Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract', window );"><strong>Organization and Business [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issuable under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfFDAApprovedProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of products approved by FDA.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfFDAApprovedProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfFDALicensedPlasmaCollectionFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of plasma collection facilities having FDA license.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfFDALicensedPlasmaCollectionFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of plasma collection facilities under various stages of development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ProductCycleFromProcurementOfRawMaterialsToFinishedProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Production cycle from procurement of raw materials to commercial release of finished product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ProductCycleFromProcurementOfRawMaterialsToFinishedProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of difference between current assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonUnitIssuanceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stated value of common units of ownership issued by a limited liability company (LLC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonUnitIssuanceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=adma_JefferiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=adma_JefferiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adma_SaleAgreement2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adma_SaleAgreement2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adma_SaleAgreement2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adma_SaleAgreement2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045389804360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Accounts Receivable (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>Customer</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Customer</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetAbstract', window );"><strong>Accounts Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts', window );">Accounts receivable, allowances for contractual credits and doubtful accounts | $</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer Concentration Risk [Member] | Six Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetAbstract', window );"><strong>Accounts Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_NumberOfCustomers', window );">Number of customers</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of account receivables</a></td>
<td class="nump">94.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer Concentration Risk [Member] | Three Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetAbstract', window );"><strong>Accounts Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_NumberOfCustomers', window );">Number of customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of account receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for contractual credits and doubtful accounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of customers accounted for company's total accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=adma_SixCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=adma_SixCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=adma_ThreeCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=adma_ThreeCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045384063208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Goodwill (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract', window );"><strong>Goodwill [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 3,529,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,529,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,529,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment charges related to goodwill</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045384971224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Impairment of Long-lived Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentChargesAbstract', window );"><strong>Impairment of Long-lived Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045389440168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Revenue Recognition (Details) - Customer<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=adma_FiveCustomersMember', window );">Five Customers [Member] | Revenues [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_NumberOfCustomers', window );">Number of customers</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of consolidated revenues</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=adma_ThreeCustomersMember', window );">Three Customers [Member] | Revenues [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_NumberOfCustomers', window );">Number of customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of consolidated revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adma_BiotestLicenseAgreementMember', window );">Biotest License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_DeferredRevenueRemainingAmortizationPeriod', window );">Amortization period</a></td>
<td class="text">22 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_DeferredRevenueRemainingAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of deferred revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_DeferredRevenueRemainingAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of customers accounted for company's total accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=adma_FiveCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=adma_FiveCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=adma_ThreeCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=adma_ThreeCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adma_BiotestLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adma_BiotestLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045388509144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Loss per Common Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Loss Per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities (in shares)</a></td>
<td class="nump">12,997,322<span></span>
</td>
<td class="nump">9,265,939<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Loss Per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities (in shares)</a></td>
<td class="nump">7,783,029<span></span>
</td>
<td class="nump">6,801,779<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Loss Per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities (in shares)</a></td>
<td class="nump">686,133<span></span>
</td>
<td class="nump">326,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Loss Per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities (in shares)</a></td>
<td class="nump">4,528,160<span></span>
</td>
<td class="nump">2,138,160<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045472112744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Stock-based Compensation (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Equity incentive plans, vesting period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Equity incentive plans, term</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045382724552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045388982136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 33,058,221<span></span>
</td>
<td class="nump">$ 32,044,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-process</a></td>
<td class="nump">49,163,125<span></span>
</td>
<td class="nump">30,293,288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">17,478,397<span></span>
</td>
<td class="nump">19,197,918<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 99,699,743<span></span>
</td>
<td class="nump">$ 81,535,599<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045472245432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 6,084,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,084,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,084,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">3,997,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,997,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,639,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">2,086,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,086,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,444,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">178,838<span></span>
</td>
<td class="nump">$ 178,838<span></span>
</td>
<td class="nump">357,676<span></span>
</td>
<td class="nump">$ 357,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember', window );">Trademark and Other Intangible Rights Related to Nabi-HB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">4,100,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">2,391,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,391,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,098,833<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">1,708,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,708,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,001,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=adma_RightToIntermediatesMember', window );">Right to Intermediates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">907,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">907,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">907,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">529,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">529,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">464,513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">378,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">378,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">442,908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerContractsMember', window );">Customer Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">1,076,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,076,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,076,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">1,076,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,076,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,076,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=adma_RightToIntermediatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=adma_RightToIntermediatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045384908040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS, Future Aggregate Amortization Expense (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Estimated Aggregate Amortization Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Remaining of 2021</a></td>
<td class="nump">$ 357,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths', window );">2022</a></td>
<td class="nump">715,352<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo', window );">2023</a></td>
<td class="nump">715,352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree', window );">2024</a></td>
<td class="nump">$ 298,065<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045389017048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipments, gross</a></td>
<td class="nump">$ 57,442,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,442,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,457,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(10,955,523)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,955,523)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,863,942)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">46,486,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,486,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,593,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation expense</a></td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember', window );">Manufacturing and Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipments, gross</a></td>
<td class="nump">15,082,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,082,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,468,874<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment and Computer Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipments, gross</a></td>
<td class="nump">3,649,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,649,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,253,528<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipments, gross</a></td>
<td class="nump">2,516,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,516,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,039,398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember', window );">Construction in Process [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipments, gross</a></td>
<td class="nump">5,966,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,966,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,336,557<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipments, gross</a></td>
<td class="nump">7,192,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,192,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,272,490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipments, gross</a></td>
<td class="nump">4,339,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,339,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,339,441<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and Building Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipments, gross</a></td>
<td class="nump">$ 18,694,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,694,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,746,744<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045468634952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Expenses and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_AccruedRebatesCurrent', window );">Accrued rebates</a></td>
<td class="nump">$ 3,721,888<span></span>
</td>
<td class="nump">$ 2,604,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued distribution fees</a></td>
<td class="nump">1,928,901<span></span>
</td>
<td class="nump">828,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll</a></td>
<td class="nump">691,483<span></span>
</td>
<td class="nump">734,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount', window );">Accrued testing</a></td>
<td class="nump">1,673,120<span></span>
</td>
<td class="nump">779,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued incentives</a></td>
<td class="nump">1,539,491<span></span>
</td>
<td class="nump">3,210,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits', window );">Accrued severance</a></td>
<td class="nump">789,534<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">1,145,822<span></span>
</td>
<td class="nump">207,262<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 11,490,239<span></span>
</td>
<td class="nump">$ 8,365,143<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_AccruedRebatesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of rebates for Medicaid or other third parties related to sale of product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_AccruedRebatesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability from premium deficiency and loss recognition testing on long-duration contract issued by insurance entity. Excludes closed block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 60<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509248&amp;loc=SL117422156-227712<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability for amount due employees, in addition to wages and any other money that employers owe employees, when their employment ends through a layoff or other termination. For example, a company may provide involuntarily terminated employees with a lump sum payment equal to one week's salary for every year of employment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045388657720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_SeniorNotesPayableBeforeDebtDiscount', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,122,983)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,122,983)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,031,134)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorLongTermNotes', window );">Senior notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,877,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,877,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,968,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_RepaymentsOfDebtInterest', window );">Payments of debt interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,830,590<span></span>
</td>
<td class="nump">$ 7,787,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,879,208<span></span>
</td>
<td class="nump">$ 17,987,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adma_PerceptiveCreditAgreementMember', window );">Perceptive Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  01,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Credit agreement, Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Credit agreement, Interest rate provided</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Increase basis points</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adma_PerceptiveCreditAgreementMember', window );">Perceptive Credit Agreement [Member] | Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 55,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adma_PerceptiveCreditAgreementMember', window );">Perceptive Credit Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adma_PerceptiveCreditAgreementMember', window );">Perceptive Credit Agreement [Member] | LIBOR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_DebtInstrumentTermOfVariableRate', window );">Term of variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adma_PerceptiveCreditFacilityMember', window );">Perceptive Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes [Member] | Perceptive Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_DebtInstrumentTermOfVariableRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of the interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_DebtInstrumentTermOfVariableRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_RepaymentsOfDebtInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_RepaymentsOfDebtInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_SeniorNotesPayableBeforeDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding debt discount and current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_SeniorNotesPayableBeforeDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage increase (decrease) in the stated rate on a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorLongTermNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorLongTermNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adma_PerceptiveCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adma_PerceptiveCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adma_PerceptiveCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adma_PerceptiveCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045389796568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY, Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of nonredeemable preferred shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045378870920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY, Common Stock (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 28, 2021</div></th>
<th class="th"><div>Feb. 03, 2021</div></th>
<th class="th"><div>Aug. 05, 2020</div></th>
<th class="th"><div>Feb. 21, 2020</div></th>
<th class="th"><div>Feb. 11, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,872,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,872,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,902,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,073,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,073,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,054,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,054,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issuable under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,189,560<span></span>
</td>
<td class="nump">$ 41,912,515<span></span>
</td>
<td class="nump">$ 88,704,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,102,075<span></span>
</td>
<td class="nump">$ 88,704,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwritten Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,300,000<span></span>
</td>
<td class="nump">$ 82,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adma_SaleAgreement2020Member', window );">2020 Sale Agreement [Member] | Jefferies LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adma_SaleAgreement2020Member', window );">2020 Sale Agreement [Member] | Jefferies LLC [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issuable under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adma_SaleAgreement2020AmendedMember', window );">2020 Sale Agreement, As Amended [Member] | Jefferies LLC [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issuable under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adma_SaleAgreement2021Member', window );">2021 Sale Agreement [Member] | Jefferies LLC [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issuable under agreement</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,528,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,528,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,528,160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issuable under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 883<span></span>
</td>
<td class="nump">$ 1,808<span></span>
</td>
<td class="nump">$ 2,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares sold during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,827,045<span></span>
</td>
<td class="nump">18,080,708<span></span>
</td>
<td class="nump">27,025,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Underwritten Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares sold during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,525,000<span></span>
</td>
<td class="nump">23,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | 2020 Sale Agreement [Member] | Jefferies LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares sold during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,907,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | 2021 Sale Agreement [Member] | Jefferies LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares sold during the period (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_GrossProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of gross proceeds from issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_GrossProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adma_SaleAgreement2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adma_SaleAgreement2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adma_JefferiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adma_JefferiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adma_SaleAgreement2020AmendedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adma_SaleAgreement2020AmendedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adma_SaleAgreement2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adma_SaleAgreement2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045382469032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY, Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_WarrantsAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">17,073,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 2.82<span></span>
</td>
<td class="nump">$ 2.82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_WarrantsAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">4,528,160<span></span>
</td>
<td class="nump">4,528,160<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_WarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_WarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045380684424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY, Equity Incentive Plans (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_RestrictedStockUnitsAbstract', window );"><strong>Restricted Stock Units [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted stock units vested over a period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Total stock-based compensation expense, Amount [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 805,189<span></span>
</td>
<td class="nump">$ 715,608<span></span>
</td>
<td class="nump">$ 1,586,586<span></span>
</td>
<td class="nump">$ 1,392,156<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Total stock-based compensation expense, Amount [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">42,479<span></span>
</td>
<td class="nump">105,029<span></span>
</td>
<td class="nump">147,706<span></span>
</td>
<td class="nump">198,603<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Plasma Center Operating Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Total stock-based compensation expense, Amount [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">13,637<span></span>
</td>
<td class="nump">8,510<span></span>
</td>
<td class="nump">24,455<span></span>
</td>
<td class="nump">15,754<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Total stock-based compensation expense, Amount [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">665,836<span></span>
</td>
<td class="nump">539,256<span></span>
</td>
<td class="nump">1,254,327<span></span>
</td>
<td class="nump">1,063,145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Product Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Total stock-based compensation expense, Amount [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">83,237<span></span>
</td>
<td class="nump">$ 62,813<span></span>
</td>
<td class="nump">160,098<span></span>
</td>
<td class="nump">$ 114,654<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adma_EquityIncentivePlanMember', window );">Equity Incentive Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_StockOptionsWeightedAverageExercisePriceAbstract', window );"><strong>Stock Options, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense, stock options</a></td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions and Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_StockOptionsAbstract', window );"><strong>Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,658,050<span></span>
</td>
<td class="nump">1,232,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life of stock options, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life of stock options, expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life of stock options, exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_StockOptionSharesAbstract', window );"><strong>Stock Option, Shares [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options outstanding, vested and expected to vest, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,922,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(404,782)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber', window );">Expired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(393,170)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,658,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options outstanding, vested and expected to vest, ending balance (in shares)</a></td>
<td class="nump">7,783,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,783,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable (in shares)</a></td>
<td class="nump">5,011,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,011,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_StockOptionsWeightedAverageExercisePriceAbstract', window );"><strong>Stock Options, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options outstanding, vested and expected to vest, weighted average exercise price, beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice', window );">Forfeited, weighted average exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice', window );">Expired, weighted average exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice', window );">Granted, weighted average exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice', window );">Exercised, weighted average exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options outstanding, vested and expected to vest, weighted average exercise price, ending balance (in dollars per share)</a></td>
<td class="nump">$ 3.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 4.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions and Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.38%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions and Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.14%<span></span>
</td>
<td class="nump">1.68%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_RestrictedStockUnitsAbstract', window );"><strong>Restricted Stock Units [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of restricted stock units granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">542,244<span></span>
</td>
<td class="nump">341,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities', window );">Shares withheld for tax withholding obligation (in shares)</a></td>
<td class="nump">26,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities', window );">Amount of shares withheld for tax withholding obligation</a></td>
<td class="nump">$ 59,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Unvested RSU, Shares [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">326,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">542,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(87,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(94,361)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">686,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">686,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Unvested RSU, Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, Weighted average grant date fair value, beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested, Weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited, Weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, Weighted average grant date fair value, ending balance (in dollars per share)</a></td>
<td class="nump">$ 2.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_RestrictedStockUnitsAbstract', window );"><strong>Restricted Stock Units [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted stock units vested over a period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_RestrictedStockUnitsAbstract', window );"><strong>Restricted Stock Units [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted stock units vested over a period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Equity Incentive Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_StockOptionsWeightedAverageExercisePriceAbstract', window );"><strong>Stock Options, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Unvested RSU, Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense, non option</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_RestrictedStockUnitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_RestrictedStockUnitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The shares value withheld by the Company to cover employees' tax liabilities under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares withheld by the Company to cover employees' tax liabilities under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares under fully vested and expected to vest options that were exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares under fully vested and expected to vest options for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, for fully vested and expected to vest that were expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares under fully vested and expected to vest options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, for fully vested and expected to vest that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares under fully vested and expected to vest options that were granted during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_StockOptionSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_StockOptionSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_StockOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_StockOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_StockOptionsWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_StockOptionsWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adma_EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adma_EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=adma_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=adma_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045468874856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 11, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Public offering price (in dollars per share)</a></td>
<td class="nump">$ 3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=adma_ViceChairmanMember', window );">Dr. Grossman [Member] | Direct [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares sold during the period (in shares)</a></td>
<td class="nump">22,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=adma_ViceChairmanMember', window );">Dr. Grossman [Member] | Indirect [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares sold during the period (in shares)</a></td>
<td class="nump">22,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Lawrence P. Guiheen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares sold during the period (in shares)</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=adma_PresidentAndChiefExecutiveOfficerMember', window );">Mr. Grossman [Member] | Direct [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares sold during the period (in shares)</a></td>
<td class="nump">28,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=adma_PresidentAndChiefExecutiveOfficerMember', window );">Mr. Grossman [Member] | Indirect [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares sold during the period (in shares)</a></td>
<td class="nump">57,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember', window );">Brian Lenz [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares sold during the period (in shares)</a></td>
<td class="nump">7,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=adma_ChiefScientificOfficerAndChiefMedicalOfficerMember', window );">Dr. James Mond [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_EstimatedPaymentForSeparationAndTransitionAgreement', window );">Estimated payment for separation and transition agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement', window );">Period of scheduled installments for separation and transition agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares sold during the period (in shares)</a></td>
<td class="nump">4,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=adma_PerceptiveCreditHoldingsIILPMember', window );">Perceptive [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_MinimumPercentageOfCommonStockHeldByLender', window );">Minimum percentage of common stock held by lender</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares sold during the period (in shares)</a></td>
<td class="nump">4,563,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adma_ArethLLCMember', window );">Areth, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adma_GenesisBPSMember', window );">Genesis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Purchased materials amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_EstimatedPaymentForSeparationAndTransitionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of estimated lability of payment for separation and transition agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_EstimatedPaymentForSeparationAndTransitionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_MinimumPercentageOfCommonStockHeldByLender">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock held by lender and administrative agent of credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_MinimumPercentageOfCommonStockHeldByLender</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of scheduled installments for separation and transition agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=adma_ViceChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=adma_ViceChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=adma_DirectOwnershipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=adma_DirectOwnershipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=adma_IndirectOwnershipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=adma_IndirectOwnershipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=adma_PresidentAndChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=adma_PresidentAndChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=adma_ChiefScientificOfficerAndChiefMedicalOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=adma_ChiefScientificOfficerAndChiefMedicalOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=adma_PerceptiveCreditHoldingsIILPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=adma_PerceptiveCreditHoldingsIILPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adma_ArethLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adma_ArethLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adma_GenesisBPSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adma_GenesisBPSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045389646984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>Facility </div>
<div>Term </div>
<div>Center</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_VendorCommitmentsAbstract', window );"><strong>Vendor Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_PlasmaSupplyAgreementTerm', window );">Plasma supply agreement term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_PlasmaPurchased', window );">Plasma purchased from Grifols | $</a></td>
<td class="nump">$ 17.5<span></span>
</td>
<td class="nump">$ 3.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_PercentageOfInventoryPurchases', window );">Percentage of inventory purchases</a></td>
<td class="nump">67.00%<span></span>
</td>
<td class="nump">42.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adma_PlasmaPurchaseAgreementOneMember', window );">2011 Plasma Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_VendorCommitmentsAbstract', window );"><strong>Vendor Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_NumberOfRenewalTerms', window );">Number of renewal terms</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_PlasmaPurchaseAgreementRenewalPeriod', window );">Plasma purchase agreement renewal period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_PlasmaPurchaseAgreementTerm', window );">Plasma purchase agreement term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity', window );">Number of plasma collection centers transferred to BPC | Center</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_PercentageOfPlasmaPurchasePriceEqualToCost', window );">Percentage of plasma purchase price equal to cost</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adma_PlasmaPurchaseAgreementOneMember', window );">2011 Plasma Purchase Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_VendorCommitmentsAbstract', window );"><strong>Vendor Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_NumberOfPlasmaCollectionFacilities', window );">Number of plasma collection facilities | Facility</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adma_PlasmaPurchaseAgreementTwoMember', window );">2017 Plasma Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_VendorCommitmentsAbstract', window );"><strong>Vendor Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_NumberOfRenewalTerms', window );">Number of renewal terms</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_PlasmaPurchaseAgreementRenewalPeriod', window );">Plasma purchase agreement renewal period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_PlasmaPurchaseAgreementTerm', window );">Plasma purchase agreement term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of plasma collection centers that company may purchase RSV plasma.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfPlasmaCollectionFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of wholly-owned plasma collection facilities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfPlasmaCollectionFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfRenewalTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of renewal terms to extend purchase agreement, if agreed to by the parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfRenewalTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_PercentageOfInventoryPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of inventory purchases related to raw material plasma.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_PercentageOfInventoryPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_PercentageOfPlasmaPurchasePriceEqualToCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of plasma purchase price equal to cost purchased from collection centers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_PercentageOfPlasmaPurchasePriceEqualToCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_PlasmaPurchaseAgreementRenewalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Plasma purchase agreement renewal period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_PlasmaPurchaseAgreementRenewalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_PlasmaPurchaseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Plasma purchase agreement term, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_PlasmaPurchaseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_PlasmaPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of plasma purchased during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_PlasmaPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_PlasmaSupplyAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Plasma supply agreement term period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_PlasmaSupplyAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_VendorCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_VendorCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adma_PlasmaPurchaseAgreementOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adma_PlasmaPurchaseAgreementOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adma_PlasmaPurchaseAgreementTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adma_PlasmaPurchaseAgreementTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045385436792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTS (Details)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>Facility</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>Facility</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationProfitLossAbstract', window );"><strong>Segment Reporting Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_NumberOfFDALicensedPlasmaCollectionFacilities', window );">Number of FDA-licensed plasma collection facilities | Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment', window );">Number of plasma collection facilities under development | Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 17,830,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,787,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,879,208<span></span>
</td>
<td class="nump">$ 17,987,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_CostOfProductRevenueExcludingAmortizationExpense', window );">Cost of product revenue</a></td>
<td class="nump">18,832,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,495,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,602,746<span></span>
</td>
<td class="nump">30,324,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(15,581,232)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,123,825)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,745,481)<span></span>
</td>
<td class="num">(33,893,611)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Interest and other expense, net</a></td>
<td class="num">(3,324,071)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,054,266)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,539,763)<span></span>
</td>
<td class="num">(5,529,710)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(18,905,303)<span></span>
</td>
<td class="num">$ (18,379,941)<span></span>
</td>
<td class="num">(20,178,091)<span></span>
</td>
<td class="num">$ (19,245,230)<span></span>
</td>
<td class="num">(37,285,244)<span></span>
</td>
<td class="num">(39,423,321)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,046,735<span></span>
</td>
<td class="nump">6,243,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">1,325,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">885,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,555,622<span></span>
</td>
<td class="nump">1,674,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">232,813,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191,541,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232,813,792<span></span>
</td>
<td class="nump">191,541,568<span></span>
</td>
<td class="nump">$ 207,673,394<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationProfitLossAbstract', window );"><strong>Segment Reporting Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">15,424,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,797,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,102,848<span></span>
</td>
<td class="nump">15,453,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">International [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationProfitLossAbstract', window );"><strong>Segment Reporting Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">2,405,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">990,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,776,360<span></span>
</td>
<td class="nump">2,533,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember', window );">Corporate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationProfitLossAbstract', window );"><strong>Segment Reporting Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">35,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,417<span></span>
</td>
<td class="nump">71,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_CostOfProductRevenueExcludingAmortizationExpense', window );">Cost of product revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(4,449,608)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,351,681)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,137,328)<span></span>
</td>
<td class="num">(7,188,167)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Interest and other expense, net</a></td>
<td class="num">(3,244,912)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,818,791)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,438,706)<span></span>
</td>
<td class="num">(5,055,363)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(7,694,520)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,170,472)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,576,034)<span></span>
</td>
<td class="num">(12,243,530)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">1,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,397<span></span>
</td>
<td class="nump">4,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">42,420,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,893,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,420,872<span></span>
</td>
<td class="nump">74,893,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | ADMA BioManufacturing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationProfitLossAbstract', window );"><strong>Segment Reporting Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">16,347,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,502,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,768,923<span></span>
</td>
<td class="nump">14,246,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_CostOfProductRevenueExcludingAmortizationExpense', window );">Cost of product revenue</a></td>
<td class="nump">17,382,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,237,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,832,049<span></span>
</td>
<td class="nump">26,689,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(8,337,405)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,852,835)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,843,093)<span></span>
</td>
<td class="num">(25,328,980)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Interest and other expense, net</a></td>
<td class="num">(78,793)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(235,442)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,307)<span></span>
</td>
<td class="num">(474,314)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(8,416,198)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,088,277)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,943,400)<span></span>
</td>
<td class="num">(25,803,294)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,725,432<span></span>
</td>
<td class="nump">5,064,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">1,055,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">772,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,065,307<span></span>
</td>
<td class="nump">1,447,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">169,799,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,105,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,799,509<span></span>
</td>
<td class="nump">109,105,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Plasma Collection Centers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationProfitLossAbstract', window );"><strong>Segment Reporting Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,447,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,249,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,038,868<span></span>
</td>
<td class="nump">3,669,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_CostOfProductRevenueExcludingAmortizationExpense', window );">Cost of product revenue</a></td>
<td class="nump">1,450,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,258,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,770,697<span></span>
</td>
<td class="nump">3,635,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(2,794,219)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(919,309)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,765,060)<span></span>
</td>
<td class="num">(1,376,464)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Interest and other expense, net</a></td>
<td class="num">(366)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(750)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,794,585)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(919,342)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,765,810)<span></span>
</td>
<td class="num">(1,376,497)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,321,303<span></span>
</td>
<td class="nump">1,178,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">268,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">486,918<span></span>
</td>
<td class="nump">222,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 20,593,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,542,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,593,411<span></span>
</td>
<td class="nump">$ 7,542,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_CostOfProductRevenueExcludingAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of product sold and service rendered, excluding amortization expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_CostOfProductRevenueExcludingAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfFDALicensedPlasmaCollectionFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of plasma collection facilities having FDA license.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfFDALicensedPlasmaCollectionFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of plasma collection facilities under various stages of development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=adma_ADMABioManufacturingSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=adma_ADMABioManufacturingSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=adma_PlasmaCollectionCentersSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=adma_PlasmaCollectionCentersSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045389233640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASE OBLIGATIONS (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 11, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>Lease</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASE OBLIGATIONS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_OperatingLeaseIncrementalBorrowingRatePercent', window );">Incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Aggregate lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash payments for lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease', window );">Right to use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_NumberOfNewPropertyLeases', window );">Number of new property leases | Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Payments Under Lease Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 595,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 595,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Year ended December 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,512,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,512,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,526,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,526,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,399,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,399,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,405,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,405,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,137,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,137,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,486,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,486,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,063,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,063,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,604,431)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,604,431)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(385,858)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(385,858)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(365,682)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Balance at June 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,073,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,073,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,334,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract', window );"><strong>Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Initial term of lease</a></td>
<td class="text">90 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit and initial payment</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rental payment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract', window );"><strong>Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_OperatingLeasesRentExpense', window );">Rental expense</a></td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract', window );"><strong>Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_OperatingLeasesRentExpense', window );">Rental expense</a></td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease liability recognized in connection with property lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right to use assets recognized in connection with property lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfNewPropertyLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new property leases related to additional plasma collection facilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfNewPropertyLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_OperatingLeaseIncrementalBorrowingRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average incremental borrowing rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_OperatingLeaseIncrementalBorrowingRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_OperatingLeasesRentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_OperatingLeasesRentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045389270584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL CASH FLOW INFORMATION [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">$ 5,534,279<span></span>
</td>
<td class="nump">$ 4,192,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash Financing and Investing Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities', window );">Equipment acquired reflected in accounts payable and accrued liabilities</a></td>
<td class="nump">1,005,546<span></span>
</td>
<td class="nump">1,228,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-to-use assets in exchange for lease obligations</a></td>
<td class="nump">$ 2,844,875<span></span>
</td>
<td class="nump">$ 1,723,594<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equipment acquired in a noncash (or part noncash) acquisition and reflected in accounts payable and accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140045384771656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 26, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_SubsequentEventsSaleOfStockAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,102,075<span></span>
</td>
<td class="nump">$ 88,704,039<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | 2020 Sale Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_SubsequentEventsSaleOfStockAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares sold under sale agreement (in shares)</a></td>
<td class="nump">897,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_SubsequentEventsSaleOfStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_SubsequentEventsSaleOfStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adma_SaleAgreement2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adma_SaleAgreement2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>68
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M[:*3U;4"'W?PDG 4AK!2TB1?"-RG]2G#E;K]7IG^!UAS"^(/,$#7#WS<PM\
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M,66KON58SP-W9)%(/6 />CE:X!#+^WS*5<^N66*2XDP0E@&.YWUKZ%P$#M0
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M?3WOD=[;A6GTM"K*"_V+L^?P2<]T<?]\E\%9?Y=E&:UUDD=I@C+]>-X;D-.
M^F5 A?@6Z==\[QB55![2],_RY'IYWL/E$^E8+XHR10@_+WJHX[C,!,_Q5YVT
MMVNS#-P_?LO^I2(/9!["7 _3^'NT+%;G/=5#2_T8;N)BFKY>Z9J0*/,MTCBO
M_J/7+5;2'EIL\B)=U\'P!.LHV?Z&/VHA]@(@CSN U@'4#. M :P.8,>VP.L
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M/#X2..SZ=ETG:\0O:_W15$G-?;4#L;7*XMMQYB(L"/JS12=HQ"]H-]ES>Q4
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MKIOFBF<%KXT!?+^4D.9V#V:"_?\YSO\'4$L#!!0    ( +R("U-?K%?PZ X
M #4G   8    >&PO=V]R:W-H965T<R]S:&5E=#<N>&ULK5K;;ALY$GW75Q#>
M["(!VK)E)Y/,Y +(]B1QD(L1)UE@%_M =5,2U]W-'I)M1?OU>ZI(]L62,S/
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MO:GXY5I)E"+=@.M+ ]?$-W1 ]TNY5_\'4$L#!!0    ( +R("U.IT^%=.A8
M  E"   8    >&PO=V]R:W-H965T<R]S:&5E=#@N>&ULM5QM<QLWDOX^OP*E
MV[VRJT841?DU<5Q%R796>['CL^SDKJ[N S@#DHB' RXP(TKY]=<O>!MRZ-C9
MO0^[H<@!T-WH?OKI!L8O=L9^=FNE.G&W:5KWP\FZZ[;?G9VY:JTVTDW,5K7P
MR]+8C>S@3[LZ<UNK9$V#-LW9;#I]<K:1NCUY^8*^>V]?OC!]U^A6O;?"]9N-
MM/>7JC&['T[.3\(7'_1JW>$79R]?;.5*W:CNT_:]A;_.XBRUWJC6:=,*JY8_
MG,S/O[M\A,_3 []HM7/99X&:+(SYC']<US^<3%$@U:BJPQDD_.=67:FFP8E
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M;('?2MV0+$RP0K +QA$,83)+_06[A'9IJ&0\#\HA>%+\"/EQ!W1+Q ]6^2:
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MT.@J'_A$=8[838S<.Q=:2X.>YH8[_(F L@&XOY'2G"<V0?];&G\'4$L#!!0
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M9K[[/BPW_T$ _ER7B*.*K[#5F\WC(R;-M_+FC1([_4WX4B@EMOKEAF.,E+0
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M8EI?RM)H5].D\1=Y/K3>"04\V(O)U <@42V.IN82[FU#S7K5BIP10S845Z
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MV2@"T_::=N)T'>I[I1U%$H85M6<T_@#MK[5V^XEWT#7\Z4]02P,$%     @
MO(@+4T_28B 9%P  :$@  !D   !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL
MK5Q=<]NXDGWGKT!Y[]U*JFA%DB>V,Y.DRG:2N=Z=9+)Q,K-;6_L D9"$A")T
M"=*RY]=O?^"+$J4XR7V8B4P10*/1??IT ]#SC6F^V*52K;A;5;5]<;1LV_7/
M3Y[88JE6TH[,6M7PS=PT*]G"G\WBB5TW2I;4:%4]F8['IT]64M='+Y_3L_?-
MR^>F:RM=J_>-L-UJ)9O[2U69S8NCR9%_\$$OEBT^>/+R^5HNU(UJ/ZW?-_#7
MD]!+J5>JMMK4HE'S%T<7DY\O)Z?8@-[X0ZN-33X+G,K,F"_XQW7YXFB,$JE*
M%2UV(>&?6W6EJ@I[ CG^Z3H]"F-BP_2S[_T-31XF,Y-679GJ3UVVRQ='YT>B
M5'/95>T'L_F'<A-ZBOT5IK+T?['A=Y_^="2*SK9FY1J#!"M=\[_RSBDB:7 ^
MWM-@ZAI,26X>B*1\)5OY\GEC-J+!MZ$W_$!3I=8@G*YQ56[:!K[5T*Y]>?/I
M[=N+#_\C?G\C;JY_?7?]YOKJXMU'<7%U]?NG=Q^OW_TJWO_^V_75]>L;\>B]
MJ72AE7W\_$D+0V,'3PHWS"4/,]TSS*EX:^IV:<7KNE1EO_T3$#G(/?5R7TX/
M=O@?73T2)^-<3,?3R8'^3H(>3JB_DQ_7P_]>S&S;@#G]WX%Q?PKC_D3C_K1G
MW$MIM15F+L"GK*I;B;8ZI-_OZ$9\7"HP^\*LUK*^U_5"=+7L2MVJ4A0&%J*V
M_,G"PI82'\]U+>M"RTI8Z$.!^[56+.6M$C.E:NQ]+1MX3]?8#D%!M_=@LNTR
MPX&ZNL5AUHV&3M:5LF*A:M7(JKI'0=2ZY;8M"/:I)D%N<!P2_6*E&EU(\>C?
M_^U\.AW_\FET,Q*_7ER\I[\GOSP6,!ZT;N&U52*IKAF<8,8C<5'?(UBH1M6%
M<D-9)6J#@[1&R/4:C%C.*B46'4R:WK)BI63=XO?4%C^$T86T,'!7!\$OXD1!
M^+J436FS*U/J.71,>O<SN+BY"K+#BX,MQ:=U21J(C3Z%1J 5'/%-F.M@#Y<&
M_A&/\$W7QYN+FTO?R>A?909V:;JJ!$,0"/_.!#YW-<,KV@ *F\FZ[J!A,L)7
M^D7-N/59PKKA(I$]X'-<<9S7O9*-4(@=XI4JU&H&BW0R(>\?@R1%U971LJYX
MIJB R=DO%FR")/J@UJ9I!<B*>"XFX^/_!($J:.=EYT6_4477Z!: CD1X?5<L
M9;V@;E?:4CA*=7WS.BXR?/56-L4RFSYE9!I0?D\A,UF1"7($YGGO3G #7Y1@
M];>HPL:L2%:OX&&=?I,&24KPDCW6L.MR0^"0I>" ,V[8NX)R=0VPV9&UD"OZ
M5?@O]HVFU05XY3D*_D$MNHI]Z>;XOW-Z@8P#9J.$ = 1,"TOKBA4TP(!@;F:
MEBT)&QALD:(#6!E\0BQ*+0:7IE*M>H"E)C/,MF<8\ (PJ*I89V[5_2JS6! Z
M:BN=&B*TJDI#>'?Z3F0A5+MFPS9K7>,\0$,K60-I0K%RMH8?]V^G% $:<IHB
M>1MT!P#T12;+ST!(^.5'FZ4NEM2KMBTB/I Z#:I%LRN*!AS.YD+9%I[[!9$6
MN-_:K?]2MD*#Q$5+\@])])B[!\L'D6LP6FN!.*+IN"@GYE(W,.:0T\<.U\9J
M9H#D%, <5& .))>&^4"'P./H!6"\#>D=)L"N;S-8$O7/#F,=-BBD78HY$%H;
MW*M=-DK1EU;?B163'7:WWH C\:I#97Y3(WH%'34G:VW4$FDQ6$YEK"5T .%@
MIJ 9[+8&*,%O,KG"8&&]NE1$ WBP5D2(!<Q6F])Z\-S&JB'S28RFIZ^1^)T_
M0U.OT#1F^Z' AQ#QPYIJ<LF2PB=(Y**>[X%,927O,?*H.Q0[F<B\ VN=:UO(
M*D.(&QW@9$\#)WMZD$Q]LB1#,-XA.O9M/5 48/1@)((O!WVP02N#B2?^C:NZ
MDE_4UYQ)SN>*G2EK*-*!EKP!H%-:JURPK;2<Z2I&N!+4!_;2-20TK#0N((Z\
MKPV[+-J"7ZN]@9T7<E><1MVJNG,"X*J"E4&0B[[!C8A-DM4 K!8M&KDWBX+8
M"+ N(&R9BXK&)FJ"2*X7-;$RF$O4GL<Y'D56^B^B@[>RZI2#+Q83D$_I6_PR
MIV_#TND:A&]-<Y_WEJ&S#-[KQGQ&YP+9YUV+:JTT+&L9X6.M6YH)+38I:[@G
M4BU@7"+<ANCF H((:A1HJ6H&\<_!%4P6NB<_AQC$ZH8NL#EH H8,\:96?2)'
MWU)\@V$YJJ[E/:G*+VQ4"L0,LZ&7O6-NRU,BL48@;^6=,ZQ#OGH:?/7TH*>]
MZ6DG30J0;)!JA]SWASLECRY D823B6%[+N(<8W]82CK+G4T2Y&)L"4$&5Q$$
MH9>R <-D*/#/W?KD!+! US<U^FIA($!SN(;LIS%WS@\2PRKA/Q<\H%G3'@->
MKP2P$8<)G$0E$C.O+=4,B%C76DQ%F'CL,T>(/QHLPR*90"/ _BLC@4I;"('O
MP+S$V>-]\F6)?+<0+FCF%%3 JT5#.(3.HBV)=,BNSH)=G1TT@8M=70_9T3=W
M(H:>:9M@9+L#2CE%='1^[V4<5A&IL0Z!J%B 5K7#W-)TLQ8"8S08']O)3+&G
MOXU'4['2547."VW@P20^: ?XQT[6D"<LH@(H=";6(*H6!I#WKPABC.$.<BLB
M$2X"\.212ZN2K<J93J;N6N!"UDT-UQ\GR#4QU5@JQ@$"KFD&0O406DDDI^[5
M >=#8N-((;H:CP#V@Z ^$J]#7W8WP/6; I(9>$Q<FWMIM/U"0! $196  C /
M@==87%,O#'K,# LWAPSV/!CL^4%;NW8Q20_SE0<W%A_D1J #@IM5-H8Z3_5)
M(^B$IK/)>^L.TEY:$ K%ML,Z"TP^SR*TN:3"&GB7XI%=R;P7Z\#[2\X0]^&G
M>P, Z$_3?#G6]3$\01;)R2[D1Y!*EV)AF-+&:46<.7F,59[*D26&1V0DO7D#
MI]XHH);2T@OL<"5$:VA%.4/M_JCDS#1YD@!92/9PQ#S; (-CN6:J5G/M>DE*
M4 I23W.O%(7_,*#D>%H$:S:WJEEBS85%\1[D$/$2WA1O9('T[#Z))%WK"!M*
MAR0=OH7@BW^[JARB#H LRX@E?' XA)><%KM;D8QN*1VT*&"Q:.^4EE)M(Y4T
MZ\L2Y$;?#8:DTZI@XL0X%\_2(,> C*91E-*#&KTY]/OG)-)^IPFQ'I$:.46V
M!EG9\,!S-R;FXL&HTKC-YDQ1B1(X7&G 1^EB]-#7%,%J2%PZZTN5.\)"'M#-
M$>.1&%/Z!Y"". 0!@B=)PRBL.KD5 C0V:\H<:,O#F0#."?F*YAB#8T$P 3@G
MRF^IH()A9H<1EPJ#-0 &F/&]P\+&MN!ZN?L$#$"L%+!O /!W0UWT5CSVEVTM
MOL_V>6*)-ES:9[E BV%30;11M2LK)88%.6J9BPKQ@'T%6I2J@@;-ULMNS=&:
MUQJ>L37'+&&^3Q\I_R>M\BQ,W8O'.$>+.J79<631F*3B5& 1D"I3Z/%TD8I5
M20X0BEY!"3.8!RRN2_=LAPN>Y P<>*4U-0H;[93TPO$7!:BP/GZKU88!!/(N
MY'CL21A>/:5UBV]@/$S5U5VA%)=*AK3"TJ8%(L\#,*YG,-"FT2WV!YR41$]R
M*,HX)*BO04)AF$I"-&D6Y)H>H)W?>N*01Q/8$AJT'A7.S5E\2_)'C!F:"17;
M9,DA/G=6E$3YD![U@<;MAG"^U&2J7H"%*\IF*^.+&!M*65&=6*[1\WM$>PT>
M76+?N$=R*W5%LC"_\\XN&$?0A4DMY0&]^'JZ3S,=#4LA^!#?>!;XQK.#E.%7
MB+ ;X(M#9.-A+47XT"A7H;(<!.XHH./4'*O \(J*]6[<SXEK%4L5!:74 :J<
M[XRR,-;#N"T5U?YV,GKJ.3%7=?=$E(7O7&-QI&WTK&MI%1UGO7CU]B*[U.9M
M"N9BUEG0C,7<:,%PC;QB)[Q/QY,S 8U;S'4^QN+Q*.I/LX\"O6]:6FX8GV0!
MI5CKH\T*8ST-Q!34;=3,>.NP$2NLK<^Q* 'O8$5NGK3)7'W. %M0=^!=/:XN
M8)%<A9JQVWC""WY-MMYRI&6)6(AYU!NAM L+Z-9<N:<YD%25_J*HSBMKFBEY
MTZXA<"'7UXVZFGN@:$!->P#'R5 :PH,XL!"9WSV U':A*=/FFH6X[MD .CZ5
MDZP72F-=Q<&2552=QY'%JL,Z>=!*M)FX+K3$LWLJ\LI0">O/L5\;HSGZS*B'
M@K@5FO;M\#3)MKR!49Z5%@Y]Q\&^M_ U!=,H7,XK8WRHB(PJIIU1P\P:O1"4
M]*9#]ZW+:8U'=&:[5W]<Y?^]: TZ]"1D@U0=3KL-T^,>LX?VZ!"BU RS7(^D
M3:]!H5CQN^$\ML?ER/#13JL>&(3.OW7/(6P?',+]R3B>&!D?3A83()E#=*L7
MQQ5M3;*'#!X.^:$>>[;@,,UZ]H8Q@4O3]QX"=CKPM0E?^0WI$!6?(6*L/?YF
MF$&VRK7>\7[F' K#D$UKR[>\%]+X_2(JJ>JFZ%98&BOH <&G2M<8]S1H ] 4
MN,6&]8_KN4B UJ0(S+";^^HRHCH7E[L:"_CH8JJW-35$6F@:3"0(8\BRL@%<
M'(;DT,4^:'#P0FM2*7\< QT$WTDFD^(0IKSPEV=3>IC4>>AC?^")X+9<( L)
M3A(932BDV=Z6&N'N<_:=>W ]+X[9D0]*H%QD#[7IA=QMT\R^7@.?)(>X)@<=
MZ(.C?J[PMN\,T;?W(C[X?9KO!IU@;8VF/&DN'NG'<?_'GV?(B.+N(5C D;O:
M+"HSZRK>8*$,/A>7UW]<_WKQ-A<7-U>OWUW_0:.^ SPX_L=E#@/!2%OT.(XH
M_(C+#GB[S] +4U7L7C!3TRV6@P*]YY>O^&54U!5NL&)5<HO5D13Z<4@.^QD]
M80Z5D"2E:E8UM[H@W'=)SB-].Z"M(#O5$%P" =3AV*OF%]+$(VA;07]X2"(>
MB0B]Q:+5-FLE+M>UQ]P8!<4#6D['\+WGH[ 8P$^GO$?9?%%,8BT6LH@)>>7#
M>Z\[1%V:,!_*I%UE@!HJS\$+[R#^+\7%G Z!^6CY5I<EB/1:(N/THR+;A)YO
M=:GZ,95PSJ?409>N,NB/ \A[?]YA\)B*1Q@_6-#? @P_Y>EF5NF%#\[0:Y\6
M.B'<SE#F-_,8LG7<)X+\ D8QM>*4&9@*)OD0"E[Y#;.D4!X9ODOHP*^2M(AV
M57REK"]^'I,L,CM?D<==A;CI I8PG1)3 H1\OY57.LAVA?V8?+LZMZ#=%[5B
M?5!<(YLW5130F<,(U,3?:)NE]25?20F=!_O!XV=ZO<:O&U_1P3" 9J);L)"U
M9%9@>D*-/(#U H[F_,<%.F:?5!"VWUZ'XA!$83\.MN.F QB2[0&U?7J.. 8V
MXOC/S@Y'B<6-6G+M(N23;MIN%RG6/QHUPUI7[M)K&*'UAZ5QAWB1[./'5?8;
MROWJ)TQXW9(7>#)"9,E45 )M7"R>R>*+S2(2)2_,E;+^'%IRTB&MKR5%G7]I
M%:T_7%I#>V,2M-SF4_L1/5WZ+$5HFP>?H&-@<XP86R8;.G!9#Y>4&&N('H$K
MP"<[UX->V,HOB.R&:')2!??F$TQSJU3?\#<2<;LICX$;XL%>4,C28'DZE-IQ
M4^&OW0++-EH\/,RZ3'ZG2M][#R=2N @+,F6)@[CVL(0)X/3GC/&"#MEYI3<Q
M^_6*\SE"+%03*[>]_J%?A*$5U8MW9KRU];G5T($6U552@VP4FJ[=)SL?B<GB
ML&\<$3M,O[ V?ZN23<@ _X2:$,T@G"W<"9[SIW_?!U*]<U]^I@\4@J@RLL4'
M2C'9)X48EN(0=9Y&ZCP]2'JOAJNH@_3YNWH2^YYK7SC:7V..R+*7&K]Y=<$1
M''.*2(Q[J+.-2<X5MS9BDQW(<" K*3^D%6X(&^ JL0).62GE8;WM)Z2"!6ZN
M8*+,0JAB61."QU.# <3PT%Q\2FQHBY8RQP1YPC9P]J='P+C9%4^L?*6[6FV2
ML%NGPN>N-.;T0#D,Z,EJ@EUI]V^Z^38'S3->2YF<'#2JW_"$YUKQ9@" H(4X
M.FR<!_O!RUT_V[4LU(LC\L#F5AT-=R[P+DG!1TMWOM.64KFNY0A0@L9Y:]\=
M.=U1,;?.P/^++Q#L2TJ1.'1LZ,84:A/+!9"HUQW5X ED9</KZ$?']KVC1LE1
M07] \)6N2+#]HLNJZ-B@OT%XD0I/;L+[7,DI5,5G+Q'E409 WLR&6P0Y(CZX
M;/[]$^=3FMSS-ZGDO<':KN:-U\$.="Q?JWW#TTE U$G<I[_#C2DZY9JE(CBA
M_)9D<M@0#WJ$<\_(L3I,=^EUOW?\ &$1FMS1_< ORH/+SN8J_;9$K^!->YYN
M5VZ&3++5QW[@D;C@LA36B["VG:V'Q+/)99$F8'HXC9".3A<R[CV.]\Y9[TR!
M9??'"K_A:/:^VR!]QN'/FD73IX,I /[NB'86PO1#"<=6?6QN\*P:F434T 9K
M8WX!L[" WBV=D@ZOYTP5LK,^'.JFOVK.$^W/F9?Z!J1.[QX&J3.4&O\WSFY2
MJ\W.\K/SDWP\?9:=YN?C27YV]BS[ #D"9!Y\^!U?QDT*FYV>G^:3DY/L9'J:
MC\?C[$]G[-E/^=/I>3XY'6=3>($_3:;YLV=G^<ETFCW+IZ=/\V<GS\2A(!'O
M$$X.W_XC^8\Y3T(3 ;O8>X_P.[OJU>!Y<7MI:G+[+]RK8T(=CK2C>?&I9->_
MK\3T]N!8?PB%Z:+DZ+NSH9.%P<S[5Q'XX%8BOPO+,9MDZXE%XYUS[23*B":]
MTTO"B_A$-FU\^=-<#J_Q?!B6\8G.N6J4F_HMY>F+>)C09OVT'W-P@==,,50<
MXRKYC=K;6(?W?-'W%FLZ] (*UILO3XDGN+NK2.^/1,\9Q'<?-(]Y%)6")-ZA
M;([I%MJ6N%RL][6KR3CS]2?(OCIW+?/BYI-X9T98;#P]'C_+Q?6**"_C&[SP
MVNE>W"!*'%_2K-^S@:6W)A]]-&M@-V>3\\>'7"]>%9D<ONEQS26XCWBN;M#=
M'MZ\YV+!% 9/SN]<R0A$)-R/X4(C-L'X0)OZ!8=VWJW**/S%^V>[D>MK407/
M%*#R80C(8;L&[_]\<F9"5VHQJN</$G\K<PY[#>!1IL$[7WS-@Z<P4^U&.=*/
M?:*%?^V*"SE[EMQZBC.*&\\^W()>5"UY#P GYVZ->):7WJBDYXQS^P663;(P
M5#H$'[9JM+/@B"-R\%:%X<,+0[K$8QI[3TIDX:1$+)'3];[6.6B+!SSG<TUI
M&G;KSM:368*LKMZS;_3^'+ TU<T^T\G:4)W&E]6=7+FR)-'_E?R,2I1WI/8.
M#*6)=HQQ ANQ?BT""_E]N,ZZQ@-L>/PXW"?#DP$.DVWF6-XV3E'U,^P#$KF@
M+4;HD1"<#W[MN]79W_73X:96.;Q1*FD&X>9A/W?'JO?PL1:*<19R"TGU<*+;
MB>Y\ I&<(-[2X7T:2\'<#=*BR#W#[NEZK?"4,R@3G<15%ET.CQE++VK$I!UO
MZ+?A3+R?'AL!N2*?<QX(UC!CXOR</&/KB@XXM,GID-#:U1H7D":T!">@GZ?C
MOWM]T:L\07>\C12%F\PK,FC5MI7B:MDKE>YFHAIZ@GI3JNY3:?EJ63S8T>[X
M*>^A8$\>:=QIY(UK6G:%RN+!M)&X]!KE,RRRNH=HWK>J)5WS[N\G:ZY>HG7
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M^C;R-3*;<S_?LTQ;EN@3ECZY$UR7BESS HKW>!\SZM**#FE-HY.$MQM^3N+
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M9BDT[J 52WST0!H'/%\)H0^*"= ]HY._4$L#!!0    ( +R("U->(E25; ,
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M25_Y9'&!F8=JD@0KQ2,^,ZSI.*SIV6']_X"2S[WI%2IUK:#&WKPX1'+UB,^
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M4HD6I!%*$@WUS%^$5\O$V0\&OPO8FS.9N$PV2GUWRH=JYC-'"!HHK4/@^'N
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M$AK;WRX+G+<@C0.>KX70>\,$Z"?X]"]02P,$%     @ O(@+4XY.F,$$ P
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M$#M!*#"S#H'1ZQ'G*(0#(AF_3IA!2^D"7]K/Z$N?.^6R8P;G2GSCN2TFP3"
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MK5BYLA0891944-?WO+9;(,*<J&MC$Q%U^5I1PO!$@%P7!1*_^YCR3<]I.=O
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MQ[<PN;]+DW0XO8"T*!$1^I HX$NXXVQU2?5;SB"6$BL)9P.L$*'R'"YA-AW
MV8?SKJMTD4;*7=0%]:N"_ ,%!3#B3.42ABS#V1[\X#B^?03OZN$T$_*W$^K[
M1PF_K-D5!-X%^)[?VE-/<CK<V]?._ZD/_UG]KV$$S7$)+%]P@.^](_ CGDLE
M]-?_\XA8V(B%5BP\28R^BB$KMN]L581M2V@L\CG273_OOJUW,P;O9@R/952=
MNCM?9('%REJAA 5?,U5-NXDV;AM;DWD3[[<Z26M/?*#=N3+35_K*VD=(K B3
M0/%22WE7'[5AB,HNJXWBI?6#.5?:7>PRUW\8+$R"?K[D7&TW1J#Y9T5_ %!+
M P04    " "\B M3[(]0X H#  "?"0  &0   'AL+W=O<FMS:&5E=',O<VAE
M970S-BYX;6R]5FUOVC 0_BM6I$F;U)$77DHK0 IIV9@*1=!NFJI],,E!K"8V
MLQUHI_WXV4X(M(.T']9]B5_B>^ZYNT=G=S:,WXL80**'-*&B:\52KLYM6X0Q
MI%C4V JH^K-@/,52+?G2%BL..#)&:6)[CM.R4TRHU>N8O0GO=5@F$T)API'(
MTA3SQSXD;-.U7&N[,27+6.H-N]=9X27,0-ZN)ERM[!(E(BE001A%'!9=RW?/
M [>N#<R)KP0V8F^.="ASQN[U8AAU+4<S@@1"J2&P&M800))H),7C9P%JE3ZU
MX?Y\BSXPP:M@YEA P))O)))QUVI;*((%SA(Y99O/4 34U'@A2X3YHDUQUK%0
MF G)TL)8,4@)S4?\4"1BST#A'#;P"@/ON4'CB$&],#"9LW-F)JP++'&OP]D&
M<7U:H>F)R8VQ5M$0JLLXDUS])<I.]F:WHY$__8ZN!V@V_#0>#H:!/[Y!?A!<
MWXYOAN-/:')]-0R&E[,3-(4UT S4&+(E):8,[R] 8I*(#^@C"@Q=X!U;*F8:
MWPX+%OV<A7>$10N-&)6Q0)<T@NBIO:TB*L/RMF'UO4K +QFMH;IS@CS'<P_P
M"5YO[E30J9=9KAN\QA&\@9)JF1Z![D:0SH'_0+^W.7VRMSV( D9#H))CD^HI
M$??EL0I2C9)4PY"J'R%UJ)QW_EPH?Z&L<M L'30KHQYGFBIBBT+(*O1#TLA!
MF@9$=YUUK]FQUP?\MDJ_K4J_$^ Z;:H+&=^,"I:0"$N(5./)TWV(1S5HNUES
MG'<563DMV9U6 MW$'/Z?&-HEJ_;;B.&L='#V#\00G/TEAOIA,;C.KL,Y;R"'
MX 74MON"'MR]%NQ60O4)DR DNB**IP#D+Y5"U%4I7U-@U]NY\=ZFQ.ZNS;G5
M?<Y/&9?D5R[1%7#"HH.7036*YZ%'P,_UD5.R]ZXZI:&E>0$(5=6,ROQZ*'?+
M5X9O[M9G^WW]^C!7Z XF?[J,,%\2*E ""P7IU$Z5&GG^&L@7DJW,A3IG4@G9
M3&/U@@*N#ZC_"Z;J62RT@_)-UOL#4$L#!!0    ( +R("U-ZV.&W"0,  ,0)
M   9    >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;+56VV[B,!#]%2M/K=1M
M$@<2J ")II=E52Z"LM6JV@>3#& UB5G;E/;OUW;2<$=]X878SIPS9\X0VXT5
MXV]B#B#11YIDHFG-I5S<V+:(YI 2<<T6D*DW4\93(M64SVRQX$!B TH3&SN.
M;Z>$9E:K8=8&O-5@2YG0# 8<B66:$OYY"PE;-2W7^EH8TME<Z@6[U5B0&8Q
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MI 68^:40^KUC*T?WH\C^ U!+ P04    " "\B M3AP\@#5@$    $P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6R]6-ENXS84_17"Z,,,,(E(:@\<
M ][423%)@SC3/@SZ0%NT+40279*.I_WZ4DNT65+4S" OMB2?<^\])"^/S/&)
M\2>QIU2"[U$8B^O17LK#E::)S9Y&1%RR XW5+UO&(R+5+=]IXL I\5-2%&H8
M0DN+2!"/)N/TV3V?C-E1AD%,[SD0QR@B_)\9#=GI>H1&+P\>@MU>)@^TR?A
M=G1%Y=?#/5=W6A'%#R(:BX#%@-/M]6B*KCR,$T**^".@)U&Y!HF4-6-/R<V-
M?SV"244TI!N9A"#JZYG.:1@FD50=?^=!1T7.A%B]?HGNI>*5F#41=,["/P-?
M[J]'S@CX=$N.H7Q@I\\T%V0F\38L%.DG.&58RQJ!S5%(%N5D54$4Q-DW^9X/
M1(6@XK03<$[ 38+10=!S@CXT@Y$3C*$9S)Q@#B58.<%*QSX;K'2D%T22R9BS
M$^ )6D5++M+I2MEJ@(,X65DKR=6O@>+)R<W=X_3NUYO9ER68KE;+QQ7XL*"2
M!*'X""[ U]4"?/CEXUB3*E5"T#9YV%D6%G>$U<$MB^5>@&7L4[^%O^CG6SU\
M34DL=.(7G3/<&_"W8WP)=/@)8(A12SWSX738)N?'LB]_++O73U_0C:*C-GIM
M+/5BS>AI/+TCGA?$@:077]26X(.;6))X%ZQ#"J9"4"D^@3NU(7Z;KH7D:M_X
MJR>A420TTH1&1\(Y$[)M#68L*V4E6^CSQ(*. ;$QUIZKDS,0Y[V.JY5O%N6;
MO>5/-YMC= R)5,-%(L9E\"])MM4V25DDLU*"[KJV:;L-20-Q7@O.4DBHMTNR
M"DE6KR0UQ6W56V?9,'0LPS ;U0_$>2TXPS!0TD-MU=M%]7;_A%0F ; M",HU
M3-(UW*;-/JL%V8ZC._62Y_;9&FJ#+<ZCZ:9MV58=MCR/UH#5]#N%?J=7_R,G
MOGI!X4^ Q#[X7>XIK_9Q^GHAP /-EJQDX(ZL@XO/,_#MED9KROMZVBUJ<-]G
M$T&PM#KXIFTDIU4GPT 00J,Q&XNA0&\ L*ZA8M?HI^TE>:A:^^@NLER]J6L@
MT&L#0E<M[X[M!.%2%W[+AI*SZET''=T\DS 0Z+4 U5NXVE*Z))2NB/1>"6G;
M)-VB5C/E$?4#-4MB2,^@T@B1\4Y=4YH7ZG>OSJXYMQ87VD9E;\YG9AC.>QU7
M%U!:%>KWJO_5,N>.8V)7QTW['8CS6G"&99B=BZUT,-1O85W]TN(KM@-=W*Q_
M&,YKP1D&=J'347_I0*C?@N;I7QOE.W/UGI\LUD%]4IH+>B=WP:6[X+>Y"S[W
M @1MRS3MQIP,!7H#@'4-I;O@G^<N^-P+.G0-!'H#@'5=I;O@-[E+SJJ^7L%F
M\:]"O%Y(5K!6^8.N%OTN/4H18,..L<S^=Q5/B^.::7I(T7@^0U=SU/)\@:Z6
MV6%,&3X[&[HE?!?$ H1TJU+!2UL-+\^.6[(;R0[I\<":2=61Z>6>JO=#G@#4
M[UO&Y,M-DJ X])K\!U!+ P04    " "\B M3:JM2.S4"  !!!0  &0   'AL
M+W=O<FMS:&5E=',O<VAE970T,BYX;6R5E%%OFS 0Q[^*A?;0254@$$A7$:2D
M2;=.6Q6%=GN8]N"$ ZP:S&P3LGWZV8:@J".-]H)]]MW_=V=\#AO&7T0.(-&A
MH*686;F4U:UMBUT.!18C5D&I=E+&"RR5R3-;5!QP8H(*:KN.$]@%)J45A69M
MS:.0U9*2$M8<B;HH,/^] ,J:F36VC@L;DN52+]A16.$,8I#/U9HKR^Y5$E)
M*0@K$8=T9LW'MXM ^QN';P0:<3)'NI(M8R_:>$AFEJ,3 @H[J16P&O9P!Y1J
M(97&KT[3ZI$Z\'1^5+\WM:M:MEC ':/?22+SF75CH0127%.Y8<TGZ.KQM=Z.
M46&^J&E]@ZF%=K60K.B"508%*=L1'[IS. EPQV<"W"[ -7FW()/E$DL<A9PU
MB&MOI:8GIE03K9(CI?XIL>1JEZ@X&3T\/LT?/SXLOJS0/(Y73_$UNJ]ES0'-
MLXQ#AJ6:%8Q+\@>;8UP=U'T0@*Z6(#&AXGUH2Y6'5K-W'7/1,MTSS,]U.4*>
M<XU<QQT_QTMT]>Z5BJVJZ$MQ^U)<(^N=D5T)2=1O@N12ZC_F6R&YN@\_WZ!Z
M/=4SU,D9Z@;TU2=EAEAJ"AHZCU8B,!*Z3?:1YT^#:1#:^P'TI$=/WD0KFCM$
M:Z/\$]IT['N^.TSS>YI_B>8-T?S_H@4]+;A$FPS1@G].TOUPXP3^*YI]TA'Z
M<?F*>49*@2BD*M 9356^O&W8UI"L,DVR95*UG)GFZHT#KAW4?LJ8/!JZ[_I7
M,_H+4$L#!!0    ( +R("U,4*RUB0 4  ,(9   9    >&PO=V]R:W-H965T
M<R]S:&5E=#0S+GAM;+5976_;-A3]*X2QAQ9(8Y'49^ 82&P+:Y&T7M)N&(H]
M,#9M"Y5$EZ3BY-^/DA71'S2CI5,?&DD^]UZ>>Z1#BAIL&/\A5I1*\)2EN;CL
MK:1<7_3[8K:B&1'G;$US]<N"\8Q(=<J7?;'FE,RKH"SM(\?Q^QE)\MYP4%V;
M\N& %3)-<CKE0!191OCS-4W9YK('>R\7[I+E2I87^L/!FBSI/97?UE.NSOI-
MEGF2T5PD+ ><+BY[5_ BQD$94"'^3.A&[!R#DLH#8S_*DX_SRYY3CHBF=";+
M%$3]>:0CFJ9E)C6.GW727E.S#-P]?LD>5^05F0<BZ(BE?R5SN;KLA3TPIPM2
MI/*.;7ZG-2&OS#=CJ:C^!YLMUE7@62$DR^I@-8(LR;=_R5/=B)T E<<<@.H
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MX-<6&!N T(NP$SEF>D%#+[#2&^](!>B3FO0%-3$*CNI#Z)3_]L<Y"HYNLL
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MX\P/T^"(KVF6!&&6X':^N.:+S^+3!ZUHN6SCBYL%C)/@L#(58-,N2;(X/E'
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MX0D_;M,V1U2U*6SN4X/9#+)OEU+]CB\!LR>,#X,JR+P=N,NFZE'8W*0,,CG
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M0/--DLJP;*PL"/VH^-][*@>BTD#U8VZ RP:XV8!V-"!E ])H@+LTT+(!'=J
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MWD+$F8#Z?2EENOV2*=B]2'GZ?U!+ P04    " "\B M3"?R>UX,$  #_%
M&0   'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6R]F&MOVS84AO\*86Q "G26
M2/F6PC;@V&F7(ND,)]TP%/U 2\<6$4E422I.AOWXD9(B*HBEN>OL?(A%B>?"
M1X>O2(YW7-S+$$"AQSA*Y*03*I6^<QSIAQ!3V>4I)/K)AHN8*MT46T>F FB0
M&\610UQWX,24)9WI.+^W%-,QSU3$$E@*)+,XIN+I B*^FW1PY_G&BFU#96XX
MTW%*MW +ZG.Z%+KE5%X"%D,B&4^0@,VD,\/O%M[ &.0]?F>PD[5K9(:RYOS>
M-*Z"2<<U&4$$OC(NJ/YY@#E$D?&D\_A6.NU4,8UA_?K9^_M\\'HP:RIASJ,_
M6*#"26?400%L:!:I%=_]"N6 ^L:?SR.9_T>[HN_0ZR _DXK'I;'.(&9)\4L?
M2Q U ]QK,""E 3G4P"L-O$,->J5!+R=3#"7GL*"*3L>"[Y PO;4W<Y'#S*WU
M\%EBWONM$OHITW9JNKJ\GMU=+M!RMKK[$]VM9I]N9_.[J]\^W:*S!2C*(OD&
M_8(^WR[0V4]OQH[2,8VEXY?^+PK_I,'_>UAW$<9O$7&)N\=\WF[^,4NZR',;
MS1>'F^.7YHX&5=$B%2V2^_.::$%$%01H285Z0G>")I+F]2O1E]E:*J%;7UOB
M>%4<+X_3:XBSS-81\Q'?;$"P9(M2P7Q 9RQ! 8\B*B1*04_>D K8^TX*[Z/<
MNYGY#U.OVQ\[#WM2ZE4I]5I36H@N^B"XE#%-T)<;B-<@OJ*_T8()/86K.RV#
M[U>1^D>%/*CB#%I'-.=QK)5'3S'_OF ID>11@((LAZY",)@9#W+R18^]N(LX
M_1IN0D;]X7[@PRJ]X7\"?I4$!R,?5;%&1T5^7L4Y/Q'R\^]!CEVKAFYK@M=T
M)R#1<VVIX6=,RVIR"&=<DUM\5-+82A4F)V)=!GH!V]5_#;"MR.%VE;OY84G!
M5KUP[[C<K7KA_JFX]U]SUS6.&[A;W</MPM?$_7N4!5L9P\/CDK<BAD>G(C]Z
M15YS[WD-Y*W\X7;]NQ!,([^&Y*]#&!,K6\0]*F-B]8O@$S$N ]49:\1D/V)2
M6Z&URY[Y;'ZDL4[KAB?!09BM8!'ON)BM7)'VU=:E5"S.8Z7T26^S%-);/"0A
MI8(6^R4]-F428$5S*P!,OWUKY#+6H$9ZY#8+.+%21]JE;EF\:+Y!9C\:9)'.
MER52T2@RN<@?2KH]-':1KD,5RC;<5A')J9:"Y/5:L*=%NX&T%5'2OAC4I'U(
MS1;YH(JVDDF.N_ C5OI(N_3=L(3%66PP^OJ5TRV8NO'KX$/0Q-=/*((D +&W
M*-IC8+?KNC^W[;^LHGKM"\'_KR+*0"\JHC_PADW3S[-:[+5K\4R "M^BZ^OY
M(47A60GUCKS+K6USVU> *Z-L\)A"(F'?X4!I7E>NP0OA*LKB7[N]3,^JL->N
MPA\@ <GD072M:'K'W=YZ5M6\=E5;9L(/J=2QS*=$+STBB6C,L_V"6SJK0\3[
MOA).[;#)' W>4+'5HJ]G[48;NMVA'KXH3MN*AN)I?OZTYDKQ.+\,@>H9;CKH
MYQO.U7/#'&E59Y[3?P!02P,$%     @ O(@+4TF"1H76 P  C X  !D   !X
M;"]W;W)K<VAE971S+W-H965T-3$N>&ULM5=1C]HX$/XK5K0GM=*)Q&&!W0J0
M(+OM[4E05+;M0W4/)IF U3A.;6=9I/OQ9SLA87=#H+WN"\2.YYMO/.//F>&6
MB^]R Z#0(TM2.7(V2F7O7%>&&V!$=G@&J7X3<\&(TD.Q=F4F@$36B"6N[WE]
MEQ&:.N.AG5N(\9#G*J$I+ 22.6-$[*:0\.W(P<Y^XA-=;Y29<,?#C*QA">IS
MMA!ZY%8H$6602LI3)" >.1/\+O"M@5WQA<)6'CPC$\J*\^]F<!>-',\P@@1"
M92"(_GN  )+$(&D>/TI0I_)I# ^?]^CO;? ZF!61$/#D*XW49N1<.2B"F.2)
M^L2W?T$94,_@A3R1]A=MB[7]2P>%N52<E<:: :-I\4\>RXTX,.A>'S'P2P/_
MF8'>F6:#;FG0M8$6S&Q8-T21\5#P+1)FM48S#W9OK+6.AJ8FC4LE]%NJ[=0X
M^#B;W=W/;N?W2S29WZ#@X_S^;O[A=A[<W2[1FQM0A";R+;I -$4SFB1Z[^70
M5=JU 7##TLVT<.,?<=-',YZJC42W:0314WM74ZYX^WO>4[\5\.\\[:"N]R?R
M/1]_7MZ@-Q=OWY.0)E3M[D&P %(%HH%H<#ZN5^*VT.U6V]RUL-TCL%\@C;A
M 6>,*GT*E$3?)BNIA"[C?UKP+RO\2XM_>01_D1#)B#Z,69;L$%D+ .,%Z3U@
M3=EJ1\,>V@$1LH58KR+6.X=8EHMPHT];A&+!&?H@:*P+%_V++IK8%9#7%M+H
MT,,8#SJ]H?MPF,>7B[J=0;7F"=E^1;;?3A9$J'=-RQ?BL2[X!SW@8E>Q;RS\
M=LC^H.-Y?S358;O=I?_2[DE,@RJF02N0[V&,RBPLRCC0I"J0;S-@*Q!M-7A5
M>;IZE1J_KO"O6R.9YX:IR8R %+8DL=7=F),"J'=0&WYS96"OUDGO9PKYX(SM
MV60@*(\:M;$=NG?RM.$#.<>_2/.8%)P /$,+L%^S\\],85;PU-?7_D(/K6)+
MI.LEE3$(H<5"<31=!%HFCLKYM/1X3JYKL<;=G]"![-F69H*&@.!';BJ0ZQ"D
M:B36[J-WXGSC6OIQNUJ?><+U+L[((V4Y.^?0XUK@<>]5CCVN51FW:V%;U<3%
MG4_!7";[#X#&=/1?U$GO2)W4THI/:NO@_VDKKL45OXZZXEI>\6_35WRVP/JU
MP/JO)[ GH/V3$N;7 NO_;H$] =BB_N[!=ST#L;;MCM3EGZ>J^%2N9JN6:F(;
MB6?S4]UJ%8U1#5/T:3,BUC25*(%80WJ=@<ZI*%J?8J!X9KN'%5>Z%[&/&]TN
M@C +]/N8<[4?& =5 SK^#U!+ P04    " "\B M36K >^_D(  ")+0  &0
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MK%?;\L!=$FYPM5W'71BT% *O0R$0P@42" \>)T\)(><UHW;P,K04 F]$(4!
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M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " "\B M3%0-XZ9@$  !H)
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M;W!S+V%P<"YX;6Q02P$"% ,4    " "\B M3>..<VNX    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " "\B M3
MF5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( +R("U.0?IM#E 4  +08   8              "
M@0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " "\B M3
M#B4ZUH(&  #*&   &               @('7#0  >&PO=V]R:W-H965T<R]S
M:&5E=#(N>&UL4$L! A0#%     @ O(@+4VJC[\'C @  N0D  !@
M     ("!CQ0  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (
M +R("U.#FPWZMP8  "D;   8              " @:@7  !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6Q02P$"% ,4    " "\B M36!5WV"T(   .+0  &
M            @(&5'@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#
M%     @ O(@+4_0@%;:>!@  \Q@  !@              ("!^"8  'AL+W=O
M<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( +R("U-?K%?PZ X  #4G
M   8              " @<PM  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q0
M2P$"% ,4    " "\B M3J=/A73H6   )0@  &               @('J/
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ O(@+4\CP&2,#
M!   D @  !@              ("!6E,  'AL+W=O<FMS:&5E=',O<VAE970Y
M+GAM;%!+ 0(4 Q0    ( +R("U,Y@+>&I ,  !((   9              "
M@9-7  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ O(@+
M4[N%>IQ%!   / D  !D              ("!;EL  'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6Q02P$"% ,4    " "\B M3X^U1M?T"  "B!@  &0
M        @('J7P  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0
M   ( +R("U.3;:-<5 @  "\5   9              " @1YC  !X;"]W;W)K
M<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ O(@+4S U.WCC"P  )B$
M !D              ("!J6L  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q0
M2P$"% ,4    " "\B M3FPQX1AL&  #Q#@  &0              @('#=P
M>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( +R("U.+S+XS
M%Q,  +XV   9              " @15^  !X;"]W;W)K<VAE971S+W-H965T
M,38N>&UL4$L! A0#%     @ O(@+4^EDSQE5!P  'A$  !D
M ("!8Y$  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " "\
MB M3FCU"N= &  "]$0  &0              @('OF   >&PO=V]R:W-H965T
M<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( +R("U/!I+%]]P(  ($&   9
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M970R,RYX;6Q02P$"% ,4    " "\B M37B)4E6P#  "]!P  &0
M    @(%CPP  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (
M +R("U.R: 4*6 ,  , &   9              " @0;'  !X;"]W;W)K<VAE
M971S+W-H965T,C4N>&UL4$L! A0#%     @ O(@+4S/\,?4* P  >08  !D
M             ("!E<H  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"
M% ,4    " "\B M3GW2M0G4"  !!!0  &0              @('6S0  >&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( +R("U-/IK=38P4
M .L,   9              " @8+0  !X;"]W;W)K<VAE971S+W-H965T,C@N
M>&UL4$L! A0#%     @ O(@+4\6^(#UG!@  K@\  !D              ("!
M'-8  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " "\B M3
M/Y)]L.L"  #-!0  &0              @(&ZW   >&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;%!+ 0(4 Q0    ( +R("U..3IC!! ,  $<&   9
M      " @=S?  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%
M  @ O(@+4WYTP)#3!   6A4  !D              ("!%^,  'AL+W=O<FMS
M:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " "\B M3ZY5A?" #  #?"0
M&0              @($AZ   >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+
M 0(4 Q0    ( +R("U/$/H _H0(  ,L'   9              " @7CK  !X
M;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ O(@+4P28)Q1V
M @  OP8  !D              ("!4.X  'AL+W=O<FMS:&5E=',O<VAE970S
M-2YX;6Q02P$"% ,4    " "\B M3[(]0X H#  "?"0  &0
M@(']\   >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( +R(
M"U-ZV.&W"0,  ,0)   9              " @3[T  !X;"]W;W)K<VAE971S
M+W-H965T,S<N>&UL4$L! A0#%     @ O(@+4TBI"YE  @  . 4  !D
M         ("!?O<  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4
M    " "\B M3SX=XFQT"  !S!   &0              @('U^0  >&PO=V]R
M:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( +R("U/UOKR-<@(  #0&
M   9              " @4G\  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL
M4$L! A0#%     @ O(@+4X</( U8!    !,  !D              ("!\OX
M 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " "\B M3:JM2
M.S4"  !!!0  &0              @(&! P$ >&PO=V]R:W-H965T<R]S:&5E
M=#0R+GAM;%!+ 0(4 Q0    ( +R("U,4*RUB0 4  ,(9   9
M  " @>T% 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @
MO(@+4[+*<5LF P  %PD  !D              ("!9 L! 'AL+W=O<FMS:&5E
M=',O<VAE970T-"YX;6Q02P$"% ,4    " "\B M3>T2]V>($   $%P  &0
M            @('!#@$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4
M Q0    ( +R("U.WQ!,M5 (  /H%   9              " @=H3 0!X;"]W
M;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ O(@+4_^DD.FB!0
MSQT  !D              ("!918! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX
M;6Q02P$"% ,4    " "\B M3[(_Q!7@"  !T!@  &0              @($^
M' $ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( +R("U,@
MCI;L 0H  %0Y   9              " @>T> 0!X;"]W;W)K<VAE971S+W-H
M965T-#DN>&UL4$L! A0#%     @ O(@+4PG\GM>#!   _Q0  !D
M     ("!)2D! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +R("U.%233#C0(  .H&   9              "
M@?)# 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ O(@+
M4[@2 P@; P  ,!(   T              ( !MD8! 'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    " "\B M3EXJ[',     3 @  "P              @ '\20$
M7W)E;',O+G)E;'-02P$"% ,4    " "\B M3%0-XZ9@$  !H)   #P
M        @ 'E2@$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ O(@+4[P!
MUL'@ 0  ["   !H              ( !JD\! 'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ O(@+4Q34<>30 0  K2   !,
M     ( !PE$! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #\ /P P$0
&PU,!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>193</ContextCount>
  <ElementCount>350</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>68</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>040000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>060100 - Disclosure - ORGANIZATION AND BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/OrganizationAndBusiness</Role>
      <ShortName>ORGANIZATION AND BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>060200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>060300 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/Inventories</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>060400 - Disclosure - INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/IntangibleAssets</Role>
      <ShortName>INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>060500 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/PropertyAndEquipment</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>060600 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>060700 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/Debt</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>060800 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>060900 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>061000 - Disclosure - COMMITMENT AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/CommitmentAndContingencies</Role>
      <ShortName>COMMITMENT AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>061100 - Disclosure - SEGMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/Segments</Role>
      <ShortName>SEGMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>061200 - Disclosure - LEASE OBLIGATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/LeaseObligations</Role>
      <ShortName>LEASE OBLIGATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>061300 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation</Role>
      <ShortName>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>061400 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>070200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>080200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>080300 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/InventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/Inventories</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>080400 - Disclosure - INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/IntangibleAssetsTables</Role>
      <ShortName>INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/IntangibleAssets</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>080500 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/PropertyAndEquipment</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>080600 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>080700 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/DebtTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/Debt</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>080800 - Disclosure - STOCKHOLDERS EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>081100 - Disclosure - SEGMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SegmentsTables</Role>
      <ShortName>SEGMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/Segments</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>081200 - Disclosure - LEASE OBLIGATIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/LeaseObligationsTables</Role>
      <ShortName>LEASE OBLIGATIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/LeaseObligations</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>081300 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables</Role>
      <ShortName>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>090100 - Disclosure - ORGANIZATION AND BUSINESS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/OrganizationAndBusinessDetails</Role>
      <ShortName>ORGANIZATION AND BUSINESS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/OrganizationAndBusiness</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>090200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>090202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>090204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Impairment of Long-lived Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Impairment of Long-lived Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>090206 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Revenue Recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Revenue Recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>090208 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Loss per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesLossPerCommonShareDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Loss per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>090210 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Stock-based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Stock-based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>090212 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>090300 - Disclosure - INVENTORIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/InventoriesDetails</Role>
      <ShortName>INVENTORIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/InventoriesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>090400 - Disclosure - INTANGIBLE ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/IntangibleAssetsDetails</Role>
      <ShortName>INTANGIBLE ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/IntangibleAssetsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>090404 - Disclosure - INTANGIBLE ASSETS, Future Aggregate Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails</Role>
      <ShortName>INTANGIBLE ASSETS, Future Aggregate Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>090500 - Disclosure - PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/PropertyAndEquipmentDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>090600 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>090702 - Disclosure - DEBT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/DebtDetails</Role>
      <ShortName>DEBT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/DebtTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>090800 - Disclosure - STOCKHOLDERS' EQUITY, Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/StockholdersEquityPreferredStockDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY, Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>090802 - Disclosure - STOCKHOLDERS' EQUITY, Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/StockholdersEquityCommonStockDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY, Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>090804 - Disclosure - STOCKHOLDERS' EQUITY, Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/StockholdersEquityWarrantsDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY, Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>090806 - Disclosure - STOCKHOLDERS' EQUITY, Equity Incentive Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY, Equity Incentive Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>090900 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/RelatedPartyTransactions</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>091000 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>091100 - Disclosure - SEGMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SegmentsDetails</Role>
      <ShortName>SEGMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/SegmentsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>091200 - Disclosure - LEASE OBLIGATIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/LeaseObligationsDetails</Role>
      <ShortName>LEASE OBLIGATIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/LeaseObligationsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>091300 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails</Role>
      <ShortName>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="brhc10027771_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>091400 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SubsequentEventsDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/SubsequentEvents</ParentRole>
      <Position>55</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="brhc10027771_10q.htm">brhc10027771_10q.htm</File>
    <File>adma-20210630.xsd</File>
    <File>adma-20210630_cal.xml</File>
    <File>adma-20210630_def.xml</File>
    <File>adma-20210630_lab.xml</File>
    <File>adma-20210630_pre.xml</File>
    <File>brhc10027771_ex10-2.htm</File>
    <File>brhc10027771_ex31-1.htm</File>
    <File>brhc10027771_ex31-2.htm</File>
    <File>brhc10027771_ex32-1.htm</File>
    <File>brhc10027771_ex32-2.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>74
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "brhc10027771_10q.htm": {
   "axisCustom": 0,
   "axisStandard": 28,
   "contextCount": 193,
   "dts": {
    "calculationLink": {
     "local": [
      "adma-20210630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "adma-20210630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "brhc10027771_10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "adma-20210630_lab.xml"
     ],
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-doc-2021-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "adma-20210630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-ref-2021-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "adma-20210630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-parts-codification-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd"
     ]
    }
   },
   "elementCount": 508,
   "entityCount": 1,
   "hidden": {
    "http://admabiologics.com/20210630": 2,
    "http://fasb.org/us-gaap/2021-01-31": 1,
    "http://xbrl.sec.gov/dei/2021": 6,
    "total": 9
   },
   "keyCustom": 48,
   "keyStandard": 302,
   "memberCustom": 28,
   "memberStandard": 36,
   "nsprefix": "adma",
   "nsuri": "http://admabiologics.com/20210630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000100 - Document - Document and Entity Information",
     "role": "http://admabiologics.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060400 - Disclosure - INTANGIBLE ASSETS",
     "role": "http://admabiologics.com/role/IntangibleAssets",
     "shortName": "INTANGIBLE ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060500 - Disclosure - PROPERTY AND EQUIPMENT",
     "role": "http://admabiologics.com/role/PropertyAndEquipment",
     "shortName": "PROPERTY AND EQUIPMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060600 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "role": "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilities",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060700 - Disclosure - DEBT",
     "role": "http://admabiologics.com/role/Debt",
     "shortName": "DEBT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060800 - Disclosure - STOCKHOLDERS' EQUITY",
     "role": "http://admabiologics.com/role/StockholdersEquity",
     "shortName": "STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060900 - Disclosure - RELATED PARTY TRANSACTIONS",
     "role": "http://admabiologics.com/role/RelatedPartyTransactions",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061000 - Disclosure - COMMITMENT AND CONTINGENCIES",
     "role": "http://admabiologics.com/role/CommitmentAndContingencies",
     "shortName": "COMMITMENT AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061100 - Disclosure - SEGMENTS",
     "role": "http://admabiologics.com/role/Segments",
     "shortName": "SEGMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061200 - Disclosure - LEASE OBLIGATIONS",
     "role": "http://admabiologics.com/role/LeaseObligations",
     "shortName": "LEASE OBLIGATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061300 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION",
     "role": "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation",
     "shortName": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061400 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://admabiologics.com/role/SubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "070200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080300 - Disclosure - INVENTORIES (Tables)",
     "role": "http://admabiologics.com/role/InventoriesTables",
     "shortName": "INVENTORIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080400 - Disclosure - INTANGIBLE ASSETS (Tables)",
     "role": "http://admabiologics.com/role/IntangibleAssetsTables",
     "shortName": "INTANGIBLE ASSETS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080500 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "role": "http://admabiologics.com/role/PropertyAndEquipmentTables",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080600 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "role": "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080700 - Disclosure - DEBT (Tables)",
     "role": "http://admabiologics.com/role/DebtTables",
     "shortName": "DEBT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080800 - Disclosure - STOCKHOLDERS EQUITY (Tables)",
     "role": "http://admabiologics.com/role/StockholdersEquityTables",
     "shortName": "STOCKHOLDERS EQUITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "081100 - Disclosure - SEGMENTS (Tables)",
     "role": "http://admabiologics.com/role/SegmentsTables",
     "shortName": "SEGMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210630",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "U003",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210630",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "081200 - Disclosure - LEASE OBLIGATIONS (Tables)",
     "role": "http://admabiologics.com/role/LeaseObligationsTables",
     "shortName": "LEASE OBLIGATIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "081300 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)",
     "role": "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables",
     "shortName": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20200401to20200630",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "adma:NumberOfPlasmaCollectionFacilitiesUnderDevelopment",
      "reportCount": 1,
      "unitRef": "U004",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090100 - Disclosure - ORGANIZATION AND BUSINESS (Details)",
     "role": "http://admabiologics.com/role/OrganizationAndBusinessDetails",
     "shortName": "ORGANIZATION AND BUSINESS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": "INF",
      "lang": null,
      "name": "adma:NumberOfFDAApprovedProduct",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U005",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210630",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Accounts Receivable (Details)",
     "role": "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Accounts Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210630",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Goodwill (Details)",
     "role": "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillImpairmentLoss",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210401to20210630",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210401to20210630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Impairment of Long-lived Assets (Details)",
     "role": "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Impairment of Long-lived Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210401to20210630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_FiveCustomersMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "adma:NumberOfCustomers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U006",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090206 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Revenue Recognition (Details)",
     "role": "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Revenue Recognition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_FiveCustomersMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "adma:NumberOfCustomers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U006",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090208 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Loss per Common Share (Details)",
     "role": "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesLossPerCommonShareDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Loss per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090210 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Stock-based Compensation (Details)",
     "role": "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Stock-based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:UnrecognizedTaxBenefits",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090212 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Income Taxes (Details)",
     "role": "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:UnrecognizedTaxBenefits",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210401to20210630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210401to20210630",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090300 - Disclosure - INVENTORIES (Details)",
     "role": "http://admabiologics.com/role/InventoriesDetails",
     "shortName": "INVENTORIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090400 - Disclosure - INTANGIBLE ASSETS (Details)",
     "role": "http://admabiologics.com/role/IntangibleAssetsDetails",
     "shortName": "INTANGIBLE ASSETS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20201231",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090404 - Disclosure - INTANGIBLE ASSETS, Future Aggregate Amortization Expense (Details)",
     "role": "http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails",
     "shortName": "INTANGIBLE ASSETS, Future Aggregate Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090500 - Disclosure - PROPERTY AND EQUIPMENT (Details)",
     "role": "http://admabiologics.com/role/PropertyAndEquipmentDetails",
     "shortName": "PROPERTY AND EQUIPMENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20201231",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "adma:AccruedRebatesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090600 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "role": "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "adma:AccruedRebatesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "adma:SeniorNotesPayableBeforeDebtDiscount",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090702 - Disclosure - DEBT (Details)",
     "role": "http://admabiologics.com/role/DebtDetails",
     "shortName": "DEBT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20201231",
      "decimals": "0",
      "lang": null,
      "name": "adma:SeniorNotesPayableBeforeDebtDiscount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210630",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090800 - Disclosure - STOCKHOLDERS' EQUITY, Preferred Stock (Details)",
     "role": "http://admabiologics.com/role/StockholdersEquityPreferredStockDetails",
     "shortName": "STOCKHOLDERS' EQUITY, Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210630",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090802 - Disclosure - STOCKHOLDERS' EQUITY, Common Stock (Details)",
     "role": "http://admabiologics.com/role/StockholdersEquityCommonStockDetails",
     "shortName": "STOCKHOLDERS' EQUITY, Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20200101to20200630_SubsidiarySaleOfStockAxis_OverAllotmentOptionMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090804 - Disclosure - STOCKHOLDERS' EQUITY, Warrants (Details)",
     "role": "http://admabiologics.com/role/StockholdersEquityWarrantsDetails",
     "shortName": "STOCKHOLDERS' EQUITY, Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210630",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U003",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090806 - Disclosure - STOCKHOLDERS' EQUITY, Equity Incentive Plans (Details)",
     "role": "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails",
     "shortName": "STOCKHOLDERS' EQUITY, Equity Incentive Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210401to20210630_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20191231_StatementEquityComponentsAxis_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "role": "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20200101to20200331_StatementEquityComponentsAxis_CommonStockMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20200211",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssuedPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U003",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090900 - Disclosure - RELATED PARTY TRANSACTIONS (Details)",
     "role": "http://admabiologics.com/role/RelatedPartyTransactionsDetails",
     "shortName": "RELATED PARTY TRANSACTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20200211",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssuedPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U003",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adma:PlasmaSupplyAgreementTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091000 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "role": "http://admabiologics.com/role/CommitmentsAndContingenciesDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adma:PlasmaSupplyAgreementTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20200401to20200630",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "adma:NumberOfFDALicensedPlasmaCollectionFacilities",
      "reportCount": 1,
      "unitRef": "U004",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091100 - Disclosure - SEGMENTS (Details)",
     "role": "http://admabiologics.com/role/SegmentsDetails",
     "shortName": "SEGMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210401to20210630_StatementGeographicalAxis_US",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210401to20210630",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "adma:OperatingLeaseIncrementalBorrowingRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U007",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091200 - Disclosure - LEASE OBLIGATIONS (Details)",
     "role": "http://admabiologics.com/role/LeaseObligationsDetails",
     "shortName": "LEASE OBLIGATIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210401to20210630",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "adma:OperatingLeaseIncrementalBorrowingRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U007",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestPaidNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091300 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Details)",
     "role": "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails",
     "shortName": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestPaidNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091400 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "role": "http://admabiologics.com/role/SubsequentEventsDetails",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210726to20210726_SubsequentEventTypeAxis_SubsequentEventMember_TypeOfArrangementAxis_SaleAgreement2020Member",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "040000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:GainLossOnDispositionOfAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060100 - Disclosure - ORGANIZATION AND BUSINESS",
     "role": "http://admabiologics.com/role/OrganizationAndBusiness",
     "shortName": "ORGANIZATION AND BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://admabiologics.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060300 - Disclosure - INVENTORIES",
     "role": "http://admabiologics.com/role/Inventories",
     "shortName": "INVENTORIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027771_10q.htm",
      "contextRef": "c20210101to20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 68,
   "tag": {
    "adma_ADMABioManufacturingSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component of ADMA BioManufacturing that usually provides financial, operational and administrative support and is considered an operating segment.",
        "label": "ADMA BioManufacturing Segment [Member]",
        "terseLabel": "ADMA BioManufacturing [Member]"
       }
      }
     },
     "localname": "ADMABioManufacturingSegmentMember",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for contractual credits and doubtful accounts.",
        "label": "Accounts Receivable, Allowance for Contractual Credits and Doubtful Accounts",
        "terseLabel": "Accounts receivable, allowances for contractual credits and doubtful accounts"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_AccruedRebatesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of rebates for Medicaid or other third parties related to sale of product.",
        "label": "Accrued Rebates, Current",
        "terseLabel": "Accrued rebates"
       }
      }
     },
     "localname": "AccruedRebatesCurrent",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_AmortizationOfLicenseRevenue": {
     "auth_ref": [],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash revenue related to amortization of license revenue.",
        "label": "Amortization of License Revenue",
        "terseLabel": "Amortization of license revenue"
       }
      }
     },
     "localname": "AmortizationOfLicenseRevenue",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_ArethLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the entity associated with related party.",
        "label": "Areth, LLC [Member]"
       }
      }
     },
     "localname": "ArethLLCMember",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_BiotestLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of license agreement.",
        "label": "Biotest License Agreement [Member]"
       }
      }
     },
     "localname": "BiotestLicenseAgreementMember",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_ChiefScientificOfficerAndChiefMedicalOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person with designation of chief scientific officer and chief medical officer.",
        "label": "Chief Scientific Officer and Chief Medical Officer [Member]",
        "terseLabel": "Dr. James Mond [Member]"
       }
      }
     },
     "localname": "ChiefScientificOfficerAndChiefMedicalOfficerMember",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_CostOfProductRevenueExcludingAmortizationExpense": {
     "auth_ref": [],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of product sold and service rendered, excluding amortization expense.",
        "label": "Cost of Product Revenue, Excluding Amortization Expense",
        "terseLabel": "Cost of product revenue (exclusive of amortization expense shown below)",
        "verboseLabel": "Cost of product revenue"
       }
      }
     },
     "localname": "CostOfProductRevenueExcludingAmortizationExpense",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_DebtInstrumentTermOfVariableRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of the interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Debt Instrument, Term of Variable Rate",
        "terseLabel": "Term of variable rate"
       }
      }
     },
     "localname": "DebtInstrumentTermOfVariableRate",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "adma_DeferredRevenueRemainingAmortizationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period of deferred revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Amortization period"
       }
      }
     },
     "localname": "DeferredRevenueRemainingAmortizationPeriod",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "adma_DepositsAndOtherNoncurrentAssets": {
     "auth_ref": [],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and amount of noncurrent assets classified as other.",
        "label": "Deposits and Other Noncurrent Assets",
        "terseLabel": "Deposits and other assets"
       }
      }
     },
     "localname": "DepositsAndOtherNoncurrentAssets",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_DirectOwnershipMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Direct owner refers to individuals and entities who directly own shares or are partners in any legal entity.",
        "label": "Direct Ownership [Member]",
        "terseLabel": "Direct [Member]"
       }
      }
     },
     "localname": "DirectOwnershipMember",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_EmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A group of person working with the entity.",
        "label": "Employees [Member]"
       }
      }
     },
     "localname": "EmployeesMember",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equipment acquired in a noncash (or part noncash) acquisition and reflected in accounts payable and accrued liabilities.",
        "label": "Equipment Acquired Reflected in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Equipment acquired reflected in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity compensation is often a significant portion of the total compensation paid to employees and other service providers.",
        "label": "Equity Incentive Plans [Member]"
       }
      }
     },
     "localname": "EquityIncentivePlanMember",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_EstimatedPaymentForSeparationAndTransitionAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of estimated lability of payment for separation and transition agreement.",
        "label": "Estimated Payment for Separation and Transition Agreement",
        "terseLabel": "Estimated payment for separation and transition agreement"
       }
      }
     },
     "localname": "EstimatedPaymentForSeparationAndTransitionAgreement",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person with designation of executive vice president and chief financial officer.",
        "label": "Executive Vice President and Chief Financial Officer [Member]",
        "terseLabel": "Brian Lenz [Member]"
       }
      }
     },
     "localname": "ExecutiveVicePresidentAndChiefFinancialOfficerMember",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_FiveCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about number of customers accounting for a percentage of consolidated revenues.",
        "label": "Five Customers [Member]"
       }
      }
     },
     "localname": "FiveCustomersMember",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_GenesisBPSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the entity associated with related party.",
        "label": "GenesisBPS [Member]",
        "terseLabel": "Genesis [Member]"
       }
      }
     },
     "localname": "GenesisBPSMember",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_GrossProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of gross proceeds from issuance of common stock.",
        "label": "Gross Proceeds from Issuance of Common Stock",
        "verboseLabel": "Gross proceeds from issuance of common stock"
       }
      }
     },
     "localname": "GrossProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_IncreaseDecreaseInDepositsAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deposits and operating assets classified as other.",
        "label": "Increase Decrease in Deposits and Other Assets",
        "negatedLabel": "Deposits and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInDepositsAndOtherAssets",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_IndirectOwnershipMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indirect Ownership means an interest in an entity that has direct or indirect ownership interest in the Applicant. The amount of indirect ownership in the Applicant that is held by any other entity is determined by multiplying the percentage of ownership interest at each level.",
        "label": "Indirect Ownership [Member]",
        "terseLabel": "Indirect [Member]"
       }
      }
     },
     "localname": "IndirectOwnershipMember",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_JefferiesLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity owned or controlled by another entity.",
        "label": "Jefferies LLC [Member]",
        "terseLabel": "Jefferies [Member]",
        "verboseLabel": "Jefferies LLC [Member]"
       }
      }
     },
     "localname": "JefferiesLLCMember",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/OrganizationAndBusinessDetails",
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease liability recognized in connection with property lease.",
        "label": "Lessee Operating Lease Liabilities Related to Property Lease",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use assets recognized in connection with property lease.",
        "label": "Lessee, Operating Lease, Right-of-Use Asset Related to Property Lease",
        "terseLabel": "Right to use assets"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_MinimumPercentageOfCommonStockHeldByLender": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of common stock held by lender and administrative agent of credit facility.",
        "label": "Minimum Percentage of Common Stock held by Lender",
        "terseLabel": "Minimum percentage of common stock held by lender"
       }
      }
     },
     "localname": "MinimumPercentageOfCommonStockHeldByLender",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adma_NumberOfCustomers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of customers accounted for company's total accounts receivable.",
        "label": "Number of Customers",
        "terseLabel": "Number of customers",
        "verboseLabel": "Number of customers"
       }
      }
     },
     "localname": "NumberOfCustomers",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "adma_NumberOfFDAApprovedProduct": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of products approved by FDA.",
        "label": "Number of FDA Approved Product",
        "terseLabel": "Number of FDA approved product"
       }
      }
     },
     "localname": "NumberOfFDAApprovedProduct",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/OrganizationAndBusinessDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "adma_NumberOfFDALicensedPlasmaCollectionFacilities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plasma collection facilities having FDA license.",
        "label": "Number of FDA-Licensed Plasma Collection Facilities",
        "terseLabel": "Number of FDA-licensed plasma collection facilities"
       }
      }
     },
     "localname": "NumberOfFDALicensedPlasmaCollectionFacilities",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/OrganizationAndBusinessDetails",
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "adma_NumberOfNewPropertyLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new property leases related to additional plasma collection facilities.",
        "label": "Number of New Property Leases",
        "terseLabel": "Number of new property leases"
       }
      }
     },
     "localname": "NumberOfNewPropertyLeases",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plasma collection centers that company may purchase RSV plasma.",
        "label": "Number of Plasma Collection Centers Transferred to Acquired Entity",
        "terseLabel": "Number of plasma collection centers transferred to BPC"
       }
      }
     },
     "localname": "NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "adma_NumberOfPlasmaCollectionFacilities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of wholly-owned plasma collection facilities of the entity.",
        "label": "Number of Plasma Collection Facilities",
        "terseLabel": "Number of plasma collection facilities"
       }
      }
     },
     "localname": "NumberOfPlasmaCollectionFacilities",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plasma collection facilities under various stages of development.",
        "label": "Number of Plasma Collection Facilities Under Development",
        "terseLabel": "Number of plasma collection facilities under development"
       }
      }
     },
     "localname": "NumberOfPlasmaCollectionFacilitiesUnderDevelopment",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/OrganizationAndBusinessDetails",
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "adma_NumberOfRenewalTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of renewal terms to extend purchase agreement, if agreed to by the parties.",
        "label": "Number of Renewal Terms",
        "terseLabel": "Number of renewal terms"
       }
      }
     },
     "localname": "NumberOfRenewalTerms",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "adma_OperatingLeaseIncrementalBorrowingRatePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average incremental borrowing rate for operating lease calculated at point in time.",
        "label": "Operating Lease Incremental Borrowing Rate Percent",
        "terseLabel": "Incremental borrowing rate"
       }
      }
     },
     "localname": "OperatingLeaseIncrementalBorrowingRatePercent",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adma_OperatingLeasesRentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Rental expense"
       }
      }
     },
     "localname": "OperatingLeasesRentExpense",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_PercentageOfInventoryPurchases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of inventory purchases related to raw material plasma.",
        "label": "Percentage of Inventory Purchases",
        "terseLabel": "Percentage of inventory purchases"
       }
      }
     },
     "localname": "PercentageOfInventoryPurchases",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adma_PercentageOfPlasmaPurchasePriceEqualToCost": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of plasma purchase price equal to cost purchased from collection centers.",
        "label": "Percentage of Plasma Purchase Price Equal to Cost",
        "terseLabel": "Percentage of plasma purchase price equal to cost"
       }
      }
     },
     "localname": "PercentageOfPlasmaPurchasePriceEqualToCost",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adma_PerceptiveCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A Perceptive credit agreement is a legally-binding contract documenting the terms of a loan agreement; it is made between a person or party borrowing money and a lender.",
        "label": "Perceptive Credit Agreement [Member]",
        "terseLabel": "Perceptive Credit Agreement [Member]"
       }
      }
     },
     "localname": "PerceptiveCreditAgreementMember",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_PerceptiveCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount from lender.",
        "label": "Perceptive Credit Facility [Member]",
        "terseLabel": "Perceptive Credit Facility [Member]"
       }
      }
     },
     "localname": "PerceptiveCreditFacilityMember",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_PerceptiveCreditHoldingsIILPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Lender in credit facility agreement.",
        "label": "Perceptive Credit Holdings II, LP [Member]",
        "terseLabel": "Perceptive [Member]"
       }
      }
     },
     "localname": "PerceptiveCreditHoldingsIILPMember",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of scheduled installments for separation and transition agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Period of Scheduled Installments for Separation and Transition Agreement",
        "terseLabel": "Period of scheduled installments for separation and transition agreement"
       }
      }
     },
     "localname": "PeriodOfScheduledInstallmentsForSeparationAndTransitionAgreement",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "adma_PlasmaCollectionCentersSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component of Plasma Collection Centers segment that usually provides financial, operational and administrative support and is considered an operating segment.",
        "label": "Plasma Collection Centers Segment [Member]",
        "terseLabel": "Plasma Collection Centers [Member]"
       }
      }
     },
     "localname": "PlasmaCollectionCentersSegmentMember",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_PlasmaPurchaseAgreementOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plasma purchase agreement to purchase plasma containing antibodies to RSV to be used in the manufacture of ASCENIV.",
        "label": "Plasma Purchase Agreement One [Member]",
        "terseLabel": "2011 Plasma Purchase Agreement [Member]"
       }
      }
     },
     "localname": "PlasmaPurchaseAgreementOneMember",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_PlasmaPurchaseAgreementRenewalPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plasma purchase agreement renewal period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Plasma Purchase Agreement Renewal Period",
        "terseLabel": "Plasma purchase agreement renewal period"
       }
      }
     },
     "localname": "PlasmaPurchaseAgreementRenewalPeriod",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "adma_PlasmaPurchaseAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plasma purchase agreement term, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Plasma Purchase Agreement Term",
        "terseLabel": "Plasma purchase agreement term"
       }
      }
     },
     "localname": "PlasmaPurchaseAgreementTerm",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "adma_PlasmaPurchaseAgreementTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plasma purchase agreement to purchase normal source plasma (\"NSP\").",
        "label": "Plasma Purchase Agreement Two [Member]",
        "terseLabel": "2017 Plasma Purchase Agreement [Member]"
       }
      }
     },
     "localname": "PlasmaPurchaseAgreementTwoMember",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_PlasmaPurchased": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of plasma purchased during the period.",
        "label": "Plasma Purchased",
        "terseLabel": "Plasma purchased from Grifols"
       }
      }
     },
     "localname": "PlasmaPurchased",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_PlasmaSupplyAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plasma supply agreement term period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Plasma supply agreement term",
        "terseLabel": "Plasma supply agreement term"
       }
      }
     },
     "localname": "PlasmaSupplyAgreementTerm",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "adma_PreferredSharePurchaseRightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The right of the existing shareholder to buy additional shares in proportion to the number of shares already owned.",
        "label": "Preferred Share Purchase Right [Member]",
        "terseLabel": "Preferred Share Purchase Right [Member]"
       }
      }
     },
     "localname": "PreferredSharePurchaseRightMember",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_PresidentAndChiefExecutiveOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person with designation of president and chief executive officer.",
        "label": "President and Chief Executive Officer [Member]",
        "terseLabel": "Mr. Grossman [Member]"
       }
      }
     },
     "localname": "PresidentAndChiefExecutiveOfficerMember",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_ProductCycleFromProcurementOfRawMaterialsToFinishedProduct": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Production cycle from procurement of raw materials to commercial release of finished product.",
        "label": "Product Cycle from Procurement of Raw Materials to Finished Product",
        "terseLabel": "Production cycle from procurement of raw materials to release of finished product"
       }
      }
     },
     "localname": "ProductCycleFromProcurementOfRawMaterialsToFinishedProduct",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/OrganizationAndBusinessDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "adma_RepaymentsOfDebtInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt interest.",
        "label": "Payments of Debt, Interest",
        "terseLabel": "Payments of debt interest"
       }
      }
     },
     "localname": "RepaymentsOfDebtInterest",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_RestrictedStockUnitsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units [Abstract]"
       }
      }
     },
     "localname": "RestrictedStockUnitsAbstract",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adma_RightToIntermediatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's established relationships with its customers through contracts.",
        "label": "Right to intermediates [Member]",
        "terseLabel": "Right to Intermediates [Member]"
       }
      }
     },
     "localname": "RightToIntermediatesMember",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_SaleAgreement2020AmendedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An agreement of sale constitutes the terms and conditions of sale of a property by the seller to the buyer, as amended during the previous fiscal period.",
        "label": "Sale Agreement 2020, Amended [Member]",
        "terseLabel": "2020 Sale Agreement, As Amended [Member]"
       }
      }
     },
     "localname": "SaleAgreement2020AmendedMember",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_SaleAgreement2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An agreement of sale constitutes the terms and conditions of sale of a property by the seller to the buyer during the previous fiscal period.",
        "label": "Sale Agreement 2020 [Member]",
        "terseLabel": "2020 Sale Agreement [Member]"
       }
      }
     },
     "localname": "SaleAgreement2020Member",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/OrganizationAndBusinessDetails",
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails",
      "http://admabiologics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_SaleAgreement2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An agreement of sale constitutes the terms and conditions of sale of a property by the seller to the buyer during the current fiscal period.",
        "label": "Sale Agreement 2021 [Member]",
        "terseLabel": "2021 Sale Agreement [Member]"
       }
      }
     },
     "localname": "SaleAgreement2021Member",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/OrganizationAndBusinessDetails",
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_SaleAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An agreement of sale constitutes the terms and conditions of sale of a property by the seller to the buyer.",
        "label": "Sale Agreement [Member]",
        "verboseLabel": "Sale Agreement [Member]"
       }
      }
     },
     "localname": "SaleAgreementMember",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_SeniorNotesPayableBeforeDebtDiscount": {
     "auth_ref": [],
     "calculation": {
      "http://admabiologics.com/role/DebtDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_SeniorLongTermNotes",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding debt discount and current portion.",
        "label": "Senior Notes Payable Before Debt Discount",
        "terseLabel": "Notes payable"
       }
      }
     },
     "localname": "SeniorNotesPayableBeforeDebtDiscount",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The shares value withheld by the Company to cover employees' tax liabilities under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Shares Value Withheld for Employees Tax Liabilities",
        "terseLabel": "Amount of shares withheld for tax withholding obligation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares withheld by the Company to cover employees' tax liabilities under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Shares Withheld for Employees Tax Liabilities",
        "terseLabel": "Shares withheld for tax withholding obligation (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under fully vested and expected to vest options that were exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercised, Number",
        "terseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercised.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercised, Weighted Average Exercise Price",
        "terseLabel": "Exercised, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under fully vested and expected to vest options for which rights to exercise lapsed.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Expired, Number",
        "negatedLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, for fully vested and expected to vest that were expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Expired, Weighted Average Exercise Price",
        "terseLabel": "Expired, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under fully vested and expected to vest options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Forfeited, Number",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, for fully vested and expected to vest that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Forfeited, Weighted Average Exercise Price",
        "terseLabel": "Forfeited, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under fully vested and expected to vest options that were granted during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Granted, Number",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest granted.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Granted, Weighted Average Exercise Price",
        "terseLabel": "Granted, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "adma_SixCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about number of customers accounting for a percentage of consolidated revenues.",
        "label": "Six Customers [Member]"
       }
      }
     },
     "localname": "SixCustomersMember",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_StockOptionSharesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option, Shares [Abstract]"
       }
      }
     },
     "localname": "StockOptionSharesAbstract",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adma_StockOptionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options [Abstract]"
       }
      }
     },
     "localname": "StockOptionsAbstract",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adma_StockOptionsWeightedAverageExercisePriceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "localname": "StockOptionsWeightedAverageExercisePriceAbstract",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adma_SubsequentEventsSaleOfStockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events, Sale of Stock [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsSaleOfStockAbstract",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adma_TaxesPaidOnVestedRestrictedStockUnits": {
     "auth_ref": [],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow related to taxes on vested Restricted Stock Units.",
        "label": "Taxes Paid on Vested Restricted Stock Units",
        "negatedLabel": "Taxes paid on vested Restricted Stock Units"
       }
      }
     },
     "localname": "TaxesPaidOnVestedRestrictedStockUnits",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_ThreeCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about number of customers accounting for a percentage of consolidated revenues.",
        "label": "Three Customers [Member]"
       }
      }
     },
     "localname": "ThreeCustomersMember",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's established relationships with its customers through contracts.",
        "label": "Trademark and other intangible rights related to Nabi-HB [Member]",
        "terseLabel": "Trademark and Other Intangible Rights Related to Nabi-HB [Member]"
       }
      }
     },
     "localname": "TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_VendorCommitmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vendor Commitments [Abstract]"
       }
      }
     },
     "localname": "VendorCommitmentsAbstract",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of shares withheld to cover grantees' income tax liability.",
        "label": "Vesting of Restricted Stock Units, net of shares withheld for taxes and retired, amount",
        "terseLabel": "Vesting of Restricted Stock Units, net of shares withheld for taxes and retired"
       }
      }
     },
     "localname": "VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of shares withheld to cover grantees' income tax liability.",
        "label": "Vesting of Restricted Stock Units, net of shares withheld for taxes and retired, shares",
        "terseLabel": "Vesting of Restricted Stock Units, net of shares withheld for taxes and retired (in shares)"
       }
      }
     },
     "localname": "VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "adma_ViceChairmanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person who acts for and assists a chairman.",
        "label": "Vice Chairman [Member]",
        "terseLabel": "Dr. Grossman [Member]"
       }
      }
     },
     "localname": "ViceChairmanMember",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_WarrantsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Abstract]",
        "terseLabel": "Warrants [Abstract]"
       }
      }
     },
     "localname": "WarrantsAbstract",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adma_WorkingCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of difference between current assets and liabilities.",
        "label": "Working Capital",
        "terseLabel": "Working capital"
       }
      }
     },
     "localname": "WorkingCapital",
     "nsuri": "http://admabiologics.com/20210630",
     "presentation": [
      "http://admabiologics.com/role/OrganizationAndBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States [Member]"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityListingsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Listings [Line Items]"
       }
      }
     },
     "localname": "EntityListingsLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityListingsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container for exchange listing information for an entity",
        "label": "Entity Listings [Table]"
       }
      }
     },
     "localname": "EntityListingsTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r97",
      "r240",
      "r245",
      "r253",
      "r367",
      "r368",
      "r369",
      "r370",
      "r419",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities Axis"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/OrganizationAndBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r97",
      "r240",
      "r245",
      "r253",
      "r367",
      "r368",
      "r369",
      "r370",
      "r419",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/OrganizationAndBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r97",
      "r148",
      "r161",
      "r162",
      "r163",
      "r164",
      "r166",
      "r168",
      "r172",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r248",
      "r250",
      "r252",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r97",
      "r148",
      "r161",
      "r162",
      "r163",
      "r164",
      "r166",
      "r168",
      "r172",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r248",
      "r250",
      "r252",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lawrence P. Guiheen [Member]",
        "terseLabel": "Directors [Member]"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r179",
      "r311",
      "r315",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r258",
      "r284",
      "r319",
      "r321",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r471",
      "r475",
      "r502",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails",
      "http://admabiologics.com/role/LeaseObligationsDetails",
      "http://admabiologics.com/role/OrganizationAndBusinessDetails",
      "http://admabiologics.com/role/PropertyAndEquipmentDetails",
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r258",
      "r284",
      "r319",
      "r321",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r471",
      "r475",
      "r502",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails",
      "http://admabiologics.com/role/LeaseObligationsDetails",
      "http://admabiologics.com/role/OrganizationAndBusinessDetails",
      "http://admabiologics.com/role/PropertyAndEquipmentDetails",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r179",
      "r311",
      "r315",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r174",
      "r311",
      "r313",
      "r436",
      "r470",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r174",
      "r311",
      "r313",
      "r436",
      "r470",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r258",
      "r284",
      "r317",
      "r319",
      "r321",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r471",
      "r475",
      "r502",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails",
      "http://admabiologics.com/role/DebtDetails",
      "http://admabiologics.com/role/LeaseObligationsDetails",
      "http://admabiologics.com/role/OrganizationAndBusinessDetails",
      "http://admabiologics.com/role/PropertyAndEquipmentDetails",
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r258",
      "r284",
      "r317",
      "r319",
      "r321",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r471",
      "r475",
      "r502",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails",
      "http://admabiologics.com/role/DebtDetails",
      "http://admabiologics.com/role/LeaseObligationsDetails",
      "http://admabiologics.com/role/OrganizationAndBusinessDetails",
      "http://admabiologics.com/role/PropertyAndEquipmentDetails",
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r107",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r107",
      "r112",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r175",
      "r176",
      "r311",
      "r314",
      "r473",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r175",
      "r176",
      "r311",
      "r314",
      "r473",
      "r486",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r107",
      "r112",
      "r230",
      "r320",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r181",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r36",
      "r422"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Abstract]"
       }
      }
     },
     "localname": "AccountsReceivableNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r6",
      "r21",
      "r182",
      "r183"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r40"
     ],
     "calculation": {
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued incentives"
       }
      }
     },
     "localname": "AccruedBonusesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses and Other Liabilities [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r40"
     ],
     "calculation": {
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued distribution fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r40"
     ],
     "calculation": {
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued payroll"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r35",
      "r216"
     ],
     "calculation": {
      "http://admabiologics.com/role/PropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r22",
      "r352",
      "r422"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r349",
      "r350",
      "r351",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r71",
      "r83",
      "r271",
      "r392"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r83",
      "r201",
      "r207"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of intangible assets",
        "verboseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Potentially dilutive securities (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails",
      "http://admabiologics.com/role/OrganizationAndBusinessDetails",
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails",
      "http://admabiologics.com/role/SubsequentEventsDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentChargesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-lived Assets [Abstract]"
       }
      }
     },
     "localname": "AssetImpairmentChargesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetUnderConstructionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset in process of being built.",
        "label": "Construction in Process [Member]"
       }
      }
     },
     "localname": "AssetUnderConstructionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r96",
      "r156",
      "r163",
      "r170",
      "r189",
      "r240",
      "r241",
      "r242",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r251",
      "r253",
      "r254",
      "r367",
      "r369",
      "r382",
      "r420",
      "r422",
      "r452",
      "r463"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Total assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets",
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r57",
      "r96",
      "r189",
      "r240",
      "r241",
      "r242",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r251",
      "r253",
      "r254",
      "r367",
      "r369",
      "r382",
      "r420",
      "r422"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r323",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Buildings and Building Improvements [Member]"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r33",
      "r422",
      "r484",
      "r485"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash balance"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r33",
      "r85"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r78",
      "r85",
      "r87"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents - end of period",
        "periodStartLabel": "Cash and cash equivalents - beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r78",
      "r383"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/OrganizationAndBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION"
       }
      }
     },
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r93",
      "r96",
      "r115",
      "r116",
      "r117",
      "r119",
      "r121",
      "r128",
      "r129",
      "r130",
      "r189",
      "r240",
      "r245",
      "r246",
      "r247",
      "r253",
      "r254",
      "r282",
      "r283",
      "r287",
      "r291",
      "r382",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Weighted average exercise price of warrants (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Warrants outstanding (in shares)",
        "terseLabel": "Warrants outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r306",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r46",
      "r229",
      "r456",
      "r467"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENT AND CONTINGENCIES [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r226",
      "r227",
      "r228",
      "r236",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CommitmentAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common stock, available for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r99",
      "r100",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://admabiologics.com/role/DocumentAndEntityInformation",
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Abstract]"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value (in dollars per share)",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized (in shares)",
        "verboseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r20",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r20",
      "r422"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock - voting, $0.0001 par value, 300,000,000 and 150,000,000 shares authorized, 131,872,026 and 104,902,888 shares issued and outstanding"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonUnitIssuanceValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stated value of common units of ownership issued by a limited liability company (LLC).",
        "label": "Sales of common stock"
       }
      }
     },
     "localname": "CommonUnitIssuanceValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/OrganizationAndBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r138",
      "r139",
      "r179",
      "r379",
      "r380",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r138",
      "r139",
      "r179",
      "r379",
      "r380",
      "r483",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r138",
      "r139",
      "r179",
      "r379",
      "r380",
      "r483",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r138",
      "r139",
      "r179",
      "r379",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Percentage of account receivables",
        "terseLabel": "Percentage of consolidated revenues"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r135",
      "r138",
      "r139",
      "r140",
      "r379",
      "r381",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedule of Product Information [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r138",
      "r139",
      "r179",
      "r379",
      "r380",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r308",
      "r309",
      "r312"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Current portion of deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateMember": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component of an entity that usually provides financial, operational and administrative support and is considered an operating segment. Excludes intersegment elimination and reconciling items.",
        "label": "Corporate Segment [Member]",
        "terseLabel": "Corporate [Member]"
       }
      }
     },
     "localname": "CorporateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Product Revenue [Member]"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of product revenue"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OPERATING EXPENSES:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r136",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerContractsMember": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's established relationships with its customers through contracts.",
        "label": "Customer Contract [Member]"
       }
      }
     },
     "localname": "CustomerContractsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DEBT [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r95",
      "r97",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r274",
      "r275",
      "r276",
      "r277",
      "r395",
      "r453",
      "r454",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Credit agreement, Interest rate provided"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r42",
      "r273",
      "r393",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument.",
        "label": "Debt Instrument, Interest Rate, Increase (Decrease)",
        "terseLabel": "Increase basis points"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r42",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Credit agreement, Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r43",
      "r258",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r44",
      "r95",
      "r97",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r274",
      "r275",
      "r276",
      "r277",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r44",
      "r95",
      "r97",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r276",
      "r277",
      "r299",
      "r302",
      "r303",
      "r304",
      "r392",
      "r393",
      "r395",
      "r396",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r262",
      "r392",
      "r396"
     ],
     "calculation": {
      "http://admabiologics.com/role/DebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_SeniorLongTermNotes",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedLabel": "Less: Debt discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instruments [Abstract]"
       }
      }
     },
     "localname": "DebtInstrumentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "DeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r83",
      "r214"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r83",
      "r151"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r66",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r113",
      "r115",
      "r119",
      "r120",
      "r121",
      "r124",
      "r125",
      "r374",
      "r375",
      "r458",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "BASIC LOSS PER COMMON SHARE (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r66",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r115",
      "r119",
      "r120",
      "r121",
      "r124",
      "r125",
      "r374",
      "r375",
      "r458",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "DILUTED LOSS PER COMMON SHARE (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Per Common Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r122",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Loss per common share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Unrecognized compensation expense recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r346"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Unrecognized compensation expense, non option"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r346"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Unrecognized compensation expense, stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Stock Options [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS' EQUITY [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r61",
      "r62",
      "r63",
      "r99",
      "r100",
      "r101",
      "r103",
      "r109",
      "r111",
      "r127",
      "r190",
      "r298",
      "r305",
      "r349",
      "r350",
      "r351",
      "r363",
      "r364",
      "r373",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r476",
      "r477",
      "r478",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r377",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair value of financial instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r400",
      "r404"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Payments on finance lease obligations"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r206"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Remaining of 2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r202",
      "r203",
      "r206",
      "r209",
      "r437",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite Lived Intangible Assets By Major Class Axis"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated Aggregate Amortization Expense [Abstract]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r206",
      "r438"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r202",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r206",
      "r437"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "auth_ref": [
      "r83",
      "r213",
      "r219"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "negatedLabel": "Loss on disposal of fixed assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r194",
      "r196",
      "r422",
      "r451"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INTANGIBLE ASSETS [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill, Impaired, Accumulated Impairment Loss [Abstract]",
        "terseLabel": "Goodwill [Abstract]"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r83",
      "r195",
      "r197",
      "r199"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Impairment charges related to goodwill"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r83",
      "r212",
      "r218"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.",
        "label": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r220",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r60",
      "r356",
      "r357",
      "r359",
      "r360",
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Other current and non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "INTANGIBLE ASSETS"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r200",
      "r204"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r64",
      "r150",
      "r391",
      "r394",
      "r459"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r77",
      "r79",
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "verboseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INVENTORIES [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://admabiologics.com/role/InventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r5",
      "r54",
      "r422"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://admabiologics.com/role/InventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets",
      "http://admabiologics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r12",
      "r55",
      "r90",
      "r126",
      "r191",
      "r192",
      "r193",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://admabiologics.com/role/InventoriesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://admabiologics.com/role/InventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r69",
      "r149"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASE OBLIGATIONS [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescriptionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease [Abstract]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescriptionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Payments Under Lease Obligations"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r407"
     ],
     "calculation": {
      "http://admabiologics.com/role/LeaseObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://admabiologics.com/role/LeaseObligationsDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r407"
     ],
     "calculation": {
      "http://admabiologics.com/role/LeaseObligationsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r407"
     ],
     "calculation": {
      "http://admabiologics.com/role/LeaseObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "verboseLabel": "Year ended December 31, 2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r407"
     ],
     "calculation": {
      "http://admabiologics.com/role/LeaseObligationsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r407"
     ],
     "calculation": {
      "http://admabiologics.com/role/LeaseObligationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r407"
     ],
     "calculation": {
      "http://admabiologics.com/role/LeaseObligationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r407"
     ],
     "calculation": {
      "http://admabiologics.com/role/LeaseObligationsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r407"
     ],
     "calculation": {
      "http://admabiologics.com/role/LeaseObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Remainder of 2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r407"
     ],
     "calculation": {
      "http://admabiologics.com/role/LeaseObligationsDetailsCalc2": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Initial term of lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "LEASE OBLIGATIONS"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r39",
      "r96",
      "r164",
      "r189",
      "r240",
      "r241",
      "r242",
      "r245",
      "r246",
      "r247",
      "r249",
      "r251",
      "r253",
      "r254",
      "r368",
      "r369",
      "r370",
      "r382",
      "r420",
      "r421"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "TOTAL LIABILITIES"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r26",
      "r96",
      "r189",
      "r382",
      "r422",
      "r455",
      "r465"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r41",
      "r96",
      "r189",
      "r240",
      "r241",
      "r242",
      "r245",
      "r246",
      "r247",
      "r249",
      "r251",
      "r253",
      "r254",
      "r368",
      "r369",
      "r370",
      "r382",
      "r420",
      "r421",
      "r422"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount": {
     "auth_ref": [
      "r480",
      "r482"
     ],
     "calculation": {
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability from premium deficiency and loss recognition testing on long-duration contract issued by insurance entity. Excludes closed block.",
        "label": "Accrued testing"
       }
      }
     },
     "localname": "LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicenseAndServiceMember": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License Revenue [Member]"
       }
      }
     },
     "localname": "LicenseAndServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r38",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r38",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "LIBOR [Member]"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "DEBT"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r44",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r237",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ManufacturingFacilityMember": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure used in the manufacturing of goods.",
        "label": "Manufacturing and Laboratory Equipment [Member]"
       }
      }
     },
     "localname": "ManufacturingFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r78",
      "r81",
      "r84"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r58",
      "r59",
      "r63",
      "r65",
      "r84",
      "r96",
      "r102",
      "r104",
      "r105",
      "r106",
      "r107",
      "r110",
      "r111",
      "r118",
      "r156",
      "r162",
      "r166",
      "r169",
      "r172",
      "r189",
      "r240",
      "r241",
      "r242",
      "r245",
      "r246",
      "r247",
      "r249",
      "r251",
      "r253",
      "r254",
      "r375",
      "r382",
      "r457",
      "r468"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "NET LOSS",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "International [Member]"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash Financing and Investing Activities [Abstract]"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Other expense, net",
        "verboseLabel": "Interest and other expense, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER INCOME (EXPENSE):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayableAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Notes Payable [Abstract]"
       }
      }
     },
     "localname": "NotesPayableAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment and Computer Software [Member]"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenseMember": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations.",
        "label": "Plasma Center Operating Expenses [Member]"
       }
      }
     },
     "localname": "OperatingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r156",
      "r162",
      "r166",
      "r169",
      "r172"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "LOSS FROM OPERATIONS",
        "verboseLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r399"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "verboseLabel": "Aggregate lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments Under Lease Obligations [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r398"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r398"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://admabiologics.com/role/LeaseObligationsDetailsCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Current portion of lease obligations",
        "negatedLabel": "Current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets",
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r398"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://admabiologics.com/role/LeaseObligationsDetailsCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Lease obligations, net of current portion",
        "terseLabel": "Balance at June 30, 2021"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets",
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r401",
      "r404"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash payments for lease"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r397"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Right to use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r406",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r164",
      "r166",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ORGANIZATION AND BUSINESS [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r3",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "ORGANIZATION AND BUSINESS"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/OrganizationAndBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r40"
     ],
     "calculation": {
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCostAndExpenseOperating": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.",
        "label": "Plasma center operating expenses"
       }
      }
     },
     "localname": "OtherCostAndExpenseOperating",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingExpense": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Expense",
        "negatedLabel": "Other expense"
       }
      }
     },
     "localname": "OtherNonoperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Underwritten Public Offering [Member]"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForRent": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payments to lessor's for use of assets under operating leases.",
        "label": "Payments for Rent",
        "terseLabel": "Rental payment"
       }
      }
     },
     "localname": "PaymentsForRent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment",
        "terseLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r323",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of nonredeemable preferred shares reserved for future issuance.",
        "label": "Preferred Stock, Capital Shares Reserved for Future Issuance",
        "verboseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Abstract]"
       }
      }
     },
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value (in dollars per share)",
        "verboseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://admabiologics.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r19",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock, shares outstanding (in shares)",
        "verboseLabel": "Preferred stock, outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://admabiologics.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r19",
      "r422"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r7",
      "r31",
      "r32"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from issuance of common stock, net of offering expenses",
        "terseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails",
      "http://admabiologics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from sales of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/OrganizationAndBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance or Sale of Equity [Abstract]",
        "terseLabel": "Organization and Business [Abstract]"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/OrganizationAndBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from issuance of note payable"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from the sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r75",
      "r348"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from the exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product Revenue [Member]"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r35",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type Axis"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r222",
      "r489",
      "r490",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "PROPERTY AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r34",
      "r215"
     ],
     "calculation": {
      "http://admabiologics.com/role/PropertyAndEquipmentDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, plant and equipments, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r13",
      "r14",
      "r217",
      "r422",
      "r460",
      "r466"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://admabiologics.com/role/PropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets",
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r13",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r13",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r184",
      "r186",
      "r187",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r318",
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails",
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction, Due from (to) Related Party [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDueFromToRelatedPartyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r412"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Rent expense"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Purchases from Related Party",
        "terseLabel": "Purchased materials amount"
       }
      }
     },
     "localname": "RelatedPartyTransactionPurchasesFromRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r318",
      "r412",
      "r416",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails",
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r410",
      "r411",
      "r413",
      "r417",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r354",
      "r435",
      "r504"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units [Member]",
        "terseLabel": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r23",
      "r305",
      "r352",
      "r422",
      "r464",
      "r479",
      "r481"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Cumulative losses",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets",
      "http://admabiologics.com/role/OrganizationAndBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r99",
      "r100",
      "r101",
      "r103",
      "r109",
      "r111",
      "r190",
      "r349",
      "r350",
      "r351",
      "r363",
      "r364",
      "r373",
      "r476",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r147",
      "r148",
      "r161",
      "r167",
      "r168",
      "r174",
      "r175",
      "r179",
      "r310",
      "r311",
      "r436"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Total revenues",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/DebtDetails",
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r138",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer for specified product or service, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer, Product and Service Benchmark [Member]",
        "terseLabel": "Revenues [Member]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerProductAndServiceBenchmarkMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Net Revenues According to Geographic Area"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SegmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r91",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "REVENUES:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r405",
      "r408"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-to-use assets in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Calculation of Diluted Loss Per Common Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Summary of Outstanding Senior Notes Payable"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r202",
      "r205",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r202",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r208",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r12",
      "r28",
      "r29",
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Components of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r35",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r414",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r156",
      "r159",
      "r165",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r156",
      "r159",
      "r165",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Summarized Financial Information Concerning Reportable Segments"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SegmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r323",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r327",
      "r336",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule of Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r48",
      "r93",
      "r128",
      "r129",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r287",
      "r291",
      "r296",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in restricted stock units (RSUs).",
        "label": "Schedule of Unvested RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Intangible Asset Future Aggregate Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security deposit and initial payment"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r144",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r161",
      "r162",
      "r163",
      "r164",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r172",
      "r179",
      "r224",
      "r225",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEGMENTS [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r156",
      "r160",
      "r166",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r178",
      "r179",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "SEGMENTS"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/Segments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingInformationProfitLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingInformationProfitLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorLongTermNotes": {
     "auth_ref": [
      "r44",
      "r422"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://admabiologics.com/role/DebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders.",
        "label": "Senior notes payable, net of discount",
        "totalLabel": "Senior notes payable"
       }
      }
     },
     "localname": "SeniorLongTermNotes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets",
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Total stock-based compensation expense",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based Compensation [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total stock-based compensation expense, Amount [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period",
        "terseLabel": "Equity incentive plans, term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Restricted stock units vested over a period",
        "terseLabel": "Equity incentive plans, vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Forfeited, Weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Granted, Weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Unvested RSU, Shares [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Unvested, Weighted average grant date fair value, ending balance (in dollars per share)",
        "periodStartLabel": "Unvested, Weighted average grant date fair value, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Unvested RSU, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Vested, Weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Assumptions and Methodology [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Number of restricted stock units granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Number of stock options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options, Vested and Expected to Vest [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "periodEndLabel": "Options outstanding, vested and expected to vest, ending balance (in shares)",
        "periodStartLabel": "Options outstanding, vested and expected to vest, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding, vested and expected to vest, weighted average exercise price, ending balance (in dollars per share)",
        "periodStartLabel": "Options outstanding, vested and expected to vest, weighted average exercise price, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r322",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r323",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r340",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining contractual life of stock options, exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining contractual life of stock options, outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Weighted average remaining contractual life of stock options, expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Public offering price (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r89",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r1",
      "r144",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r161",
      "r162",
      "r163",
      "r164",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r172",
      "r179",
      "r198",
      "r221",
      "r224",
      "r225",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r93",
      "r96",
      "r115",
      "r116",
      "r117",
      "r119",
      "r121",
      "r128",
      "r129",
      "r130",
      "r189",
      "r240",
      "r245",
      "r246",
      "r247",
      "r253",
      "r254",
      "r282",
      "r283",
      "r287",
      "r291",
      "r298",
      "r382",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r50",
      "r61",
      "r62",
      "r63",
      "r99",
      "r100",
      "r101",
      "r103",
      "r109",
      "r111",
      "r127",
      "r190",
      "r298",
      "r305",
      "r349",
      "r350",
      "r351",
      "r363",
      "r364",
      "r373",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r476",
      "r477",
      "r478",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS' OF CHANGES IN STOCKHOLDERS EQUITY [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r127",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r19",
      "r20",
      "r298",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Common stock shares sold during the period (in shares)",
        "terseLabel": "Issuance of common stock, net of offering expenses (in shares)",
        "verboseLabel": "Common stock shares sold under sale agreement (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails",
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails",
      "http://admabiologics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r19",
      "r20",
      "r298",
      "r305",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r19",
      "r20",
      "r298",
      "r305"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Issuance of common stock, net of offering expenses",
        "terseLabel": "Common stock issuable under agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://admabiologics.com/role/OrganizationAndBusinessDetails",
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r50",
      "r298",
      "r305"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r20",
      "r24",
      "r25",
      "r96",
      "r185",
      "r189",
      "r382",
      "r422"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "TOTAL STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets",
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "STOCKHOLDERS' EQUITY",
        "verboseLabel": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets",
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r94",
      "r283",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r305",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r390",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/OrganizationAndBusinessDetails",
      "http://admabiologics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r390",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r390",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/OrganizationAndBusinessDetails",
      "http://admabiologics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r390",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/OrganizationAndBusinessDetails",
      "http://admabiologics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r423",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/OrganizationAndBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/OrganizationAndBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION [Abstract]"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL CASH FLOW INFORMATION [Abstract]"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability for amount due employees, in addition to wages and any other money that employers owe employees, when their employment ends through a layoff or other termination. For example, a company may provide involuntarily terminated employees with a lump sum payment equal to one week's salary for every year of employment.",
        "label": "Supplemental Unemployment Benefits, Severance Benefits",
        "terseLabel": "Accrued severance"
       }
      }
     },
     "localname": "SupplementalUnemploymentBenefitsSeveranceBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails",
      "http://admabiologics.com/role/OrganizationAndBusinessDetails",
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails",
      "http://admabiologics.com/role/SubsequentEventsDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r355",
      "r358"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r131",
      "r132",
      "r133",
      "r134",
      "r141",
      "r142",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrants [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r114",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r113",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2443-110228"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "http://asc.fasb.org/topic&trid=2122478"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124509248&loc=SL117422156-227712"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r505": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r506": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r507": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r508": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r509": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r511": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8,17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "230",
   "URI": "http://asc.fasb.org/topic&trid=2134446"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>75
<FILENAME>0001140361-21-027950-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-21-027950-xbrl.zip
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M=X96^6V(*<)7UDW<^1W<>?G+_P!02P,$%     @ O(@+4Y:*U?$L#P  6-
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MMQORST;%Z"5#9#0)6-54W$$#1%$MJSC"?J.VB'I<XZ2K9\I:+T7^=SO\_#%
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M[E9VO<&X=Q8?]I$',^T-@%Z<9Z\'^.YDV6N)"!]<B&A@T"TO!>2=N NW=('
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MWDNG7_;F<.RR/3BX:QG#&T2YH_>HB-F=X2QR]R@.<5(_1?N,MCA!Q3%_F/K
ML_8Z15ATIU(1=TVCA\J*MJ#&F8'OU('FU]@K(]U1P+$497IP"0C2NVLCNLKV
M6NJ!;)EU6#[T+$WY!L<[>LQ2F#0X<H 4C8&B1>$NYG*%M(:!%B.&JV6_\]81
M&A#S+Z" #R8M1/+KGT!*(O75#QT;D?AG?YE1*#XU2)K6E"K$B;T7D3!_<Y#$
MJI^B"&JLI!3?%(Z.B# 7-^Z=V[*!8<QB(@ZZ]L/=A>@!Z$I#VB&&$,!NA:T/
M@+CC56@99,@SLA_*0G])/9S=B2NO;2) !S[N]^[VS+(CGZ1K8KDN(CQ/GOX
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MJ'A.S4NRU[H"GU_K7Z 0<.V"Q[<(U O.8<_:NR$T-K(Z=;CAJEF7"SR)Y!,
M=F+_S+D'REA!R4;TKG(5;9-PZQRZ!_3="'E[X(.!\H;0%P?4#\1_O/W@?R":
MF21$Z<W-.;ATX!-4>D($MF+L^7T2*VC"0^QTP RQ<*-GWN>/:1B$7O)*5R75
M7 -=$LOHV%J03S>'F5M539V+83Y+-]9[-;%H&L#UMC;2P('=R@5J&P19 8MW
MQU+,<0^=&Q;"JX'M!F2<'1DKS!M*-Q6 .Z8"7CJ;L17Q[?,P:W'G&GK]C))5
M%.&,[G/73U1$<*D@I:L:24!G*X6 ^JB U?5L&(.T!FH5 LY+IKBQ-OD*&>-D
M>_A.YC@+:7N6S'%+YK@E<QR<.<Y[X6>.@[ZQS''-;XYECA,(+LH<URSF8,::
M*BXU=2553#-.]D:<,T9"+(I'OAF4189SOL,:DY/IA?>YDK/[V6Y B:QUL50C
M((R PY1VEBXS-W9P?^QH>04K&!XV+[ *Y?AYV^[#D)R7+V35'*;H+@EI3!2S
M\.IK>J9B.JH\1/8DYS%/(]-L&P.6)Z_1C7M#4'@HTDU.*#(LBW%N?6U&,=Y-
MUS":<6]_7L+>G Y[4[", 5%O?.Y+T)OUBXLEZ&T)>EN"WI:@M_&"WJP?ZI1_
M7L<^D3U\1G>1%]L_X"GRQ7SVR'*(MBOIKUYI%4>_S\^O)Y([[[6(Z/CF)0'O
M$,@<0[9@,<#0XC*NK_177ECEM4W3_%#<@U&GW"\HV^. 6MLKYSQKPAJ'(J13
MHZUK47/FC&U@TY@6!^M2+)2GT&&D$"$Z)J^KFCF]1T!2STG6(7D;]BG7?@2#
M BL=Q]=S@PC_T,^JMP"^$DUXEJ!">O3G%9&^"<O0: WS%B*NW(VC/8ZF45$G
M_5L<% <0X38L?[B.K\+8B_W0BX[[%>ZH- IS\?3=F_F;L/=16WRR2;FWN(ZX
M\X):*?4-)1M_T[9JR>9<R9S=6\=;')>+$;9?9\_5I3_1<^/.4QWC5S1TFZ50
MT1ON!R,@X="F2D%T1Q*,]]6P^.-GL@(\YCAN7]"/P7IHGP-9_[%[F;RU'>I7
MH+ #LZ_S3B7ZRMCI\L7[5P][KQH2TC(9^"]AMM^CB+X]<'EXBO K0NF#]W(3
M>H]A1%J[FZG=&8&&]D*# OVQ^^Y8R#K4XPVJ.##GOJ5QHCB;=6ZPT)1JHA%#
M6:IEV!@-X_F-'<IZ#GR;P?:27=H<9-?R3-96*-C@*"(-00M--JZ(*A]]^( K
M7T:)H8C-:3" U7'E-8[QU?X%4<]+%*R>4>+M4'%0<>%EZ'A!;'54Z"/==,.&
MGG3+N#(ZYK,<>/3T;;P:8]$9MEHMW:/D.?01W$Q'%8L621]PYD7U[^<XS6YQ
M]I\HVR ?[V+Z1O2)4UFHW6QMAUO;<C"77GMRO(EQQ14<S8\@%C5C8X5E#VH7
MQE 'ERX.KE?>R&#B1E/^ 58FIR'&38<O XU1*)U>Q^6]DSOC3$^Y1A]LM.5:
M1IP1<9[3L*.M*1M[G'2,,]$B/Q>CL'MC3T^Y1A][M.5:QIX1<9[3V*.M*1M[
MYNI8*6V1*YQL49CE]);=F8&GCU"CCSIZ0BU#SE@(SVF\T5.3#39S]1I5WW'>
MYM!K05/7.]V)#*MW&14&X#2GCM_1A/7MOGZLSO?MYK;.TOF(I>./I6,/06E.
M_;JM".O6?=U.G>_6S1V3I:,'2R<+2[<>@M*<NG5;$=:MWZPS:+4QL="SN35/
MM8%?^K<QK.;4Q0%=6+J3N7I_@FN2GQ*<&HL7D=<PM->*:OAC]T[EMG>H%XID
M9KW-]BMD5/!'N6Z/'-UJ"==;1WH;1$V*_'Z.XR*E1^Y%#R@Y? _U1CL2U'OK
MU!*\G=YL%;N1>OO4.K'1P 6?Q0&ZEQN'51Q<OCPAFBSK =.?])L$S*_@E&"&
MQ@Z3@BU#RIA(NS?2F%25#4 N>#0.:)+J%0Z:4=_22#-  D-#2B\)EK'#"';N
M#1*]=&*CP5Q]#,4#I.FLU7JU&3HBD-;V=GKT9)BX=W0@E9_U5,L>>>.%>]4R
M,T\6! G4.7K 8Z/.-]%W;> SIT#&AA:L'UMV=AM-V_+L\PHGU4^4KKWTME/Y
MV#V;4_G2Q8<B-J.^SE&'=7K3V1Q/(TNA@L)#$S!=][6)-MV;L&+5=ACUW8EV
MS<PV3&?PJ\TZK?U@XP53A;=)=(H#[Y:H%7]K!M:GU<9][T1-(&:.<W4!ZGMD
MVFB.:0X,-(49]SQ!69BWT5%=0G0VIQ'*ZK%G<OIZ&)G.2BM6Z^@B97](T!)E
MW %!491E.#"+YFP& T7EV%!@^GF]<90B_PH3%P8"#4'&'0:4!%D& 9-(SF8(
M4%*-#0"&7U<<2:7J)1O[ X"&(.,. $J"+ . 221G,P HJ<8&@+X>1U.O $KA
M'1@"M$09>Q6@),HR#)A%<S8#@:)R;"B8N;L1W]5JS%%"LU9# X)RK4O?[XV1
M>]U<60_6H^>:*$SYP--LZIZ>U4YV!; D[AF.DGN]6ET1UJW[>BE9.L"?LI-R
M*IWH4'[IH$,1FDWW[*C!.J<K;\,J'1).V37!*B<Y)E^ZY3!T9M,I6TJP+NG*
M,ZQ*QW93=DFPRDD.KI<N.0R=V73)EA*L2_9U9+-T[#SM/ E6.M%1\M(QAR(T
MFZ[94:/JG'^>>0JJVC'9*/V6R]_\X>[2&S7:W;V.!TC,^MA<$T\=,\2OTC0_
M,#6K8<5D0@?EBH;F;5"HZ.UTORF0<"@+@X+HK$.ZD/NI3T.)5/P91X1-%&:O
M&R\S=O.I7^/0B5&GQK?35R?%QJ')4T<'UGM=2)QD6M>+\#D,4!Q,U7>A^L;L
MN<WZEG[; Y>9]-JF!JS/SM7?"-)T$Z:_724(7<<92LC>>NP^*ZIOC#X+U[?T
MV1ZX.-YG80U8G[7M4>3O49!':+V5ZISRE'Z@V_%VWS3-E_5!<WS'[&M>%(W:
MPT9JW1%ZDCE)68\IG'6RLQ_\"!/"']]G"7U=C_Z 20][R2ZC@MV/[U.THW^Q
MV;U*^4DUJY>PG>\+_%8!T?HVIJGN2<G$SQ_1!_(K@86P;9FN<6/#8N4;5FBJ
M<FJ,K4K9,S".KYJX>IW4B8.[R(MOO0.Z*"9YW872@"I4UT:]JAAU.<2L_4/0
M4*@T>M@^518WP]NR;O\-.926)KWJ7[K"@"I^!1]@F&MG0%LOCS*+O:'3G)/W
MAU]K+Q@XDK_PE.#H"P)N8*5T[:R 73I7MYY#QE.LWC):2]\>,C7R\75E<6,
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M)7A%*]XSVIP_Q SK:J5)/W,K=KAIZM>4N%E[K"MD;\=V *C=R7) "7YS.[U
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MR'/X2ANP]8(6LOBUZ:!XVD(:</("^ LMC@[[VJSS)-[D:UOJEZ3S7.:Z39)
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M4QAWFJX-][KIU,5D\G/G$23T*CK!]KHIM)1\LK['3>/ V8!6ZJT/T&1I^ZM
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MI-G0EC-)[K3[6T9,M/&:/.%E%F:XF"Q8YSM=A<=?@62KY*>6[9O&5-:M)B2
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M[&AI!-7%:MYF="((@T1 3[8%\+H@!^:V#?L1MSBU(;1M&.S36K2GQQMMZ;R
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MNGL6&NGVYJ.!-[O,-'>LYJBIO:!4.4&E4CY;V%1#GPJ%T?O%+G@B%L+,L]S
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M#$8Z-F> 84B_EG48@/1Q&*Q(%FY1*NG8\Q>F<8I/T.2)[&+OYXSZ,D _-+&
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M0\0FL^.,G28A'!Z*11K#0EZD]W"P:=#N,%!H6SW\$ZA4P[[#K?S #A]&>Y*
M$=@#%HWNFM+-49W(TE#H/:?D2<+M+-[@_[^]K^UM'$?6_2O$?ID9(+/8N''O
MQ<$%#*33W;LYM[L3='IG<,Y^.)!E.A9&%CV2G+3WUU^2HF2]D!0IEB3:R8?=
MZ5CU0HE/%8O%(OGC_^&C%+X*F@9^.S3. &Y)A$6P7+@>PC*>$L/B&>(/$7WJ
M XI5_48,/[,,QRWR)I"ELJ9"\J<H%O=82$'<?=S ;_VQ,W1/PF!1VY&K!VR+
MO,0J^QD5O_N 4DG'D/Z/*</FB;()R[:$J1#Y/?AQMZ8F$6VBD-><:>#90]O
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MR\EVY4P%V8\[G#[12.3O*7G)M[JP0$O9@+""TAG*4KFPD-:IT$-;S5E"O*1
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MZ$+K'C&*:-M(^:06,,;\WU M'/:[60)4XT(5&V)\2#"^*D@;Y1=&PS1H%L)
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M?P4@O')98 WUP )A@G/ QHQM>S1$KSKT).H*W33LL"8.W=;LL)18X>G-#/N
MY;T=.H;L0*T C-H!6S2V-2YJUIC6K+$:%3.[8?'-'/O@Y;TYPM[U2)_BV_*V
M/OE-CAJ2\IY&*8G3K5D2B> !L4:)^LHK%<_R+J&6N"NN+@]6Y)"CI"IH/MV'
M* R1K<XSPPW8=DI6/L(J,1DA23(21VM>7RGN2)\[EM4"@!AV6.N2*@GUZ0HJ
MI:@Q$ 5T$:%&NC66V"6"[!&JGOERYYD+$E3W^@V!0C<D =A_5NEIP4?YO+7?
MK/8<8B-')6ZT_65M#;T[-YH,M0T;'?^&UR(NV>V#A%T:FQ-6F1AT8QE/-I%U
M.[>]HT/:'_*-'">[;6_@: D!QPGLYK".:#N$-#:#54_.LK][MGP9=CC0%J^&
MS!&V=G7DVW7[0NH9SK+;>S9L&79[-V)W[_9W-MW^C-,5L>WX=]8=_^YR.OX=
M2,>_@PQ3'J,?^HF:FD"\A(S !9A=>>"ABE*%$ID*CLN=GFFZG1AU5!/B7=H*
MXRHQ\!B""6/4LBW10P,9^L"[Z=C@GE=$,]9=#SH-8PO=^?$N8>86/>,'VD%2
M-]=+5ZOB5-"Y5J!(Q8Y2=ZG3I"T:43,NB\=\;H:3K/"(44;=6XY9F606/271
M)@J#A&WO3?ECZOK8SI)B$M=@W <1W[B"=_N8'#&NUUMG.'V.0LRV\C]':XH<
M#THD]<@A-IW<+?B0LC0J.31"1P,E7'VA5L4P.%Y7>*P($*/PQ<<"8493FN<
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MQ@V9Y#*1,\S1]+;[?#(TIJ\RTRG;,Y38X$+SI:9:S(U_FF.]/4NS]+9IHA/
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M-CI]$,^0>'B%Q..S!H0B]AV(",>(42D7,)C3ZK#'Q>*$"^%?SAH.BD!@(!Q
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M*>&-9C/BD'&BK)))?^/L?- O'NX*N>63F4=Q!R02$&PTK=M>5F7Z0YLQO5G
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M98X-,JCW)"<]:WF;)SP;J!D?B(!GZAOI<H1@>88^)T0%)2I)T=W=%?K\X,D
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MDOC?Z%*E-!N>Y=4T_D_>-_X%43*+DIMTB=[^%WKGMKZ IM?\ QK_VU^NEB8
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M%LBW8OA$S"8,2^3,3P!:!@-UZWL),>/N%@S+,.Q=._K 9[_?5I,KSLNA>\S
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M<M,DHSOFP<0V7\:-?K9/D)SD%Y33 Y'SU3WY2Q8OBN9!@J]$Y/P6%>U^%TW
M\XR2);':8_16O4]&UJHQ$?]L@\N4C83;9MNTM#VV(?:NB8PZNOO8D\O9\[*3
M]8[ZN_7>T6=KK7>T;#]F[^ :U8/>T<HUXMBR%PF&*K7K!P$NRXS8I!XAJQ=)
M;M%K]648M] HTUW3JLN$"'(3<]A9^:HK#?@ M4##NN-I0E-02([-0:$C J?<
M(%.A<U"K^2EN_[UG=QER]8:R19P/CO\;EP=X54'Y(P(QV$R3>EN! );/'7J
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M*/Z >MMV;_VJ7%S-L02O6F<TH]L.=UE,U-_2!Q_J"!F#,1!M8W %;:!HT[&
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M8_+G*>VGS!!MN?* ;Y_S3-$]&-<UQ=FBB%]:YZ33,<P82CJ#+L- .L H.YF
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MPX-P/Y1<K7]#[N/8P6M/N6OBZ0X>)SK5*7Q14\UQ.J"SQ:+<E-62J9M5%0Y
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MZ:_\5^?U=)7UW_XS\TJ^SG;H@1"1YOJ$$0L XDW&3Q-\:&3ZU(&'(,.GU7/
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MKV>,F?O6!B!;@FSBGQ,8BP#A;-3$%1@*(YY&CCDT$7;>?:[KGM0+3))FU++
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MG*8B&@R:(_GLQE=C/AY"R9955&@;48]OZ4MYJLQB,JNL#\D8@Q',0P)$ (]
M0*AK#1,  NKP+1]I>TCK%KWV)!6=!172,4?K.'0> @6JE0H,$C[.DH1.,B%J
M$<YF3E90<:=$'2H/H0'32&]2U.%B^7UM=XCX%=%1%RW/R P^6J-[1*^JM!]I
M@M3/4JC BW,Q!"GN/;BT;:"'.@A[\UU'S^#8&8+;)<AE*7J6V*2HU)6)BCI\
M^4@R37EO9:TAL:SN%,3Y(DK^"T7L_<;QC #33!4C9UW9""F*F:B6U?I=7D<<
MU615)4; MW5!:A-3W:*WXO$5)2_H"TZ+Y\&C8"/9Z "?R^8X8:^VV % SQ4B
M_# F5'?:Q1]?L2'@F=*:.-^5/EIX\^US&%3OZG9XX\0%F$G-.L$Q:7D30-?E
MCQO2'!L=$-1U[>%?4M%1^AJ71A-R3G$#4-?%CQK3' L=#M)UY>:AX6 FVI6R
M\<L8!]TM;@+EJOAQ0WEHH0-"N:K</.@=#)3/5@7*1N*9RT,3U R/HT6VS%:'
M@3<C0< 1?*C&AK V1/(1@]<)7D?=)<)%E/@]0_Z:+N.\2JN(EE=O"T)ZMJ'_
MT@&MB@<$P6(>QP5GH*TFQ+98 H.[3#_50$_1FI[3< YU@<H799:I#C^+B.6;
M[COBX%"JI?TX.*JJ,KA!%0;N;G&ZT('>D%Z.OB[]L0!0:(-),-BMK=VOL'H(
MW\.#$EH[]&9'<T2LS6_+>C+;K[2\1/DBB[?4)+P7Y@"4O1F1@/*PJ<+OHW2-
M.#G/![^WZ='VOSL0E)L[FO.E*RP_=_34XGZ)TWA3;K@"<[\U(C/?G#D5GE&Q
M7/2^R^@PH/Z"*>C/L0A8:T9OXM;D?6M;L__-N]:4B"YOS7[!<-.4#]T<ECD4
MCE':Q..]0N%>2(<,8E@\/+#3!B&SG<F"?]N.K^1,D!4<2"V=*,Q\R 7.BS5T
M9!3>E=8J)8D@<4OY90YZ.GB^:K.; BS!+R Q EO L=N MZL@7"8U ,^W*&L4
MA<78F@)V0 ^(+&7)FO82;7$>#_/N<[_N,NLS7T-"D%PU8[@,V/KSK)5Q#KQK
MG-T/PU&"KTPVN]W7D+ A5\T8&P.VOMW/[FN14R$A61EXA-P89)\P)$2 %38&
MAZR&*:Y-.U\6#*>M@G%=/<6#+!QFW11AX&J.?BVFMZ306J$I68>[\A='S>%Q
M7-@M=P$G2_D#_4G/=1$EBQ]W8DU3]4.YW29-1J7+.%\D."\S1";R4?Y\G>#7
M3CHTYTG#NK*V\EW5/P@?R=(HTL[@044<KDXX\G5:2<,0DE(26W!+N3/'#7WO
M&^7%710O;Q&KMN!KH][@J[O\B)K-@U6J,:D08>RIBQVP-1_N?;G90/>FB=(W
MZ0O1BTQMSM+E=9Q&Z8+\O1IV!7U&N]S^;05H.7OKE%W.[B:G]_(>K>@+5VAY
MDYXMJF-*="N9#I4T]_)BD96D&??;S(SNMM@U)AG/SEG7U$<!MFZ^?F\&2T3[
M\WA)0D^IR.3AFC^1:4Q*U;]Z6SS3'9-KG,'2REC@U&ZDC^$45E>P9[01O6"4
M$%.\ NCWW,)TY#.>=6A4&.X*66LQ@DWG[.HV8.NL8O30NL)-@OU0/N7HCY(&
M$5^J W7NU[-]@81+-SG9;JTF(G.Y5NW)Q#OD)R/A:V;[6-]HK4B%G -_"BJ!
M;CLJK]2[Q#07CUK!/IU8Q9;.&R6Y!]&D-'SEG!],4S<*ABG&#B,"MO78P647
M[CZ!JNL.32@$O]*,[7$W"</C,>3@N160CY3;</>$BHA7P"=1J!+SU5F6T25*
MM8@?CC-2FL:" AJ';V7M1<G)7)],_Z/]+X_D;WE4/<Z><QVS8>GV]2W=TO:"
M= ]1@L[6&:JJ(I]_X(\[<JIVY!%1.>OMILV"H2KW'8%F=96/$%4S18SK@):7
M^P \ML?T[<ZMK'K(3;>2XQW8($X9-JP). 5\A([1="8XV*TBXT_ 9Z..<HO<
M-K.TIFYDOGHH\.)WX)I=4D*P?.>6<-AH5)";/"_1\K+,XG1]A[(8+Q^>21?)
M;]%K]6G0A%J%6D, "_G2]Z5MBPV-(/4-O!JKT0U84_@[NG<97B"TS*])@U"M
MHG1!SZS@S0:GE178<[E0^O:DKIH^%/CIJFZ$/$ EP6^B*$:CX6H6X/2EQI[U
M'G"%\ Y\%JL9+1#-"(S"!;/!$4RK)] =^@?^SI(RZ"[W _VM(QXSFU@4;Q8U
M7^@?3U&._OW_ U!+ P04    " "\B M3$W<:&%// @ @]1T %    &)R:&,Q
M,# R-S<W,5\Q,'$N:'1M['UK=]LXDO;W/6?_ ]>SO=M]#IW@1@)PIWV.XSC=
MGDULC^W,Y?TR!S?:G)9)-RDE\?SZ%R I6;(H6[8EBY*1F4YTH4@ 5<^#JD*A
M\.ZR?]4+OE_ULG+GNRQZZ2];E_W^]<[;M]^^?7OC/GF3%Q=O$0#X;9J5?9$I
ML]5<WTNSW^^YW'TM13FZ_/O4]=]P=37DG+^MOAU=6J9M%]K;PK=___SI3%V:
M*[%]MSWN\?KVA^.MB=_67PXO3<N<($COZVQ]Q>@'WV=="]W V,:;O[\__71[
M>;_]^MM+W_8+D95)7ER)?IIG[D[1-D#;*!Z[R79IU,2-[/LW%_G7!^_#MC$<
MWF=0;E\(<3VZ3R)*636F^<+^!,%M ,=^HLV=<1P^UWY173ZZ=[^8.8C\K?UV
M>*'*!UF_N&F_:_/EQ)W5H"A,IF;]HOEVXB>92%79?GWUU<3%9:K:+[5?3%[8
MORYF7&F_F;C4?%>7[9>Z;R;O6O2G!6(_;!-&O]CNWUR;LGVD[==OW=?NE\#]
M\O8A0E^)T8_<&YGFO?S"#L4;E5]5CP(Q!LWEL['I2&)K]S__X]VE$=K^&]@_
M[_IIOV=VW[VM_VT^_*_M[>!3JDQ6&AWT\YW@?9$+7:3ZPM175'\^Y&IP9;)^
MH HC^O;*09EF%\'!AU_W3I/4:O9%&9R<'MN7)F!O@/O?V*_W\^N;(KVX[ >V
M=5&P';A^C#THV-X>-N?*]$7@>K5M_ABD7W_9VL^SOGWP]KD=L*U U>]^V>J;
M[_VW52^#MZZ?;YN.VI<RUS=!V;_IF5^VI%"_7Q166?6VL@-9[ 1_2JH_/P?#
M]Z#Z\W,U6CK]&J3ZEZT/9R<?4X?5WU*M3;8UO)U.R^N>N-D)LCPS]B?OTN\[
M[L&FJ%]65U<O[05'=L2*5 69N'(_->G.GAU"[8;Q8T]<;%5/^BA4_Y\P)HA(
MF@C!%9$BDI)$((X%UA0@'"5-O[_W3TWRRY:JM,#^KY_?ZD--)[]L60K:D7G>
M,R)+1,]R^6[US[NW$VV:W<3]"J;]CVFI1.\?1A0'F?Y@)3[66H9Y@@2CS'#;
M[DASR3'7"'- 6,2I?F1KM;W[E?W!I18W6[L061S-W=JA6MXV]Z/]I!QKK)%,
M"I% !+@F$ .1:/L!9S&#TL2</=S87??JB2TZL=_F>JI- J%$HH012HEM&7-#
MJ P7F@&0Z#D&</<O:.X6'606[S?[MDV%Z!UFVGS_/W,SWIJ$6JV%]OE8$" %
M([9MC @ =4RDE'.TQN('XIA%D,S=JJ/\O!#:\L;9S97,>W< @2B6+ ;(P(@2
MQ(%0Q B"F !&Q((_/$+_/.L[M;*=WN^)LCQ.SOJY^GWO>UK^\Z0PB;%*KL\N
M16%.!H6ZM#;/J:.GS^9*FJ(53/UB8+'D_IZKBXZZ=TZ*7 ]4?_]&]<S'(K^R
M[^TL6+7J.#D5WS[;)A:IA>=Y_C'-TO+2Z.8G8T,182FD9$FL44PH2H1,8*R-
MBJ"()1#DX:$X%=F%J;K^V3[E:G#5='/WA'Z>JS.-U>'Z<VV*_LU)SX['7J8/
M+$-?N]Y\*4TRZ'U*DW&: #&): (I-8D@26(D9P(RS"A%5KD$?4[#\3]F-/QC
M81]MC:H),9C"3F]]<6&.$]OT\DH,A7YB?VEL+T3O/-_/RXEA1R1.>"QU'#,B
M ;'@H!%5$<%*6W[F#[?>35C'R5Y1N%ZX4:JU;Z(!>Q>%J?4A,T/E&V1I?=,O
M -A!LJ).KZR._+*%+-#>@&C8\V%7=ZL/QJ:>2K^MJ67*W7?.1M\I*^O;WC.H
M;/:=R\+=WHW-]K"U;[Z7%E3UU\XT^66K3*^N>U;EW[V=O$?]N/%G5&_+W';)
MO:M\DIUF<*KQ;*6,YCI3D=/P7:K=^R0U15 ]S[1:TON'_S=).7=_O#O\:/+N
MUQ49#]]93Z3HNYEM=VB_ 3C\W>UWHV;JL4OC;0QN'U%_,WP_?,C;B7&8<UB>
MQ5I+'M)F9,R%:U[]5MN'?;_NI2IMVA#HU'Y;6J6\)8V97=K:;4CR@8Z]>]OZ
MK-$0CYJT>4+?SZ^L952]7ULA#R^9ZLL&RI6!N /,5D=9^DW_F.WBZ$;--T_M
M7S>8>[)_X_)[7O\ 1-:%[U3_P';C#RVD?X TO ,JWFELS>/BS!1?K2%444X3
M"K#67?-I-XFG+/H[;>V_Y9L9'5D:ZX!M0.9D';#,V<1+=1/FDCM8[0 K=439
M2<?=B'F'9<': CVS+Y/9Y^6 92I[NU2;#]=5EA/-7R:+=Q>77H*=QN <UI67
M8(<MJ;E8U,^-:\>L<_BR'I<=-N7OS(U=,^57-.% WKD@%.0+#4*Y_MV&O-T2
M8O]F/[^ZSC/[MJQP>VKZ(LV,/A!%YC)+N@G@J=AW6U]NT=S>J47">DEQPUHE
M'Q#9GM:I6XP4O1.1ZL-L7URG?=';",G=V[?E"'"AF)M+@!YS:R>R]5L=O%]:
M2UTA7.5\YLFQN[/;7 +T2.N"H,8<!NQ%UI%0&QZ3[V(#-=Y>68*]TI'@S022
M.^#M=@( =V-:GN"61G KCW@]/(%Y@EOGJ>QVU>AA27OW8+5K38MD\,<@W,M]
M0_'>-8-F57!X' UZ@V;=Z.YQ\O4&S3I+^C&^N4?RNGGDCY.O-UPV1>Z/"SEX
MN6].*.(Q<O<S]SI+VEMF+Y%O,V%L/7>?93=\R,E]EHOKGX^-K&+)?-$*ZGV
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MXEQ'41Q'!(&$Q5"K2 L*B:8D>3A\M*"\&\I#!-H.4?=,XIG$,\D:,$F$:*P
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MK$:$2D2-2PG52D+E4*HP@<)K(J8Q2'R@=$;4PX!T#->N-;4$3,?#<$HX"IG
M FJOVSLCM;!68\HAH\[0-8^YG:<L,MC#..WQ-O9@[SBP!4O:,P=N,@F%>,52
M"Z&E98H@;H2PSEO=!D@#,!>-G4O:X.GS0J+'"0VZYS$R87M==QVSMO:XU%1@
M:J'A!"/B-.>8 (Z-\@Q):<KT/;RZ#7TSY"V&@63\:1UYAW!5M2M-L;UC1XXL
M7'!DP8 GF5W8"I+I*/S)4GC;NC@SQY7!&@@H.>$I5$!1G89AYU@2#!N[.)-I
ME"S%X-EG$K:"!3N)T4F,/4D,1U*"H!,XU=YR=DI@0U-#%0.*:((;X^J/D1B[
M]KUQ0'N0=U.1.T'2"9*#"A)K)+<XM=8838@,)0T* B&]%B)3RQM=]X\1),^D
MLKD5?-B)C4YL[$EL("A@F NG##($X%02*8FC$G% #&"K+99.AS@"'V?7=; +
MJ[0OK/*8KH.,<&F-@@BCE#"OUACAC!$"2F.X$XV-6[;H65DK%8_W.&(]0)Y6
M>XF.(Y\31][;P$5B"*7BD&OF"+-8.8BM  @IBP3DI!6NSD6&Y+ACQ7:MJ25@
M.FI6U)H2P2Q'U&EBI>3!#: @82AUV*C&E*$V^1 A\^H_[Z6L:SG8LC6U!$Q'
MS9U"8692C*#3BG"EE9 F=10@BZ3"J+&[2.>8ZQBQC6 Z:D9$1J>$<R>9(D0(
M++P5*206B#L59H'MP]45CSK1HREX4AQVB+2]KN5@5__?U?\?85)@>VFQXZ>.
MG_;3+(P19ICFD$@K"<5*4:,M@T  !01!&YOL3S]1L+T<V$F13HKL1XK0%&J1
M(FP%XP1#I;C3U#&7$J4)?8!%T[4</ IN["1*)U'VU7)0,"80H9P 2X!R'*:I
MUBXU L-4N(T5D[VT'!2 ]C!H8:ROA<W!.E'4B:)VBB*.*0%<I1Y(F!CAI&2I
M$\91Y74="AO'JC_&7]M)E:?5<G 1#"2 X;!]"/\^&=@$@R-K0_AP0+92/)OA
M1/7M/E:]52'\N&5_FX*;"7/]]H?8"US#B4FE,\09*80@#*8XA-,H9XU:X6%R
M+B&&/;^@'FAC+Z@#,U8G ;;&2O^Q35IZ6F+D6PUS' 2*.JF%X(98C)5!3$.-
M+1$$$];8T/XPJ:(0]R!O83Y:)T(Z$?*L18C%E#F,.4NM(!I3*1""2A'*=9BY
MTYA.=_@45\)%#WM#(!6HDRF=3.EDRO;WODG331BZWJJ4.6X< 1AR(1SP,H5@
M0_@]C?S:X.O&C/48!3VO.ST9L;(.[EOH[NYD4R>;MJ'O&(L52+5$"EBB@1'*
M<@F01L*IE)M&+_B6<I4A[%&!>Q0_ YVET6$]^_O?_\W_*#V5U'XO$C?4*/E;
M_<L2,/.7-6U5^W/"CG[R&!B,3[[80*QAIWWCZ>7-<)2,KVWR\7ID;2(')KG*
MOB;O_)77>?)Z8*R9N98]QD'S6Q^RN+@IOY9^@)'V$(U4$3Z7$"[HI5A^7*J3
M-UG_[L?DKQ^S&YLG%_9+\F%X(P=_+;>29__RT(?!KYTLH[:*112L-T,I"%T*
M$MV7N:=0[<9Q7=_=@XTIPK892FB,HC2'#W;A,W[XZW?NOEX=)5RQKO1!$98'
M\$%2N':2*"$/(W-:A)<6+67%6]'6"&!FF#>C?\W'!BO_)-M94^6.I-I,4EI/
M;B9];[F9#O_M6<J^\/]Q.-ZN,*FK[__Y%XX@^^EIT-6^DC@ZS6MKFM?VI&21
M#O T"+DCCFT?H3?#R6#<$4=[EM(BXBAC9QUUM&<I+:*.,^LRG76RHT5+:0]U
M%-[OIT$;^]*>'S;*:G\YSV=6QSCG \>O0]&:O.<C*TXYLM*3O5?-?BNAV6+I
M&,*<<86(U(X;@* VB DG5*KQ4E0-"H@.,L^=BAZ&O(=I"[O(MH)A.OY^.,.T
M(0:_?SGPS? Z2L,_'&H+"")$$B!1R@Q+@4:X(;R^#4&P5CB>]D0; _&M8*I.
M!G0R8 ,9X*!+'7*0,4!2YS4 +B6T0&BE)+/+U4T/D@&[3BE& O0$P#W&.JG0
M285.*C1N:Y.D8,JET X #2 F*7="0J\M8 MBJ0%8[J[S(+&P^Z1@E)(>@VF/
M/CF3X1XDMR#[MQ,@3U2 ;"0_./06A0U=^0E%6A$O1; 5Q$+M[+WR8QNJ0=J#
M O<@Z69J[<[9NF./:B2M$Q7FO/DK9H/>#B_K6BC0VNCP/.(.O6U4T3NJVRW5
MM6TPI03.*8NTHZDB@G-.'$1,(&_V8IH:MESW @ LNS\!@/?CHFMU/\N.BUNP
MI&?.Q48[QJ#G7*P=<=1RIH%5Q!C@@*9I0V'MX[AXUTZVE'D[FO".N=NUII:
MZ;DS-U"$I=P:Y2QQSBA%TQ2F5C  M<8-,UD?Q]S=9*N.E3M6W@LK4T.E)H(2
M&AK\22ZXPEI1AZ$&.D7+^3"+K-R=M6WQ2QTN"? 8Q\ _(\?]L\CY>^Q<>6DD
M!8A1:R0BRBE!+"-,>CF$$'"FH9W85MT,:Z4$AJ'RB/8 :.$0P5;P4\?^'?L_
M:"0HI4(SB#!"&!)JC.144^6X]']K0!OZD1[ R;C(_3W6QB;TK>"DCO$[QG\0
MXS,J..!,<$PLL5(K2+S)XU)"*!98-W35:I=?DG,O!6 /XQ9V.6\%:W62H),$
M#Y($)'@Y.+1*64N@1$H9 :"$3D)K&!>=$[/==-DQ?<?TCV9Z#31T$ AEM"+(
M4ND/4R&=8Y(IPTW#X,SMNSOC$4YZ '=)>D>;I/?ZJQWI+(\>S^CJ3(:%[_WP
MCLT6BK$VRJI#^"'K09J*@DQ-.B&#B"&4: DI8<(J$,:#H]3)5 +K8!M]DK G
MZ-,*W72<^9PX,ZH*JQB36<N<<,QH#8CVUH+A2J94<<*EUG!UE+3+2>SX\?!+
M>C+\Z B6VF&4 HT)U48*#E+.2:JIX?[(;+L7C_4@:^'@CHY)6["D)\.DFBO+
M44C\30V!&DMI@3>RJ3>ZI1!8=0ZV%E!;QY3/BRF!\98D5FD*%"'0*JFYL:E"
M0!#&;4/_JQTXP)[>Z7>(;+]'#G_?L4/LPHZ3_C!O@?_KD7!IHRQ;W9?SV (#
MN]W0/5+T\/6T[:7%CI\Z?MJN5N)/@/.!'M[8M_X8J'?<-(!"E*:8.DL(5=)!
M":@%J>/"ZQ.D\YT=+P=V4J23(ON1(AS+E MB*)228"H$%,RDC@*K(&:$ML[C
MUTF43J)T$F4O$F5%K[_[1(K&$"CEQ4=*4L)PZ.RGF#(0N/#MYJG NV_X!T4/
M$=I#N(7U0-MGSWNPWX(F@)THZD311J)(>IF#F!'"IH0(ZX2!FA*6IM(X2OAJ
M&ZF3*@>3*D\ON;$VT^6='.GK!PYT"=/(\W8,=&FA@&VCC#S _!4'E0%:0@A%
MR'-4G *-*&7: >5,<P+V81(;>=K#7@QBV,*:RS;:8QW/'3PF?%]#8DRII4 :
M;30C3F-!TY1 !P352C/>F%=\F!IGWDMQ"YN7=_S6@B4=#[]9J3%4&&.*'8$I
MDFEH94I<RKRJ*F5C>N+ADQ(Q!SW$>8_C[L1KV9I: J8]<^ F,SRDY QHB+%D
ME$B'I)'6I$QX@]I!3!M;%+;!I8<X[HD4]A@_RF.PO3ZZCEE;>UR&XGN#_7^X
ML$1 *[C0C@"NK/+:(%D>P[6U3$3A;3Q,>RE_6B?>(=(1#Y9YV-YY&4<6 3@R
M__Z33!AL!<ET%/YD*;QM[8<=8M!HK13CBFB3*L4MTRA%D''F=&,73C(-?*48
M//ODP%:P8"<Q.HFQKX;E"'!LH"(V=01SI807 RE-K24&0-KH6WN,Q-AYZ2_T
M]@9H8<>,5G!F)T@Z0;*O.6,B)<Y)1+4@A#DG!,*6$V8T0A+JQCECCQ$DSZ0\
MN15\V(F-3FSL26RD(*4*:&J  $0:I@AB*906:ZJYT8T)+'-BH],ACL"=V;4/
M;)$4;*.H:V/[0.JHQ008'6JD4F25M$)*QQ2B5N+FR:E;=*:LE65'>FG:0D'6
M1M6EX\P6<N:#FJX8E1I*H$Z!,@2)5!AL+, I0@Y1)5;K#,_>R]GQ8PN6]&3X
M$3J)F5/,I!@2G*9*24:]5N\$"@. &CN3M<F'F/80/<KTH(Y).R9]*)-*(CD1
MJ:0NE812PH%E"F(A'2#.R,:LH,X_US%E&\'T9)B240>=\*Q)M"0@)5(Y9T&*
ME,(2:M4X-&?;WJ^G=_H=(E^O:Q^XKPKCKI;_.&OY#Y\-V%Y:[/BIXZ?]-/Y2
MEC".()%:&&)3S U/>6I2$3I@<+QKI_83L #:RX&=%.FDR'ZD".0L%<QA)Q C
M%F!N4>HX%9)+99S>V)G0M0]L!S=V$J63*'OJV84PQ$R!5"AIB-=-1!I*_#&S
M!',N5&//KIW[)[-'U1J#'F2\!P1\#B+F'NRWH#2Y$T6=*-I(%.'42,P 32%S
MA&,CN/^3:X%39X471YMZ93NI\J3:!RZ!@00P-.YUMU[?6J/!OT\&-L'@R/H,
M/AR0K13/9CA1?;N/56]5"#]NV>O%R+[1PE I&E0^Q3%%A$DK!6%(*8:! (;(
MQNR1PR17QA:&HB?X$8CB/;-.Q^./89;_V":Y')TL^%;O&H!52++&TB*O:5$@
M4DM-*JQ#DAG&&YO([\DI?1RM%3LYT,F!)R '4.I9VWG6Q\00!IE$RFI%#66.
M2\D:$V,.GTB*.>P!"'JI2#O)T$F&3C*LZ9CYMHH H$L%QY(P0*CV"H.V1A-!
MN%$$@#55A-V[AS$@/8A%C[.G(QR.QPG<"9$-T= ^(;*!#&$,2ZV%,H1*(K#D
M4 M@K0002^%(8]>;+=6:IUX B!YI8\KMMGFFT1<[^_O?_\W_*#T=U'XO$*M&
MR=_J7Y: F;^L::O:RW,[^NF[7SY>V\1CV,MX.;CS>_(K']L\D2/_]2#)_%6?
M1K+O=SP:AZ+Q\;7-;<"YL8.B\>4@AB;\B6$2EPWD0&?^\KPZ0O(7:ZPI>=R^
M=-_*4<33]=0)/![>>E2!FENXPE7\TN.E+W-/C6=7[]^\EY_LRY&5?Y[Z_\PS
MT:JE+C[F8A(.P^(Y<PYEY[GDQ,F;K'_W8_+7C]F-A_&%_9)\&-[(P5]_2N+O
M>?8O3SH\+#I^_F*#F C$Y+FD7UT4'CC][IX5^$-TP5=]WZYN_3TG*NS^1#J_
MIQ]E_XN\R^^!T**(^?EZ5#VH '/DA01$?BCY!8"9>"N_ S\EU^7>8B2D"G\4
M0J\Q,E+]5$?V=YY(5NVOOHJE/?UFI0G 6MA4Y#6/XWY@7>V9(LJJ\+ED_/BY
MV%(AT!Z-Y((T%S<WM]A[9-F2W&@(ULRN#I*O 1+-]%:25K#T,NT7\+-,KD=!
MAO_E_.+L]7]]]\NY9_NOB\PY![J_R5\:Y?"]\:;%;37)ND8!L/#-_.?ZI^+%
MQ><Z93P:6\M'Q0+^"I25*Z@?43_/GU<KI,H\\RM_,OLGGYZ].TU>GE^^O?SU
M_-55+SF_>/4B.;TX2ZY^?WEU?G9^^N'\]=6C96WCJUY=>FQ?7+T^2_Q?5Y=O
MS\]./_H/5Q_]_[Q[??'Q*KE\\_/_.CDY'>CKX>CDQ,MK&36&5Z=7O[UY>_F/
M*T\Z]=\#583?DOCC=A;Y_>\#.3'^Q#4_;.>!#SET'B88=D9?2:,PTVX<U_7=
M/=K#E/FV&=5M#&@W1W)W$;Y[^.MW'DE<G;"Q8EWI@X+=#Z#@J^QK\LY_?YTG
MK[V@-M/8]F'TY6WC:%\)"QUI;XVTT;9(._&&);Q/\7@:Y-V1S'9))N;K/&F*
MV9= W&F"5J,".M45DS<?+M\EE^]??SC]>'[Q:W+ZZN/Y'^<?O:K[XSY<=H?A
MH=4<LB?G:QMWW\'\X.*@,$)8ND;?S8VE!DSCEVTJW#^RA/D=)!VW(7S2GJ3X
M%!,F*( J99@X*111,O3\HE@*)&U#?0X$L$R*A]M.BL>LASCM(4+:%T5YHE4U
MG3SHY$%='E!*M E-BF1*20J(4EI+:96QS"C!&T.H<%=%,ECT",(]C%J8F?VL
MZF&B^K1C':G6I#X9#Y.1]82FL[Y-!J7R%+X-?VN97R>3$,_-!LGPUH[D.(2"
M V%\SL:9S;=J;76]VS8BH$U[MSTQ,'74U%%39R'/I#^BI?0_L[=>XF=QZ$@B
M!R:1-T._WG]U0VI;,V#DJ-3?;VN_=6H['9C3&JW5=&&. 0=::V-23:!52EI.
M$6>.0HNYH9O:Q@^J$^]12GLI0D], ^YF6K5TM4^+A;5DF $%%!26I$X()1A)
MJ=!4&D!LNJDY^Q 6AKV4D1X1X+FP\-,Q3J?J2?"2))X&39;?#G/9#]G%+OOJ
M;5"9YW;< L=^"V58&P75CJ31KS(;!!JY')Q%"HGUB)?N-!)'W;T&*4J1M((H
M3K"27#JD#!<4:<2=W%BE>)1[C?$>;&.Q<QNUAXZ]CH&]4L]#P*16IJ'5'(8*
M"2D UEJ"U*$FC7V7WNL>A4]K:-OS<DG$4K,3)8O*H=E,U,.?]9TILQ%YM<V4
M:1Z]6W=$&*J1\L*,(D0,@4)C@D JB'0$6+(71P3L49Z&?]LGT5K!#AWW=MS;
MS+TI T8Z#JWVO"HM%9 3[2R#5%FF],8A]8=Q+Q:H!^FSX=XGZ(.HN[B"_\%8
M-0X.">UA-SZ\4M)"V=5& ;4C*50GCDMWYDGCK*2,]R-[DTUN:@+)&8&,<(08
M3 @3C*>2FI1++#@V2+I]J!,"<"^.6IC7TT:-H6.MHV$MB)71S%$I(/'*.2>*
M"(H)3AU.*6GL8K3MLYXSTF.XA0'#(SO.#^=Y6#SI^YD.#4R2D?UL!Q-[^+.^
M,V$VHK+69 -+<R,7Y-O;@M8^%*16;Y]O*;,4"X E)51#J;VL(XI1J0!SVNXW
M= %[!++VB;BN2J#C]R?"[UQ(82 B4FI D+4"6Z&038D#G%$+]AI+Z?C]F50!
MO+J6@T\V7TCMCW&^F!;:SZ3*^EV:_Q,SS)X8F#IJZJBILVR;+%L='2=Y*.^R
MV>?0">SP4KS3;G?(K0>H;3T?Z)&5N3VSQ?^>#RJR^S"ENOK46V,@$!H+A0&Q
M3 NH">.$6252HG%#CO .HNN@AP'S_W:5[QW7MVJU3Y7KA>*.:$8=99AHHSDE
M K@T-8([BQ#;AZ<>]P A/42>6E2^,VR7-9_SP6=_U7#D#=?#R[X6"K@V2K']
MB:H:=<R-2R(&AHD&FF/B !228:PQ-0@R9ES#Q-H=:":\!U/2@VWLR7/,ZD?'
M@D?!@E*H%!*@/<]A(IU1G(%4*>6@\;H#WKBBX&$UP *G/;^,9\F!S\M!\GYD
M;V5F$OLUI)+:PND]'%_;4:(GHY%_0FLJ#CL#:B-Z.P(#JB3&,^NL)SWSNJ#)
MTX&Y# 2Y5'WEJ%^2PYPI;8DB0(H4,F@,DBG5C,O]]$M(*>UAT<4*.S'0JM4^
M'S&@&?,Z$P-"0D.$9HJBE"GD(#7&0K67>H=0ZR!ZWFKJQ,#AM:G=MXX*%<%U
M5:DM*E(+!6 ;I=Q.TIR6Y5A%*/=*+N6-.FPP$DI0PE+&!7/<88"-<,ZJO11&
M0$*\"M-"]>68=92.#X^+#YT @$NF1&H(LD"F+G0C%TPJIHEL\'ON0(/@N ?%
M479'.4HEH04Y*;?RKDM(Z4RJ?8:FWQ<D5R^S<)RGAG$$A2# 8&F%532TGQ1
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MDO&U37)/-FU6F[JXTV84=["XTPH16A+B&T^'5YX$+]U#9&C*!),(,RZ-(E@
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MB,&*0"X458H)B+WRL@]_"$Q[/&VA .Q:VG?,_J2875H"A.&.*,V(IE8Y)IE
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MOP,_)=?EWJ*Q57%+(3@;&:GZJ8[L[SR1K-I??15+>_K-2A. M;"IR$X>Q_W
MG2'Y+DJJ\+ED^_BYV%(ASAZ-Y((T%S<WM]A[)-F2:&@P*6=7![G7 (EF>BM)
M*QM[*M=^ 3_+Y'H4)/A?SB_.7O_7=[^<>\[^NLB<<Z#[F_RE40K?:Q4O;JM)
MG#4*@(5OYC_7/Q4O+C[7*>/;V.HE\9M>DGNKU#7@;OG86,!F@<!R/0]^[_IO
M6GQ/@[Q*5NRYV/)].VXRZVL(D87.4$S".'U[]?'TX^MWKR\^7GE"^E\G)Z<#
M?3T<G9S\$FC$8Z*%3/98?\T28[UH9MP#X.7T[-UI\O+\\NWEK^>OKGK)^<6K
M%\GIQ5ER]?O+J_.S\],/YZ^OFK6H ZSVXO+CZZODXV7R_>\7I[^?G7]\??9#
M\NK2"YV+J]=GX:^KR[?G9YZ@SI(I@24S"MNL^.K!NM2W94YY:2%D'G/Z/P1@
MG^4HDX.:+A#Q,A[)01XTZ/#]P'I()O<>^W63P2L)_F5ZP6*X''V2@^Q?L5+]
MU51U\Q^\I?!^Y%6[P3A^O'1O*EWN:JK*G66Y[@_SR<A^]"M[V9\VM X?_\DY
M1D(2)(FUQ  GT]0 )0W6*%62NP>D]UAO,]P&@AQ-2ILC&TRL.1V7KZ#,2HBL
M$MY&(4QS99BATG^G(.,8DVA'M0DUE5%3(F/^O/,_E5N,()]!<O4VUX -^N[A
M$KFF0KW-\O''HLG&NL)Y3BEYQ$'7)+"_I0_=*[2C]K-H\'GKH4E0;4'P/918
MX(MOJ%%-&Y&3\;!Y(TWG48-&<JB=SG%CO,98/1Q%LO\Q\2: '?6S>.7EAU]/
M+\[_O]./YY<7\2Q[^?O5^<7KJZL%QEK:ZGUN@7N"-+._9Z=!9-8Z1VZ)7=$Z
M[(I;*<IV !V\#G3(H:'39""5 $MV#3&R#L3HH2&V+WJBZT GK:!3P<5D^6U?
MWOTXA^XF"W,N8(KQ"T9K]LCHD_H>])+P_S_L4]X6ED'F%_$IT]Z^/1_H%\GW
M__D7CA#X*?P8_X0_)<-1'!A1_O*J< *6/_Z09'EP =J!.1D/3T( -\R8"LW!
M97^>\E4VO+V6?DG:3N+9E)3^Q,18XS\'W^!XF/AM3IS4XTD82=4+3KL_[3AV
M _#/-O:S[0]OP\?\UH9WC.\2CX/\1OK38I1]#BT$JBT%EW)<^7ADY3@HI\$W
MF=W<3 9#8UVFL_#5K2>=&'Z6XV24Y7_&N[)!2"<-)!7>.O0/&<U?H/WY*K/!
M],))GGAJ".FI^8ODX[6=WWH-9I#]E"=C.?IDPW[+ER>WP]M)O^@,%2H^^A-C
MBX7:DP"DT? F]%KW/WFBRLQ$]O/DR_4PR2=A=%?1$],CH3@CHW^VN#FIMJGO
MPO*B"1W0&>Z]D7>)FKXEG]S>>LT^O"1L[R9BI)^$A%N_IA>[YL=T'7YDST5:
ML76@P[<KK1;TLP/+KBGDG]_!SM<A!O%<6$6LY1$ 3_!D']Y:;SOY=XRO1\/)
MI^LD&\=#H]^_.QE^&7A!GT]4GIG,/]1?56D#[^:/W[=O7\WI!/,TOWC]5"D(
MIV;UQ%?169@GO]KAZ%,FE_6,VD75 UXTKR?Y(N.I?A//PN3O_C<YNDL0@"RH
M#OZZK)\%3U0\]J7^GTF69Y& BJ!D>* 'R3B<T"-Y>Y>\G.3>I,SS.%!BNJB7
M'U_^/MU*/%Q?OG^5O(]J1J4GQ57XP[9ZY#Q@WL\I.KE7 $:WI2G[P^PU[U]5
M*I:'5\_OP"L%?F')EVQ\/5WJZ:^]2O4JOYHNS>_K[^&43WL1!%'QF-MUJ4J8
MJ;HB_0GOR>#[FCXW?4_\:?9LEP0P]$+ 6E_/GA3N?'-V>M+/=!';?7G^Q_FO
MI^\BRB^DRDY^>UGJ6)_Z0S7Q)GOH[F0F>ISWYH$4[O"R:.YIA2[G@5[$]PON
MGU,)*RS?)?UAH33Z-[ST?R8?Y'@XZ"5OWL[O+_STIKQGNKTF"'P,C%2\=T:'
M 0C)M?0K&]G/0<_K![7)#B(@EO2ZZVQD3D(4_"Z*H;"+VNKMZ,425V3AKA7J
M8CZ<C+2M8..%2[]43E5%OI%BOM&IOP@&7[J"AE]-GU#"Q0N WX/N>%:HUT%5
MK@\AQ- 9IU/H""% ( 68!XZSQDE*#'CLY Q23P$YOWAS3Q+(26YU2 3YXK76
MW Z^^R6ZI9820!J@XJ:;"J01A&90S_.Q_.2_\70M;T.[,:_=UBR*L.5Y)%34
M58K/X60<4?[[BZL7O8> VI/UVY*J[X=Z#<I4I<!)R%/().$L%<AQK1G #AEJ
MA-P3E,=?ALLP]D KQ( _/B+/%B#TT"D9MR# "C[)F^'01.B>C2:?DE-SDPVR
M?%S(OSG6\T":LJ1_0]^+KWDL1(Z:L?RUE_]R9K0F)823T]O;?C AX_,KMGX[
M>_:M-TR#[/#OFZ)_YT8-!&LI(^V,3^P"/FN%*"#J#)LG:=C M5S@\-GXP.%:
M3G!(GI9M\W&F=L73X&$G\6EY7KTO--'ZL8L)22$2#EE*&'$<I(!;1X5T#FOZ
MV-:+=-UC]WID[?+!&W3CZ5D[5:,3V>_/SN20A*DGHY%'D]=-"W^I+8[?F2O6
M_R(_RZP?HE@_)M]G/TSU]N_/"U?AKY6V?A[TUL]VX)6F7O+;Q"/PAUXX\VO?
M)XOW5&=N>&9UZ,Y+D7+QT859*%:-WMGW(P\[;]+Y]PY#1NGYG+=6WTW?]/Z\
M>D\ 1SY,_AQXJ]8;.--'+-UZ5CAH:X\X.ZL]9% LJ0!J3;M/1E;;Z%FN:P_!
M^'HG[Q(1;2\Q _= VSK@D]RC/RJBIY-/DT4[,=SZDT>'Q\?IU:O7%^=_/ 0?
M47N"WFS,^R/IF>A_>SW(&WVFQ)/'P8/!?=Y[[*9/;T=9/X&-VW;9R-M139N_
MU..A9\9RP_ZN>3AX"'@05.;C][_9X!@?>]OHY2*IS4BR-$SS57N4>C(.XZYO
M8U)*\!.H?M!/ U][FSBHA?7W^8N\NAGRFL?9)SLC[=]>YJ?S#HX8%O :<!Q1
M63T_#R^H/>^%QU\2LB:B=/*_!3=,G2\7;.**2>^UH>>P5/9-SINLS2IFXA\7
M7 ]#SQ)> G_V&G,^%\+0_3+^X:_U&RZ]1M[:M?Z@J0T,#[B, 91@N(8 0?"S
MJ+N3:F7^HA AL?FD/Y[=U;R- (O;,*@ESU_, Z NWW-K_XSP+(TTK_K?9K<V
M9 '$,L'YN,\X^G2BRR4OV#F >KJZ\$7%%=I_B-GH10I[V-' %.$G99-)7C2B
MOKV^R[WL"#I%$6ORF Z@T_&"8>C'53@D0L!H.5@S#2Q%V\A?TQ _FM][4S!I
MYUK%6H%B^&PBQ7"M4#'<<JRX,U+:8J2L%:F$SR94"=>*5<(M!RL/;:2<1C]C
M],UC$#0E!.?/[>!0]KK_G^'XT/(V%%J$._[C&];,/XK+7Q57URP8#@6AG#EN
M4T@,$=QAY3\18SD$K&F:V:I:X!,Z-5O2%2,]\(OEFKS$0[B?!5=\5K7JNF]G
M]1K%6M7AZ?B5'(U"(L,?LC^ICVY+.=;6:493QHF%E&,K& AUB=P"Z1JG%FUI
MLP2]6&X#."^%RHT'5-[;J_-%\E(&]6!R.VP.(I2V7%!6_MO&F>>E+A8?Y_7,
MX,L,T82\#N"*BNJ_E]IYR8U>1[GMQQQM60^)+;U^JIN6&>#5:SV1QT_3_N.]
MIOL7 "('\E-\9\U$55Z#\SLJ%<:H#WL8]98@U;L'!*$0<1(4J\)&B=KR%P_Y
MH+N%C)@RL2<$!"=E''*ZNR(J&O)L>L%6G"TJ%"M.PJL"4/VM86MN.!EYU>U_
M)G(T#HDS+G)RU.B+5!I_W;4WS>IOC9L8#^?!$-<1-CI[?517;:RTFQ<-P>X(
M8WR"<IJ-BXT-;*&<CJ17"Z?61,B@*K&NK"?<(NI9]M#XUOH_QO),FX\]88?7
MA%2@HI5>HF:TF7N0!Q,\6!/#T1RQ17-@HH/Z?@\9S>]_R2(,9D1-.>\MF"TC
M>7-[,KE=HC6/>7L[]E9B# ;XA\SAMLQY6C*9YG3Y0%658N[U\%MY%U.[!D5D
MLPH6S6;0#&\K=,EQE3,U,])*0BDW/V?K]5;']6I)<S6[2-]I_^1H0 43R3-R
M9<F.Y)<D8,P?0OUH%]7@.K+EC$$7%I_EUW;.W$G&\D^/73O^$F*7<TI(\$6=
M9%]/KC/C3]$?2Z^8DDIQEQJ4$H:<5 ZF7A)2*%,%)/GNET =@U*I6 [K-I:7
MQ&.L],"]"IL,(SK?S[9XZ3[(+^^J_7T<OBGWL>RTDXQ(@S2B5J?$\E1Q:&'*
M('5&$Z'02J?=/S\$:C_]FN7_?">_9C>3FW<VELLN.>G,9'3CGW4=)G8N%FHD
M\9>"CH;>A!P7CK;^T#_;<_4HR+)(SR'38BSC[YZ+O.@;%Q,B/9'6<5K%,F?.
MA7FVF.+^_A3#FD0+WM'!,/AD;B*A9.5+@_E9$R%34N]57!#\B9X\/*'[VV6>
M3T9QAF7D@+JDJF1NQ0D>7,'!TO3L8"T'KT')1[%NO.3E)2[JE;:RA^6+Y$V0
M8/Y&+]V\ 'J J GKO2EYMIX/Z3=>";SR$,W+ W+JZ2A< 7KH :C'O2!\ []'
M ?\MV9L/O=(7_$X>9C/HS\2XV;T-OU9.&#RVI+#EHHZ&KS:"XUK98PC,X-A8
M$?VP[375-F^V';16_!G!A>T\$#M-Y??K+WV]ZC5T?!2]A]X5Q]R]@GZC>\4V
M^U>TM8/%QCTLVMO%HJF/Q;<[6>RRE\7]_2J^T;'B,0L>#;]4+7[67WSS2S8M
MU']0<7XCVV[67N# :[_82;.!<E-KT-)R96I3!Y1[CMKM'K]KI>(@O"4O;CK%
MXEX.[;-)5/ 'P:H+QG\(TA6FP610QNEB,JF7MD.=10,BAO1"9#PD!=LOP3<2
M8H2%V1%]5&7$/#BI^E5IVTJ'P-1C4<:Q^U)YL]Y4$>[X=&_@YQ-]7?.=>'-S
M&%V _FG]+-IJA>E9-&0HO9!!](_O:HX\ZSP4BKJW)C_@7-YTD1TQ"5[%!@?A
M/9[$V0KG/4??MM]*YXX'UU 5.>O&;R;$FOU_!^,BK]>_<3XUIC"<(UK\5[?>
M'HLQ6S<#VV#.XHRV:+"$)\5HI:;USQO?9;@ZN@V_^+,S_&_T2<TLPGER\79S
M//>GV[[\X_SL!(K$O\38FTPGW^?6)A=#OS4(?EA(CJ\;VEDP92M+N;)BB\U6
M+[PKUG)3.$9CE+Z8EF%F\87)V/-B00ZE']*O;,Y?7)*-F?I.YY,5%A.F:_ZY
M%_7 _9(K>][5&-VT*CAVHP^K<#S*19=A-M*3F^ UT7%AG^3(5(;\-.U]CLSM
MYV'_LWWA:3;KEXD>E4?"PW!@ _9"7M#,*1&(*_$KLS%O:A"L^ B<P7SB5%$$
M6:,;/9ST3>$8D#/GC32?[2CX5>,HDN0>[_YT[9YD"]?ZM!_>0L*4'45?U$#;
M,IFA?*\*CMV1+K!DO'2Y"^+"B]I*8B]@K>32WM0=6,=@2$7H9X-8[#G#9GQ@
MTY,CD57)0)4 B0ZEP=TJ,1#=9$L)&'.$$WQ6\U 8V5O_CD#%DYM8(>MAWA_F
MP7?CX:BCP\;>EL4N1<0- 4"F14]S,;AOA-BJ0-0'&]C)FM=R%#*#\E-=OMB:
MLYA)5G=#&LAY:I2 2#/""90RQ5@;BAER#/'&PH@'!*,61E1].RJ%&7NQW(JW
MBD1Y72R/QT6O[,E8.O,+;]8\J.M.RM"QU+.WJJH>%G%:D])3VHBI^=5)%"3A
MH"I(JO6-7-D)TK\Z-)><5D''D(CY[TGE,IT_3D,(:!C"%&IV3$6S:"KY8P98
M*&T*V3HQI#B5DJ6[<T'N+-WMCU15U9,448"@64;WZ$RF5.E.'F!^M[;@A2BW
MIQ)ZYVY M%:",#IXFXQ]Y2:@M5*=T,%3G0Z9[X+62G]"Z:%AMC>:6BL?"+'C
MM)3J1W70Y,(I9&K1D4K5K$[?VXGJ>STW'OS9YZ"T!H4MAFZ=#5IUJ6GXLV:J
ME06#9C1/[)4AD"@Y^#/Q>JW75V<U8?X)T5-0Q.UU66EK8T5@D?I:)3$4Q6KQ
M"!B-@M99]!Z.IU25W5I3YZNUEBN,RF09C,Y<P'ILLN75PEZIF96YKWZIQJN@
M5<)OT_EIOV9Y5+_S\5#_&:KJRBATL)7B@3T/@1"B&A<Q\"+!/_2PGM@JCAZ4
MO1"Q#P^K$!.R9(NM^:,TZN%Z<8.!C)0_3(L2TH4MS P(EWT-^:X>E9_DS,(M
MMAQ3[V<WA</8X[%*!IX^,S87;X1$+2/" [J(>DYI8<$T['LL#Z(.F"^'VNO6
MDC=J^L,B ;H6K[LG1;I&"K7(ZU1/G].6;X,V&K2W2 5%!GJ =YF'77]=/Z;D
METI2/4E@YR)IK10\Q)^-R%XK6HH.'BT]J!JP5F04@T/#;&_]Z=8*M6)XG&K
M62$Y8Q98]K7*@BE**+Z1]!IU!+/* @\)0=::/"0'G>?Y)#A +D=7_GB^=*_C
MB5R?\NID"HGC%EA*'",2(8@A-!BE$,O4K$X$>E4S2%^7[L68%_1W&W44F[]]
M^ZI(#OKGQ[M;OXC3V8$1+PQ+._TTLO&;,/6B2B7:/.64BA?P7MN^9G3>VD&E
M%T0]1E;+20I#NR@]2VC$"H@N3 _S@*_>7#E^^#4)^TFF&YJ5YP=WXQ0H<XUA
MIM_.JNEN)Z. NNCAFQ:7W9.Q%)6$J!'&\S>W_7ZOW)RGV7A\^O_M)66R:)&1
MUYLJF<.8ASE=0R_)K^7(WI>8.*\KS3RP_(>H4OQ]TK^K$B4;J5<.ZH?\-FE9
M &)3@1VSV!$-!<>: L53ID@J)&WT)C%<T;+_ZU&T?#51N5=P/89?!]TRD'9!
MS?/?'XKRX8OE^8!3PH]Y71$Y#00[36.;*Q/VJJR^+MO7W!09?Z4?*&9,^B>6
M*FN9^59B^YMOVKDFA]?*@L''E@6S/GS6:YI[\(X!A]3D\%I.0OQLG(1X+2<A
MIL>IR5T61>R(-^EKT:L2H\_^?)7)P*_@,F@:[PI-8UX87KU;U"3@MS2)>>*O
M'=Z-BL.<TVF+FL+D-GP1CO1/GT*(<6P?$"*Z"II#.,VM*13A]W%<::Q4\EB*
MO\S/VJ6.ZQ0 (14!-I564R894P(3+FECLCI%O#S7_5^/.M?O26Q_X D.5Y[@
M#Y[B#7H Q']7U$R%?(8'*VPQGA7J/@J%%L(:W8YL$9*-W=E6E)O%1X:>?Y56
MMEAG1H-1H0B!%!MBF%28DI0!JA45S*6B"6D<'EX%6XW D_0>%6RI)\F@H1/8
MM'QG3HV>4Y,*OI]'\AYUIK4"%OC9!"SP6@$+?/ "YH/J3&MY5/&S\:CB;95O
M[S^<]<!:IUGBPV(SIFD5U%S*T.=,QKA0S.,KNJ)8.5J,ZBRD4_5B3M"X(5>O
M-^UR642ZU"3KFY/A9%P+FE2QM^PFKO"F;#U2E<7&8DTWZ<=2UU ('/Q"U?+*
M5C+U[*"BKVJL(BW2_J;57B4$YA-WLKR>TU5D4)9'1%&GZ*_RA]]BOY/X A7Z
MK^KK06CJ6*1P+,P)F _8>&J9A("2S6=YA3T/DG',&^EG-UF1']+S6PFY;47@
M:U"/!X;$K5K8IS<7Y%%W<RIG:.Y2A-ANK3_/0_*,/_Z",CQ==%QD-A@,/U>E
MQ?-O_M,N=/FYM:-\.!C8?DS*&I=]2T-+F]'PUN]L'')*9C#I56V6JO3.:?KI
M+%[U*:3!#&)U=R@&_30=)U#/1IU+F/OF4=P&L34GG-HA09?JT5I\&K9EK<NG
M4/-$NG:NKKUK:]/*GLELU3:!?(Y V[FTA\R:O/(0C^F6WJ M^GH$CXHWH;4_
MX(/VN3A!TEB  4R1\GHH(5P(#C$)KA2&L."NT3)_Y 1)RPW6P>17P!%F4HE4
MFG*JC( ZM(!J3X?F=N![O0&6JZ&\!FJZ 99M&V")N@&6V>( RZO?W[T[_?#_
MDLLWR=7YKQ?G;\Y?G5Y\3$Y?O;K\_>+C^<6OR?O+M^>O8NED:R=:KF;%-?CW
MX+&Y;?E,5F]T#>@</ JWGA?NFPK 2YEG^:5;./SOBO\V*0!0<8(,$1!C_P>W
MDB*&"%/8:)5R_)".W:L4  E208@A0$M J%(JU9B!T E)0<R5\PK ^IAO##"N
MNNG@10@M-LH;"&XMA60UUM<@%;0)J33&,E;=M-1ZMJ&30"M/Q2@)"B_8;,;\
MPW"]AH!>C;@UL(TWP79C9&;530</S#R0&W> H<8C=-5-9!,,-<:!5MVT%!QI
M[.QQ*&&ZYHF^(Y0VGHVK;J*;H+2Q&&#530>O!3@<TS4>2:MN2C?!4&/IP4KG
MP;9&>AZ@PFZN8'HRD!,3(UJA0VTQ)'%U$?4L$<:?I;>RR.(*]X67A=#B<@Z6
MG"K@H5C//_$V9'H4 R'B^)C8/6,6%@S9,_[3U3CV=0@Y.5'7DM.L\#@)[M?3
MT_>S49IQLG9HEW!36W8V*))0BG+U.'K$V:)<K7A5'H*SXV*RABP&O07WSJ>)
MAT"\*D]N;)DR%N\-?TS?GL21H;&91;'PF:41%C\P<F06XI*OAF96 3Z=5'KU
MZC_KTS^:'I/\?EM,E9C=-!LD6J8WO9ENO/$)+X?^?^9GY)U>O9S.H]P_PS=J
M):MN8ILP?//<O)5WM<<KNW<<->HEJV[B&^%H+>_LUF;WI7$F1J<S%7A< _EB
M(^2OY=H[ADE]7;_.P6;].M.N7V?7KW/QCJY?Y^(_7;_.KE_G(_IUKC[-UPEB
M@(UT@+4"6%N;1GN<9GE^777P\V=:99+_]V10Y']6,]07DX0];OI)[74K7A*,
MT])>#OG-P6@NQMX/9@,R[_Q)5A;LGUD=2T827!33@*KUFKFO+^9IL:(/L35?
MR&]]XT'EH7KR?_R"^E5WU.DP^*MIWYRXA-=?RXZ/H0@GRV,KTKJY>_5Z9F?'
M&:M+:=.HJ&.'+_[S+S#UQ]:WF\PIV8]>@OS:VG$)BN4]?Y&ATTLQ2'):5U_!
MO!G,CP)J-73G'FI9]HHT.7,6DHAKGIVP_9&9Y0;'R9N#?#R:E#UI/1546/J_
MA?LBI%=X-8.'77R8Y@LG5R?_51L$$J<*#6^RHE%DN?;IY% W'(X+2IOE(=>\
M.253]>_F**K*/G\ )==VN.RKJF]WZNSQ9UF_7T"SI(<*_V6[O\#9LH3)S$EF
M0];XH,1$;6'!)542V?F@;+60#<I<[=ELJ^EPHDWEP[3I89CY%(%73B@)#9R6
M^R'5VB)^7]1*AE=D>9@=%F8@9T4O [^PD6?8O%?KPQJSPFNC4HI17'[Y99NF
MIN7]4#S>Q*+06>]#3UIEP"YQ,AOU[QJ%QNR!M\.\&(8KEZ?D3<>V%BVEX@7U
MD5V%Z%@N(RA;=4WGK;F^U]ZFC!F':Q<5H]]L5W( [UJSKVOE71LE(#2/?%UY
M5VM2$ Z I;5"_W"CV'_SX-F5=QV\D+%=SK%F5]7*NS:*XS?/B%UYUS..Y&\(
M[[7"\EN;.7NXYEL//=?B)47GISB@W%Z'-IAE)^VH^H8.^_VJ4>' Z\GAEP5M
MH^R:7)[U=J;W^B_B[ /_P-O8"B&O+(=%K;Q)$:JI/W.'?:EXE>K7Y;1A?:49
MU(.)U6O#!+=0!%@I)UG4/8O9"9]M%8&KGE ?Z1C:X.OZID*II%=:0J7\/!R"
MEO\H16$#PEXK.:$]<]V.(E=P2\4*:V4IH(,W2-Q!0N_O>>AN5ED:M<1=;K00
MD&-N"276.&X4]<< 2Q$3BH#&V<V/3-SEJ148&6>HU$0QRJ'CT*3&<"<L(ILE
M[C;/TUMY5VOBTD?!CNNE[J[&^QK$LI'ZWCS!<.5=2P'R8TG>_;V8/3SU,.Q,
MEUR-M350O9'^V3PM:^5=QQ\.7QM'C;&#53=ME+G;/!MCY5U+X8IGG+N[&C]K
M('6CW-WF@1XK[WK"CJS=@GLMCQ1:JD<Y#CL[1)6* (2LNK,T^NS+EBIY+1X0
M#.D;^:==Y6^7Q:2PI9#?=.A5;9Y;G&&4EV,L9@.)8@LA;Z5Z>STTZ8F-V6)*
M:1S/=L\]A8O?E.T.[W/W3_OH-BUG-C1]4!NG;F:^B>*FF$T<C?,7R:D>3V(+
MFL+Z+MH^FRRTQ9O??AE_&^8U +Y(:HT":G"M(B;%*^.PLY \,YV.468U!S1I
MFWTNNC*%7Z=(S0:AR=YP%+KLU&?'YT4PZ'8T#%V-PD;*1DBSP0[E8,5LO-!9
MI_E)$<XR&]46]V4Y]_B3)\3Q7.?AI=DA1:PC##X;%$Z7OBS[_'R)78U"("FV
MIRR#60,['U^.O\IR'$@1O[N5=Q%N%<IG$)+]_O!+O+CRC"RNQX24ZS@T4'XM
M26Y/_I'FX3LK[VJ-H_4H#+(M%8.OY:,]_%"2'?A'WG@9$-N-7KII+<!YC-5'
MX5$4/M?<)B(%UI_H7H65ED"KE0I^=/_?U  BQ38:GC!'_:7(&B@1P8X)21BV
MR&C-H*:.;>8V6<N+>?AY*T?%I>NY35;C?0UBV<QMLI8?%2]5>QV+V^3-G$)0
M+XJ:"H2=&0NK$;D&]C?RI#2/T5EY5VL\K/O'4:-;8]5-&WE2FH=2K+SK(8[-
MY^))68V?-9"ZD6G?/$ECY5U/V(6Y6W"OY8W$1YP\O31\.7@JRC32>_K^-QZ&
MO5G/WR+3;YKR%\QB?Y#&BQHKF^L^@,(?4WU?6K^]F#^07P^_#(*/1 _S<3F"
M(O;/_5JZ'&HVO)G8*FG"WS;RF[>C&Z_NCTM?3%&\7%M^/64Y#A4-/9Q#[6^1
M,WJ?R9_;0>:M[V*<O8E3Z)/^T#/<;'X5^^&^5<X#H[;DB+\ C)A&8?UNX]S4
M.+@^R^/Z]F3(-P]=67E7:QRY1V$B;*EOV5I.X,//5]B!(?]A*D[R;W0K,TP:
M#*SC'!-DN: &,Z11BB5"HNKYLY'UCEBJ"(4, :Z(35-A(0L/U\10E;IT(^N]
M>5[$RKLZ']ONK??5>%^#6#:RWIL'9:R\ZV$=DAYN5!\(SZ?+>D:3U$EF]%"*
MG[9O[&&[V+H*OII4UZ#OS?P3:[DR<6M<F?O'T6;@7LL92(ZT]5.#^ BMC6;1
MU_%2A+,7<[5#)+&*TA5YT0%H8617B+=J;S%D9337#"=J[";]>^RC*FM[.A?U
MGDEXTMS('ZOESK2@TVH1;X:C5[,5O"H6<#HP9^7KJUMK\]:<D-9J9"U!BD#*
MI:4LE5  DB*M.6M2DZ)RM/FH6? "W3]J-D!M?U#@Q"KCJ/]'8@(PD0));H$2
M@'DUDJEE* "(@D-N&U#XQJ1I3WK+!05+-:Z]6B5 _ZY7V<ZC$)G7PT\#SQC3
M0'B1%%"&[?NQ$*!,*2AH/M1WAAE#<P*S[%<Q^J2^Q[B78-9+"/RA]#"4-O/B
M*>6!9<-PWX(-@ND;I_E,\O'0ZUIYHF2<\WL;<9W8N=2 ,#-X>FF#7R)4-)2E
MC,$+4;S!F\XAF^!%\GKZK'PYS6+^5IGG0_]U+!<MGA(F*$4?R72A 8X>:@&%
M87)37.YP\&D8/ <J=$Y]49W$+\.6YN$PK!JIS3:8SP_[#$.2_:+*.MVB''2<
MSRTG]%G+!H%<7B2GX\5)[]]@DJ(YS*5[56VF/L$]I=KXX\,HQ8D_8#E-+4!:
M2N*<]1SPH GN(1.BT)<^^(6^O'MI!_HZ#$2/,Q*7>;0<J=APYW0(8[76I6O*
M>]_)__;\76VHF,68?9U^T32&,:TSYOG%FWLF:2[-8<RSK\NL62.,8GME[8I<
M+)6N3S9=-15S8:OO[2A\(3]96,.8-3I5VA_RQ E_]#N94@/\<8R45HP!^H0P
MQNH80U-\G:!OBE)!EM#UO^]S<HZ'(7FH,4LI"H9QDYA=D]44A\Q!XK4DY(]9
MP$2J'&-&L-1PQEC#@'DP15P\9]J#N(^A\FTGS!9KZA[!;C.?:_]N._QE+- $
MPE@F20!,!36$:<DHYX@@@Y\4FM;DL&6-K>*PQ4Z>#V2W/3FZR5H!;M*: /=1
M>-.VX^@F:\6Y"3HTJG;@Z#ZO4F3O=W/+5'L#!8O424"4U1PH#H!TUBB,#6PX
M6QZ?I$8E$MP;2)IPPE,J('+<:"F4TPXAM=E0CK4"X*0U ?"C8,PUD]16XGT-
M8MG(S4W6&][SD&*B5B:I5?R?[;"L;S7"UL#R1MY'LE90FK0F*+U_'#4GHZVX
M::-D-+)6-)H\9$3.LTE&6XF?-9"Z478462OD3%H3<MX_CAJY8-5-&PWE(&M%
M>LFV>N[@%XS6.A@'CS#H)>'_?]CG$?I!?DF"Z>^O[N>S2K*J#5_T^X9G#2=Y
M[;K;R4A?1[=SK'3+)V&FA;>/%]+69HEN92O ?.AOC.5>^8WLS=65W8Z&9C*=
M(M_D:"JOR%\D_QB._O20//'?A"XY10O+;)#EU_YYGX9%^Y[I@5]+,<,_A/$:
M_;)DL<B/"Z6 <T"0>?+%]OM)="?G99\>DXW"7;&YWZ#\T)=J..K5.A7FLB_#
M&Q? \$5^*LL,E1U8EY6/K T"L3>W_>&=M;'N;OIV6=2NZ:DW?_C9CJY#V]5B
M7578H4R&>^FO3-Y('8HD[VJPGXS+LLFPU-"=R/\ZEE_#YW(V2HC0R6Q4K/%&
MAF2ZX.6WO4@&DYNXQA+)91C.WGH09'%E+XKVI?65SN]_?F'3381 QI3>LOJ@
MEEI$(VRLJI4T2?X_DQ!$"%T[/4PK0IE_?N'XS]<DK@*HH2:QA&KA;VE^L2O?
MN8.NBZM%WQKR<J.9)F2MS 'RA#,'5H-[#1QM--.$K)5N0+>5;E">:0N&V8%/
MN -/&F^7*MS(PZMNVFC2"EW+7TQ;XR_>/XXV _=:/E^ZK:E&+=%J:^Z>>KE%
MH7?&8H'88C)H82/KM;:BFJ+IYUA8,%CLH#C)J\EN2XJ$W\K$A829T$<B=JN\
ML:.0,)']J]2.XCMM: I?JE*?;7]X&[MNA$C0YU)7"_I&J#G)BL2I\*[^\(L=
M%1TR\MC//.1.+?6,,#945V2#T#G^KDS:&.4!2;WRK^%DG-S8\77H:7'1](@Y
M;6SVO'D@+&AINNRL7>RRGIA1=*;,B^%V(5QEDR_7=E"V>*]I@/FP;WI)/ZCT
MA8;K[S"V[V\8+5Q<*F=!![W-_'>%#CIKJN'N TZ]748$<;&+X6 NXRQL. \
MCKLK\F&RI3Z:85\>/:&S1,R>J8J!8A?Y6O^,:3?Z*424WY1'>]E$)9\$4JCU
MVR@2CF0^',3 7G)>!U*1=Q16TP^#!C]G]DMA ]A!;* R2WRI"I9*LACZ]X76
MHO:KMK;H4=X$HC)L7^O,7N4_A7RF>0CXMWX99>/P\"^#8A^U9B2Q6X?T@!V%
MK*IA42+D[<;1IZA=5]97J7I7V5.]&7$L[,#C8X:*XO9B+WG<S,Q,:-I6@&(2
MA@\%$/=*^JIE+4U;B\S;"KH8.%GT&EGH\F('GSQ7V-@PIC^LVK%^B5UA J!#
M1]K,W053+O-2P&1%B%U^EED_+JQ(=*P$1%((HL#V$4;F&T"J1F14S5O*Q+2Z
M2;6G>#!=*^Q$N[#3_N/!=*V@#R6'1M5Z*O268+96"(4>00BE&PN8U&,FJ\8"
MLFXL8#<6</&.;BS@XC_=6,!N+&!QX'PK'>O7X=!\R?K]TX$Y'XREUZ-#V4EL
MO%?]M-1$#""('3; I:DB@CIO;U-!L!288XCL-LJ0M6*$.NB099H80Y4R3EC&
MB'$0.;U9$S&Z5J"?SLK.CT)372]!:C7@U\#61@E2=*T(/F7'FB!5L=W.O)ZK
ML;4&BC?*CJ)K)0#0@S=TW)UG>C6XU\#11ME1=*V@(Q5==M2#D=IHX*ZZ::/L
M*+I6E#(]^*29PS%>H^JPZJ:-LJ/2M<)V*3S.PO7J] N),,5PL+S(//D:\XN"
M_[7,> K9/L$57(4DYMMA#^RL9;F.W;2G,9C2]5^VSYIG_NGK'U:E'.>=W5/2
MO:AAUXOG"/9Z,S 2&$2(E=+CSV%(+(92&-70A7=KI=F/7BMS@DDF%'(I)HP2
MR34DA&LJ+/*$UEA3NZ5B>OR"+I5FW5M77G5#"S-[[\DL^E0A-PM]Z\>C3$T*
M/TA9R!T,UX5\J6SXKAY%3-0D]UI:'KJH?2KBA"$-;2D!S..+A9O'H1':Q]F<
MX!VD)ZV6/6L(K(W2DYI[!:V\Z^#%3H<[5!K5WU4W;92>U-SO9N5=!X\5M4MA
M:U2)5]VT45))NE;@*#UXX.APO+49N->*.:7TR'6OK$A/D#=AZDJ(9_N#,AZ:
M7J'*\RH?YR9D*L=#L&@@(@>#D+$1^X>$# %_M]?*PBP3?TT8GNIJ]RRFI\>Y
MJL-1[A6]+"^32.KM1,*I.KPM$EJ&5>^21!:1_7&1)UPLKUB1FYWV,76E3)P)
M&0TQ*22+&XI+[&=_VCAHWN\A;#OF#BQKE,4D^6H03=!NPA-BBDR\=2[1HVA[
M5,]XFB[':PP+_52*!4V]K]7<D^1\3HV9=E3)JQ5F839+F9Z1V]B")2PCN9EX
MK6,&HIG:,\-85$S471SA*Z=S=N8W/#]Y)VZXZG@SEPWR(CD=U)]=YI746N]4
M:I$-_7/NG5%4O66JKRTDG=0S3&8K[14X&U;)-+-,\5GKJ1GLB]3X:D6Q"U;]
MU?-T5X*P>&-)W?<"4T;CY%*/A\% @-.6/W'$;ZU3[Z)26CQW86[/ U]2&B$F
M*S)0BFE((1VN&>D%8I9SH,+]#[,+SJ</>SO,Z^U O.5B4V_ 2"13$EI.64HU
MD% A+"S #58" *3J,['"7@ /;;>QX1Z,,U*D@D@H'+'<BW6FF712,:.93763
MI4/FPQH'WP,F7$*G'3$($.C7;H76-N5,(.9QTH@'V#(\((0!P( 8Y0AQ3$EH
MK(<P <@Y;,%#9M1LOH?!<+7IN?J+<2D"%]HH>9Y;8LLY&W+*O=6<K$=/9]]3
MSEFZ5B@M/7@'YV>8<Y:N%4=+#UX)NXL>)%/FNQR=>=5\F,O^I7L[''QZZ_5(
M4X2_SRO5;3$N7L3#[V]?0@F51D+B@)/!T2< XYAJH4.',__/%L+CQJL6@C(+
MC-8$6*8T]):/_X"Q$<BBC<+CZ5K1N+0UT;BCX.GUHO.K\;X&L6P4G4_7"@NF
M#PD+MC(Z?UZS>EW2]R+C)%1%F-)HVYF;8S42U\#\1D'[=*W8(7O"L</5X%X#
M1QL%[=E:L4.V%#M\QD'[U?A9 ZD;!>V;<[!6WO6$XRN[!?=:H1*&C],'7/=_
ME>[>O"KP"Z'V8O+W7>4073H JT[=U2SM:9^+.-O[?R;9;14V79C3G7F3W9:/
M6O*%%I5H-H3Z\_KH[L\Q/R#4;EW[&^(([T1G(SVY"8.P=/PB>I9MW>"^D<&G
M_-DF0ZTG8=IT=+76?-##NJ>Z\$CWJN'=P?M=S.[V:D&65_U;X]@PUQ]^:2YE
MB]LH*LJBQS6:^0L^\&7_<;/K>OJ\^QREI><U8JL?W;-WI6\P7%/;6=U%&[J<
M^$]5P5W67/=7>84+3T6Q*W_I+#NCYD*.Q8NU*L- "#(NH1S;_B)YLUC(MY:O
M8[[Y>*WHMO+D>["'1(UO^Z5J1N&B*?B;[1N_U-]S.]<!F4NFL(, &\(-4X *
M"H#Q=A[27O2TP-7VV"V)U!K(G2&.*((LD(X1ZPP3-"2I + 7S]MVMT0UU9(+
MKIS1Q#F@5"J$P,*DC*#8,OC@CNG';@D9K+#2AF#D,:6D0II9S(A!EE"KW5[\
MU-OQC\X%$1=/E 6G:1$4VX];LSF_=N5=K0FS'X4+9#MNS>:LV95W';PL="<S
M!&-%^H=B0$JX_GXG)78* :JT=-!YX0"YQIHR@1VG6E.S#2<EL40R+IR!7DX9
M;04(8@L@!G'*!) ;.2F;$W%7WM4%'G;OI%R-]S6(92,G97,2Y,J[CK:$J!0$
MU:BD<,'.;._5B%L#VQLY)IO3*5?>U9KXQ?YQU*CMK+II,\?D6F$#UE43/1RI
MC7K1JILV\Y2M%1'@3S@BL!K<:^!HHVHBOE9$@!]I-5%Y$.;KY]%,?7:C+'8G
M<\GWV0]5[Z>\:+J\E,\8VT?=4X22W=Q,!L-/_:&:^--ZVNVVE[P\_^/\U]-W
MO>3TZM7KB_,_XA(NI,I.?GO9\V_UKUUH/35[_?2-UQ,/PJI]GA[V^X7'TF][
M./ETW;B@]\7%KXJ+ S&]BET6\J5BE[@*OXQ /\&"G^^PM^S3C5V99>R6YK'Y
M.=,QR:EL+?9]]KD!CM.-Q&Y_9:>N1-V=5'#Z*8+E>W^OE_5VD!?(+%)HIT^;
M]8%>+/.):<23\4EQ<UBU?U<%</][5;/C,1-JKL)78="5+0I]\M ..N;=5ICP
MU[V>!!?W\N[]Q07PHXLXMK_V5U\,1^/KY-2%SFG31,QWF3%^?:]ER'RNEA"R
MGOUK/F?&SJ=K1J=RU>)N"MBR\W8Y$O+V_V?O79O;1JY%T>^WZOX'E+.S:Z:*
MUNX7&MTS<UTE2W*B?3R2CR4G>W]*]0L6,Q2I *1MY=??[@9 @B1(4" I@A(F
ML2V!!-"]UNKU?HC'K&.<2P95SL7K^Z9-_=&%![=XV1287^WY*!<VC>2@_[5(
M2[-/G<](SA>1>:O3Q9SN+*<X<Y;WX^FW[;FWK[0'-.MG)]2=Z\"G3X)S$QOG
MCB]/[YSEH.<]U>Q9+!7].2*9-I^>WTMO5D+HJ;,8$^HFW%8-6INWJ?T O&)!
M4\/:=>2V#SO-%N59[R?_U/+<U3"R7%8"2D-",$6<2 E(:)DKQ-*$]4[4?[@I
M:=?Q:9*XF(9#AI]_EF_O8[:[TP)1Q2"T16>=GB0N]?C-.X06S3B?D_PT5]IN
MQ%VE&59WTU:U:*Q1K)2]X%AI/;@;X&BK6C36*,#*7EDM6CT*&N!MJ^(HULA)
MSEKC)']^'%7:1[7N,K 5DAJYQ]F15K!]6NC-F@>X\W'ALVZV^111][EV8M1K
M-SXEP.NVH\%,P\@UO1.K]&2?]!?TG'*3YZ*#\?1-4SW1*M%W_8<']W%2=%)V
M$72G ?;'5OE[$%FJQ6ANA2?!Y^5)YEZI&TYS!+(R)C]+)7UZ_^<L>N_3)V8O
M6U+'*PR'!6VOVJQ9A8&9)6/5OSS#9&DXNG9]A(=^%[U9H7T. ]?@P=5835L-
M)T:ZAM.]O"^$?<,XMV?$3)/*].09_OWT60N&^>;D=O</8Z_M%AD>/@-E-/ =
MRI,\I\&U<5R PLP6*7T[-B;UA65IN2_V7,?K4C/EG;:RGG]=N9'UAU')7EK,
M6%EMX)6)8E'=GQEL:6]ZCK(SZJS)!<J>/BVOLLOZ.F?6AN=P]L38G]*X7WER
MQ^(/9^B-?(I2?S9-IB"L*04OC+Q)LD^$,^,2_?9!N-RD[Q8Z=R/72GXZLL9-
MZOGW<L^0YY<9L-)A4WO75L$UUBBXQEH37#L EAH%M>!642W6**K%CK6@9U^8
M:Q2@@EM%J%BC"!4[_@A5U]RZKKDUZYI;=\VM%^_HFELO_M<UM^Z:6R]?:ZX$
M-,J @%NE0+!&*1!L*07B*#TSFX<N\UX\2U-"Y[[G *_RJ*6UY1:[RTS]#_G#
MK%%<\O3,&XXN[":-,S=SRS69]:\IK,^BR&4VF<M7DJ1SS[?/=2Z?>S\3:VG[
MQ22GBH79&W,'D>^95#;Q$^.< >FJM6MOIR^$(8LU'$"U;I2" K?*06&-<E#X
M*\Y!@8V24.!662B\418*/_@HRI:9KHWBJ7"K@"IO%%#EKSB@NB6\&P5'^9%6
MGW[(T[36)V?U5E3R^9R-S)"^CL]R65WN+$45@%1C@R,L"(B,$(2RB""!F0I-
M=2_C^=2,LY&/&&2AE<_]](_WC^_-4-VY)"&?I9%'4#Y8[>8L]Z+_O3^^*U:3
MZP&G0WV3)>Y,[\[R.*I>X-)!_+.+ARQ])[_W=_'/43+=M[_E@U4CIE>*5)%R
M]1<M5W]=7GW8M/XKM@]>+N<J%*1TEGOC@UR!^/HU,2Z/R*DLZ\OAEG;WR23N
M@K7X80F7PO4#"U$D&0($<2+<#%\M9.A.0JS,*\1E5,8EFF+R+5K;99LM-]G^
M\T8A/Q=F' WZ.H^^98IM%EFJ/<.@\1G&E& 0,F Y+K>G%XDH)#B.#(H%0I'0
MM66W1X?W6Y>SNI=#[+-A#WJ*$382:RT1D1&)3"00$2 6!MD?*445/1=?/C8;
M'F.X\3%><7*?I[26-\H:XJW)&CJ*PKW=E-;R1KE#_"66UIZ-TO%U?&,/8KJZ
MII8J$7&EW7@,0UA(F98:,XA0'$&%XGJ5I+ZF5G+ %*2QBF)#J&',4/L$^WP*
MJ*)";A7VYXW"_KPU8?\6',UY%_5>RFOK2: !W6R5B, ;)2+PHRVO/:N>!+\W
M#T,]\AI@?*L$!MXH@8$??P)#8QQ5:CUU-VT57^*-XDN\*['='*F5^E'=35N%
M-WBC\ 8$+SB^L5=X0] H4F$7<)P.V!6BK6CGYTS'=%S=XFZ6*[RR]O7#^6E6
M>[?4W6E6!CN71[R8<IP'B=/1)'$IWCX&W'.MZ[Z[RDR1^NSI83K?3-^B;YI@
M+,58W15O\WGE]F??NT[;G0Y&T^Z$UNKNN]3PV)H"?A%&W0U]@G;>QLZ:T-.T
MY-24K_JBQH6ZTZR(U*ZGV.C)_/[_7B0X.]/]6W_LJD4S(-8_>V@I899O/RSO
MI)>/7<F!XFN971)5WV=5"P>FU(C$@L3ML0R"XIYG\@JX ]/HG+4FL-0"X^.Y
M_ (.ZHV0=:PE>^L\ Q<B<27!Z2>3W-S9 [;:/2"=3U/ 2!B#"8DU4Y@APID.
M&: QDSMP#U"N18@Y$5(P(H!@V!C"2$1X!%D41UNY!QS^&J&]\]WMO^E6/>8;
MD,M67@&']T;DLE1[F*?9)E_E3Z 7N/__7)DNVDIG@1MNY&J<7!.1>PN_U#&)
MO2G#]1AM0 9;N0H</AN106O<BL^/I4H^6W?35LX"!^Y&6%IRXFUZ6%^+#Z$>
M;0UPO:5-V\A[!\$+=M_5 [P!EK9*D73@;H2E72:(/ZD::I>8?B]2JVD/JF2G
M*\]U#;DFXZP\UVZ@[\NV746XOV/10,[N7JPV2,=6/;\;#;1O=965^69%%,XT
M=LWSOYI@Z#-1LEQN^VYOE!>+<?>[9E)NU(!?0)9^710U]T>ZF/MYWA_XU:[>
MCQBH2>:P>,*.YK;@W2!"_W.2CO,!O=[TCV.CO$='NS7TOYDE,!AEE^T<#CV7
M;2Z&C[WFT/!>A/Q%3X%3\&GD)L/V?2Y]]0/ZL^&W9M7K^VDZ\2":/.2-#\P/
MDZA^NERN'LRM*%_C0^YDL;OX[IL&.(?4)"T6.W8%]!/7S<Q__=Z,[S9<NW-,
M^>7K6=V#7DL4&87G'1P6IN>Z$O5Q\'TT&5AR<6T"QOVWQ8M/@M-LD(.;L.!F
MXRYN^Z%JM3,B\#ZB'-9Z.@6BM)B1IY'"P^=ZBWD?G\?KXHZRK>3=P8J'S=UB
M&9QV?B8]GY,R:V1F430N.C>D"[40;G*OH\[9.7%D;W>6DU6ZM/<BF>ED*DG6
MF?8WZL[HR<#UXK(0*X!U,X7518[3++5H"J+K>-$G4.4-B,)(*\6%BK4D@H?,
MA!&-$,!"&AJ"733@EBK$&/,XCI@F4<@9Q+&$860%5D0E=C[J.?:^6,[XU$*T
M@TF+S=*&%^:%Q*/!8/3=G_X9]7]WLT**L[I(/M.C6[#K_#RL/\G2*#%)"Y]X
M/YD_KSF'3G^9JC;Y/_-.@#V$36J)HP%%K748U*M+#72LK9+K(6@63H-'&4[;
M%Z54IQ_4W+36IU"/] :4LE6/.EC=AJ7^MA=3LK0OZJE.C*BY::VOHYX0&E#/
M5IWR8'5[F/K;6A/=:@.E5&=;U-RTUE-2C_0F,9:M^O7!ZGXT];=EL;7-6E\T
M[7?AB23O5C P<5T'C*)AAXK'?EV+[1R6Z_]7=9:8=97XYE___[W)&L-,MV(-
MU+&+SA>KRS[^-<AW/>TCXUN6/-?Q<57B8_/68<*W8?B>B =[IC*GP(J&"2]I
MIXXZBA8@>]IUWINFV'1.AX&W)#,0U*R,5O<8J>O1L=K+7=&'XUEMH!MK _V>
MV4 7<S;0JNX='2'.,Z"J7B4=9WI9.ST&SH3VRID.%WYSKI@JHV3&C^:-D^7/
M._+L=OU"#^7ASB3HSN31Z1"YM171/U?V73P[N[CX\&&5L-^(CHMH\-OH!)7:
M<CKCS[XWN[::N)^%=F_*L;OG(M#"SJT$O(,$ J07(,SL7V'XC/ X&&OM(+((
MD;(@2!R7GP*)-SBO<PNN.[L'/I+K6T-L&4P]]>'D4@\)"8RB,@9(<D B P6-
M0R&@ 2PVD5*HOA/,EBMZ_UC] -_OX>+^83!Z-,:SJ6O/I:J:/L!-IK O]GR(
M>A'#/8!XQ:3UC@]V?+"#2#LATDF&YY$,2'!@H%&6O6H24<F0""FFD5 QPB&L
M:,BQV%WH6"4#[3$ >U'428878MZ];!ONLTG'2=_W>\XR)MT!.(0Q=QQ$V.UU
M!V*VDZ5/DJ5&0:8-$H8)3"B*)("2:JDU,!&/>'Q8*VO&0+PT_>+8Q^>;+[N3
MIXSV(,9MD*8O_MAV>WV9>^W8\0[9<22XC&+(20B!-6T0-V&(8\%@J*24847Y
MP'.:-OMFQQC1'@"@8\=M-ULV,_TJPWTOV^+Y>UY?UEIS_(A#L,\)IH6, @NE
M/)O@,(354N&^4UAVFL*3- 6*H!$,\)@S2C1! AH#-4-:268MMXJ&^<]IN.5\
M<&>: >F%B/4LA;=!-^@X;0>F3B!U JD32'.F:P0(@QI0J4,B*1 DI !*Q14R
M(<054YB>TW3=M4!"/8@[@?32[=Q%D)'#@VS_ JF%FWYFB3PO']SX=#V:N K,
M3MB6A6UUUGT.*K)!VGTG0A=$:&Q"^W\:TA@20C#C0DF@9(BM54>+7GYKF\=L
M+=@@ZG$>]3!";9!LKYX7O7H =,RX8\8'8<8$&((IE2J,(F) R '2"H0&"4!#
M@.M#<3M@QKR':-CCN!7Y?D?,BE;8#^7?7!,4W\[BP.U0MNILLFV3DF:=X&%K
M.L$_1S^;3<#1"(IM'K#8<(I"YI<1J=&.]YIAFC%?GQ1].M27?KRJY=>?!G8M
MV8B%4B]%")D]$3S&D<"$<,T9Q4@JB2&",(K9#GHI*A9;C@YXR*S"+103)A:
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M.Y\/-#;J;NA*KP(7R1JGQ=Z*O686LO=@6(,[[H\K<K(6MV]$.G&@M':M>]3
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M>G-S<=OFR7WU)Z[!,7TQ <WZC3: SDN?W*=-W!_VQ^9C_YO1B])_Y2 _R)G
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MJ-F.1P_/:HHL$>3"&,OH9$H[-:K[_.[$9#RJWEV]>;:\CD-!Q'_'VCNCK ?
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MGJZ^8_4<2_?ZNY6^WF?Y8IMU@A;7*BR6ADIJ\8)SQUTY$F3YL_IAY+,G:II
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M-F>S=_,[]\MF./:UHP,SGO@378](9_4/?4?WL.L1/B@:HK[*;F_21>\[ORO
MRV7/OBP['2Z]MQ0PY']2.6IP2R:'N)-Y<N<0.1CZ7$3OQSP4E+5]7_89Y@*$
M 8VA2MRA)G%'\.K:/><K9,<C7QD=KO>;(T_WN[=^N-HF#<W/% J-@@G@;*()
MH%$X ::'AL\A%3%LY-7"L_%J8;/,-3Q^17PG30CZ.*'7]S(^]]$>X_3MCW*L
MF _"].:EN5/'?N+T5.(JWXC3'9J+!S\\,_EJ^V8PS/T,U7EJ+Z:FY+;4F?GD
MB^8'KTCC)\-,AJ^Z[U[\NCDY7:J0=V\O+^2#.^!7/VW53\ETRF%\G_2<(@B:
M*_Q6N$7Q:_Y.3E\6]D6AZJJ'4+;7=19('K2)-$YM.=G?"X=SM_#-)R,_K+/K
MNQV6AL6&"\K%^-R]ZLY&USP,[=?N8)P7$SN#(NT-_"R:<LJJ4Z$]IVP=B5PX
M@M*V'+>:A)K*^1FO7_Q<DGY0^WY@RKCGWEIH=V\]^ FPW0)N^2!H5!.,'!U4
MOX/K>&@+B\!1SX\PQM=9&1=>_?ES?I5:E\?./9[#<>?QY2%4I:#>X)L=%@/G
M"CJ<!X09](.&GYDRWC0H4)A,4;ARO.W\@&(_)34,*:Z$44OB]7-<[KJE ;EH
M+163R/VW3K1_@=$I#>?CAP=' 0N@GKW:_:G[U08*] ;+XW-V%[G 828,GIE:
MGHXO+\J#.;-MP5(KCY(GX[R@9 _\F3U9$(]'ZK"KQA/Z\E<KV74!9-UEB(5O
M<(;0G2QNYN_H 5M&9D.WT&1:<_'J*7C<%X>J#T]>W2]]W]_D#6CW8 !W/G_U
MT>";')H\W& H'[JF:N;7WF-JZA>$6)!JIWJZ>6+TD77;FP34Y7#XHYA_. _6
M;M_)*"= ?A1DVAT%(BY!^R#S40FR13^CD 8>>H7U;_W0J8$?_5V"QU@_P:>S
M[(0LN0=C9Z#ZP52V_V42A'>6LS-L/>V$T==V:!W#^7K8Z5/>&"Z(8C(\6F:9
M[#HT9%W;,R49]FT9C'<$X@WQKF\M<Y#R-.0MZW'?/1I0-NVC#)+^X>Y'WG4B
MHE\ES3LK>Z,[[=T 1T^9#9,K"V=AQA?!27(RQ?VUE'".)0;YR$G[<+5Y6/A<
M0M(/!?G^S[];QV[S@[DFM[NWUI_3?5DV'H;C]+KWW=%DL-@B4"<NA$?]])ZV
MO)SCR\)OF( ^G[@5GQ>$F<-M+QS;JZ$PU7UH[VP_]TR=CYTK$ 1C=S@:^RS'
M"OS=.2GXU3>(ZI[[W$-UP2N=/>>_,[@ESC$:!XP5&B1PB$.._3KH??5WGM&C
M]YZ">^B%YV\O;U].0381DSNWF!K%M.'9Q+1AHY@V/.O2(=@H/@W/)CX-&\6G
MX5;7W^S72YDJ7CT8._U64;WK%$"(5?G?FTUA<O:E'S12QOJ^C'LRF !R/+HK
MI>D\V1=QNQ\3*VAF&Y6&@D]*>W?(VT1]O]EAFKCVQKV#B;?S;3$E4GI[2<]2
MV\[ZNN\&73I50Y6)F;GU[TZ<TS$<%4IR>;F$-WW[ Z\SBS#6Y(I%J"W8:).O
M2":[ *:N3VG&.>_BSCDASE+H.IN_"-W-PR!4(>3.]APYR/X1;N(G8SJ"Z/V8
M3$?T:C+W,YAT>$\14]1WSEHK"@/*H)^?U>B5YPQ6G<1V S:Z_=)T\: I-:N/
M+Y;QU]?.,THF4Y]>)I?.( E3'_S/9F\+$/':NF=+E^\?8W?(.> Y $V)98:D
M&E):--FGU.)'-[D+!JKR_FQI:JZ"YA2 GICZ[NM606IH[XN0<Q'_7KCEU#=V
MS.\'>(W"@A!MNU^+Q2LS8JY@.'BH%2HHR;8DKCO9RV; Z3LKUOFR0V_$Y=Z6
M6XR:^HM\[0;/?!KS=MZF__HR8NOAWIU,->\6_MP$QL-0/;+$>A4N"+]399)
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M84!B   '"!*%@<G<?Q'<\\ROITFS#L2X(T LUX@R+<JT*--F5EZ:&<LEP9F
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MWI)0,VNLDW]6:X-3822A3@S"3 (%&&4;C-0YZIJP,&(L5LI&21@EX;E+0FL
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M\,/W)'WX/M.J:>JS)X.AL<.+\K/T+\E=>4'H?W624$G#/[6YELF/JCA_X63
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M,P 8\RMN ,4)R)0Y"%Y><?IT5I79(IT;16W45\5LQC,3_\UJV-1D4M[4/^^
MH0=/PH+P.5C0*[/O>\@="LO8P1V%3[JCZ#EWU"OG[WMHR&+>V,&]14^ZM_@Y
M]]:K>-SWD+_K>]LA;3T+V@)P9/88*9^@+96"@"!3$?^>L2Q3?S\(J#V 7+7V
M5+Z 1?_76GF6]6<TZ2:L!K,US>>TKV7[?PMI ?+41^+OGPUG]GV;355>8)K6
M'IUT"PZI!-0@7C6'EGAH4*Q&@.">G04/3 R1[TTI5"-A<\/1!8:;F63;=%-]
MO:HX-S["(U>U<3K-0-G[C\64&ZYE;MJ_,V+;>.I726,7Q?>1PO8@[V^ 8!J9
MSY"8C[,IYH.FP6Y,$G1V]IF3+>OIFI6KWX^8.)YZ_^EO=^1GC>2W:T1\G:<>
MR6^4?H- Q-=YZI'\1NFWGW;Q,'IJ;0]-?YO"03*#TFDWWC?K2364F,3H6)YI
M.&X$_^7[6TQEW!G#W%8?_^TAUI^VA4P[K/H>2H:MEE3V%E;%'_U>S*]48MGI
M]W2R0.9_4M<<_I-]9=_U)CH)#U/+96D:1Y[K9XD=.TX26*X7I;GOY'W)9)Z>
M3-8FX[?Y:VQ"B?B_76PB+=<W/<<S(S=^\;S<D6.-$!EY^,C#]XV'![Z?!J[O
MNEED>[F3)=S)@IS;?N RSE329K=ZPNLOJ'H9'AZ881R:=OCRI14CPQHA,K+P
MD87O&PN/;=OWL]BVXBCS?"M.')\EONT$:<19H+)"[ZCI>&D6[L2F;3EFY$4C
M#]\/CC5"Y""XSLC#]X6'^SQTN).GH(TGGNMDS+4<EZ>>Y\"';OJ8SITOYTKQ
M7=/SW)&''T:0HC>N<S#AB;,IU<@B@K+)#C!TCZ-F&R+1;B07SB^CN+OI-3'0
M#AX/A-(H)J6IXWJI&R1N$B?<\_R$!9[-7![$869SUW:>$W'X5$Y_JS?7"\ST
M+-\,_9=O_3,RHQ$ (S<>N?'VN;&5AG;"@,%FJ>_E7L+\U(M\/_;SS// H'E.
M[&"SW#B.+8P$C[QX *SHU0-@Y,4C+]XX+TXR[OI1G$26S[P\2"(W#'D<>B[/
MF!=Z_#E!@,WR8L\,P\!T@T$$=%\],WKU !BY\<B--\Z->1[DF14&(7::<7V<
M-NB[+(F!/WM>$O5D1C[<G;]I/X7ONF:TA:[EA\V,AN+%]Q!D.Z@_L(-M>_B_
MECB]6W7H&P"VK@']_D:F7D3 JI*NK%Q@YZPGX>M )<I0PNVO!N O:E Y5A#:
M5L8C+_?<G"<>]QW?\YEO6SF/>T8C+84:-A%T#\W(M4Q_"WW%1WXW@FD4"Z-8
M. 2 OZAE%P6AZR1N%C++"[T(X,%L)XW]/+"B,&'WQCPV(!9",XQ"D J#C&>,
M[&X$TR@51JDP.("_:"4T2\%:\-,@CCPO"Z.$)6F0IMP+W-")O)YYARMC-9XM
M%="-%\:F8PVBRF+D=R.81K$PBH7! _PEQ4*:NE'@<,]!(X!';N(RB[L>?)QE
M$9@%6QE-%YHQ6 NN.XJ%'<:!]+\>/RUO".,Y]!,,9%)(9TL#GSPSE+W>!\-F
M,.B$LXI(^*J)],W+F7JG_$21,7W8C!]Y=W'^_IQ=\C<59W_@/+IE?G]/-[Z5
MA3XM,-HM5GH$W#JPBAI0J39_"E+B1[A@\]F:'6!SOCO@USW8#!X[2A $1RR'
M8_W,)C?LMEX#IE61^+>K2BTEH$W<TK"H3$N;^J)DM?S,^JMQ)0](X?/E@3$]
M8EM]I=_Y#X#1]Y^Q=_J,.M??.<L09BL'>]C,''&L9XW/N7-8SEH)M_I9?_R^
M?0)E8@]$^M%/8EHQ!Z1/D7LPXZI""?]O9Y_>G?X7EJYE_/O?_L)^62.'[T@V
M>,R&J_)&";2G;[[_)0_LM_F8J^Q0KC:;8HEN?SEY]_'$>'/V^</G7\_>7IC&
MV:>WQ\;)IW?&Q6]O+L[>G9U\.3N]6*?X['COGSY_/;TPOGXV?OSMT\EO[\Z^
MGK[[R7C[&;#BT\7I._S7Q></9^].X'/C_=FGDT]OSTX^&!=?X8./IY^^WGFL
MI^#2JF[3*B[=M7MDR<IG/9\,2 XN[VZX>QO2SB3VR&T^W'XSQ)Z,=9NZ=^Z9
MX#PM0%YNPMK0QN-U$'286U,X>M<XXP]H+O//,UZ!D3.]_, 9&- X=V]Y8K'-
MT\S.$FZYC'EQEL9IEH3,<T-L<./XT28F%J=.RD(>QEX2>+Z3)E$<V?!/S^&,
M.7DZF(G%NW[]FBG%';Z_?I[BO5!^PM4X6QC"V-&*[N<7NAK\H:CG7S<UB7%)
M22.E;-GE B;:>GUC*\AB.\?W^H^Z)V&+>=E_D@?Z"7=UU XYTF\RGI85X?W/
M!EA8O)H4],L/IR<7I\;G-Q_.?CWY>@9ZW+(<73[BB[B6-D.G_1.<[WEH#R8X
M;P8Z_;.3[WEH3V<G;P9B_5.+[WEH#Z86;P8Z_E.@$_RPI(YG13V;L-N?.]?=
MI[=W$OW=8,L9_5?<>%M> UAO0;:B0@@RO)JS8FK,JG*& @(^8M/,X/]<%#.L
MCL'(AU',:T/8_47YEHSTVJ@725UD!:MNZ0&U3O-@%]>75_G(IHN<I?-%!<J#
MMI:)P8'T2NT.=O6MR+@QAXU3# VDEK&HQ0>"_]_B J /\+G8>84[J+A8P9BQ
M6]Q,#0]4Y>+R2JS$ZQE/Y\4W]2LXT'4MW\R_S_!Q-C<0JN6B-C(<P- LX%BN
M<VQHD/SW?XL<._QK+==BEQ7GXIU9V07"M)P3KB&<\ JN86&X.*RQ@.,OX!_?
MV&3!C<L%@ZN;<W@K@$W_U1RT0=IW6G[C4_A-??S2]!$\A3["U\(]PJ= )]HU
M='8IC:*G0"S>-<2VA4_QD\QG:__%4<:1"8,R7QM%#MS18!7\_I(XJ5$@:S=*
MY<M0G!:^F*9\AA ^-H2# VS)^17^N)@6<V2:N*I1YEU<MQWCNJ1)R,!?)[R&
MY8'E(WNNT+[ X<AP:2@J$C9A\ ZCON)\?FR<3"9&"9]72D#A<W<^(S<DY%/%
M9\#$^90.\2"91H(3OV@%%4DY\>>D8$DQ*4AJKZQ=)F#G"?2;+PFB:_;'BH"$
M.ZOQT;PJK]LW'AM?<(M'\_((MZC)V=4=*%A<3@$A,KR>=N-I>0VO2<5UHD %
M*-4MR.36I?PK\^7-@;3K!0/<_V0!^D%)2% C) '5.'R#8".$PG?!DUT B&5N
MKCB]_E9NG=7E%&R[VT:9@>42#BOR*BU@MT+LK^RUW5>S7T#8!J$SN%QU)\LJ
M ^R_(I@ IB9E594W^,L*]PP+]V?.L.R:_=SUZYVUR[Q1JWR!1<YAX_"IW@;5
MS\/43W,O8IGGY%[BNF'*0^9EEAURN[>5]1U%5Z&>,.,T"3-'SMT9,ZLM3O]\
METH%*AF?PO\6M8Y? ! &;*QBA*#H!T"<*NY %GP\GX#FQQ%SC/,)JZ^9C#II
MW$6^3J#Y!9_ TI>F<<FG\(,)?0A7 /P%WTW*F'H ^,,E:'^7>'WT[B[2J6,H
MDNX];-U\#0HGYXI/\<[$=@-O@W:">4S&#8.]SD!7_EZ@L@@(_*>[DZZZV',J
M]J5A21BS(,S<C$=V[MD\85%FI2S)0Q;:=N[VS*QX>&G>D=^@27 GEEC'J^47
M!DBE"9X'S_[,0SJQ;V59GMO,\;S<9['K<Q8F;IX -;B)_YQ"DT<<<K5_H3JD
MJ1DJD]L5Y%K!I[KXOAMT\;F=YP :EMJ>ESAQXCB.SZW0@O\.XS!\3G+V(R 9
MOBBZQ)F=V7;*/0[<T_&L),S#*(VX'UA6QJ+[&TAOYI#.>G3I<ILN[KQE]16(
MIR(;'/<YES)3QZ<\S6/F>5'D6EX._\S2T.=YY/I>E*0\W1+[6952.CYUH?W<
M(T=YD 5!'K$H3+TTR>.,YW!@QV%)DKG]V+539O1HA-H2=^J!;>*&7@QH%'(G
M] +.P8QR@RB(<SN-<L_K8?0OPIY6&\ \G3WU89"5IE:0IB$+4L^W[#APTHS!
M&4-F6W$V;/[TTF:U;3W)KAY.7/JEX?.DV+#M;-#O@(=]?=XP^TG!/OO51/OL
M)X7[;&^CB+DC&+\3P9'[A:>IR]^."R;+"C&@H>-I6HY[:UZ=M*R0,9?3K/6S
MZ3Z>,E\GJ,@MT9=T]*%]_ N?@$C/OI;G(MIT2S_0#<\L2WP'M#PW!ID=PZUZ
MW$V3T/)LU_/3K$]4;TAT/?)4Y!;[G/]6<ZQ,FM][LMP%<]H%>1S!2<"<9CY8
M39D3NUD0\2#HM9$V=#+GN*\R:9TN4DQQ)U,NH$#>RSM (]+V/^=  9V3ZYI)
M%N5Q9$5.E 26QV,GRG/.[,!GEN_96=!3I'67.H^BO 7"V:?W:\JTCFJ>(B1N
MRBJK^?2'7\BB63WW%&A7!C^;H.C-%:]XAZB**7H5R<$(/YWJE#63;J1R,I%
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MYRK<\=X_??YZ>F%\_6S\^-NGD]_>G7T]??>3\?8S8,6GB]-W^*^+SQ_.WIW
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M*P(>1Z9R1%Y?/:%.)2]*PKT&NBJ 0#J*H%R67EK(--EEBF<@;:>71P3H=G<
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M#,VKZS:R(0E;,04]1[;'N++#I0WHRV!AK7+Q+LA-L!)577]TO<K@'?*<ADN
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ME$'V(S:B<DS+W1NWQ.//N$TC9&"X-MR=#8L*?#.T(J"";<J[D0I&*A@4%7A
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M18X=_M5X_^Y$(!JPN!I'KW]DMT8LIK^+A695,1'CW6WXO.+U3(R3G]R:R*V
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M26:PI>^3[!*DW9KC"?V'O\]+?0R?,!GJT1Y%_<68W]MS3HW\;N]I-)>-48)
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M"6O[)'IYY,7]-N>#>KS(X]W1=E\6>0(\[X*<SI/,^Y8F9IR(&'HR<%8*;),
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M((./X]'^;9IL0_3G$RRN-L9=VL6XNX6K&_RHV_#/CX[CQ\>WJ57^A-<Z4-5
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MZ<;P,7@H>+OPST<I;""93)I%PW$+"E+ TYL<.+OFXT)R 9&7L,452PR"IF_
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M!$0!(BM)2P\QQO>KVR],\UF9@.1NJ"F1G2.L\@CB K .+@SAX6YZ""R#@4#
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M IL5T#JEZ$P.<J'(%[: =&:FW/9!Z7T.5!83*O"MED4N\R)(@JAXG\A,3(N
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MFE"E!_<#:6!7["6N$EUQ=OMR7F2FY;]V#P%M6IHBW8&.E42QF(J<3I$E!CA
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MQW*?;PN)NB=NJL2:K2RSB+E -;UVGJQ,E:(045)1/*H.Y%\HZ5HRS!L&Z@[
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M>CQ45PW554-UU: 3;UPG<@-:5?=UFJR/DHDR.L=B&*W-PO2!-1@]I44]--B
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MKM#%YY:C' (=13KEJ@' #Y9H_&7&V7?$8@I#Q-E!^B6=6EI765 Y[.F#]P)
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MTM>X 9.*CL^@ $O&:VZX&D)MA, D+4S4/$&'@+*(?F;PS"4^L*FXCB)\HT/
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MP*IK[BOVGCYR!O9]+<EP 36BF.FU?$\BPJ!IMDO+G/%Q_BH]PA@5N_61=6R
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M1WCJ0Q>M!FJ(.WDASW?W%!PVW%^;53DE=NQ4H3IM(_:<#L=*VB=#?IS!MJ+
M?:\%\4WZUH/KD11GZ>'2()"<J22VFE/5\J2B,/T I48U> ?53\SJ*O&UM@SR
M;8>G4'D"/Z99J Q,[?AFE<(QX49%_I$;#M(.5$U@<F" ,$0VFH-G$AY88>[^
M<<$5CM%& R(V*42V';?6M'NTSGJ3'R*]I-R4^*-Q5.2AA^/4(ZYF6HX::!LM
MN^3U0EM] S!P(B(7O$ *IQG+?7#"Q;T1R=-IP!6FQ8:*:8?QH[%)!,?%UY)D
M$ ;/TQ2N:B1 1$CIPE%-$[%0I,0#)E(8$6*:9G;7%K?D[(J)NY, -0PKCS#
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MA"NN)L'Y<UB4#-W1\*F(N=M(23_)-)XHY09Q]I00;&L8_\7LPDHA<+]? !=
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M#2=I!8$5+[G"Z&SS+<&U2VVW&;A0(S ^1=)K_./NXQN,KI-8K)HGS-_.@4^
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MSM/@Q00MW A"[EWG(OHF<D/WUG'E34.,\ -=_G0/XC+H9NRQY,9N?ACQ2ZW
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M^X3K^;H4H+DX3L8+QC ^9 S,\ %.YO>R&FP9^\20HA+G;/=LRCZVKRO6*15
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M&W%!TL4 6F)=<XW/AZYE"@@97W:+CG4@7:#VU\#MZ)RB2UY]1W2-Q(/"BYJ
M9VF1L\<*&%&!6,IA-$)A_0@;%TP_TJ39K*PX-N)Z!7_:AC&=/WOF6LC>1JV,
M)C*D<NF/L9>3VU^D*SJV6I[./DP\X_0_0D[Y;#/<Q;T:8(!^SMTO@%,8B'A1
M7BO@]OTD^UCW^S%UOU\<ZWZ/=;]_EKK?^[:6F4ZVGH5\HGY0M=?T#79*O.?:
M=B2>6E#=9$Y>2&\1Z;&?2N$.)B8MM"DS:.-ELW#(%DD7TH$/QNZD1'U/OO#%
M#@Q=_M'\JZ2G_%6P!V_1ID-8Z[140NU-O)W9S&J2UAT3:_F.%^N=7&HQ-;JA
MC8_6UL4U$Z(#!I 8A&E-+U@SG>T*"#8%US9]?M,FH9C('-P6]]D[]C8@F1,P
M-MA8"5]-J=08=\M)EW&ADVE/O33%H-ON_*N_&E7NI,TT6@$O=;KNB<!$J4@D
MAZ<A,C'>>,/(CCRIQ+Y&',_HP]L"=VB!1BZ"_ =A.&-*!P&1\C21$;0:?YR8
M^-2ZQS6*76%#X#"67>?Y&,@<0^,1\ HQ&5?;:R7SJ.+1OF';JS%$/&_%#-&4
M-DI,K?M J^=Z_>8&%IL,D%JWUP)3[J>D?+0[/ ?@40ICKG1XC'8J*&[J=JV]
M^J'%*H\5\ >OMS]#\(8AE ^(&(41F-Z7>$5*%(L>\U]'R;H[+$C;P->(HTED
M>E(F =#&36K57%:, 1D^=I,O<L968%>0L>$WW)-;5'1! HZ?G+U99"_>,4 U
MNEXS"4>)V3'X'' _">-2"@[D2WONE6,8_"CO]RKVXXKD?YNX0[7VO6+8J\T\
MK_/F7;!4RL4[I9(.=L2R9)P'#IA$(N*B)#@B?J;4O3!<#GVC5!0Y:>&#>74-
M/!@FJR#2%@K"TO\*L@<.(+^!2A#)< )6T+)5'F+ZY"2$ZB<6_H\TLQ,32GOB
MGYP]U:4W>_0[#K4GR'\_Y"B77%7SBE94PG?U[F15ULZ4]2X55A1(FH(VD<?"
M]&!1SRO9)0;M;\R^TEWEU<PT\D\!*HJ(]:U:H)OVJDP1]/ H##"Z ,'J9[)>
M^J,$'X,"((NO*P7K( ,V$/L'Y\__J@I-:*A%QEA_4G:@%0H@^_X,,1E&YQ2O
M4=PI0S,PNUD">S2->;D@?J #<]\VM?IFDVM7>50HMFT%%H&<.F&E96 ?I9#Z
M&1BR!-X3DPHTMY*)<9U1"Q3&X$V<J+\1S)F\!^24 !B;R<T.(W>[1J)P.+-S
M1HF0JV,](J-'8/B N_4S&>:.5AAG-O8?NOGSK=3YY]!])-[N?,?Y#\5+JZMW
M95VMVK;@<>_:K:5)IOR5W2B.6C5,\DR0JA6CF25G; +'&K6BC0:.:9P>LV)_
MK".;<+>()B?E3?;J*WQC3OA6)9/T0/'= @B3X3 5E(<D*E+^),%Y2[]I*#BF
M*Q\"0NS':.TP??1":,Z*=DT'(P]KTW:;$U"%N*4P-:_D&:91@('#2ZW'TJ!^
MSI\[,LO<@X<(^ W.=\]PK\MPO?]5B+T.OED%".D"LK_BYD1#;&AJ*;;PAK_6
M!N^_$VAAX=]B<3!CBQ%EV(G7#G- @JD&D-0'5I/SJ<.1.DZ9,$<:-#T :HCN
M25W"W6APG5&CQX%RQ>F4@IK03NG8AG[]>$F+MN39:0 L6L6X890JG/'5=C(J
M7I:-_;5/7/K4H1\LJ<'P_"ZPZ(IDU=#FS,!; Z:?UC:H*521 DZU4.1KTZLM
MD=66G'7;,F7 A4>\,4*P-?4P5KE!5$-9*M@W]%W?AH<P^!BMTE5>-0^*W^5F
M/9@<"@$-Z=I8XZ"(%</-:)[B,C'>G]XUX:ZF.OT^SE9I W%U>\8P(C_HVEN"
MJ5@FJ, 3,LL0V!X^'0DTO-,I $)*CY2.T,!H(MT60)=GAE".Y=F\F9.W?)]3
MWVEV%VV0,]'V/_ #9&$J>WB7?&AP+TY\0B"/ $*?/I'XY3&1>$PD_H$3B7M.
MX6^#XLX+MG5;P48&N4<MVGD(D4H?^4?>%_G_F7U7M_.@#E]S]L'@+/''F/N[
M-?O9E:L4I3Q_H&(CF%M$WO'HHWOPA?R2\J/+0GVXRZ5[*@IM@/-.Q,XS_B3=
MESSJ3+P=-?'5SXA%+O"$=I$T1V'"QUKZ@7")/ B4N\4W@%U6 .W)#8I%._WN
M.@B"QHP(_>]4HT7[)"/NJIA[B9 L" .PJW*?"1L5'\5MS31C)3>JQK7"#L>=
M]!:EU6@"UL2+B06G9-/9[V#7PA-W\#[=N;UD-[9-A+,<U2(YN,#PVCE1D$@[
M-SD_H+>\(N!RG6C"C"[IXTB-SIUIY'?6-BJBBW>I0?AW2G:"_*49K['K/$G1
M:=%GA!V"+Z^1%>")@V^&7*K!^<L;BTE(2&)948WD*$!.9QC<*M.I;P)[G(<]
M*6\DTJ&I2H'C5BQ6%P'A(T50^0F39F2;T<1K>OYI6,JALB-CC!T98%RK(S,\
MYD+*(P7!.0<J-2" XF!WB/1AQ;1*9%F 04X!#J%@4 ZNQJ'[8U^D:$!(=G>3
MB^=*)6H*I%ZM4HN=D5)V(LSI"81%J<JL6HX4JBC3GIA?C<8T2U"=PWIT5?^.
M<<LJ#4;=O2PZA$_C](@M2;PFU7)W?][@-V732(C9-4:Q!R%%>[L!="=1A-VO
M>N/0"#\(8V]*N[\H8UWB 43NH<H/QZR]G?WE^>G9&4AUH:BR\1=3.A4NY7Q^
M=?+U?CX J"X%XG78VUQ5N>Y(B!=#$/6&*JS?!8.V*,/'.A=SY>=AL;DHP>E=
M<M(1Y^TE0 )@7"H.F@?Q6A$6?ECF]EJ+5_(%DY@@@BL:Q($L4R$%TTZD@PEC
M0+",>+%)$459^? AR.TY-1*]3,$K@0RC(V30=#?AYE*]>[\U!G7+L4A20$M;
MA9BK$R8)CK@F?[&+69\:8T)TC2?1]0A/G==V0TE11L]1VG=->UN7A7)@2,W'
MQ.L<ATHE!?V95]D.-3&YW-U'6LADF!%BI]<:<F9R(UV"9!NC%;)WZ2B_HIPO
MI#&YR$R1GT>+1**#Z&[.7$]K21C$FFP)N#F%HJ#T' VIPP2ZH$AM<7&E)#D-
M(GH;D',X <RX$)J"G75+B8-9OPA"1\<T+&*=5T9>XK[D^QA0S1-10TF%"V"T
M.[KS;?#.J 8'I[I@ON3!&6';I"^G[CD7BQU\BS-87/0]40<5U=' PC-$T .9
M> WC[RG0ADI1^ZQUV7CE0FQ=@96S6L+OKG_?RRJ&\9&AT+RI#YLK$$N&=&\I
M#"7OTUA:3(0,LKW"ZHXO.@4^F3<95;>KP"DD@JO6.[ CG__B_'%45C@H6-7L
M>=F/\N;;-8G'^5EV=H;_=VOS7RBE[DS"EWK_9Q/EE!\Z[Z=G4Q-/+?G)BE/.
MB\&;/G]^GIT]?Y9]<?ZE/B/H#-%7:4^+#B"3''#PE$";(.U"81^>9%]__67V
M],F3^_1^*+I[EX06DM)4QH5?,W4FJHW);RT+\9__V52R0=J+0[LSG"Z_1_8,
MAPD.W+:_X\#ZIJ&$;OA9=O;E%]G9T^=QP9!^+.R^DQB\+IBK% V7!-.'L-D&
MGE8&^P1$"6 4Z9(/4OO;,H_YK"K^O_]QN2FOGYS^C__XG__7R<E%LPAB='+R
M'Q3I^F]7/_3L^;[*G^G06EBXV9/3!RP&2E9O\/9_-HYLR/JKOF$!>>L[:(O9
M/_D6?$/D6&7Q4)4X:1#\A#;*%/<'Z/VIK_^C;?9D1^XMXD^/(OX;1?SI[R7B
MK\IE#FS8?Y+M^K9LR.!^.ZZV>!@QGK(_/M)\^01B_.PHQK]1C)_]7F+\FE(:
M;_-E&13S*W/Z_I#BNW%<>1\IR,^/@OP;!?GY[R7(/R)8=AF9&G\'$?XX";Z[
MHH'W>OS=V6%QRF;X34;DF=5R+%QA\9H13($O6$,A!0)7B.*]+=>YN':QC(7;
M*&MB#$WI>2<^;,V4<%C_,Z?AOJ8F4$W>TC\L=>NW:]G6=7M+/A7EUPC:HV&X
M1.?O*@G95^(V[1G-J^"KVD#@]ZXXTG=-58)4)!,<II>KJES.7A-=5W"8?N3&
M1<R5__*6.#+A^=H?T\HTN%]4!D=\?O5..#(Y"#A5P"9^=5A*92+^-HQH]M7)
M_Z+V$:'A\2MB3)8RZ_-G/.W3V=OHC*)#,596(L07QM1*WPH72&>"I#"QN5)
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M]R*?\\?S'L=="=ZR>Q'A3\E!3FS%3%>]L@-3B3$%I^A$WCA*@^ASBIVF@O?
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M^CD[@;-N6;4R.DJ.UZEUDDG4E62A<#YX,[:,?BML<I?TM0LW;<Z&'$4F2E;
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M#@ +.&FJ(2QTP<V%C61*V_?Y*T1U:P8GBQN5W0BD<06=-F_U=1/\1#[/U%+
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M0(5D'N7P99DA:]N-'MF-8)>&O<Q$2%!VU]G0Z3?1Z?/A[T$GOO-.=#H7%D)
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MZH!?N]+'V@(!511MV%4KM6RK5:^XK2XMGX0P*<-[);7&_"_"2%'-+/,2N';
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ML"^":AD(7%-.[HFBJ$CA7.(T'5@M;]^<U>M>JR/CA(B5:]5:AV7 \9Y4,29
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ML.O_V N[N)6MO);:1_8'"R?DO\G\!5!+ 0(4 Q0    ( +R("U/=<"1ETQ$
M '/,   1              "  0    !A9&UA+3(P,C$P-C,P+GAS9%!+ 0(4
M Q0    ( +R("U.6BM7Q+ \  %C0   5              "  0(2  !A9&UA
M+3(P,C$P-C,P7V-A;"YX;6Q02P$"% ,4    " "\B M32&C5 #)"  !Z<00
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M,#(W-S<Q7S$P<2YH=&U02P$"% ,4    " "\B M3>G)4\GLV  #4%P$ %P
M            @ 'C/00 8G)H8S$P,#(W-S<Q7V5X,3 M,BYH=&U02P$"% ,4
M    " "\B M3F8XXJG\)  #>,   %P              @ &3= 0 8G)H8S$P
M,#(W-S<Q7V5X,S$M,2YH=&U02P$"% ,4    " "\B M3\2"U2D0(   1+0
M%P              @ %'?@0 8G)H8S$P,#(W-S<Q7V5X,S$M,BYH=&U02P$"
M% ,4    " "\B M3;128'KT$  #E$0  %P              @ ' A@0 8G)H
M8S$P,#(W-S<Q7V5X,S(M,2YH=&U02P$"% ,4    " "\B M3GF%U/<<$  "<
M$0  %P              @ &RBP0 8G)H8S$P,#(W-S<Q7V5X,S(M,BYH=&U0
52P4&      L "P#F @  KI $

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
